Clustering O 0 0.00013845975627191365
of O 0 8.267078897006286e-07
missense O 0 0.00031446103821508586
mutations O 0 9.39976962399669e-05
in O 0 1.6705535017536022e-06
the O 0 0.000488664663862437
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 1.0
gene O 0 8.124149462673813e-05
in O 0 1.964248781405331e-07
a O 0 1.7174495781091537e-07
sporadic B-Disease 0 0.0014657777501270175
T I-Disease 1 0.998630702495575
- I-Disease 0 0.09321745485067368
cell I-Disease 0 0.19411639869213104
leukaemia I-Disease 0 0.4695909917354584
. O 0 1.973770167751354e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.05146518722176552
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 8.829819364564173e-08
is O 0 6.140125741183056e-09
a O 0 5.084727305870729e-08
recessive B-Disease 0 0.03169816732406616
multi I-Disease 0 0.05867619439959526
- I-Disease 1 0.9999905824661255
system I-Disease 1 0.9999706745147705
disorder I-Disease 1 0.9957873225212097
caused O 0 1.31752665311069e-06
by O 0 4.1385323612530556e-08
mutations O 0 9.478088145442598e-07
in O 0 1.608425392873869e-08
the O 0 2.0171212256059334e-08
ATM O 0 8.335627171618398e-06
gene O 0 2.133881480403943e-06
at O 0 3.9866134216026694e-07
11q22 O 0 3.555445346137276e-06
- O 0 4.454397640074603e-06
q23 O 0 5.615548161586048e-06
( O 0 1.499109316682734e-07
ref O 0 3.813860530499369e-06
. O 0 1.1385251852402689e-08
3 O 0 9.195614580903566e-08
) O 0 8.945922758130109e-08
. O 0 3.119153575426026e-07

The O 0 1.9462488580757054e-06
risk O 0 2.1773760181531543e-06
of O 0 5.676005443433496e-08
cancer B-Disease 0 1.3729715647059493e-05
, O 0 2.2141659172802974e-08
especially O 0 1.247895511369279e-07
lymphoid B-Disease 0 9.546997171128169e-05
neoplasias I-Disease 0 7.713359809713438e-05
, O 0 1.6716908746161607e-08
is O 0 9.254838673200538e-09
substantially O 0 4.737345307148644e-07
elevated O 0 9.050276275957003e-06
in O 0 1.2125177590860403e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.0006148439133539796
and O 0 7.693988379742223e-08
has O 0 2.092507322970505e-08
long O 0 1.7749430369917718e-08
been O 0 1.612630740055465e-08
associated O 0 6.759115223076151e-08
with O 0 4.0445766558150353e-07
chromosomal O 1 1.0
instability O 1 0.9999972581863403
. O 0 5.213637905399082e-06

By O 0 5.258403689367697e-06
analysing O 0 0.00010136532364413142
tumour B-Disease 1 0.9999991655349731
DNA O 0 9.026597581396345e-06
from O 0 2.1856051546365052e-07
patients O 0 3.028242474556464e-07
with O 0 2.6342865666606485e-08
sporadic B-Disease 0 0.005586231593042612
T I-Disease 1 0.9935272336006165
- I-Disease 0 0.0054045566357672215
cell I-Disease 0 0.015395655296742916
prolymphocytic I-Disease 0 0.4119302034378052
leukaemia I-Disease 1 0.9968003034591675
( O 0 1.907738578665885e-06
T B-Disease 0 0.021090524271130562
- I-Disease 0 2.077922545140609e-05
PLL I-Disease 0 4.239758709445596e-05
) O 0 2.1983353803989303e-08
, O 0 2.311581370761928e-09
a O 0 1.0648272485980215e-08
rare O 0 1.0429819496948767e-07
clonal B-Disease 0 1.7109379086832632e-06
malignancy I-Disease 0 9.247733942174818e-06
with O 0 9.328386063600647e-09
similarities O 0 8.838480169970353e-08
to O 0 1.8200140061708225e-08
a O 0 1.8802394663453015e-07
mature B-Disease 0 1.516842530691065e-06
T I-Disease 0 0.00919116660952568
- I-Disease 0 5.689000681741163e-05
cell I-Disease 0 0.0007299357675947249
leukaemia I-Disease 0 0.001364511321298778
seen O 0 1.1249991302975104e-06
in O 0 2.996909813646198e-07
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999864101409912
T I-Disease 1 1.0
, O 0 1.7419077735780775e-08
we O 0 1.5034058442608966e-09
demonstrate O 0 3.2897020663114063e-09
a O 0 5.5398667875294905e-09
high O 0 2.274911281574532e-08
frequency O 0 2.774540064365283e-07
of O 0 5.184190854379267e-09
ATM O 0 3.840443241642788e-05
mutations O 0 8.018254447961226e-06
in O 0 9.277655408368446e-07
T B-Disease 0 0.0854225680232048
- I-Disease 0 0.00019400031305849552
PLL I-Disease 0 0.0007453126600012183
. O 0 2.4573798782512313e-06

In O 0 1.8349276160734007e-06
marked O 0 1.0839604556167615e-06
contrast O 0 1.794479373984359e-07
to O 0 1.5473624159767496e-08
the O 0 3.1820562185203016e-08
ATM O 0 2.6379042537882924e-05
mutation O 0 2.0065704120497685e-06
pattern O 0 2.810019850585377e-06
in O 0 6.167059609651915e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
, O 0 1.1584369019601581e-08
the O 0 3.6696827798721188e-09
most O 0 1.803457494453653e-09
frequent O 0 4.246326312795645e-08
nucleotide O 0 1.1479204431452672e-07
changes O 0 5.316484674722233e-08
in O 0 1.6676462877285303e-08
this O 0 9.710577586474756e-08
leukaemia B-Disease 0 0.00013114417379256338
were O 0 1.5706186218267248e-07
missense O 0 5.022441109758802e-05
mutations O 0 4.656658347812481e-05
. O 0 1.7283313127336442e-06

These O 0 5.922240120526112e-07
clustered O 0 1.6751465636843932e-06
in O 0 2.9755106822904054e-08
the O 0 6.237627747651686e-09
region O 0 1.2237679314353045e-08
corresponding O 0 1.0729208632653808e-08
to O 0 1.9746488888472413e-09
the O 0 5.634506639040637e-09
kinase O 0 4.619103606273711e-07
domain O 0 2.8500441118239905e-08
, O 0 7.673287005793838e-10
which O 0 1.0948520978715237e-09
is O 0 5.161062688330276e-10
highly O 0 4.188072999511405e-09
conserved O 0 3.646680468705199e-08
in O 0 1.926043147193468e-08
ATM O 0 1.3461504750011954e-05
- O 0 6.490279815807298e-07
related O 0 7.100387477976255e-08
proteins O 0 4.5106478552270346e-08
in O 0 2.1455072385379026e-08
mouse O 0 1.5970800859577139e-06
, O 0 1.4504468737186471e-08
yeast O 0 1.510960601081024e-06
and O 0 7.007754021515211e-08
Drosophila O 0 3.364883923495654e-06
. O 0 5.707095738216594e-07

The O 0 1.6383888805648894e-06
resulting O 0 2.1837311123817926e-06
amino O 0 1.9567303297662875e-06
- O 0 3.3349240311508765e-06
acid O 0 7.246902669066912e-07
substitutions O 0 2.223400770162698e-07
are O 0 2.6196145253010172e-09
predicted O 0 1.1781959585732693e-07
to O 0 8.71533423207893e-09
interfere O 0 9.057695393721588e-08
with O 0 1.0172752418213804e-08
ATP O 0 6.716116445204534e-07
binding O 0 4.4098334228692693e-07
or O 0 1.3585598424015188e-07
substrate O 0 2.3668301309953677e-06
recognition O 0 3.632276559528691e-07
. O 0 5.388060912991932e-07

Two O 0 5.160807745596685e-07
of O 0 8.069476820082855e-08
seventeen O 0 1.061922716871777e-06
mutated O 0 2.649398084031418e-05
T B-Disease 0 0.0010117905912920833
- I-Disease 0 1.0531752195674926e-05
PLL I-Disease 0 2.9116854420863092e-05
samples O 0 2.98499855944101e-07
had O 0 2.8456007328259147e-08
a O 0 1.549669015332711e-08
previously O 0 1.3608887172722461e-07
reported O 0 2.1667952751158737e-05
A B-Disease 1 0.9999923706054688
- I-Disease 1 0.9999681711196899
T I-Disease 1 0.9999998807907104
allele O 0 0.00019443365454208106
. O 0 2.3511227027483983e-06

In O 0 2.2623123641096754e-06
contrast O 0 6.584381253560423e-07
, O 0 1.5387859875204413e-08
no O 0 1.2024465867455092e-08
mutations O 0 3.6305382877799275e-07
were O 0 2.353180761360818e-08
detected O 0 3.499568492770777e-07
in O 0 8.844108556615993e-09
the O 0 1.0245969406241784e-08
p53 O 0 2.0480740658967989e-07
gene O 0 1.1029645463622728e-07
, O 0 1.9262846873147055e-09
suggesting O 0 2.6684924492315076e-08
that O 0 4.8504440464114396e-09
this O 0 4.639341000256536e-08
tumour B-Disease 1 0.9999997615814209
suppressor O 0 0.00015967863146215677
is O 0 8.14393885661957e-09
not O 0 3.1122577848208266e-09
frequently O 0 5.53749259779579e-08
altered O 0 1.5263065051840385e-06
in O 0 4.896458349890054e-08
this O 0 2.939948444691254e-07
leukaemia B-Disease 0 0.002017972758039832
. O 0 6.495357069979946e-07

Occasional O 0 0.000431697117164731
missense O 0 0.0019751046784222126
mutations O 0 0.00031131994910538197
in O 0 1.2846028312196722e-06
ATM O 0 4.822734263143502e-05
were O 0 1.565592384622505e-07
also O 0 3.3007843569521356e-08
found O 0 2.44618831857224e-08
in O 0 1.429985445611237e-07
tumour B-Disease 1 0.9999996423721313
DNA O 0 2.5242391075153137e-06
from O 0 9.341421502995217e-08
patients O 0 8.43267571326578e-08
with O 0 1.4662124847575342e-08
B B-Disease 0 1.931869064719649e-06
- I-Disease 0 3.162542043355643e-06
cell I-Disease 0 1.6615953427390195e-05
non I-Disease 0 2.762284111668123e-06
- I-Disease 0 0.09615002572536469
Hodgkins I-Disease 1 0.9974144697189331
lymphomas I-Disease 0 0.2041812688112259
( O 0 4.292612914014171e-07
B B-Disease 0 2.7965299977950053e-06
- I-Disease 0 1.679241108831775e-06
NHL I-Disease 0 7.190376436483348e-07
) O 0 9.710000803409002e-09
and O 0 4.268288833486622e-09
a O 0 5.17119751464179e-08
B B-Disease 0 2.6158918444707524e-06
- I-Disease 0 3.481344492684002e-06
NHL I-Disease 0 2.7869612040376524e-06
cell O 0 1.9975674149463885e-05
line O 0 5.131472789798863e-05
. O 0 5.576135322371556e-07

The O 0 2.329624209096437e-07
evidence O 0 3.449902052921061e-08
of O 0 1.2206690103155893e-09
a O 0 5.075248665775689e-09
significant O 0 5.829520866029725e-09
proportion O 0 7.871801877001872e-09
of O 0 2.8066005075544354e-09
loss O 0 8.83229347437009e-07
- O 0 1.5217093505270896e-06
of O 0 1.312342945425371e-08
- O 0 4.036148311570287e-06
function O 0 2.2568683277768287e-07
mutations O 0 1.508652616166728e-07
and O 0 1.9084345215247822e-09
a O 0 7.797726908620461e-09
complete O 0 1.850255593183192e-08
absence O 0 1.558115947375427e-08
of O 0 7.145800062779983e-10
the O 0 5.94454352409457e-09
normal O 0 4.716779145041983e-08
copy O 0 1.0979668729760306e-07
of O 0 1.5222912930212829e-09
ATM O 0 6.779528121114708e-07
in O 0 9.446504023458147e-09
the O 0 4.441544465549896e-09
majority O 0 1.2187830300547375e-08
of O 0 1.2530157356138716e-08
mutated O 0 0.0002113784576067701
tumours B-Disease 1 0.9999983310699463
establishes O 0 2.165159003197914e-06
somatic O 0 3.3596700177440653e-06
inactivation O 0 6.417868462449405e-06
of O 0 2.862556414129358e-09
this O 0 2.9932691880674156e-09
gene O 0 8.21497465608445e-08
in O 0 7.864793261092018e-09
the O 0 1.365664914487752e-08
pathogenesis O 0 6.648133989983762e-07
of O 0 1.112274361503296e-08
sporadic B-Disease 0 0.00010368559014750645
T I-Disease 1 0.7416254281997681
- I-Disease 0 7.963487587403506e-05
PLL I-Disease 0 5.453344783745706e-05
and O 0 3.677434179394368e-08
suggests O 0 2.8278860142449957e-08
that O 0 4.192252767154514e-09
ATM O 0 8.835992275635363e-07
acts O 0 6.707220023827176e-08
as O 0 2.930245734944492e-08
a O 0 8.685523766871484e-07
tumour B-Disease 1 0.9999994039535522
suppressor O 0 0.0014870469458401203
. O 0 2.117475560226012e-06

As O 0 9.625556458559004e-07
constitutional O 0 3.593459894091211e-07
DNA O 0 4.6439359380201495e-07
was O 0 3.348460779761808e-07
not O 0 1.8329902040647994e-09
available O 0 3.2721614307007485e-09
, O 0 1.3411211030600612e-09
a O 0 1.726069243090933e-08
putative O 0 3.997728981630644e-06
hereditary O 0 0.0900946706533432
predisposition O 0 9.86320010269992e-05
to O 0 2.1392302187450696e-06
T B-Disease 1 0.7335439920425415
- I-Disease 0 7.780006853863597e-05
PLL I-Disease 0 5.884789061383344e-05
will O 0 3.507198798047284e-08
require O 0 2.2994630199946187e-08
further O 0 1.677504002373098e-08
investigation O 0 1.20452909868618e-07
. O 0 4.1112397042297744e-08
. O 0 2.2217474793251313e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00209088739939034
kinase O 0 0.002722806064411998
is O 0 6.925503726051829e-08
involved O 0 1.1361000140652777e-08
in O 0 7.330275497707817e-09
the O 0 1.2250477077202504e-08
modulation O 0 1.8539829227393056e-07
of O 0 2.8528106543745935e-09
the O 0 2.1569794839138012e-08
Ca2 O 0 3.4980178043042542e-06
+ O 0 5.949934234195098e-07
homeostasis O 0 1.969928780454211e-05
in O 0 1.8187097339250613e-07
skeletal O 0 0.0037532001733779907
muscle O 0 0.004687561187893152
cells O 0 2.5125542379100807e-05
. O 0 1.7062809547496727e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9982641339302063
DM B-Disease 1 1.0
) O 0 9.030239311869082e-07
, O 0 1.0091565805225855e-08
the O 0 8.357127434521772e-09
most O 0 1.552692907580422e-08
prevalent O 0 0.00021337199723348022
muscular B-Disease 1 0.9999208450317383
disorder I-Disease 1 0.9989663362503052
in O 0 7.355505658779293e-06
adults O 0 9.315654097008519e-06
, O 0 2.4042796198386895e-08
is O 0 1.1544488032200206e-08
caused O 0 2.835491841324256e-07
by O 0 4.94890635138745e-08
( O 0 9.1225921039495e-08
CTG O 0 4.772416104970034e-06
) O 0 3.026463701871762e-08
n O 0 4.900447834188526e-07
- O 0 3.7067650282551767e-07
repeat O 0 2.3417058514496603e-07
expansion O 0 5.2002572914489065e-08
in O 0 5.593613572330014e-09
a O 0 1.613987876680767e-08
gene O 0 1.7552659414832306e-07
encoding O 0 1.625406582661526e-07
a O 0 6.606005342746357e-08
protein O 0 1.0729207815529662e-06
kinase O 0 2.931640119641088e-05
( O 0 6.25892710104381e-07
DM B-Disease 1 0.9999892711639404
protein O 0 2.958538743769168e-06
kinase O 0 1.6113252058858052e-05
; O 0 3.660073488731541e-08
DMPK O 0 4.665038886741968e-06
) O 0 5.60073409872075e-09
and O 0 2.1797168514581244e-09
involves O 0 5.844272177313314e-09
changes O 0 2.211329963586195e-08
in O 0 2.6951731513236155e-08
cytoarchitecture O 0 4.364015694591217e-06
and O 0 1.0637720038175758e-07
ion O 0 6.814585503889248e-05
homeostasis O 0 0.010374793782830238
. O 0 2.2122003429103643e-06

To O 0 8.778850428825535e-07
obtain O 0 1.5352100035670446e-07
clues O 0 3.7921867601653503e-07
to O 0 1.4043419760412235e-08
the O 0 3.6000091796495326e-09
normal O 0 3.20428661382266e-08
biological O 0 1.5200900094214376e-08
role O 0 4.848667689572039e-09
of O 0 9.94870186232788e-10
DMPK O 0 1.1502955885589472e-06
in O 0 5.3440366798440664e-08
cellular O 0 2.335337285330752e-06
ion O 0 1.0376941645517945e-05
homeostasis O 0 0.0024628217797726393
, O 0 1.297758966956053e-08
we O 0 1.8105470456220019e-09
have O 0 1.6197014840457769e-09
compared O 0 1.0396646210608651e-08
the O 0 1.4657259406192225e-08
resting O 0 4.409698703966569e-07
[ O 0 9.243128573643844e-08
Ca2 O 0 7.036362035250932e-07
+ O 0 2.6302456035409705e-07
] O 0 7.064252827149176e-08
i O 0 1.4797596925575363e-08
, O 0 7.286376502158021e-10
the O 0 3.237631496233462e-09
amplitude O 0 3.9833441434211636e-08
and O 0 3.34389205214336e-09
shape O 0 7.672592516883014e-08
of O 0 7.47193062977658e-09
depolarization O 0 8.767915460339282e-07
- O 0 4.040061412524665e-06
induced O 0 3.911380190402269e-06
Ca2 O 0 2.2167239421833074e-06
+ O 0 3.847301286441507e-07
transients O 0 7.570557158942393e-07
, O 0 2.2911088581878403e-09
and O 0 1.04209807449962e-09
the O 0 2.5301898354257446e-09
content O 0 1.7441019295461047e-08
of O 0 2.1810435679725515e-09
ATP O 0 5.570384473685408e-07
- O 0 9.057744705387449e-07
driven O 0 7.859208039917576e-07
ion O 0 1.607522790436633e-06
pumps O 0 1.9497024368320126e-06
in O 0 5.273300729413677e-08
cultured O 0 1.6645676623738836e-06
skeletal O 0 9.127116936724633e-05
muscle O 0 2.326784306205809e-05
cells O 0 1.8641134147401317e-07
of O 0 6.1242895199598024e-09
wild O 0 1.6977725181277492e-07
- O 0 6.275564373936504e-06
type O 0 2.0963332644896582e-05
and O 0 9.91145583384423e-08
DMPK O 0 7.907747203717008e-05
[ O 0 1.3024751979173743e-06
- O 0 5.287875683279708e-05
/ O 0 0.00015763875853735954
- O 0 3.118480526609346e-05
] O 0 1.9450612853688654e-06
knockout O 0 4.5507003960665315e-05
mice O 0 0.00027520590811036527
. O 0 7.892918461038789e-07

In O 0 1.2118645827285945e-05
vitro O 0 9.973267879104242e-05
- O 0 2.727044375205878e-05
differentiated O 0 9.506273272563703e-06
DMPK O 0 9.833129297476262e-05
[ O 0 3.2177410957956454e-06
- O 0 3.598884723032825e-05
/ O 0 9.453867096453905e-05
- O 0 8.495119800500106e-06
] O 0 6.225827178241161e-07
myotubes O 0 1.8650181345947203e-06
exhibit O 0 2.076073428725067e-07
a O 0 7.188594253193514e-08
higher O 0 6.539624450851989e-07
resting O 0 9.02346471320925e-07
[ O 0 2.4623057015560335e-07
Ca2 O 0 1.616411168470222e-06
+ O 0 5.342874942471099e-07
] O 0 2.7556276904761035e-07
i O 0 4.295839772794352e-08
than O 0 6.2459615257637324e-09
do O 0 9.737263440001698e-09
wild O 0 7.909098087566235e-08
- O 0 7.476562132069375e-06
type O 0 1.6514941307832487e-05
myotubes O 0 1.8066898519464303e-06
because O 0 2.920741648537728e-09
of O 0 3.8570099891721554e-10
an O 0 1.8033268212036546e-09
altered O 0 3.403426944714738e-07
open O 0 1.7229378812544383e-08
probability O 0 4.341562220844253e-09
of O 0 2.6844901857003833e-09
voltage O 0 4.809255187865347e-06
- O 0 1.5827167771931272e-06
dependent O 0 5.03646162997029e-07
l O 0 6.524426225951174e-06
- O 0 1.2184457318653585e-06
type O 0 2.4660992039571283e-06
Ca2 O 0 2.0305562884459505e-06
+ O 0 3.5282374710732256e-07
and O 0 2.6300492450559432e-08
Na O 0 1.0744505516413483e-06
+ O 0 6.477455372078111e-07
channels O 0 1.3357552006709739e-06
. O 0 6.418337648028682e-07

The O 0 2.0808872704947134e-06
mutant O 0 9.696753295429517e-06
myotubes O 0 6.552661943715066e-06
exhibit O 0 8.575407264288515e-07
smaller O 0 1.9133601369958342e-07
and O 0 2.7475863362269592e-08
slower O 0 3.186932872267789e-06
Ca2 O 0 3.069676040468039e-06
+ O 0 4.254701195804955e-07
responses O 0 9.866263894764415e-08
upon O 0 1.845564234770336e-08
triggering O 0 6.197984703248949e-07
by O 0 4.6585469704041316e-08
acetylcholine O 0 4.362094841781072e-05
or O 0 4.031214473343425e-07
high O 0 8.646358082842198e-07
external O 0 2.7847506771649932e-06
K O 0 3.912558895535767e-06
+ O 0 2.9619263841595966e-06
. O 0 6.51082473268616e-07

In O 0 6.940862249393831e-07
addition O 0 6.182705192259164e-08
, O 0 5.821454429622008e-09
we O 0 1.7638827065624696e-09
observed O 0 1.2987494635297026e-08
that O 0 2.090164707979625e-09
these O 0 4.93695884173917e-09
Ca2 O 0 1.0441686981721432e-06
+ O 0 5.758223551310948e-07
transients O 0 1.3411943200480891e-06
partially O 0 7.12420160198235e-07
result O 0 2.2155433043735684e-08
from O 0 2.8528868156740828e-09
an O 0 1.3146095323435247e-09
influx O 0 7.065866558519929e-09
of O 0 1.743422517463955e-09
extracellular O 0 3.039057219211827e-07
Ca2 O 0 7.974534810273326e-07
+ O 0 1.1947109612719942e-07
through O 0 2.441312751955138e-08
the O 0 5.537809855127307e-08
l O 0 1.0510841093491763e-05
- O 0 2.419572865619557e-06
type O 0 6.691656835755566e-06
Ca2 O 0 1.0591417776595335e-05
+ O 0 5.104052434035111e-06
channel O 0 9.290421985497233e-06
. O 0 1.6731220284782466e-06

Neither O 0 2.577404984549503e-06
the O 0 1.2837463714276964e-07
content O 0 1.8294430503829062e-07
nor O 0 5.186587159755618e-08
the O 0 9.463546390975353e-09
activity O 0 6.415081799104883e-08
of O 0 8.706013687742598e-09
Na O 0 1.5783710978212184e-06
+ O 0 1.201987743115751e-06
/ O 0 2.0437282728380524e-06
K O 0 1.0293940704286797e-06
+ O 0 1.1687501455526217e-06
ATPase O 0 5.110354777571047e-06
and O 0 1.2018968220672832e-07
sarcoplasmic O 0 6.772115739295259e-05
reticulum O 0 5.819484795210883e-05
Ca2 O 0 2.4537393983337097e-05
+ O 0 3.888951596309198e-06
- O 0 3.751815029318095e-06
ATPase O 0 1.0272100553265773e-05
are O 0 1.9139509532806187e-08
affected O 0 1.898719972359686e-07
by O 0 8.647729288213668e-08
DMPK O 0 9.178936306852847e-05
absence O 0 2.9664099656656617e-06
. O 0 6.15927774560987e-07

In O 0 1.1785572269218392e-06
conclusion O 0 1.468208381538716e-07
, O 0 9.601544448401e-09
our O 0 4.289802735257808e-09
data O 0 3.473387266694772e-08
suggest O 0 1.9486648739075463e-08
that O 0 1.945425820437663e-09
DMPK O 0 4.4469172166827775e-07
is O 0 1.5317280777082942e-09
involved O 0 1.3235007534362353e-09
in O 0 4.579502554946657e-09
modulating O 0 5.943060727986449e-07
the O 0 9.204472739554603e-09
initial O 0 3.2872577548914705e-08
events O 0 8.58193427433207e-09
of O 0 5.0744741741937105e-09
excitation O 0 3.1524548376182793e-06
- O 0 1.5293666365323588e-05
contraction O 0 1.684901690168772e-05
coupling O 0 2.847821633622516e-06
in O 0 1.6251772194664227e-07
skeletal O 0 0.004513868130743504
muscle O 0 0.0006258874200284481
. O 0 1.7362827975375694e-07
. O 0 5.226658004175988e-07

Constitutional O 0 0.00033632185659371316
RB1 O 0 0.01584302820265293
- O 0 0.00020884785044472665
gene O 0 5.915611836826429e-05
mutations O 0 3.8579964893870056e-05
in O 0 1.6893851295662898e-07
patients O 0 4.199914087621437e-07
with O 0 7.286397618599949e-08
isolated O 0 1.9270431948825717e-05
unilateral B-Disease 0 0.00018212141003459692
retinoblastoma I-Disease 0 0.14335483312606812
. O 0 5.403449904406443e-06

In O 0 3.90362902180641e-06
most O 0 1.7101666571761598e-07
patients O 0 1.3899418149776466e-07
with O 0 1.6199864560917376e-08
isolated O 0 1.7705291384118027e-06
unilateral B-Disease 0 1.5771971447975375e-05
retinoblastoma I-Disease 0 0.000659022422041744
, O 0 1.1612069528155189e-07
tumor B-Disease 0 4.186088972346624e-06
development O 0 1.5886955750943343e-08
is O 0 4.879515902445064e-09
initiated O 0 3.981551444098841e-08
by O 0 8.68228422490347e-09
somatic O 0 1.0144743782802834e-06
inactivation O 0 3.4427089303790126e-06
of O 0 3.940014980940987e-09
both O 0 8.110673022088122e-09
alleles O 0 1.3370330975703837e-07
of O 0 5.606986874795439e-09
the O 0 2.682253068542195e-07
RB1 O 0 0.00014685903443023562
gene O 0 9.155010047834367e-06
. O 0 1.041675204760395e-06

However O 0 2.096491698466707e-06
, O 0 3.2589397847004875e-08
some O 0 2.3881996380481496e-09
of O 0 1.603893684531954e-09
these O 0 4.3379202452342724e-09
patients O 0 4.4881890204351294e-08
can O 0 3.307035711941353e-08
transmit O 0 0.00013049189874436706
retinoblastoma B-Disease 0 0.0005528187029995024
predisposition O 0 1.4552968423231505e-05
to O 0 3.077238730497811e-08
their O 0 9.092401143107054e-08
offspring O 0 1.4042690281712567e-06
. O 0 3.1756965768181544e-07

To O 0 7.86100713412452e-07
determine O 0 1.6208215924962133e-07
the O 0 3.9121452743984264e-08
frequency O 0 5.620745014311979e-06
and O 0 1.3502230444828456e-08
nature O 0 6.260608031993797e-09
of O 0 2.3768118584399645e-09
constitutional O 0 4.4122734266238695e-07
RB1 O 0 0.00011634856491582468
- O 0 4.852847723668674e-06
gene O 0 4.608223207469564e-06
mutations O 0 3.0009562124178046e-06
in O 0 6.587320200424074e-08
patients O 0 8.603966250575468e-08
with O 0 2.3785862168779204e-08
isolated O 0 2.443852736178087e-06
unilateral B-Disease 0 1.5014392374723684e-05
retinoblastoma I-Disease 0 0.00014881121751386672
, O 0 2.4614694282831806e-08
we O 0 3.4778135926671894e-09
analyzed O 0 4.700254407907778e-08
DNA O 0 1.0043161324801986e-07
from O 0 3.740878184999019e-08
peripheral O 0 7.5619591370923445e-06
blood O 0 1.4896791071805637e-06
and O 0 4.66471767879284e-08
from O 0 1.8309127369775524e-07
tumor B-Disease 0 0.0001471294235670939
tissue O 0 0.000160169365699403
. O 0 1.4495943787551369e-06

The O 0 9.393600066687213e-07
analysis O 0 1.3098830322633148e-06
of O 0 8.920144978219469e-08
tumors B-Disease 1 0.9999973773956299
from O 0 2.1625166368721693e-07
54 O 0 5.327773351382348e-07
( O 0 4.248611062962482e-08
71 O 0 1.1197270310958629e-07
% O 0 5.488803633824091e-09
) O 0 1.864495891013007e-09
of O 0 2.565582413183165e-09
76 O 0 9.515093779555173e-07
informative O 0 1.8668438315216918e-06
patients O 0 2.036071236943826e-06
showed O 0 4.4937933125765994e-05
loss O 0 8.772757951192034e-07
of O 0 1.568612084668075e-08
constitutional O 0 9.776866818356211e-07
heterozygosity O 0 6.48890490992926e-05
( O 0 1.291804323955148e-06
LOH O 0 0.0031635211780667305
) O 0 1.0602069977494466e-07
at O 0 5.718820830225013e-07
intragenic O 0 2.5353238015668467e-05
loci O 0 1.180752497020876e-05
. O 0 8.033171638999193e-07

Three O 0 6.579296609743324e-07
of O 0 6.315263334499832e-08
13 O 0 2.712900197821e-07
uninformative O 0 7.191573240561411e-05
patients O 0 3.779019834837527e-06
had O 0 5.353713277145289e-07
constitutional O 0 8.800024033916998e-07
deletions O 0 5.145879549672827e-05
. O 0 1.6694211808498949e-06

For O 0 3.364819804119179e-06
39 O 0 5.083358701085672e-06
randomly O 0 1.8135880281988648e-06
selected O 0 1.7257438003071002e-06
tumors B-Disease 1 0.9999992847442627
, O 0 1.2354549028259498e-07
SSCP O 0 7.472185097867623e-05
, O 0 9.027444036746601e-08
hetero O 0 8.811362931737676e-06
- O 0 1.5581240404571872e-06
duplex O 0 2.3495771529269405e-05
analysis O 0 6.94302784154388e-08
, O 0 4.0405492285344735e-09
sequencing O 0 2.0397619593381933e-08
, O 0 1.5029471001071215e-09
and O 0 2.219323169683207e-09
Southern O 0 3.823591043783381e-08
blot O 0 4.164253368799109e-06
analysis O 0 3.1487537910379615e-08
were O 0 3.562529382605817e-09
used O 0 9.845411597098064e-09
to O 0 9.592318939155575e-09
identify O 0 4.902607884105237e-07
mutations O 0 6.312870482361177e-06
. O 0 3.07398067889153e-07

Mutations O 0 0.0006657400517724454
were O 0 1.0925172091447166e-06
detected O 0 3.6741889744007494e-06
in O 0 1.1506507036074254e-07
21 O 0 2.5975208473028033e-07
( O 0 2.320585323900559e-08
91 O 0 9.393468758389645e-08
% O 0 6.588398715479116e-09
) O 0 4.475039894202837e-09
of O 0 5.56095569592685e-09
23 O 0 3.263348116888665e-05
tumors B-Disease 1 1.0
with O 0 2.2041869669919834e-05
LOH O 1 0.9993544220924377
. O 0 4.248175628163153e-06

In O 0 2.27998202717572e-06
6 O 0 1.2125107105021016e-06
( O 0 6.373517180691124e-08
38 O 0 9.719379789885352e-08
% O 0 6.166627208870068e-09
) O 0 2.2430139967610785e-09
of O 0 3.6008951376231835e-09
16 O 0 1.1251599062234163e-05
tumors B-Disease 1 1.0
without O 0 1.8206150116384379e-06
LOH O 0 0.05131504312157631
, O 0 1.3173411694822335e-08
one O 0 6.821330611472831e-09
mutation O 0 3.270846775649261e-07
was O 0 2.3566354911963572e-07
detected O 0 5.413396593212383e-07
, O 0 3.193436848292208e-09
and O 0 2.547681399178714e-09
in O 0 1.2457261888698667e-08
9 O 0 1.2483334899116016e-07
( O 0 9.293825264933275e-09
56 O 0 2.656051911742452e-08
% O 0 1.4014298610476317e-09
) O 0 7.461985473966593e-10
of O 0 1.1024882118348955e-09
the O 0 1.2857868796345429e-06
tumors B-Disease 1 1.0
without O 0 1.5252223874995252e-06
LOH O 0 0.002281604567542672
, O 0 1.0561840291245517e-08
both O 0 1.2472431087928726e-08
mutations O 0 6.013139000060619e-07
were O 0 1.9862122613290012e-08
found O 0 9.541430756598857e-08
. O 0 3.533318420068099e-07

Thus O 0 1.5380838931378094e-06
, O 0 2.5819211657562846e-08
a O 0 4.80491957333129e-09
total O 0 1.1476358752204874e-09
of O 0 8.980174937001095e-10
45 O 0 1.5303358580354143e-08
mutations O 0 1.3004206778077787e-07
were O 0 1.3169893620101902e-08
identified O 0 7.622458753075989e-08
in O 0 4.0172676563088316e-07
tumors B-Disease 1 0.9999997615814209
of O 0 2.7111047629091445e-08
36 O 0 1.321364607065334e-06
patients O 0 2.288320729348925e-06
. O 0 7.851334657971165e-07

Thirty O 0 3.025193655048497e-05
- O 0 3.383089506314718e-06
nine O 0 4.6909939044326165e-08
of O 0 3.935035852720148e-09
the O 0 1.2598360576987488e-08
mutations O 0 4.721423749742826e-07
- O 0 1.2447101482848666e-07
including O 0 5.8320899221087075e-09
34 O 0 3.136226567335143e-08
small O 0 2.6444959999594175e-08
mutations O 0 7.756830768812506e-07
, O 0 5.162935856617423e-09
2 O 0 8.743372248432024e-09
large O 0 1.4361733136070143e-08
structural O 0 1.5862359532547998e-06
alterations O 0 4.228624220559141e-06
, O 0 5.723270302127048e-09
and O 0 1.7507545635453425e-08
hypermethylation O 0 2.7283789677312598e-05
in O 0 7.20109539997793e-07
3 O 0 0.00010132096213055775
tumors O 1 1.0
- O 0 0.0010690526105463505
were O 0 7.337902729886991e-08
not O 0 4.4853627478858016e-09
detected O 0 1.4207500953489216e-07
in O 0 3.3926785825144634e-09
the O 0 3.196422682094635e-09
corresponding O 0 6.19953297587017e-08
peripheral O 0 4.163895482633961e-06
blood O 0 3.0066912586335093e-06
DNA O 0 5.337117272574687e-06
. O 0 1.4149359230941627e-06

In O 0 5.0071748773916624e-06
6 O 0 1.0605058378132526e-06
( O 0 7.71734178783845e-08
17 O 0 3.142861615401671e-08
% O 0 1.898323942484126e-09
) O 0 4.5261647207972544e-10
of O 0 3.0986210819428095e-10
the O 0 1.2685623218544606e-08
36 O 0 5.87209747493489e-08
patients O 0 2.1828467922091477e-08
, O 0 1.4708164686183522e-09
a O 0 2.4393486341978132e-08
mutation O 0 4.399973931867862e-07
was O 0 5.88163572956546e-07
detected O 0 5.438461698759056e-07
in O 0 1.385449710511466e-08
constitutional O 0 4.1400483041798e-08
DNA O 0 1.434153631407753e-07
, O 0 3.0427729225124267e-09
and O 0 1.50313639313282e-09
1 O 0 9.37836919234769e-10
of O 0 3.226890421537121e-10
these O 0 1.9675880924552303e-09
mutations O 0 4.261141128836243e-08
is O 0 7.151254033388454e-10
known O 0 3.177221152839138e-09
to O 0 3.507103718547455e-09
be O 0 3.811909010664749e-09
associated O 0 1.8100887899663576e-08
with O 0 2.8386349271158906e-08
reduced O 0 4.6864647629263345e-06
expressivity O 0 0.00021893689699936658
. O 0 1.5200370171442046e-06

The O 0 4.459866431716364e-07
presence O 0 8.053593347767674e-08
of O 0 1.6987474760199461e-09
a O 0 1.7122808060321404e-08
constitutional O 0 6.022332854627166e-08
mutation O 0 4.542034446330945e-07
was O 0 1.8380750077540142e-07
not O 0 1.3187708702844247e-09
associated O 0 3.1297533453766846e-09
with O 0 7.491591236252759e-10
an O 0 2.623494754772082e-09
early O 0 7.02509714756161e-06
age O 0 2.176312108304046e-07
at O 0 9.795812729862519e-07
treatment O 0 9.206966637975711e-07
. O 0 3.5409925658314023e-07

In O 0 5.349153070710599e-06
1 O 0 6.972981054786942e-07
patient O 0 1.3023087603869499e-06
, O 0 2.717088953829716e-08
somatic O 0 2.2903905119164847e-06
mosaicism O 0 2.0772487914655358e-05
was O 0 6.803414862588397e-07
demonstrated O 0 4.637465522705497e-08
by O 0 5.175911255150822e-09
molecular O 0 4.549677257159601e-08
analysis O 0 8.344878565935687e-09
of O 0 9.792967547994635e-10
DNA O 0 5.514641898685113e-08
and O 0 7.1712817906188775e-09
RNA O 0 3.4254065894856467e-07
from O 0 7.259305334628152e-08
peripheral O 0 6.979465251788497e-05
blood O 0 4.3798398110084236e-05
. O 0 1.7465607697886298e-06

In O 0 3.455158321230556e-06
2 O 0 1.1559425274754176e-06
patients O 0 3.9274686969292816e-07
without O 0 1.6448698403337403e-08
a O 0 5.8874171315892454e-08
detectable O 0 8.38091000332497e-06
mutation O 0 1.1359480822648038e-06
in O 0 8.385680416722607e-08
peripheral O 0 6.134856812423095e-05
blood O 0 1.2363060704956297e-05
, O 0 2.8692049625078653e-08
mosaicism O 0 9.147835953626782e-06
was O 0 1.362531861559546e-06
suggested O 0 3.946741244931218e-08
because O 0 2.9200231121961906e-09
1 O 0 3.0044797760808706e-09
of O 0 8.25396362369446e-10
the O 0 5.140897840760772e-08
patients O 0 1.0187312682319316e-06
showed O 0 0.0015445372555404902
multifocal O 1 0.9999960660934448
tumors B-Disease 1 1.0
and O 0 1.0719046628082651e-07
the O 0 8.528037831467827e-09
other O 0 2.6013957654669184e-09
later O 0 9.444507753642029e-08
developed O 0 6.216921519808238e-07
bilateral B-Disease 0 1.5513777498199488e-06
retinoblastoma I-Disease 0 0.0005945286247879267
. O 0 3.1697375106887193e-06

In O 0 1.6762747918619425e-06
conclusion O 0 2.912308332270186e-07
, O 0 1.939469029821339e-08
our O 0 8.884483371218721e-09
results O 0 2.8213081648686966e-08
emphasize O 0 1.9124110295365426e-08
that O 0 1.0808322015165572e-09
the O 0 3.7425178511796275e-09
manifestation O 0 6.691770693123544e-08
and O 0 4.139540710212941e-09
transmissibility O 0 2.219727122110271e-07
of O 0 2.48154030657588e-09
retinoblastoma B-Disease 0 5.181900633033365e-07
depend O 0 5.230255339938594e-09
on O 0 3.6190332508567735e-08
the O 0 2.9204909601787676e-09
nature O 0 2.188523584578661e-09
of O 0 1.6869838859179254e-10
the O 0 1.0508846015611084e-09
first O 0 4.835488898180529e-09
mutation O 0 4.251966956303477e-08
, O 0 7.209665087160033e-10
its O 0 1.971025120894865e-09
time O 0 3.090937505945135e-09
in O 0 1.0938480121680527e-09
development O 0 4.1511297177443396e-10
, O 0 3.4357014455643764e-10
and O 0 3.848243390613959e-10
the O 0 1.1323352255843133e-09
number O 0 5.221192367343974e-10
and O 0 2.686368627546898e-10
types O 0 8.761564807002742e-10
of O 0 3.820423422062902e-10
cells O 0 1.6844680317262828e-08
that O 0 2.240251983920416e-09
are O 0 1.898048607174019e-09
affected O 0 3.7767534877275466e-08
. O 0 1.464027210573704e-08
. O 0 1.3351575489650713e-07

Hereditary B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9996861219406128
of I-Disease 0 8.09063678275379e-08
the I-Disease 0 5.35365707321489e-08
fifth I-Disease 0 1.8913898713890376e-07
component I-Disease 0 7.167852089651205e-08
of I-Disease 0 3.061950470950592e-09
complement I-Disease 0 9.828154645674658e-08
in O 0 7.365105147982831e-08
man O 0 2.3719096589047695e-06
. O 0 7.019392000984226e-07

I O 0 0.0008474923088215292
. O 0 4.531451850198209e-05

Clinical O 0 0.00011824528337456286
, O 0 4.6893970306882693e-07
immunochemical O 0 1.582218101248145e-05
, O 0 3.5011435528531365e-08
and O 0 2.9867294415453216e-08
family O 0 3.01655205703355e-07
studies O 0 3.10049898644138e-07
. O 0 5.640697509079473e-07

The O 0 8.201413947972469e-07
first O 0 1.029606622182655e-07
recognized O 0 4.296814992699183e-08
human O 0 2.6388930152165813e-08
kindred O 0 3.885318619722966e-06
with O 0 1.443615246898844e-06
hereditary B-Disease 1 0.9999985694885254
deficiency I-Disease 0 0.12613144516944885
of I-Disease 0 3.412453208895272e-09
the I-Disease 0 1.1234509322832764e-08
fifth I-Disease 0 9.822363722378213e-08
component I-Disease 0 2.5194809794015782e-08
of I-Disease 0 3.6058436236885427e-09
complement I-Disease 0 2.174030271362426e-07
( O 0 1.675841900805608e-07
C5 O 0 1.902888106997125e-05
) O 0 2.1943932893009332e-08
is O 0 1.3726949354975204e-08
described O 0 5.173397994440165e-07
. O 0 4.858752049585746e-07

The O 0 2.5674717107904144e-06
proband O 0 2.9181508580222726e-05
, O 0 3.642391277480783e-08
a O 0 1.4763092082148432e-08
20 O 0 3.851243235430957e-08
- O 0 5.970237566543801e-07
year O 0 6.620233250487217e-08
- O 0 1.760192049005127e-06
old O 0 5.652668733091559e-07
black O 0 2.723414240790589e-07
female O 0 2.468465822857979e-07
with O 0 1.5246656403178349e-05
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.018123235553503036
age O 0 3.62660421160399e-06
11 O 0 1.2666600923694205e-07
, O 0 1.5794862306961477e-08
lacked O 0 4.253851329849567e-06
serum O 0 2.7712247174349613e-05
hemolytic O 0 0.0003489939554128796
complement O 0 1.00584668416559e-06
activity O 0 1.1595043361012358e-06
, O 0 1.599278753872113e-08
even O 0 3.546199422999052e-08
during O 0 6.638757099608483e-07
remission O 0 1.2337421139818616e-05
. O 0 7.166771638367209e-07

C5 O 0 0.0047683920711278915
was O 0 6.1396463024721015e-06
undetectable O 0 4.396695203467971e-06
in O 0 5.6686051408405547e-08
her O 0 5.234859301594952e-08
serum O 0 5.804260467812128e-07
by O 0 8.557840658340865e-09
both O 0 2.6663455443554085e-08
immunodiffusion O 0 2.1823068891535513e-05
and O 0 5.624459049613506e-07
hemolytic O 0 0.02290169708430767
assays O 0 0.00043551885755732656
. O 0 4.026298938697437e-06

Other O 0 2.8900549864374625e-07
complement O 0 5.717315616493579e-07
components O 0 1.6871729258127743e-07
were O 0 1.2217156175609034e-08
normal O 0 8.628337155869303e-08
during O 0 2.309370756847784e-07
remission O 0 4.794120513906819e-07
of O 0 2.0215965790271184e-08
lupus O 0 9.285486885346472e-05
, O 0 2.288808254036212e-08
but O 0 4.226166439025292e-08
C1 O 0 6.339289029710926e-06
, O 0 1.8502166909684092e-08
C4 O 0 7.118440407793969e-06
, O 0 3.100894474528104e-08
C2 O 0 3.3492158308945363e-06
, O 0 1.530899318424872e-08
and O 0 5.920196599618066e-08
C3 O 0 6.95756243658252e-05
levels O 0 3.775684263018775e-06
fell O 0 0.0004965355037711561
during O 0 3.9892629501991905e-06
exacerbations O 0 0.00048346060793846846
. O 0 4.3195454964006785e-06

A O 0 9.648951163399033e-06
younger O 0 2.9495236049115192e-06
half O 0 2.3958710926308413e-07
- O 0 1.1840360457426868e-05
sister O 0 6.6764991970558185e-06
, O 0 1.1581783532221834e-08
who O 0 1.2823998751798626e-08
had O 0 5.542522885093604e-08
no O 0 2.1970693708794897e-08
underlying O 0 4.6773607209615875e-06
disease O 0 3.340329203638248e-05
, O 0 5.410906833702711e-09
was O 0 8.543929652660154e-07
also O 0 1.1154015489012181e-08
found O 0 1.6681426018294587e-08
to O 0 3.387804881072043e-08
lack O 0 7.605516429975978e-07
immunochemically O 0 0.0005730707198381424
detectable O 0 0.0008935877704061568
C5 O 0 0.00039197414298541844
. O 0 1.3666025324710063e-06

By O 0 1.405990042258054e-05
hemolytic O 0 0.4465786814689636
assay O 0 0.0007711958605796099
, O 0 5.304623869051284e-07
she O 0 1.3932171327724063e-07
exhibited O 0 4.520255458828615e-07
1 O 0 2.2215054684693314e-08
- O 0 1.776064664227306e-07
2 O 0 1.1134714483773678e-08
% O 0 1.0541225670124277e-09
of O 0 4.4509051999597204e-10
the O 0 6.1689804375930635e-09
normal O 0 3.1555057944387954e-07
serum O 0 1.916893779707607e-06
C5 O 0 2.559131417001481e-06
level O 0 4.4598408521778765e-08
and O 0 7.499172838265622e-09
normal O 0 6.674956409824517e-08
concentrations O 0 4.8059487056661965e-08
of O 0 1.090735501918516e-09
other O 0 1.770999014105712e-09
complement O 0 8.757396585679089e-08
components O 0 8.205012136386358e-07
. O 0 4.665002393267059e-07

C5 O 0 0.0007807672373019159
levels O 0 1.5062358897921513e-06
of O 0 8.169266152435739e-09
other O 0 2.1453956389194673e-09
family O 0 1.0412303907969545e-08
members O 0 1.1478417105692529e-09
were O 0 2.472771098993576e-09
either O 0 3.092364364576383e-09
normal O 0 6.433142374362433e-08
or O 0 1.90167348534942e-08
approximately O 0 1.2974669338916556e-08
half O 0 3.819858918063801e-08
- O 0 1.4070252518649795e-06
normal O 0 3.0031125675122894e-07
, O 0 5.0079278501868885e-09
consistent O 0 7.69872983141795e-08
with O 0 3.862719566427586e-08
autosomal O 0 0.0009985603392124176
codominant O 0 1.341436927759787e-05
inheritance O 0 1.5299687561309838e-07
of O 0 5.593698393369095e-09
the O 0 9.118364374671728e-08
gene O 0 0.00011082242417614907
determining O 0 0.0001164206987596117
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 5.080373284727102e-06

Normal O 0 0.0003728327574208379
hemolytic O 1 0.9343838095664978
titers O 0 0.0015878946287557483
were O 0 1.2203297501400812e-06
restored O 0 1.971298388525611e-06
to O 0 3.0366983594376507e-08
both O 0 8.695413811210528e-08
homozygous O 0 0.001760626444593072
C5 B-Disease 1 1.0
- I-Disease 1 0.9999985694885254
deficient I-Disease 1 1.0
( O 0 1.2728160072583705e-05
C5D B-Disease 1 1.0
) O 0 1.7577970368165552e-07
sera O 0 6.340561640172382e-07
by O 0 3.1942408718066417e-09
addition O 0 2.154359357575686e-09
of O 0 1.5422582100299564e-09
highly O 0 8.193488554297801e-08
purified O 0 1.3165821428628988e-06
human O 0 4.374773254767206e-07
C5 O 0 8.779067866271362e-05
. O 0 1.2690834410022944e-06

In O 0 2.703792461034027e-06
specific O 0 9.36073490720446e-07
C5 O 0 6.423091690521687e-05
titrations O 0 1.759861333994195e-05
, O 0 2.521634634433667e-08
however O 0 1.1696132062866127e-08
, O 0 1.6869943220143568e-09
it O 0 2.4801112274985826e-09
was O 0 3.060293707335404e-08
noted O 0 1.8457816386430181e-09
that O 0 3.1353383778132127e-10
when O 0 1.4127717884448998e-09
limited O 0 2.1255028848088386e-09
amounts O 0 3.0059930100634347e-09
of O 0 2.4283359767451884e-09
C5 O 0 1.481538333791832e-06
were O 0 9.920605670288296e-09
assayed O 0 1.633269164358353e-07
in O 0 3.7171492550669427e-09
the O 0 4.433453604235638e-09
presence O 0 1.3418329558589903e-08
of O 0 3.2848617159686455e-09
low O 0 6.019829470460536e-07
dilutions O 0 2.7333851448929636e-06
of O 0 1.104052227418606e-08
either O 0 3.641023340605898e-07
C5D B-Disease 1 0.9999996423721313
serum O 0 1.4550844753102865e-05
, O 0 1.181880016076775e-08
curving O 0 2.7741799613067997e-07
rather O 0 1.4052074170933793e-08
than O 0 3.939969683841582e-09
linear O 0 4.56732749398725e-08
dose O 0 5.077362175143207e-07
- O 0 3.362807206030993e-07
response O 0 8.567431564188155e-08
plots O 0 1.312546231702072e-07
were O 0 3.423942729341434e-08
consistently O 0 7.138299906728207e-08
obtained O 0 7.178424965559316e-09
, O 0 1.4651410085164684e-09
suggesting O 0 3.407076576422696e-08
some O 0 1.1206986449963097e-08
inhibitory O 0 1.6759838672442129e-06
effect O 0 1.3103116316415253e-06
. O 0 5.250799404166173e-07

Further O 0 3.077895598835312e-06
studies O 0 6.169865400806884e-07
suggested O 0 1.7200787283400132e-07
that O 0 1.7567053589573334e-08
low O 0 1.2778239124600077e-06
dilutions O 0 2.2259890101850033e-05
of O 0 1.948528023376639e-07
C5D B-Disease 1 0.9999998807907104
serum O 0 1.3523306733986828e-05
contain O 0 1.7072561320219393e-07
a O 0 4.6061970238042704e-08
factor O 0 4.7723702323310135e-08
( O 0 8.058599121341103e-09
or O 0 1.3242210883390726e-08
factors O 0 9.416641688630989e-09
) O 0 2.8302320487227917e-09
interfering O 0 4.447650781003176e-08
at O 0 2.5523178237563116e-08
some O 0 1.4677674631258242e-09
step O 0 1.6691865667439743e-08
in O 0 1.337473864992944e-08
the O 0 7.250255862345512e-08
hemolytic O 0 0.00012405146844685078
assay O 0 3.2875698252610164e-06
of O 0 1.994423293183445e-08
C5 O 0 9.12790528673213e-06
, O 0 4.531142572261615e-09
rather O 0 3.6279124149274367e-09
than O 0 2.951621613789257e-09
a O 0 2.3991535869072322e-08
true O 0 2.596955823719327e-07
C5 O 0 3.114762876066379e-05
inhibitor O 0 3.882318196701817e-06
or O 0 3.7452264223247766e-07
inactivator O 0 3.397485488676466e-05
. O 0 1.348989599136985e-06

Of O 0 8.661114065944275e-07
clinical O 0 4.622105734597426e-06
interest O 0 2.102717928664788e-07
are O 0 9.211093221495048e-09
( O 0 1.1616496209398974e-08
a O 0 1.8168336168855603e-08
) O 0 5.4479283306818616e-09
the O 0 5.2315725085350095e-09
documentation O 0 5.1140620627165845e-08
of O 0 4.701276878904537e-08
membranous O 1 0.9451147317886353
glomerulonephritis B-Disease 1 1.0
, O 0 6.392825162038207e-05
vasculitis B-Disease 1 1.0
, O 0 5.339326435205294e-06
and O 0 0.0018364315619692206
arthritis B-Disease 1 1.0
in O 0 2.586343157418014e-07
an O 0 2.0080809903788577e-08
individual O 0 1.1699770041673219e-08
lacking O 0 1.3378869425650919e-06
C5 O 0 6.639392086071894e-05
( O 0 2.0861230964897004e-08
and O 0 3.4599563214499085e-09
its O 0 2.1563831609228146e-08
biologic O 0 7.725750492681982e-07
functions O 0 1.5054181901064112e-08
) O 0 3.3968423629460176e-09
, O 0 1.2099298229983901e-09
and O 0 4.909023854082761e-09
( O 0 1.2639276292247814e-08
b O 0 3.560126415891318e-08
) O 0 1.6497265775683445e-09
a O 0 5.221981957959088e-09
remarkable O 0 4.145595156046511e-08
propensity O 0 1.2777167057720362e-06
to O 0 4.830927991861245e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 4.661347077217215e-07
the O 0 9.430431902046621e-08
proband O 0 3.6429444207897177e-06
, O 0 3.3640366048359738e-09
even O 0 5.649788192840788e-09
during O 0 2.287176137372171e-08
periods O 0 7.60369758268098e-08
of O 0 4.348407411924882e-09
low O 0 9.806910384213552e-06
- O 0 3.5652683436637744e-06
dose O 0 2.417667701593018e-06
or O 0 3.9583582633895276e-08
alternate O 0 1.1219631801395735e-07
- O 0 1.2647182074942975e-06
day O 0 4.820532240046305e-07
corticosteroid O 0 0.00012269133003428578
therapy O 0 1.98461002582917e-05
. O 0 6.395979426088161e-07

Other O 0 3.6457802821132645e-07
observations O 0 1.256605514754483e-06
indicate O 0 3.185566868069145e-07
that O 0 1.0437237740745786e-08
the O 0 4.644281048626908e-08
C5D B-Disease 1 0.9999967813491821
state O 0 4.149882926185455e-08
is O 0 3.8073970642926724e-09
compatible O 0 4.37289564558796e-08
with O 0 2.4989910141215432e-09
normal O 0 7.651605926639604e-08
coagulation O 0 1.377952543180072e-07
function O 0 5.19300868973005e-09
and O 0 8.160199738149743e-10
the O 0 1.6532891722320642e-09
capacity O 0 7.066351948026295e-09
to O 0 8.372763815600592e-09
mount O 0 5.941338372394966e-07
a O 0 4.7523047896902426e-07
neutrophilic O 0 0.00072858901694417
leukocytosis O 0 0.0010666080052033067
during O 0 5.367159974412061e-05
pyogenic B-Disease 0 0.497173011302948
infection I-Disease 1 0.7996846437454224
. O 0 5.053440190749825e-07
. O 0 1.2715705679511302e-06

Susceptibility O 1 0.8539624214172363
to O 0 0.2609720826148987
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9238765835762024
twins O 0 0.006973443552851677
: O 0 8.437690546259091e-09
the O 0 2.414701549824372e-09
role O 0 3.0518751970021185e-09
of O 0 6.01606986450065e-10
genes O 0 3.120087299635088e-08
, O 0 7.3546577716854244e-09
HLA O 0 9.028629506246943e-07
, O 0 1.5074574921669637e-09
and O 0 2.3089505862827764e-09
the O 0 4.2815166523269e-08
environment O 0 1.1725683179975022e-06
. O 0 5.26823441759916e-07

OBJECTIVE O 0 4.566039933706634e-06
To O 0 9.663020250627596e-08
determine O 0 1.852038522542898e-08
the O 0 7.2824484220745944e-09
relative O 0 2.6907917671792347e-08
effects O 0 5.401917135827716e-08
of O 0 1.4611251097917943e-09
genetic O 0 6.1356445257843e-08
and O 0 6.563777077417399e-09
environmental O 0 2.0854150406535155e-08
factors O 0 1.8049414407528275e-08
in O 0 5.5553716293843536e-08
susceptibility O 0 0.0001931260630954057
to O 0 0.2664281129837036
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0018341385293751955
AS B-Disease 1 0.9999880790710449
) O 0 3.7644701933459146e-07
. O 0 4.168868485976418e-07

METHODS O 0 5.8111494581680745e-05
Twins O 0 7.612316403537989e-05
with O 0 1.1901871488362303e-07
AS B-Disease 1 0.7020005583763123
were O 0 1.839407204329291e-08
identified O 0 9.912643150755684e-09
from O 0 2.4176787238872066e-09
the O 0 1.0394068716834681e-08
Royal O 0 1.1135839486087207e-06
National O 0 1.3472524074131798e-07
Hospital O 0 4.959090438205749e-05
for O 0 1.0926474942607456e-06
Rheumatic B-Disease 1 0.9999992847442627
Diseases I-Disease 1 0.5744227766990662
database O 0 2.7366730137146078e-05
. O 0 2.9484999686246738e-06

Clinical O 0 0.00012147711095167324
and O 0 6.033289423612587e-07
radiographic O 0 5.0993156037293375e-05
examinations O 0 4.191985681245569e-06
were O 0 9.079975171744081e-08
performed O 0 9.178371840334876e-08
to O 0 1.0963195684610128e-08
establish O 0 3.227146692097449e-07
diagnoses O 0 5.1563914894359186e-05
, O 0 4.83067026380013e-08
and O 0 2.6324717055103974e-06
disease O 0 0.00452436413615942
severity O 0 0.006430073641240597
was O 0 0.00011249070666963235
assessed O 0 1.628764465522181e-07
using O 0 2.2707757452167243e-08
a O 0 3.325048680835607e-08
combination O 0 1.575446191282026e-07
of O 0 1.4419840432822184e-08
validated O 0 1.6270424794129212e-06
scoring O 0 6.935761120985262e-07
systems O 0 5.842260361532681e-05
. O 0 1.1577717486943584e-06

HLA O 0 0.007281187456101179
typing O 0 0.00023664992477279156
for O 0 1.045164026436396e-06
HLA O 0 0.0001725883485050872
- O 0 9.21244645724073e-06
B27 O 0 1.1655927664833143e-05
, O 0 1.198067565155725e-07
HLA O 0 5.650810635415837e-06
- O 0 5.377101501835568e-07
B60 O 0 9.231048352376092e-07
, O 0 8.243867810620031e-09
and O 0 4.3063650423391664e-08
HLA O 0 6.394989759428427e-05
- O 0 4.174675632384606e-05
DR1 O 1 0.7726428508758545
was O 0 2.3034240257402416e-06
performed O 0 4.1082532931113747e-08
by O 0 4.800174480124042e-09
polymerase O 0 3.426667944950168e-07
chain O 0 1.1475924566184403e-06
reaction O 0 8.917660920815251e-08
with O 0 3.29847305025055e-09
sequence O 0 3.3784676389814194e-08
- O 0 1.560923124088731e-07
specific O 0 2.3663233150728047e-08
primers O 0 9.610504321244662e-07
, O 0 4.786113727561769e-09
and O 0 5.327922547593289e-09
zygosity O 0 2.843097036020481e-06
was O 0 5.042002726440842e-07
assessed O 0 1.990896976167278e-07
using O 0 5.641488201035827e-07
microsatellite O 0 5.149777280166745e-05
markers O 0 2.523884359106887e-05
. O 0 1.4007807749294443e-06

Genetic O 0 5.18732049386017e-05
and O 0 2.8028071596963855e-07
environmental O 0 1.6647678080516926e-07
variance O 0 1.0218942492201677e-07
components O 0 2.143031281320873e-07
were O 0 1.992932752159504e-08
assessed O 0 1.2302036722644516e-08
with O 0 3.078710841819543e-09
the O 0 1.9973356302216416e-08
program O 0 5.922319701312517e-08
Mx O 0 8.792507628641033e-07
, O 0 2.293277345799538e-09
using O 0 4.708893719396201e-09
data O 0 2.1372976277689304e-08
from O 0 4.059800051692264e-09
this O 0 1.0654280790944881e-09
and O 0 1.5304139067140454e-09
previous O 0 2.9559499736819816e-08
studies O 0 5.574442241140787e-09
of O 0 1.4720906715837145e-09
twins O 0 7.544078357568651e-07
with O 0 3.4248703428829685e-08
AS B-Disease 1 0.9983482360839844
. O 0 1.4641160532846698e-06

RESULTS O 0 3.31567571265623e-05
Six O 0 4.244253659635433e-07
of O 0 6.141955566363322e-08
8 O 0 1.808731099117722e-06
monozygotic O 0 8.423040708294138e-05
( O 0 3.4942033835250186e-06
MZ O 1 0.9901592135429382
) O 0 3.4570692264423997e-07
twin O 0 0.0007092873565852642
pairs O 0 1.1646022812783485e-06
were O 0 7.019552299425413e-07
disease O 0 7.039354841253953e-06
concordant O 0 2.6324164537072647e-06
, O 0 1.594816012584488e-08
compared O 0 5.888034593226621e-08
with O 0 6.300354460364588e-09
4 O 0 3.215011901147591e-08
of O 0 2.762097661701546e-09
15 O 0 5.5115187080900796e-08
B27 O 0 1.514691575721372e-06
- O 0 4.323258963268017e-06
positive O 0 1.1087454367952887e-06
dizygotic O 0 2.4612576453364454e-05
( O 0 1.9128857786654407e-07
DZ O 0 0.00021952364477328956
) O 0 6.765590399027133e-08
twin O 0 8.711715054232627e-06
pairs O 0 1.24119665656508e-07
( O 0 2.1434907182538154e-08
27 O 0 4.595464631051982e-08
% O 0 2.118452524513259e-09
) O 0 1.580073072382504e-09
and O 0 2.353269357158183e-09
4 O 0 1.3673903787037034e-08
of O 0 3.3068385807411005e-09
32 O 0 2.801364473725698e-07
DZ O 0 0.008186531253159046
twin O 0 6.844949530204758e-05
pairs O 0 1.2637956103844772e-07
overall O 0 2.6093613314515096e-07
( O 0 1.3153501399187917e-08
12 O 0 1.0451082665952072e-08
. O 0 2.1811850103858887e-09
5 O 0 2.9064610274076585e-08
% O 0 1.0845933040570799e-08
) O 0 2.6481504988851157e-08
. O 0 1.330850523117988e-07

Nonsignificant O 0 0.00024901851429603994
increases O 0 3.5180369195586536e-06
in O 0 4.783661466944977e-08
similarity O 0 4.2323780036213066e-08
with O 0 4.758434091201025e-09
regard O 0 8.973279008728241e-09
to O 0 4.014578536271074e-08
age O 0 3.3499586038487905e-07
at O 0 1.556458846607711e-05
disease O 0 0.002625131281092763
onset O 0 0.0032941862009465694
and O 0 4.303901590674286e-08
all O 0 7.020885539610333e-10
of O 0 1.3785295127632935e-09
the O 0 1.2414955108397407e-06
disease O 0 0.0021399271208792925
severity O 0 3.329395622131415e-05
scores O 0 5.925437562837033e-07
assessed O 0 1.9916755888971238e-07
were O 0 5.908408340360438e-08
noted O 0 1.0467704214534024e-07
in O 0 1.2502199524533353e-06
disease O 0 0.24356809258460999
- O 0 0.006232236046344042
concordant O 0 0.21415911614894867
MZ O 1 0.999995231628418
twins O 0 0.000370020599802956
compared O 0 1.2264384849913768e-06
with O 0 2.262048468537614e-07
concordant O 0 0.0026846216060221195
DZ O 1 0.9999076128005981
twins O 0 0.003008433384820819
. O 0 3.437194436628488e-06

HLA O 0 0.02478591725230217
- O 0 4.984123006579466e-05
B27 O 0 2.0616420442820527e-05
and O 0 1.6841988781379769e-07
B60 O 0 9.345214948552893e-07
were O 0 2.078089167412145e-08
associated O 0 1.8389020084441654e-08
with O 0 2.7255582235596876e-09
the O 0 2.017229547846e-07
disease O 0 1.4837194612482563e-05
in O 0 2.8726546474899806e-08
probands O 0 7.547837867605267e-06
, O 0 4.193276392783218e-09
and O 0 1.7915676719937323e-09
the O 0 4.724493241070604e-09
rate O 0 9.65777530836931e-07
of O 0 6.088393789127622e-09
disease O 0 1.8266621282236883e-06
concordance O 0 5.743875703956292e-07
was O 0 3.786216780099494e-07
significantly O 0 3.904698360202019e-07
increased O 0 1.3374538809785008e-07
among O 0 1.6989556428370634e-08
DZ O 0 0.0028346313629299402
twin O 0 6.836859392933547e-05
pairs O 0 5.21754479620995e-08
in O 0 1.6641321209931448e-08
which O 0 1.154898132682547e-08
the O 0 3.7034361355381407e-08
co O 0 1.158765940090234e-06
- O 0 4.0204204196925275e-06
twin O 0 6.358673999784514e-05
was O 0 1.5308502554489678e-07
positive O 0 5.86818682535295e-09
for O 0 2.4403570275666198e-09
both O 0 1.1259523091666779e-08
B27 O 0 2.785021479212446e-06
and O 0 1.987137352443824e-07
DR1 O 0 0.34278836846351624
. O 0 4.566788902593544e-06

Additive O 0 5.527782195713371e-05
genetic O 0 6.7738683355855756e-06
effects O 0 1.2177905546195689e-06
were O 0 1.1817830269933438e-08
estimated O 0 3.10562819905158e-09
to O 0 3.0108477933055156e-09
contribute O 0 5.103038880349686e-09
97 O 0 1.5191451652185606e-08
% O 0 5.656071722093259e-10
of O 0 1.5740803105401824e-10
the O 0 5.358200549920866e-09
population O 0 1.234455737630924e-08
variance O 0 9.671300205127409e-08
. O 0 1.58948580519791e-07

CONCLUSION O 0 9.13495932763908e-06
Susceptibility O 0 2.5686213120934553e-05
to O 0 2.8180255640108953e-07
AS B-Disease 1 0.56861412525177
is O 0 6.492567816707151e-09
largely O 0 1.794126269771823e-08
genetically O 0 6.302339983221827e-08
determined O 0 4.9423316994534616e-08
, O 0 1.7598601464996477e-09
and O 0 1.4349266219682022e-09
the O 0 3.731241982052325e-09
environmental O 0 1.1173988845314398e-08
trigger O 0 2.2469303075922653e-06
for O 0 4.149231624950289e-09
the O 0 2.0334579176051193e-07
disease O 0 3.314907371532172e-05
is O 0 2.2992086456952165e-08
probably O 0 3.294633756922849e-07
ubiquitous O 0 3.909664428647375e-06
. O 0 4.507354276483966e-07

HLA O 0 0.0033290849532932043
- O 0 1.889582199510187e-05
B27 O 0 4.557504325930495e-06
accounts O 0 1.0970311592473081e-07
for O 0 2.828451028946688e-09
a O 0 3.5155018895949297e-09
minority O 0 3.3426228451816087e-09
of O 0 4.2924688803402944e-10
the O 0 3.6902625399903854e-09
overall O 0 2.0231017572314158e-07
genetic O 0 7.103786856532679e-07
susceptibility O 0 2.60228875959001e-06
to O 0 3.0330059530569997e-07
AS B-Disease 1 0.9997681975364685
. O 0 1.3921176105213817e-06

Cell O 0 0.0007837165612727404
cycle O 0 0.00015226514369715005
- O 0 1.0212711458734702e-05
dependent O 0 7.010788749539643e-07
colocalization O 0 2.589882569736801e-06
of O 0 2.4822847777272727e-08
BARD1 O 0 1.22990413728985e-05
and O 0 1.0941829486910137e-07
BRCA1 O 0 3.0524465728376526e-06
proteins O 0 1.19861169878277e-07
in O 0 3.999842590474145e-08
discrete O 0 8.710018164492794e-07
nuclear O 0 4.080930011696182e-06
domains O 0 4.718890068033943e-06
. O 0 8.38109713185986e-07

Germ O 0 0.022868894040584564
- O 0 0.007534305099397898
line O 0 3.609484701883048e-05
mutations O 0 3.2516929877601797e-06
of O 0 9.742985973559826e-09
the O 0 4.3534551963375634e-08
BRCA1 O 0 7.843223102099728e-06
gene O 0 1.2087931509086047e-06
predispose O 0 7.172295681812102e-07
women O 0 2.2596157833731922e-08
to O 0 1.6752434106592773e-08
early O 0 2.5501325580989942e-05
- O 1 0.7502849102020264
onset O 1 0.9999992847442627
breast B-Disease 1 1.0
and I-Disease 1 0.9999274015426636
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 8.747630886318802e-08
compromising O 0 1.7883680811792146e-06
the O 0 2.397593767966555e-08
genes O 0 3.5273859566586907e-07
presumptive O 0 5.421867626864696e-06
function O 0 5.983815043464347e-08
as O 0 1.5761278504555776e-08
a O 0 1.7543020192078984e-07
tumor B-Disease 0 5.626587153528817e-05
suppressor O 0 0.00017056950309779495
. O 0 1.4141656947685988e-06

Although O 0 2.073514451694791e-06
the O 0 1.400250226879507e-07
biochemical O 0 1.3308901998243527e-06
properties O 0 1.7548575215187157e-07
of O 0 1.4688100513637892e-08
BRCA1 O 0 3.495123337415862e-06
polypeptides O 0 4.712067607215431e-07
are O 0 4.173432266441068e-09
not O 0 4.109732554269385e-09
understood O 0 1.0441120856796715e-08
, O 0 7.569786464323158e-10
their O 0 3.4658214076443983e-09
expression O 0 3.6444134821067564e-08
pattern O 0 3.344627828028024e-07
and O 0 7.4543935468796e-09
subcellular O 0 4.1159873376273026e-07
localization O 0 3.8054824358368933e-07
suggest O 0 3.84462310876188e-08
a O 0 5.750889098266043e-09
role O 0 8.910176596543806e-09
in O 0 2.9658613343030993e-08
cell O 0 1.9690627595991828e-05
- O 0 3.405555980862118e-05
cycle O 0 1.556587994855363e-05
regulation O 0 8.642798093205784e-06
. O 0 6.554484457410581e-07

When O 0 4.626475856639445e-06
resting O 0 3.8770940591348335e-06
cells O 0 5.580045012720802e-07
are O 0 8.317942779001442e-09
induced O 0 2.6603873948261025e-07
to O 0 1.1501016139447984e-08
proliferate O 0 5.136600407240621e-07
, O 0 2.660085929306888e-09
the O 0 4.454125956954158e-09
steady O 0 5.5450965419368e-07
- O 0 7.006939028997294e-08
state O 0 2.7230433463643067e-09
levels O 0 5.192840379919517e-09
of O 0 9.451581739483572e-10
BRCA1 O 0 1.3134628318312025e-07
increase O 0 5.832657468118896e-09
in O 0 1.2624049361420475e-08
late O 0 5.308254003466573e-06
G1 O 0 9.648485956859076e-07
and O 0 3.484008193055388e-09
reach O 0 5.580761630596953e-09
a O 0 1.0936149763551839e-08
maximum O 0 5.5345680038954015e-08
during O 0 3.226408011869353e-07
S O 0 1.9388111468288116e-05
phase O 0 2.425660568405874e-06
. O 0 7.50376727864932e-07

Moreover O 0 9.025151484820526e-06
, O 0 1.2897471890482848e-07
in O 0 5.097691158084672e-08
S O 0 1.8443874978402164e-06
phase O 0 2.3660258818836155e-07
cells O 0 7.195466196208145e-07
, O 0 4.355639759978658e-08
BRCA1 O 0 3.174508037773194e-06
polypeptides O 0 9.645947329772753e-07
are O 0 1.1486503304070084e-08
hyperphosphorylated O 0 2.978116526719532e-06
and O 0 6.292958687481587e-08
accumulate O 0 1.3544115518016042e-06
into O 0 4.9716692984702604e-08
discrete O 0 6.957756113479263e-07
subnuclear O 0 2.1901587388128974e-05
foci O 0 2.1966014173813164e-05
termed O 0 8.753555448492989e-06
" O 0 5.003700493944052e-07
BRCA1 O 0 3.543611819623038e-05
nuclear O 0 7.645530786248855e-06
dots O 0 8.293745486298576e-05
. O 0 2.7505861908139195e-06

" O 0 1.1450953024905175e-05
BRCA1 O 0 0.00017149743507616222
associates O 0 6.38505480310414e-06
in O 0 9.39658661991416e-08
vivo O 0 1.2262046311661834e-06
with O 0 2.142558841455866e-08
a O 0 2.3218211708808667e-07
structurally O 0 6.825153832323849e-05
related O 0 1.2609426676135627e-06
protein O 0 5.121835783938877e-06
termed O 0 4.748344872496091e-05
BARD1 O 0 0.001272472902201116
. O 0 7.314019512705272e-06

Here O 0 1.5892006786089041e-06
we O 0 4.345308823872074e-08
show O 0 8.840975596058342e-08
that O 0 2.756629147171452e-09
the O 0 8.678542329221273e-09
steady O 0 3.2155034546121897e-07
- O 0 8.998975431495637e-08
state O 0 5.3683173462104605e-09
levels O 0 1.2860104092737856e-08
of O 0 6.528451668152968e-10
BARD1 O 0 7.774916639391449e-07
, O 0 1.5058683189295152e-09
unlike O 0 2.6608066860944746e-09
those O 0 3.767411105304319e-10
of O 0 6.498634963492123e-10
BRCA1 O 0 4.650193830002536e-07
, O 0 2.7807787184030985e-09
remain O 0 8.107873483709227e-09
relatively O 0 2.1125785565345723e-08
constant O 0 4.791724705910383e-08
during O 0 3.7502266536648676e-07
cell O 0 5.820222941110842e-05
cycle O 0 4.596610597218387e-05
progression O 0 2.5929868570528924e-05
. O 0 1.017652607515629e-06

However O 0 5.084391432319535e-06
, O 0 2.4065792558758403e-07
immunostaining O 0 7.95870892034145e-06
revealed O 0 1.4333676290334552e-06
that O 0 2.178234126404277e-08
BARD1 O 0 5.981498361506965e-06
resides O 0 2.9969356774017797e-07
within O 0 4.263620567712678e-08
BRCA1 O 0 3.019855512320646e-06
nuclear O 0 3.801195305186411e-07
dots O 0 2.3676338969380595e-06
during O 0 5.00754822496674e-07
S O 0 1.3415524335869122e-06
phase O 0 1.8827186920589156e-08
of O 0 7.086351505591892e-10
the O 0 4.18939105628624e-09
cell O 0 6.041914843990526e-07
cycle O 0 4.791304490936454e-07
, O 0 9.71581259889831e-10
but O 0 4.6083278859576637e-10
not O 0 6.918935979705054e-10
during O 0 1.1590910453662673e-08
the O 0 3.718831464993855e-08
G1 O 0 5.576460807787953e-06
phase O 0 8.457591889055038e-07
. O 0 5.232562898527249e-07

Nevertheless O 0 2.789551581372507e-05
, O 0 3.958993488595297e-07
BARD1 O 0 1.1403025382605847e-05
polypeptides O 0 1.642837105464423e-06
are O 0 4.358230221157555e-09
found O 0 2.4155490940813706e-09
exclusively O 0 3.862710151736337e-09
in O 0 2.9485156538555657e-09
the O 0 3.907221657328819e-09
nuclear O 0 2.065018733787838e-08
fractions O 0 1.084587086808142e-08
of O 0 6.96741830896741e-10
both O 0 7.01714109041518e-09
G1 O 0 2.723518036873429e-06
- O 0 8.510410225426313e-07
and O 0 5.778369427389407e-08
S O 0 1.3219936590758152e-05
- O 0 2.37794779422984e-06
phase O 0 9.421520417163265e-07
cells O 0 2.233355871794629e-06
. O 0 4.737823928735452e-07

Therefore O 0 2.4101398139464436e-06
, O 0 8.284032304572975e-08
progression O 0 6.77213563449186e-07
to O 0 2.352404493422e-08
S O 0 1.5594262094964506e-06
phase O 0 6.032713883996621e-08
is O 0 1.919305603337307e-09
accompanied O 0 9.030746817018098e-09
by O 0 1.507644342702008e-09
the O 0 6.593276147270899e-09
aggregation O 0 1.1769898122793165e-07
of O 0 4.679526099948816e-09
nuclear O 0 5.885810878680786e-07
BARD1 O 0 1.2666648217418697e-05
polypeptides O 0 1.2312481203480274e-06
into O 0 2.79184035889557e-07
BRCA1 O 0 1.954798244696576e-05
nuclear O 0 4.091763912583701e-06
dots O 0 3.419190761633217e-05
. O 0 9.319085165770957e-07

This O 0 1.8760907778414548e-06
cell O 0 1.7298239981755614e-05
cycle O 0 2.1099398509250022e-05
- O 0 2.8203508009028155e-06
dependent O 0 2.7877987918145664e-07
colocalization O 0 1.7330019090877613e-06
of O 0 8.379856808460318e-09
BARD1 O 0 1.4235472008294892e-05
and O 0 4.379038642809974e-08
BRCA1 O 0 1.9737965430977056e-06
indicates O 0 3.954245997306316e-08
a O 0 1.0902160951786755e-08
role O 0 1.9241632287503307e-08
for O 0 8.997100842123018e-09
BARD1 O 0 4.229063961247448e-06
in O 0 3.1595649829796457e-07
BRCA1 O 0 0.00011576755787245929
- O 0 4.610113683156669e-05
mediated O 0 0.0001566211285535246
tumor B-Disease 0 0.0005521330749616027
suppression O 0 1.1308333341730759e-05
. O 0 1.228477799486427e-06

Ethnic O 0 2.9380246360233286e-06
differences O 0 2.568277523096185e-06
in O 0 2.470411004651396e-07
the O 0 4.367636279312137e-07
HFE O 0 0.0006663624080829322
codon O 0 0.00012230934225954115
282 O 0 2.5121780709014274e-05
( O 0 3.0590558708354365e-06
Cys O 0 0.2406889796257019
/ O 0 0.0006769396713934839
Tyr O 0 8.243722550105304e-05
) O 0 5.437248091766378e-07
polymorphism O 0 2.0623225282179192e-05
. O 0 8.47574369799986e-07

Recent O 0 6.698169727314962e-06
studies O 0 7.303399911506858e-07
have O 0 3.188447550428464e-08
shown O 0 4.6499008021783084e-07
that O 0 6.314941856544465e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0005824915715493262
HH B-Disease 1 0.9996706247329712
) O 0 3.5530646869119664e-08
is O 0 5.067287922599917e-09
likely O 0 2.150025579794601e-08
to O 0 6.14961948031123e-09
be O 0 3.544209592476477e-09
caused O 0 4.13050429415307e-08
by O 0 8.150419006369702e-09
homozygosity O 0 1.1680815532599809e-06
for O 0 5.328959495898289e-09
a O 0 1.0855354304339926e-07
Cys282Tyr O 0 7.701924005232286e-06
mutation O 0 1.003025545287528e-06
in O 0 2.0648061038741616e-08
the O 0 6.802078900136621e-08
HFE O 0 3.71876303688623e-05
gene O 0 2.4907444640120957e-06
located O 0 9.686397106634104e-07
4 O 0 5.44014255865477e-07
. O 0 2.95511114245528e-07

5 O 0 0.0001337869034614414
Mb O 0 0.0018304678378626704
telomeric O 0 0.0005449661985039711
to O 0 4.561974492389709e-06
HLA O 0 0.00024454062804579735
- O 0 7.085734068823513e-06
A O 0 2.170964990000357e-06
. O 0 1.1372943617971032e-06

Population O 0 9.931796967066475e-07
studies O 0 1.2482550459935737e-07
of O 0 6.30396090883778e-09
this O 0 9.803699185795267e-09
polymorphism O 0 4.5593637310048507e-07
are O 0 2.7918325429254764e-09
facilitated O 0 2.40013768859626e-08
by O 0 4.450686486023869e-09
the O 0 7.249050248958611e-09
fact O 0 2.1342290157377874e-09
that O 0 1.9541874785033997e-09
the O 0 2.1931755966875244e-08
Cys282Tyr O 0 5.172976671019569e-06
mutation O 0 8.99346503047127e-07
creates O 0 7.638162458079023e-08
a O 0 6.956641840361044e-08
Rsal O 0 1.0187422049057204e-05
restriction O 0 1.3534702247852692e-06
site O 0 1.2630234778043814e-06
. O 0 3.074212315823388e-07

We O 0 9.703298928798176e-07
have O 0 9.407346368561775e-08
studied O 0 8.369589465928584e-08
the O 0 3.7570313082824214e-08
codon O 0 5.964528554613935e-06
282 O 0 1.8337030951443012e-06
( O 0 9.967378673536587e-07
Cys O 0 0.11384784430265427
/ O 0 0.0002936596574727446
Tyr O 0 1.6824098565848544e-05
) O 0 5.322125673501432e-08
polymorphism O 0 6.369203333633777e-07
in O 0 1.5494149963046766e-08
different O 0 7.861688189336746e-09
ethnic O 0 1.0882653000976461e-08
groups O 0 3.459463115973449e-08
. O 0 1.989071307662016e-07

In O 0 1.5666140598113998e-06
agreement O 0 1.2664040127674525e-07
with O 0 1.0703904429476552e-08
previous O 0 8.67864500264659e-08
observations O 0 1.637192639236673e-07
the O 0 3.209289900496515e-08
Tyr O 0 2.6402733510622056e-06
allele O 0 1.0955232028209139e-06
appeared O 0 6.775016458959726e-07
to O 0 1.3121026931628421e-08
be O 0 2.28226815224275e-09
rare O 0 9.047107951687394e-09
or O 0 1.4416429827690536e-08
absent O 0 8.563429076957618e-08
in O 0 2.0023174229777396e-08
Asiatic O 0 3.828488388535334e-07
( O 0 6.58062493386069e-09
Indian O 0 2.5286122085077523e-09
, O 0 1.7392177698027922e-09
Chinese O 0 2.149048716759694e-09
) O 0 1.5458667235179746e-08
populations O 0 1.8651483912890399e-07
. O 0 2.553828153395443e-07

The O 0 1.993965042856871e-06
highest O 0 1.4009569895279128e-06
allele O 0 4.8022106966527645e-06
frequency O 0 4.840603651246056e-06
( O 0 3.629291356332942e-08
7 O 0 3.167275863802388e-08
. O 0 1.658927661907228e-09
5 O 0 7.535676971315297e-09
% O 0 1.246381553521303e-09
) O 0 1.633656987465315e-09
was O 0 4.9116298583840035e-08
found O 0 2.690622302736756e-08
in O 0 1.0708951236892972e-07
Swedes O 0 1.3157903595129028e-05
. O 0 1.1818437997135334e-06

Saamis O 0 0.0003211265429854393
( O 0 2.086625954689225e-06
2 O 0 2.4899009076762013e-07
% O 0 1.5119299590082846e-08
) O 0 7.962176695741618e-09
and O 0 9.475069617792542e-09
Mordvinians O 0 1.0861997452593641e-06
( O 0 1.7801982110654535e-08
1 O 0 6.810112473942809e-09
. O 0 1.1726997151129126e-09
8 O 0 1.400030757991999e-08
% O 0 1.758209466906635e-09
) O 0 1.419083184295289e-09
had O 0 2.5799913316859602e-08
significantly O 0 1.7004380481466796e-07
lower O 0 9.027759801938373e-07
frequencies O 0 3.9006565089039213e-07
of O 0 7.113140298997678e-09
the O 0 1.2256781189989852e-07
Tyr O 0 2.7033365768147632e-05
allele O 0 1.487048120907275e-05
. O 0 6.86624332502106e-07

Comparisons O 0 6.8030913098482415e-06
with O 0 2.190093084664113e-07
allele O 0 3.780469114644802e-06
frequencies O 0 1.8890657429437852e-06
based O 0 1.0332205135910044e-07
on O 0 2.826876084327523e-07
prevalence O 0 2.9750963221886195e-06
estimates O 0 1.6290441351429763e-07
of O 0 1.7767177951100166e-08
HH B-Disease 1 0.983849287033081
showed O 0 7.283934792212676e-06
some O 0 3.884587318481181e-09
disagreements O 0 4.683984400344343e-08
with O 0 2.309659796750907e-09
the O 0 1.5399045594222116e-08
RFLP O 0 1.8513889017413021e-06
data O 0 9.361487940395818e-08
, O 0 2.952584399196212e-09
particularly O 0 1.1270266497831471e-08
in O 0 4.2463423000072e-08
Finns O 0 4.632546733773779e-06
. O 0 6.171142672428687e-07

The O 0 2.401160145382164e-06
newly O 0 4.472581167647149e-06
described O 0 2.6892375899478793e-06
HFE O 0 6.610198761336505e-05
marker O 0 1.6816032939459546e-06
provides O 0 1.9532455652893077e-08
a O 0 1.2499937085408419e-08
new O 0 2.3472770394050713e-08
approach O 0 1.7870156909793877e-08
to O 0 4.379872020621178e-09
the O 0 6.629770954447167e-09
screening O 0 5.716574591474455e-08
of O 0 4.477917592282665e-09
HH B-Disease 0 0.002195709617808461
as O 0 1.0682855489108078e-08
well O 0 2.691976197510826e-09
as O 0 1.2982831476548995e-09
studies O 0 1.89472815215197e-09
of O 0 2.132405085841782e-10
the O 0 2.466172155379809e-09
relationship O 0 1.3666395126676889e-08
between O 0 1.2839319829538454e-08
the O 0 6.833509047510233e-08
HFE O 0 0.00012124243221478537
Tyr O 0 9.651666005083825e-06
allele O 0 1.2918203537992667e-06
and O 0 2.2161138701903838e-08
different O 0 1.6512456113559892e-07
disorders O 0 0.21033357083797455
including O 0 1.4322239394459757e-06
cancer B-Disease 1 0.5304723978042603

Autosomal B-Disease 1 0.9999871253967285
dominant I-Disease 1 0.9999005794525146
neurohypophyseal I-Disease 1 0.9999973773956299
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9980575442314148
associated O 0 1.7859658328234218e-05
with O 0 2.3423177708536969e-07
a O 0 1.6952935766312294e-06
missense O 0 0.0005526106106117368
mutation O 0 7.520838698837906e-05
encoding O 0 2.6707242795964703e-05
Gly23 O 0 0.0006626048707403243
- O 0 0.0004232407081872225
- O 0 0.00011190184886800125
> O 0 1.1688275662891101e-05
Val O 0 4.4050178985344246e-05
in O 0 7.268587296493934e-07
neurophysin O 0 0.00019212745246477425
II O 0 0.0002867939474526793
. O 0 1.972565996766207e-06

Autosomal B-Disease 1 0.9999903440475464
dominant I-Disease 1 0.9997410178184509
neurohypophyseal I-Disease 1 0.9999973773956299
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9995332956314087
( O 0 1.4722657397214789e-05
ADNDI B-Disease 0 0.0005902137490920722
) O 0 1.7870438284717238e-07
is O 0 4.596648395249758e-08
an O 0 3.4390666314720875e-06
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.001168751739896834
by O 0 1.0961125553876627e-06
progressive O 0 0.09765605628490448
degeneration O 0 0.00034171988954767585
of O 0 9.805383172079019e-09
the O 0 9.565447101067548e-08
magnocellular O 0 1.1238174010941293e-05
neurons O 0 9.826615041674813e-07
of O 0 7.323553763427526e-09
the O 0 1.5610103432095457e-08
hypothalamus O 0 8.023356485864497e-07
leading O 0 2.267823795421009e-08
to O 0 5.779777545456e-09
decreased O 0 7.454979567000919e-08
ability O 0 1.10392166519091e-08
to O 0 3.6417502347063646e-09
produce O 0 1.9638585868619884e-08
the O 0 5.611633469015942e-08
hormone O 0 1.6989432651826064e-06
arginine O 0 2.152604110960965e-06
vasopressin O 0 2.723273837546003e-06
( O 0 1.056073628546983e-07
AVP O 0 4.942632585880347e-06
) O 0 1.0807053740791162e-07
. O 0 2.795767670704663e-07

Affected O 0 4.5722531467617955e-06
individuals O 0 3.53540734465696e-08
are O 0 3.1213773787897026e-09
not O 0 8.03047406350288e-09
symptomatic O 0 1.6426208730990766e-06
at O 0 2.9500581604224863e-06
birth O 0 8.225718374887947e-06
, O 0 5.203111719254139e-09
but O 0 9.893905250635271e-09
usually O 0 3.0611172974204237e-07
develop O 0 1.3853876225766726e-05
diabetes B-Disease 0 0.18323089182376862
insipidus I-Disease 0 0.000627669389359653
at O 0 1.4553425899066497e-05
1 O 0 1.4823834817434545e-06
- O 0 0.00015856589016038924
6 O 0 1.805201804927492e-06
yr O 0 1.3043525541434065e-05
of O 0 2.4481860094738295e-08
age O 0 4.304706351376808e-07
. O 0 3.0589635002797877e-07

The O 0 1.4858539998385822e-06
genetic O 0 5.19545619681594e-06
locus O 0 2.999711796292104e-06
of O 0 2.976237389873404e-08
the O 0 5.442955171020003e-07
disease O 0 5.420649176812731e-05
is O 0 1.53938195524006e-08
the O 0 7.17915327186347e-08
AVP O 0 3.402867878321558e-05
- O 0 2.520243106118869e-05
neurophysin O 0 4.66609162685927e-05
II O 0 3.4558634069981053e-05
( O 0 6.391132245653353e-08
NPII O 0 2.466644900778192e-06
) O 0 2.24039418128541e-08
gene O 0 1.543784264868009e-07
, O 0 3.977397522447745e-09
and O 0 6.7863057395811666e-09
mutations O 0 3.1917460319164093e-07
that O 0 8.868771494974226e-09
cause O 0 3.5593328107097477e-07
ADNDI B-Disease 0 1.785337553883437e-05
have O 0 1.4621211796850275e-08
been O 0 3.7128409235975823e-09
found O 0 2.3425885675720792e-09
in O 0 1.3948749932879423e-09
both O 0 1.04469721762257e-09
the O 0 5.049978213378381e-09
signal O 0 6.773207701371575e-07
peptide O 0 9.720454841044557e-08
of O 0 1.4728320785195592e-09
the O 0 1.896276557999954e-08
prepro O 0 6.674951691820752e-06
- O 0 3.2013838335842593e-06
AVP O 0 7.492592885682825e-06
- O 0 1.429695089427696e-06
NPII O 0 4.0059530874714255e-06
precursor O 0 4.448694710390555e-07
and O 0 1.8922227340567588e-08
within O 0 4.3542275562913346e-08
NPII O 0 2.9200775315985084e-05
itself O 0 2.395716364844702e-06
. O 0 8.188753213289601e-07

An O 0 1.8892676507675787e-06
affected O 0 3.6455230656429194e-06
girl O 0 1.5622064893250354e-05
who O 0 2.973394508387628e-08
presented O 0 2.031887191833448e-08
at O 0 4.0722881067267735e-08
9 O 0 2.9640006005138275e-08
months O 0 9.432352676697064e-09
of O 0 1.0123852867138794e-09
age O 0 1.4956842875335497e-08
and O 0 3.805255222033566e-09
her O 0 2.201692161918345e-08
similarly O 0 1.7278254915709113e-07
affected O 0 8.485175584382887e-08
younger O 0 1.3129317721904954e-07
brother O 0 7.017425218691642e-08
and O 0 8.151771702102906e-09
father O 0 1.449454600788158e-07
were O 0 3.486833488608454e-09
all O 0 4.0597977757350634e-10
found O 0 2.3150228400936612e-09
to O 0 3.1654503462874573e-09
have O 0 2.2179182934678465e-09
a O 0 2.6479737513795953e-08
novel O 0 4.186118474081013e-07
missense O 0 1.2852061445300933e-05
mutation O 0 5.98427641307353e-06
( O 0 1.6030847405090753e-07
G1758 O 0 9.26419670577161e-06
- O 0 6.290461169555783e-05
- O 0 5.947592944721691e-05
> O 0 4.151144821662456e-06
T O 0 8.564899871998932e-06
) O 0 1.4426801087097374e-08
encoding O 0 1.0005610562302536e-07
the O 0 1.3830496747857524e-08
amino O 0 1.8216780972579727e-07
acid O 0 4.5265838366503885e-07
substitution O 0 5.664124955728767e-07
Gly23 O 0 4.1893239540513605e-05
- O 0 4.976163836545311e-05
- O 0 4.081490624230355e-05
> O 0 9.45417195907794e-06
Val O 0 3.921040479326621e-05
within O 0 6.30847978300153e-07
NPII O 0 0.00027336174389347434
. O 0 4.371563136373879e-06

The O 0 3.363238192832796e-06
mutation O 0 3.173414370394312e-05
was O 0 6.68428867811599e-07
confirmed O 0 3.143005926631304e-07
by O 0 4.865642466711506e-08
restriction O 0 1.572037717778585e-06
endonuclease O 0 7.660684786969796e-05
analysis O 0 2.1540704437938984e-06
. O 0 9.261389664061426e-07

A O 0 5.1293394790263847e-05
T1 O 0 0.009419208392500877
- O 0 2.831450547091663e-05
weighted O 0 7.292747795872856e-06
magnetic O 0 3.2493894650542643e-06
resonance O 0 7.069467756082304e-06
imaging O 0 8.477201845380478e-06
of O 0 2.0935891242856997e-08
the O 0 1.709494767965225e-07
fathers O 0 2.7752173537010094e-06
pituitary O 0 1.4074240425543394e-05
gland O 0 5.05453817822854e-06
demonstrates O 0 2.316893130682729e-07
an O 0 9.004434531334482e-08
attenuated O 0 9.023631719173864e-05
posterior O 0 0.0001799619203666225
pituitary O 0 0.0005947785684838891
bright O 0 0.0001922467490658164
spot O 0 6.549417594214901e-05
. O 0 2.7430733098299243e-06

This O 0 1.8908754100266378e-06
mutation O 0 2.5176634153467603e-05
may O 0 5.225721224633162e-07
be O 0 2.491181483321725e-09
valuable O 0 3.003729487360829e-09
for O 0 1.2421760287040229e-09
developing O 0 1.7553654529933738e-08
models O 0 1.5906276473742764e-07
of O 0 1.2003270377647368e-08
dominantly B-Disease 0 0.004128478933125734
inherited I-Disease 1 0.9900676012039185
neurodegeneration I-Disease 1 1.0
, O 0 5.4337142785243486e-08
as O 0 6.400559637853576e-09
the O 0 5.9163896004577055e-09
early O 0 2.2344358967529843e-06
age O 0 2.998916670549079e-08
of O 0 1.927923820588262e-09
onset O 0 2.764849523373414e-05
of O 0 3.446771401627302e-08
symptoms O 0 0.05417916551232338
suggests O 0 4.586585333754556e-08
that O 0 1.1446933401160209e-09
this O 0 4.701345979185589e-09
mutation O 0 6.115724318078719e-07
may O 0 3.015470326772629e-07
be O 0 6.621581949417532e-09
particularly O 0 1.9411492857557278e-08
deleterious O 0 1.2023086810586392e-06
to O 0 2.3969080942265464e-08
the O 0 1.2653681835672614e-07
magnocellular O 0 2.082783066725824e-05
neuron O 0 3.331704283482395e-05
. O 0 1.65533222684644e-07
. O 0 3.6755974974767014e-07

Frequent O 0 0.00017235481936950237
inactivation O 0 0.0006636548787355423
of O 0 1.6323766658388195e-06
PTEN O 0 0.0025004902854561806
/ O 0 0.00021229223057162017
MMAC1 O 0 0.00033845502184703946
in O 0 2.4183722416637465e-05
primary O 1 0.9973257780075073
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1566104149096645e-05

Sporadic B-Disease 1 0.9999924898147583
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 4.4074536731386615e-07
the O 0 2.0274274703524497e-08
most O 0 6.393104712287823e-09
common O 0 7.473145302583362e-08
male B-Disease 0 3.8055333106967737e-07
cancer I-Disease 0 5.882365599063633e-07
in O 0 8.157759801008524e-09
the O 0 1.3270200049930736e-08
Western O 0 4.654470586729076e-08
world O 0 3.4989870556501046e-08
, O 0 1.3908899587633528e-09
yet O 0 8.004855112098141e-10
many O 0 7.776063820630341e-11
of O 0 7.753448577618727e-11
the O 0 1.8531683965150592e-09
major O 0 3.86590137679832e-09
genetic O 0 2.302965640410548e-08
events O 0 3.6265979108662805e-09
involved O 0 1.6287257098568375e-09
in O 0 4.397131547762001e-09
the O 0 9.154032198921414e-09
progression O 0 8.994221900593402e-08
of O 0 8.390600436669615e-10
this O 0 1.3799798637137428e-08
often O 0 2.357735411351314e-06
fatal O 1 0.7595973610877991
cancer B-Disease 0 0.0009169993572868407
remain O 0 1.3269153953388013e-07
to O 0 2.8311243127632224e-08
be O 0 5.282441151166495e-08
elucidated O 0 8.471124601783231e-06
. O 0 5.234679747445625e-07

Numerous O 0 1.6632722690701485e-05
cytogenetic O 0 0.000883012602571398
and O 0 1.3841231520927977e-06
allelotype O 0 3.209516216884367e-05
studies O 0 2.7323062568029854e-07
have O 0 2.545545463306098e-08
reported O 0 8.30507303817285e-07
frequent O 0 8.216366609303805e-07
loss O 0 2.291262262588134e-06
of O 0 2.7187580187160165e-08
heterozygosity O 0 1.2789438187610358e-05
on O 0 9.237677659257315e-06
chromosomal O 0 0.06813142448663712
arm O 0 0.008403491228818893
10q O 0 2.085380765493028e-05
in O 0 6.883276455482701e-06
sporadic B-Disease 1 0.9999990463256836
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.004559392953524e-06

Deletion O 0 0.0006690936861559749
mapping O 0 4.843498390982859e-05
studies O 0 2.9414673008432146e-06
have O 0 9.441175308211314e-08
unambiguously O 0 1.1639182275757776e-06
identified O 0 2.4604414505802197e-08
a O 0 8.41453218214383e-09
region O 0 1.4687372207333738e-08
of O 0 4.86975304525572e-09
chromosome O 0 1.0375370038673282e-06
10q23 O 0 3.028618209555134e-07
to O 0 8.711561250152045e-09
be O 0 2.327588122241764e-09
the O 0 2.467762438840282e-09
minimal O 0 5.288499949074321e-08
area O 0 3.212235455407608e-08
of O 0 1.1990250570192984e-08
loss O 0 2.6074012566823512e-06
. O 0 6.548292503794073e-07

A O 0 1.693681588221807e-05
new O 0 4.872757017437834e-06
tumor B-Disease 0 7.227391324704513e-05
suppressor O 0 8.705059008207172e-05
gene O 0 1.3133921129337978e-05
, O 0 1.673382428180048e-07
PTEN O 0 0.00013680747360922396
/ O 0 4.059596540173516e-05
MMAC1 O 0 5.599300129688345e-05
, O 0 2.7526168011604568e-08
was O 0 1.2971754870250152e-07
isolated O 0 1.6628636956284026e-07
recently O 0 2.914945298471139e-07
at O 0 3.713324048248978e-08
this O 0 2.694996892316226e-09
region O 0 8.888517477600999e-09
of O 0 3.1091014207618173e-09
chromosome O 0 7.952008900247165e-07
10q23 O 0 2.0308630155341234e-07
and O 0 6.076676051236518e-09
found O 0 5.182836382289224e-09
to O 0 2.444298097259434e-09
be O 0 2.8544981933720237e-09
inactivated O 0 1.504864712842391e-07
by O 0 2.3790205361251537e-09
mutation O 0 1.1100811292408252e-07
in O 0 3.5445697932345865e-08
three O 0 1.7489812307758257e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.0015557388542219996
lines O 0 0.00035556755028665066
. O 0 1.8941385633297614e-06

We O 0 2.3067368601914495e-06
screened O 0 2.5431505491724238e-05
80 O 0 9.66374955169158e-06
prostate B-Disease 1 0.9994416832923889
tumors I-Disease 1 0.9999998807907104
by O 0 2.2455797932252608e-07
microsatellite O 0 9.9401077022776e-06
analysis O 0 1.3127615261510073e-07
and O 0 1.28625812223504e-08
found O 0 6.64018884322104e-08
chromosome O 0 1.3532650200431817e-06
10q23 O 0 7.136312092370645e-07
to O 0 4.18277394942379e-08
be O 0 9.351633245557878e-09
deleted O 0 2.462573718275962e-07
in O 0 1.6294535498673213e-08
23 O 0 1.0219157076107876e-07
cases O 0 6.833066379385855e-08
. O 0 2.989391418850573e-07

We O 0 5.337049060472054e-07
then O 0 5.883645215476463e-08
proceeded O 0 5.843829598006778e-08
with O 0 2.528375953048112e-09
sequence O 0 3.39446017960654e-08
analysis O 0 1.1995808790743467e-08
of O 0 2.6418831566843437e-09
the O 0 3.235984991079022e-08
entire O 0 1.1381494005036075e-06
PTEN O 0 0.00015364470891654491
/ O 0 1.6608031728537753e-05
MMAC1 O 0 1.85184817382833e-05
coding O 0 4.081070073880255e-06
region O 0 1.4100379530646023e-07
and O 0 3.8225262954938444e-08
tested O 0 3.776617347739375e-07
for O 0 6.823309028902713e-09
homozygous O 0 8.67195865339454e-07
deletion O 0 3.685745468828827e-07
with O 0 1.9154773767127153e-08
new O 0 3.709523639372492e-07
intragenic O 0 9.755438441061415e-06
markers O 0 4.0680654933566984e-07
in O 0 8.570697040966024e-09
these O 0 1.6333392416356673e-09
23 O 0 2.1352562384890916e-08
cases O 0 3.795165515185772e-09
with O 0 8.520201433270813e-09
10q23 O 0 3.7847764815523988e-06
loss O 0 9.57127554102044e-07
of O 0 7.79960416252834e-08
heterozygosity O 0 3.536235453793779e-05
. O 0 1.5899086065473966e-06

The O 0 6.517819883811171e-07
identification O 0 3.3047601277758076e-07
of O 0 5.260610169699476e-09
the O 0 1.4435277861934992e-08
second O 0 5.298728211755588e-08
mutational O 0 4.414522663864773e-06
event O 0 6.855925249737993e-08
in O 0 4.287057109308989e-08
10 O 0 3.788578339936066e-08
( O 0 2.4426261902021906e-08
43 O 0 1.0454098031686954e-07
% O 0 4.920481444514735e-08
) O 0 1.1275801625743043e-06
tumors B-Disease 1 1.0
establishes O 0 0.0002482670242898166
PTEN O 0 0.005472499877214432
/ O 0 9.686809062259272e-05
MMAC1 O 0 2.6868978238780983e-05
as O 0 5.473981445902609e-08
a O 0 3.7376690187329586e-08
main O 0 9.206495832358996e-08
inactivation O 0 1.261500756299938e-06
target O 0 6.752376435770202e-08
of O 0 5.272020597857363e-09
10q O 0 1.313740085606696e-06
loss O 0 7.733416964583739e-07
in O 0 1.86125134860049e-06
sporadic B-Disease 1 0.9999992847442627
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.1452364030192257e-07
. O 0 8.104643143269641e-07

Risk O 0 0.00014225597260519862
reversals O 0 4.83721996715758e-05
in O 0 7.995049031706003e-07
predictive O 0 3.8236768887145445e-05
testing O 0 5.60351945750881e-05
for O 0 1.8099966837326065e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 9.587211934558582e-06

The O 0 1.6625543821646716e-06
first O 0 6.161280907690525e-07
predictive O 0 7.357462891377509e-06
testing O 0 4.075244305568049e-06
for O 0 1.7492044435130083e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 5.721886395804177e-07
HD B-Disease 0 0.0031908750534057617
) O 0 2.2657397735770246e-08
was O 0 1.1908819175232566e-07
based O 0 1.110254377323372e-08
on O 0 2.8554905995292756e-08
analysis O 0 1.6829201143764294e-08
of O 0 2.0919992405055154e-09
linked O 0 7.160759309954301e-07
polymorphic O 0 2.7840710572490934e-06
DNA O 0 6.457859171860036e-07
markers O 0 6.025888978911098e-07
to O 0 1.0904718905635491e-08
estimate O 0 2.3729990417109548e-08
the O 0 5.222439813934443e-09
likelihood O 0 3.2335417898821106e-08
of O 0 3.0297948594437685e-09
inheriting O 0 3.0992100619187113e-07
the O 0 2.7340050223756407e-08
mutation O 0 6.684447839688801e-07
for O 0 5.846962380928744e-08
HD B-Disease 0 0.00011644979531411082
. O 0 1.1135754220958916e-06

Limits O 0 5.509539278136799e-06
to O 0 1.5568778621855017e-07
accuracy O 0 2.019795601881924e-07
included O 0 1.9592118150058013e-08
recombination O 0 9.336559259054411e-08
between O 0 6.104766470116374e-09
the O 0 1.1224742912929742e-08
DNA O 0 1.7007511132760555e-07
markers O 0 1.9520581417964422e-07
and O 0 2.165065460246751e-09
the O 0 1.3584841696001604e-08
mutation O 0 4.031344928989711e-07
, O 0 4.544861376132303e-09
pedigree O 0 2.7754398956858495e-07
structure O 0 5.353023979637328e-08
, O 0 1.06779196595852e-09
and O 0 7.96776367106844e-10
whether O 0 2.7743420893955317e-09
DNA O 0 2.026321865855607e-08
samples O 0 1.2284896655501143e-08
were O 0 2.886691996550894e-09
available O 0 5.648452372497559e-09
from O 0 5.2643036596577986e-09
family O 0 2.6963970611859622e-08
members O 0 2.2960358947443638e-08
. O 0 2.058966543927454e-07

With O 0 3.867910152166587e-07
direct O 0 2.5468864350841613e-07
tests O 0 1.3464354253756028e-07
for O 0 2.872357240946144e-09
the O 0 1.1114875242412836e-08
HD B-Disease 0 6.019591091899201e-05
mutation O 0 7.066421403578715e-07
, O 0 6.0068199303486836e-09
we O 0 1.160045837167445e-09
have O 0 7.239636667932814e-10
assessed O 0 2.400383891654201e-09
the O 0 1.8449508587536911e-09
accuracy O 0 1.5394876484720044e-08
of O 0 5.944902903287641e-10
results O 0 1.4096663392137998e-08
obtained O 0 4.454720592406147e-09
by O 0 3.1940763367543923e-09
linkage O 0 1.10623226134976e-07
approaches O 0 1.4100185907750529e-08
when O 0 4.241256679193839e-09
requested O 0 4.6215689053497044e-09
to O 0 4.90733853553138e-09
do O 0 2.100563722962079e-09
so O 0 7.767336773767397e-10
by O 0 9.503444697855912e-10
the O 0 5.285250459508006e-09
test O 0 8.652712324419554e-08
individuals O 0 6.560135101807418e-09
. O 0 1.3532685727568605e-07

For O 0 1.8040988436496264e-07
six O 0 2.6254932450342494e-08
such O 0 1.4637360212788053e-09
individuals O 0 1.2203361654528067e-09
, O 0 1.4890285671143033e-09
there O 0 2.2549175859865045e-09
was O 0 7.148628355935216e-08
significant O 0 5.882901277232122e-09
disparity O 0 3.682684379668899e-08
between O 0 1.0063464728204963e-08
the O 0 1.2320568032464507e-07
tests O 0 4.51607274953858e-06
. O 0 5.304806336425827e-07

Three O 0 4.2651339526855736e-07
went O 0 2.217302323970216e-07
from O 0 1.5984218393327865e-08
a O 0 4.073251602676464e-08
decreased O 0 1.2894608971691923e-06
risk O 0 1.5594121549611373e-08
to O 0 1.9026014097534016e-09
an O 0 2.735792925534497e-09
increased O 0 1.7260271079067024e-07
risk O 0 5.0186493183446146e-08
, O 0 8.579523758101004e-10
while O 0 1.3584161573376718e-09
in O 0 2.870396587084656e-09
another O 0 2.8402635798840947e-09
three O 0 1.1010885536677506e-09
the O 0 7.108379662668085e-09
risk O 0 1.2086864842331124e-07
was O 0 7.755735964565247e-07
decreased O 0 3.367092404005234e-06
. O 0 4.0932323486231326e-07

Knowledge O 0 8.38127277802414e-07
of O 0 1.3844036139687432e-08
the O 0 8.956214436750543e-09
potential O 0 4.832676481214548e-09
reasons O 0 2.424217271368434e-09
for O 0 5.164489391695781e-10
these O 0 5.88699533565773e-10
changes O 0 1.2440308339023431e-08
in O 0 1.088173906538259e-08
results O 0 3.50074344623863e-07
and O 0 2.7277740066722345e-09
impact O 0 5.923999957246906e-09
of O 0 3.8863712248371485e-10
these O 0 3.099828616015543e-09
risk O 0 2.50627163467243e-08
reversals O 0 6.206513347706277e-08
on O 0 1.1761124341092e-07
both O 0 2.0825412505587337e-08
patients O 0 2.3626117950925618e-08
and O 0 3.5299747569439432e-09
the O 0 1.188177112254607e-08
counseling O 0 3.099215462043503e-08
team O 0 4.830732258653825e-09
can O 0 2.219865180563829e-09
assist O 0 2.5867403774526565e-09
in O 0 2.005484889266995e-09
the O 0 1.9152939234601263e-09
development O 0 7.650854949581287e-10
of O 0 2.1901384872347052e-10
strategies O 0 8.471781498542441e-09
for O 0 8.131657569521167e-10
the O 0 1.8922589717362825e-08
prevention O 0 2.0944364109709568e-07
and O 0 4.225503502652828e-09
, O 0 5.637567634941831e-10
where O 0 1.247794423342441e-09
necessary O 0 3.84042886381053e-09
, O 0 9.612387552593304e-10
management O 0 6.857832079987247e-09
of O 0 6.086532389204535e-10
a O 0 3.242490365096273e-08
risk O 0 8.071939561204999e-08
reversal O 0 6.728027557301175e-08
in O 0 1.0588363963393022e-08
any O 0 7.277824121132426e-09
predictive O 0 6.687993163723149e-07
testing O 0 5.570102530327858e-07
program O 0 6.697069920846843e-08
. O 0 2.0788663235293825e-08
. O 0 1.561761422408381e-07

A O 0 1.3646837942360435e-05
novel O 0 4.014053047285415e-06
common O 0 1.1642646313703153e-06
missense O 0 7.275228563230485e-05
mutation O 0 1.0853862477233633e-05
G301C O 0 5.527590928977588e-06
in O 0 1.318138345141051e-07
the O 0 8.549426411263994e-08
N O 0 7.376826488325605e-06
- O 0 1.0736377589637414e-05
acetylgalactosamine O 0 6.233648309716955e-05
- O 0 1.5934585462673567e-05
6 O 0 1.4419833860301878e-06
- O 0 1.3258154467621353e-05
sulfate O 0 1.9480281480355188e-05
sulfatase O 0 7.538560021203011e-05
gene O 0 5.246741693554213e-06
in O 0 4.925303755953792e-07
mucopolysaccharidosis B-Disease 0 0.00011442662071203813
IVA I-Disease 0 0.00035399312037043273
. O 0 3.431171535339672e-06

Mucopolysaccharidosis B-Disease 0 0.01797383464872837
IVA I-Disease 1 0.7241178750991821
( O 0 0.00047297030687332153
MPS B-Disease 1 0.999993085861206
IVA I-Disease 1 0.9999921321868896
) O 0 4.071193870913703e-07
is O 0 3.130214665247877e-08
an O 0 1.3778658569663094e-07
autosomal B-Disease 1 0.999396562576294
recessive I-Disease 1 0.9999997615814209
lysosomal I-Disease 1 0.9999996423721313
storage I-Disease 1 1.0
disorder I-Disease 1 0.9999921321868896
caused O 0 1.579171475896146e-05
by O 0 1.1419597001349757e-07
a O 0 3.703110269270837e-05
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.048074523168907e-06
N O 0 4.284554233890958e-05
- O 0 2.8672338885371573e-05
acetylgalactosamine O 0 0.00027124382904730737
- O 0 4.2203038901789114e-05
6 O 0 2.3689369754720246e-06
- O 0 5.632664033328183e-05
sulfate O 0 3.419660424697213e-05
sulfatase O 0 8.276522567030042e-05
( O 0 4.852861934523389e-07
GALNS O 0 3.457501588854939e-05
) O 0 5.722617970604915e-07
. O 0 8.759297998039983e-07

In O 0 8.481597433274146e-07
previous O 0 3.529418677317153e-07
studies O 0 5.540524838920646e-08
, O 0 3.1372180409050543e-09
we O 0 7.976187488267783e-10
have O 0 4.353633842324456e-10
found O 0 8.015259567173416e-10
two O 0 8.443015175885193e-10
common O 0 1.8556804093350365e-08
mutations O 0 1.6383391709950956e-07
in O 0 1.3273187882134607e-08
Caucasians O 0 5.274789671716462e-08
and O 0 5.208701914227731e-09
Japanese O 0 2.069735529630634e-07
, O 0 1.9675553630804643e-08
respectively O 0 3.8243319977482315e-07
. O 0 2.536135070840828e-07

To O 0 4.53178563475376e-06
characterize O 0 1.6071875506895594e-05
the O 0 3.6012409054819727e-07
mutational O 0 3.939807720598765e-05
spectrum O 0 1.6426381534984102e-06
in O 0 1.6908703770468492e-08
various O 0 2.503647289486821e-09
ethnic O 0 2.3048454256269224e-09
groups O 0 4.3399723814729896e-09
, O 0 2.9649489530214623e-09
mutations O 0 8.529327288897548e-08
in O 0 5.746668030326418e-09
the O 0 2.605066562466618e-08
GALNS O 0 3.4486963613744592e-06
gene O 0 3.382797899575962e-07
in O 0 3.876743193131915e-08
Colombian O 0 9.128715987571923e-07
MPS B-Disease 1 0.9999988079071045
IVA I-Disease 1 0.9999997615814209
patients O 0 2.2583597456105053e-05
were O 0 8.876932611201482e-08
investigated O 0 2.3600675547186256e-07
, O 0 6.014432507583933e-09
and O 0 1.1289586154816789e-08
genetic O 0 6.658667217607217e-08
backgrounds O 0 2.8485819925094802e-08
were O 0 1.1760042717412489e-08
extensively O 0 1.594099074964106e-07
analyzed O 0 7.282590530621746e-08
to O 0 5.711928707796687e-09
identify O 0 1.9174770216068282e-08
racial O 0 1.2845982944043044e-08
origin O 0 3.217881738848405e-09
, O 0 8.102458703973525e-10
based O 0 2.2040902436515353e-09
on O 0 2.636885554352375e-08
mitochondrial O 0 9.122780966208666e-07
DNA O 0 6.091126465435082e-07
( O 0 5.91186868348359e-08
mtDNA O 0 9.709278856462333e-07
) O 0 5.9455786072248884e-08
lineages O 0 2.0580080217769137e-06
. O 0 5.121974027133547e-07

Three O 0 2.7094561119156424e-06
novel O 0 4.316630111134145e-06
missense O 0 0.00010887655662372708
mutations O 0 4.008478936157189e-05
never O 0 4.4781160113416263e-07
identified O 0 6.380486894386195e-08
previously O 0 2.2798241516852613e-08
in O 0 2.7312776484933465e-09
other O 0 9.491126773397696e-10
populations O 0 4.892562799341249e-09
and O 0 2.296713486060753e-09
found O 0 8.438978404967656e-09
in O 0 1.2260621851112319e-08
16 O 0 9.526607058774061e-09
out O 0 1.1983682934868511e-09
of O 0 1.1355967277637546e-09
19 O 0 5.450935347539598e-08
Colombian O 0 4.5410337179419e-07
MPS B-Disease 1 0.9994869232177734
IVA I-Disease 1 0.99909508228302
unrelated O 0 5.035245521867182e-06
alleles O 0 1.28493127249385e-06
account O 0 1.3153380962194205e-07
for O 0 3.9004401486408824e-08
84 O 0 1.3835082199875615e-06
. O 0 7.051382340250711e-07

2 O 0 2.5024082788149826e-06
% O 0 5.1033431702762755e-08
of O 0 2.158950129782511e-09
the O 0 1.1175694147880222e-08
alleles O 0 1.0935298888625766e-07
in O 0 1.1719222037243071e-08
this O 0 8.475240953487173e-09
study O 0 8.580546762004815e-08
. O 0 3.8207303987292107e-07

The O 0 1.7676273955657962e-06
G301C O 0 2.528539152990561e-05
and O 0 2.4107413310048287e-07
S162F O 0 7.360761628660839e-06
mutations O 0 7.091047791618621e-06
account O 0 1.6361718735424802e-07
for O 0 2.993990122490686e-08
68 O 0 1.4954281368773081e-06
. O 0 9.222397920893854e-07

4 O 0 1.0015239240601659e-05
% O 0 2.316248099987206e-07
and O 0 7.290331893727853e-08
10 O 0 1.5332143732393888e-07
. O 0 3.1053696147864684e-07

5 O 0 2.5900751552399015e-06
% O 0 5.1674906131893295e-08
of O 0 7.260576584400269e-09
mutations O 0 5.626454822049709e-07
, O 0 9.545267687371961e-09
respectively O 0 3.3507951968658745e-08
, O 0 2.5572575168553158e-09
whereas O 0 8.52959924912966e-09
the O 0 3.743096055330852e-09
remaining O 0 8.337385004608677e-09
F69V O 0 1.538491574137879e-06
is O 0 2.154910250240505e-09
limited O 0 5.313410600393809e-09
to O 0 2.703053558761326e-09
a O 0 2.4309507296038646e-08
single O 0 3.4578309282551345e-07
allele O 0 1.2149520443927031e-05
. O 0 6.182446554703347e-07

The O 0 3.4850781958084553e-06
skewed O 0 2.623703949211631e-05
prevalence O 0 5.984265044389758e-06
of O 0 1.9627838909741513e-08
G301C O 0 8.074093216237088e-07
in O 0 3.4289488581862315e-08
only O 0 7.660188927616218e-09
Colombian O 0 1.0515631032603778e-07
patients O 0 2.1377709913394938e-07
and O 0 3.109008162027749e-08
haplotype O 0 3.988373009633506e-06
analysis O 0 8.433093512394407e-08
by O 0 1.3642173612993247e-08
restriction O 0 1.6415735615282756e-07
fragment O 0 4.508037818595767e-07
length O 0 1.8793430456298665e-07
polymorphisms O 0 1.6780405758254346e-06
in O 0 2.0485499518940742e-08
the O 0 2.0660351651713427e-08
GALNS O 0 5.924069682805566e-06
gene O 0 3.878348877606186e-07
suggest O 0 3.93403958298677e-08
that O 0 2.6109747697233843e-09
G301C O 0 1.3232090623205295e-07
originated O 0 4.3145043093772983e-08
from O 0 5.2090896041079304e-09
a O 0 1.0196023580988367e-08
common O 0 7.696850445881864e-08
ancestor O 0 1.1831451729449327e-06
. O 0 5.773708267042821e-07

Investigation O 0 5.031904493080219e-06
of O 0 6.493115023431528e-08
the O 0 5.0783985017233135e-08
genetic O 0 2.3812015115254326e-07
background O 0 4.556138222255868e-08
by O 0 5.938922242876288e-09
means O 0 5.043365280954504e-09
of O 0 1.5784585860600941e-09
mtDNA O 0 2.4266731202260416e-07
lineages O 0 8.347333846359106e-08
indicate O 0 8.852787658497618e-08
that O 0 1.9775396875587603e-09
all O 0 5.916691026008891e-10
our O 0 5.159293436918233e-09
patients O 0 1.0187878984879717e-08
are O 0 5.206901576570999e-10
probably O 0 6.294612830970436e-09
of O 0 1.4082250920921524e-09
native O 0 5.156964988373147e-08
American O 0 1.9236499326780176e-07
descent O 0 2.2027223167242482e-05

Low O 0 0.00016244321886915714
frequency O 0 4.982611790183e-05
of O 0 2.250476427434478e-07
BRCA1 O 0 5.573302769334987e-05
germline O 0 5.818430508952588e-05
mutations O 0 8.123950465233065e-06
in O 0 1.1727320980980949e-07
45 O 0 1.1835198847620632e-06
German O 1 0.9999996423721313
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.7955654736142606e-06
. O 0 3.3462656574556604e-06

In O 0 8.858680189405277e-07
this O 0 6.490044057727573e-08
study O 0 4.408924780818779e-08
we O 0 6.385828754673639e-09
investigated O 0 1.3100125784148986e-07
45 O 0 1.9192448519333993e-07
German O 1 0.9999867677688599
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.263761788550255e-07
for O 0 3.560011307968125e-08
germline O 0 2.2097581677371636e-05
mutations O 0 7.815880053385627e-06
in O 0 9.827236624460056e-08
the O 0 4.373029867110745e-07
BRCA1 O 0 0.00013540401414502412
gene O 0 2.5657665901235305e-05
. O 0 1.6604374195594573e-06

We O 0 1.2129387414461235e-06
identified O 0 2.7874239094671793e-07
four O 0 5.904206190621153e-08
germline O 0 9.045159458764829e-06
mutations O 0 3.242616230636486e-06
in O 0 8.687571551035944e-08
three O 0 9.020513402901997e-07
breast B-Disease 1 0.9980893731117249
cancer I-Disease 0 6.494561966974288e-05
families O 0 1.2361685897133157e-08
and O 0 5.235765154765204e-09
in O 0 6.824326703736006e-08
one O 0 3.801868297159672e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 7.917111020105949e-07
. O 0 3.1285656287849406e-09
among O 0 4.995246993821922e-10
these O 0 1.0627854152289729e-09
were O 0 6.9644454647743714e-09
one O 0 6.2380562937391915e-09
frameshift O 0 1.2238085218996275e-05
mutation O 0 6.971437755964871e-07
, O 0 6.752991943415054e-09
one O 0 1.1443904490704426e-08
nonsense O 0 9.397757594342693e-07
mutation O 0 6.524437026200758e-07
, O 0 5.082872789330395e-09
one O 0 2.71755395964135e-09
novel O 0 3.038030982338569e-08
splice O 0 5.182106178835966e-06
site O 0 1.1943434401473496e-06
mutation O 0 1.214049689224339e-06
, O 0 1.3692433853407238e-08
and O 0 1.8336589135969916e-08
one O 0 8.082631808292717e-08
missense O 0 8.29956989036873e-05
mutation O 0 7.91778220445849e-05
. O 0 2.6789323328557657e-06

The O 0 6.464294528996106e-06
missense O 0 0.0007073766901157796
mutation O 0 0.00020981347188353539
was O 0 9.438612323720008e-06
also O 0 3.5846493773306065e-08
found O 0 3.5749877724811085e-08
in O 0 3.677602578022743e-08
2 O 0 5.507325795406359e-07
. O 0 4.920050287182676e-07

8 O 0 2.503659061403596e-06
% O 0 3.006711679631735e-08
of O 0 6.903762561627502e-10
the O 0 2.1101811409351967e-09
general O 0 2.2698651847008477e-09
population O 0 1.4607991483117644e-09
, O 0 8.854045829842505e-10
suggesting O 0 2.1639396052819393e-08
that O 0 2.6184756585223568e-09
it O 0 5.481877618507269e-09
is O 0 7.318945893786122e-09
not O 0 5.188734419903085e-08
disease O 0 8.160506695276126e-06
associated O 0 8.561858635403041e-07
. O 0 9.756096233104472e-07

The O 0 1.6357425920432433e-06
average O 0 4.982951395504642e-06
age O 0 2.2312133296509273e-07
of O 0 3.608962373391478e-08
disease O 0 0.00012980685278307647
onset O 0 0.0033498932607471943
in O 0 1.5198529013105144e-07
those O 0 1.3600189419094022e-08
families O 0 1.9729743172547387e-08
harbouring O 0 4.278669621271547e-06
causative O 0 2.8580680009326898e-06
mutations O 0 4.6201089389796834e-06
was O 0 5.283806672196079e-07
between O 0 8.14013816352599e-08
32 O 0 1.310230459239392e-06
. O 0 1.038390223584429e-06

3 O 0 1.2752971997542772e-05
and O 0 8.517968694832234e-07
37 O 0 2.400313178441138e-06
. O 0 8.347204243364104e-07

4 O 0 5.214114935370162e-06
years O 0 8.579581844969653e-08
, O 0 1.0478627743282232e-08
whereas O 0 1.645516256587598e-08
the O 0 1.4213377141913952e-08
family O 0 7.434631044134221e-08
harbouring O 0 6.041453843863565e-07
the O 0 3.888777655447484e-08
missense O 0 9.9697072073468e-06
mutation O 0 1.5571614540021983e-06
had O 0 8.467246459531452e-08
an O 0 6.096086302420645e-09
average O 0 1.2887831246644055e-07
age O 0 2.2248723752227306e-08
of O 0 4.113520191140196e-09
onset O 0 1.8988348529092036e-05
of O 0 4.954686616542858e-08
51 O 0 2.5687845663924236e-06
. O 0 6.062011266294576e-07

2 O 0 1.5745310520287603e-05
years O 0 2.8732795271935174e-06
. O 0 1.2060548897352419e-06

These O 0 1.2759473975165747e-06
findings O 0 1.089606939785881e-06
show O 0 3.694282781907532e-07
that O 0 1.7849139055670094e-08
BRCA1 O 0 1.7385873434250243e-06
is O 0 5.728753027511857e-09
implicated O 0 5.681887316200118e-08
in O 0 3.776456036774789e-09
a O 0 4.9516231115376286e-09
small O 0 5.177441586567966e-09
fraction O 0 4.1613919421479295e-08
of O 0 9.07135188299435e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.868700097584224e-08
suggesting O 0 1.8690015224365197e-07
the O 0 1.1355323792372474e-08
involvement O 0 1.415091777090538e-08
of O 0 1.393757997902867e-09
another O 0 4.680358856035127e-08
susceptibility O 0 4.542061560641741e-06
gene O 0 8.574314961151686e-06
( O 0 1.0138176094187656e-06
s O 0 0.00014833282330073416
) O 0 4.083238309249282e-06

Paternal O 0 0.49874135851860046
transmission O 1 0.9999573230743408
of O 0 0.0002907828602474183
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0011739771580323577

We O 0 1.3597048109659227e-06
report O 0 2.9845998028577014e-07
a O 0 2.1077205758501805e-08
rare O 0 4.8352703174714406e-08
case O 0 5.5044168334461574e-08
of O 0 1.42896837473927e-07
paternally O 1 0.9999537467956543
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9364421963691711
DM B-Disease 1 1.0
) O 0 8.708509085408878e-06
. O 0 3.530853064148687e-06

The O 0 1.9064584648731397e-06
proband O 0 3.32021591020748e-05
is O 0 5.1210314211402874e-08
a O 0 3.041161633632328e-08
23 O 0 1.3520171648906398e-07
year O 0 3.760945688213724e-08
old O 0 2.6932082619168796e-05
, O 0 1.8640010921444627e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 0.9999998807907104
male O 0 1.580189746164251e-05
who O 0 9.686743396741804e-06
suffers O 1 0.980144739151001
severe O 1 0.9999797344207764
muscular B-Disease 1 0.9999997615814209
weakness I-Disease 1 0.9999988079071045
. O 0 4.176232687314041e-05

He O 0 2.7603484795690747e-06
presented O 0 3.127204308839282e-07
with O 0 1.8558758085873706e-07
respiratory O 1 0.8775563836097717
and O 0 3.356123841058434e-07
feeding O 0 4.739848918688949e-06
difficulties O 0 3.9632996617910976e-07
at O 0 1.6762155610194895e-06
birth O 0 5.085475277155638e-05
. O 0 7.326085551540018e-07

His O 0 1.5631485439371318e-05
two O 0 2.145541657228023e-06
sibs O 0 0.0438738651573658
suffer O 0 0.00016874459106475115
from O 0 5.747268915001769e-06
childhood O 1 0.6935380697250366
onset O 1 0.9999991655349731
DM B-Disease 1 1.0
. O 0 6.407918408513069e-05

Their O 0 1.104861212297692e-06
late O 0 7.559264486189932e-05
father O 0 1.1690243582052062e-06
had O 0 3.485791211232936e-08
the O 0 4.587860757965245e-09
adult O 0 5.057808749597825e-08
type O 0 2.571360369074682e-07
of O 0 2.048980007884893e-08
DM B-Disease 1 1.0
, O 0 1.7826852882762978e-08
with O 0 1.9203573842219157e-08
onset O 0 6.72346941428259e-05
around O 0 3.488173092591751e-07
30 O 0 1.4324011488042743e-07
years O 0 3.556332828225095e-08
. O 0 1.2091868484276347e-07

Only O 0 1.922193888503898e-07
six O 0 1.6560264270992775e-08
other O 0 1.3913782348495829e-09
cases O 0 2.6289845855842486e-09
of O 0 4.0032213100005265e-09
paternal O 0 0.0003487325448077172
transmission O 1 0.999760091304779
of O 0 2.4497270715073682e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 9.564728316036053e-06
been O 0 5.562777118939266e-07
reported O 0 9.42457245400874e-06
recently O 0 6.9628677010769024e-06
. O 0 7.568521596112987e-07

We O 0 5.17511523412395e-07
review O 0 2.2174927494233998e-07
the O 0 2.710199886735154e-08
sex O 0 1.21363598282187e-07
related O 0 6.176623656983793e-08
effects O 0 1.3712422060052631e-06
on O 0 1.2770035027642734e-05
transmission O 1 0.9988804459571838
of O 0 4.067936060891952e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.604008866706863e-05

Decreased O 0 0.00021310566808097064
fertility O 0 7.749238648102619e-06
of O 0 3.447994245675545e-08
males O 0 1.659622199667865e-07
with O 0 4.4293901879655095e-08
adult O 0 1.940679612744134e-05
onset O 1 0.9999492168426514
DM B-Disease 1 1.0
and O 0 1.4479971923719859e-06
contraction O 0 5.608627816400258e-06
of O 0 3.6684721926860675e-09
the O 0 1.1983140701943285e-08
repeat O 0 1.1803350474792751e-07
upon O 0 9.292141278649524e-09
male O 0 4.014249199713049e-08
transmission O 0 2.6026859814010095e-06
contribute O 0 2.4742476956163273e-09
to O 0 1.951364181351778e-09
the O 0 4.784580287520157e-09
almost O 0 1.0283403462096885e-08
absent O 0 6.202158431278804e-08
occurrence O 0 7.698906046016418e-08
of O 0 6.721214251825813e-09
paternal O 0 0.0001383935014018789
transmission O 1 0.9967723488807678
of O 0 6.1110526985430624e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 2.759481139946729e-05

Also O 0 1.399589677930635e-06
the O 0 6.981205302736271e-08
fathers O 0 4.746335235950028e-08
of O 0 1.498076107608881e-09
the O 0 1.8298822013207428e-08
reported O 0 2.5752680812729523e-05
congenitally O 0 0.0008727154927328229
affected O 0 8.018643598006747e-07
children O 0 3.0229443837015424e-08
showed O 0 7.12030953309295e-07
, O 0 3.763218625607578e-09
on O 0 1.1859269477554335e-07
average O 0 3.1103550668376556e-07
, O 0 1.828758655619822e-08
shorter O 0 6.887301879032748e-06
CTG O 0 6.156597464723745e-06
repeat O 0 1.351891114609316e-06
lengths O 0 4.665794790525979e-07
and O 0 1.7922110018275816e-08
hence O 0 1.0798522964705626e-07
less O 0 2.1070015066015912e-07
severe O 1 0.6077883243560791
clinical O 0 0.020999442785978317
symptoms O 1 0.9973480701446533
than O 0 2.753987438097738e-08
the O 0 1.6880451880751934e-07
mothers O 0 9.543851575699591e-08
of O 0 1.89739357558949e-09
children O 0 5.428203309065793e-08
with O 0 1.1891236681549344e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 3.418206324568018e-05

We O 0 4.486639966216899e-07
conclude O 0 7.581047611893155e-07
that O 0 4.051277713301715e-08
paternal O 0 4.1393381252419204e-05
transmission O 1 0.9707023501396179
of O 0 4.451828317542095e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 3.300646653769945e-07
rare O 0 1.4579961771232774e-07
and O 0 1.7665030327407294e-08
preferentially O 0 2.75805689398112e-07
occurs O 0 2.9179256344491478e-08
with O 0 1.062486010283692e-08
onset O 0 8.602943125879392e-05
of O 0 9.822981894558325e-08
DM B-Disease 1 1.0
past O 0 8.562822131352732e-07
30 O 0 3.482249155695172e-08
years O 0 2.0137296274924665e-09
in O 0 2.368819140841083e-09
the O 0 1.3122903652629248e-08
father O 0 1.812939842693595e-07
. O 0 1.984542130628597e-08
. O 0 1.1482872253054666e-07

The O 0 1.2037901797157247e-05
RB1 O 0 0.0005477169761434197
gene O 0 2.3447868443327025e-05
mutation O 0 8.62949946167646e-06
in O 0 1.364962400884906e-07
a O 0 1.7239838712157507e-07
child O 0 1.5785864206918632e-06
with O 0 6.74341833928338e-07
ectopic B-Disease 1 0.9999804496765137
intracranial I-Disease 1 0.9999699592590332
retinoblastoma I-Disease 1 0.9670288562774658
. O 0 2.7834479624289088e-05

The O 0 9.174053047900088e-06
RB1 O 0 0.0007837140001356602
gene O 0 4.344381159171462e-05
mutation O 0 1.652697756071575e-05
was O 0 1.0821684099937556e-06
investigated O 0 3.4217009670101106e-07
in O 0 2.363612239264512e-08
a O 0 1.1079384165668671e-07
child O 0 7.432631150550151e-07
with O 0 1.9581888466291275e-07
ectopic B-Disease 1 0.990802526473999
intracranial I-Disease 0 0.36001846194267273
retinoblastoma I-Disease 0 3.782426938414574e-05
using O 0 4.1722771015884064e-07
DNA O 0 4.342086299402581e-07
obtained O 0 3.984127161515971e-08
from O 0 1.054728571148189e-08
both O 0 3.1862330551746254e-09
the O 0 2.515044528195176e-08
pineal B-Disease 0 1.449506999051664e-05
and I-Disease 0 6.505970873149636e-07
retinal I-Disease 0 0.0010092747397720814
tumours I-Disease 1 0.9999998807907104
of O 0 1.6689128301550227e-08
the O 0 6.90726494667615e-07
patient O 0 3.8951682654442266e-05
. O 0 1.8005047195401858e-06

A O 0 2.229099118267186e-05
nonsense O 0 4.212905332678929e-05
mutation O 0 4.0642764361109585e-05
in O 0 6.210207743606588e-07
exon O 0 2.9855114917154424e-05
17 O 0 1.4976589000070817e-06
( O 0 1.6571470951021183e-07
codon O 0 2.6248681024299003e-06
556 O 0 4.27006654035722e-07
) O 0 6.012046860348619e-09
of O 0 8.490185776643955e-10
the O 0 4.2724455084908186e-08
RB1 O 0 2.1782690964755602e-05
gene O 0 5.145420232111064e-07
was O 0 2.593179431187309e-07
found O 0 5.869172259309607e-09
to O 0 2.80103362726436e-09
be O 0 1.5041859979803007e-09
present O 0 4.257166619225927e-09
homozygously O 0 1.9105193871382653e-07
in O 0 3.5442504486837834e-09
both O 0 1.921389713999133e-09
the O 0 1.0220245094672009e-08
retinal B-Disease 0 5.263082130113617e-07
and I-Disease 0 4.361683636489033e-08
the I-Disease 0 5.827389486512402e-07
pineal I-Disease 0 0.4196508228778839
tumours I-Disease 1 0.9999998807907104
. O 0 2.8545703116833465e-06

The O 0 1.1408247928557103e-06
same O 0 5.197767904974171e-07
mutation O 0 2.0670679532486247e-06
was O 0 1.4166370476687007e-07
present O 0 2.0276981871347743e-08
heterozygously O 0 4.408715028603183e-07
in O 0 4.810082110395797e-09
the O 0 2.204666227356711e-09
DNA O 0 1.3512483576505474e-08
from O 0 3.0362625746960248e-09
the O 0 2.6101680816736916e-09
constitutional O 0 7.695070358693101e-09
cells O 0 6.775919381141193e-09
of O 0 3.1132599276340045e-10
the O 0 1.2127932436101219e-08
patient O 0 2.9063400575068954e-07
, O 0 3.1888596208062836e-09
proving O 0 2.192916248588972e-08
it O 0 2.1889283718934394e-09
to O 0 1.3651797470259908e-09
be O 0 6.31663110706171e-10
of O 0 1.018493955839972e-09
germline O 0 1.0188771284447284e-06
origin O 0 1.2599470267105062e-07
. O 0 4.032871459003218e-07

The O 0 1.2753841929225018e-06
initial O 0 1.8459043076290982e-06
mutation O 0 5.088431862532161e-06
was O 0 6.304053385974839e-07
shown O 0 3.2722439868848596e-08
to O 0 6.873913438454338e-09
have O 0 2.7874162977781225e-09
occurred O 0 5.945555869857344e-08
in O 0 1.5036189182637827e-08
the O 0 1.2752659017678525e-07
paternally O 0 2.9525059289881028e-05
derived O 0 2.9387729227892123e-06
RB1 O 0 0.0002810859296005219
allele O 0 5.4587508202530444e-05
. O 0 1.97655617739656e-06

The O 0 1.7598276826902293e-06
mutation O 0 9.921422133629676e-06
is O 0 2.5246666979228394e-08
in O 0 4.1374961234907914e-09
an O 0 1.5557690691281323e-09
area O 0 7.020621417552775e-09
of O 0 7.579061267470877e-10
the O 0 5.63061774982998e-09
gene O 0 4.020103006041609e-08
that O 0 1.3974047474718532e-09
encodes O 0 2.5290766814123344e-08
the O 0 5.37676125844655e-09
protein O 0 6.924803841457106e-08
- O 0 8.774183157811422e-08
binding O 0 5.3570481384213053e-08
region O 0 9.027681713291713e-09
known O 0 6.239222472004258e-09
as O 0 2.285378331023935e-09
the O 0 8.442037291445104e-09
pocket O 0 3.7243651149765356e-06
region O 0 3.506730550384418e-08
and O 0 1.7206094327093524e-08
has O 0 6.106827488139288e-09
been O 0 5.407780001576157e-09
detected O 0 1.310270079102338e-07
in O 0 4.416842891430406e-09
other O 0 1.0023900598454816e-09
cases O 0 2.6568003352878122e-09
of O 0 4.245344076281299e-09
retinoblastoma B-Disease 0 6.9517204792646226e-06
. O 0 7.785587996522736e-08
. O 0 4.340057842000533e-07

Low O 0 0.00016284009325318038
levels O 0 1.653752747188264e-06
of O 0 2.5072470322129448e-08
beta O 0 2.505801433017041e-07
hexosaminidase O 0 1.6459516700706445e-06
A O 0 1.0965751329194973e-07
in O 0 2.702807400112306e-08
healthy O 0 1.447956918809723e-07
individuals O 0 1.3098715445636344e-09
with O 0 1.5286147458937194e-08
apparent O 0 0.0010284744203090668
deficiency O 0 0.0004368435766082257
of O 0 3.7055962742726933e-09
this O 0 2.799961329458256e-08
enzyme O 0 2.4169301013898803e-06
. O 0 4.873984380537877e-07

Appreciable O 0 0.0002251431142212823
beta O 0 3.0001927370904014e-05
hexosaminidase O 0 3.524240310071036e-05
A O 0 1.1104153827545815e-06
( O 0 2.2704125512973405e-07
hex O 0 8.916179581319739e-07
A O 0 5.076703502027158e-08
) O 0 5.336710184877802e-09
activity O 0 4.200290248945748e-08
has O 0 6.9949046554995675e-09
been O 0 7.80999087623968e-09
detected O 0 2.5311041440545523e-07
in O 0 3.133751036443755e-08
cultured O 0 2.3045402031129925e-06
skin O 0 0.11314757168292999
fibroblasts O 0 4.406702828418929e-06
and O 0 3.173716436322138e-07
melanoma B-Disease 0 0.00023700033489149064
tissue O 0 1.584028359502554e-05
from O 0 6.705454325128812e-08
healthy O 0 3.4281060834473465e-07
individuals O 0 1.7295253007532096e-09
previously O 0 5.980506045943912e-08
reported O 0 6.993972419877537e-06
as O 0 7.075970529513143e-07
having O 0 6.176203896757215e-06
deficiency B-Disease 0 8.218872608267702e-06
of I-Disease 0 1.7496387672011338e-09
hex I-Disease 0 2.762869257821876e-07
A I-Disease 0 2.5442444595569214e-08
activity O 0 6.175857691914644e-08
indistinguishable O 0 7.972331417249734e-08
from O 0 1.9290862240950446e-09
that O 0 1.3182201996642107e-09
of O 0 3.2967184537824323e-09
patients O 0 2.3621120703865017e-07
with O 0 3.23670610669069e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.999994158744812
( O 0 2.349956957914401e-06
TSD B-Disease 0 0.0004249469784554094
) O 0 4.772451802637079e-07
. O 0 5.569831387219892e-07

Identification O 0 1.9242466805735603e-05
and O 0 3.2931572491179395e-07
quantitation O 0 1.6128242350532673e-05
of O 0 3.2209044320552493e-08
hex O 0 3.058315314774518e-06
A O 0 8.087288705382889e-08
, O 0 7.196836904199699e-09
amounting O 0 2.2246005926263024e-08
to O 0 2.71031872500771e-08
3 O 0 2.3518039427017357e-07
. O 0 3.558450600849028e-07

5 O 0 3.6681423807749525e-05
% O 0 2.3346869966189843e-06
- O 0 1.787808105291333e-05
6 O 0 2.3484603843826335e-06
. O 0 1.3150674931239337e-06

9 O 0 9.979487003874965e-06
% O 0 1.277737027294279e-07
of O 0 3.9573753163324454e-09
total O 0 6.1766098902182875e-09
beta O 0 9.155013458439498e-08
hexosaminidase O 0 7.274509812305041e-07
activity O 0 1.72005243825879e-07
, O 0 3.911874379980418e-09
has O 0 2.330599935262967e-09
been O 0 1.1500616015069909e-09
obtained O 0 5.201206576543882e-09
by O 0 1.6434336558290852e-08
cellulose O 0 0.0001200864280690439
acetate O 0 6.395647505996749e-05
gel O 0 1.7315585864707828e-05
electrophoresis O 0 2.0267971194698475e-06
, O 0 3.741784482258481e-08
DEAE O 0 6.629699328186689e-06
- O 0 2.0237898752384353e-06
cellulose O 0 3.049577026104089e-05
ion O 0 3.263379994677962e-06
- O 0 1.0693476042433758e-06
exchange O 0 4.775538968715409e-07
chromatography O 0 1.1438512501626974e-06
, O 0 8.66530935894616e-09
radial O 0 4.288185664336197e-07
immunodiffusion O 0 1.2930171351399622e-06
, O 0 2.1861799481825983e-08
and O 0 3.23875717356259e-08
radioimmunoassay O 0 3.01683339785086e-05
. O 0 7.652991484974336e-07

Previous O 0 1.5236510989780072e-05
family O 0 1.5242874269461026e-06
studies O 0 7.517046896055035e-08
suggested O 0 4.601911740564901e-08
that O 0 1.4758354538457752e-09
these O 0 1.319931053345158e-09
individuals O 0 1.168437679943679e-09
may O 0 1.2403916116454639e-08
be O 0 1.3672148968524311e-09
compound O 0 5.513516398991669e-08
heterozygotes O 0 1.8287103387137904e-07
for O 0 2.981747071473251e-09
the O 0 7.193090123536194e-09
common O 0 9.519889232478818e-08
mutant O 0 1.2375579672152526e-06
TSD B-Disease 0 2.1556736101047136e-05
gene O 0 1.263063268197584e-06
and O 0 1.9527426786680735e-08
a O 0 6.942194374914834e-08
rare O 0 5.654177925862314e-07
( O 0 1.438258436792239e-07
allelic O 0 1.0077871593239252e-05
) O 0 2.3156869133345026e-07
mutant O 0 3.2128534712683177e-06
gene O 0 1.24615562526742e-05
. O 0 1.0181155403188313e-06

Thus O 0 2.9326752155611757e-06
, O 0 6.755777803846286e-08
the O 0 3.5905134865288346e-08
postulated O 0 7.712205842835829e-07
rate O 0 4.846562546845234e-07
mutant O 0 6.083323569328059e-07
gene O 0 4.4974356683269434e-07
appears O 0 8.170236753812787e-08
to O 0 4.402871844888523e-09
code O 0 1.3239659146790927e-08
for O 0 6.656680762162637e-10
the O 0 2.0371868636459567e-09
expression O 0 9.624298691335298e-09
of O 0 1.0251633986158026e-09
low O 0 2.1320133214430825e-07
amounts O 0 1.0565527119865692e-08
of O 0 7.79867814770796e-09
hex O 0 3.048844973818632e-06
A O 0 8.77592867709609e-07
. O 0 5.215092073740379e-07

Heterozygotes O 0 0.00015387136954814196
for O 0 1.703655101437107e-07
the O 0 2.536298460142916e-08
rare O 0 1.5227023197894596e-07
mutant O 0 2.3385130134556675e-06
may O 0 5.944568783888826e-07
be O 0 7.928987244554264e-09
indistinguishable O 0 1.2341712363195256e-07
from O 0 1.9850684651601114e-08
heterozygotes O 0 3.934872836452996e-07
for O 0 3.6305287665072683e-09
the O 0 2.498167894771086e-08
common O 0 5.251881134427094e-07
TSD B-Disease 0 0.00015706005797255784
mutant O 0 1.816039548430126e-05
. O 0 1.4336219464894384e-06

However O 0 1.8528247665017261e-06
, O 0 4.673293574342097e-08
direct O 0 6.573188926495277e-08
visualization O 0 1.0936045100606862e-06
and O 0 1.8841053162077515e-08
quantitation O 0 3.5264815778646152e-06
of O 0 1.4819600657745013e-08
hex O 0 9.852419680100866e-07
A O 0 2.1145538653399854e-08
by O 0 4.662971786473236e-09
the O 0 9.269624179353286e-09
methods O 0 8.490599157084944e-08
described O 0 4.7531571567560604e-07
may O 0 1.4051221342015197e-07
prevent O 0 6.398743579438815e-08
false O 0 2.5436071382500813e-07
- O 0 2.709776481424342e-06
positive O 0 8.257355261775956e-07
prenatal O 0 3.360217306180857e-05
diagnosis O 0 3.358538742759265e-05
of O 0 2.3701764106931478e-08
TSD B-Disease 0 3.938125155400485e-05
in O 0 5.585832241195021e-07
fetuses O 0 2.436947852402227e-06
having O 0 1.195738619230724e-08
the O 0 1.2876082422508262e-08
incomplete O 0 3.015499316916248e-07
hex B-Disease 0 3.106959638898843e-06
A I-Disease 0 7.3065880314970855e-06
deficiency I-Disease 0 1.648597390158102e-05
of O 0 1.6158597793136664e-09
the O 0 2.5255189939343836e-08
type O 0 7.530689799750689e-06
described O 0 2.2694730716921185e-07
in O 0 1.8083184727402113e-08
the O 0 1.7013455533287924e-08
four O 0 4.8463686397326455e-08
healthy O 0 1.6763067378633423e-06
individuals O 0 3.195175395376282e-07

The O 0 1.3964051504444797e-05
tumor B-Disease 0 0.0004441946221049875
suppressor O 0 0.0005472062039189041
gene O 0 5.770181451225653e-05
Smad4 O 0 0.00022728658223059028
/ O 0 4.211463237879798e-05
Dpc4 O 0 6.4818887040019035e-06
is O 0 1.3463321124618233e-08
required O 0 9.466705641614226e-09
for O 0 2.9185807104425976e-09
gastrulation O 0 4.5929368752695154e-07
and O 0 1.1036354052862407e-08
later O 0 6.188982126786868e-08
for O 0 2.571103330240021e-09
anterior O 0 1.4489017985397368e-07
development O 0 3.7418752540929745e-09
of O 0 1.587455722429354e-09
the O 0 3.9383191818842533e-08
mouse O 0 2.985004539368674e-05
embryo O 0 8.945289664552547e-06
. O 0 7.609724548274244e-07

Mutations O 0 0.0009489892399869859
in O 0 4.856315172219183e-06
the O 0 2.277678277096129e-06
SMAD4 O 0 0.0019381893798708916
/ O 0 0.0003531861293595284
DPC4 O 0 0.0006719130906276405
tumor B-Disease 0 0.00013164056872483343
suppressor O 0 5.422401591204107e-05
gene O 0 1.7833608580986038e-06
, O 0 1.1437075286835352e-08
a O 0 1.978506425359683e-08
key O 0 6.060808743768575e-08
signal O 0 2.3968543700902956e-06
transducer O 0 1.1674455890897661e-06
in O 0 2.1161879359965496e-08
most O 0 7.618909059203816e-09
TGFbeta O 0 3.448719326115679e-06
- O 0 9.350234222438303e-07
related O 0 6.059479318309968e-08
pathways O 0 8.90486262505874e-08
, O 0 1.0870427891163104e-09
are O 0 2.6690599730372355e-10
involved O 0 1.338353650126578e-09
in O 0 5.07791098058874e-09
50 O 0 1.4544110804592947e-08
% O 0 8.116522565160267e-09
of O 0 3.008008064853129e-08
pancreatic B-Disease 1 0.938510537147522
cancers I-Disease 0 0.17640621960163116
. O 0 2.884093191823922e-06

Homozygous O 0 0.00245933816768229
Smad4 O 0 0.001377735286951065
mutant O 0 0.00029782240744680166
mice O 0 0.004539008717983961
die O 0 8.669023372931406e-05
before O 0 1.575697183398006e-06
day O 0 7.232230814224749e-07
7 O 0 2.362187160542817e-06
. O 0 6.127107781139784e-07

5 O 0 1.0863492207136005e-05
of O 0 8.087749279184209e-07
embryogenesis O 0 0.00010611603647703305
. O 0 8.889103810361121e-06

Mutant O 0 4.3635180190904066e-05
embryos O 0 2.9271875519043533e-06
have O 0 1.0562871466390789e-07
reduced O 0 2.183205367600749e-07
size O 0 5.328026873030467e-07
, O 0 3.0012397900236465e-08
fail O 0 5.100370685795497e-07
to O 0 3.2812064176823696e-08
gastrulate O 0 3.333677796035772e-06
or O 0 3.674587389923545e-08
express O 0 8.614623681069133e-08
a O 0 3.939092607652128e-08
mesodermal O 0 1.0587555152596906e-06
marker O 0 1.261926740880881e-06
, O 0 7.520227995883033e-09
and O 0 8.891857916637491e-09
show O 0 9.800129419090808e-07
abnormal O 0 7.4025915637321305e-06
visceral O 0 8.035347491386347e-06
endoderm O 0 5.35409344593063e-05
development O 0 1.0507988008612301e-06
. O 0 1.3057111800662824e-06

Growth B-Disease 1 0.9999997615814209
retardation I-Disease 1 0.9999997615814209
of O 0 1.336395740736407e-07
the O 0 3.795747147705697e-07
Smad4 O 0 0.0005232372786849737
- O 0 0.00019845308270305395
deficient O 0 5.1059578254353255e-05
embryos O 0 2.281221185285176e-07
results O 0 1.012894230711936e-07
from O 0 2.2598012350272256e-08
reduced O 0 1.325727794210252e-07
cell O 0 1.0293587138221483e-06
proliferation O 0 2.497470461548801e-07
rather O 0 2.3656328451693298e-08
than O 0 9.260594957538615e-09
increased O 0 2.6891248694482783e-07
apoptosis O 0 8.289758625323884e-06
. O 0 8.362869721167954e-07

Aggregation O 0 6.15284443483688e-05
of O 0 4.052971007695305e-07
mutant O 0 1.2403119399095885e-05
Smad4 O 0 3.443772948230617e-05
ES O 0 5.724261427531019e-06
cells O 0 6.426753316191025e-07
with O 0 2.477838201286886e-08
wild O 0 7.928383638500236e-07
- O 0 5.563007289310917e-05
type O 0 3.6755027394974604e-05
tetraploid O 0 1.6891812265384942e-05
morulae O 0 6.543136987602338e-05
rescues O 0 2.355686046939809e-05
the O 0 1.2827249520341866e-06
gastrulation B-Disease 0 0.0008048083982430398
defect I-Disease 0 0.0014264460187405348
. O 0 5.312340817908989e-06

These O 0 5.144713668414624e-07
results O 0 6.359406938827306e-07
indicate O 0 1.827659161790507e-07
that O 0 7.695438064558857e-09
Smad4 O 0 7.20033995094127e-07
is O 0 4.315621637829281e-09
initially O 0 1.3301115764363658e-08
required O 0 1.1853039660891795e-09
for O 0 2.319167080599982e-10
the O 0 1.905521296308166e-09
differentiation O 0 7.881131303122402e-09
of O 0 5.582068141052332e-10
the O 0 7.136772506299849e-09
visceral O 0 2.4341599669241987e-07
endoderm O 0 1.1181193713127868e-06
and O 0 7.446463889948518e-09
that O 0 2.0243353660021057e-09
the O 0 2.0901099517800503e-08
gastrulation B-Disease 0 3.730373009602772e-06
defect I-Disease 0 1.686984433035832e-06
in O 0 1.2403064353350146e-08
the O 0 3.0971591513662133e-08
epiblast O 0 6.062166448828066e-06
is O 0 1.076865441262953e-08
secondary O 0 7.218505260198071e-08
and O 0 7.104814958580619e-09
non O 0 2.5735186426345535e-08
- O 0 1.0210706022917293e-06
cell O 0 2.2087726847530575e-06
autonomous O 0 9.35461343942734e-07
. O 0 6.674982273580099e-07

Rescued O 0 0.0001637298846617341
embryos O 0 5.5066688219085336e-05
show O 0 3.215943797840737e-05
severe O 0 0.0008099534315988421
anterior O 0 0.00031291667255572975
truncations O 0 0.00010955025936709717
, O 0 1.1042970271546437e-07
indicating O 0 4.477791435419931e-07
a O 0 4.686478050075493e-08
second O 0 3.495591727187275e-08
important O 0 2.2770416663320248e-09
role O 0 7.872267282493794e-09
for O 0 2.5783812862556488e-09
Smad4 O 0 9.188301532958576e-07
in O 0 8.542580332004945e-08
anterior O 0 1.1511578122735955e-05
patterning O 0 0.00011522043496370316
during O 0 5.658025656885002e-06
embryogenesis O 0 0.00015030776557978243
. O 0 2.6848404104384826e-06

Prevalence O 0 0.00028607682907022536
of O 0 4.3621707845886704e-07
p16 O 0 1.8612176063470542e-05
and O 0 2.850686371402844e-07
CDK4 O 0 0.00010334189573768526
germline O 0 8.303091453853995e-05
mutations O 0 3.319684765301645e-05
in O 0 4.3195026933062763e-07
48 O 0 2.4113991457852535e-05
melanoma B-Disease 1 0.9982635378837585
- O 0 0.0779229924082756
prone O 0 0.0003920474264305085
families O 0 7.733388684982856e-08
in O 0 2.148218527509016e-07
France O 0 1.7854907127912156e-05
. O 0 6.300849690887844e-07

The O 0 3.0022904411453055e-06
French O 0 5.756199607276358e-05
Familial B-Disease 0 0.08325918763875961
Melanoma I-Disease 0 0.46535012125968933
Study O 0 1.1691826102833147e-06
Group O 0 7.19082891009748e-07
. O 0 5.376332410378382e-07

Germline O 0 0.0035791664849966764
mutations O 0 0.000537106127012521
in O 0 5.218460614742071e-07
the O 0 6.054453649539937e-08
p16 O 0 1.1392766054996173e-06
and O 0 2.6232006788973194e-08
CDK4 O 0 6.058455710444832e-06
genes O 0 9.221221830557624e-08
have O 0 3.767585354808034e-09
been O 0 4.236923256684122e-09
reported O 0 8.151059915917358e-08
in O 0 5.705156347346474e-09
a O 0 1.2185784825646806e-08
subset O 0 3.013135696505742e-08
of O 0 7.9491417892541e-09
melanoma B-Disease 0 3.962044866057113e-05
pedigrees O 0 1.801896019060223e-06
, O 0 5.305713646208687e-09
but O 0 5.4220952172556736e-09
their O 0 2.2958344558787758e-08
prevalence O 0 9.161080924968701e-07
is O 0 4.7714756590266916e-09
not O 0 1.4077954357816225e-09
well O 0 4.0427230452166896e-09
known O 0 9.029234604440717e-08
. O 0 1.880468971648952e-07

We O 0 7.241534376589698e-07
searched O 0 1.5308050933526829e-06
for O 0 1.4852737706405605e-08
such O 0 1.9162593289934193e-08
germline O 0 7.263277439051308e-06
mutations O 0 2.0071177004865604e-06
in O 0 1.1386081411046689e-07
48 O 0 9.327122825197875e-07
French O 0 0.00035460342769511044
melanoma B-Disease 1 0.9993277788162231
- O 0 0.4679800570011139
prone O 0 0.0006028483621776104
families O 0 1.7813393426990842e-08
selected O 0 5.7771982753251905e-09
according O 0 2.312114721902958e-09
to O 0 1.368958058023395e-09
two O 0 1.117163916930508e-09
major O 0 3.0243330062518226e-09
criteria O 0 6.97179514119739e-09
families O 0 1.3981940050200592e-09
with O 0 1.2482777034250603e-09
at O 0 5.6676103810104905e-08
least O 0 2.7548896497364694e-09
three O 0 1.6054146900756905e-09
affected O 0 9.010152624000511e-09
members O 0 3.0205915546588358e-09
( O 0 8.657297101422046e-09
n O 0 1.6018300641462702e-07
= O 0 8.058218270434736e-08
20 O 0 9.299180092625647e-09
) O 0 1.2868144327882192e-09
or O 0 4.0427230452166896e-09
families O 0 6.673028796200242e-10
with O 0 9.198939387999872e-10
two O 0 2.203111026943816e-09
affected O 0 6.3766401048326316e-09
members O 0 4.6284737154067557e-10
, O 0 3.065232789811745e-10
one O 0 1.7400531016065202e-10
of O 0 1.4206559539875485e-10
them O 0 4.056423252851715e-10
affected O 0 2.3456914188813016e-09
before O 0 4.552669796709097e-09
the O 0 4.854664226172645e-09
age O 0 3.294166273093424e-09
of O 0 3.296050099521608e-10
50 O 0 5.792722745923129e-09
( O 0 9.835971148675071e-09
n O 0 2.5649825374784996e-07
= O 0 1.5686755716615153e-07
28 O 0 4.7392067159535145e-08
) O 0 3.2753959544606914e-09
, O 0 6.988766787507927e-10
and O 0 1.4337474540937478e-09
one O 0 1.5776848716342329e-09
additional O 0 8.319910982379497e-09
minor O 0 6.571884227923874e-07
criterion O 0 3.0655919545097277e-06
. O 0 6.656762252532644e-07

Sixteen O 0 1.63429431268014e-05
different O 0 1.143700728789554e-06
p16 O 0 4.575975617626682e-05
germline O 0 6.612159631913528e-05
mutations O 0 2.0234278053976595e-05
were O 0 6.042213840373734e-08
found O 0 1.8973654647425064e-08
in O 0 1.749319267219107e-08
21 O 0 3.1469525652028096e-08
families O 0 3.2238653968619246e-09
, O 0 1.5985917034555541e-09
while O 0 3.638959134022457e-09
one O 0 1.0190618127126072e-08
germline O 0 2.1320427094906336e-06
mutation O 0 9.957317388398224e-07
, O 0 1.482624512050279e-08
Arg24His O 0 1.3484442433764343e-06
, O 0 1.7119901940532145e-08
was O 0 2.447234237479279e-07
detected O 0 6.748912824150466e-07
in O 0 2.1431798558069204e-08
the O 0 9.80869785394134e-08
CDK4 O 0 5.4435608035419136e-05
gene O 0 1.6604770280537196e-05
. O 0 1.009058564704901e-06

The O 0 1.6219502185776946e-06
frequency O 0 8.702480954525527e-06
of O 0 6.076481184891236e-08
p16 O 0 8.694675670994911e-06
gene O 0 2.9299274046934443e-06
mutation O 0 1.4415364830711042e-06
in O 0 2.4794834629915385e-08
our O 0 1.1430510760135348e-08
sample O 0 5.2606427658474786e-08
( O 0 1.0562182239937101e-08
44 O 0 9.853941662640864e-09
% O 0 1.8110755117817234e-09
) O 0 8.153649422304454e-10
is O 0 5.823972415441858e-10
among O 0 4.841725353976756e-10
the O 0 3.2660010251817084e-09
highest O 0 4.7829498583951136e-08
rates O 0 9.746389878273476e-06
yet O 0 2.3336882648550272e-08
reported O 0 3.2427939800072636e-07
and O 0 3.956250882453105e-09
the O 0 1.6164616312153157e-08
CDK4 O 0 1.9203747797291726e-05
mutation O 0 1.9413718632677046e-07
is O 0 1.1213053818792673e-09
the O 0 2.689117817311626e-09
second O 0 4.260905583919339e-08
mutation O 0 2.685885363007401e-07
detected O 0 2.2485372142000415e-07
in O 0 9.079572649284273e-09
this O 0 7.648830013806673e-09
gene O 0 6.231981615201221e-07
worldwide O 0 3.851996837056504e-07
. O 0 5.379471303967875e-07

In O 0 3.6781400467589265e-06
summary O 0 6.5075546444859356e-06
, O 0 2.6250626561363788e-08
our O 0 1.7358946280410237e-08
results O 0 4.67548666449602e-08
show O 0 5.6627911249051976e-08
frequent O 0 3.029888873129494e-08
involvement O 0 2.0636013786656804e-08
of O 0 1.1127533339205797e-09
the O 0 1.2731217857719912e-08
p16 O 0 1.4098135352469399e-06
gene O 0 5.821102035952208e-07
in O 0 1.2452231601400854e-07
familial B-Disease 0 0.0002347852278035134
melanoma I-Disease 0 0.01607281155884266
and O 0 6.157861065503312e-08
confirm O 0 4.1488706870040915e-07
the O 0 8.232208692504628e-09
role O 0 8.30177704358448e-09
of O 0 1.1269121191759268e-09
the O 0 7.617934727477405e-09
CDK4 O 0 2.455761205055751e-06
gene O 0 2.3926378389660385e-07
as O 0 1.4988685848038585e-08
a O 0 3.647066932899179e-07
melanoma B-Disease 0 0.0007819989114068449
- O 0 1.3949542335467413e-05
predisposing O 0 8.446842912235297e-06
gene O 0 5.0644389375520404e-06
. O 0 1.3362885908918543e-07
. O 0 4.653427367884433e-07

Progression O 0 0.0002550246717873961
of O 0 9.663432365414337e-07
somatic O 0 7.821113104000688e-05
CTG O 0 0.00020964948635082692
repeat O 0 1.3260202649689745e-05
length O 0 6.634807618866034e-07
heterogeneity O 0 1.0163732895307476e-06
in O 0 2.908873497631248e-08
the O 0 2.1953811213393237e-08
blood O 0 7.734036557849322e-07
cells O 0 1.2689999948634068e-06
of O 0 2.710210537770763e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.34354695677757263
. O 0 7.032148005237104e-06

The O 0 1.1450233614596073e-06
genetic O 0 3.720169615917257e-06
basis O 0 6.839141519776604e-07
of O 0 1.949101942955167e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.42258521914482117
DM B-Disease 1 1.0
) O 0 1.6770569288837578e-07
is O 0 4.691913080279164e-09
the O 0 3.6814746806612675e-09
expansion O 0 1.2073647859267567e-08
of O 0 1.118711900893743e-09
an O 0 2.0627593855238047e-08
unstable O 0 4.7578632802469656e-05
CTG O 0 1.0551012564974371e-05
repeat O 0 9.507328968538786e-07
in O 0 1.4807648440751109e-08
the O 0 1.1097780472368868e-08
34 O 0 3.6823895044335586e-08
UTR O 0 3.006465476573794e-07
of O 0 3.6199010455817415e-09
the O 0 1.5393251828754728e-07
DM B-Disease 1 0.9999970197677612
protein O 0 1.800226527848281e-06
kinase O 0 1.0199659300269559e-05
gene O 0 1.6346729125871207e-06
on O 0 3.080234023400408e-07
chromosome O 0 9.023637176142074e-06
19 O 0 9.378338177157275e-07
. O 0 3.69146164302947e-07

One O 0 3.734811286904005e-07
of O 0 5.8654343604302994e-09
the O 0 8.833421105691741e-09
principal O 0 1.2148352546148544e-08
features O 0 1.0145121187576933e-08
of O 0 3.1401994338153827e-09
the O 0 1.5850806676098728e-06
DM B-Disease 1 1.0
mutation O 0 2.1257499611238018e-05
is O 0 2.0429858693660208e-08
an O 0 4.739800996134136e-09
extraordinarily O 0 2.4808844045765e-07
high O 0 1.5854782020596758e-07
level O 0 2.5051056340430478e-08
of O 0 4.443680090560065e-09
somatic O 0 9.827571147980052e-07
mosaicism O 0 5.418218279373832e-06
, O 0 1.1401942501265694e-08
due O 0 4.039194934080115e-08
to O 0 4.994782365486117e-09
an O 0 4.448140522583799e-09
extremely O 0 2.1213087109117623e-07
high O 0 1.6639900479731295e-07
degree O 0 1.2936393289919579e-08
of O 0 2.0581365500760285e-09
somatic O 0 1.0575879514362896e-06
instability O 0 7.325722322093497e-07
both O 0 4.7258903457247925e-09
within O 0 5.871389152645179e-09
and O 0 2.777063023984283e-09
between O 0 5.9513274308642394e-09
different O 0 3.675119941703997e-08
tissues O 0 1.5836823877179995e-05
. O 0 4.432166349488398e-07

This O 0 2.1153966827114346e-06
instability O 0 4.752037511934759e-06
appears O 0 1.3807544974042685e-07
to O 0 1.1263066923561382e-08
be O 0 3.4664098258474496e-09
biased O 0 3.2067077881947625e-08
towards O 0 2.020208222930364e-09
further O 0 4.218738691719182e-09
expansion O 0 1.2252299619319729e-08
and O 0 8.860549516320759e-10
continuous O 0 7.3285284507562665e-09
throughout O 0 6.184519563134927e-09
the O 0 4.529085995130799e-09
life O 0 9.081578267178259e-10
of O 0 1.477175326503044e-10
an O 0 3.960997918550646e-10
individual O 0 3.033204798441602e-10
, O 0 4.1864650635048406e-10
features O 0 1.349069833622707e-08
that O 0 1.1285339329702992e-09
could O 0 6.158176191206621e-09
be O 0 2.08255190869977e-09
associated O 0 5.095550204003985e-09
with O 0 9.375400455979843e-10
the O 0 1.3337138504709856e-08
progressive O 0 3.365855434367404e-07
nature O 0 6.3008349648896456e-09
of O 0 3.0596152278405953e-09
the O 0 5.835330512127257e-07
disease O 0 0.00013045109517406672
. O 0 4.600858858339052e-07

Although O 0 2.224209765699925e-06
increasing O 0 7.53467361391813e-07
measured O 0 1.6118377743623569e-06
allele O 0 2.7877426873601507e-06
size O 0 3.190169479694305e-07
between O 0 9.209744433746891e-08
patients O 0 1.7917705008585472e-07
clearly O 0 4.385341156876166e-08
correlates O 0 6.229557669712449e-08
with O 0 1.1156860990624295e-09
an O 0 4.615684279229981e-09
increased O 0 9.474259599073775e-08
severity O 0 5.408894139691256e-06
of O 0 3.579470231329651e-08
symptoms O 0 0.022104470059275627
and O 0 5.7329723190946424e-09
an O 0 2.938488563586361e-09
earlier O 0 5.750907803303562e-07
age O 0 2.0291025748520042e-08
of O 0 9.924140398354098e-10
onset O 0 7.560055564681534e-06
, O 0 1.952987549458385e-09
this O 0 1.1136536137712483e-09
correlation O 0 2.3001474502848396e-08
is O 0 1.0738518962938315e-09
not O 0 4.908600192976564e-10
precise O 0 1.4779573120904388e-08
and O 0 4.438419853869391e-09
measured O 0 1.5699957600645575e-07
allele O 0 3.847396783385193e-07
length O 0 5.214778298068268e-08
cannot O 0 2.8215449532353887e-08
be O 0 1.9041661580843083e-09
used O 0 7.271774737915848e-09
as O 0 1.1559643242620155e-09
an O 0 1.984166608792748e-09
accurate O 0 3.7869500602027983e-07
predictor O 0 1.2105026598874247e-06
of O 0 4.291758948227198e-09
age O 0 3.689103422743756e-08
of O 0 1.8230402076824248e-08
onset O 0 0.0007138618966564536
. O 0 1.8019545677816495e-06

In O 0 1.1099125458713388e-06
order O 0 9.985534177303634e-08
to O 0 1.615906874974371e-08
further O 0 3.054100972121887e-08
characterize O 0 3.4694946293711837e-07
the O 0 6.530848395414068e-08
dynamics O 0 2.746706741163507e-06
of O 0 1.4373753742802364e-07
DM B-Disease 1 1.0
CTG O 0 0.00016255541413556784
repeat O 0 2.09652916964842e-05
somatic O 0 1.4888958503433969e-05
instability O 0 1.3778010725218337e-05
, O 0 2.219578298934266e-08
we O 0 2.9189872741142153e-09
have O 0 2.2006332311974575e-09
studied O 0 2.337403515184633e-08
repeat O 0 2.8132433271821355e-07
length O 0 1.1421045797987972e-07
changes O 0 1.3251728603336232e-07
over O 0 1.8135512647177165e-08
time O 0 4.153145383156698e-08
in O 0 2.568169747974025e-07
111 O 0 0.0667433887720108
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 2.269558717671316e-05
with O 0 5.2483756007859483e-08
varying O 0 1.3098967883706791e-06
clinical O 0 8.68473853188334e-06
severity O 0 0.0010428791865706444
and O 0 5.016026989324018e-07
CTG O 0 3.7980447814334184e-05
repeat O 0 2.8399510938470485e-06
size O 0 2.0086561391963187e-07
over O 0 2.2288775269885264e-08
time O 0 1.9296136244406625e-08
intervals O 0 1.6759888410433632e-07
of O 0 2.9963993508630438e-09
1 O 0 2.4535150799920302e-08
- O 0 6.205175395734841e-07
7 O 0 2.3343567079336935e-07
years O 0 6.5845071617332e-08
. O 0 1.9580599541768606e-07

We O 0 1.2970334637429914e-06
have O 0 3.472665000003872e-08
found O 0 6.343207736847489e-09
a O 0 5.5601701021146255e-09
direct O 0 1.0122312765759034e-08
progression O 0 6.363823246147149e-08
of O 0 8.404599238787114e-10
the O 0 2.392914311144523e-09
size O 0 4.403344533443487e-08
heterogeneity O 0 6.8270090025635e-08
over O 0 1.0187625854030102e-08
time O 0 1.2720052566805862e-08
related O 0 1.0584567888827223e-08
to O 0 6.1848024479616015e-09
initial O 0 1.0213349810328509e-07
CTG O 0 1.3552642030845163e-06
repeat O 0 2.2452157111274573e-07
size O 0 4.499640482436007e-08
and O 0 2.299159307384002e-09
the O 0 5.688444382201396e-09
time O 0 1.95250446921591e-08
interval O 0 8.510395588245956e-08
and O 0 4.614900905863806e-09
always O 0 5.780151912659903e-09
biased O 0 4.112596485583708e-08
towards O 0 7.991357797720866e-09
further O 0 3.315568619655096e-08
expansion O 0 6.001428687341104e-07
. O 0 6.821567239967408e-07

Attempts O 0 1.0639729225658812e-05
to O 0 4.465595111469156e-07
mathematically O 0 9.866166692518163e-07
model O 0 2.653135879882029e-07
the O 0 3.403783210842448e-08
dynamics O 0 6.223096988833277e-07
have O 0 8.306464849283657e-09
proved O 0 3.962822958669676e-08
only O 0 4.347296300721837e-09
partially O 0 8.218092517608966e-08
successful O 0 7.847381411352217e-09
suggesting O 0 3.379356883215223e-08
that O 0 8.465300127546982e-10
individual O 0 8.938257356483348e-10
specific O 0 2.908761009834393e-09
genetic O 0 8.524643391183417e-08
and O 0 8.613834268089704e-08
/ O 0 2.734197914833203e-05
or O 0 1.4712836104990856e-07
environmental O 0 3.7007882980333306e-08
factors O 0 1.0499314306855467e-08
also O 0 4.247676432811431e-09
play O 0 6.4843503899680854e-09
a O 0 6.449615508330453e-09
role O 0 2.5887903376542454e-08
in O 0 5.419244430981962e-08
somatic O 0 6.665295586572029e-06
mosaicism O 0 1.9984039681730792e-05
. O 0 8.015420149831698e-08
. O 0 3.8962545545473404e-07

Aspartylglucosaminuria B-Disease 1 0.9994722008705139
among O 0 2.8288088742556283e-06
Palestinian O 0 5.8900391195493285e-06
Arabs O 0 4.951246410200838e-06
. O 0 2.523825287426007e-06

Aspartylglucosaminuria B-Disease 1 0.9999998807907104
( O 0 0.009471056051552296
AGU B-Disease 1 0.9999997615814209
) O 0 7.103340067260433e-07
is O 0 3.4481061561564275e-08
a O 0 6.019610765406469e-08
rare O 0 3.442137767706299e-06
disorder B-Disease 0 0.014908933080732822
of I-Disease 0 3.1550058565699146e-08
glycoprotein I-Disease 0 3.3269829145865515e-05
metabolism I-Disease 0 0.010527366772294044
caused O 0 2.8697195375571027e-06
by O 0 3.81990261644205e-08
the O 0 2.14122860597854e-06
deficiency B-Disease 0 4.6383898734347895e-05
of I-Disease 0 6.245103989499512e-09
the I-Disease 0 2.0460477401229582e-07
lysosomal I-Disease 0 0.0003068919468205422
enzyme I-Disease 0 8.903763955458999e-06
aspartylglucosaminidase I-Disease 0 3.309168459963985e-05
( O 0 5.256721351543092e-07
AGA O 0 9.96474591374863e-06
) O 0 2.8152990694252367e-07
. O 0 4.0091842379297304e-07

AGU B-Disease 1 0.9999997615814209
is O 0 1.9552158846636303e-05
inherited O 0 0.00017134510562755167
as O 0 2.065712862986402e-07
an O 0 2.2299751378795918e-07
autosomal O 1 0.9984322190284729
recessive O 1 0.9998816251754761
trait O 0 7.242982974275947e-05
and O 0 7.058730489006848e-08
occurs O 0 2.524560827055211e-08
with O 0 1.642567748483259e-09
a O 0 3.9634201698390825e-08
high O 0 7.658365461793437e-07
frequency O 0 7.95112646301277e-05
in O 0 1.378218001946152e-07
Finland O 0 3.2347929845855106e-06
because O 0 3.5539711173981914e-09
of O 0 8.040140775378291e-10
a O 0 1.9173672427541533e-08
founder O 0 4.2408709077790263e-07
effect O 0 9.130231433118752e-07
. O 0 4.0268801626552886e-07

While O 0 1.617325551706017e-06
very O 0 2.6211182557744905e-07
few O 0 1.3022351197378157e-07
patients O 0 2.9916100174887106e-07
with O 0 3.1721006621410197e-07
AGU B-Disease 1 1.0
have O 0 1.9167316622770159e-07
been O 0 1.9668087603008644e-08
reported O 0 1.5120546947855473e-07
from O 0 6.790643158893772e-09
non O 0 1.6069137132035394e-08
- O 0 4.847417471864901e-07
Finnish O 0 4.54736976962522e-07
origin O 0 1.7470584978696024e-08
, O 0 1.656007420081096e-08
we O 0 4.328145308818421e-08
diagnosed O 0 3.277682844782248e-05
the O 0 3.452252599345229e-07
disorder O 0 0.00110651645809412
in O 0 7.09236118723311e-08
8 O 0 3.7232820204735617e-07
patients O 0 5.1292619929199645e-08
originating O 0 1.019035025251469e-07
from O 0 2.1106773218093622e-08
3 O 0 3.3956258249645543e-08
unrelated O 0 4.2198678329441464e-08
families O 0 2.902869500331917e-09
, O 0 5.658467028268888e-10
all O 0 1.619567674415734e-10
Palestinian O 0 6.248844997003289e-09
Arabs O 0 5.334705122095329e-09
from O 0 1.9770380887962347e-09
the O 0 3.853210195359225e-09
region O 0 2.2467016691507524e-08
of O 0 9.677643575400907e-09
Jerusalem O 0 3.180999556207098e-06
. O 0 8.117971219689935e-07

The O 0 8.256998626166023e-06
clinical O 0 0.0002179272414650768
diagnosis O 1 0.548622727394104
of O 0 1.253518576049828e-06
AGU B-Disease 1 1.0
is O 0 1.0141019401999074e-06
often O 0 4.832135402921267e-08
difficult O 0 3.3042237390645823e-08
, O 0 1.099585977826223e-09
in O 0 1.3598885351129297e-09
particular O 0 1.1900270768805399e-09
early O 0 7.633763488001932e-08
in O 0 6.586715173284574e-09
the O 0 4.719161506017144e-09
course O 0 9.872715978076485e-09
of O 0 2.721484426704279e-10
the O 0 9.638355180641156e-08
disease O 0 8.05808485893067e-06
, O 0 1.3056510317355219e-09
and O 0 6.960803600186694e-10
most O 0 5.073358955165475e-10
of O 0 5.28485477602203e-10
the O 0 1.2071095056853665e-07
patients O 0 2.821685711751343e-07
are O 0 1.5109497653043036e-08
diagnosed O 0 7.593198461108841e-06
after O 0 3.680696991636978e-08
the O 0 5.275151693240332e-08
age O 0 9.141261081424545e-09
of O 0 1.194889853728398e-09
5 O 0 4.4005570742911004e-08
years O 0 5.228562827142014e-08
. O 0 1.9314332178055338e-07

However O 0 2.574913878561347e-06
, O 0 1.0184385246247984e-07
since O 0 7.174307370405586e-08
these O 0 1.7174095034988568e-08
patients O 0 1.0485789658787326e-07
excrete O 0 2.9389227051979105e-07
early O 0 5.198898733738133e-08
large O 0 4.084249827229769e-09
amounts O 0 4.998156111213348e-09
of O 0 2.190745362895541e-09
aspartylglucosamine O 0 1.0754798722700798e-06
in O 0 4.971043310320056e-08
urine O 0 1.179087803393486e-06
, O 0 1.1428526569545738e-08
biochemical O 0 6.304095450104796e-07
screening O 0 7.663435894755821e-07
is O 0 1.8010176461302763e-08
easy O 0 3.6968373251511366e-08
by O 0 5.350135268145095e-08
urine O 0 3.1417462196259294e-06
chromatography O 0 2.879792191379238e-06
. O 0 8.203293333508554e-08
. O 0 3.9589480138602084e-07

Detection O 0 3.755326906684786e-05
of O 0 2.829754066624446e-07
heterozygous O 0 7.630357686139178e-06
carriers O 0 6.006650892231846e-07
of O 0 4.00482740303687e-08
the O 0 1.2020694157399703e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 0 2.9760326469840948e-06
ATM O 0 6.276703061303124e-05
) O 0 1.4444950124925526e-07
gene O 0 7.544941809101147e-07
by O 0 6.974284616489967e-08
G2 O 0 1.9836166757158935e-05
phase O 0 1.3463920822687214e-06
chromosomal O 0 0.00012717320350930095
radiosensitivity O 0 1.920261092891451e-05
of O 0 1.466727752585939e-07
peripheral O 0 0.0005557751865126193
blood O 0 0.00035917756031267345
lymphocytes O 0 0.00037242707912810147
. O 0 4.603027264238335e-06

In O 0 0.005675287451595068
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.009274941869080067
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.786591259493434e-07
patients O 0 5.026528810958553e-07
, O 0 8.042782440043084e-09
mutations O 0 1.9644042481559154e-07
in O 0 6.288360943074167e-09
a O 0 9.959624236444142e-09
single O 0 1.8890784048153364e-08
gene O 0 1.211066944506456e-07
, O 0 1.9076775714665928e-09
ATM O 0 6.007687716191867e-07
, O 0 4.201113679158652e-09
result O 0 1.975052654756837e-08
in O 0 1.4268876213918702e-07
an O 0 0.006698483135551214
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 3.8827599269097846e-07
embraces O 0 1.5438902778441843e-07
a O 0 1.3477684746021623e-08
variety O 0 5.768972854980348e-09
of O 0 2.0234705022659227e-09
clinical O 0 9.018821600648153e-08
features O 0 9.070399755728431e-07
and O 0 3.023383214895148e-07
manifests O 0 2.3324860194406938e-06
extreme O 0 2.7712869723472977e-06
radiosensitivity O 0 8.436665666522458e-06
and O 0 1.701261176378921e-08
a O 0 4.0330824901957385e-08
strong O 0 3.5933535968979413e-07
pre O 0 0.00024528903304599226
- O 0 0.00010830330575117841
disposition O 0 9.288135515816975e-06
to O 0 4.396622443891829e-07
malignancy B-Disease 0 5.346052785171196e-05
. O 0 5.341927362678689e-07

Heterozygotes O 0 0.0003946395590901375
for O 0 4.383141742891894e-07
the O 0 1.5781529327796306e-07
ATM O 0 1.6755757314967923e-05
gene O 0 1.7923019868248957e-06
have O 0 1.9911583493126273e-08
no O 0 1.0268390582268694e-08
clinical O 0 4.595683833485964e-08
expression O 0 2.360881978802354e-08
of O 0 7.040226179810816e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 0.00012064780457876623
may O 0 0.006469282787293196
be O 0 1.3208355085225776e-06
cancer B-Disease 0 2.9464392355293967e-05
prone O 0 5.811383516629576e-07
with O 0 3.356550815070136e-09
a O 0 3.957913108365574e-08
moderate O 0 1.7230747744179098e-06
increase O 0 4.4508755792094234e-08
in O 0 1.963072193689186e-08
in O 0 6.075542557937297e-08
vitro O 0 8.9492159531801e-06
radiosensitivity O 0 3.3582891774130985e-05
. O 0 1.0406962474007742e-06

We O 0 1.3154099178791512e-06
performed O 0 8.619501841167221e-07
a O 0 2.387267841186258e-07
blind O 0 1.6747934523664298e-06
chromosomal O 0 1.916839937621262e-05
analysis O 0 4.552985046757385e-07
on O 0 6.960822247492615e-07
G2 O 0 7.181650289567187e-05
- O 0 3.5637249311548658e-06
phase O 0 6.655035917901841e-07
lymphocytes O 0 2.749332679741201e-06
from O 0 4.9614953923082794e-08
7 O 0 1.0269628347714388e-07
unrelated O 0 8.690204822414671e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.2574287211464252e-05
, O 0 1.474491284625401e-08
13 O 0 3.921379132520997e-08
obligate O 0 2.56909061135957e-07
A B-Disease 1 0.9999868869781494
- I-Disease 1 0.99998939037323
T I-Disease 1 1.0
heterozygotes O 0 0.00022005448408890516
( O 0 6.770044080894877e-08
parents O 0 1.1847554048927122e-08
of O 0 6.91731227853154e-10
the O 0 2.0834429292904133e-08
patients O 0 5.7110490558898164e-08
) O 0 2.4724644553941744e-09
, O 0 1.0702387864824914e-09
and O 0 3.570794993024151e-09
14 O 0 2.220594552682087e-08
normal O 0 3.039231160073541e-07
controls O 0 2.1523705072468147e-05
following O 0 3.439128022364457e-07
X O 0 3.284040212747641e-05
- O 0 8.48648426199361e-07
irradiation O 0 5.969280891804374e-07
with O 0 1.2056111664549007e-08
1 O 0 3.660778347125415e-08
Gy O 0 1.4323372852231842e-06
in O 0 6.606922120511172e-09
order O 0 4.520886776049338e-09
to O 0 2.8930198237020477e-09
evaluate O 0 1.804927762805164e-08
this O 0 2.758291373083921e-09
cytogenetic O 0 8.838748044581735e-07
method O 0 1.4250865376652655e-08
as O 0 3.56009088875453e-09
a O 0 1.153458395464213e-08
tool O 0 8.156519015756203e-08
for O 0 9.234344400255168e-10
detection O 0 5.326340257738593e-08
of O 0 4.9676289748390445e-09
ATM O 0 2.5846913558780216e-05
carriers O 0 2.507764520487399e-06
. O 0 9.603348871678463e-07

Both O 0 1.2173945833637845e-05
A B-Disease 1 0.9991472959518433
- I-Disease 1 0.9991801381111145
T I-Disease 1 0.9999992847442627
homozygotes O 0 0.00015113846166059375
and O 0 2.4954348987193953e-07
heterozygotes O 0 6.296216270129662e-06
showed O 0 5.036615107201214e-07
significantly O 0 3.416578522319469e-07
increased O 0 5.192110563712049e-08
levels O 0 4.1192535604750447e-08
of O 0 1.0475350364913538e-08
radiation O 0 0.0016783055616542697
- O 0 0.0006874854443594813
induced O 0 6.951010436750948e-05
chromatid O 0 3.327842932776548e-05
damage O 0 1.3272892829263583e-06
relative O 0 1.8268940493726404e-07
to O 0 1.2782630953722673e-08
that O 0 1.479335653975511e-09
of O 0 1.7998732504409531e-09
normal O 0 5.99222119035403e-07
controls O 0 0.0002796990447677672
. O 0 5.226040116212971e-07

These O 0 7.615162189722469e-07
results O 0 2.221044184125276e-07
show O 0 2.2033816549082985e-07
that O 0 4.6753685367662e-09
the O 0 3.020892336280667e-08
G2 O 0 1.5815949154784903e-05
- O 0 2.404588485660497e-06
phase O 0 6.577552653652674e-07
chromosomal O 0 2.9013714083703235e-05
radiosensitivity O 0 5.98264477957855e-06
assay O 0 3.738218538273941e-06
can O 0 1.1398593180445005e-08
be O 0 1.0896604729637716e-09
used O 0 2.5991391261470653e-09
for O 0 4.13807044186143e-10
the O 0 1.0677960737837111e-09
detection O 0 1.0136846384511955e-07
of O 0 2.017459799219523e-08
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999889135360718
T I-Disease 1 1.0
heterozygotes O 0 0.00033390463795512915
. O 0 1.9212791357858805e-06

In O 0 2.5268234367104014e-06
combination O 0 1.8025389181275386e-06
with O 0 6.431793053707224e-08
molecular O 0 1.3199804698160733e-06
genetic O 0 7.625976650160737e-07
analyses O 0 5.768050641563605e-07
, O 0 7.084394848533293e-09
this O 0 6.702383092971331e-09
test O 0 1.5124036281122244e-06
may O 0 6.902793643348559e-07
be O 0 1.3991597880291806e-09
of O 0 3.791401359531932e-10
value O 0 9.022186331364423e-10
in O 0 2.0395118927041267e-09
studies O 0 2.7862259166511194e-09
of O 0 1.0997810440116496e-09
familial B-Disease 0 7.43335419883806e-07
and I-Disease 0 8.401353568388004e-08
sporadic I-Disease 0 0.00016128200513776392
cancers I-Disease 0 0.0009834329830482602
aimed O 0 4.668963811127469e-07
at O 0 5.4527902193513e-07
determination O 0 4.2401349986675996e-08
of O 0 8.296612286073923e-10
the O 0 1.6076118214414237e-09
potential O 0 1.4232495182397997e-09
involvement O 0 4.2317465087649e-09
of O 0 1.9252890393062216e-09
ATM O 0 1.4007797290105373e-05
mutations O 0 3.122095904473099e-06
in O 0 2.610229898891703e-07
tumor B-Disease 0 9.842932195169851e-05
risk O 0 2.8090477144360193e-07
or O 0 3.004985771326574e-08
development O 0 2.2259547094449772e-08
. O 0 4.23124788540008e-08
. O 0 2.4063635351012636e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
: O 0 1.0788183999466128e-06
identification O 0 2.9921352506789844e-07
and O 0 1.3752448957404795e-08
detection O 0 1.6587299001002975e-07
of O 0 4.72530414796779e-09
founder O 0 6.122260174379335e-07
- O 0 1.1476482768557617e-06
effect O 0 2.905450458001724e-07
mutations O 0 4.822155119654781e-07
in O 0 6.723022583088323e-09
the O 0 1.604050581249794e-08
ATM O 0 4.0511649785912596e-06
gene O 0 5.968438472336857e-07
in O 0 3.0975254361464977e-08
ethnic O 0 4.31801154832101e-08
populations O 0 3.0182209798113036e-07
. O 0 2.1207058864547434e-07

To O 0 4.0724168570704933e-07
facilitate O 0 1.4806045101067866e-07
the O 0 2.3438412100063033e-08
evaluation O 0 3.322899644331301e-08
of O 0 2.9149089808555573e-09
ATM O 0 5.357372629077872e-06
heterozygotes O 0 1.0894032129726838e-06
for O 0 8.582277999380494e-09
susceptibility O 0 3.859803712202847e-07
to O 0 1.696675866469377e-08
other O 0 1.6778175293552522e-08
diseases O 0 2.1409057353594108e-06
, O 0 1.5030445776886836e-09
such O 0 6.460622703485797e-09
as O 0 0.0001955448678927496
breast B-Disease 1 0.9997910857200623
cancer I-Disease 0 0.0010185203282162547
, O 0 7.699254567228309e-09
we O 0 1.4292887984268532e-09
have O 0 7.900060050580748e-10
attempted O 0 3.9651439465160365e-08
to O 0 6.7655108182407275e-09
define O 0 1.4937114656277117e-08
the O 0 4.155694455221237e-09
most O 0 2.388509612316625e-09
common O 0 2.0509974163474e-08
mutations O 0 1.2273939375972986e-07
and O 0 2.4407480481158927e-09
their O 0 7.4863812926651e-09
frequencies O 0 2.292586759722326e-05
in O 0 0.00010919586929958314
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 6.591761484742165e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999964237213135
T I-Disease 1 1.0
) O 0 8.658126660066046e-08
homozygotes O 0 1.9251526737207314e-06
from O 0 3.4067323184672205e-08
10 O 0 1.3480718763503319e-08
ethnic O 0 2.414979327625133e-08
populations O 0 3.1522995413979515e-07
. O 0 3.992510642092384e-07

Both O 0 3.0647004223283147e-06
genomic O 0 4.5102362491888925e-05
mutations O 0 3.187694528605789e-05
and O 0 5.115047230219716e-08
their O 0 3.431382822327578e-08
effects O 0 6.527959612867562e-07
on O 0 1.739086741281426e-07
cDNA O 0 1.1980087037954945e-06
were O 0 8.950548391339908e-08
characterized O 0 1.9061311604673392e-06
. O 0 5.435371690509783e-07

Protein O 0 0.0001116824641940184
- O 0 2.2340153009281494e-05
truncation O 0 2.1268266209517606e-05
testing O 0 1.555956032461836e-06
of O 0 6.807540753328567e-09
the O 0 1.19492691297296e-08
entire O 0 1.0319541132730592e-07
ATM O 0 3.0659664389531827e-06
cDNA O 0 2.2043368517188355e-06
detected O 0 3.5806633604806848e-06
92 O 0 6.742325240338687e-07
( O 0 6.713964495475011e-08
66 O 0 1.6670713876010268e-07
% O 0 1.2857405806698807e-08
) O 0 2.422952150027413e-08
truncating O 0 4.86796352561214e-06
mutations O 0 1.2188118034828221e-06
in O 0 3.711709695153331e-08
140 O 0 3.4775442259160627e-07
mutant O 0 5.933155534876278e-06
alleles O 0 1.1402254131098744e-05
screened O 0 1.3072314686723985e-05
. O 0 1.1410425031499472e-06

The O 0 2.6551126666163327e-06
haplotyping O 0 2.327727634110488e-05
of O 0 6.478221337147261e-08
patients O 0 2.4857487801455136e-07
with O 0 2.909095364600489e-08
identical O 0 3.296543945907615e-05
mutations O 0 1.048959165927954e-05
indicates O 0 1.0819758955449288e-07
that O 0 2.1985187004247564e-09
almost O 0 2.2392694365436228e-09
all O 0 1.7401957652651845e-10
of O 0 1.6309537054226553e-10
these O 0 3.68183816767953e-10
represent O 0 7.765159071304595e-10
common O 0 3.8760314957642095e-09
ancestry O 0 1.615068612181858e-08
and O 0 2.7099142929642994e-09
that O 0 1.848794117798036e-09
very O 0 1.1279728262536537e-08
few O 0 4.4205702209865194e-08
spontaneously O 0 6.157533221085032e-07
recurring O 0 3.0690321182191838e-06
ATM O 0 0.00012513867113739252
mutations O 0 4.8117322876350954e-05
exist O 0 1.0432778481117566e-06
. O 0 1.7453420468882541e-06

Assays O 0 0.00015301922394428402
requiring O 0 1.6006983969418798e-06
minimal O 0 3.560392087820219e-07
amounts O 0 4.777798423560853e-08
of O 0 4.345414694739702e-09
genomic O 0 5.12214000991662e-07
DNA O 0 3.661718324110552e-07
were O 0 5.07197057686426e-08
designed O 0 3.7179523815211724e-07
to O 0 5.31885557819578e-09
allow O 0 9.155516345060732e-09
rapid O 0 4.062978860019939e-07
screening O 0 3.0197728051462036e-07
for O 0 4.7217909582286666e-09
common O 0 4.534092923336175e-08
ethnic O 0 6.173949884669128e-08
mutations O 0 1.0026574273069855e-05
. O 0 9.817013051360846e-07

These O 0 2.6016759875346906e-06
rapid O 0 1.949869874806609e-05
assays O 0 9.732603211887181e-05
detected O 0 6.720616511302069e-05
mutations O 0 7.301168352569221e-06
in O 0 8.914685167837888e-08
76 O 0 3.615108141730161e-07
% O 0 8.12966138852289e-09
of O 0 2.2328037196928108e-09
Costa O 0 8.219659974884053e-08
Rican O 0 3.375942867478443e-07
patients O 0 4.0873774764804693e-07
( O 0 1.691857498542504e-08
3 O 0 8.739004186963939e-09
) O 0 1.5015431120701805e-09
, O 0 6.436328137127134e-10
50 O 0 2.1984138953712318e-09
% O 0 4.606781345284361e-10
of O 0 7.217246245083686e-10
Norwegian O 0 6.952025614737067e-06
patients O 0 5.781262188975234e-07
( O 0 1.111281910937123e-08
1 O 0 1.3929880360308289e-08
) O 0 2.3567550133662962e-09
, O 0 7.507955368524222e-10
25 O 0 5.05886710300274e-09
% O 0 9.893975638775032e-10
of O 0 1.2818123229507705e-09
Polish O 0 4.154841008130461e-05
patients O 0 3.871397780130792e-07
( O 0 1.3100422080469798e-08
4 O 0 2.9564292347572518e-08
) O 0 2.596349579775392e-09
, O 0 1.0222422908157114e-09
and O 0 2.2072876859624557e-09
14 O 0 4.644518103447126e-09
% O 0 9.091630226443215e-10
of O 0 4.90809504150036e-10
Italian O 0 7.178235250648868e-07
patients O 0 4.474487695915741e-07
( O 0 8.182459154681965e-09
1 O 0 7.64910712547362e-09
) O 0 1.875864352740564e-09
, O 0 7.037684879307449e-10
as O 0 9.89578752275122e-10
well O 0 1.1661133170193239e-09
as O 0 1.4902219458434729e-09
in O 0 7.447657157655385e-09
patients O 0 1.712519193119988e-08
of O 0 3.4004463689285558e-09
Amish O 0 7.52556006773375e-05
/ O 0 4.8431335017085075e-05
Mennonite O 0 2.0078907255083323e-05
and O 0 7.164297954886933e-08
Irish O 0 9.029869261212298e-07
English O 0 9.708760444482323e-07
backgrounds O 0 1.6045881920945249e-06
. O 0 1.0557539553701645e-06

Additional O 0 2.2656504370388575e-06
mutations O 0 1.096162941394141e-05
were O 0 6.612800262928431e-08
observed O 0 9.235743902991089e-08
in O 0 1.2138647420556481e-08
Japanese O 0 9.42397662129224e-08
, O 0 5.0374722171397934e-09
Utah O 0 2.427892553669153e-08
Mormon O 0 1.8632100307058863e-08
, O 0 1.2558982742660874e-09
and O 0 2.0070038964092873e-09
African O 0 8.934359030376982e-09
American O 0 3.698071537883152e-08
patients O 0 4.952112249156926e-07
. O 0 3.9088229186745593e-07

These O 0 1.3446585853671422e-06
assays O 0 1.609250648471061e-05
should O 0 1.395730606645884e-07
facilitate O 0 1.0499578451117486e-07
screening O 0 3.5097929185212706e-07
for O 0 1.8034789661669492e-08
A B-Disease 1 0.9999607801437378
- I-Disease 1 0.999686598777771
T I-Disease 1 1.0
heterozygotes O 0 9.57129850576166e-06
in O 0 2.9671570089817578e-08
the O 0 1.3905033569017178e-08
populations O 0 3.547525295743981e-08
studied O 0 5.559611437888634e-08
. O 0 1.6881893216691424e-08
. O 0 2.1487798562702665e-07

The O 0 4.1396855522179976e-05
von B-Disease 1 0.8635403513908386
Hippel I-Disease 1 0.9977927207946777
- I-Disease 1 0.9027361273765564
Lindau I-Disease 1 0.987810492515564
tumor I-Disease 0 0.0028730209451168776
suppressor O 0 0.00018572091357782483
gene O 0 6.057739483367186e-06
is O 0 1.3709628099434212e-08
required O 0 4.2286640855593305e-09
for O 0 3.4681226779298413e-09
cell O 0 1.52717416312953e-06
cycle O 0 2.199276423198171e-06
exit O 0 7.69636415043351e-07
upon O 0 8.763579018022938e-08
serum O 0 4.376489869173383e-06
withdrawal O 0 2.0543077425827505e-06
. O 0 7.698919262111303e-07

The O 0 3.909306542482227e-06
inactivation O 0 4.268636621418409e-05
of O 0 8.196286671591224e-08
the O 0 6.596756634280609e-07
von B-Disease 1 0.969597578048706
Hippel I-Disease 1 0.9985789060592651
- I-Disease 1 0.9582683444023132
Lindau I-Disease 1 0.9867445826530457
( I-Disease 0 4.845157036470482e-06
VHL I-Disease 0 0.0013605975545942783
) I-Disease 0 1.2575908385770163e-06
tumor I-Disease 0 7.061880023684353e-05
suppressor O 0 0.00020193084492348135
gene O 0 2.4202041458920576e-05
predisposes O 0 1.4115804333414417e-05
affected O 0 2.1253424620226724e-07
individuals O 0 4.1601833089544016e-09
to O 0 5.220209153833366e-09
the O 0 1.5343084669439122e-07
human O 0 2.5525536329951137e-05
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 8.581283594821798e-08
is O 0 1.1241883868251534e-08
associated O 0 5.6977647489020455e-08
with O 0 8.11592215654855e-08
sporadic B-Disease 1 0.9897168874740601
renal I-Disease 1 0.9999997615814209
cell I-Disease 1 0.9999990463256836
carcinomas I-Disease 1 1.0
( O 0 0.00012715575576294214
RCC B-Disease 1 0.6926199197769165
) O 0 3.147067104691814e-07
and O 0 3.1371902764476545e-07
brain B-Disease 0 0.0006435132236219943
hemangioblastomas I-Disease 0 0.0005021311226300895
. O 0 3.1958472845872166e-06

VHL O 1 0.7300974726676941
- O 0 0.0031658795196563005
negative O 0 9.694627078715712e-05
786 O 0 9.771829354576766e-05
- O 0 6.328209565253928e-05
0 O 0 1.4072182921154308e-06
RCC B-Disease 0 3.923958138329908e-05
cells O 0 3.08011067318148e-07
are O 0 4.378835960494598e-09
tumorigenic O 0 9.942153837982914e-07
in O 0 1.3178443225569936e-07
nude O 0 2.6285699277650565e-05
mice O 0 2.906519512180239e-05
which O 0 4.013307730588167e-08
is O 0 4.1235281855733774e-09
suppressed O 0 6.435094235257566e-08
by O 0 1.6042087658263426e-09
the O 0 6.5103256119414254e-09
reintroduction O 0 5.415813006948156e-07
of O 0 7.059794171482281e-08
VHL B-Disease 0 0.00031257380032911897
. O 0 1.169511619991681e-06

Remarkably O 0 0.00022962884395383298
, O 0 1.353684098148733e-07
this O 0 1.1030503621611842e-08
occurs O 0 3.0776554638123343e-08
without O 0 5.295825999951376e-09
affecting O 0 1.9061911160633827e-08
the O 0 7.853520500589184e-09
growth O 0 1.2673778826410853e-07
rate O 0 6.491796398222505e-07
and O 0 1.4239019741069114e-08
cell O 0 8.550891266168037e-07
cycle O 0 4.0624053099236335e-07
profile O 0 3.8763513288131435e-08
of O 0 9.652807442250833e-10
these O 0 2.3570112528403797e-09
cells O 0 3.66729153711276e-08
in O 0 2.377556640453804e-08
culture O 0 1.0339573464079876e-06
. O 0 5.470421911013545e-07

The O 0 3.702486765178037e-06
786 O 0 5.127427357365377e-05
- O 0 6.2419303503702395e-06
0 O 0 2.0435594194623263e-07
cell O 0 1.6120008012876497e-06
line O 0 2.9900493245804682e-06
, O 0 3.9902543491621145e-09
like O 0 2.668079090994979e-09
many O 0 4.327259883751822e-09
cancer B-Disease 0 1.178433535642398e-06
cells O 0 9.645325604878963e-08
, O 0 7.2178831800329135e-09
fails O 0 2.0676127121532772e-07
to O 0 5.508289824263102e-09
exit O 0 6.728322432536515e-08
the O 0 1.0752049917073236e-08
cell O 0 5.731444048251433e-07
cycle O 0 4.76686665251691e-07
upon O 0 3.495191691627042e-08
serum O 0 2.4315668269991875e-06
withdrawal O 0 1.6293639646391966e-06
. O 0 4.309676739921997e-07

Here O 0 1.4552680340784718e-06
, O 0 4.8621174641994e-08
it O 0 7.74125119562541e-09
is O 0 1.5370280603832498e-09
shown O 0 7.481770758488437e-09
that O 0 1.0193412780523659e-09
reintroduction O 0 4.345491078083796e-08
of O 0 1.3740565352193812e-09
the O 0 1.1374182484757966e-08
wild O 0 3.934332539756724e-07
- O 0 8.877394429873675e-05
type O 0 0.00022684645955450833
VHL B-Disease 0 0.00014488075976260006
gene O 0 3.6075491607334698e-06
restores O 0 3.5110992939735297e-06
the O 0 2.6293220045658927e-08
ability O 0 8.188833078293101e-08
of O 0 2.8377524330380766e-08
VHL O 0 0.00959291122853756
- O 0 0.015140138566493988
negative O 0 0.0008806498371995986
RCC B-Disease 1 0.9341849088668823
cancer I-Disease 0 5.8454479585634544e-05
cells O 0 3.094068574682751e-07
to O 0 2.1054184173863177e-08
exit O 0 2.17211947983742e-07
the O 0 3.018773142571263e-08
cell O 0 1.011264657790889e-06
cycle O 0 6.454245067288866e-07
and O 0 1.4518529489748744e-08
enter O 0 2.840097863554547e-07
G0 O 0 5.7833032769849524e-05
/ O 0 1.0934857527900022e-05
quiescence O 0 3.361550625413656e-05
in O 0 9.712354085422703e-07
low O 0 8.00643174443394e-05
serum O 0 6.559424946317449e-05
. O 0 1.740023776619637e-06

Both O 0 1.9138295101583935e-05
VHL O 0 0.008641318418085575
- O 0 0.00012705090921372175
positive O 0 1.0430371730763e-06
and O 0 3.889186075411999e-07
VHL O 0 0.0019153255270794034
- O 0 0.00015343358973041177
negative O 0 1.0223138815490529e-05
RCC B-Disease 0 8.823523967294022e-05
cells O 0 6.784042625440634e-07
exit O 0 3.57328417521785e-07
the O 0 2.597703563367304e-08
cell O 0 1.3758163959209924e-06
cycle O 0 5.12715928380203e-07
by O 0 1.8604046303494215e-08
contact O 0 1.463799094381102e-06
inhibition O 0 7.167316653067246e-06
. O 0 8.422722999057441e-07

The O 0 5.919805516896304e-06
cyclin O 0 0.00034672991023398936
- O 0 6.093954198149731e-06
dependent O 0 8.099211186163302e-07
kinase O 0 1.1543095752131194e-05
inhibitor O 0 1.9081608115811832e-06
, O 0 2.568683399317706e-08
p27 O 0 1.7662858908806811e-06
, O 0 1.6541100933409325e-08
accumulates O 0 3.6100229294788733e-07
upon O 0 2.0962662716783598e-08
serum O 0 6.0463071349659e-07
withdrawal O 0 4.3158539853038747e-08
, O 0 1.5049350654550153e-09
only O 0 4.166232359104072e-10
in O 0 6.477078318134488e-10
the O 0 1.5861937319172625e-09
presence O 0 1.0369612724048238e-08
of O 0 3.980076712650771e-09
VHL B-Disease 0 5.887388397241011e-06
, O 0 2.3393915693503686e-09
as O 0 9.475209505893645e-10
a O 0 2.9544549029481004e-09
result O 0 3.2288869356023042e-09
of O 0 3.608669474353121e-10
the O 0 3.1819999968263346e-09
stabilization O 0 4.796333286094523e-08
of O 0 1.0623172341794884e-09
the O 0 1.6897260479709075e-08
protein O 0 5.188636009734182e-07
. O 0 1.9159237751864566e-07

We O 0 6.49592720947112e-07
propose O 0 7.318033681258385e-07
that O 0 7.373957444656298e-09
the O 0 3.9603427204326636e-09
loss O 0 3.238510259961913e-08
of O 0 1.4854402152764123e-09
wild O 0 1.6643058131649013e-07
- O 0 0.00014419632498174906
type O 0 0.002295337850227952
VHL B-Disease 0 0.00020967947784811258
gene O 0 2.2807519144407706e-06
results O 0 9.999619976497343e-08
in O 0 5.04992092587031e-09
a O 0 8.282213137533745e-09
specific O 0 1.5600875258314773e-08
cellular O 0 4.314243142289342e-06
defect O 0 4.929038368572947e-06
in O 0 7.68641896797817e-08
serum O 0 2.631239340189495e-06
- O 0 9.415134059054253e-07
dependent O 0 1.473884623237609e-07
growth O 0 1.872844705985699e-07
control O 0 5.37183268534136e-07
, O 0 4.2285512869000286e-09
which O 0 1.4389563318673027e-08
may O 0 1.7805912477797392e-07
initiate O 0 2.266793671878986e-06
tumor B-Disease 0 3.212676529074088e-05
formation O 0 2.8371168809826486e-06
. O 0 9.763001571627683e-07

This O 0 9.094843562706956e-07
is O 0 6.353963755145742e-08
corrected O 0 5.375665637075144e-07
by O 0 4.7068278163919786e-09
the O 0 5.3004032274373e-09
reintroduction O 0 1.9978945431375905e-07
of O 0 6.300426846905793e-09
wild O 0 4.5700986106567143e-07
- O 0 0.003878178773447871
type O 0 0.04286514222621918
VHL B-Disease 0 0.006391753908246756
, O 0 1.2117669712097268e-07
implicating O 0 9.054601832758635e-06
VHL B-Disease 0 3.7345638702390715e-05
as O 0 2.7055358842176247e-08
the O 0 1.3410244470435373e-08
first O 0 8.225462977407005e-08
tumor B-Disease 0 3.9431779441656545e-06
suppressor O 0 2.318306542292703e-06
involved O 0 1.194867671472366e-08
in O 0 5.836173766482489e-09
the O 0 5.467811536874478e-09
regulation O 0 9.851314075604023e-08
of O 0 1.176910124911501e-09
cell O 0 7.418949508064543e-07
cycle O 0 1.3887139402868343e-06
exit O 0 4.534853701443353e-07
, O 0 5.141689296550567e-09
which O 0 3.890667787942448e-09
is O 0 7.214658870324797e-10
consistent O 0 4.564852051913704e-09
with O 0 4.973712552924781e-10
its O 0 1.5147559651040865e-08
gatekeeper O 0 2.422638090138207e-07
function O 0 1.0110677628460962e-08
in O 0 8.861399614090715e-09
the O 0 8.117734040524738e-08
kidney O 0 2.214346977780224e-06
. O 0 5.282955584107185e-08
. O 0 6.226100595085882e-07

Piebaldism B-Disease 1 0.9999997615814209
with O 0 0.01689849980175495
deafness B-Disease 1 1.0
: O 0 2.916129631103104e-07
molecular O 0 2.6760929472402495e-07
evidence O 0 1.8712945859533647e-08
for O 0 6.145281172820205e-09
an O 0 9.546108969971101e-08
expanded O 0 0.03981742635369301
syndrome O 1 0.9999948740005493
. O 0 2.1802934497827664e-06

In O 0 7.236343435579329e-07
a O 0 1.462453838030342e-07
South O 0 1.2915391778278718e-07
African O 0 4.520880381164716e-08
girl O 0 3.9342728541669203e-07
of O 0 1.0746453504850706e-08
Xhosa O 0 1.5315123164327815e-05
stock O 0 4.989642093278235e-06
with O 0 7.632744569718852e-08
severe O 0 0.0015377883100882173
piebaldism B-Disease 0 0.13415409624576569
and O 0 3.958098022849299e-05
profound O 0 0.20081067085266113
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.00010112106974702328
identified O 0 8.818507239993778e-07
a O 0 8.046868060773704e-08
novel O 0 1.6882481190805265e-07
missense O 0 2.7226610654906835e-06
substitution O 0 1.6380454326281324e-07
at O 0 1.4713593543547177e-07
a O 0 2.944729082798858e-08
highly O 0 4.789002261418318e-08
conserved O 0 1.777830647142764e-07
residue O 0 2.191618477809243e-07
in O 0 5.067239516876043e-09
the O 0 6.51564224796175e-09
intracellular O 0 3.1722760240882053e-07
kinase O 0 1.6096641957119573e-06
domain O 0 6.810206087948245e-08
of O 0 5.67623015257368e-09
the O 0 9.228470787547849e-08
KIT O 0 0.00022782075393479317
proto O 0 0.0006005523609928787
- O 0 2.1242381990305148e-05
oncogene O 0 4.906976755592041e-05
, O 0 1.6261896007563337e-07
R796G O 0 1.0740616744442377e-05
. O 0 1.305539399254485e-06

Though O 0 2.0365532691357657e-05
auditory B-Disease 0 0.0005142936715856194
anomalies I-Disease 0 0.03472800925374031
have O 0 1.3893853179069993e-07
been O 0 5.452546858464302e-08
observed O 0 1.1414763179118381e-07
in O 0 4.325067237687108e-08
mice O 0 5.492217042046832e-06
with O 0 2.640433827139077e-08
dominant O 0 3.7595407320623053e-06
white O 0 1.203571855512564e-06
spotting O 0 1.2613150829565711e-05
( O 0 2.762974702363863e-07
W O 0 0.007887889631092548
) O 0 8.074970025973016e-09
due O 0 8.956764929735073e-08
to O 0 2.257651914305825e-07
KIT O 1 0.8139224052429199
mutations O 0 0.0013208567397668958
, O 0 2.651901468198048e-06
deafness B-Disease 1 1.0
is O 0 1.6141362380039936e-07
not O 0 1.0395297955767546e-08
typical O 0 1.5367071171112912e-07
in O 0 4.776431694608618e-08
human O 0 1.0875228184659136e-07
piebaldism B-Disease 0 4.3264375563012436e-05
. O 0 8.936711992646451e-07

Thus O 0 2.196249852204346e-06
, O 0 5.5037975954519425e-08
the O 0 2.0211995632735125e-08
occurrence O 0 5.805998739560891e-07
of O 0 2.0071549045042048e-07
sensorineural B-Disease 1 0.9999997615814209
deafness I-Disease 1 1.0
in O 0 9.038260941451881e-06
this O 0 1.5768048911013466e-07
patient O 0 1.111599885916803e-06
extends O 0 1.655600527783463e-07
considerably O 0 4.136015832045814e-07
the O 0 1.767949164843685e-08
phenotypic O 0 3.1395757105201483e-07
range O 0 5.585940243690857e-08
of O 0 2.696560086334898e-09
piebaldism B-Disease 0 1.4657199471912463e-06
due O 0 1.7543388253216108e-07
to O 0 4.903374062337207e-08
KIT O 0 3.6735473258886486e-05
gene O 0 1.207779064316128e-06
mutation O 0 4.93082552566193e-07
in O 0 1.4744687248935406e-08
humans O 0 3.922702873637718e-08
and O 0 2.2303275670765288e-08
tightens O 0 0.0002301584172528237
the O 0 4.988025281704722e-08
clinical O 0 2.2667042287594086e-07
similarity O 0 1.317356748131715e-07
between O 0 6.16384241425294e-08
piebaldism B-Disease 0 8.874222658050712e-06
and O 0 1.3474342530628292e-08
the O 0 2.4870652204356247e-09
various O 0 2.985514502285014e-09
forms O 0 4.473591275200306e-08
of O 0 5.554576318900217e-07
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999982118606567
. O 0 1.6004740643893456e-07
. O 0 4.3493969315022696e-07

Cycloheximide O 0 0.00014158149133436382
facilitates O 0 8.96124038263224e-06
the O 0 1.7990063838624337e-07
identification O 0 1.6030388394483452e-07
of O 0 9.666040412525945e-09
aberrant O 0 3.2202153761318186e-06
transcripts O 0 9.5935820354498e-07
resulting O 0 2.9710312787756266e-07
from O 0 2.078882133105253e-08
a O 0 3.636109369153928e-08
novel O 0 2.3470940391234763e-07
splice O 0 2.651536306075286e-05
- O 0 8.850734957377426e-06
site O 0 1.0683546634027152e-06
mutation O 0 8.807362519291928e-07
in O 0 3.844946050435283e-08
COL17A1 O 0 3.769308932533022e-06
in O 0 4.7491877097627366e-08
a O 0 1.2564996154651453e-07
patient O 0 4.840742349188076e-06
with O 0 1.2044088180118706e-06
generalized O 0 0.029464976862072945
atrophic B-Disease 1 0.9999867677688599
benign I-Disease 1 0.9999940395355225
epidermolysis I-Disease 1 0.9998937845230103
bullosa I-Disease 1 0.9945480227470398
. O 0 2.8525610105134547e-05

Patients O 0 0.0007947065168991685
with O 0 2.3657070414628834e-05
generalized O 0 0.21751612424850464
atrophic B-Disease 1 0.999997615814209
benign I-Disease 1 0.999995231628418
epidermolysis I-Disease 1 0.9998979568481445
bullosa I-Disease 1 0.9974377155303955
often O 0 7.562284736195579e-05
show O 0 1.6460631741210818e-05
decreased O 0 5.606836111837765e-06
expression O 0 3.1106932851798774e-07
of O 0 2.881082927785883e-08
type O 0 5.5202388466568664e-05
XVII O 0 0.00023286613577511162
collagen O 0 6.9317743509600405e-06
, O 0 1.2669857163416509e-08
a O 0 9.199860073749733e-08
transmembrane O 0 7.765950158500345e-07
hemidesmosomal O 0 4.654453277908033e-06
protein O 0 6.699592631775886e-07
encoded O 0 3.8164367310855596e-07
by O 0 2.0301619940710225e-07
COL17A1 O 0 0.00010373207624070346
. O 0 8.108663678285666e-07

This O 0 1.1517741995703545e-06
report O 0 5.174838975108287e-07
documents O 0 1.0035445541234367e-07
a O 0 3.175708229719021e-08
novel O 0 8.771756654368801e-08
splice O 0 1.782831532182172e-05
- O 0 5.275985131447669e-06
site O 0 5.050231948189321e-07
mutation O 0 4.449806283446378e-07
in O 0 1.60926312275933e-08
COL17A1 O 0 2.316697418791591e-06
in O 0 2.568114965129098e-08
a O 0 8.272696305766658e-08
patient O 0 1.973096459551016e-06
with O 0 2.9916671451246657e-07
generalized O 0 0.0012705406406894326
atrophic B-Disease 1 0.9999603033065796
benign I-Disease 1 0.9999480247497559
epidermolysis I-Disease 1 0.9987894892692566
bullosa I-Disease 1 0.702587366104126
, O 0 3.278535700701468e-07
and O 0 3.273967053019078e-08
applies O 0 2.9295359027514678e-08
a O 0 1.1702849356254319e-08
new O 0 6.674230945691306e-08
methodology O 0 4.140553500064925e-08
to O 0 4.130084718667604e-09
define O 0 2.3188686526509628e-08
and O 0 5.653496781832246e-09
characterize O 0 1.184871081250094e-07
the O 0 1.5547970022566915e-08
resulting O 0 1.437582426433437e-07
mRNA O 0 1.480474907111784e-06
splice O 0 9.192031575366855e-05
variants O 0 7.731829100521281e-05
. O 0 4.907528364128666e-06

Mutational O 0 0.0019086938118562102
analysis O 0 4.127809916099068e-06
of O 0 1.9854931565532752e-07
COL17A1 O 0 2.8814658435294405e-05
identified O 0 7.910907129371481e-07
a O 0 7.148232157305756e-07
maternally O 0 0.00016719901759643108
inherited O 0 0.0002302435750607401
G O 0 0.0001822955091483891
- O 0 3.064889824599959e-05
to O 0 4.879536845692201e-07
- O 0 5.998652341077104e-05
T O 0 0.00010840510367415845
transversion O 0 4.8924903239822015e-06
at O 0 1.5331090708059492e-07
the O 0 2.226065021204704e-08
- O 0 2.448859106607415e-07
1 O 0 1.3459649395031192e-08
position O 0 1.5796489449826367e-08
of O 0 1.9164341225064163e-09
exon O 0 1.8352286588196876e-06
32 O 0 4.3147269934706856e-07
. O 0 2.7419122261562734e-07

This O 0 2.39157543546753e-06
acceptor O 0 1.6150974261108786e-05
splice O 0 0.0001385281648254022
- O 0 2.2561232981388457e-05
site O 0 1.2706977940979414e-06
mutation O 0 1.1903385939149302e-06
led O 0 2.4209931837049226e-08
to O 0 2.3211330635319882e-09
the O 0 2.284066713542643e-09
formation O 0 1.290034479239921e-08
of O 0 6.951250686171306e-10
aberrant O 0 3.202576408511959e-07
transcripts O 0 3.3959892675738956e-07
present O 0 5.736847796811162e-08
at O 0 3.5038698342759744e-07
extremely O 0 1.0954687468256452e-06
low O 0 3.957592343795113e-05
levels O 0 6.619830401177751e-06
. O 0 6.992306111897051e-07

Based O 0 1.661270630393119e-06
on O 0 3.523260829751962e-07
our O 0 1.9246879645606896e-08
recent O 0 2.1849002607154944e-08
finding O 0 8.522071048844282e-09
that O 0 1.0776749270746677e-08
cycloheximide O 0 8.81247251527384e-06
stabilized O 0 4.706917025032453e-05
mutant O 0 2.4912553726608166e-06
COL17A1 O 0 4.417343916429672e-06
transcripts O 0 9.342809335066704e-07
in O 0 9.496476849335522e-08
keratinocytes O 0 2.8390979878167855e-06
homozygous O 0 1.7118094319812371e-06
for O 0 1.2038441354889073e-08
a O 0 1.0829462127048828e-07
frameshift O 0 0.00018340014503337443
mutation O 0 3.337880116305314e-06
, O 0 6.232490523672141e-09
the O 0 7.4368542435365725e-09
effects O 0 1.0806228800674944e-07
of O 0 1.3136570720106988e-09
the O 0 8.537836215793959e-09
splice O 0 1.4572522559319623e-05
- O 0 1.7217064396390924e-06
site O 0 2.0631810571103415e-07
mutation O 0 1.8286057468230865e-07
on O 0 1.8817674529714168e-08
splicing O 0 2.7440052008387283e-07
of O 0 3.4185314579104897e-09
COL17A1 O 0 1.4190698038873961e-06
transcripts O 0 2.206438978191727e-07
were O 0 1.3640612195331414e-08
determined O 0 3.073039067658101e-08
using O 0 8.405569218439268e-08
reverse O 0 4.3182521949347574e-06
transcriptase O 0 1.0191969522566069e-05
polymerase O 0 5.5795308071537875e-06
chain O 0 2.9206316867202986e-06
reaction O 0 1.071354844839334e-07
of O 0 3.2394600335550194e-09
total O 0 4.1682692852873515e-09
RNA O 0 3.313286924822023e-07
from O 0 7.510225685791738e-08
keratinocytes O 0 3.708360054588411e-06
incubated O 0 7.62194872550026e-07
for O 0 1.791800841033364e-08
2 O 0 2.0589314431163075e-07
. O 0 3.487028834570083e-07

5 O 0 6.9555535446852446e-06
h O 0 6.622937689826358e-06
in O 0 3.093121136998889e-08
the O 0 1.0465664779246708e-08
presence O 0 3.034238105215081e-08
or O 0 1.522271908527273e-08
absence O 0 1.981210218104934e-08
of O 0 3.320629993197599e-09
10 O 0 3.6950186910189586e-08
microg O 0 4.204027845844394e-06
cycloheximide O 0 1.859722033259459e-05
per O 0 1.1633989061010652e-06
ml O 0 0.0002667516528163105
. O 0 2.0662164388340898e-06

Using O 0 1.3072200317765237e-06
this O 0 4.1000884465347553e-08
approach O 0 5.9542145436353167e-08
, O 0 6.301580590672984e-09
an O 0 1.0978408404582751e-08
abnormally O 0 1.4905751413607504e-05
spliced O 0 3.496901990729384e-05
transcript O 0 0.00015594340220559388
was O 0 1.211567564496363e-06
identified O 0 1.5743010450819384e-08
that O 0 9.47864342570881e-10
contains O 0 1.5999612745787317e-09
an O 0 9.177769100254807e-10
extra O 0 7.117958222835341e-09
264 O 0 2.194606807393029e-08
bases O 0 9.872754169748532e-09
upstream O 0 2.5416399651589927e-08
from O 0 1.2677447536191266e-08
exon O 0 5.438638481791713e-07
32 O 0 6.079460490582278e-08
, O 0 2.421024269949612e-09
resulting O 0 1.5367591643666856e-08
in O 0 2.3739540111478163e-08
a O 0 9.369649092150212e-07
premature O 0 7.676479435758665e-05
termination O 0 5.011713255953509e-06
codon O 0 1.3904278603149578e-05
27 O 0 7.20234538675868e-07
bp O 0 6.835398949078808e-07
downstream O 0 2.2556204726242868e-07
from O 0 1.7897582083037378e-08
the O 0 7.241342103725401e-08
cryptic O 0 9.203962690662593e-06
splice O 0 0.00010893565195146948
site O 0 1.2979372513655107e-05
. O 0 2.166968897654442e-06

Three O 0 6.590726115973666e-07
other O 0 3.797651260128987e-08
splice O 0 4.005754817626439e-06
variants O 0 5.629524935102381e-07
, O 0 3.4608538257430155e-09
including O 0 9.207575812908431e-10
one O 0 1.4675239912165239e-09
derived O 0 3.3229932139278162e-09
from O 0 1.6100391020401617e-09
the O 0 2.2662918208737892e-09
skipping O 0 4.1865735767032675e-08
of O 0 1.2447707309348743e-09
exon O 0 3.37788804927186e-07
32 O 0 4.6859771174467824e-08
, O 0 4.682946030953872e-09
were O 0 1.3567337475706154e-08
also O 0 3.297185102724143e-08
identified O 0 4.1406332229598775e-07
. O 0 3.158483536935819e-07

These O 0 1.1135637123516062e-06
results O 0 7.751950192869117e-07
indicate O 0 2.1817857032147003e-07
the O 0 2.8226644133155787e-08
usefulness O 0 1.25151856877892e-07
of O 0 7.231166776477949e-09
cycloheximide O 0 6.85200393490959e-06
treatment O 0 1.230025787890554e-07
in O 0 1.6237510891414786e-08
evaluating O 0 5.0136261364741586e-08
the O 0 9.751778939914857e-09
abnormal O 0 3.0004159157215327e-07
processing O 0 2.0980383652613455e-08
of O 0 1.2991921982674626e-09
mRNA O 0 7.066988416681852e-08
due O 0 6.368218663510561e-08
to O 0 1.7120195039410646e-08
splice O 0 1.8917713532573543e-05
- O 0 1.089819306798745e-05
site O 0 1.5367729702120414e-06
mutations O 0 1.8485624195818673e-06
, O 0 3.915546997745878e-09
because O 0 7.815684099909959e-09
( O 0 1.8489044961711443e-08
i O 0 5.477699360767474e-08
) O 0 1.2585030795264629e-08
aberrant O 0 6.400293273145508e-07
splicing O 0 1.1730626283679157e-06
often O 0 8.346123792080107e-08
generates O 0 3.4484818911550974e-07
a O 0 1.816550110333992e-07
premature O 0 1.2107949260098394e-05
termination O 0 1.4456516055361135e-06
codon O 0 3.959789410146186e-06
, O 0 1.5734364922082023e-08
( O 0 1.4642840717726813e-08
ii O 0 3.5271773413114715e-07
) O 0 3.1672680034233736e-09
transcripts O 0 1.263882438706787e-07
with O 0 2.9100277743054903e-08
premature O 0 7.655008630536031e-06
termination O 0 1.0485183565833722e-06
codons O 0 1.3862156720279017e-06
can O 0 3.430119832614764e-08
occur O 0 1.8859175554553076e-08
at O 0 9.4767358405079e-08
low O 0 7.626844308106229e-06
or O 0 1.452137468049841e-07
undetectable O 0 2.257644382552826e-06
levels O 0 1.1180922854236996e-07
due O 0 7.497701659531231e-08
to O 0 1.7527625573166006e-08
nonsense O 0 4.6941536879785417e-07
- O 0 1.4143718374270975e-07
mediated O 0 2.2992355752649019e-07
mRNA O 0 1.6277272152365185e-07
decay O 0 4.7456020979552704e-07
, O 0 4.891564486797506e-09
and O 0 2.9111530963632504e-09
( O 0 8.168627552151975e-09
iii O 0 2.156930776209265e-07
) O 0 1.9233732384549285e-09
the O 0 4.9144763814013e-09
levels O 0 1.5505442263474833e-08
of O 0 4.003425646548209e-10
these O 0 6.894419479763769e-10
transcripts O 0 4.072055048709444e-08
can O 0 2.8358193571165202e-09
be O 0 1.2844236785269914e-09
increased O 0 1.5400983599533902e-08
by O 0 2.423728595601915e-08
cycloheximide O 0 9.354717803944368e-06
. O 0 4.255756209659012e-07

A O 0 1.3535484868043568e-05
deletion O 0 6.193952140165493e-05
mutation O 0 1.3470557860273402e-05
in O 0 1.7749337644090701e-07
COL17A1 O 0 1.913650703500025e-05
in O 0 4.3560135054576676e-08
five O 0 1.3032011025870816e-08
Austrian O 0 7.706082215008792e-06
families O 0 1.0067480360476111e-07
with O 0 5.331239094630291e-07
generalized O 0 0.04278235882520676
atrophic B-Disease 1 0.9999972581863403
benign I-Disease 1 0.9999978542327881
epidermolysis I-Disease 1 0.9995802044868469
bullosa I-Disease 0 0.22607886791229248
represents O 0 1.9616370536823524e-06
propagation O 0 8.536062523489818e-07
of O 0 8.414612118201603e-09
an O 0 2.9275083690549764e-08
ancestral O 0 5.419924036687007e-06
allele O 0 4.361533501651138e-05
. O 0 1.0873170595004922e-06

Patients O 0 0.000965008104685694
with O 0 1.9373306713532656e-05
generalized O 0 0.34618133306503296
atrophic B-Disease 1 0.9999994039535522
benign I-Disease 1 0.9999991655349731
epidermolysis I-Disease 1 0.9999762773513794
bullosa I-Disease 1 0.9984174966812134
, O 0 2.449658268233179e-06
a O 0 5.619794478661788e-07
usually O 0 4.4188973902237194e-07
nonlethal O 0 1.7631236914894544e-06
form O 0 6.418404723262938e-07
of O 0 4.324778615227842e-07
junctional B-Disease 0 0.4231446385383606
epidermolysis I-Disease 1 0.919026792049408
bullosa I-Disease 0 0.15770338475704193
, O 0 7.242563810905267e-07
have O 0 7.051490769072188e-08
generalized O 0 3.305023028588039e-06
blistering B-Disease 0 0.06924597918987274
, O 0 3.7889653867750894e-06
nail B-Disease 1 1.0
dystrophy I-Disease 1 0.9999916553497314
, O 0 6.601646873605205e-07
patchy B-Disease 1 0.9998785257339478
alopecia I-Disease 1 0.9999994039535522
, O 0 8.110271778605238e-07
and O 0 6.580616627616109e-06
dental B-Disease 1 0.9996902942657471
abnormalities I-Disease 1 0.9999990463256836
. O 0 1.4289658793131821e-05

Skin B-Disease 1 0.9999945163726807
fragility I-Disease 0 0.12116872519254684
in O 0 3.882767600771331e-07
most O 0 9.709666848323195e-09
cases O 0 3.6759946198117177e-09
is O 0 1.5940520015078619e-09
due O 0 1.868619570188912e-08
to O 0 1.9826240205134127e-08
mutations O 0 2.6779363793139055e-07
in O 0 4.660891228525088e-09
the O 0 2.0084218732563386e-08
gene O 0 1.016923988572671e-06
encoding O 0 1.956502728717169e-06
type O 0 0.00018236608593724668
XVII O 0 0.0006111328839324415
collagen O 0 7.165053830249235e-05
( O 0 5.235069124864822e-07
COL17A1 O 0 3.197516343789175e-05
) O 0 3.228494733775733e-07
. O 0 5.492324817168992e-07

Recently O 0 2.7100582883576863e-05
, O 0 1.4503741851967789e-07
we O 0 1.3285092137493848e-08
reported O 0 1.4970578376960475e-07
five O 0 1.6549780212926635e-08
Austrian O 0 2.220555870735552e-06
families O 0 5.258115010065012e-08
with O 0 3.0952224960856256e-07
generalized O 0 0.0026770846452564
atrophic B-Disease 1 0.9999898672103882
benign I-Disease 1 0.9999915361404419
epidermolysis I-Disease 1 0.9997273087501526
bullosa I-Disease 1 0.9743597507476807
who O 0 3.5289913284941576e-06
share O 0 4.773180535266874e-07
the O 0 1.229181521011924e-07
same O 0 5.877823241462465e-07
COL17A1 O 0 0.0004332476237323135
mutation O 0 4.399799581733532e-05
. O 0 1.2026986269120243e-06

Affected O 0 6.974789357627742e-06
individuals O 0 4.07073521557777e-08
in O 0 8.982560473214107e-09
three O 0 2.797007958577069e-09
families O 0 5.081273179996515e-09
are O 0 9.123071187389087e-10
homozygous O 0 1.645382212700497e-07
for O 0 5.170524008946131e-09
4003delTC O 0 3.909639474386495e-07
, O 0 4.471695458363456e-09
whereas O 0 6.441207123231152e-09
those O 0 1.0007376038956295e-09
in O 0 2.4265578435489488e-09
two O 0 2.088650363774036e-09
others O 0 8.434537512869156e-09
are O 0 2.732241544123326e-09
compound O 0 8.008700547179615e-07
heterozygotes O 0 1.933030944201164e-05
. O 0 7.698786816945358e-07

To O 0 7.844920446586912e-07
determine O 0 2.0444073811631824e-07
if O 0 7.268668333892947e-09
the O 0 2.575511137692388e-09
occurrence O 0 4.321125501860479e-08
of O 0 1.799454585338367e-09
4003delTC O 0 5.026087706028193e-07
in O 0 1.5445463574792484e-08
these O 0 2.3031445639531967e-09
unrelated O 0 1.581125985694598e-08
families O 0 4.733368363929458e-09
signifies O 0 1.1147847978065784e-08
propagation O 0 1.3000432730336797e-08
of O 0 4.3641090741175503e-10
an O 0 2.181018476932195e-09
ancestral O 0 1.4329613406971475e-07
allele O 0 8.113227067951811e-07
or O 0 3.001984083539355e-08
a O 0 7.674861279838296e-08
mutational O 0 4.424248982104473e-05
hot O 0 3.6999652365921065e-05
spot O 0 4.192585493001388e-06
, O 0 2.35156996097885e-08
haplotypes O 0 8.264997859441792e-07
were O 0 4.308139622821727e-08
determined O 0 6.768623705966093e-08
for O 0 7.017997738500981e-09
polymorphisms O 0 6.976958957238821e-07
both O 0 7.26489846059053e-09
within O 0 1.1109513309293106e-08
and O 0 2.7844317074254832e-08
flanking O 0 0.00014773868315387517
COL17A1 O 0 0.0051152510568499565
. O 0 2.15505883716105e-06

Five O 0 3.833585196844069e-06
intragenic O 0 5.1474991778377444e-05
polymorphisms O 0 4.357808211352676e-05
were O 0 9.733906125575231e-08
chosen O 0 2.4713719071201012e-08
based O 0 1.246282277378441e-08
on O 0 7.806733037796221e-08
their O 0 6.601886326507156e-08
informativeness O 0 3.4399981814203784e-05
. O 0 7.659811558369256e-07

One O 0 1.7093154269787192e-07
of O 0 1.2751704581148715e-08
these O 0 4.692306987408301e-09
, O 0 2.3000235049863704e-09
not O 0 1.8042901617221219e-09
previously O 0 1.777551794646115e-08
reported O 0 7.608077794429846e-07
, O 0 7.880860408704393e-09
was O 0 1.21035668598779e-07
2988 O 0 2.6676434572436847e-07
A O 0 1.4228001532501366e-07
or O 0 8.553373476161141e-08
C O 0 9.340296855953056e-07
that O 0 1.6588896922797858e-09
introduces O 0 2.6984753986880605e-08
a O 0 8.737170986705678e-09
new O 0 1.6153244075667317e-08
restriction O 0 2.8799291840186925e-08
site O 0 4.123160124436254e-08
for O 0 5.693264082395899e-09
Eco0109 O 0 1.0307123829988996e-06
I O 0 9.258775435228017e-07
. O 0 2.977884889787674e-07

All O 0 3.0756785918129026e-07
the O 0 1.51686123217587e-07
4003delTC O 0 3.2680143249308458e-06
alleles O 0 1.8941095731861424e-06
showed O 0 3.3351548722748703e-07
the O 0 2.7043391526149207e-08
same O 0 5.410981529507808e-08
haplotype O 0 2.1301850665622624e-06
for O 0 5.837164529509664e-09
these O 0 5.011090209450231e-09
five O 0 4.015765497911161e-08
polymorphic O 0 2.5507406462565996e-05
markers O 0 4.487575642997399e-05
. O 0 1.9348358364368323e-06

Fourteen O 0 6.080805906094611e-05
microsatellite O 0 0.00025432510301470757
polymorphisms O 0 0.00022017874289304018
were O 0 3.597012039335823e-07
selected O 0 6.464718182996876e-08
based O 0 1.0801876726418413e-08
on O 0 1.6698107785373395e-08
their O 0 6.753069659026778e-09
high O 0 3.3585382652745466e-07
heterozygosity O 0 4.17339464320321e-07
and O 0 4.744449721982846e-09
their O 0 6.051219525460283e-09
location O 0 1.192693588336624e-07
within O 0 5.376742961971104e-08
10q23 O 0 2.6572733986540698e-06
- O 0 3.5336522614670685e-06
q25 O 0 7.085396191541804e-06
near O 0 8.544910997443367e-06
COL17A1 O 0 0.00013486488023772836
. O 0 1.1910368584722164e-06

Three O 0 1.2057557796651963e-06
families O 0 1.0140399808733491e-06
shared O 0 8.830331239551015e-07
microsatellite O 0 6.289045995799825e-05
polymorphisms O 0 0.00012885774776805192
covering O 0 5.745378075516783e-06
at O 0 9.531432283438335e-07
most O 0 3.186891106565781e-08
19 O 0 1.663939173113249e-07
cM O 0 3.998996476184402e-07
, O 0 6.676634800584225e-09
whereas O 0 1.2867684695549997e-08
the O 0 1.1154823731374108e-08
others O 0 2.7566451343830067e-09
shared O 0 1.9016217489564724e-09
smaller O 0 9.89213155833113e-09
regions O 0 1.8647494215429106e-08
consistent O 0 8.499851134047276e-08
with O 0 6.623451120901791e-09
cross O 0 1.8515586930334393e-07
- O 0 1.4165008224154008e-06
over O 0 2.1294400909255273e-08
events O 0 1.1371579233809825e-08
during O 0 1.406046568064312e-08
passage O 0 4.9016604108942374e-09
of O 0 4.980054146841439e-10
this O 0 1.4037144779877053e-09
mutation O 0 4.351579008243789e-08
through O 0 4.791228747080822e-09
several O 0 1.2658987635916219e-08
generations O 0 1.2117808978473477e-07
. O 0 1.7478959080108325e-07

These O 0 1.1058963309551473e-06
results O 0 6.032236683495285e-07
indicate O 0 3.887313653194724e-07
that O 0 1.3228653727992423e-08
4003delTC O 0 1.047013597599289e-06
occurs O 0 5.320420726206976e-08
on O 0 1.5240907202951348e-08
a O 0 1.219708511968065e-08
single O 0 3.4911472823750955e-08
ancestral O 0 5.593871605924505e-07
allele O 0 2.0254387891327497e-06
. O 0 3.767580025737516e-08
. O 0 1.9552552998902684e-07

The O 0 9.774156751518603e-06
haptoglobin O 0 0.0006641884101554751
- O 0 7.244545122375712e-05
gene O 0 3.356771048856899e-05
deletion O 0 1.7995254893321544e-05
responsible O 0 6.846653377579059e-07
for O 0 1.839137695469617e-07
anhaptoglobinemia B-Disease 0 9.836054960032925e-05
. O 0 2.103071892634034e-06

We O 0 6.651875423813181e-07
have O 0 1.6274626091217215e-08
found O 0 8.24724821768541e-09
an O 0 3.091562561507999e-09
allelic O 0 5.153130473445344e-07
deletion O 0 2.904522204971727e-07
of O 0 3.2266151972493162e-09
the O 0 3.271176751695748e-08
haptoglobin O 0 7.1981962719291914e-06
( O 0 4.648455487199499e-08
Hp O 0 7.127700882847421e-07
) O 0 8.639548632061178e-09
gene O 0 4.0743938001241986e-08
from O 0 3.0406728246390458e-09
an O 0 1.2832458429201665e-09
individual O 0 2.4676778398458055e-09
with O 0 2.1929203342097026e-08
anhaptoglobinemia B-Disease 0 7.03640325809829e-05
. O 0 5.904915383325715e-07

The O 0 4.995622475689743e-06
Hp O 0 3.116684820270166e-05
gene O 0 4.233405434206361e-06
cluster O 0 5.315237672220974e-07
consists O 0 2.340276417100995e-08
of O 0 4.042676859938865e-09
coding O 0 7.037986051727785e-07
regions O 0 3.46162138953332e-08
of O 0 3.748547694470972e-09
the O 0 2.5051628327332764e-08
alpha O 0 1.1615890826988107e-07
chain O 0 1.287584495912597e-06
and O 0 1.0850650156157826e-08
beta O 0 6.316865608368971e-08
chain O 0 2.842072888142866e-07
of O 0 2.7994258022800977e-09
the O 0 1.891623746530513e-08
haptoglobin O 0 3.2048665161710232e-06
gene O 0 6.48820048354537e-07
( O 0 2.1272885675216457e-08
Hp O 0 2.2275138178429188e-07
) O 0 2.813971056170317e-09
and O 0 5.364814148478558e-10
of O 0 3.3976116364797804e-10
the O 0 5.267598357505676e-09
alpha O 0 3.5303468592928766e-08
chain O 0 2.8396132734087587e-07
and O 0 5.311120432338612e-09
beta O 0 4.2857976723098545e-08
chain O 0 3.0587128208026115e-07
of O 0 2.712613467181768e-09
the O 0 2.079619676464972e-08
haptoglobin O 0 3.887230832333444e-06
- O 0 1.6012770629458828e-06
related O 0 4.465126721697743e-07
gene O 0 1.949101942955167e-06
( O 0 7.259070144982616e-08
Hpr O 0 4.334781351644779e-06
) O 0 1.0009194362226026e-08
, O 0 2.036433244256841e-09
in O 0 3.98164834436443e-09
tandem O 0 1.1853530850203242e-06
from O 0 8.394798634014933e-09
the O 0 1.5177173295910507e-08
5 O 0 8.491295488965989e-08
side O 0 1.044781356540625e-06
. O 0 3.3648603903202456e-07

Southern O 0 2.666977707121987e-05
blot O 0 0.0006059653824195266
and O 0 3.9577551547154144e-07
PCR O 0 7.255620585056022e-05
analyses O 0 2.1810856196680106e-06
have O 0 1.9432496500826346e-08
indicated O 0 1.3292344647197751e-07
that O 0 8.546222618477373e-10
the O 0 2.705369261946089e-09
individual O 0 7.056408790617752e-10
with O 0 2.748156147092118e-09
anhaptoglobinemia B-Disease 0 1.9164333480148343e-06
was O 0 1.102520741369517e-07
homozygous O 0 5.244463352482853e-08
for O 0 8.450443123031448e-10
the O 0 2.82304002396927e-09
gene O 0 9.890079155638887e-08
deletion O 0 1.5588567237045936e-07
and O 0 2.345109884061003e-09
that O 0 8.806549378626016e-10
the O 0 3.394652781096852e-09
gene O 0 1.1018648393701369e-07
deletion O 0 1.440915013972699e-07
was O 0 1.2300704099743598e-07
included O 0 3.6369260936197634e-09
at O 0 1.560239226705562e-08
least O 0 2.0228108077446905e-09
from O 0 1.8512960053840288e-09
the O 0 4.611521831066057e-09
promoter O 0 2.48636069954955e-07
region O 0 2.531586318355039e-08
of O 0 8.514191129904702e-09
Hp O 0 1.962018586709746e-06
to O 0 3.374422874458105e-08
Hpr O 0 4.435698883753503e-06
alpha O 0 1.2564025553274405e-07
but O 0 4.45592718278931e-09
not O 0 3.1377627163209354e-09
to O 0 1.0852493126378704e-08
Hpr O 0 7.340250704146456e-06
beta O 0 6.710565685352776e-07
( O 0 1.7082464864870417e-07
Hpdel O 0 5.734993465011939e-06
) O 0 1.597182119894569e-07
. O 0 2.3627316636520845e-07

In O 0 1.0425956133985892e-06
addition O 0 8.383329941352713e-08
, O 0 6.474290881186562e-09
we O 0 1.1075148576011884e-09
found O 0 1.365682456011541e-09
seven O 0 1.3868158843521883e-09
individuals O 0 2.170240792631617e-10
with O 0 1.4945257253984323e-09
hypohaptoglobinemia B-Disease 0 1.9519554825819796e-06
in O 0 1.1245122166769761e-08
three O 0 1.4630968658835286e-09
families O 0 8.763336722950044e-10
, O 0 7.526781420352791e-10
and O 0 1.1714568204368447e-09
the O 0 7.067147311801136e-09
genotypes O 0 4.9705786153708686e-08
of O 0 3.6539382630706996e-10
six O 0 1.009471839452658e-09
of O 0 2.01629601903619e-10
the O 0 1.6778199940503669e-09
seven O 0 1.574456343078623e-09
individuals O 0 2.1574876607477478e-10
were O 0 1.3235814666501255e-09
found O 0 3.706366769051783e-09
to O 0 1.2695063666967599e-08
be O 0 7.744045404933786e-08
Hp2 O 0 4.8596630222164094e-05
/ O 0 4.621778498403728e-05
Hpdel O 0 5.9314446843927726e-05
. O 0 9.38212167511665e-07

The O 0 2.7770122414949583e-06
phenotypes O 0 2.7326206691213883e-05
and O 0 1.0019876128808392e-07
genotypes O 0 2.4265236788778566e-06
in O 0 1.8647352106881954e-08
one O 0 1.450681352821448e-09
of O 0 2.416737088228871e-10
these O 0 2.9028016101939613e-10
three O 0 4.30252666827613e-10
families O 0 1.0071621314722279e-09
showed O 0 3.1572213288200146e-08
the O 0 4.525942731703481e-09
father O 0 4.960548949384247e-08
to O 0 7.90414933504735e-09
be O 0 1.033969176944538e-08
hypohaptoglobinemic B-Disease 0 9.414119404027588e-07
( O 0 2.3773843338403822e-08
Hp2 O 0 5.664649052050663e-07
) O 0 1.0218373702741701e-08
and O 0 1.6044085171529332e-08
Hp2 O 0 8.334132871823385e-06
/ O 0 5.01565318700159e-06
Hpdel O 0 8.027121225495648e-07
, O 0 3.73294328781526e-09
the O 0 5.671803915419105e-09
mother O 0 4.325990943243596e-08
to O 0 5.4249089664892836e-09
be O 0 3.6907272793484935e-09
Hp2 O 0 5.589077431977785e-07
- O 0 2.57181653751104e-07
1 O 0 1.9210240509437426e-08
and O 0 1.371138047545628e-08
Hp1 O 0 3.227502020308748e-06
/ O 0 3.6846699913439807e-06
Hp2 O 0 1.1504348549351562e-06
, O 0 2.6657644980332407e-09
one O 0 3.4964217632271755e-10
of O 0 1.9474072354697114e-10
the O 0 1.5285147592081216e-09
two O 0 1.4030185901958703e-09
children O 0 2.1037833697334918e-09
to O 0 2.2391541953936667e-09
be O 0 6.335469482365852e-09
hypohaptoglobinemic B-Disease 0 6.019243414812081e-07
( O 0 2.2603442673130303e-08
Hp2 O 0 6.888241159686004e-07
) O 0 9.03417518571814e-09
and O 0 1.1245314901486836e-08
Hp2 O 0 5.475366833707085e-06
/ O 0 6.623139597650152e-06
Hpdel O 0 2.3498673726862762e-06
, O 0 2.8563498233324935e-09
and O 0 7.400146606606484e-10
the O 0 1.5427378263765945e-09
other O 0 1.0275692519101653e-09
child O 0 1.9429421627137344e-08
to O 0 3.989188979147684e-09
be O 0 4.7150678916807465e-09
Hp1 O 0 6.060589612388867e-07
and O 0 2.843804658425597e-08
Hp1 O 0 8.788787454250269e-06
/ O 0 5.7078968893620186e-06
Hpdel O 0 3.12810107061523e-06
, O 0 5.040230455222172e-09
showing O 0 8.229590520159036e-08
an O 0 4.903474515316475e-09
anomalous O 0 4.7120045110204956e-07
inheritance O 0 1.2202349353174213e-07
of O 0 8.652196292757708e-09
Hp O 0 3.99482860302669e-06
phenotypes O 0 1.5058193412187393e-06
in O 0 1.5275013254267833e-08
the O 0 5.159296279089176e-08
child O 0 2.66199123188926e-07
with O 0 4.7814449288807737e-08
Hp1 O 0 5.0393809942761436e-05
. O 0 1.05471031019988e-06

The O 0 1.2237886949151289e-05
Hp2 O 0 0.0003312969347462058
/ O 0 7.789702794980258e-05
Hpdel O 0 9.68458152783569e-06
individuals O 0 4.612975601503422e-08
had O 0 4.752477167357938e-08
an O 0 7.873618201870158e-09
extremely O 0 2.12466147786472e-07
low O 0 2.0251375190127874e-06
level O 0 6.402063945643022e-08
of O 0 1.3808460153086344e-08
Hp O 0 4.183766122878296e-06
( O 0 7.456884532075492e-08
mean O 0 1.8488256614546117e-07
+ O 0 4.889673732577648e-07
/ O 0 8.912795237847604e-06
- O 0 4.887351224169834e-06
SD O 0 0.0009869246277958155
= O 0 1.9346753106219694e-06
0 O 0 2.9276378654685686e-07
. O 0 4.365145755969024e-08
049 O 0 2.1961490347166546e-05
+ O 0 1.9048462718274095e-06
/ O 0 7.69177950132871e-06
- O 0 2.7816026886284817e-06
0 O 0 3.050195402920508e-07
. O 0 8.507766580123644e-08
043 O 0 2.101694371958729e-05
mg O 0 0.000349787762388587
/ O 0 3.3266500395257026e-05
ml O 0 1.4799630662309937e-05
; O 0 7.611750874048084e-08
n O 0 6.065804996069346e-07
= O 0 4.164548954577185e-07
6 O 0 5.7923390528458185e-08
) O 0 5.723062912466048e-09
, O 0 1.526003767793327e-09
compared O 0 7.152403558308151e-09
with O 0 2.618320671388119e-09
the O 0 8.451671362763591e-09
level O 0 3.5561836142505854e-08
( O 0 8.367893933325377e-09
1 O 0 5.316350026873806e-09
. O 0 1.5699941346980495e-09
64 O 0 6.615386638486598e-08
+ O 0 2.0861517668890883e-07
/ O 0 2.0325169316492975e-06
- O 0 7.703840196882084e-07
1 O 0 4.7974953787388586e-08
. O 0 2.3906439494680853e-08
07 O 0 2.5096951503655873e-06
mg O 0 0.00022171974705997854
/ O 0 1.3997596397530288e-05
ml O 0 5.318586318026064e-06
) O 0 7.631925313944521e-09
obtained O 0 2.0051187377134738e-08
from O 0 1.2757567446897156e-08
52 O 0 1.2099978619062313e-07
healthy O 0 1.8734628781658103e-07
volunteers O 0 4.246561147169814e-08
having O 0 7.610822194692446e-08
phenotype O 0 4.40437952420325e-06
Hp2 O 0 2.018677832893445e-06
, O 0 6.007702335608656e-09
whereas O 0 1.5792995355923267e-08
the O 0 1.1516294584623665e-08
serum O 0 4.858385977968283e-07
Hp O 0 2.524922706470534e-07
level O 0 1.2921276493216283e-08
of O 0 5.469686370496163e-10
an O 0 1.7709923527675642e-09
individual O 0 2.9834537063067046e-09
with O 0 1.2558413864383056e-08
Hp1 O 0 0.00013220224354881793
/ O 0 9.765886352397501e-05
Hpdel O 0 5.835422416566871e-05
was O 0 5.092238097859081e-06
0 O 0 1.149358013208257e-06
. O 0 5.227565793575195e-07

50 O 0 3.326091609778814e-05
mg O 0 0.09032239019870758
/ O 0 0.0006126681691966951
ml O 0 8.547600009478629e-05
, O 0 1.3712138979826705e-08
which O 0 6.126883000945327e-09
was O 0 1.3965902212476067e-08
approximately O 0 2.146533395475103e-09
half O 0 2.3769568535669805e-09
the O 0 1.3126978393174227e-09
level O 0 5.093421684421173e-09
of O 0 1.2458967191264492e-09
Hp O 0 4.136859956815897e-07
in O 0 3.5616004367966525e-08
control O 0 6.1218147493491415e-06
sera O 0 1.6805677205411484e-06
from O 0 1.1695463264516093e-08
the O 0 2.2793328113834832e-08
Hp1 O 0 5.989174951537279e-06
phenotype O 0 3.760706022148952e-06
( O 0 1.522908021911462e-08
1 O 0 9.783860832612845e-09
. O 0 2.6181559142912647e-09
26 O 0 3.511147639301271e-08
+ O 0 2.0995859983941045e-07
/ O 0 1.469655671826331e-06
- O 0 4.330631213633751e-07
0 O 0 3.831110007013194e-08
. O 0 9.054358152127406e-09
33 O 0 2.517252823963645e-07
mg O 0 0.0002252951671835035
/ O 0 2.8783049856428988e-05
ml O 0 1.4212600035534706e-05
; O 0 5.057808749597825e-08
n O 0 3.945319235754141e-07
= O 0 2.867422210783843e-07
9 O 0 1.0879128353735723e-07
) O 0 3.5469689407818805e-09
, O 0 9.128136024827427e-10
showing O 0 6.581104372571644e-08
a O 0 4.704578060454878e-08
gene O 0 4.9465702431916725e-06
- O 0 2.5885075956466608e-05
dosage O 0 6.097610094002448e-05
effect O 0 3.690261337396805e-06
. O 0 7.662375764994067e-07

The O 0 5.39592292625457e-07
other O 0 7.938962909292968e-08
allele O 0 5.039867119194241e-06
( O 0 6.603448099440357e-08
Hp2 O 0 8.946048524194339e-07
) O 0 4.051190494180901e-09
of O 0 4.749535764680957e-10
individuals O 0 9.621503593848502e-10
with O 0 4.104765416457212e-09
Hp2 O 0 3.560704499250278e-05
/ O 0 3.431345248827711e-05
Hpdel O 0 1.0791520253405906e-05
was O 0 1.1305143061690615e-06
found O 0 7.046069949723233e-09
to O 0 1.986764308625766e-09
have O 0 9.721021765329851e-10
, O 0 3.8954922620959564e-10
in O 0 2.0335377826086187e-09
all O 0 1.3451429969890683e-09
exons O 0 1.5145889165069093e-07
, O 0 4.763210270652962e-09
no O 0 5.5016116107253765e-09
mutation O 0 8.992301303578643e-08
, O 0 1.9713934928944354e-09
by O 0 1.282629824572723e-08
DNA O 0 4.992504045731039e-07
sequencing O 0 1.9317899386805948e-06
. O 0 6.023102514518541e-07

On O 0 9.151912081506453e-07
the O 0 1.7970304355685585e-08
basis O 0 3.6575940054461853e-09
of O 0 5.228656951850041e-10
the O 0 2.3793427228469e-09
present O 0 3.1937352762412274e-09
study O 0 2.1248138803997563e-09
, O 0 7.394093670676227e-10
the O 0 2.5057158570263027e-09
mechanism O 0 2.0780019482913303e-08
of O 0 1.9301977793872993e-09
anhaptoglobinemia B-Disease 0 9.525799100629229e-07
and O 0 5.206467257323766e-09
the O 0 6.285926446025769e-09
mechanism O 0 4.272119369375105e-08
of O 0 1.9989849775470248e-09
anomalous O 0 4.766293386637699e-07
inheritance O 0 1.586880529202972e-07
of O 0 7.833548920643807e-09
Hp O 0 4.755469490191899e-06
phenotypes O 0 2.5659737730165944e-06
were O 0 4.173211110014563e-08
well O 0 8.569163867377938e-08
explained O 0 1.2625863519133418e-06
. O 0 5.845846544616506e-07

However O 0 2.0421637145773275e-06
, O 0 6.418459719270686e-08
the O 0 2.0125479949228975e-08
mechanism O 0 1.830032800853587e-07
of O 0 1.2950908789832738e-08
hypohaptoglobinemia B-Disease 0 8.515195986547042e-06
remains O 0 1.174560452454898e-06
unknown O 0 2.38470647673239e-06

ATM O 0 0.00209330627694726
mutations O 0 0.0007368560181930661
and O 0 1.5866203284531366e-06
phenotypes O 0 0.0002808657009154558
in O 0 0.00015820178668946028
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
families O 0 1.1266396313658333e-06
in O 0 9.603488848597408e-08
the O 0 3.3248522157691696e-08
British O 0 9.908882248055306e-07
Isles O 0 1.5630563439117395e-06
: O 0 3.5870755255018594e-09
expression O 0 6.534210506004001e-09
of O 0 6.054864387650127e-10
mutant O 0 8.059463851850523e-08
ATM O 0 5.284124995341699e-07
and O 0 7.493738962693897e-09
the O 0 1.1431621871338393e-08
risk O 0 7.904348109377679e-08
of O 0 2.017305789081547e-08
leukemia B-Disease 1 0.8542147874832153
, O 0 2.6293344490113668e-05
lymphoma B-Disease 1 1.0
, O 0 5.868475454917643e-06
and O 0 0.009077987633645535
breast B-Disease 1 0.9999985694885254
cancer I-Disease 0 0.21628709137439728
. O 0 3.234941004848224e-06

We O 0 9.402392606716603e-07
report O 0 2.713182425395644e-07
the O 0 2.940609356016921e-08
spectrum O 0 3.5338845805199526e-07
of O 0 6.1562621667121675e-09
59 O 0 1.4013670579515747e-07
ATM O 0 2.5265360818593763e-05
mutations O 0 7.196686510724248e-06
observed O 0 2.5556387299729977e-06
in O 0 0.00027285635587759316
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0009690398583188653
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.3726103393073572e-07
patients O 0 1.397304743022687e-07
in O 0 1.045455189085942e-08
the O 0 4.746733495153421e-08
British O 0 3.966274562117178e-06
Isles O 0 1.9493249055813067e-05
. O 0 7.046730843285332e-07

Of O 0 8.630046295365901e-07
51 O 0 2.7372093427402433e-06
ATM O 0 1.3235666301625315e-05
mutations O 0 2.6764093945530476e-06
identified O 0 6.625147364047734e-08
in O 0 7.2903145742486686e-09
families O 0 1.8715935468094358e-09
native O 0 3.0749782720107532e-09
to O 0 2.425577072528995e-09
the O 0 6.445065814375539e-09
British O 0 5.594383765128441e-07
Isles O 0 7.743306014162954e-07
, O 0 1.359997559013948e-09
11 O 0 6.4565206514544116e-09
were O 0 9.902040964959724e-09
founder O 0 9.123009903078128e-08
mutations O 0 1.9582860488753795e-07
, O 0 2.1247448245276246e-09
and O 0 2.4846755763974215e-09
2 O 0 5.607040165500621e-09
of O 0 1.0893964619285157e-09
these O 0 3.4509797242066043e-09
11 O 0 1.1792229415164002e-08
conferred O 0 3.334117693043481e-08
a O 0 4.1699490083146884e-08
milder O 0 0.0009039370925165713
clinical O 0 1.2685143701673951e-05
phenotype O 0 2.747989128693007e-05
with O 0 1.544254679686219e-08
respect O 0 7.673730095802966e-09
to O 0 1.7142676611570096e-08
both O 0 6.32194030458777e-08
cerebellar B-Disease 0 0.004129516426473856
degeneration I-Disease 0 0.029031997546553612
and O 0 2.69672426611578e-07
cellular O 0 3.8937010685913265e-05
features O 0 3.216367258573882e-05
. O 0 2.5004712824738817e-06

We O 0 1.3787283705823938e-06
report O 0 3.8186539086382254e-07
, O 0 7.204321583742512e-09
in O 0 7.315038352828651e-09
two O 0 1.4149838634125445e-08
A B-Disease 1 0.9999896287918091
- I-Disease 1 0.9999889135360718
T I-Disease 1 1.0
families O 0 2.518918762461908e-08
, O 0 3.047582186610498e-09
an O 0 6.080119074880486e-09
ATM O 0 2.455307730997447e-05
mutation O 0 3.260163566665142e-06
( O 0 4.928145713734011e-08
7271T O 0 1.7603531432541786e-06
- O 0 6.6040547608281486e-06
- O 0 8.031432116695214e-06
> O 0 1.1188361668246216e-06
G O 0 8.943805369199254e-06
) O 0 5.688422621830114e-09
that O 0 3.918476210174049e-09
may O 0 4.5118955682710293e-08
be O 0 6.578325106865179e-10
associated O 0 1.5019097077129118e-09
with O 0 6.37700114936024e-10
an O 0 2.3590938091899716e-09
increased O 0 1.786416845561689e-07
risk O 0 1.8923191191788646e-07
of O 0 8.242518845236191e-08
breast B-Disease 1 0.9868647456169128
cancer I-Disease 0 2.057042729575187e-05
in O 0 5.2834995045714095e-08
both O 0 4.9037481630875845e-08
homozygotes O 0 3.158868139507831e-06
and O 0 6.517583983622899e-08
heterozygotes O 0 2.3730499378871173e-06
( O 0 2.69506514882778e-08
relative O 0 1.3761770389919548e-07
risk O 0 1.486609164658148e-07
12 O 0 2.8487177061720104e-08
. O 0 3.765250777831852e-09
7 O 0 9.944935186467774e-08
; O 0 5.717643247749038e-08
P O 0 5.2857587434118614e-05
= O 0 6.089708790568693e-07
. O 0 1.8890963460194143e-08
0025 O 0 7.191225449787453e-06
) O 0 1.0868153488274856e-08
, O 0 1.0762098989758329e-09
although O 0 1.5998575797482317e-09
there O 0 7.592068085315873e-10
is O 0 4.283080556888308e-10
a O 0 5.5535354093194655e-09
less O 0 1.3428756062694447e-07
severe O 0 0.42294538021087646
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 0.01621037721633911
in O 0 2.450634184469891e-08
terms O 0 3.9710381649626925e-09
of O 0 3.3128472187726743e-10
the O 0 4.800468023091753e-09
degree O 0 3.5148868704482084e-08
of O 0 4.4316884384443256e-08
cerebellar B-Disease 0 0.21084581315517426
degeneration I-Disease 1 0.6984423398971558
. O 0 3.3942940262932098e-06

This O 0 4.248969617037801e-06
mutation O 0 3.079797170357779e-05
( O 0 8.747536526243493e-07
7271T O 0 1.5134992281673476e-05
- O 0 4.858912143390626e-05
- O 0 1.3277158359414898e-05
> O 0 1.9835258626699215e-06
G O 0 4.542170245258603e-06
) O 0 9.711574655568711e-09
also O 0 4.95789809207281e-09
allows O 0 4.700171807314746e-09
expression O 0 5.5976907553656474e-09
of O 0 6.210414960072796e-10
full O 0 1.388142312208629e-08
- O 0 7.889993725029854e-08
length O 0 5.480374554167611e-08
ATM O 0 6.768648859178938e-07
protein O 0 5.1697181646659374e-08
at O 0 2.9404354506823438e-08
a O 0 1.0458141908031848e-08
level O 0 1.461337806318852e-08
comparable O 0 3.4089744360699115e-08
with O 0 1.6308301376000145e-09
that O 0 2.86511281366586e-09
in O 0 2.3668514259611584e-08
unaffected O 0 4.384267867862945e-06
individuals O 0 8.586686561784518e-08
. O 0 3.3455080483690836e-07

In O 0 6.500661697828036e-07
addition O 0 4.1145895579575154e-08
, O 0 4.54344872835577e-09
we O 0 1.274644612081488e-09
have O 0 8.126494477345148e-10
studied O 0 1.928344239843227e-08
18 O 0 6.616988912355737e-08
A B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.771824478666531e-06
, O 0 1.979018948716771e-09
in O 0 5.133644176424923e-09
15 O 0 5.2743742706695684e-09
families O 0 1.1866997384757383e-09
, O 0 2.336849602713187e-09
who O 0 2.2543982680645058e-08
developed O 0 0.0007750194636173546
leukemia B-Disease 1 0.995012104511261
, O 0 2.3008307834970765e-05
lymphoma B-Disease 1 1.0
, O 0 5.812314611830516e-07
preleukemic O 0 0.0014943761052563787
T O 0 0.018801748752593994
- O 0 6.58154567645397e-06
cell O 0 8.8638025772525e-06
proliferation O 0 2.1821197151439264e-06
, O 0 1.3975447643588268e-07
or O 0 0.02137402445077896
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 3.574203688572197e-08
mostly O 0 2.271152510502361e-08
in O 0 2.801554046527599e-07
childhood O 0 7.140961679397151e-05
. O 0 1.0762082638393622e-06

A O 0 7.048423867672682e-06
wide O 0 7.359417395491619e-07
variety O 0 1.1423496459883609e-07
of O 0 1.591649656518257e-08
ATM O 0 4.760649972013198e-05
mutation O 0 2.512983655833523e-06
types O 0 8.156985842333597e-08
, O 0 4.143688059343731e-09
including O 0 6.677386643616501e-09
missense O 0 1.154170877271099e-05
mutations O 0 5.877839612367097e-06
and O 0 4.8825441467670316e-08
in O 0 1.8764883691346768e-07
- O 0 1.0634394129738212e-05
frame O 0 0.0006885742768645287
deletions O 0 6.162937893350318e-07
, O 0 3.749627275340117e-09
were O 0 2.2940516153369117e-09
seen O 0 1.9864243583356256e-08
in O 0 1.0633578462204696e-08
these O 0 2.7878220620891625e-08
patients O 0 4.3304410723976616e-07
. O 0 3.658451248611527e-07

We O 0 4.020728852083266e-07
also O 0 2.7679160297111594e-08
show O 0 2.0682904278146452e-08
that O 0 7.180023242625566e-10
25 O 0 1.3587478919774298e-09
% O 0 2.864608550368075e-10
of O 0 2.536953980225576e-10
all O 0 3.708120477341481e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.0362561624788214e-05
carried O 0 7.429916308865359e-07
in O 0 1.0534864003375333e-07
- O 0 3.1222177767631365e-06
frame O 0 2.7124264306621626e-05
deletions O 0 2.428852894809097e-06
or O 0 9.006582502024685e-08
missense O 0 4.845267994824098e-06
mutations O 0 1.2692129303104593e-06
, O 0 3.0864895084192767e-09
many O 0 3.684163252248851e-10
of O 0 4.1059769473328345e-10
which O 0 1.0417130269502195e-08
were O 0 3.879463417177931e-09
also O 0 2.6154407528622414e-09
associated O 0 4.776975703890685e-09
with O 0 2.4406596743631326e-09
expression O 0 2.5854053120610843e-08
of O 0 5.316106665986808e-09
mutant O 0 1.335236902377801e-06
ATM O 0 1.1145253665745258e-05
protein O 0 5.8869950407824945e-06
. O 0 8.17007844489126e-07

The O 0 3.3697201615723316e-06
DMPK O 0 0.00017882170504890382
gene O 0 1.908609556267038e-05
of O 0 3.8962471649028885e-07
severely O 1 0.9959347248077393
affected O 1 0.9385780692100525
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9824419617652893
is O 0 4.826756025977375e-07
hypermethylated O 0 4.842408452532254e-05
proximal O 0 5.6644887081347406e-05
to O 0 1.0166451858140135e-07
the O 0 4.057866576090419e-08
largely O 0 2.086052290906082e-07
expanded O 0 1.329672272731841e-06
CTG O 0 4.660238846554421e-05
repeat O 0 2.098956065310631e-05
. O 0 2.3167217477748636e-06

Using O 0 1.6226500520133413e-05
methylation O 0 6.206220859894529e-05
- O 0 2.577032137196511e-05
sensitive O 0 5.684158168151043e-06
restriction O 0 6.968301136112132e-07
enzymes O 0 6.75265994232177e-07
, O 0 1.0576980180587725e-08
we O 0 3.5343807880394706e-09
characterized O 0 3.464646525230819e-08
the O 0 9.600408468202204e-09
methylation O 0 5.212128826315165e-07
pattern O 0 2.0328873233665945e-06
on O 0 1.584861450965036e-07
the O 0 1.904827939824827e-08
5 O 0 1.5032576072826487e-08
side O 0 1.9938566353516762e-08
of O 0 1.2013295913604338e-09
the O 0 2.6626963745002286e-08
CTG O 0 1.8082498627336463e-06
repeat O 0 2.0862471217242273e-07
in O 0 7.0669452512106545e-09
the O 0 1.0285560847478337e-08
DMPK O 0 1.1092383829236496e-06
gene O 0 1.2824884265683067e-07
of O 0 2.2298842772272565e-09
normal O 0 7.653547839936437e-08
individuals O 0 1.108167890784273e-09
and O 0 2.242556140785723e-09
of O 0 5.010564851914978e-09
patients O 0 1.5355585958332085e-07
affected O 0 1.9828667063848116e-07
with O 0 0.00021621168707497418
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.6903489097330748e-07
showing O 0 1.515633698545571e-06
expansions O 0 8.2512156041048e-07
of O 0 7.645111210763389e-09
the O 0 1.1893452267486282e-07
repetitive O 0 8.230825187638402e-05
sequence O 0 3.5060800200881204e-06
. O 0 1.2937782685185084e-06

The O 0 1.5157478401306435e-06
gene O 0 1.0485981874808203e-05
segment O 0 2.531273366912501e-06
analyzed O 0 5.48219361462543e-07
corresponds O 0 1.466053731746797e-07
to O 0 3.271345150324123e-08
the O 0 1.1254729059828605e-07
genomic O 0 5.415046416601399e-06
SacI O 0 4.464993253350258e-05
- O 0 3.5298260172567097e-06
HindIII O 0 7.264399300765945e-06
fragment O 0 1.5044701058286591e-06
carrying O 0 1.0849848308680521e-07
exons O 0 1.685008214735717e-06
11 O 0 3.367306362633826e-07
- O 0 2.552834985181107e-06
15 O 0 6.56813710975257e-07
. O 0 5.060182388660905e-07

There O 0 1.5890324220890761e-06
is O 0 1.051531057782995e-07
constitutive O 0 1.0781662922454416e-06
methylation O 0 1.8186245824836078e-06
in O 0 9.807948941897848e-08
intron O 0 6.9574243752867915e-06
12 O 0 5.105485101353224e-08
at O 0 2.205251981024503e-08
restriction O 0 2.1087780410766754e-08
sites O 0 5.2281605711357315e-09
of O 0 1.6782968348394434e-09
SacII O 0 5.048815978625498e-07
and O 0 1.2312741048958742e-08
HhaI O 0 1.1877893939526984e-06
, O 0 6.2590319593880395e-09
localized O 0 4.239261670591077e-07
1 O 0 3.880516175058801e-08
, O 0 4.261732300392396e-09
159 O 0 2.5378477630511043e-07
- O 0 1.5987654933269368e-06
1 O 0 3.220449684704363e-08
, O 0 3.463633824196677e-09
232 O 0 8.313632804402005e-08
bp O 0 2.3681975847011927e-07
upstream O 0 4.354659566274677e-08
of O 0 2.3895301293208604e-09
the O 0 2.8699931320375072e-08
CTG O 0 2.430261474728468e-06
repeat O 0 3.8905139376765874e-07
, O 0 3.1526341537357894e-09
whereas O 0 4.004986120520471e-09
most O 0 7.393501921804102e-10
, O 0 4.0080710972389966e-10
if O 0 2.4092489114835303e-10
not O 0 4.5106521295856794e-10
all O 0 1.1379704817349179e-10
, O 0 1.1328487453665659e-10
of O 0 6.143435066219283e-11
the O 0 4.6329076686113524e-10
other O 0 2.6706281630595186e-10
sites O 0 2.7438771255106076e-09
of O 0 7.086554121293887e-10
SacII O 0 4.6399426878451777e-07
, O 0 3.824624617010386e-09
HhaI O 0 2.851942610959668e-07
, O 0 3.777940182914108e-09
and O 0 2.708989033095577e-09
HpaII O 0 3.0904737968739937e-07
in O 0 1.2420605877139224e-08
this O 0 2.807317933672948e-09
region O 0 1.782263758798308e-08
are O 0 1.9833568121185863e-09
unmethylated O 0 2.6612931947056495e-07
, O 0 2.0168122727426407e-09
in O 0 3.5046829882645625e-09
normal O 0 9.425863822798419e-08
individuals O 0 6.499874527499117e-10
and O 0 7.306347193924978e-10
most O 0 4.588418534012817e-10
of O 0 1.0750691448180305e-09
the O 0 1.1789298781650359e-07
patients O 0 8.803516493571806e-07
. O 0 4.4482874272944173e-07

In O 0 1.228688574883563e-06
a O 0 6.103243066490904e-08
number O 0 3.6452667551145623e-09
of O 0 8.06556099686162e-10
young O 0 7.976068694404148e-09
and O 0 7.218546471676746e-08
severely O 1 0.6353812217712402
affected O 0 2.9106940928613767e-06
patients O 0 4.2815329948098224e-07
, O 0 5.949523096404619e-09
however O 0 9.2698186904272e-09
, O 0 6.262994012296019e-10
complete O 0 1.3113065078229624e-09
methylation O 0 4.099454997685825e-08
of O 0 7.817826941369788e-10
these O 0 5.645121037289869e-10
restriction O 0 8.557448971657777e-09
sites O 0 5.767509581033892e-09
was O 0 1.8762158049412392e-08
found O 0 2.3204869137316564e-09
in O 0 4.9293560344665366e-09
the O 0 1.8326520745404196e-08
mutated O 0 6.348479018924991e-06
allele O 0 1.3230341210146435e-05
. O 0 7.391266194645141e-07

In O 0 1.4326406017062254e-06
most O 0 2.020833456128912e-08
of O 0 2.411516764055932e-09
these O 0 3.4470457599411475e-09
patients O 0 2.5593230645881704e-08
, O 0 1.8155578151990426e-09
the O 0 8.585389288384704e-09
onset O 0 2.0618585040210746e-05
of O 0 1.169336627526718e-08
the O 0 1.1259026905463543e-05
disease O 1 0.9933559894561768
was O 1 0.7154502868652344
congenital O 1 0.9999958276748657
. O 0 3.1221254630509065e-06

Preliminary O 0 3.49760266544763e-05
in O 0 3.354954060341697e-06
vivo O 0 2.1466761609190144e-05
footprinting O 0 6.482063326984644e-05
data O 0 5.989867304379004e-07
gave O 0 3.0937407302644715e-08
evidence O 0 6.3505196656876706e-09
for O 0 2.053470282703529e-09
protein O 0 3.3335009419488415e-08
- O 0 9.694866776044364e-08
DNA O 0 1.8831393333584856e-07
contact O 0 1.703161416344301e-07
in O 0 1.5491519178567614e-08
normal O 0 8.968834208644694e-08
genes O 0 4.754145166430135e-08
at O 0 2.5473424258848354e-08
an O 0 3.6507634693094815e-09
Sp1 O 0 4.96232814839459e-07
consensus O 0 4.1853677856806826e-08
binding O 0 4.200562742084912e-08
site O 0 2.8543089669597066e-08
upstream O 0 1.9708981113808477e-08
of O 0 7.198933116292494e-10
the O 0 8.369058335233603e-09
CTG O 0 1.5392753311971319e-06
repeat O 0 2.2092434903697722e-07
and O 0 2.5709219197977973e-09
for O 0 4.4731179871249083e-10
a O 0 1.471523569662736e-09
significant O 0 1.8611454599692934e-09
reduction O 0 3.869664144673379e-09
of O 0 1.7881186809010075e-10
this O 0 4.478555581943766e-10
interaction O 0 2.8533548857012647e-09
in O 0 5.911392264579263e-09
cells O 0 3.3161565937689375e-08
with O 0 6.137245822657178e-09
a O 0 1.0823990237440739e-07
hypermethylated O 0 9.019636308948975e-06
DMPK O 0 1.1296368029434234e-05
gene O 0 1.6146826737895026e-06
. O 0 5.698438343415546e-08
. O 0 1.8823672576218087e-07

The O 0 4.1630035411799327e-05
hemochromatosis B-Disease 1 0.9999992847442627
gene O 0 5.247923400020227e-05
product O 0 9.452749623051204e-07
complexes O 0 2.5745995912984654e-07
with O 0 4.6534558428845685e-09
the O 0 1.4284283089693872e-08
transferrin O 0 1.6249227883236017e-06
receptor O 0 5.532888849302253e-07
and O 0 2.324395076414021e-08
lowers O 0 2.40705480791803e-06
its O 0 2.5350555432623878e-08
affinity O 0 6.733046831186584e-08
for O 0 7.2382873028686845e-09
ligand O 0 5.524990456251544e-07
binding O 0 1.411780658600037e-06
. O 0 4.118892888982373e-07

We O 0 1.5690811778767966e-06
recently O 0 1.5965744069035281e-06
reported O 0 5.987000122331665e-07
the O 0 2.1964366325732954e-08
positional O 0 9.384403938383912e-07
cloning O 0 1.2462591314488236e-07
of O 0 2.583776970155327e-09
a O 0 1.3557610145653598e-08
candidate O 0 1.1634571706053976e-07
gene O 0 3.4771767332131276e-06
for O 0 3.378117980901152e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.544414758682251
HFE O 1 0.8472274541854858
. O 0 8.55280268297065e-06

The O 0 5.436014589577098e-07
gene O 0 3.037005171790952e-06
product O 0 1.3325980319223163e-07
, O 0 2.1741861644386518e-09
a O 0 5.695925064941321e-09
member O 0 3.856401420421207e-09
of O 0 4.325326485865588e-10
the O 0 1.1015239387290876e-08
major O 0 5.031703409485999e-08
histocompatibility O 0 3.7540630728472024e-06
complex O 0 1.0968277592837694e-06
class O 0 1.3853566542820772e-06
I O 0 6.234363354451489e-06
- O 0 7.481843908863084e-07
like O 0 1.9515736582320642e-08
family O 0 2.311291424916817e-08
, O 0 9.087053332024198e-10
was O 0 1.758364653881017e-08
found O 0 8.4060097771399e-10
to O 0 1.5925233354252555e-09
have O 0 1.5564101119025509e-09
a O 0 1.602555066426703e-08
mutation O 0 5.427373821476067e-07
, O 0 2.371333884809701e-08
Cys O 0 4.968490975443274e-05
- O 0 2.109584329446079e-06
282 O 0 2.904859456975828e-06
- O 0 1.7267400835407898e-05
- O 0 1.4495236428047065e-05
> O 0 2.6267364319210174e-06
Tyr O 0 4.174432433501352e-06
( O 0 2.4605727233506514e-08
C282Y O 0 1.3635806794809469e-07
) O 0 3.03414382507583e-09
, O 0 4.46171655177352e-10
in O 0 1.8334587181811912e-09
85 O 0 1.5695459154585478e-08
% O 0 1.8334727069913015e-09
of O 0 2.5082789179009524e-09
patient O 0 2.3427965061273426e-06
chromosomes O 0 5.466861694003455e-06
. O 0 1.0973216149068321e-06

This O 0 1.9717138002306456e-06
mutation O 0 1.8697979612625204e-05
eliminates O 0 4.119869117857888e-06
the O 0 7.100184262753828e-08
ability O 0 8.398677664445131e-08
of O 0 1.5951659548818498e-08
HFE O 0 2.2421043468057178e-05
to O 0 5.669200220381754e-08
associate O 0 7.155407644177103e-08
with O 0 2.7084066545057794e-08
beta2 O 0 0.00015513655671384186
- O 0 7.63288771850057e-05
microglobulin O 0 8.969891496235505e-05
( O 0 5.842926498189627e-08
beta2m O 0 8.562070661355392e-07
) O 0 4.551688803644538e-09
and O 0 1.3625107708747919e-09
prevents O 0 2.3928061310130033e-08
cell O 0 7.006190116953803e-07
- O 0 1.4650448747488554e-06
surface O 0 5.843282906425884e-07
expression O 0 1.1585029824345838e-06
. O 0 2.7588987450144487e-07

A O 0 4.769876795762684e-06
second O 0 8.444607715318853e-07
mutation O 0 1.7387166053595138e-06
that O 0 1.096037394177074e-08
has O 0 8.958896735578037e-09
no O 0 2.1976003239387865e-09
effect O 0 1.102808422359658e-08
on O 0 1.1767428986786399e-07
beta2m O 0 3.447315293669817e-06
association O 0 3.348035448880182e-08
, O 0 3.0034370546161426e-09
H63D O 0 1.275663862543297e-06
, O 0 4.611099946316699e-09
was O 0 4.944056897215887e-08
found O 0 6.43872555272651e-09
in O 0 3.295705930383974e-09
eight O 0 2.035462465244109e-09
out O 0 2.077668037614444e-09
of O 0 6.476189029491763e-10
nine O 0 5.990641316344636e-09
patients O 0 2.8963558662553623e-08
heterozygous O 0 1.0375929093697778e-07
for O 0 2.341324467636241e-09
the O 0 4.8004519470623563e-08
C282Y O 0 4.027535396744497e-06
mutant O 0 5.373454769141972e-06
. O 0 7.079480610627797e-07

In O 0 1.1373703046047012e-06
this O 0 4.107516815565759e-08
report O 0 1.686201329675896e-07
, O 0 3.038388429743577e-09
we O 0 1.0387563031954983e-09
demonstrate O 0 6.80960532406516e-09
in O 0 7.3821762036629934e-09
cultured O 0 3.295840542705264e-07
293 O 0 3.690729499794543e-07
cells O 0 7.285847800631018e-07
overexpressing O 0 9.761134606378619e-06
wild O 0 5.251931156635692e-07
- O 0 5.196204710955499e-06
type O 0 7.690913662372623e-06
or O 0 6.47812257170699e-08
mutant O 0 5.834106673319184e-07
HFE O 0 4.323271241446491e-06
proteins O 0 5.963784133200534e-08
that O 0 1.1680878486686197e-09
both O 0 1.4065286713105252e-09
the O 0 4.049174773257391e-09
wild O 0 1.354314207446805e-07
- O 0 1.4270240171754267e-05
type O 0 4.114779949304648e-05
and O 0 1.4027736483512854e-07
H63D O 0 5.0931146688526496e-05
HFE O 0 6.52224916848354e-05
proteins O 0 4.830311013392929e-07
form O 0 9.869953032648482e-08
stable O 0 1.4365014067152515e-06
complexes O 0 1.3270205556636938e-07
with O 0 7.368221144332665e-09
the O 0 3.521872571354834e-08
transferrin O 0 5.3179674068815075e-06
receptor O 0 4.707307198259514e-06
( O 0 3.710301825776696e-07
TfR O 0 2.8685575671261176e-05
) O 0 1.9338955326020368e-07
. O 0 5.231475483924442e-07

The O 0 4.5019596655038185e-06
C282Y O 0 3.946102151530795e-05
mutation O 0 1.3974336070532445e-05
nearly O 0 3.597999977955624e-07
completely O 0 5.166505161469104e-07
prevents O 0 1.1768057106564811e-07
the O 0 2.063152670928048e-08
association O 0 2.4390274688812497e-08
of O 0 1.2956460349045074e-09
the O 0 1.8404600510280034e-08
mutant O 0 1.4847532838757616e-06
HFE O 0 2.451227373967413e-05
protein O 0 3.7514323025789054e-07
with O 0 2.820845423912033e-08
the O 0 4.985324721928919e-07
TfR O 0 0.00012080527812941
. O 0 7.189964890130796e-07

Studies O 0 1.2951254575455096e-05
on O 0 1.418797864971566e-06
cell O 0 8.679340680828318e-06
- O 0 4.211122359265573e-06
associated O 0 6.33214995104936e-07
transferrin O 0 2.813747414620593e-06
at O 0 2.0625239471883106e-07
37 O 0 9.23803469277118e-08
degrees O 0 8.131819839718446e-08
C O 0 3.639752776507521e-06
suggest O 0 4.9979490768237156e-08
that O 0 3.4409628479892262e-09
the O 0 3.145716220842587e-08
overexpressed O 0 6.873043730593054e-06
wild O 0 6.614855578845891e-07
- O 0 7.603183803439606e-06
type O 0 1.516391694167396e-05
HFE O 0 3.827726322924718e-05
protein O 0 4.900621206616051e-07
decreases O 0 1.3727466807722521e-07
the O 0 6.079203362929775e-09
affinity O 0 2.846680935419954e-08
of O 0 2.484078498454778e-09
the O 0 5.763146759818483e-08
TfR O 0 4.433770300238393e-06
for O 0 5.4263399107412624e-08
transferrin O 0 1.0942035260086413e-05
. O 0 8.712468684279884e-07

The O 0 4.137974428886082e-06
overexpressed O 0 0.000176411253050901
H63D O 0 6.808077887399122e-05
protein O 0 4.8100851017807145e-06
does O 0 1.374202014403636e-07
not O 0 2.3818855776625014e-09
have O 0 6.183914491586506e-10
this O 0 6.821014864044628e-10
effect O 0 5.470451203137827e-09
, O 0 3.7454866985697777e-10
providing O 0 2.950032995663321e-10
the O 0 7.423939796247225e-10
first O 0 9.598133399180142e-10
direct O 0 2.003882615397856e-09
evidence O 0 2.4154938049747443e-09
for O 0 1.387067127822661e-09
a O 0 9.362342012764202e-09
functional O 0 3.016792859966699e-08
consequence O 0 1.4842995277319915e-08
of O 0 1.896022450154078e-09
the O 0 1.499544026728472e-07
H63D O 0 0.00023187202168628573
mutation O 0 1.3574551303463522e-05
. O 0 8.330520131494268e-07

Addition O 0 2.5513234049867606e-06
of O 0 1.2956819261944474e-07
soluble O 0 7.70818496675929e-06
wild O 0 2.8629401640500873e-06
- O 0 0.0002872399927582592
type O 0 0.005845197942107916
HFE O 0 0.12590986490249634
/ O 0 0.00023478656657971442
beta2m O 0 2.4434206352452748e-05
heterodimers O 0 7.3487117333570495e-06
to O 0 6.034520083630923e-08
cultured O 0 3.985685737006861e-07
cells O 0 2.446487314955448e-07
also O 0 1.7820225295395176e-08
decreased O 0 5.509879130727313e-08
the O 0 5.256838964129429e-09
apparent O 0 3.554840688479999e-08
affinity O 0 2.3073623012237476e-08
of O 0 1.1133584054690004e-09
the O 0 1.1903773078358881e-08
TfR O 0 4.510953317549138e-07
for O 0 7.144927427482628e-10
its O 0 2.3618129674218835e-09
ligand O 0 1.4666095893289821e-08
under O 0 6.894265602852556e-09
steady O 0 5.7733450375963e-07
- O 0 2.0874053063835163e-07
state O 0 6.928011497819853e-09
conditions O 0 7.947417657305778e-08
, O 0 4.0330630501905773e-10
both O 0 6.293889298625288e-10
in O 0 2.27033281063882e-09
293 O 0 5.168219985307587e-08
cells O 0 5.668216118692726e-08
and O 0 9.191507110983821e-09
in O 0 7.850977823409266e-08
HeLa O 0 2.0814050003536977e-05
cells O 0 4.138977146794787e-06
. O 0 1.2637705140150501e-06

Furthermore O 0 1.195357799588237e-05
, O 0 1.4574845863535302e-07
at O 0 1.1634727314913107e-07
4 O 0 6.082616010871789e-08
degrees O 0 3.961879144753766e-07
C O 0 1.1406570592953358e-05
, O 0 7.482826802629461e-09
the O 0 1.9426011022005696e-08
added O 0 1.6654314549668925e-07
soluble O 0 2.8961582643205475e-07
complex O 0 6.323640633354444e-08
of O 0 5.0021640163322445e-08
HFE O 0 0.0018980471650138497
/ O 0 3.5106415452901274e-05
beta2m O 0 1.0727626431616955e-05
inhibited O 0 1.0340795597585384e-06
binding O 0 1.2338628607722057e-07
of O 0 7.684672453933672e-09
transferrin O 0 8.545755463273963e-07
to O 0 4.715169410474118e-08
HeLa O 0 6.2860885918780696e-06
cell O 0 2.392227997916052e-06
TfR O 0 3.496296585581149e-06
in O 0 1.4205435938663413e-08
a O 0 4.3373429292614674e-08
concentration O 0 9.243601084563124e-07
- O 0 2.2947260731598362e-06
dependent O 0 4.817544549950981e-07
manner O 0 1.964932380360551e-06
. O 0 8.466275289720215e-07

Scatchard O 0 0.00041930118459276855
plots O 0 7.674020707781892e-06
of O 0 1.8678749214018353e-08
these O 0 4.010145548960509e-09
data O 0 5.311123274509555e-08
indicate O 0 5.038752703967475e-08
that O 0 1.908438074238461e-09
the O 0 9.665394706814823e-09
added O 0 2.665186293882016e-08
heterodimer O 0 3.804328514434019e-07
substantially O 0 2.823225315751188e-07
reduced O 0 2.5630161104572835e-08
the O 0 8.750045132899231e-09
affinity O 0 7.930760403951354e-08
of O 0 1.2871219645660403e-08
TfR O 0 5.735091690439731e-06
for O 0 4.945905729414335e-08
transferrin O 0 2.21492718992522e-05
. O 0 1.0701024848458474e-06

These O 0 3.222404529878986e-07
results O 0 4.5666047299164347e-07
establish O 0 1.4207338949745463e-07
a O 0 4.2563161883890643e-08
molecular O 0 2.805334418098937e-07
link O 0 1.3436690551316133e-06
between O 0 7.72106716340204e-08
HFE O 0 5.4934720537858084e-05
and O 0 1.768927226919459e-08
a O 0 1.664690785219136e-08
key O 0 2.0020424429390005e-08
protein O 0 1.78081300816757e-08
involved O 0 2.682841948598025e-09
in O 0 1.6481422449032834e-08
iron O 0 6.422601472877432e-06
transport O 0 4.7730164709491874e-08
, O 0 1.7926409245916375e-09
the O 0 1.0024785446205442e-08
TfR O 0 1.4627300970460055e-06
, O 0 2.0204700135195708e-09
and O 0 1.969608254270838e-09
raise O 0 1.0483145906903246e-08
the O 0 1.832116347522117e-09
possibility O 0 7.85954412663159e-09
that O 0 9.557067359722282e-10
alterations O 0 6.533315399792627e-08
in O 0 5.344064302192919e-09
this O 0 6.304429422954172e-09
regulatory O 0 7.035919225018006e-07
mechanism O 0 1.0987457699229708e-06
may O 0 3.325861541725317e-07
play O 0 2.749435568105696e-09
a O 0 2.6983815182290982e-09
role O 0 3.254540192898503e-09
in O 0 4.4928802900301434e-09
the O 0 2.6563354182940202e-08
pathogenesis O 0 3.832386028079782e-06
of O 0 3.7373945360741345e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 5.363793661672389e-06
. O 0 1.0249018487229478e-06

Genomic O 0 0.0001881939242593944
organization O 0 2.0500647224253044e-06
of O 0 1.08896330175412e-07
the O 0 5.552855100177112e-07
UBE3A O 0 0.0003365502052474767
/ O 0 3.465255576884374e-05
E6 O 0 1.3555455552705098e-05
- O 0 3.325990110170096e-05
AP O 0 2.7333375328453258e-05
gene O 0 2.9394147986749886e-06
and O 0 3.885537580572418e-08
related O 0 5.56119118755305e-07
pseudogenes O 0 1.9163662727805786e-05
. O 0 2.284705260535702e-06

The O 0 8.983659427030943e-06
UBE3A O 0 0.0006212841253727674
gene O 0 1.6728297850931995e-05
encodes O 0 3.920017661585007e-06
the O 0 1.6896139243272046e-07
E6 O 0 8.812195119389798e-06
- O 0 6.764727004338056e-06
AP O 0 2.0525985746644437e-05
ubiquitin O 0 4.039190116600366e-06
- O 0 5.750025025008654e-07
protein O 0 2.3893042566669465e-07
ligase O 0 2.107705086018541e-07
and O 0 1.3698180367782697e-08
has O 0 5.343412379232859e-09
recently O 0 3.777214274691687e-08
been O 0 2.9422013714253126e-09
shown O 0 1.1918039888314524e-08
to O 0 3.717326446661673e-09
be O 0 1.066170529639976e-08
mutated O 0 1.767487447068561e-05
in O 0 0.20778042078018188
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00012585872900672257
who O 0 1.4198209896676417e-07
lack O 0 3.044539766960952e-07
15q11 O 0 1.6684611182427034e-05
- O 0 1.1261045983701479e-05
q13 O 0 8.990498827188276e-06
deletions O 0 1.185636119771516e-05
or O 0 9.007352446133154e-07
chromosome O 0 2.676948315638583e-05
15 O 0 1.2785942544724094e-06
paternal O 0 0.00018205458763986826
uniparental B-Disease 0 0.0052321236580610275
disomy I-Disease 0 0.0012296716449782252
. O 0 8.018039807211608e-06

Previous O 0 4.479510971577838e-05
UBE3A O 0 0.0005432340549305081
cDNA O 0 2.9963899578433484e-05
analysis O 0 1.083369284060609e-06
has O 0 5.9157493126349436e-08
shown O 0 4.782247486900815e-08
a O 0 4.9565578308374825e-08
coding O 0 1.6532228528376436e-06
region O 0 4.3602199184533674e-08
of O 0 1.0423609531073907e-08
approximately O 0 4.289559996095704e-08
2 O 0 2.2528557508394442e-07
. O 0 2.838600323684659e-07

6 O 0 4.3014373659389094e-05
kb O 0 6.830539496149868e-05
and O 0 1.0108368542205426e-07
a O 0 9.023019487131023e-08
3 O 0 4.043280910082103e-07
- O 0 5.757544386142399e-06
untranslated O 0 6.959083293622825e-06
region O 0 6.966865839785896e-07
( O 0 8.391567973831116e-08
UTR O 0 1.6784822491899831e-06
) O 0 7.619940234349087e-09
of O 0 2.7398816548895866e-09
< O 0 1.3392767073128198e-07
50 O 0 2.0641996556491904e-08
bp O 0 3.877405845287285e-07
, O 0 3.299681416990552e-09
whereas O 0 1.5712021905756046e-08
Northern O 0 2.3509196367399454e-08
analysis O 0 2.2970784385734078e-08
has O 0 5.269346736724856e-09
indicated O 0 3.482382382458127e-08
mRNA O 0 4.1400873840302665e-08
sizes O 0 6.27334060254725e-08
of O 0 2.364494600115563e-09
5 O 0 1.0730072119713441e-07
- O 0 7.700352398387622e-06
8 O 0 1.2814507499570027e-06
kb O 0 0.00019407045328989625
. O 0 1.5030447002573055e-06

We O 0 7.584793593196082e-07
have O 0 2.4598078240956056e-08
analyzed O 0 6.298026278273028e-08
additional O 0 1.4323460639786845e-08
cDNA O 0 2.523420619127137e-07
clones O 0 3.2726066478971916e-07
and O 0 2.9899938081001665e-09
provide O 0 1.4464788256063343e-09
evidence O 0 2.137239496491361e-09
for O 0 6.02168426233618e-10
an O 0 2.1469144240171545e-09
additional O 0 3.0804507389348146e-08
0 O 0 2.502720519714785e-07
. O 0 2.041276445652329e-07

5 O 0 2.2426391296903603e-05
kb O 0 5.671125472872518e-05
of O 0 1.6797106638932746e-07
5 O 0 4.01859352905376e-07
- O 0 1.7493746327090776e-06
UTR O 0 4.360512775747338e-06
and O 0 9.371689202453126e-08
> O 0 3.8526948742401146e-07
2 O 0 1.0726142818384687e-07
kb O 0 6.913190190971363e-06
of O 0 1.744953692650597e-08
3 O 0 9.049948062056501e-07
- O 0 2.383737955824472e-05
UTR O 0 0.0001035200257319957
. O 0 2.4552668946853373e-06

We O 0 6.053033985153888e-07
have O 0 1.6635324229241633e-08
established O 0 8.152611030709522e-09
the O 0 5.542900360921976e-09
genomic O 0 1.417126185287998e-07
organization O 0 1.3600086390397337e-08
of O 0 4.19836609921731e-09
UBE3A O 0 3.861890945699997e-06
and O 0 6.754821146870427e-09
the O 0 7.160771087200146e-09
sequence O 0 3.048002383820858e-08
of O 0 2.5970692263399542e-08
intron O 0 4.258731860318221e-05
- O 0 2.3850292564020492e-05
exon O 0 2.7750800654757768e-05
borders O 0 3.8467619560833555e-06
. O 0 1.2542755030153785e-06

We O 0 1.215059683090658e-06
have O 0 4.174723855498996e-08
also O 0 2.444565083692396e-08
mapped O 0 3.916651678537164e-07
two O 0 5.5667603859888e-09
highly O 0 5.638541367147809e-08
homologous O 0 4.099213413155667e-07
processed O 0 2.2174504010763485e-07
pseudogenes O 0 8.235665518441238e-07
, O 0 2.5925357860501208e-08
UBE3AP1 O 0 4.143661044508917e-06
and O 0 3.7868950641950505e-08
UBE3AP2 O 0 3.085998969254433e-06
, O 0 4.156558652823605e-09
to O 0 7.510051247550109e-09
chromosomes O 0 4.488343208208789e-08
2 O 0 1.0813358208849877e-08
and O 0 4.86818363398811e-09
21 O 0 1.0745572431858363e-08
, O 0 8.581700350340782e-10
respectively O 0 9.358432251360682e-09
, O 0 1.287934203730856e-09
and O 0 4.32904290192937e-09
determined O 0 1.948114913830068e-08
their O 0 1.6493970633746358e-08
genomic O 0 1.0284883273925516e-06
organization O 0 4.124380268422101e-07
. O 0 5.334698016667971e-07

These O 0 4.0613360852148617e-07
results O 0 5.129115834279219e-07
will O 0 1.0942700967575547e-08
form O 0 3.522932390254141e-09
the O 0 2.687441158499837e-09
basis O 0 1.9586430255458254e-09
for O 0 5.387619794738896e-10
studies O 0 2.859031456026173e-09
of O 0 1.6043220085748544e-09
mutation O 0 3.5792047015092976e-07
and O 0 2.3117587844012633e-08
imprinting O 0 5.635763045575004e-06
of O 0 9.499211728325463e-08
UBE3A O 0 0.00021727244893554598
. O 0 2.92980985250324e-06

Mutation O 0 0.002953400369733572
spectrum O 0 0.00020442054665181786
and O 0 3.1477081847697264e-06
genotype O 0 0.0006321275723166764
- O 0 0.0003681252128444612
phenotype O 0 0.0003730666940100491
analyses O 0 6.829327503510285e-06
in O 0 2.103842234646436e-06
Cowden B-Disease 1 0.9941285848617554
disease I-Disease 1 0.6942611336708069
and O 0 3.875759375659982e-06
Bannayan B-Disease 1 0.9971959590911865
- I-Disease 1 0.9999994039535522
Zonana I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
, O 0 1.4851298146822955e-07
two O 0 2.708285933294974e-07
hamartoma B-Disease 0 0.37530311942100525
syndromes I-Disease 0 0.001799768186174333
with O 0 1.8567621964393766e-06
germline O 0 0.007238168269395828
PTEN O 0 0.16085347533226013
mutation O 0 0.0007760192966088653
. O 0 6.790464794903528e-06

The O 0 6.055009725969285e-05
tumour B-Disease 1 0.999998927116394
suppressor O 0 0.030533647164702415
gene O 0 0.0002658604644238949
PTEN O 0 0.0004679909034166485
, O 0 7.325401440994028e-08
which O 0 3.3511149410969665e-08
maps O 0 3.248675284339697e-07
to O 0 8.494097869515826e-08
10q23 O 0 1.0214845133305062e-05
. O 0 5.056733130004432e-07

3 O 0 8.931838237913325e-06
and O 0 1.9674772033795307e-07
encodes O 0 1.5142193205974763e-06
a O 0 1.4292247385583323e-07
403 O 0 8.324341820298287e-07
amino O 0 6.169618700369028e-07
acid O 0 1.2376488029985921e-06
dual O 0 1.692984710643941e-06
specificity O 0 3.2092953006213065e-06
phosphatase O 0 0.000255007907981053
( O 0 3.077491612657468e-07
protein O 0 1.3262427955851308e-06
tyrosine O 0 3.588274557841942e-05
phosphatase O 0 0.00033769692527130246
; O 0 1.3242492968856823e-07
PTPase O 0 3.134366124868393e-06
) O 0 1.2559564055436567e-08
, O 0 2.927166287136629e-09
was O 0 1.398405942154568e-07
shown O 0 1.751085143553155e-08
recently O 0 8.423929642731309e-08
to O 0 3.4519473945948675e-09
play O 0 1.200015731228632e-08
a O 0 2.1742909694921764e-08
broad O 0 1.1766307039806634e-07
role O 0 3.399663128789143e-08
in O 0 5.317265916460201e-08
human O 0 6.207430374161049e-07
malignancy B-Disease 0 0.00011139933485537767
. O 0 1.0486604651305242e-06

Somatic O 0 0.0009735511848703027
PTEN O 0 0.003699759254232049
deletions O 0 0.00015754980267956853
and O 0 1.2352963949524565e-06
mutations O 0 9.121979019255377e-06
were O 0 4.854120660979788e-08
observed O 0 1.1523803067348126e-07
in O 0 8.075696911191699e-08
sporadic B-Disease 0 0.006027557421475649
breast I-Disease 1 0.8752719163894653
, I-Disease 0 2.556342622028751e-07
brain I-Disease 0 0.006975455675274134
, I-Disease 0 1.2772244417647016e-06
prostate I-Disease 1 0.997735857963562
and I-Disease 0 0.0011153457453474402
kidney I-Disease 1 0.6913257837295532
cancer I-Disease 0 0.009944086894392967
cell O 0 7.501156505895779e-05
lines O 0 1.9897966922144406e-05
and O 0 1.672303184818702e-08
in O 0 4.446418344628e-09
several O 0 1.0318847998291858e-08
primary O 0 2.302323764524772e-06
tumours B-Disease 1 0.9999942779541016
such O 0 6.882680025910304e-08
as O 0 8.165762665157672e-06
endometrial B-Disease 1 0.9999593496322632
carcinomas I-Disease 1 1.0
, O 1 0.9597640037536621
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999725818634033
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 3.237928467569873e-05

In O 0 1.5850988575039082e-06
addition O 0 4.424628059496172e-07
, O 0 6.065653934683723e-08
PTEN O 0 2.2867281586513855e-05
was O 0 8.896762437871075e-07
identified O 0 4.510690843062548e-08
as O 0 3.1695162050482395e-09
the O 0 9.192296701598934e-09
susceptibility O 0 9.910205562846386e-07
gene O 0 5.218848286858702e-07
for O 0 2.2103810337625873e-08
two O 0 9.96800622488081e-07
hamartoma B-Disease 1 0.999982476234436
syndromes I-Disease 1 0.999972939491272
Cowden B-Disease 1 0.9999765157699585
disease I-Disease 1 0.9999865293502808
( O 0 3.4072243124683155e-06
CD B-Disease 0 0.0008887947769835591
; O 0 8.225139822570782e-07
MIM O 0 8.571924263378605e-05
158350 O 0 5.517110366781708e-06
) O 0 3.745090282336605e-08
and O 0 3.789423885791621e-08
Bannayan B-Disease 0 6.623380613746122e-05
- I-Disease 0 0.00021828470926266164
Zonana I-Disease 0 0.00068246154114604
( I-Disease 0 3.4479489841032773e-07
BZS I-Disease 0 8.17303043731954e-06
) I-Disease 0 4.03609874410904e-08
or I-Disease 0 1.2681370264999714e-07
Ruvalcaba I-Disease 0 4.437427924131043e-05
- I-Disease 0 0.00012494157999753952
Riley I-Disease 0 0.0023082669358700514
- I-Disease 1 0.9981182813644409
Smith I-Disease 1 0.9639076590538025
syndrome I-Disease 1 0.9999961853027344
( O 0 1.7722725260682637e-06
MIM O 0 0.00016724511806387454
153480 O 0 3.867117266054265e-05
) O 0 1.158159420810989e-06
. O 0 1.0052348216049722e-06

Constitutive O 0 0.00012294523185119033
DNA O 0 9.942042197508272e-06
from O 0 3.449698624535813e-07
37 O 0 4.808983931070543e-07
CD B-Disease 0 2.582178012744407e-06
families O 0 2.8494895332187298e-08
and O 0 1.3019638700484393e-08
seven O 0 2.8362807213966335e-08
BZS B-Disease 0 4.159553554927697e-06
families O 0 3.80989781945118e-08
was O 0 1.9753133528865874e-07
screened O 0 8.329884622071404e-07
for O 0 1.179065947098934e-07
germline O 0 0.00023616617545485497
PTEN O 0 0.0023476534988731146
mutations O 0 0.0003010970540344715
. O 0 4.537385848379927e-06

PTEN O 0 0.01362821739166975
mutations O 0 0.0007717928383499384
were O 0 5.596694450105133e-07
identified O 0 1.1381543885136125e-07
in O 0 1.6263021151985413e-08
30 O 0 9.780222853805753e-09
of O 0 1.5309072898261888e-09
37 O 0 2.5376243328878445e-08
( O 0 8.686739327856685e-09
81 O 0 5.838147387748904e-08
% O 0 4.397601394146022e-09
) O 0 2.7081366038572696e-09
CD B-Disease 0 1.2594488225659006e-06
families O 0 9.297370873184718e-09
, O 0 1.6016467041524152e-09
including O 0 3.0956397445436323e-09
missense O 0 1.5240243556036148e-06
and O 0 9.205125905964451e-08
nonsense O 0 1.3993146694701863e-06
point O 0 2.718369955800881e-07
mutations O 0 1.248051944457984e-06
, O 0 6.6952918764684455e-09
deletions O 0 3.618806090344151e-07
, O 0 1.293760210074879e-08
insertions O 0 6.084461006139463e-07
, O 0 1.0095781988184171e-08
a O 0 1.4992208718922484e-07
deletion O 0 1.1698424714268185e-05
/ O 0 8.279029316327069e-06
insertion O 0 1.141858888331626e-06
and O 0 8.290323449955395e-08
splice O 0 5.147921547177248e-05
site O 0 1.182282721856609e-05
mutations O 0 5.388658246374689e-05
. O 0 9.219338039656577e-07

These O 0 8.151804422595887e-07
mutations O 0 5.277348464005627e-06
were O 0 6.01293237423306e-08
scattered O 0 7.83476181709375e-08
over O 0 1.5755626137092804e-08
the O 0 8.86819684353668e-09
entire O 0 2.2001557908879477e-08
length O 0 2.3584243891150436e-08
of O 0 4.608303960651483e-09
PTEN O 0 4.093852112418972e-06
, O 0 2.2443920055792432e-09
with O 0 5.52263623720961e-10
the O 0 2.0547163970263682e-09
exception O 0 2.717595481982471e-09
of O 0 2.691353528927465e-10
the O 0 3.4609923815764887e-09
first O 0 1.4421379646023524e-08
, O 0 1.5672416697753988e-09
fourth O 0 3.886174937406395e-08
and O 0 1.5599447067415895e-08
last O 0 2.4184646463254467e-07
exons O 0 6.906310318299802e-06
. O 0 7.631025482623954e-07

A O 0 1.1767146133934148e-05
hot O 0 1.6907300960156135e-05
spot O 0 2.104219447573996e-06
for O 0 9.927764210715395e-08
PTEN O 0 3.3090200304286554e-05
mutation O 0 2.1028633909736527e-06
in O 0 4.638571482473708e-08
CD B-Disease 0 8.31260513223242e-06
was O 0 3.5699360978469485e-07
identified O 0 1.4791841529415706e-08
in O 0 8.401670470448153e-09
exon O 0 3.272344599736243e-07
5 O 0 1.843653762989561e-08
that O 0 1.085010747914339e-09
contains O 0 3.551531735368485e-09
the O 0 1.3941283683038819e-08
PTPase O 0 8.783975999904214e-07
core O 0 1.7593180245967233e-07
motif O 0 2.7695804760696774e-07
, O 0 1.2404097748941467e-09
with O 0 6.709734434728887e-10
13 O 0 4.796258057382374e-09
of O 0 4.6424697419666927e-10
30 O 0 8.210067292679923e-09
( O 0 4.693577970726892e-09
43 O 0 1.1298848967555841e-08
% O 0 1.6868141328174602e-09
) O 0 3.0686446716998717e-09
CD B-Disease 0 9.563725143379997e-06
mutations O 0 6.572887514266768e-07
identified O 0 3.825013195069005e-08
in O 0 3.0337456990991996e-08
this O 0 7.598102058636869e-08
exon O 0 2.6950530809699558e-05
. O 0 1.1522872682689922e-06

Seven O 0 6.89035005052574e-07
of O 0 4.268486719638531e-08
30 O 0 8.137762819160343e-08
( O 0 2.121360864748567e-08
23 O 0 2.3583526242987318e-08
% O 0 1.8619585873125288e-09
) O 0 1.5628595084749008e-09
were O 0 4.0211669549705675e-09
within O 0 4.967572131420184e-09
the O 0 8.657215389007433e-09
core O 0 1.0285624085781819e-07
motif O 0 1.1489379403428757e-07
, O 0 8.476287449710185e-10
the O 0 1.7464013568613268e-09
majority O 0 3.094689393634553e-09
( O 0 1.7031338561679377e-09
five O 0 6.772828409218334e-10
of O 0 2.408481469817758e-10
seven O 0 1.712861297242796e-09
) O 0 6.78763545369776e-10
of O 0 2.704367285666365e-10
which O 0 4.141198939322521e-09
were O 0 1.843861419104087e-08
missense O 0 1.76184801148338e-06
mutations O 0 9.750831395649584e-07
, O 0 7.096390586269763e-09
possibly O 0 5.7167710565408925e-08
pointing O 0 1.5536265607352107e-07
to O 0 7.995657469450634e-09
the O 0 1.3130365239533148e-08
functional O 0 3.104469215031713e-08
significance O 0 7.302714433166102e-09
of O 0 1.657264214749432e-09
this O 0 7.3154842183953406e-09
region O 0 2.8859454914709204e-07
. O 0 4.922542302665533e-07

Germline O 0 0.010348930954933167
PTEN O 0 0.042343951761722565
mutations O 0 0.0028169627767056227
were O 0 6.748442729076487e-07
identified O 0 1.2106718827453733e-07
in O 0 7.286658387783973e-09
four O 0 2.2538511057490496e-09
of O 0 1.2822818362678845e-09
seven O 0 1.0352597001883623e-08
( O 0 1.7922179296192553e-08
57 O 0 5.4136659599635095e-08
% O 0 8.115779159822978e-09
) O 0 2.5342385967519476e-08
BZS B-Disease 0 5.857192263647448e-06
families O 0 1.0494453306364449e-07
studied O 0 1.1021502359653823e-06
. O 0 1.034945853461977e-06

Interestingly O 0 4.5719756599282846e-05
, O 0 1.0551353568644117e-07
none O 0 1.3968326051383428e-08
of O 0 8.246867078121056e-10
these O 0 3.277876858831519e-09
mutations O 0 5.222238996793749e-07
was O 0 9.989630456175291e-08
observed O 0 4.9183235262262315e-08
in O 0 2.0062625338823636e-08
the O 0 9.054414107367847e-08
PTPase O 0 8.736758900340647e-06
core O 0 3.0661944947496522e-06
motif O 0 1.678276930761058e-05
. O 0 6.434332817661925e-07

It O 0 6.927854769855912e-07
is O 0 4.59882336656392e-08
also O 0 8.744373225511026e-09
worthy O 0 1.074428102043612e-08
of O 0 2.0114725440834036e-09
note O 0 1.2668171223140234e-07
that O 0 1.863980525484976e-09
a O 0 6.33938590510752e-09
single O 0 4.038932743810619e-08
nonsense O 0 1.9873155565619527e-07
point O 0 3.329935793772165e-08
mutation O 0 1.1278398659442246e-07
, O 0 2.7446571682077092e-09
R233X O 0 1.6373910227684974e-07
, O 0 3.7021485876920224e-09
was O 0 3.15470494172132e-08
observed O 0 7.245746225237326e-09
in O 0 1.8120982492320081e-09
the O 0 4.689068244800865e-09
germline O 0 1.9632656744761334e-07
DNA O 0 3.6367890032806827e-08
from O 0 3.316104502104622e-09
two O 0 2.402820831193253e-09
unrelated O 0 7.45060049212043e-08
CD B-Disease 0 7.515780453104526e-06
families O 0 2.2951033074036786e-08
and O 0 1.135409011254751e-08
one O 0 3.447343388529589e-08
BZS B-Disease 0 1.5346056898124516e-05
family O 0 1.1008393130396144e-06
. O 0 5.003672072234622e-07

Genotype O 0 0.012685953639447689
- O 0 0.0049188523553311825
phenotype O 0 0.0004525507101789117
studies O 0 3.137321868962317e-07
were O 0 2.7851008610468853e-08
not O 0 2.744201754723008e-09
performed O 0 3.938844628237348e-08
on O 0 1.1678699785022673e-08
this O 0 7.393163303781591e-10
small O 0 1.5458393454181873e-09
group O 0 3.6314844464868656e-09
of O 0 3.7565923705074056e-09
BZS B-Disease 0 6.9098809944989625e-06
families O 0 1.5982273282588721e-07
. O 0 3.781749455811223e-07

However O 0 6.010907782183494e-06
, O 0 6.452472689488786e-07
genotype O 0 4.960168735124171e-05
- O 0 3.806308450293727e-05
phenotype O 0 7.47146550565958e-05
analysis O 0 4.797458927896514e-07
inthe O 0 6.3883685470500495e-06
group O 0 5.1035382142572416e-08
of O 0 3.4789615632746518e-09
CD B-Disease 0 3.54098619936849e-06
families O 0 1.8961065606504235e-08
revealed O 0 3.9449798094892685e-08
two O 0 1.960018147784126e-09
possible O 0 8.111245008990409e-09
associations O 0 6.392665952148491e-09
worthy O 0 6.6335910098302975e-09
of O 0 9.772759268500408e-10
follow O 0 9.55038927941132e-08
- O 0 1.9321105355629697e-06
up O 0 7.131047397024304e-08
in O 0 3.7148190301650175e-08
independent O 0 1.1848892000898559e-07
analyses O 0 1.7371586409353768e-06
. O 0 5.306764023771393e-07

The O 0 4.647108085009677e-07
first O 0 1.2091096834865311e-07
was O 0 6.48747047193865e-08
an O 0 2.7838884530950736e-09
association O 0 1.7505174199072826e-08
noted O 0 6.9851453510239025e-09
in O 0 3.3180025393875212e-09
the O 0 4.293879918293442e-09
group O 0 5.114975998310456e-09
of O 0 5.429916516419553e-10
CD B-Disease 0 8.368526209778793e-07
families O 0 1.1242011765943971e-08
with O 0 5.607384423456097e-07
breast B-Disease 1 0.9992154836654663
disease I-Disease 0 0.02413048781454563
. O 0 7.061429982968548e-07

A O 0 5.5483251344412565e-06
correlation O 0 3.1959662010194734e-06
was O 0 4.831259730053716e-07
observed O 0 4.531343478220151e-08
between O 0 7.295683612795756e-09
the O 0 1.2778926361534104e-08
presence O 0 1.2419900485838298e-07
/ O 0 1.6827968920551939e-06
absence O 0 1.6994968987660286e-08
of O 0 1.5518452078921996e-09
a O 0 4.3290370399518e-08
PTEN O 0 2.0549212422338314e-05
mutation O 0 3.643600621217047e-07
and O 0 3.4675207150058895e-09
the O 0 1.3428135048343393e-08
type O 0 1.0543402595430962e-06
of O 0 2.832771883731766e-08
breast O 0 0.00015011857612989843
involvement O 0 1.1005232636307483e-06
( O 0 6.222431920832605e-07
unaffected O 0 0.00023382484505418688
versus O 0 0.00015851781063247472
benign O 1 0.9577286243438721
versus O 0 0.0046117911115288734
malignant O 0 0.4282550513744354
) O 0 8.054850582084327e-07
. O 0 8.455624538328266e-07

Specifically O 0 4.228878424328286e-06
and O 0 4.883661830490382e-08
more O 0 1.7808629015902966e-09
directly O 0 5.3690341061951585e-09
, O 0 1.5950648579732274e-09
an O 0 2.507924978800702e-09
association O 0 4.603570857852901e-08
was O 0 4.0916168586591084e-07
also O 0 4.8017221310203695e-09
observed O 0 1.2193596354848069e-08
between O 0 1.0197729327643401e-09
the O 0 1.5260852581633344e-09
presence O 0 2.579296332072545e-09
of O 0 8.499129733330335e-10
a O 0 4.9455280759502784e-08
PTEN O 0 0.0002239072637166828
mutation O 0 2.8327660402283072e-05
and O 0 3.311147520435043e-05
malignant B-Disease 1 0.9999996423721313
breast I-Disease 1 0.9999991655349731
disease I-Disease 1 0.9978251457214355
. O 0 2.98058557746117e-06

Secondly O 0 0.00014254679263103753
, O 0 2.4630057282593043e-07
there O 0 7.500488230505198e-09
appeared O 0 1.4338540665903565e-07
to O 0 4.371309092476849e-09
be O 0 1.463526633216361e-09
an O 0 3.5484981619759992e-09
interdependent O 0 4.153827433128754e-07
association O 0 2.9911817023275944e-08
between O 0 1.2734787446788687e-08
mutations O 0 4.7396090963047754e-07
upstream O 0 1.1117869291865645e-07
and O 0 7.4211685685554585e-09
within O 0 9.501781583765023e-09
the O 0 2.8783585293012948e-08
PTPase O 0 2.7109033453598386e-06
core O 0 2.886710888105881e-07
motif O 0 5.160999307918246e-07
, O 0 2.624555683894414e-09
the O 0 5.032142702532383e-09
core O 0 6.279769593220408e-08
motif O 0 6.06063537134105e-08
containing O 0 6.551581943625706e-09
the O 0 2.2753181561085967e-09
majority O 0 3.435952189434488e-09
of O 0 1.9706680731701454e-09
missense O 0 2.037197646131972e-06
mutations O 0 1.0866659749808605e-06
, O 0 3.104432044764849e-09
and O 0 1.8243123678374218e-09
the O 0 6.007232489224634e-09
involvement O 0 1.547766714793397e-08
of O 0 1.6761790844199709e-09
all O 0 1.8101568022288461e-09
major O 0 2.0763220476283095e-08
organ O 0 3.802817809628323e-05
systems O 0 0.0008035558275878429
( O 0 8.326883715881195e-08
central O 0 2.1660698621417396e-06
nervous O 0 0.03787998855113983
system O 0 0.0003258275974076241
, O 0 7.831040420569479e-07
thyroid O 0 0.02911320887506008
, O 0 4.3446544850667124e-07
breast O 0 0.10288610309362411
, O 0 1.7601819308765698e-06
skin O 1 0.9999986886978149
and O 0 0.1366710215806961
gastrointestinal O 1 0.9999992847442627
tract O 1 0.9933171272277832
) O 0 2.2839558369014412e-06
. O 0 2.273273139508092e-06

However O 0 1.5479801049878006e-06
, O 0 2.1264042970869923e-08
these O 0 2.6715825107714863e-09
observations O 0 3.042333673874964e-08
would O 0 5.777760048175651e-09
need O 0 1.8688397496191556e-09
to O 0 2.0415591439615355e-09
be O 0 1.1775141972591996e-09
confirmed O 0 5.612508235941505e-09
by O 0 1.3739726023587195e-09
studying O 0 2.6386199891703654e-09
a O 0 3.4769447321281177e-09
larger O 0 6.4063119253887635e-09
number O 0 1.4009221560584706e-09
of O 0 1.7200442181675157e-09
CD B-Disease 0 1.0478773219801951e-05
families O 0 1.1016441447964098e-07
. O 0 3.24497221981801e-07

Molecular O 0 0.011115841567516327
defects O 1 0.9976648092269897
leading O 0 1.2428969284883351e-06
to O 0 1.0449133469592198e-07
human O 0 1.0412248485636155e-07
complement B-Disease 0 2.4296914489241317e-06
component I-Disease 0 0.4126766324043274
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.418318073045157e-08
an O 0 1.1007678324403969e-08
African O 0 2.6829047428122976e-08
- O 0 1.068344545274158e-06
American O 0 6.351528014647556e-08
family O 0 4.7430322069885733e-07
. O 0 3.2534438787479303e-07

Complement B-Disease 0 0.001887350925244391
component I-Disease 1 0.9993200302124023
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.145228780951584e-06
C6D B-Disease 0 0.0007684968295507133
) O 0 4.6521716967617976e-07
was O 0 9.257601050194353e-05
diagnosed O 0 6.888245115987957e-05
in O 0 3.185888175494256e-08
a O 0 1.5501900918479805e-07
16 O 0 5.248616616881918e-07
- O 0 2.069531547022052e-06
year O 0 5.0108535987192226e-08
- O 0 8.817708021524595e-07
old O 0 2.538336616453307e-07
African O 0 5.530027991085262e-09
- O 0 8.24781807295949e-08
American O 0 1.2843067054291168e-08
male O 0 1.1353336049069185e-07
with O 0 5.906863975724264e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 7.576099051220808e-06

The O 0 2.6328609692427563e-06
patients O 0 2.5118097255472094e-06
father O 0 3.0806805284555594e-07
and O 0 9.358396724223894e-09
two O 0 8.90684592746993e-09
brothers O 0 1.944517862284556e-06
also O 0 1.881239697354431e-08
had O 0 6.188108869764619e-08
C6D B-Disease 0 7.75763146521058e-06
, O 0 8.725746347693075e-09
but O 0 3.729690778442318e-09
gave O 0 1.3831182421597532e-08
no O 0 3.0878144485768644e-09
history O 0 5.549977366570147e-09
of O 0 1.1500533858566087e-08
meningitis B-Disease 1 0.9999867677688599
or O 0 2.673592973678751e-07
other O 0 5.8835663452327935e-08
neisserial B-Disease 0 0.010722175240516663
infection I-Disease 0 0.17022092640399933
. O 0 1.440716118850105e-06

By O 0 1.970783387150732e-06
using O 0 1.7683961459624697e-06
exon O 0 2.1338864826248027e-05
- O 0 3.3597855235711904e-06
specific O 0 3.808081885381398e-07
polymerase O 0 1.3770575606031343e-05
chain O 0 4.141715544392355e-05
reaction O 0 6.939453214727109e-06
( O 0 1.331556376271692e-07
PCR O 0 1.780841739673633e-05
) O 0 7.383263778137916e-08
/ O 0 5.27367831182346e-07
single O 0 5.636089639438069e-08
- O 0 4.720613731024059e-07
strand O 0 1.2402883839968126e-06
conformation O 0 3.892691893270239e-06
polymorphism O 0 4.7484542164966115e-07
as O 0 1.0679106487998524e-08
a O 0 1.2451940811786244e-08
screening O 0 1.0848626885717749e-07
step O 0 1.4465016739961811e-08
and O 0 3.7364551452867545e-09
nucleotide O 0 3.539577164701768e-08
sequencing O 0 1.7139308639002593e-08
of O 0 1.5710784895262009e-09
target O 0 7.139484381468719e-08
exons O 0 2.87406379584354e-07
, O 0 4.2193666338619096e-09
we O 0 1.6649377432287338e-09
determined O 0 1.1639161634491302e-08
that O 0 1.3144891841676554e-09
the O 0 1.2632528800793352e-08
proband O 0 2.1199023194640176e-06
was O 0 5.182078055554484e-08
a O 0 6.685950459939249e-09
compound O 0 1.0830329699729191e-07
heterozygote O 0 5.853405582456617e-07
for O 0 5.3218287554557264e-09
two O 0 3.3712193925339307e-08
C6 O 0 0.0002137163100996986
gene O 0 2.7426040105638094e-05
mutations O 0 3.333385393489152e-05
. O 0 1.7526642750453902e-06

The O 0 9.965553999791155e-07
first O 0 2.1455078069720912e-07
, O 0 1.422360096370312e-08
1195delC O 0 8.629552894490189e-07
located O 0 6.949745312567757e-08
in O 0 1.6331499708144293e-08
exon O 0 8.32621481094975e-07
7 O 0 1.1830668000811784e-07
, O 0 2.2358850326753554e-09
is O 0 7.95330856728782e-10
a O 0 4.4460626291709104e-09
novel O 0 1.8320928774073764e-08
mutation O 0 5.8300908989394884e-08
, O 0 9.719056670576265e-10
while O 0 7.446460115190234e-10
the O 0 1.8952415192785566e-09
second O 0 1.6666128033193672e-08
, O 0 1.3461800563163706e-09
1936delG O 0 8.536699880323795e-08
in O 0 1.4478900745018564e-08
exon O 0 4.081674660483259e-07
12 O 0 2.712728885967408e-08
, O 0 2.939161358739284e-09
has O 0 3.857497432591117e-09
been O 0 2.5237216760842784e-09
described O 0 1.545498129473799e-08
before O 0 7.615145847239546e-09
to O 0 8.09264033563295e-09
cause O 0 6.483487169361979e-08
C6D B-Disease 0 1.944896439454169e-06
in O 0 8.054557021353048e-09
an O 0 4.441544465549896e-09
unrelated O 0 1.237579851931514e-07
African O 0 3.919494417914393e-08
- O 0 3.256529623740789e-07
American O 0 3.720839458765113e-08
individual O 0 3.1852138704380195e-08
. O 0 2.1749241341240122e-07

Both O 0 4.889607680524932e-06
mutations O 0 6.291175668593496e-05
result O 0 7.816773859303794e-07
in O 0 7.685370064791641e-07
premature O 0 0.0001329158985754475
termination O 0 1.8211017959401943e-05
codons O 0 3.27748894051183e-05
and O 0 1.7825871054810705e-06
C6 O 0 0.0029239680152386427
null O 0 6.0666036006296054e-05
alleles O 0 5.506027810042724e-05
. O 0 3.707790710905101e-06

Allele O 0 0.0004293189267627895
- O 0 9.318568118033e-06
specific O 0 2.1368333591453847e-07
PCR O 0 2.1070927687105723e-05
indicated O 0 1.1423162504797801e-06
that O 0 3.733591658061641e-09
the O 0 6.688973375190699e-09
probands O 0 6.805316274949291e-07
two O 0 7.398499146660242e-09
brothers O 0 9.577730679666274e-07
also O 0 4.0224580999392856e-08
inherited O 0 5.585800408880459e-07
the O 0 1.6238718814065578e-08
1195delC O 0 1.3031659591433709e-06
mutation O 0 3.2282548545481404e-07
from O 0 1.0790222049195108e-08
their O 0 1.516759340347562e-08
heterozygous O 0 1.7300725403401884e-06
mother O 0 2.1574533093371429e-07
and O 0 4.318272850412086e-09
the O 0 1.081133760294506e-08
1936delG O 0 1.1346000974299386e-06
mutation O 0 4.1919949467228435e-07
from O 0 1.0326920651948512e-08
their O 0 1.190463638778283e-08
homozygous O 0 1.1405506938899634e-06
father O 0 2.701756613987527e-07
. O 0 2.4963151545875917e-08
. O 0 1.9080357560596894e-07

PAX6 O 0 0.22161610424518585
mutations O 0 0.26463526487350464
reviewed O 0 0.000843479298055172
. O 0 3.319190727779642e-05

Mutations O 0 0.0010960173094645143
in O 0 3.724915814018459e-06
PAX6 O 0 8.78975770319812e-05
are O 0 2.828468659288319e-08
responsible O 0 4.2983884895875235e-08
for O 0 5.5566720114086365e-09
human O 0 2.990759639942553e-08
aniridia B-Disease 1 1.0
and O 0 5.655925860992284e-07
have O 0 1.1095684371298375e-08
also O 0 7.127087364722229e-09
been O 0 3.6683391879677174e-09
found O 0 9.271640344366006e-09
in O 0 3.252680258469809e-08
patients O 0 1.1095033158881051e-07
with O 0 1.0881075240831706e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.520145348076767e-07
with O 0 0.0008228421793319285
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9957212209701538
, O 0 6.093298310361206e-08
with O 0 2.0508886677816918e-07
autosomal B-Disease 1 0.9820995330810547
dominant I-Disease 0 0.11511214822530746
keratitis I-Disease 0 0.07876630872488022
, O 0 8.273737250874547e-08
and O 0 1.993978493430859e-08
with O 0 1.224113930220483e-07
isolated B-Disease 0 0.15424083173274994
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 1.6477688404847868e-05

No O 0 2.08070082408085e-06
locus O 0 4.672011073125759e-06
other O 0 1.9957514751922645e-08
than O 0 2.2149770018131676e-08
chromosome O 0 1.82282838068204e-06
11p13 O 0 1.6839238696775283e-06
has O 0 5.076122278069306e-08
been O 0 1.9961511554811295e-08
implicated O 0 3.748278061266319e-07
in O 0 2.1977783148940944e-07
aniridia B-Disease 1 0.9999998807907104
, O 0 5.203620645488627e-08
and O 0 1.6651544143542196e-08
PAX6 O 0 4.39451969214133e-06
is O 0 1.3605846227449092e-08
clearly O 0 7.977864591168782e-09
the O 0 2.6382172002570314e-09
major O 0 3.995662023470459e-09
, O 0 1.5946814979628243e-09
if O 0 1.0088962998366924e-09
not O 0 6.270284846898733e-10
only O 0 8.539329798828987e-10
, O 0 2.1259449756172444e-09
gene O 0 1.7284550324347947e-07
responsible O 0 1.7337545443751878e-07
. O 0 3.2822836715240555e-07

Twenty O 0 1.2825418707507197e-05
- O 0 2.7694745767803397e-06
eight O 0 7.681348535015786e-08
percent O 0 4.6724291991040445e-08
of O 0 1.6395816926362272e-09
identified O 0 1.0963763941163052e-07
PAX6 O 0 1.8978247680934146e-05
mutations O 0 3.15324268740369e-06
are O 0 2.006874844084905e-08
C O 0 3.878588540828787e-05
- O 0 0.0004188553721178323
T O 0 0.00043201862717978656
changes O 0 4.009627900813939e-07
at O 0 4.07883788966501e-07
CpG O 0 4.21991853727377e-06
dinucleotides O 0 1.1791418046414037e-06
, O 0 3.775483925494427e-09
20 O 0 5.118538481951873e-09
% O 0 1.2794332260313013e-09
are O 0 4.6306194989576e-10
splicing O 0 2.0289252233851585e-07
errors O 0 1.4692756167278276e-07
, O 0 2.246623331814135e-09
and O 0 7.521672729104978e-10
more O 0 5.685578119418722e-10
than O 0 1.0535859962246263e-09
30 O 0 9.10558739519729e-09
% O 0 2.291414835653427e-09
are O 0 9.259883415602133e-10
deletion O 0 1.3915227725647128e-07
or O 0 4.467349867809389e-08
insertion O 0 1.5371365407190751e-06
events O 0 7.746556320853415e-07
. O 0 1.2570010312629165e-06

There O 0 1.038065533975896e-06
is O 0 7.01228728416936e-08
a O 0 1.5861678548390046e-07
noticeably O 0 4.975707997800782e-05
elevated O 0 1.824561331886798e-05
level O 0 9.4889259116826e-08
of O 0 4.404501208199463e-09
mutation O 0 1.581894224500502e-07
in O 0 4.5233363721308706e-09
the O 0 5.707343930794195e-09
paired O 0 3.810064796994084e-08
domain O 0 1.658536241677666e-08
compared O 0 1.711085850786276e-08
with O 0 7.726511097594368e-10
the O 0 3.9404808305221195e-09
rest O 0 2.830491174776739e-09
of O 0 2.868298931701929e-10
the O 0 6.413158004647812e-09
gene O 0 6.464680382123333e-07
. O 0 2.2276498157225433e-07

Increased O 0 8.997172699309886e-06
mutation O 0 7.317689323826926e-06
in O 0 7.054167383557797e-08
the O 0 1.895723400480165e-08
homeodomain O 0 1.0363345381847466e-06
is O 0 4.345472426336983e-09
accounted O 0 9.902248798709934e-09
for O 0 8.579556509680231e-10
by O 0 1.1656756448985561e-08
the O 0 1.0050960952412424e-07
hypermutable O 0 5.109981429995969e-05
CpG O 0 4.830785110243596e-05
dinucleotide O 0 8.66721438796958e-06
in O 0 2.696083925002313e-07
codon O 0 1.0970623407047242e-05
240 O 0 2.753158014456858e-06
. O 0 1.0206227898379439e-06

Very O 0 1.0262280056849704e-06
nearly O 0 1.2938544102780725e-07
all O 0 8.148010266495476e-09
mutations O 0 5.089865453555831e-07
appear O 0 1.3306194546203187e-07
to O 0 6.973101562834927e-08
cause O 0 1.3986661997478222e-06
loss O 0 2.040108739720381e-07
of O 0 1.3992104141991035e-09
function O 0 5.309297446132177e-09
of O 0 4.2657963272851873e-10
the O 0 5.397588598299308e-09
mutant O 0 2.4795835429358704e-07
allele O 0 1.2812439820208965e-07
, O 0 7.544331270814553e-10
and O 0 3.391389669094025e-10
more O 0 2.905670981601105e-10
than O 0 6.32177754589236e-10
80 O 0 3.606283938140109e-09
% O 0 1.472798438761913e-09
of O 0 1.298397056537226e-09
exonic O 0 2.0060574570379686e-06
substitutions O 0 2.8810342200813466e-07
result O 0 8.994702227482776e-08
in O 0 1.3419705169326335e-07
nonsense O 0 8.62072192830965e-06
codons O 0 1.95546199392993e-05
. O 0 1.1630039580268203e-06

In O 0 2.1649525479006115e-06
a O 0 2.9762978215330804e-07
gene O 0 8.742290447116829e-07
with O 0 1.084189982236694e-08
such O 0 1.2282037609168128e-08
extraordinarily O 0 5.379265530791599e-07
high O 0 1.7543270303121972e-07
sequence O 0 3.7244891615273445e-08
conservation O 0 7.410051239276072e-09
throughout O 0 6.883491110443174e-09
evolution O 0 1.3973602719374867e-08
, O 0 1.6411398906512886e-09
there O 0 1.0239712411319601e-09
are O 0 7.324695294741446e-10
presumed O 0 8.348145286163344e-08
undiscovered O 0 1.8118232958386216e-07
missense O 0 2.8874756026198156e-06
mutations O 0 8.957787258623284e-07
, O 0 4.105219719718889e-09
these O 0 1.6289245508005479e-09
are O 0 8.548292629306786e-10
hypothesized O 0 3.2734739363604604e-08
to O 0 4.851369528324767e-09
exist O 0 5.682458947831037e-09
in O 0 5.6303388618061945e-09
as O 0 3.2058455445849177e-08
- O 0 8.258103889602353e-07
yet O 0 5.898611732391146e-08
unidentified O 0 8.458947604594869e-07
phenotypes O 0 1.7120200936915353e-06
. O 0 4.456524749230084e-08
. O 0 4.983670010005881e-07

Genetic O 0 0.00030664625228382647
heterogeneity O 0 9.676477930042893e-05
and O 0 4.5045092633699824e-07
penetrance O 0 1.9507382603478618e-05
analysis O 0 1.9800700101768598e-07
of O 0 1.1400789645676923e-08
the O 0 9.28109216147277e-08
BRCA1 O 0 1.3392831533565186e-05
and O 0 1.8710132110300037e-07
BRCA2 O 0 3.071056926273741e-05
genes O 0 3.420608436499606e-06
in O 0 2.1222902432782575e-05
breast B-Disease 1 0.9999613761901855
cancer I-Disease 0 0.008862324990332127
families O 0 1.0340263543184847e-06
. O 0 1.5956885590640013e-06

The O 0 0.014161325059831142
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 0.0004412810958456248
Consortium O 0 4.4217813410796225e-05
. O 0 3.024940269824583e-06

The O 0 5.065590471531323e-07
contribution O 0 8.841094256695214e-08
of O 0 1.1487533591036936e-08
BRCA1 O 0 3.4404836242174497e-06
and O 0 1.4576055207271565e-07
BRCA2 O 0 0.00017032994946930557
to O 0 0.0011758556356653571
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.002280304441228509
assessed O 0 2.947691370991379e-07
by O 0 1.816372652285736e-08
linkage O 0 1.4732115687365877e-06
and O 0 2.815158772762061e-08
mutation O 0 2.8421624165275716e-07
analysis O 0 2.585592540071957e-08
in O 0 8.90767903882761e-09
237 O 0 4.990937441107235e-08
families O 0 6.055837609153514e-09
, O 0 1.5115372287155537e-09
each O 0 5.699693494953806e-10
with O 0 2.003160304298035e-09
at O 0 6.066903779355926e-08
least O 0 1.9000627737852938e-09
four O 0 1.1368211927376137e-09
cases O 0 4.483703186508592e-09
of O 0 2.9755106822904054e-08
breast B-Disease 1 0.9951580166816711
cancer I-Disease 0 1.2435273674782366e-05
, O 0 1.5993145696668876e-09
collected O 0 1.9764461178795045e-09
by O 0 9.440236148350323e-09
the O 0 0.0007944869576022029
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999992847442627
Linkage O 0 4.670761336456053e-05
Consortium O 0 5.279080141917802e-06
. O 0 9.079383289645193e-07

Families O 0 1.1058078825953999e-06
were O 0 4.6026578104374494e-08
included O 0 8.916024363259112e-09
without O 0 2.8437978638606864e-09
regard O 0 2.92538593349434e-09
to O 0 9.54841317124533e-10
the O 0 4.033795963920284e-09
occurrence O 0 7.508879207307473e-08
of O 0 2.308145852225607e-08
ovarian B-Disease 0 0.00108938233461231
or I-Disease 0 8.872108026025671e-08
other I-Disease 0 1.3955522604192083e-07
cancers I-Disease 0 0.0011493903584778309
. O 0 1.7374849221596378e-06

Overall O 0 0.00044051173608750105
, O 0 8.364077984879259e-06
disease O 0 0.0020987431053072214
was O 0 1.2505968243203824e-06
linked O 0 1.4744653071829816e-06
to O 0 3.954140126438688e-08
BRCA1 O 0 9.548327852826333e-07
in O 0 3.93577126445166e-09
an O 0 7.047840089313695e-10
estimated O 0 1.521455517128345e-09
52 O 0 6.046247058577592e-09
% O 0 3.961972416810511e-10
of O 0 2.2027317470030283e-10
families O 0 1.2963531359488911e-09
, O 0 9.449436788599996e-10
to O 0 6.879041336560476e-09
BRCA2 O 0 3.4193294595752377e-07
in O 0 5.843257877558017e-09
32 O 0 8.451833011235976e-09
% O 0 3.683854332692249e-10
of O 0 1.3568203505176513e-10
families O 0 1.486304523901083e-09
, O 0 4.592656255297811e-10
and O 0 8.264770534616162e-10
to O 0 1.345568989563617e-09
neither O 0 7.897352105601385e-09
gene O 0 3.3601395443838555e-08
in O 0 4.419034027591806e-09
16 O 0 9.844849380158394e-09
% O 0 2.5710542583823326e-09
( O 0 4.491886418378499e-09
95 O 0 7.188648964984168e-08
% O 0 1.6682475845186673e-08
confidence O 0 7.34286516035354e-07
interval O 0 2.4103121631924296e-06
[ O 0 4.554644021936838e-07
CI O 0 7.474323410860961e-06
] O 0 1.1665680688111024e-07
6 O 0 4.668509490102224e-08
% O 0 1.0116214532729373e-08
- O 0 1.993427645174961e-07
28 O 0 6.636124538772492e-08
% O 0 3.160744332930676e-09
) O 0 1.7747221470187924e-09
, O 0 2.029132639691511e-09
suggesting O 0 1.0610040135361487e-07
other O 0 2.8538950758161263e-08
predisposition O 0 4.876959337707376e-06
genes O 0 1.3525681197279482e-06
. O 0 5.919654313402134e-07

The O 0 1.4975246358517325e-06
majority O 0 4.5765710865453e-07
( O 0 8.598421175065596e-08
81 O 0 1.8976376736645761e-07
% O 0 4.400134923088217e-09
) O 0 1.1492371498889042e-09
of O 0 1.5753214288594108e-09
the O 0 2.099901030305773e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.984962842513596e-08
were O 0 1.232681690055415e-08
due O 0 4.305954348637897e-08
to O 0 3.303706819224317e-08
BRCA1 O 0 2.518939027140732e-06
, O 0 2.676422639069642e-09
with O 0 1.1146609191214907e-09
most O 0 3.2762641488659483e-09
others O 0 6.150229658885564e-09
( O 0 9.756988106346398e-09
14 O 0 1.6157342130895813e-08
% O 0 3.0092341951615253e-09
) O 0 4.059358627017673e-09
due O 0 1.2354077227882954e-07
to O 0 2.8116932071498013e-07
BRCA2 O 0 9.998502355301753e-05
. O 0 1.1494676073198207e-06

Conversely O 0 1.7056438082363456e-05
, O 0 5.5373345020370834e-08
the O 0 8.623990410683291e-09
majority O 0 4.58843807393805e-09
of O 0 6.994501089430116e-10
families O 0 2.3084441025389424e-09
with O 0 2.202346305324454e-09
male B-Disease 0 4.6482870885711236e-08
and I-Disease 0 7.01627413945971e-08
female I-Disease 0 6.510540970339207e-06
breast I-Disease 1 0.987506628036499
cancer I-Disease 0 3.455668775131926e-05
were O 0 1.8472757545850982e-08
due O 0 1.6870151853254356e-07
to O 0 1.4271189741066337e-07
BRCA2 O 0 1.8845650629373267e-05
( O 0 1.0021079788202769e-07
76 O 0 4.110279974156583e-07
% O 0 1.9185195654358722e-08
) O 0 4.754562255016026e-08
. O 0 2.01908875396839e-07

The O 0 1.4390682281373302e-06
largest O 0 6.362622002598073e-07
proportion O 0 1.372703479773918e-07
( O 0 4.02564310775233e-08
67 O 0 5.385118129197508e-08
% O 0 2.397720466618125e-09
) O 0 6.004250985292003e-10
of O 0 3.9897044001868665e-10
families O 0 1.3617054150927288e-09
due O 0 1.2326228926440308e-08
to O 0 3.4273384130756313e-09
other O 0 1.0503555802898745e-09
genes O 0 2.500742191102745e-08
was O 0 2.2352470807618374e-07
found O 0 9.271976075808652e-09
in O 0 8.253747907360776e-09
families O 0 1.397212900933198e-09
with O 0 7.854850103683475e-10
four O 0 2.1084192169951166e-09
or O 0 3.7086649307127573e-09
five O 0 1.2182895803292126e-09
cases O 0 2.47625409066643e-09
of O 0 6.526836848763651e-09
female O 0 1.0785142876557074e-05
breast B-Disease 1 0.978274941444397
cancer I-Disease 0 5.011527900933288e-05
only O 0 9.790454669200699e-08
. O 0 4.770286068378482e-07

These O 0 2.4664797138029826e-07
estimates O 0 2.2277220068644965e-07
were O 0 1.4313055629600058e-08
not O 0 3.797728798105027e-09
substantially O 0 2.122632167811389e-07
affected O 0 1.4435250328403981e-08
either O 0 3.58396379240844e-09
by O 0 3.2427982521454624e-09
changing O 0 3.9097283632827384e-08
the O 0 9.36714616983636e-09
assumed O 0 1.0328717792162934e-07
penetrance O 0 5.359736974241969e-07
model O 0 5.610060327398969e-08
for O 0 3.6304457218250263e-09
BRCA1 O 0 3.114816422566946e-07
or O 0 4.572572542826947e-09
by O 0 1.3052801062229946e-09
including O 0 7.219448927564542e-10
or O 0 4.333952574597788e-08
excluding O 0 5.014142629988783e-07
BRCA1 O 0 2.4580582248745486e-05
mutation O 0 5.664623131451663e-06
data O 0 3.0512824196193833e-06
. O 0 1.3675438594873413e-06

Among O 0 1.0539562254052726e-06
those O 0 7.745079955157053e-08
families O 0 3.246915625254587e-08
with O 0 6.100135863107425e-08
disease O 0 4.935265678795986e-05
due O 0 1.3608788549390738e-06
to O 0 2.767568503259099e-07
BRCA1 O 0 1.1032902875740547e-05
that O 0 7.397595869207407e-09
were O 0 2.013254452037927e-08
tested O 0 6.055897472379002e-08
by O 0 1.364518498192524e-09
one O 0 4.881365867070997e-10
of O 0 2.0682490442514023e-10
the O 0 3.3940119603670382e-09
standard O 0 5.476894671119226e-07
screening O 0 7.613101615788764e-08
methods O 0 3.0861436073337245e-08
, O 0 2.2986463843466254e-09
mutations O 0 7.110023148015898e-08
were O 0 5.408564263120752e-09
detected O 0 2.3688527051035635e-07
in O 0 1.2933408122250967e-08
the O 0 1.8325366113458585e-08
coding O 0 4.0216181673713436e-07
sequence O 0 6.069068092529051e-08
or O 0 1.1432646829234727e-08
splice O 0 5.116647798786289e-07
sites O 0 1.5861310487252922e-08
in O 0 3.642570023387748e-09
an O 0 1.1720467929521305e-09
estimated O 0 7.306573568399699e-09
63 O 0 2.117928410427794e-08
% O 0 2.2684021327989967e-09
( O 0 3.830523898074034e-09
95 O 0 4.181537605063568e-08
% O 0 1.9203428180958326e-08
CI O 0 1.766542027326068e-06
51 O 0 1.5024957633613667e-07
% O 0 1.3290058831216811e-08
- O 0 4.741503403238312e-07
77 O 0 2.6249031748193374e-07
% O 0 2.5305725515067934e-08
) O 0 4.443996104441794e-08
. O 0 2.2399032673092734e-07

The O 0 6.586133167729713e-07
estimated O 0 1.2143642891260242e-07
sensitivity O 0 4.147359504713677e-07
was O 0 1.0751828938282415e-07
identical O 0 3.773254420025296e-08
for O 0 8.385480088080044e-10
direct O 0 6.4905374408397165e-09
sequencing O 0 4.479525728129374e-08
and O 0 3.233940892855003e-09
other O 0 4.107819862042561e-09
techniques O 0 5.657500992128917e-07
. O 0 4.694498159096838e-07

The O 0 7.004011877143057e-06
penetrance O 0 0.0001546783751109615
of O 0 4.0227118347502255e-07
BRCA2 O 0 4.370876558823511e-05
was O 0 2.755716934643715e-07
estimated O 0 1.8046902638957363e-08
by O 0 1.0218217383339834e-08
maximizing O 0 9.118451771428226e-08
the O 0 5.0123642125754486e-08
LOD O 0 7.844282663427293e-05
score O 0 1.6655442891533312e-07
in O 0 2.3400984616728238e-07
BRCA2 O 0 0.00010011391714215279
- O 0 1.2024958778056316e-05
mutation O 0 2.092365093631088e-06
families O 0 1.1599646576598843e-08
, O 0 1.774234759110982e-09
over O 0 6.024685195171742e-09
all O 0 2.3789525904760467e-09
possible O 0 5.061234276126925e-08
penetrance O 0 7.648112841707189e-06
functions O 0 7.693972179367847e-07
. O 0 4.262929849119246e-07

The O 0 7.069805292303499e-07
estimated O 0 1.876907305131681e-07
cumulative O 0 2.890677990308177e-07
risk O 0 2.470102344886982e-07
of O 0 5.865515362302176e-08
breast B-Disease 1 0.982328474521637
cancer I-Disease 0 4.7310604713857174e-05
reached O 0 1.6635806332487846e-07
28 O 0 1.3763214212758612e-07
% O 0 3.792111957778843e-09
( O 0 3.847555607450204e-09
95 O 0 6.12440800296099e-08
% O 0 1.801863014350147e-08
CI O 0 3.089085112151224e-06
9 O 0 2.803825793762371e-07
% O 0 9.060335592891988e-09
- O 0 1.0509315728768343e-07
44 O 0 1.957669226726466e-08
% O 0 1.834350671359175e-09
) O 0 1.0251398618876806e-09
by O 0 2.75848610620244e-09
age O 0 4.356925487059016e-09
50 O 0 2.747411853576409e-09
years O 0 2.3978945495883863e-09
and O 0 2.3844584084997678e-09
84 O 0 1.7878953428862587e-08
% O 0 2.351115746535015e-09
( O 0 6.206534397534824e-09
95 O 0 7.040457461471306e-08
% O 0 3.2967324870014636e-08
CI O 0 3.055029765164363e-06
43 O 0 2.1167657848764065e-07
% O 0 1.693145712522437e-08
- O 0 1.3332183357306349e-07
95 O 0 1.3870126736037491e-07
% O 0 5.5908189189324276e-09
) O 0 2.421693956478066e-09
by O 0 5.297391858505307e-09
age O 0 1.9850570964763392e-08
70 O 0 3.715605600973504e-08
years O 0 5.018342719154134e-08
. O 0 2.1283443629727117e-07

The O 0 5.7700159231899306e-05
corresponding O 1 0.992493212223053
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0001526559062767774
were O 0 1.3014407613809453e-06
0 O 0 2.565371914897696e-06
. O 0 9.71067720456631e-07

4 O 0 1.0484471204108559e-05
% O 0 3.67103638154731e-07
( O 0 1.1387645315608097e-07
95 O 0 5.445270971904392e-07
% O 0 9.129014699738036e-08
CI O 0 8.624266229162458e-06
0 O 0 1.8416264424558904e-07
% O 0 2.2340275407373156e-08
- O 0 1.770416560020749e-07
1 O 0 1.5431535160814747e-08
% O 0 1.2834587836962896e-09
) O 0 5.516372358904675e-10
by O 0 2.1127264382414523e-09
age O 0 7.521662404030849e-09
50 O 0 3.397386594272689e-09
years O 0 1.7699048893149438e-09
and O 0 2.109694197116596e-09
27 O 0 2.8454975264935456e-08
% O 0 3.5100613526850566e-09
( O 0 8.416763286334117e-09
95 O 0 7.444535299327981e-08
% O 0 2.349911198962218e-08
CI O 0 1.8468551843398018e-06
0 O 0 6.524324902557055e-08
% O 0 7.915222255405752e-09
- O 0 9.738753448118587e-08
47 O 0 8.695578657125225e-08
% O 0 3.222033528871293e-09
) O 0 1.4672524306647006e-09
by O 0 4.0860101968576146e-09
age O 0 2.677853672139463e-08
70 O 0 4.2738797390029504e-08
years O 0 5.8661420609951165e-08
. O 0 3.3320458214802784e-07

The O 0 1.2045168205077061e-06
lifetime O 0 3.1488793865719344e-06
risk O 0 7.025211630207195e-07
of O 0 1.581235267167358e-07
breast B-Disease 1 0.9996672868728638
cancer I-Disease 0 0.001277061295695603
appears O 0 3.6401900160853984e-07
similar O 0 1.0740043876467098e-07
to O 0 1.5751089321724976e-08
the O 0 2.029052303953449e-08
risk O 0 8.975234067065685e-08
in O 0 2.50594656137082e-08
BRCA1 O 0 1.8682794689084403e-06
carriers O 0 4.286844301759629e-08
, O 0 1.754725253988454e-09
but O 0 1.404742988597718e-09
there O 0 1.1771549290884309e-09
was O 0 2.1817395889911495e-08
some O 0 6.385643125383922e-10
suggestion O 0 5.274414682787665e-09
of O 0 4.932043662364549e-10
a O 0 1.522303882950382e-08
lower O 0 0.00011223902401980013
risk O 0 2.7474246167003e-07
in O 0 6.543055519614427e-08
BRCA2 O 0 4.438762516656425e-06
carriers O 0 2.448081488637399e-07
< O 0 3.3085001405197545e-07
50 O 0 1.0436501440835855e-08
years O 0 3.522025560087627e-09
of O 0 3.432480522036485e-09
age O 0 1.0688994223073678e-07
. O 0 1.8230355181003688e-07

Eye B-Disease 1 0.8237724304199219
movement I-Disease 0 0.0014851848827674985
abnormalities I-Disease 1 0.9996083378791809
correlate O 0 2.7949679861194454e-05
with O 0 7.998892783689371e-07
genotype O 0 0.0006757868104614317
in O 0 1.0540212315390818e-05
autosomal O 1 0.9999915361404419
dominant O 1 0.9999022483825684
cerebellar B-Disease 1 0.999998927116394
ataxia I-Disease 1 1.0
type I-Disease 1 0.9999997615814209
I I-Disease 0 0.07707079499959946
. O 0 2.8207109608047176e-06

We O 0 2.335996441615862e-06
compared O 0 3.480574378045276e-06
horizontal O 0 3.253981776651926e-05
eye O 0 0.00030108762439340353
movements O 0 2.8661788746831007e-05
( O 0 2.1248804671358812e-07
visually O 0 7.464126952072547e-07
guided O 0 1.3151616258255672e-06
saccades O 0 2.550577664806042e-05
, O 0 2.8048415146031402e-08
antisaccades O 0 1.5235665387081099e-06
, O 0 2.5534998560061695e-09
and O 0 1.797218152077562e-09
smooth O 0 1.1148149781092798e-07
pursuit O 0 1.1048321368889447e-07
) O 0 5.483069998035717e-09
in O 0 8.8010798648952e-09
control O 0 2.914315928137512e-06
subjects O 0 9.745237861125133e-08
( O 0 1.794393256204785e-08
n O 0 2.363874500588281e-07
= O 0 2.7350591835784144e-07
14 O 0 2.186121683678266e-08
) O 0 3.879892851443856e-09
and O 0 1.1192632598522323e-08
patients O 0 1.1856822190736693e-08
with O 0 1.6952679260384684e-09
three O 0 2.327774417665296e-09
forms O 0 1.0591797661163582e-08
of O 0 2.324412662346731e-08
autosomal O 0 0.11516526341438293
dominant O 0 0.04974668473005295
cerebellar B-Disease 0 0.10461593419313431
ataxias I-Disease 1 0.5720767974853516
type I-Disease 1 0.9938826560974121
I I-Disease 0 0.0013591573806479573
spinocerebellar B-Disease 1 0.82418292760849
ataxias I-Disease 0 0.00010753048991318792
1 I-Disease 0 1.1623902906876538e-07
and I-Disease 0 1.0993662868941101e-08
2 I-Disease 0 3.571416584691178e-08
( O 0 2.455677972079684e-08
SCA1 B-Disease 0 4.181380973022897e-06
, O 0 2.0584556281733057e-08
n O 0 3.536277972671087e-07
= O 0 2.3168621510194498e-07
11 O 0 7.158998016620899e-08
; O 0 1.2917332981032814e-08
SCA2 B-Disease 0 2.795730097204796e-06
, O 0 1.7304632393688735e-08
n O 0 2.419345719317789e-07
= O 0 1.9158397890350898e-07
10 O 0 1.7153043430084836e-08
) O 0 1.0951889173327345e-08
and O 0 7.571121329874586e-08
SCA3 B-Disease 1 1.0
/ O 0 0.07474454492330551
Machado B-Disease 0 3.9671900594839826e-05
- I-Disease 0 0.0034042540937662125
Joseph I-Disease 0 0.0015755960484966636
disease I-Disease 1 0.6910257935523987
( O 0 8.446718311461154e-07
MJD B-Disease 1 0.9999996423721313
) O 0 1.304347989616872e-07
( O 0 1.0860055255079715e-07
n O 0 1.2713596788671566e-06
= O 0 9.384189070260618e-07
16 O 0 2.1957376361569914e-07
) O 0 1.2649326208702405e-07
. O 0 5.207771209825296e-07

In O 0 7.965231816342566e-06
SCA1 B-Disease 0 8.361977234017104e-05
, O 0 1.6469142849473428e-07
saccade O 0 1.2156636330473702e-05
amplitude O 0 1.0017541853812872e-06
was O 0 2.472350786320021e-07
significantly O 0 2.777325107672368e-07
increased O 0 8.965259468141085e-08
, O 0 5.2610515943740666e-09
resulting O 0 5.398518609922576e-08
in O 0 4.8830003152033896e-08
hypermetria B-Disease 0 3.459302388364449e-05
. O 0 4.59121565654641e-07

The O 0 9.011304769046546e-07
smooth O 0 2.5610722786950646e-06
pursuit O 0 1.3714724218516494e-06
gain O 0 1.7925377733263304e-06
was O 0 2.4913836114137666e-06
decreased O 0 6.514341748697916e-06
. O 0 8.027099056562292e-07

In O 0 7.566662588942563e-06
SCA2 B-Disease 0 0.00012658907508011907
, O 0 4.190687832306139e-07
saccade O 0 3.466388807282783e-05
velocity O 0 8.234706001530867e-06
was O 0 5.693999810318928e-06
markedly O 0 5.779212369816378e-05
decreased O 0 2.884253626689315e-05
. O 0 1.481397021052544e-06

The O 0 1.4009623328092857e-06
percentage O 0 7.685802643209172e-07
of O 0 1.5217318960480952e-08
errors O 0 1.1496108243136405e-07
in O 0 6.011487130308524e-08
antisaccades O 0 2.1491914594662376e-05
was O 0 1.1057150004489813e-06
greatly O 0 3.573290285885378e-08
increased O 0 3.788657920722471e-08
and O 0 9.541081702479914e-09
was O 0 2.38960495835272e-07
significantly O 0 3.28381133840594e-07
correlated O 0 3.507467454255675e-07
with O 0 3.972653672690285e-08
age O 0 8.635974495518894e-07
at O 0 2.176690941269044e-05
disease O 0 0.00800351332873106
onset O 0 0.027964118868112564
. O 0 3.764487928492599e-06

In O 0 1.4345052932185354e-06
addition O 0 1.7775761307348148e-07
, O 0 1.4808157366985597e-08
a O 0 1.493945056552093e-08
correlation O 0 6.806504870837671e-08
between O 0 9.185671778766391e-09
smooth O 0 1.7761935566795728e-07
pursuit O 0 4.4423096312584676e-08
gain O 0 8.735491974221077e-08
and O 0 3.54352036602279e-09
the O 0 3.0048066257393202e-09
number O 0 2.3945443405892775e-09
of O 0 3.804957682262966e-09
trinucleotide O 0 1.1555651326489169e-05
repeats O 0 1.9934055671910755e-05
was O 0 9.493521702097496e-07
found O 0 2.8160832243884215e-07
. O 0 3.919700759524858e-07

In O 0 2.9081609682179987e-05
SCA3 B-Disease 1 0.9999936819076538
, O 0 1.1757057336581056e-06
gaze B-Disease 0 9.06252462300472e-05
- I-Disease 0 6.589574331883341e-05
evoked I-Disease 0 3.866453698719852e-05
nystagmus I-Disease 0 0.00020139051775913686
was O 0 3.848691903840518e-06
often O 0 1.7409245600674694e-08
present O 0 7.758057307682975e-09
as O 0 1.0270779782217687e-08
was O 0 8.040884580395868e-08
saccade O 0 1.34018034714245e-06
hypometria O 0 1.4440324775932822e-06
and O 0 2.6705597733212016e-08
smooth O 0 4.266736652880354e-07
pursuit O 0 5.488303713718778e-07
gain O 0 8.365469739146647e-07
was O 0 3.3305475426459452e-06
markedly O 0 3.59863079211209e-05
decreased O 0 9.478138053964358e-06
. O 0 5.237480991127086e-07

Three O 0 2.357544190090266e-06
major O 0 9.687876172392862e-07
criteria O 0 5.678284082932805e-07
, O 0 4.3437758279196714e-08
saccade O 0 7.030552296782844e-06
amplitude O 0 1.4754499488844885e-06
, O 0 2.8800059226341546e-08
saccade O 0 2.5001422727655154e-06
velocity O 0 4.0726536099100485e-07
, O 0 7.474810104213248e-09
and O 0 3.601162923416723e-09
presence O 0 2.2457506076989375e-08
of O 0 9.197961503559782e-09
gaze B-Disease 0 4.4025364331901073e-05
- I-Disease 0 2.0978073735022917e-05
evoked I-Disease 0 6.263970590225654e-06
nystagmus I-Disease 0 4.5247338675835636e-06
, O 0 5.9446452205236255e-09
permitted O 0 5.959654103548928e-09
the O 0 7.107796573535552e-09
correct O 0 2.1034881569903519e-07
assignment O 0 1.796584925273237e-08
of O 0 6.452109957422181e-10
90 O 0 6.364634153044335e-09
% O 0 6.091084858717011e-10
of O 0 3.54482332376449e-10
the O 0 6.848786426871811e-09
SCA1 B-Disease 0 1.6732593621782144e-06
, O 0 2.013748945373095e-09
90 O 0 4.6741650550075065e-09
% O 0 4.343141679630236e-10
of O 0 1.4275497450810803e-10
the O 0 5.450921936045461e-09
SCA2 B-Disease 0 2.0485051663854392e-06
, O 0 2.2058608273312075e-09
and O 0 1.8990409245134288e-09
93 O 0 1.8026398151960166e-08
% O 0 1.2113244851619243e-09
of O 0 3.91793569809451e-10
the O 0 2.011227984155539e-08
patients O 0 6.030251853417212e-08
with O 0 1.297427321134137e-08
SCA3 B-Disease 1 0.9999998807907104
to O 0 5.2249738757836894e-08
their O 0 1.6492114340849184e-08
genetically O 0 1.825918616304989e-07
confirmed O 0 3.8911448996259423e-07
patient O 0 3.109266515366471e-07
group O 0 8.493639569451261e-09
and O 0 1.6617272002861228e-09
, O 0 8.411398799701431e-10
therefore O 0 1.906735436207896e-09
, O 0 1.808224459054486e-09
may O 0 5.689152970944633e-08
help O 0 7.293054160584234e-09
orient O 0 2.601700771265314e-06
diagnoses O 0 1.4455191603701678e-06
of O 0 6.868985824581841e-09
SCA1 B-Disease 0 5.916543159401044e-06
, O 0 7.44385086903776e-09
SCA2 B-Disease 0 2.0271470475563547e-06
, O 0 4.922299901011229e-09
and O 0 8.167879705922587e-09
SCA3 B-Disease 1 0.9999991655349731
at O 0 1.0299479527020594e-06
early O 0 7.938946282592951e-07
clinical O 0 1.9932184613935533e-07
stages O 0 5.126650748366046e-08
of O 0 3.405353332652794e-09
the O 0 7.238220405270113e-07
diseases O 0 4.6741257392568514e-05
. O 0 6.281254627538146e-08
. O 0 2.8931933115927677e-07

Genetic O 0 3.990544792031869e-05
basis O 0 7.436374858116324e-07
and O 0 9.770903375283524e-08
molecular O 0 8.981706741906237e-06
mechanism O 0 9.357414819533005e-05
for O 0 3.0507755582220852e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.000270346412435174

Ventricular B-Disease 1 0.9999600648880005
fibrillation I-Disease 1 0.999969482421875
causes O 0 0.00010178762750001624
more O 0 9.350013385756029e-08
than O 0 1.5827854582539658e-08
300 O 0 2.3409370442095678e-08
, O 0 4.168348777255915e-09
000 O 0 1.5513489159957317e-08
sudden O 0 4.104079209810152e-07
deaths O 0 2.004193788707198e-07
each O 0 4.923022878244865e-09
year O 0 6.348242820308769e-09
in O 0 7.546766767063673e-09
the O 0 5.670443670169334e-08
USA O 0 3.762714868571493e-06
alone O 0 3.238535271066212e-07
. O 0 2.0687330959390238e-07

In O 0 8.92457535428548e-07
approximately O 0 1.626178658398203e-07
5 O 0 1.2255902959168452e-07
- O 0 2.2413692590816936e-07
12 O 0 1.635487834050764e-08
% O 0 6.905882532493024e-10
of O 0 1.697878504458572e-10
these O 0 4.1799225192207246e-10
cases O 0 8.381514926547595e-10
, O 0 1.3556983313733895e-09
there O 0 1.6587504703124978e-09
are O 0 7.961019066193842e-10
no O 0 1.9282669683207132e-08
demonstrable O 0 1.1915813956875354e-05
cardiac O 0 0.0003889769141096622
or O 0 4.884398094873177e-07
non O 0 6.226266577868955e-07
- O 0 0.14394687116146088
cardiac O 0 0.058997541666030884
causes O 0 2.5021358851518016e-07
to O 0 6.925553908132542e-09
account O 0 5.480873976893008e-09
for O 0 9.834972836131328e-10
the O 0 4.5417505312173034e-09
episode O 0 7.961815384760484e-08
, O 0 1.3051307812261825e-09
which O 0 4.9845798599790214e-09
is O 0 1.6183056006369156e-09
therefore O 0 8.182287736246963e-09
classified O 0 1.2571888419188326e-07
as O 0 6.35440892438055e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.023281486704945564
IVF B-Disease 1 1.0
) O 0 2.3219240574690048e-06
. O 0 1.7617537650949089e-06

A O 0 2.8814320103265345e-06
distinct O 0 5.949015076112119e-07
group O 0 1.911138838295301e-07
of O 0 5.925731727529637e-08
IVF B-Disease 1 1.0
patients O 0 1.0949968782369979e-05
has O 0 6.096437488167794e-08
been O 0 1.5955096799302737e-08
found O 0 6.952765918555315e-09
to O 0 2.525378128837019e-09
present O 0 2.817515554198735e-09
with O 0 3.157436312406503e-09
a O 0 8.123603834064852e-08
characteristic O 0 3.7095519473950844e-06
electrocardiographic O 0 9.889758075587451e-05
pattern O 0 5.803783642477356e-05
. O 0 6.609067213503295e-07

Because O 0 5.849940407642862e-07
of O 0 6.0602634022188795e-09
the O 0 1.1230054219879548e-08
small O 0 6.4631495710898434e-09
size O 0 2.029849710538656e-08
of O 0 9.813142520798124e-10
most O 0 1.7595178647411558e-09
pedigrees O 0 4.794549681719218e-07
and O 0 4.949791243546997e-09
the O 0 3.52476909881716e-08
high O 0 6.2585245359514374e-06
incidence O 0 4.226878900226438e-06
of O 0 4.573654344142142e-09
sudden B-Disease 0 6.350319836201379e-06
death I-Disease 0 1.1510373951750807e-06
, O 0 2.8529412166022894e-09
however O 0 3.3664373511044232e-09
, O 0 1.3006575816376653e-09
molecular O 0 7.820533198810153e-08
genetic O 0 1.0055083521365304e-07
studies O 0 1.558032636239659e-08
of O 0 8.887297120452331e-09
IVF B-Disease 1 1.0
have O 0 3.504584356051055e-08
not O 0 4.5588222086223595e-09
yet O 0 1.99415346457954e-08
been O 0 3.054118380418913e-08
done O 0 1.1448538117520002e-07
. O 0 1.7052286693797214e-07

Because O 0 0.0003577415773179382
IVF B-Disease 1 1.0
causes O 0 0.0682402029633522
cardiac O 1 0.9910933375358582
rhythm O 1 0.78267902135849
disturbance O 0 0.013064966537058353
, O 0 1.3315867875007825e-07
we O 0 1.6551073400705718e-08
investigated O 0 1.6194834984162298e-07
whether O 0 7.444677407875133e-08
malfunction O 0 3.6971683584852144e-05
of O 0 5.499954269794216e-09
ion O 0 8.140555110003334e-07
channels O 0 5.583137863141019e-07
could O 0 5.226897314969392e-07
cause O 0 3.1240031717061356e-07
the O 0 1.6891821985609567e-07
disorder O 0 1.1618084499787074e-05
by O 0 7.039017813070814e-09
studying O 0 2.042440350180641e-08
mutations O 0 1.9060024669670383e-07
in O 0 1.0545172735021424e-08
the O 0 8.708159526804593e-08
cardiac O 0 7.603522681165487e-05
sodium O 0 6.990411748120096e-06
channel O 0 1.623513708182145e-05
gene O 0 2.111399226123467e-05
SCN5A O 0 0.0001533625036245212
. O 0 1.7572600654602866e-06

We O 0 1.5323182651627576e-06
have O 0 2.727733594554138e-08
now O 0 1.2548884598118093e-08
identified O 0 2.0510288578634572e-08
a O 0 3.984909824339411e-08
missense O 0 1.3049347217020113e-05
mutation O 0 2.2919987259228947e-06
, O 0 9.801680356247289e-09
a O 0 5.207622422176428e-08
splice O 0 0.00013045979721937329
- O 0 2.015910649788566e-05
donor O 0 5.44789372725063e-07
mutation O 0 1.091522676688328e-06
, O 0 6.327813384388037e-09
and O 0 6.677462582871385e-09
a O 0 9.047974458553654e-08
frameshift O 0 9.662158117862418e-05
mutation O 0 8.548184382561885e-07
in O 0 2.625908912534669e-08
the O 0 1.5394052255146562e-08
coding O 0 5.892753165426257e-07
region O 0 1.803272553502211e-08
of O 0 6.461744028740668e-09
SCN5A O 0 7.153932074288605e-06
in O 0 3.9966547404901576e-08
three O 0 8.762241776594237e-08
IVF B-Disease 1 0.9999957084655762
families O 0 6.278284558902669e-07
. O 0 7.253104286064627e-07

We O 0 4.820996082344209e-07
show O 0 2.258715880998352e-07
that O 0 5.4912958624697694e-09
sodium O 0 5.049653495348139e-08
channels O 0 3.323489039530614e-08
with O 0 2.8189828249480797e-09
the O 0 1.1705193259103908e-08
missense O 0 4.832356353290379e-06
mutation O 0 7.67380527122441e-07
recover O 0 5.096262043480237e-07
from O 0 3.4953320238173546e-08
inactivation O 0 4.0469676605425775e-06
more O 0 3.816070126561044e-09
rapidly O 0 8.525521622004817e-08
than O 0 3.8969507620834065e-09
normal O 0 9.356971730767327e-08
and O 0 4.847373613614536e-09
that O 0 1.698300500230232e-09
the O 0 2.3778605751090254e-08
frameshift O 0 3.137395833618939e-05
mutation O 0 6.422617389034713e-07
causes O 0 4.0260040634620964e-08
the O 0 4.683008203443251e-09
sodium O 0 2.8333266754998476e-07
channel O 0 2.785271533412015e-07
to O 0 1.0211670620208224e-08
be O 0 6.470339819486526e-09
non O 0 3.328792885781695e-08
- O 0 1.54986628331244e-06
functional O 0 1.2645637070818339e-06
. O 0 4.2360770180494e-07

Our O 0 2.0635739019780885e-06
results O 0 1.029444206324115e-06
indicate O 0 1.8422799996642425e-07
that O 0 8.548981966782776e-09
mutations O 0 2.582133618034277e-07
in O 0 2.3755530875746445e-08
cardiac O 0 1.1569480193429627e-05
ion O 0 6.1938344515510835e-06
- O 0 3.5391699384490494e-06
channel O 0 1.6573715129197808e-06
genes O 0 1.1632685925633268e-07
contribute O 0 4.8615214076619395e-09
to O 0 1.6130976554507015e-09
the O 0 4.521568008897248e-09
risk O 0 2.4564227985024445e-08
of O 0 3.4394009862381836e-09
developing O 0 6.628906703554094e-07
IVF B-Disease 1 0.9999971389770508
. O 0 2.5725131536091794e-07
. O 0 7.066771559038898e-07

Molecular O 0 8.459989476250485e-05
heterogeneity O 0 7.615728827659041e-05
in O 0 1.6393939858971862e-06
mucopolysaccharidosis B-Disease 0 5.8192516007693484e-05
IVA I-Disease 0 6.061815292923711e-05
in O 0 4.1028738451132085e-07
Australia O 0 1.1889369488926604e-07
and O 0 6.987930678548082e-09
Northern O 0 1.5756459958993219e-07
Ireland O 0 1.9514695850375574e-06
: O 0 5.081438381182579e-09
nine O 0 8.150713881605043e-09
novel O 0 3.9547209951251716e-08
mutations O 0 1.4309212303942331e-07
including O 0 4.068319015004818e-09
T312S O 0 5.632166448776843e-07
, O 0 5.716113804510314e-09
a O 0 1.4852907348483768e-08
common O 0 1.0336975719837938e-07
allele O 0 8.957667887443677e-07
that O 0 8.504760451444326e-09
confers O 0 3.019640359980258e-07
a O 0 7.41819917493558e-07
mild O 1 0.7511221766471863
phenotype O 0 0.061598364263772964
. O 0 3.144572701785364e-06

Mucopolysaccharidosis B-Disease 0 0.021311914548277855
IVA I-Disease 1 0.6574068069458008
( O 0 0.000244411698076874
MPS B-Disease 1 0.9999921321868896
IVA I-Disease 1 0.9999955892562866
) O 0 3.267236650117411e-07
is O 0 5.709524231178875e-08
an O 0 2.0711848947030376e-07
autosomal B-Disease 1 0.9993575215339661
recessive I-Disease 1 0.9999997615814209
lysosomal I-Disease 1 0.9999995231628418
storage I-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999865293502808
caused O 0 7.201629614428384e-06
by O 0 9.480857698918044e-08
a O 0 2.928644789790269e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
in O 0 2.3830332338548033e-06
N O 0 0.0001050229839165695
- O 0 4.932094452669844e-05
acetylgalactosamine O 0 0.00042114953976124525
- O 0 5.8927071222569793e-05
6 O 0 2.9788636766170384e-06
- O 0 9.121531911659986e-05
sulfate O 0 6.522740295622498e-05
sulfatase O 0 0.00015201895439531654
( O 0 9.65770141192479e-07
GALNS O 0 3.844572347588837e-05
) O 0 7.197957643256814e-07
. O 0 3.9995379097490513e-07

Previous O 0 4.3785316847788636e-06
studies O 0 2.3701542772869288e-07
of O 0 1.3016634881068967e-08
patients O 0 4.864752156663599e-08
from O 0 8.500284920387458e-09
a O 0 7.043129812700499e-08
British O 0 9.046651939570438e-06
- O 0 3.754549652512651e-06
Irish O 0 2.1446524556267832e-07
population O 0 2.7408537661699484e-09
showed O 0 2.587319158919854e-08
that O 0 6.479500269662708e-10
the O 0 6.270575170219672e-09
I113F O 0 2.777563281597395e-07
mutation O 0 1.018189905721556e-07
is O 0 9.479926843525277e-10
the O 0 1.0522243076849236e-09
most O 0 9.808651668663515e-10
common O 0 9.207405504696453e-09
single O 0 1.0167887154466371e-07
mutation O 0 2.3197549126052763e-06
among O 0 1.6361344989945792e-07
MPS B-Disease 1 0.999994158744812
IVA I-Disease 1 1.0
patients O 0 7.791136158630252e-05
and O 0 7.39501757607286e-08
produces O 0 9.705436241347343e-07
a O 0 1.4151208915791358e-06
severe O 1 0.861107587814331
clinical O 0 0.0017488593002781272
phenotype O 0 0.20678940415382385
. O 0 9.30979149416089e-06

We O 0 2.1435741928144125e-06
studied O 0 1.768153424563934e-06
mutations O 0 3.7681518278986914e-06
in O 0 4.7003354097796546e-08
the O 0 2.6769141570071042e-08
GALNS O 0 7.978558642207645e-06
gene O 0 8.458947604594869e-07
from O 0 5.122086221831523e-08
23 O 0 1.3962285549951048e-07
additional O 0 1.0863162458463194e-07
MPS B-Disease 1 0.9999983310699463
IVA I-Disease 1 0.9999997615814209
patients O 0 2.1151457985979505e-05
( O 0 3.636116119309918e-08
15 O 0 1.2674497895659442e-08
from O 0 8.343000956756441e-09
Australia O 0 1.7479784730767278e-08
, O 0 1.4756101895940787e-09
8 O 0 1.0099980407574094e-08
from O 0 3.921481361857104e-09
Northern O 0 9.411276380433264e-08
Ireland O 0 4.683229803958966e-07
) O 0 2.2934829591036987e-09
, O 0 2.986708935726057e-10
with O 0 8.337397439106553e-10
various O 0 6.118124673548664e-09
clinical O 0 9.039019346346322e-07
phenotypes O 0 2.1023257431806996e-05
( O 0 4.254660836977564e-07
severe O 0 0.010342130437493324
, O 0 5.151872173314587e-08
16 O 0 7.891407705074016e-08
cases O 0 1.7477450597880306e-08
; O 0 1.4700740180728644e-08
intermediate O 0 6.431952215280035e-08
, O 0 6.853752232416355e-09
4 O 0 4.0826549252415134e-08
cases O 0 7.067783514003168e-08
; O 0 4.2182182369288057e-07
mild O 1 0.6847245693206787
, O 0 1.7184423484195577e-07
3 O 0 2.9695954140152026e-07
cases O 0 1.0802890670902343e-07
) O 0 1.2763462109433021e-07
. O 0 6.847142799415451e-07

We O 0 6.052122216715361e-07
found O 0 4.956293153668412e-08
two O 0 5.147518411519059e-09
common O 0 3.12735011220866e-08
mutations O 0 2.333021313916106e-07
that O 0 3.418968441692982e-09
together O 0 7.51182671621109e-09
accounted O 0 8.846774868231932e-09
for O 0 8.822066965841202e-10
32 O 0 5.63754909421732e-09
% O 0 8.01940347461283e-10
of O 0 3.087577138405351e-10
the O 0 9.771812692349613e-09
44 O 0 1.5207890058377416e-08
unrelated O 0 4.821943377919524e-08
alleles O 0 1.6130191227148316e-07
in O 0 1.6558935556076904e-08
these O 0 4.015535992607511e-08
patients O 0 8.53884671414562e-07
. O 0 5.715887141377607e-07

One O 0 6.530052019115828e-07
is O 0 3.550029958887535e-08
the O 0 1.512094449651613e-08
T312S O 0 1.5588047972414643e-06
mutation O 0 8.347507218786632e-07
, O 0 5.991921625536634e-09
a O 0 2.0131929900912837e-08
novel O 0 8.709007204288355e-08
mutation O 0 5.94095297401509e-07
found O 0 1.6178743678096907e-08
exclusively O 0 3.959528882546692e-08
in O 0 1.7078652092550328e-07
milder O 0 0.4667730927467346
patients O 0 5.653878906741738e-05
. O 0 1.0200087672274094e-06

The O 0 3.69403238664745e-07
other O 0 1.083929479506196e-08
is O 0 3.590340691417282e-09
the O 0 4.53885817819355e-09
previously O 0 3.042774565642503e-08
described O 0 4.7988041984581287e-08
I113F O 0 2.995081160861446e-07
that O 0 5.314586548621492e-09
produces O 0 1.1020203771749948e-07
a O 0 3.059634821056534e-07
severe O 0 0.11729010939598083
phenotype O 0 0.02179587259888649
. O 0 2.7360895273886854e-06

The O 0 1.2228857713125763e-06
I113F O 0 1.090178921003826e-05
and O 0 1.320367744028772e-07
T312S O 0 3.82054031433654e-06
mutations O 0 2.034233148151543e-06
accounted O 0 7.955606662335413e-08
for O 0 6.745757730186597e-09
8 O 0 5.877632958117829e-08
( O 0 2.0537534339837293e-08
18 O 0 1.7255754158895797e-08
% O 0 2.98355629091418e-09
) O 0 2.7584228234900365e-09
and O 0 6.551644116115085e-09
6 O 0 4.604826386866989e-08
( O 0 9.848341697704655e-09
14 O 0 1.3091029593681469e-08
% O 0 2.3258175385620916e-09
) O 0 9.79960113056677e-10
of O 0 1.904445712241909e-09
44 O 0 4.8549910758310943e-08
unrelated O 0 3.0520692462232546e-07
alleles O 0 1.0756593837868422e-06
, O 0 4.3879598621288096e-08
respectively O 0 1.2401878848322667e-06
. O 0 1.1554697039173334e-06

The O 0 1.2875415222879383e-06
relatively O 0 1.2698159252977348e-06
high O 0 1.6259505173366051e-06
residual O 0 2.6830434762814548e-06
GALNS O 0 1.2591756785695907e-05
activity O 0 7.733903544249188e-07
seen O 0 1.6783337741799187e-07
when O 0 1.4465016739961811e-08
the O 0 6.627609128173617e-09
T312S O 0 3.610491035033192e-07
mutant O 0 1.7942979013696458e-07
cDNA O 0 3.461094024714839e-07
is O 0 1.380719627519511e-08
overexpressed O 0 8.171263061740319e-07
in O 0 1.612237099379854e-08
mutant O 0 1.7718724620863213e-07
cells O 0 4.9315215022716075e-08
provides O 0 4.24762003348178e-09
an O 0 7.751308483960884e-10
explanation O 0 7.899672027633642e-09
for O 0 1.6579185802001462e-09
the O 0 5.4668131355128935e-08
mild O 1 0.7637723088264465
phenotype O 0 0.009948190301656723
in O 0 1.1372358130756766e-06
patients O 0 2.7563689286580484e-07
with O 0 1.901303470219773e-08
this O 0 8.052610667164117e-08
mutation O 0 5.9932322074018884e-06
. O 0 4.4714246882904263e-07

The O 0 4.920862011204008e-07
distribution O 0 1.1738958249907228e-07
and O 0 7.428447634794111e-09
relative O 0 1.4079197363514595e-08
frequencies O 0 8.350582447747001e-08
of O 0 1.155770257277311e-09
the O 0 3.76863473761091e-09
I113F O 0 1.3414778265996574e-07
and O 0 5.5878337512638154e-09
T312S O 0 3.021158363480936e-07
mutations O 0 2.392240787685296e-07
in O 0 1.3774132945343354e-08
Australia O 0 2.2131947829961973e-08
corresponded O 0 3.915489443784281e-08
to O 0 4.14431244877278e-09
those O 0 8.09961542280746e-10
observed O 0 9.020778790613804e-09
in O 0 4.956035581926699e-09
Northern O 0 5.1102201581443296e-08
Ireland O 0 4.802613489118812e-07
and O 0 2.1577479802914468e-09
are O 0 1.567808938229831e-10
unique O 0 4.154076249651695e-10
to O 0 7.587566130951018e-10
these O 0 3.8457045881123975e-10
two O 0 5.606470843133593e-10
populations O 0 2.811336941022091e-09
, O 0 3.489260269606831e-10
suggesting O 0 5.66583535643872e-09
that O 0 3.476770538135554e-10
both O 0 1.0182666931868312e-09
mutations O 0 4.9360856735347625e-08
were O 0 2.5349287113840546e-09
probably O 0 8.105507376399146e-09
introduced O 0 7.562491077806044e-08
to O 0 2.509954022400507e-09
Australia O 0 6.613970704449912e-09
by O 0 2.281776323442841e-09
Irish O 0 2.4871376069768303e-08
migrants O 0 3.034890339037588e-09
during O 0 8.546829910471843e-09
the O 0 9.586282878615293e-09
19th O 0 4.4720857772517775e-07
century O 0 6.916770871612243e-07
. O 0 4.247205538376875e-07

Haplotype O 0 0.0011861290549859405
analysis O 0 5.873626378161134e-06
using O 0 5.44592523965548e-07
6 O 0 2.9904404641456495e-07
RFLPs O 0 1.2859781008955906e-06
provides O 0 1.5441163014884296e-08
additional O 0 4.684955534628443e-09
data O 0 4.900905636873176e-08
that O 0 2.27196172986055e-09
the O 0 1.0120652760292614e-08
I113F O 0 5.653989205711696e-07
mutation O 0 2.3335931587098457e-07
originated O 0 1.0572223629878863e-07
from O 0 1.1836170266121826e-08
a O 0 1.854272291268444e-08
common O 0 2.3405938520681957e-07
ancestor O 0 2.8139779715274926e-06
. O 0 1.0083005008709733e-06

The O 0 5.118399712955579e-07
other O 0 3.120069180795326e-08
9 O 0 1.5744669212836016e-07
novel O 0 7.642884014558149e-08
mutations O 0 5.476189244291163e-07
identified O 0 4.1136477335612653e-08
in O 0 1.1799068388995693e-08
these O 0 1.1046588532792612e-08
23 O 0 4.136189488690434e-07
patients O 0 4.609255199738982e-08
were O 0 5.634539057552956e-09
each O 0 8.50741699309765e-10
limited O 0 6.277383945985093e-09
to O 0 3.2237055247463786e-09
a O 0 2.19184990157828e-08
single O 0 3.1090144148038235e-07
family O 0 3.524702378854272e-07
. O 0 3.1951142887010064e-07

These O 0 3.079593682286941e-07
data O 0 3.126760077520885e-07
provide O 0 1.6840598249245886e-08
further O 0 9.628981167963957e-09
evidence O 0 1.0074968415096919e-08
for O 0 2.3468282872585178e-09
extensive O 0 8.29788575629209e-08
allelic O 0 1.149070703831967e-05
heterogeneity O 0 1.084452924260404e-05
in O 0 1.133947807829827e-05
MPS B-Disease 1 0.9999986886978149
IVA I-Disease 1 0.9999872446060181
in O 0 3.837213625956792e-06
British O 0 8.650690142530948e-05
- O 0 0.0003126879455521703
Irish O 0 2.424363174213795e-06
patients O 0 6.278188635633342e-08
and O 0 1.1852384629307267e-09
provide O 0 4.6561085542684566e-10
evidence O 0 1.040094455007079e-09
for O 0 4.896546501598209e-10
their O 0 1.081154366033843e-08
transmission O 0 0.0025019359309226274
to O 0 1.0794770410882393e-08
Australia O 0 1.071092903259796e-08
by O 0 2.9574542814714277e-09
British O 0 1.5483401227811555e-07
- O 0 6.574266535608331e-07
Irish O 0 1.549980197523837e-07
migrants O 0 4.953203003310591e-08
. O 0 2.250179775842298e-08
. O 0 2.048034986046332e-07

Identification O 0 5.149011940375203e-06
of O 0 3.6755133692167874e-07
constitutional O 0 2.4717148789932253e-06
WT1 O 0 0.0003901431628037244
mutations O 0 2.772194602584932e-05
, O 0 3.0316577692701685e-08
in O 0 4.980591228331832e-08
patients O 0 1.2779686642261368e-07
with O 0 6.84604657408272e-08
isolated O 0 0.012617852538824081
diffuse B-Disease 1 0.9999933242797852
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.9167080128900125e-07
and O 0 2.7287640591566742e-08
analysis O 0 4.804317299544891e-08
of O 0 3.070601906074444e-08
genotype O 0 0.00047716128756292164
/ O 0 0.002420856151729822
phenotype O 0 4.6793742512818426e-05
correlations O 0 8.21343633106153e-07
by O 0 1.7250489037223815e-08
use O 0 3.477251908634571e-08
of O 0 3.605410192619729e-09
a O 0 1.2940149929363542e-07
computerized O 0 0.0007590055465698242
mutation O 0 1.2732846698781941e-05
database O 0 2.076026930808439e-06
. O 0 9.779150786926039e-07

Constitutional O 0 2.4090224542305805e-05
mutations O 0 3.136402665404603e-05
of O 0 3.6075856968409425e-08
the O 0 1.4057548014534405e-07
WT1 O 0 7.032324356259778e-05
gene O 0 3.9408546399499755e-06
, O 0 4.258484409547236e-08
encoding O 0 7.453101602550305e-07
a O 0 4.235584185607877e-07
zinc O 0 0.0004348501388449222
- O 0 3.376333779669949e-06
finger O 0 1.3698157090402674e-05
transcription O 0 1.5296872106773662e-06
factor O 0 6.193859292125126e-08
involved O 0 2.0271878398148147e-08
in O 0 5.2636938363548325e-08
renal O 0 3.9563663449371234e-05
and O 0 3.6687538340629544e-08
gonadal O 0 5.543591669265879e-06
development O 0 1.2212403532885219e-08
, O 0 3.2378786318787434e-09
are O 0 5.610321651694505e-10
found O 0 3.2289237950067218e-09
in O 0 4.09387368449643e-09
most O 0 1.1252374143566612e-08
patients O 0 8.94416629648731e-08
with O 0 1.9594926925492473e-07
Denys B-Disease 1 0.9999589920043945
- I-Disease 1 0.9999986886978149
Drash I-Disease 1 0.9999996423721313
syndrome I-Disease 1 1.0
( O 0 3.3563142096681986e-06
DDS B-Disease 1 1.0
) O 0 3.147994505070528e-07
, O 0 1.230774415716951e-07
or O 0 1.6003570635803044e-05
diffuse B-Disease 1 0.9999678134918213
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 4.865645314566791e-05
DMS B-Disease 1 0.8333245515823364
) O 0 1.212983278264801e-07
associated O 0 2.6401926334074233e-07
with O 0 1.3957411226783734e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 6.220062459760811e-06
/ O 0 0.0035136728547513485
or O 0 1.8178607206209563e-05
Wilms B-Disease 0 0.16380533576011658
tumor I-Disease 0 0.2231459766626358
( O 0 5.42711268280982e-06
WT B-Disease 1 0.9999040365219116
) O 0 5.266907692202949e-07
. O 0 4.7675212044850923e-07

Most O 0 4.963330411555944e-06
mutations O 0 0.0003824633895419538
in O 0 1.0940991160168778e-05
DDS B-Disease 1 1.0
patients O 0 0.001231506816111505
lie O 0 1.170486825685657e-06
in O 0 1.8555502379058453e-07
exon O 0 5.1124266065016855e-06
8 O 0 3.200292439942132e-07
or O 0 6.316034983910868e-08
exon O 0 1.689953705863445e-06
9 O 0 3.3997545756392356e-07
, O 0 8.669673867700567e-09
encoding O 0 6.869275921417284e-07
zinc O 0 3.532295522745699e-05
finger O 0 0.00013983648386783898
2 O 0 3.8921768918953603e-07
or O 0 5.681333732354688e-07
zinc O 0 9.265373228117824e-05
finger O 0 3.4033480915240943e-05
3 O 0 4.1765716218833404e-08
, O 0 2.2066435345635682e-09
respectively O 0 8.033415710428926e-09
, O 0 6.299582522295566e-10
with O 0 2.1145125650434693e-09
a O 0 9.435127168444524e-08
hot O 0 4.7250548959709704e-05
spot O 0 3.516507831591298e-06
( O 0 2.1131386418460352e-08
R394W O 0 2.558728340318339e-07
) O 0 6.531556628885937e-09
in O 0 4.185463353678642e-08
exon O 0 6.264663625188405e-06
9 O 0 3.0043838705751114e-06
. O 0 7.891796940384666e-07

We O 0 6.95055348387541e-07
analyzed O 0 3.7921796547379927e-07
a O 0 2.1716839881946726e-08
series O 0 1.3573342450001746e-08
of O 0 2.3723685238508097e-09
24 O 0 1.4361189926148654e-07
patients O 0 2.997418135919361e-08
, O 0 2.729819481572804e-09
10 O 0 9.259323086041604e-09
with O 0 3.2136448169239884e-08
isolated B-Disease 0 9.46265208767727e-05
DMS I-Disease 1 0.9747295379638672
( O 0 4.3888724121643463e-07
IDMS B-Disease 0 7.38687813282013e-05
) O 0 3.064084452830684e-08
, O 0 5.2269046868502755e-09
10 O 0 1.3340038407250177e-08
with O 0 5.967515903648746e-08
DDS B-Disease 1 1.0
, O 0 5.838403538405146e-08
and O 0 8.388316707907961e-09
4 O 0 5.504133682165957e-08
with O 0 2.2553686562787334e-07
urogenital B-Disease 1 0.9996814727783203
abnormalities I-Disease 1 0.9999983310699463
and O 0 7.99046756583266e-06
/ O 0 0.17434191703796387
or O 0 0.0001797839067876339
WT B-Disease 1 0.9999986886978149
. O 0 3.0684907414979534e-06

We O 0 5.334028173820116e-06
report O 0 6.571523044840433e-06
WT1 O 0 0.00030298379715532064
heterozygous O 0 3.271109380875714e-05
mutations O 0 1.5642610378563404e-05
in O 0 1.935212878834136e-07
16 O 0 4.0233101117337355e-07
patients O 0 2.1379625536610547e-07
, O 0 7.655996725475234e-09
4 O 0 1.762790446946383e-08
of O 0 4.254974594886107e-09
whom O 0 3.4991941788575787e-08
presented O 0 1.3823500921716914e-07
with O 0 5.269370149107999e-07
IDMS B-Disease 0 0.0037906900979578495
. O 0 2.3313541532843374e-06

One O 0 1.0299911537003936e-06
male O 0 6.614187100240088e-07
and O 0 1.555793716079279e-08
two O 0 2.1740172329032248e-08
female O 0 5.073761144558375e-07
IDMS B-Disease 0 0.014452129602432251
patients O 0 3.0694798169861315e-06
with O 0 1.3092000017422833e-06
WT1 O 1 0.9051257967948914
mutations O 0 0.02708599902689457
underwent O 0 0.2059822976589203
normal O 0 0.0004862034402322024
puberty O 0 0.0015984739875420928
. O 0 2.4914927507779794e-06

Two O 0 1.2148859696026193e-06
mutations O 0 2.8374595785862766e-05
associated O 0 1.0853651701836498e-06
with O 0 8.043814148095407e-08
IDMS B-Disease 0 0.0003310235042590648
are O 0 4.140859211076986e-09
different O 0 1.1653683573698004e-09
from O 0 4.339864911884206e-09
those O 0 3.7595455637529085e-09
described O 0 3.4621569966475363e-07
in O 0 1.9589972453104565e-06
DDS B-Disease 1 1.0
patients O 0 0.00038016788312233984
. O 0 2.3223137759487145e-06

No O 0 1.698799678706564e-05
WT1 O 0 0.0009266267297789454
mutations O 0 0.0002014083875110373
were O 0 3.0741651357857336e-07
detected O 0 2.487347501300974e-06
in O 0 1.793907244973525e-08
the O 0 9.67212621105773e-09
six O 0 1.5303825762202905e-08
other O 0 2.592476455731685e-08
IDMS B-Disease 0 0.011526355519890785
patients O 0 2.9031681947344623e-07
, O 0 7.282184188994734e-09
suggesting O 0 2.6062849656227627e-07
genetic O 0 2.571343316049024e-07
heterogeneity O 0 2.6107028361366247e-07
of O 0 6.153151321797168e-09
this O 0 3.461628637069225e-07
disease O 0 0.004146895371377468
. O 0 1.3730166301684221e-06

We O 0 3.94907510781195e-06
analyzed O 0 2.6164603696088307e-05
genotype O 0 0.00020623576710931957
/ O 0 0.0003061292227357626
phenotype O 0 9.672300075180829e-05
correlations O 0 4.64181175630074e-06
, O 0 1.1783078512905831e-08
on O 0 2.5221542188091917e-08
the O 0 2.0849406645595536e-09
basis O 0 9.566606395949862e-10
of O 0 3.86099929805539e-10
the O 0 4.471661263494298e-09
constitution O 0 9.082725682674209e-09
of O 0 7.02128799545676e-10
a O 0 2.308753366264682e-08
WT1 O 0 1.327865265920991e-05
mutation O 0 3.434192308304773e-07
database O 0 3.394842451598379e-08
of O 0 4.535128272920019e-09
84 O 0 1.3612833527076873e-07
germ O 0 3.7977006286382675e-05
- O 0 0.00015714441542513669
line O 0 0.0008523757569491863
mutations O 0 1.8983521385962376e-06
, O 0 1.8351975494823591e-09
to O 0 3.621054345259722e-09
compare O 0 2.1239154435193086e-08
the O 0 4.885978732716012e-09
distribution O 0 7.962889903012638e-09
and O 0 4.307693757255038e-09
type O 0 1.0862354571372634e-07
of O 0 1.9833796827128936e-09
mutations O 0 1.937548859132221e-07
, O 0 8.044021559960868e-10
according O 0 9.912410892098933e-10
to O 0 3.3610223493241165e-09
the O 0 1.7634226523455254e-08
different O 0 1.0977637288078768e-07
symptoms O 0 0.00446758046746254
. O 0 6.311934157565702e-07

This O 0 1.370226641483896e-06
demonstrated O 0 1.8258748468724662e-06
( O 0 1.1545307643245906e-07
1 O 0 2.763427175977995e-08
) O 0 6.199837976339495e-09
the O 0 8.333950418659697e-09
association O 0 2.1661611171452932e-08
between O 0 1.677388894449905e-08
mutations O 0 5.17946034506167e-07
in O 0 3.214362109815738e-08
exons O 0 7.846978178349673e-07
8 O 0 1.9831655606594722e-07
and O 0 2.0673084577538248e-08
9 O 0 5.061465913058782e-07
and O 0 2.3693002049185452e-07
DMS B-Disease 0 0.09967054426670074
; O 0 1.433834881936491e-07
( O 0 2.623420947145405e-08
2 O 0 3.154608663180625e-08
) O 0 8.48552783594414e-09
among O 0 4.434637101979888e-09
patients O 0 2.2569496493929364e-08
with O 0 2.4870901782492183e-08
DMS B-Disease 0 0.05241698399186134
, O 0 3.321370956044234e-09
a O 0 1.0177759079965654e-08
higher O 0 8.538572870975258e-08
frequency O 0 6.075009650885477e-07
of O 0 9.25746856950127e-09
exon O 0 1.88469493878074e-06
8 O 0 1.3309342250522604e-07
mutations O 0 2.702034862522851e-07
among O 0 6.01847149894752e-09
46 O 0 1.0005171446891836e-07
, O 0 6.64377353132295e-08
XY O 0 5.137926200404763e-05
patients O 0 1.283795398876464e-07
with O 0 1.4818611226985468e-08
female O 0 1.161707672281409e-07
phenotype O 0 1.2321396525294404e-06
than O 0 3.056733755002483e-09
among O 0 2.446401525801889e-09
46 O 0 4.769785633129686e-08
, O 0 3.549657634493997e-08
XY O 0 3.0520386644639075e-05
patients O 0 1.7570211241491052e-07
with O 0 1.260934645586076e-08
sexual O 0 1.804794038662294e-07
ambiguity O 0 1.8237015808608703e-07
or O 0 1.8754077757421328e-07
male O 0 2.8911355798300065e-07
phenotype O 0 9.669742212281562e-06
; O 0 5.198134900297191e-08
and O 0 3.6165214822858616e-08
( O 0 1.5436450340189367e-08
3 O 0 1.423755247031977e-08
) O 0 2.159221912378939e-09
statistically O 0 1.290063966763455e-08
significant O 0 2.001682375407654e-09
evidence O 0 3.5955487476257986e-09
that O 0 5.201752362182788e-09
mutations O 0 1.3070651050384186e-07
in O 0 1.4633627642979263e-08
exons O 0 9.338631343780435e-07
8 O 0 1.504178754885288e-07
and O 0 1.5740127423669037e-08
9 O 0 1.193374004060388e-07
preferentially O 0 3.5959831734544423e-07
affect O 0 9.615072826818505e-08
amino O 0 5.321384932699402e-08
acids O 0 1.5509701967175715e-08
with O 0 1.1905538777057245e-09
different O 0 2.0036534653655735e-09
functions O 0 1.9179049459694397e-08
. O 0 2.3073535970752346e-08
. O 0 1.7798578255678876e-07

The O 0 5.724649327021325e-06
185delAG O 0 0.00019727734616026282
BRCA1 O 0 0.0002477147208992392
mutation O 0 1.1887154869327787e-05
originated O 0 5.263232765173598e-07
before O 0 2.282756916827111e-08
the O 0 4.728098801365377e-09
dispersion O 0 4.5586418195853184e-08
of O 0 7.518818345708667e-10
Jews O 0 3.479286858620867e-09
in O 0 3.0623008573371635e-09
the O 0 3.771669199181815e-09
diaspora O 0 1.6263424384987957e-08
and O 0 4.40394698486557e-09
is O 0 1.897505708114977e-09
not O 0 1.2335489296688706e-09
limited O 0 1.532854021490948e-08
to O 0 5.5288282396759314e-08
Ashkenazim O 0 3.0038629120099358e-05
. O 0 5.629127599604544e-07

The O 0 7.057194579829229e-06
185delAG O 0 8.163430175045505e-05
mutation O 0 3.0050206987652928e-05
in O 0 5.072928956906253e-07
BRCA1 O 0 1.971373967535328e-05
is O 0 5.106537059873517e-08
detected O 0 1.4103877674642717e-06
in O 0 3.610766086126205e-08
Ashkenazi O 0 6.484272603302088e-07
Jews O 0 1.5243465156800085e-08
both O 0 1.237983138224763e-08
in O 0 9.92365585261723e-08
familial B-Disease 1 0.9499298334121704
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.995112127900939e-08
in O 0 1.392501935981727e-08
the O 0 1.1685919787396415e-08
general O 0 4.778764406410119e-08
population O 0 5.368012878648187e-08
. O 0 2.2451943948453845e-07

All O 0 3.2244622616417473e-06
tested O 0 2.154154935851693e-05
Ashkenazi O 0 7.593624468427151e-05
mutation O 0 6.2045646700426005e-06
carriers O 0 7.275259008565627e-07
share O 0 1.5572639711081138e-07
the O 0 4.7890932108884954e-08
same O 0 8.633901416033041e-08
allelic O 0 3.425207978580147e-06
pattern O 0 9.650340871303342e-06
at O 0 5.067078632237099e-07
the O 0 4.7264020963666553e-07
BRCA1 O 0 7.092952728271484e-05
locus O 0 3.0499755666824058e-05
. O 0 2.1669563921022927e-06

Our O 0 1.4412493101190194e-06
previous O 0 4.63873504941148e-07
study O 0 5.2383349213869224e-08
showed O 0 7.762708520431261e-08
that O 0 3.4402278803469244e-09
this O 0 1.0775065284462926e-08
Ashkenazi O 0 1.0703672160161659e-05
mutation O 0 8.801568469607446e-07
also O 0 2.025842604780337e-08
occurs O 0 1.6773697097960394e-08
in O 0 5.666299873752223e-09
Iraqi O 0 2.059032766510427e-08
Jews O 0 4.577127565852379e-09
with O 0 2.643647523115078e-09
a O 0 1.8552452019093835e-08
similar O 0 2.9475452834049065e-07
allelic O 0 1.8026961697614752e-05
pattern O 0 9.441119618713856e-05
. O 0 1.6618727158856927e-06

We O 0 3.3421025591451325e-07
extended O 0 1.4808121306941757e-07
our O 0 1.727508447402215e-08
analysis O 0 9.948991852581912e-09
to O 0 1.8655632594288818e-09
other O 0 1.0580303300145033e-09
non O 0 1.8511272514842858e-08
- O 0 2.779115959583578e-07
Ashkenazi O 0 1.2171497019153321e-06
subsets O 0 1.2059427945132484e-07
354 O 0 8.26246164820077e-08
of O 0 1.2741632193780106e-09
Moroccan O 0 5.004683245601882e-08
origin O 0 7.683690128601484e-09
, O 0 1.875520849736745e-09
200 O 0 8.29161717064153e-09
Yemenites O 0 5.361515604818123e-07
and O 0 4.3656100956468435e-09
150 O 0 2.4979772916822185e-08
Iranian O 0 1.6372989364299428e-07
Jews O 0 2.641910441525397e-07
. O 0 5.100852149553248e-07

Heteroduplex O 0 0.0002453350753057748
analysis O 0 3.465788040557527e-06
complemented O 0 1.0808264505612897e-06
by O 0 1.5969286337735866e-08
direct O 0 3.593822839320637e-08
DNA O 0 1.7541681529564812e-07
sequencing O 0 1.6463206975458888e-07
of O 0 6.0596856421568646e-09
abnormally O 0 2.161414613510715e-06
migrating O 0 1.2313967090449296e-07
bands O 0 3.568792408259469e-07
were O 0 4.395322505956756e-08
employed O 0 3.628876754646626e-07
. O 0 4.379456868264242e-07

Four O 0 4.698023019500397e-07
of O 0 2.263286447146129e-08
Moroccan O 0 2.927112916495389e-07
origin O 0 4.6761556404817384e-08
( O 0 1.4133438419605682e-08
1 O 0 5.373347100601222e-09
. O 0 1.0554001006468638e-09
1 O 0 5.3331485894148045e-09
% O 0 8.128323569778217e-10
) O 0 6.15849038432259e-10
and O 0 6.442997246836057e-10
none O 0 1.1184090320526252e-09
of O 0 2.4976365420315005e-10
the O 0 7.209517427497758e-09
Yemenites O 0 3.9319098732448765e-07
or O 0 6.76375622177261e-09
Iranians O 0 3.625124644912603e-09
was O 0 1.0634876090875878e-08
a O 0 4.940962305965968e-09
carrier O 0 5.6095466050010145e-08
of O 0 2.1255150972621095e-09
the O 0 3.3488017692206995e-08
185delAG O 0 7.479057330783689e-06
mutation O 0 7.196157639555167e-06
. O 0 5.295697746987571e-07

BRCA1 O 0 0.014957916922867298
allelic O 0 0.0009018182754516602
patterns O 0 0.00036763318348675966
were O 0 4.005347307156626e-07
determined O 0 6.148378872694593e-08
for O 0 2.509360497171542e-09
four O 0 1.0712865039508301e-09
of O 0 3.9661310347050005e-10
these O 0 7.95021437571819e-10
individuals O 0 2.906136442604179e-10
and O 0 6.640777927557906e-10
for O 0 8.441131682523917e-10
12 O 0 7.225430920243525e-09
additional O 0 6.690057841041153e-09
non O 0 4.636572370486647e-08
- O 0 2.62646585724724e-06
Ashkenazi O 0 8.972014256869443e-06
185delAG O 0 2.7541191229829565e-06
mutation O 0 1.33857463424647e-06
carriers O 0 3.8130750112941314e-07
who O 0 4.016110892735014e-07
had O 0 0.3634475767612457
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3978707102069166e-05

Six O 0 2.407027295703301e-06
non O 0 9.593188678991282e-07
- O 0 5.936574325460242e-06
Ashkenazi O 0 8.724752660782542e-06
individuals O 0 8.177623023186698e-09
shared O 0 9.141399637258019e-09
the O 0 1.1815194156383768e-08
common O 0 1.616835447748599e-07
Ashkenazi O 0 2.2292224457487464e-05
haplotype O 0 1.7220780136995018e-05
, O 0 8.54965076513281e-09
four O 0 6.526027718223304e-09
had O 0 2.744574523205756e-08
a O 0 1.1512099717947422e-08
closely O 0 9.568785941382885e-08
related O 0 5.0987996047524575e-08
pattern O 0 4.526654265646357e-06
, O 0 6.632958626795471e-09
and O 0 2.9689612990324576e-09
the O 0 1.392528581334318e-08
rest O 0 6.22673042016686e-08
( O 0 2.3463728737738165e-08
n O 0 3.6082468568565673e-07
= O 0 2.9355106789807905e-07
6 O 0 6.564230403682814e-08
) O 0 1.0930186533641972e-08
displayed O 0 1.2702855656243628e-07
a O 0 4.86673776833868e-08
distinct O 0 2.8775139071512967e-07
BRCA1 O 0 2.2746417016605847e-05
allelic O 0 2.0086337826796807e-05
pattern O 0 0.00017953415226656944
. O 0 2.7494636469782563e-06

We O 0 5.292082505548024e-07
conclude O 0 5.726559493268724e-07
that O 0 1.3857377467729748e-08
the O 0 3.178562479888569e-08
185delAG O 0 7.970839760673698e-06
BRCA1 O 0 4.230768536217511e-05
mutation O 0 2.638244723129901e-06
occurs O 0 1.188447171784901e-07
in O 0 1.3043649715882566e-08
some O 0 6.371630778545523e-09
non O 0 5.2426827323870384e-08
- O 0 1.9601725398388226e-06
Ashkenazi O 0 4.504553544393275e-06
populations O 0 1.8957129555019492e-07
at O 0 4.084057536601904e-07
rates O 0 5.681150923919631e-06
comparable O 0 8.671678841665198e-08
with O 0 4.491552019203482e-09
that O 0 4.182779900219202e-09
of O 0 1.763728896264638e-08
Ashkenazim O 0 3.3802887628553435e-05
. O 0 8.131019058055244e-07

The O 0 4.812222869077232e-07
majority O 0 1.0204354339293786e-07
of O 0 6.667815632965812e-09
Jewish O 0 1.1723239623506743e-07
185delAG O 0 2.9787415769533254e-06
mutation O 0 2.083005711028818e-06
carriers O 0 4.352916107563942e-07
have O 0 8.051132205366685e-09
a O 0 3.0818672058785523e-08
common O 0 1.9575726639686764e-07
allelic O 0 6.216647307155654e-06
pattern O 0 1.90631744771963e-05
, O 0 8.464303924426986e-09
supporting O 0 6.851817779818248e-09
the O 0 6.577525191175937e-09
founder O 0 5.218231180492694e-08
effect O 0 1.3619918526330821e-08
notion O 0 3.816077676077612e-09
, O 0 6.396833618360631e-10
but O 0 7.940424984198557e-10
dating O 0 9.413391843793306e-09
the O 0 1.3341151516854666e-09
mutations O 0 2.1562268415209473e-08
origin O 0 9.757914476438145e-10
to O 0 8.370810711255672e-10
an O 0 5.990021256785383e-10
earlier O 0 2.096194329226364e-08
date O 0 1.5002042275114036e-08
than O 0 1.9182551103114065e-09
currently O 0 3.8997911566696075e-09
estimated O 0 1.9087085689761807e-08
. O 0 1.2041500951909256e-07

However O 0 1.8239135215480928e-06
, O 0 4.310325962819661e-08
the O 0 7.0543397789890605e-09
different O 0 1.2581718777937567e-08
allelic O 0 1.1222537068533711e-06
pattern O 0 2.8906274565088097e-06
at O 0 2.5604956022107217e-07
the O 0 1.0070496614389413e-07
BRCA1 O 0 5.405459887697361e-06
locus O 0 3.8168079186107207e-07
even O 0 1.1946626798930993e-08
in O 0 4.458639235593864e-09
some O 0 1.357571721705142e-09
Jewish O 0 4.0368380638255985e-08
mutation O 0 1.9649905880214646e-07
carriers O 0 2.4268368647994976e-08
, O 0 2.9306748139390493e-09
might O 0 1.0958680185524372e-08
suggest O 0 1.0687930540598245e-08
that O 0 1.2255798598204137e-09
the O 0 1.3399046316919794e-08
mutation O 0 3.059731170651503e-07
arose O 0 7.505499866056198e-08
independently O 0 1.4798395397974673e-07
. O 0 5.552277926312854e-08
. O 0 2.6413434284222603e-07

Crystal O 0 0.0001172670308733359
structure O 0 3.796275223066914e-06
of O 0 5.852764317637593e-08
the O 0 7.754375701551908e-07
hemochromatosis B-Disease 1 1.0
protein O 0 1.2039142347930465e-05
HFE O 0 0.00014993587683420628
and O 0 4.042925283442855e-08
characterization O 0 1.336697721399105e-07
of O 0 1.118076298212145e-09
its O 0 9.855125604474324e-09
interaction O 0 3.289910921466799e-08
with O 0 2.3211343957996178e-08
transferrin O 0 7.966226803546306e-06
receptor O 0 6.028243660693988e-06
. O 0 6.378539865181665e-07

HFE O 0 0.006543023977428675
is O 0 1.1877010592797888e-06
an O 0 1.5270155984126177e-07
MHC O 0 1.580216849106364e-05
- O 0 1.8944673456644523e-06
related O 0 8.136568396821531e-08
protein O 0 9.925663135845753e-08
that O 0 1.401355032015772e-09
is O 0 1.2598402321373214e-09
mutated O 0 7.284132408358346e-08
in O 0 1.8956365366307182e-08
the O 0 1.220186049977201e-07
iron B-Disease 1 0.9988214373588562
- I-Disease 1 0.9999933242797852
overload I-Disease 1 0.9999972581863403
disease I-Disease 1 0.9999997615814209
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00033719794009812176

HFE O 0 0.008591755293309689
binds O 0 8.884712588042021e-05
to O 0 2.797794422804145e-06
transferrin O 0 3.396837564650923e-05
receptor O 0 1.2361504559521563e-05
( O 0 4.479081496810977e-07
TfR O 0 6.433439466491109e-06
) O 0 1.7532308049794665e-08
and O 0 9.028197744953559e-09
reduces O 0 7.859937767307201e-08
its O 0 1.6619180698285163e-08
affinity O 0 1.1189840876113522e-07
for O 0 1.3144046739910209e-08
iron O 0 1.3431279512587935e-05
- O 0 4.180437542800064e-07
loaded O 0 2.4603528459010704e-07
transferrin O 0 1.338795527772163e-06
, O 0 2.195477577515703e-08
implicating O 0 6.526529432449024e-06
HFE O 0 0.00010282052244292572
in O 0 9.398859788234404e-07
iron O 0 0.0026552178896963596
metabolism O 0 0.0005312455468811095
. O 0 1.6547860468563158e-06

The O 0 4.156008799327537e-06
2 O 0 7.385654043901013e-06
. O 0 2.030432369792834e-06

6 O 0 2.6713893021224067e-05
A O 0 2.639641479618149e-06
crystal O 0 1.7414648027624935e-05
structure O 0 4.981508254786604e-07
of O 0 1.6607708985816316e-08
HFE O 0 4.918693957733922e-05
reveals O 0 3.46480589996645e-07
the O 0 7.424906023345557e-09
locations O 0 3.668089121333651e-08
of O 0 3.400992909519118e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0001046012039296329
and O 0 8.115519989360109e-08
a O 0 7.699829893681454e-07
patch O 0 0.1968531757593155
of O 0 7.158257986361605e-09
histidines O 0 7.5932925938104745e-06
that O 0 6.404528463122006e-09
could O 0 7.424084902396544e-09
be O 0 1.185462283892491e-09
involved O 0 3.234613243918716e-09
in O 0 3.5868378489567476e-08
pH O 0 1.1766404895752203e-05
- O 0 3.7389636418083683e-06
dependent O 0 4.998153713131614e-07
interactions O 0 6.464680382123333e-07
. O 0 5.03885871694365e-07

We O 0 6.78846276969125e-07
also O 0 9.833780012513671e-08
demonstrate O 0 1.289643734025958e-07
that O 0 3.864517594820427e-08
soluble O 0 3.3675100894470233e-06
TfR O 0 1.1780598470068071e-05
and O 0 9.560704938849085e-08
HFE O 0 5.836357377120294e-05
bind O 0 1.8533816046328866e-06
tightly O 0 6.222127467481187e-06
at O 0 1.659514623497671e-07
the O 0 1.4761909028493392e-08
basic O 0 2.7893324983097045e-08
pH O 0 9.087789010209235e-08
of O 0 4.36364333555872e-10
the O 0 2.7397457635913725e-09
cell O 0 1.1112590669881683e-07
surface O 0 5.553750526132717e-08
, O 0 1.0795754290526816e-09
but O 0 7.650635680533924e-10
not O 0 1.5613101922440364e-09
at O 0 2.1290096796633406e-08
the O 0 2.4963769718056028e-08
acidic O 0 1.8865956690206076e-06
pH O 0 1.0726200798671925e-06
of O 0 1.0995634625032835e-08
intracellular O 0 4.227822046232177e-06
vesicles O 0 1.8981232642545365e-05
. O 0 2.8551803552545607e-06

TfR O 0 0.07144690304994583
HFE O 0 0.016322677955031395
stoichiometry O 0 0.00039410986937582493
( O 0 4.843133865506388e-06
2 O 0 4.21276666884296e-07
1 O 0 1.3062948767128546e-07
) O 0 2.2645819441891035e-08
differs O 0 2.796759588363784e-07
from O 0 1.1425392187902617e-07
TfR O 0 1.3278058759169653e-05
transferrin O 0 3.8030696032365086e-06
stoichiometry O 0 1.889635086627095e-06
( O 0 4.5198802922641335e-08
2 O 0 4.040920842385276e-08
2 O 0 2.6462316782271955e-08
) O 0 3.125327108222109e-09
, O 0 7.996721618219738e-10
implying O 0 1.305853558619674e-08
a O 0 3.3658851261719747e-09
different O 0 1.8245595034827033e-09
mode O 0 5.699938299130736e-08
of O 0 1.205514021940246e-09
binding O 0 4.2759999985264585e-08
for O 0 5.8913118827774724e-09
HFE O 0 5.813572897750419e-06
and O 0 2.4685594013362788e-08
transferrin O 0 7.96513234035956e-07
to O 0 5.766984401134323e-08
TfR O 0 5.693533239536919e-06
, O 0 4.480779747240149e-09
consistent O 0 1.683208949998516e-08
with O 0 2.860433223617065e-09
our O 0 9.059990091486725e-09
demonstration O 0 5.734724695116711e-08
that O 0 1.0267841688005319e-08
HFE O 0 4.811195594811579e-06
, O 0 9.345018092687951e-09
transferrin O 0 3.5241242812844575e-07
, O 0 7.602461771227809e-09
and O 0 2.8304926402711317e-08
TfR O 0 4.190834260953125e-06
form O 0 4.751389326429489e-08
a O 0 1.688238313590773e-07
ternary O 0 3.917210960935336e-06
complex O 0 3.8468060665763915e-06
. O 0 1.2904363302368438e-06

Identification O 0 1.7870756892079953e-06
of O 0 4.004644083011044e-08
three O 0 2.0422456614710427e-08
novel O 0 1.454076112850089e-07
mutations O 0 7.204625944723375e-07
and O 0 1.502389146423866e-08
a O 0 6.347494974079382e-08
high O 0 4.1721736465660797e-07
frequency O 0 1.9409271772019565e-06
of O 0 2.995616421586078e-09
the O 0 2.8905942528467676e-08
Arg778Leu O 0 6.347812814055942e-06
mutation O 0 6.182594347592385e-07
in O 0 2.4805146381368104e-08
Korean O 0 3.3932764154087636e-07
patients O 0 3.302409652405913e-07
with O 0 1.8406993262942706e-07
Wilson B-Disease 0 0.0003464702167548239
disease I-Disease 0 0.008623314090073109
. O 0 1.6071427353381296e-06

Four O 0 9.031937224790454e-06
mutations O 0 0.00013251170457806438
- O 0 2.048941132670734e-05
- O 0 4.138467829761794e-06
R778L O 0 2.3965276341186836e-06
, O 0 1.436274654764702e-08
A874V O 0 2.426546075184888e-07
, O 0 6.005193231573003e-09
L1083F O 0 1.409607648383826e-07
, O 0 2.4427739830912287e-09
and O 0 2.719192426781092e-09
2304delC O 0 6.314667757578718e-07
- O 0 1.1324393653922016e-06
- O 0 4.016057175704191e-07
in O 0 1.2399278936925384e-08
the O 0 1.5429563404723012e-08
copper O 0 4.849863444178482e-07
- O 0 3.333380149683762e-08
transporting O 0 1.1684871736861169e-08
enzyme O 0 5.3822020618099486e-08
, O 0 5.7467119951581935e-09
P O 0 2.3653137759538367e-06
- O 0 4.608622532487061e-07
type O 0 2.280875833093887e-06
ATPase O 0 2.1241035028651822e-06
( O 0 4.662672026256587e-08
ATP7B O 0 1.2148209407314425e-06
) O 0 4.022417510185505e-09
, O 0 6.708365529739524e-10
were O 0 1.8015460234721559e-09
identified O 0 5.353950616182601e-09
in O 0 6.375788785817349e-09
Korean O 0 1.244147682655239e-07
Patients O 0 1.4047255092464184e-07
with O 0 3.5970256817563495e-07
Wilson B-Disease 0 0.0006005162722431123
disease I-Disease 0 0.0022007108200341463
. O 0 7.805555242157425e-07

Arg778Leu O 0 0.00021732818277087063
, O 0 2.6357673732491094e-07
the O 0 2.19387015221173e-08
most O 0 6.5353322753480825e-09
frequently O 0 6.610051173083775e-08
reported O 0 7.582927423754882e-07
mutation O 0 1.7985396993935865e-07
of O 0 1.7980101851833297e-09
this O 0 2.547331456881352e-09
enzyme O 0 2.5473717357726855e-08
, O 0 1.7512881145265169e-09
was O 0 5.1605660189579794e-08
found O 0 2.8932130025083325e-09
in O 0 1.7573544841553712e-09
six O 0 1.9132637696372967e-09
of O 0 7.332285334449296e-10
eight O 0 9.153055202659743e-09
unrelated O 0 2.5824613203440094e-07
patients O 0 1.3139164423137117e-07
studied O 0 3.9949402008687684e-08
, O 0 2.5984006057910847e-09
an O 0 6.127023333135639e-09
allele O 0 5.296465133142192e-07
frequency O 0 1.3664644029631745e-06
of O 0 2.9330136541716456e-08
37 O 0 1.4686189615531475e-06
. O 0 5.168811298972287e-07

5 O 0 2.9872874165448593e-06
% O 0 6.78963587574799e-08
, O 0 3.1742228845388354e-09
which O 0 2.7655453482822168e-09
is O 0 1.3969890799714335e-09
considerably O 0 4.161923428114278e-08
higher O 0 3.6978036632717703e-08
than O 0 1.339528377108934e-09
those O 0 4.697534583542051e-10
in O 0 1.042034458720309e-09
other O 0 1.1930089138800781e-09
Asian O 0 2.1305288200323957e-08
populations O 0 1.0646732562236139e-07
. O 0 1.6067887997905927e-07

The O 0 1.631284021641477e-06
novel O 0 1.3251427617433365e-06
single O 0 3.0356449087776127e-07
nucleotide O 0 1.6092132000267156e-06
deletion O 0 1.2958217894265545e-06
, O 0 2.188846082162854e-08
2304delC O 0 6.178415219437738e-07
, O 0 1.343472000314705e-08
was O 0 6.929943197064858e-08
found O 0 6.914229633281366e-09
in O 0 9.854054461300166e-09
one O 0 3.0625944447137954e-08
patient O 0 2.204017391704838e-06
. O 0 4.396085842017783e-07

Since O 0 9.87299245025497e-06
a O 0 1.1096615253336495e-06
mutation O 0 4.6219952309911605e-06
at O 0 6.077333409848507e-07
cDNA O 0 9.176652383757755e-06
nucleotide O 0 2.3656573830521666e-05
2302 O 0 0.00019404249906074256
( O 0 2.166194832398105e-07
2302insC O 0 8.586716830905061e-07
) O 0 1.0560631480416305e-08
had O 0 4.312315837751157e-08
been O 0 4.339517634122103e-09
previously O 0 1.3400580201050616e-08
described O 0 1.6254958268291375e-08
, O 0 9.100026843178455e-10
this O 0 4.885948312605137e-10
region O 0 4.596523162092581e-09
of O 0 7.68018371122281e-10
the O 0 4.6117264673739555e-08
ATP7B O 0 5.126806354383007e-05
gene O 0 3.7833472106285626e-06
may O 0 4.875564627582207e-07
be O 0 1.0836648911549673e-08
susceptible O 0 9.304343961957784e-07
to O 0 5.480709219796154e-08
gene O 0 7.411209026031429e-06
rearrangements O 0 0.0001482293155277148
causing O 0 0.0004539332294370979
Wilson B-Disease 0 0.0036473190411925316
disease I-Disease 0 0.1925523281097412
. O 0 3.3292487842118135e-06

Disruption O 0 0.00011139040725538507
of O 0 2.8518283556877577e-07
splicing O 0 8.830255865177605e-06
regulated O 0 1.500853159086546e-06
by O 0 2.8654641326397723e-08
a O 0 6.640505745281189e-08
CUG O 0 3.5522800317266956e-05
- O 0 2.497563855285989e-06
binding O 0 2.1542039121413836e-06
protein O 0 3.303800212961505e-06
in O 0 1.5159001122810878e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.688701897568535e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9996888637542725
DM B-Disease 1 1.0
) O 0 6.302704150584759e-06
is O 0 6.873444391430894e-08
caused O 0 1.3781037466742418e-07
by O 0 1.2963092821394184e-08
a O 0 6.059895696353124e-08
CTG O 0 1.913168034661794e-06
expansion O 0 4.5110780888535373e-08
in O 0 8.616394708838016e-09
the O 0 1.9126224160004313e-08
3 O 0 9.320118721234394e-08
untranslated O 0 8.415753995905106e-07
region O 0 1.0911838188576439e-07
of O 0 1.7182809841642666e-08
the O 0 1.4139850463834591e-06
DM B-Disease 1 1.0
gene O 0 0.00016570663137827069
. O 0 2.33385890169302e-06

One O 0 3.0045043786230963e-06
model O 0 3.5865209611074533e-06
of O 0 2.643379843902949e-07
DM B-Disease 1 1.0
pathogenesis O 0 0.0001949036231962964
suggests O 0 6.628463893321168e-07
that O 0 1.6279532388807638e-08
RNAs O 0 1.8805349100148305e-06
from O 0 1.7711554889388026e-08
the O 0 9.744583806536866e-09
expanded O 0 7.619740927111707e-08
allele O 0 3.0623789371020393e-07
create O 0 1.3496694428738465e-08
a O 0 1.2348254863070451e-08
gain O 0 8.632139980591091e-08
- O 0 1.2022819362300652e-07
of O 0 2.9249731525737843e-09
- O 0 5.786884003100567e-07
function O 0 2.9052859673583953e-08
mutation O 0 3.062465836478623e-08
by O 0 1.2339630428570558e-09
the O 0 4.958645050123778e-09
inappropriate O 0 6.158706611358866e-08
binding O 0 1.6998891183561682e-08
of O 0 1.6962059534719742e-09
proteins O 0 1.8613700802916355e-08
to O 0 9.179646376367145e-09
the O 0 7.09058980419286e-08
CUG O 0 7.961756637087092e-05
repeats O 0 3.595135058276355e-05
. O 0 6.717359042340831e-07

Data O 0 1.0986296729242895e-05
presented O 0 1.1797166052929242e-06
here O 0 2.9078972119123137e-08
indicate O 0 7.733993356850988e-08
that O 0 2.7588857864913052e-09
the O 0 8.436725096316877e-09
conserved O 0 2.3687668715410837e-07
heterogeneous O 0 3.40888419714247e-07
nuclear O 0 6.937110583749018e-07
ribonucleoprotein O 0 5.3362005019153e-06
, O 0 4.2956514789693756e-08
CUG O 0 8.018132575671189e-06
- O 0 1.2633958021979197e-06
binding O 0 6.340470690702205e-07
protein O 0 5.187814622331643e-07
( O 0 1.0754802559631571e-07
CUG O 0 3.128271418972872e-05
- O 0 2.9814995286869816e-05
BP O 0 7.836277291062288e-06
) O 0 1.675572569581618e-08
, O 0 5.295421434681202e-09
may O 0 4.827704103149699e-08
mediate O 0 2.5629802280491276e-07
the O 0 7.879691565904068e-08
trans O 0 3.3588148653507233e-06
- O 0 3.2937648484221427e-06
dominant O 0 4.75359229312744e-07
effect O 0 4.0687012869966566e-08
of O 0 1.2758168965731898e-09
the O 0 1.1883628303621663e-08
RNA O 0 1.6754532907725661e-06
. O 0 3.502393326471065e-07

CUG O 0 0.015526342205703259
- O 0 0.004747495055198669
BP O 0 9.932742977980524e-05
was O 0 3.740207716873556e-07
found O 0 1.0844754427807857e-08
to O 0 3.755130872917789e-09
bind O 0 2.8283338338042086e-08
to O 0 3.1740776673672144e-09
the O 0 1.6273757452722748e-08
human O 0 2.81244922462065e-07
cardiac O 0 0.006831384729593992
troponin O 0 0.06503928452730179
T O 0 0.00043043727055191994
( O 0 1.2965151086063997e-07
cTNT O 0 1.7837962786870776e-06
) O 0 2.9807708301632374e-08
pre O 0 9.533441698295064e-07
- O 0 1.1447908718764666e-06
messenger O 0 6.734074418091041e-07
RNA O 0 3.537175246037805e-07
and O 0 7.103514221284968e-09
regulate O 0 1.963668125881668e-07
its O 0 4.487367277761223e-08
alternative O 0 2.9297717674126034e-07
splicing O 0 7.076651854731608e-06
. O 0 5.031483283346461e-07

Splicing O 0 0.00014734955038875341
of O 0 1.1540083733052597e-06
cTNT O 0 3.821059362962842e-05
was O 0 4.464106496016029e-06
disrupted O 0 0.00016301173309329897
in O 0 2.3862396119511686e-05
DM B-Disease 1 1.0
striated O 1 0.8917100429534912
muscle O 0 0.15312620997428894
and O 0 5.668183788998249e-08
in O 0 2.4819721389235383e-08
normal O 0 3.047351810891996e-07
cells O 0 2.640398975017888e-07
expressing O 0 8.07560454063605e-08
transcripts O 0 1.5023337596176134e-07
that O 0 9.259252031768028e-09
contain O 0 3.6807537640015653e-07
CUG O 0 5.416117710410617e-05
repeats O 0 4.855512815993279e-05
. O 0 1.0382377695350442e-06

Altered O 0 0.00017502231639809906
expression O 0 4.876611001236597e-06
of O 0 8.428172293406533e-08
genes O 0 1.2212831279612146e-06
regulated O 0 2.0923491774738068e-06
posttranscriptionally O 0 4.246822754794266e-06
by O 0 8.532924056225966e-08
CUG O 0 8.644513582112268e-05
- O 0 3.991527046309784e-05
BP O 0 5.691649221262196e-06
therefore O 0 7.851696892657856e-08
may O 0 1.382024379381619e-07
contribute O 0 6.403785590691768e-08
to O 0 7.882304657869099e-07
DM B-Disease 1 1.0
pathogenesis O 0 0.0004624935972969979
. O 0 3.271476884947333e-07
. O 0 8.146612344717141e-07

Identification O 0 6.5506123974046204e-06
of O 0 8.894100744782918e-08
a O 0 1.4463064701430994e-07
novel O 0 6.752472927473718e-07
nonsense O 0 3.0849896575091407e-06
mutation O 0 2.2267586246016435e-06
and O 0 2.2999499194042983e-08
a O 0 5.645159006917311e-08
missense O 0 2.274361804666114e-06
substitution O 0 1.9387115912650188e-07
in O 0 2.2659126130974983e-08
the O 0 6.390108353571122e-08
vasopressin O 0 4.125114173803013e-06
- O 0 5.238797712081578e-06
neurophysin O 0 9.468996722716838e-06
II O 0 2.783704530884279e-06
gene O 0 2.770679259356257e-07
in O 0 1.3944075227811936e-08
two O 0 1.0987247556215607e-08
Spanish O 0 2.5942776460397e-07
kindreds O 0 4.779065875482047e-06
with O 0 3.1974187209016236e-07
familial B-Disease 0 0.33547428250312805
neurohypophyseal I-Disease 1 0.9999642372131348
diabetes I-Disease 1 0.9999984502792358
insipidus I-Disease 1 0.9908583760261536
. O 0 3.377005850779824e-05

Familial B-Disease 1 0.9998772144317627
neurohypophyseal I-Disease 1 0.9999982118606567
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999862909317017
( O 0 0.00034266142756678164
FNDI B-Disease 1 1.0
) O 0 4.099529746781627e-07
is O 0 2.138794208406125e-08
an O 0 8.45127274828883e-08
autosomal B-Disease 1 0.9993656277656555
dominant I-Disease 1 0.9996261596679688
disease I-Disease 1 0.9996806383132935
caused O 0 0.0003087861114181578
by O 0 4.729156898974907e-06
deficiency O 0 0.08068257570266724
in O 0 6.117834772112474e-08
the O 0 8.388877859033528e-07
antidiuretic O 0 0.00027167811640538275
hormone O 0 3.756953083211556e-05
arginine O 0 1.959180190169718e-05
vasopressin O 0 2.0991701603634283e-05
( O 0 4.89683202431479e-07
AVP O 0 2.9151221951906336e-06
) O 0 2.5880989795723508e-08
encoded O 0 6.19398932144577e-08
by O 0 1.2829454831830844e-08
the O 0 9.03843613286881e-08
AVP O 0 1.920411341416184e-05
- O 0 1.2888294804724865e-05
neurophysin O 0 4.0890092350309715e-05
II O 0 3.5737881262321025e-05
( O 0 3.100646779330418e-07
AVP O 0 9.55154791881796e-06
- O 0 3.096136651947745e-06
NPII O 0 1.1215806807740591e-05
) O 0 4.0033075521250794e-08
gene O 0 4.049539938932867e-07
on O 0 2.3833871409806306e-07
chromosome O 0 9.411451173946261e-06
20p13 O 0 7.55912515160162e-06
. O 0 5.475379794006585e-07

In O 0 1.6200610843952745e-06
this O 0 5.467981267770483e-08
study O 0 2.3812463112449223e-08
, O 0 2.8361168968871198e-09
we O 0 1.2208251076728516e-09
analyzed O 0 1.1217508699701284e-08
two O 0 1.4347459886820957e-09
families O 0 2.4048243396634916e-09
with O 0 5.6606501708245105e-09
FNDI B-Disease 1 0.9994014501571655
using O 0 9.923693511382226e-08
direct O 0 9.150666357982118e-08
automated O 0 1.2206382052681874e-05
fluorescent O 0 7.901339813543018e-06
, O 0 3.244691404447053e-09
solid O 0 2.4735506087836256e-08
phase O 0 2.1256257198842832e-08
, O 0 2.6896256333230895e-09
single O 0 2.1637662328544138e-08
- O 0 2.0181684590170335e-07
stranded O 0 1.0668849625972143e-07
DNA O 0 1.471670856290075e-07
sequencing O 0 9.586999283328623e-08
of O 0 1.240251989997887e-08
PCR O 0 0.0002071454655379057
- O 0 3.976815423811786e-05
amplified O 0 0.00022064147924538702
AVP O 0 7.88960896898061e-05
- O 0 1.3267235772218555e-05
NPII O 0 5.6694061640882865e-05
DNA O 0 1.4128166185400914e-05
. O 0 2.0163229237368796e-06

In O 0 5.842023824698117e-07
one O 0 1.650337999592466e-08
of O 0 1.8929691147917538e-09
the O 0 6.739442781622529e-09
families O 0 5.25529486594678e-09
, O 0 1.782235803382548e-09
affected O 0 8.033951282016005e-09
individuals O 0 9.47849909671561e-10
presented O 0 5.737785802040207e-09
a O 0 1.599702770249678e-08
novel O 0 8.152615293965937e-08
nonsense O 0 7.4410564820937e-07
mutation O 0 5.47527577055007e-07
in O 0 4.557546517958144e-08
exon O 0 7.976496476658212e-07
3 O 0 2.052637348981534e-08
of O 0 1.0344973766507337e-09
the O 0 7.583344618922183e-09
gene O 0 8.158604458685659e-08
, O 0 9.170069703579031e-10
consisting O 0 1.5414083343046059e-09
in O 0 3.874789822333469e-09
a O 0 4.385876195556193e-08
G O 0 2.5375153200002387e-05
to O 0 1.7346344804991531e-07
T O 0 2.9906517738709226e-05
transition O 0 2.743722404829896e-07
at O 0 2.0958390223313472e-07
nucleotide O 0 6.67453662117623e-07
2101 O 0 8.055110811255872e-06
, O 0 7.37291694363762e-09
which O 0 2.7038062899720217e-09
produces O 0 1.4092899291995309e-08
a O 0 1.0278403017593973e-08
stop O 0 9.59517620913175e-08
signal O 0 2.807812506944174e-06
in O 0 9.403668599361481e-08
codon O 0 3.7590780266327783e-06
82 O 0 5.393309834289539e-07
( O 0 2.018049229945973e-07
Glu O 0 2.4042439690674655e-05
) O 0 5.7527245189703535e-08
of O 0 3.395314962517659e-08
NPII O 0 5.635646448354237e-05
. O 0 9.929608495440334e-07

The O 0 9.58324562816415e-06
premature O 0 0.00022103689843788743
termination O 0 1.289835199713707e-05
eliminates O 0 3.746244829017087e-06
part O 0 5.609172148979269e-08
of O 0 4.340262371727022e-09
the O 0 3.6801566238864325e-08
C O 0 5.761471584264655e-06
- O 0 1.0130910368388868e-06
terminal O 0 8.679404572831118e-07
domain O 0 6.364138727121826e-08
of O 0 2.122148901051446e-09
NPII O 0 9.09080313249433e-07
, O 0 1.1457614856880127e-09
including O 0 4.3135453542397784e-10
a O 0 3.6792704438681767e-09
cysteine O 0 5.600032437769187e-08
residue O 0 1.0463073607525075e-07
in O 0 9.84041825802251e-09
position O 0 6.490861892416433e-08
85 O 0 1.9909800030859515e-08
, O 0 1.1294943869089025e-09
which O 0 1.3211752802888554e-09
could O 0 2.7595279394887484e-09
be O 0 5.289725879542573e-10
involved O 0 5.9732729873474e-10
in O 0 5.714424045066835e-09
the O 0 6.090370163747139e-08
correct O 0 1.2069261174474377e-05
folding O 0 5.709218839911046e-07
of O 0 6.664967688863044e-09
the O 0 1.231298085713206e-07
prohormone O 0 0.00012899520515929908
. O 0 6.618149654968875e-07

In O 0 1.0810409776240704e-06
the O 0 5.130054603341705e-08
second O 0 7.18074204542063e-08
family O 0 4.7738449637790836e-08
, O 0 2.263768728028026e-09
a O 0 5.710403705450062e-09
G279A O 0 2.0269872891276464e-07
substitution O 0 7.590279693658886e-08
at O 0 1.665709561393669e-07
position O 0 2.8658035944317817e-07
- O 0 2.3791133685335808e-07
1 O 0 2.380059926920808e-09
of O 0 1.970287405450577e-10
the O 0 4.506715445273812e-09
signal O 0 7.827799777260225e-07
peptide O 0 8.4324177862527e-08
was O 0 4.390446406432602e-08
observed O 0 1.3850110391899761e-08
in O 0 4.237868722611893e-09
all O 0 1.9209205337489266e-09
affected O 0 4.956813270950988e-08
individuals O 0 7.842383631384564e-09
. O 0 1.0852787113435625e-07

This O 0 3.1591416700393893e-06
missense O 0 0.00036722960066981614
mutation O 0 8.46485563670285e-05
, O 0 1.629665575819672e-07
which O 0 1.806626244160725e-07
replaces O 0 1.0705744898587e-05
Ala O 0 1.2500527191150468e-05
with O 0 1.0752546586445533e-07
Thr O 0 0.00032118690432980657
, O 0 1.6944831315868214e-08
is O 0 5.285260673559833e-09
frequent O 0 2.1670956584785017e-07
among O 0 7.423111014759343e-08
FNDI B-Disease 1 1.0
patients O 0 1.5311705283238553e-05
and O 0 2.1579177555963724e-08
is O 0 3.991472485864733e-09
thought O 0 6.763497761852477e-09
to O 0 4.5183696784079075e-09
reduce O 0 5.5497263673487396e-08
the O 0 8.741305457249382e-09
efficiency O 0 7.340618424223067e-08
of O 0 2.5796209612849452e-09
cleavage O 0 1.0061949069495313e-06
by O 0 5.341427566918355e-08
signal O 0 2.8207674404256977e-05
peptidases O 0 2.530664460209664e-05
. O 0 1.3385819386257936e-07
. O 0 3.98562491454868e-07

Genetic O 0 0.0001473040465498343
heterogeneity O 0 2.948052679130342e-05
of O 0 7.253685794239573e-07
Saethre B-Disease 1 0.8454920649528503
- I-Disease 1 0.999971866607666
Chotzen I-Disease 1 0.9999943971633911
syndrome I-Disease 1 0.9999998807907104
, O 0 3.14542241142135e-08
due O 0 1.4042781515399838e-07
to O 0 5.4192547338516306e-08
TWIST O 0 1.6044616131694056e-05
and O 0 3.706164193317818e-07
FGFR O 0 0.001016778638586402
mutations O 0 5.089405021863058e-05
. O 0 1.91347112377116e-06

Thirty O 0 3.4344066079938784e-05
- O 0 1.2124796739954036e-05
two O 0 5.7618500193257205e-08
unrelated O 0 7.019652912276797e-07
patients O 0 8.981467658486508e-08
with O 0 3.93615406935055e-09
features O 0 1.2300047558255756e-07
of O 0 2.0139072631764066e-08
Saethre B-Disease 1 0.8212399482727051
- I-Disease 1 0.99982750415802
Chotzen I-Disease 1 0.999988317489624
syndrome I-Disease 1 0.9999997615814209
, O 0 7.93243604135796e-09
a O 0 1.2055724596393702e-07
common O 0 7.5462180575414095e-06
autosomal B-Disease 1 0.9475918412208557
dominant I-Disease 0 0.031738605350255966
condition I-Disease 0 0.00040965824155136943
of O 0 6.199852009558526e-08
craniosynostosis B-Disease 1 0.8062602281570435
and O 0 1.715179496386554e-05
limb B-Disease 1 0.8103469610214233
anomalies I-Disease 0 0.0013460332993417978
, O 0 1.8930530032434945e-08
were O 0 1.948858141531673e-08
screened O 0 3.8412446201618877e-07
for O 0 1.5913521167476574e-08
mutations O 0 7.642809691787988e-07
in O 0 5.758081655926617e-08
TWIST O 0 5.727396001020679e-06
, O 0 3.6059482511063834e-08
FGFR2 O 0 5.44171734873089e-06
, O 0 1.890942158411235e-08
and O 0 7.45195123386111e-08
FGFR3 O 0 7.175296195782721e-05
. O 0 1.1370752872608136e-06

Nine O 0 4.318474566389341e-06
novel O 0 1.1203447911611875e-06
and O 0 6.759746895568242e-08
three O 0 3.359216904641471e-08
recurrent O 0 1.4919787645339966e-05
TWIST O 0 0.00013637830852530897
mutations O 0 3.026065132871736e-05
were O 0 3.884589006020178e-08
found O 0 1.5348550874705325e-08
in O 0 1.7338726010507344e-08
12 O 0 1.1884743855716806e-07
families O 0 9.469490436231354e-08
. O 0 3.523153395690315e-07

Seven O 0 9.036985488819482e-07
families O 0 9.677665957497084e-08
were O 0 1.7597166390714847e-08
found O 0 8.256093586567204e-09
to O 0 6.252493633951417e-09
have O 0 1.9824795138845275e-09
the O 0 1.815454808706818e-08
FGFR3 O 0 9.139438589045312e-06
P250R O 0 1.9884541870851535e-06
mutation O 0 9.931853810485336e-07
, O 0 4.7559116644890764e-09
and O 0 1.876895083796626e-09
one O 0 9.773970521820274e-10
individual O 0 5.019074600376427e-10
was O 0 7.428818804555704e-08
found O 0 2.620519135021482e-09
to O 0 2.0111079468421167e-09
have O 0 1.6248316025979648e-09
an O 0 5.4640585389620355e-09
FGFR2 O 0 8.60923682921566e-06
VV269 O 0 5.885322480025934e-06
- O 0 2.759645894911955e-06
270 O 0 2.703460040720529e-06
deletion O 0 2.7610156394075602e-05
. O 0 1.930128973981482e-06

To O 0 1.027344296744559e-06
date O 0 2.069078277600056e-07
, O 0 1.0187432231134608e-08
our O 0 1.077555822348586e-08
detection O 0 2.6290217647328973e-07
rate O 0 4.5339930920818006e-07
for O 0 6.344974767813483e-09
TWIST O 0 1.1655844218694256e-06
or O 0 1.483901002075072e-07
FGFR O 0 1.1620035365922377e-05
mutations O 0 5.078107960798661e-07
is O 0 4.837389155909477e-09
68 O 0 3.6834293837273435e-08
% O 0 2.9877362806018937e-09
in O 0 7.497627407815344e-09
our O 0 6.160915688724344e-08
Saethre B-Disease 0 0.1653769612312317
- I-Disease 1 0.9997020363807678
Chotzen I-Disease 1 0.9999918937683105
syndrome I-Disease 1 1.0
patients O 0 1.220872150042851e-06
, O 0 2.258257358889182e-09
including O 0 1.4711083462515262e-09
our O 0 5.499356081628548e-09
five O 0 8.516416016846051e-09
patients O 0 5.8983872008866456e-08
elsewhere O 0 1.0742194689328244e-07
reported O 0 1.894268621072115e-06
with O 0 1.4917219459675835e-07
TWIST O 0 0.0005140197463333607
mutations O 0 0.00011813506716862321
. O 0 1.1575167491173488e-06

More O 0 3.15395624284065e-07
than O 0 5.533111391287093e-08
35 O 0 8.740509116478279e-08
different O 0 1.3770166340520973e-08
TWIST O 0 5.6609669627505355e-06
mutations O 0 2.331647465325659e-06
are O 0 4.1787129312353954e-09
now O 0 4.935593267418881e-09
known O 0 6.969561372471844e-09
in O 0 4.893943916783883e-09
the O 0 1.2696975915105213e-08
literature O 0 6.09448420618719e-08
. O 0 1.6476337805215735e-07

The O 0 1.1212523531867191e-06
most O 0 5.63449908952407e-08
common O 0 3.937537940146285e-08
phenotypic O 0 2.2255859732922545e-07
features O 0 3.0200317269191146e-07
, O 0 2.155543077364541e-09
present O 0 4.010848986268911e-09
in O 0 2.4730069103640062e-09
more O 0 4.921790752732136e-10
than O 0 5.626331622821112e-10
a O 0 3.2221132428844612e-09
third O 0 1.7484051539895518e-08
of O 0 1.8945691682148436e-09
our O 0 2.3867892551265868e-08
patients O 0 3.359741995723198e-08
with O 0 1.34700508525043e-08
TWIST O 0 3.31408555211965e-05
mutations O 0 2.9127434117981466e-06
, O 0 5.867134778014815e-09
are O 0 2.184374015001822e-09
coronal B-Disease 0 2.858689413187676e-06
synostosis I-Disease 0 1.016477108350955e-05
, O 0 3.734597342486268e-08
brachycephaly B-Disease 0 4.5642505028808955e-06
, O 0 5.775306277655545e-08
low B-Disease 0 0.00012009237252641469
frontal I-Disease 1 0.9999526739120483
hairline I-Disease 1 0.9999995231628418
, O 0 4.2228411984979175e-06
facial B-Disease 1 0.9992170333862305
asymmetry I-Disease 0 0.0008748451364226639
, O 0 7.18603018867725e-07
ptosis B-Disease 0 0.01753908023238182
, O 0 1.9736486933652486e-07
hypertelorism B-Disease 0 9.89498439594172e-05
, O 0 6.84441445741868e-08
broad B-Disease 0 1.0790673741212231e-06
great I-Disease 0 1.1299634934403002e-06
toes I-Disease 0 7.429051765939221e-05
, O 0 1.948638939097691e-08
and O 0 4.8713069134009856e-08
clinodactyly B-Disease 0 2.1133775589987636e-05
. O 0 8.049160555856361e-07

Significant O 0 8.434857591055334e-06
intra O 0 0.00010914453741861507
- O 0 6.057430073269643e-05
and O 0 3.37403093908506e-07
interfamilial O 0 1.6207603039219975e-05
phenotypic O 0 6.903741905261995e-06
variability O 0 4.028276634926442e-06
is O 0 9.409693468853675e-09
present O 0 9.29393095816522e-09
for O 0 3.9552245922891416e-09
either O 0 7.73461295011657e-08
TWIST O 0 6.214607856236398e-05
mutations O 0 3.75964846170973e-05
or O 0 1.0695189303078223e-06
FGFR O 0 0.0008020778186619282
mutations O 0 7.27506194380112e-05
. O 0 1.969026925507933e-06

The O 0 1.2761726111421012e-06
overlap O 0 1.5595883269270416e-06
in O 0 1.2856479258971376e-07
clinical O 0 1.6501468280694098e-07
features O 0 1.5303919553844025e-07
and O 0 3.383805680101659e-09
the O 0 5.0950057506327084e-09
presence O 0 1.3537430731958011e-08
, O 0 1.1916942987966195e-09
in O 0 6.986421441368407e-10
the O 0 1.0292994234717412e-09
same O 0 2.670573540086707e-09
genes O 0 8.552015984264472e-09
, O 0 4.223728311547603e-10
of O 0 4.553770416304559e-10
mutations O 0 6.468726354569299e-08
for O 0 5.900631649957688e-10
more O 0 8.543533103200218e-10
than O 0 2.4390867103818437e-09
one O 0 6.1565557096798784e-09
craniosynostotic B-Disease 0 3.8360276448656805e-06
condition I-Disease 0 1.2547541246021865e-06
- O 0 1.9941901996389788e-07
such O 0 5.079286768960856e-09
as O 0 1.826952633621204e-08
Saethre B-Disease 0 6.042599125066772e-06
- I-Disease 0 1.1582510524021927e-06
Chotzen I-Disease 0 2.1435823782667285e-06
, I-Disease 0 7.845360805447399e-09
Crouzon I-Disease 0 3.6012238524563145e-07
, I-Disease 0 7.056869755217576e-09
and I-Disease 0 2.0901657293848075e-08
Pfeiffer I-Disease 0 0.0001459372870158404
syndromes I-Disease 0 1.3322284758032765e-05
- O 0 5.297021061778651e-07
support O 0 1.6621685361428717e-08
the O 0 8.946721585800788e-09
hypothesis O 0 4.518208029935522e-08
that O 0 1.873600830037958e-09
TWIST O 0 2.1730352273152675e-07
and O 0 8.927510286582674e-09
FGFRs O 0 4.2467070215934655e-07
are O 0 1.2076265543115028e-09
components O 0 4.521429897152984e-09
of O 0 1.3526885167536307e-10
the O 0 8.630435810452752e-10
same O 0 2.251719921630979e-09
molecular O 0 1.8632810849794623e-08
pathway O 0 9.882512586045777e-09
involved O 0 1.997281229293435e-09
in O 0 3.5217633254092107e-09
the O 0 1.8447336103122325e-08
modulation O 0 1.5574169083265588e-06
of O 0 2.6911767037063328e-08
craniofacial O 0 9.390417108079419e-05
and O 0 7.453998307482834e-08
limb O 0 8.163013262674212e-06
development O 0 1.285117878779829e-08
in O 0 2.5493353206229585e-08
humans O 0 7.724396056119076e-08
. O 0 2.3081899058752242e-08
. O 0 1.6543222614018305e-07

Mutation O 0 0.0009689637226983905
analysis O 0 1.3475671948981471e-05
of O 0 1.8690760725803557e-06
UBE3A O 1 0.6922284364700317
in O 1 0.9926255345344543
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.8693485260009766
. O 0 1.4093097888689954e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.005555340554565191
AS B-Disease 1 0.9999778270721436
) O 0 1.3962365130737453e-07
is O 0 9.483819951583428e-09
caused O 0 7.957397940572264e-08
by O 0 3.761706324212355e-08
chromosome O 0 6.72532132739434e-06
15q11 O 0 3.154511887260014e-06
- O 0 1.8174507658841321e-06
q13 O 0 2.6886914383794647e-06
deletions O 0 1.359489488095278e-06
of O 0 1.2283303263416201e-08
maternal O 0 7.906124892542721e-07
origin O 0 2.1472349231999033e-08
, O 0 8.601123369089692e-09
by O 0 3.96293629023603e-08
paternal O 0 8.15218809293583e-05
uniparental B-Disease 0 0.005362052004784346
disomy I-Disease 0 0.010066889226436615
( O 0 4.7642483878007624e-06
UPD B-Disease 1 0.9999977350234985
) O 0 8.108649751648045e-08
15 O 0 2.0710775316956642e-08
, O 0 2.6506858930019916e-09
by O 0 4.697808009268556e-08
imprinting O 1 0.9707087874412537
defects O 1 0.9983236193656921
, O 0 8.198973056039449e-09
and O 0 4.495949390559417e-09
by O 0 1.198940502433743e-08
mutations O 0 2.9350124464144756e-07
in O 0 2.0565051883636443e-08
the O 0 1.7191504753100162e-07
UBE3A O 0 0.00010529052815400064
gene O 0 1.2513146430137567e-05
. O 0 7.457047104253434e-07

UBE3A O 0 0.003464921610429883
encodes O 0 4.690405694418587e-05
a O 0 2.1565267616097117e-06
ubiquitin O 0 1.4119546904112212e-05
- O 0 2.5533122425258625e-06
protein O 0 7.598911793138541e-07
ligase O 0 9.018827427098586e-07
and O 0 3.831219785865869e-08
shows O 0 2.5145179733954137e-06
brain O 0 0.0029079443775117397
- O 0 2.979487180709839e-05
specific O 0 1.381543711431732e-06
imprinting O 0 0.00048238711315207183
. O 0 2.491630539225298e-06

Here O 0 5.554212293645833e-06
we O 0 4.919853040519229e-07
describe O 0 2.756915137069882e-06
UBE3A O 0 0.000195519722183235
coding O 0 9.71741319517605e-05
- O 0 1.9924933440051973e-05
region O 0 1.0133111345567158e-06
mutations O 0 1.0553045285632834e-05
detected O 0 2.1782066141895484e-06
by O 0 3.5300303125040955e-08
SSCP O 0 2.6643838282325305e-06
analysis O 0 5.640821854058231e-08
in O 0 1.5294020272449416e-08
13 O 0 3.8879171881944785e-08
AS B-Disease 0 0.25245606899261475
individuals O 0 6.13113826375411e-09
or O 0 3.348814558989943e-08
families O 0 8.155600994541601e-08
. O 0 4.5641317569788953e-07

Two O 0 2.8384752113197464e-06
identical O 0 1.0217767339781858e-05
de O 0 9.735957064549439e-06
novo O 0 2.3043683540890925e-05
5 O 0 7.205368319773697e-07
- O 0 2.237088438050705e-06
bp O 0 1.7973068224819144e-06
duplications O 0 1.5825884247533395e-06
in O 0 4.2378545117571775e-08
exon O 0 1.967335720109986e-06
16 O 0 7.196523199581861e-08
were O 0 2.0753560647790437e-08
found O 0 1.0887119827884817e-07
. O 0 2.4461888870064286e-07

Among O 0 4.4575619995157467e-07
the O 0 3.32733911534433e-08
other O 0 4.172126644164109e-09
11 O 0 1.7025985954433054e-08
unique O 0 1.065471177952304e-08
mutations O 0 3.7611329162245966e-07
, O 0 3.363055167682205e-09
8 O 0 1.850774289380297e-08
were O 0 8.095650372297314e-09
small O 0 7.654098688192335e-09
deletions O 0 3.2769102631391434e-07
or O 0 3.724823116613152e-08
insertions O 0 5.362594492908102e-07
predicted O 0 8.406672691307904e-07
to O 0 2.0547094692346946e-08
cause O 0 3.5867699921254825e-07
frameshifts O 0 9.758880878507625e-06
, O 0 1.3060528658570547e-08
1 O 0 2.0210066509207536e-08
was O 0 4.226698635534376e-08
a O 0 1.4195414621553937e-08
mutation O 0 7.618432107392437e-08
to O 0 3.7006522290994326e-09
a O 0 2.3308590613169144e-08
stop O 0 1.5640880235423538e-07
codon O 0 4.6184607072063955e-07
, O 0 2.8058779744100093e-09
1 O 0 1.024284301820444e-08
was O 0 3.122474723227242e-08
a O 0 2.2830050738775753e-08
missense O 0 3.149606072838651e-06
mutation O 0 4.7180301976368355e-07
, O 0 2.8475592994681165e-09
and O 0 4.379019813427476e-09
1 O 0 1.6443303607616144e-08
was O 0 7.855574040149804e-07
predicted O 0 4.058594811340299e-07
to O 0 1.2312976416239962e-08
cause O 0 4.275648990414993e-08
insertion O 0 4.701482936297907e-08
of O 0 1.3727100567351158e-09
an O 0 8.300636622493585e-09
isoleucine O 0 6.557962478836998e-06
in O 0 1.624534817779022e-08
the O 0 1.3569019685633066e-08
hect O 0 6.556671792168345e-07
domain O 0 3.211874144426474e-08
of O 0 7.060635964784012e-10
the O 0 9.442469028897449e-09
UBE3A O 0 1.8214087731394102e-06
protein O 0 6.025285159694249e-08
, O 0 1.095338708623217e-09
which O 0 1.8913919319629713e-09
functions O 0 5.470273567453887e-09
in O 0 8.27505974854148e-09
E2 O 0 1.0361191016272642e-06
binding O 0 1.215906593188265e-07
and O 0 2.440376967172142e-08
ubiquitin O 0 1.3742350120082847e-06
transfer O 0 8.972219234237855e-07
. O 0 4.111020928121434e-07

Eight O 0 5.88071657148248e-07
of O 0 1.078592148928692e-08
the O 0 1.055368414881741e-08
cases O 0 1.0288465190910756e-08
were O 0 2.6062046742936218e-08
familial O 0 2.2698632164974697e-06
, O 0 2.590598136009703e-08
and O 0 1.3068552462414118e-08
five O 0 9.120622479485974e-09
were O 0 2.4533372666724063e-08
sporadic O 0 4.758205250254832e-06
. O 0 8.112964451356675e-07

In O 0 1.2817490642191842e-06
two O 0 6.72857964900686e-08
familial O 0 5.601042630587472e-06
cases O 0 8.493466197023736e-08
and O 0 1.1789710541165732e-08
one O 0 5.4512336866707756e-09
sporadic O 0 1.586155804034206e-06
case O 0 1.0854401466531272e-07
, O 0 1.5230677163913242e-08
mosaicism O 0 2.6331597382522887e-06
for O 0 3.039920670744323e-08
UBE3A O 0 4.4903019443154335e-05
mutations O 0 8.326490387844387e-06
was O 0 5.439862320599786e-07
detected O 0 1.2651886436287896e-06
in O 0 1.759834233894253e-08
the O 0 9.621159868800078e-09
mother O 0 1.9817054663917588e-08
of O 0 3.915784363428543e-10
three O 0 1.932710214092026e-09
AS B-Disease 1 0.9981381893157959
sons O 0 6.756595212209504e-07
, O 0 1.0597632771336407e-09
in O 0 2.5198065856102403e-09
the O 0 2.0819296508989282e-08
maternal O 0 2.2942665509617655e-06
grandfather O 0 2.9920380484327325e-07
of O 0 7.541194890769987e-10
two O 0 1.6962738991210813e-09
AS B-Disease 1 0.9229840636253357
first O 0 4.946877396605487e-08
cousins O 0 1.4656791336165043e-07
, O 0 6.752254866349006e-10
and O 0 7.238172838874846e-10
in O 0 2.1323980359255756e-09
the O 0 7.782452904336878e-09
mother O 0 2.917524888346179e-08
of O 0 4.048963941905015e-10
an O 0 1.046634334755936e-08
AS B-Disease 1 0.9999357461929321
daughter O 0 4.4354987039696425e-05
. O 0 3.869054125971161e-07

The O 0 8.198442174034426e-07
frequencies O 0 2.745507345025544e-06
with O 0 1.697653573273783e-08
which O 0 1.6112350564867484e-08
we O 0 3.772575585259119e-09
detected O 0 2.8747876967827324e-07
mutations O 0 1.4146336013709515e-07
were O 0 9.061321470937855e-09
5 O 0 9.935660294502213e-09
( O 0 3.918550817161304e-09
14 O 0 5.900578248230204e-09
% O 0 8.215420010948549e-10
) O 0 3.4727279385471377e-10
of O 0 3.9249817285202937e-10
35 O 0 4.45580816688107e-09
in O 0 3.9992227307550365e-09
sporadic O 0 1.4486214467979153e-06
cases O 0 1.905129565216157e-08
and O 0 1.541488359180221e-08
8 O 0 4.72480188307145e-08
( O 0 9.296555525395434e-09
80 O 0 1.4835494610565547e-08
% O 0 1.8451410399578094e-09
) O 0 6.860418899634624e-10
of O 0 5.766263577733355e-10
10 O 0 8.041110888257208e-09
in O 0 3.442224993932541e-08
familial O 0 6.074985321902204e-06
cases O 0 1.2092756662696047e-07
. O 0 6.904163996068746e-08
. O 0 3.595242503706686e-07

The O 0 0.0001019877745420672
hemochromatosis B-Disease 1 0.9999998807907104
845 O 0 0.0033538963180035353
G O 0 0.00985198188573122
- O 0 0.0001868880062829703
- O 0 1.0132966963283252e-05
> O 0 7.730777156211843e-07
A O 0 6.845380795539313e-08
and O 0 1.5544884490736877e-08
187 O 0 2.632416453707265e-07
C O 0 9.865321771940216e-06
- O 0 1.7926107830135152e-05
- O 0 3.255549381719902e-05
> O 0 5.3479793677979615e-06
G O 0 5.260204125079326e-05
mutations O 0 1.1181299669260625e-05
: O 0 3.300803186334633e-08
prevalence O 0 4.103046080672357e-07
in O 0 4.1052921062600944e-08
non O 0 2.217156520600838e-07
- O 0 7.439988621626981e-06
Caucasian O 0 5.396971118898364e-06
populations O 0 1.4711589528815239e-06
. O 0 5.59297518520907e-07

Hemochromatosis B-Disease 1 0.9985948204994202
, O 0 9.38644188863691e-06
the O 0 0.00011912565969396383
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 1.0095188684999812e-07
iron I-Disease 1 0.6398127675056458
metabolism I-Disease 0 0.02182365022599697
, O 0 1.045778308395029e-08
leads O 0 2.7196190188760738e-08
, O 0 5.518826728945214e-09
if O 0 1.282333883523279e-08
untreated O 0 7.47511137433321e-07
, O 0 5.223934618214798e-09
to O 0 4.949236753759578e-08
progressive O 0 0.002324771136045456
iron B-Disease 1 0.9941033720970154
overload I-Disease 0 0.06786011159420013
and O 0 6.298573111962469e-07
premature B-Disease 0 0.0002215067361248657
death I-Disease 0 8.685865395818837e-06
. O 0 8.871098771123798e-07

The O 0 2.548571865190752e-05
hemochromatosis B-Disease 1 0.9999998807907104
gene O 0 0.00012700595834758133
, O 0 1.7805352570121613e-07
HFE O 0 7.485286914743483e-05
, O 0 3.546199422999052e-08
recently O 0 3.297393504908541e-07
has O 0 4.336241143931829e-09
been O 0 3.6844249873269064e-09
identified O 0 7.1977015458912774e-09
, O 0 8.367714299239992e-10
and O 0 1.2134658833318213e-09
characterization O 0 1.8588121264428992e-08
of O 0 4.0705136483687454e-10
this O 0 1.8777903676436836e-09
gene O 0 4.778053508402991e-08
has O 0 5.547353243429143e-09
shown O 0 9.064138772885144e-09
that O 0 6.168658917005132e-10
it O 0 9.139442536110209e-10
contains O 0 1.4012000448815343e-09
two O 0 1.6227628130138783e-09
mutations O 0 7.838992388542465e-08
that O 0 1.427814644294756e-09
result O 0 8.019759967226037e-09
in O 0 1.1864695004248915e-08
amino O 0 8.91677629510923e-08
acid O 0 3.7865922308810696e-07
substitutions O 0 4.704909883912478e-07
- O 0 4.988158934793319e-07
cDNA O 0 2.2900539988768287e-06
nucleotides O 0 6.102889074099949e-07
845 O 0 2.8597339678526623e-06
G O 0 1.5297619029297493e-05
- O 0 8.538996553397737e-06
- O 0 5.293594313116046e-06
> O 0 4.1444732801210193e-07
A O 0 1.0535345751350178e-07
( O 0 2.4135703213801207e-08
C282Y O 0 2.919841790571809e-07
) O 0 6.925751527830926e-09
and O 0 4.162898026294215e-09
187 O 0 1.533243505491555e-07
C O 0 8.184636499208864e-06
- O 0 2.125660830643028e-05
- O 0 4.852198617300019e-05
> O 0 6.801106337661622e-06
G O 0 2.9504708436434157e-05
( O 0 2.9216857910796534e-07
H63D O 0 3.295447459095158e-05
) O 0 2.8183023914607475e-07
. O 0 3.961977199651301e-07

Although O 0 0.00021102804748807102
hemochromatosis B-Disease 1 1.0
is O 0 2.631083475534979e-07
common O 0 1.1294566348851731e-07
in O 0 4.857797719637347e-08
Caucasians O 0 4.341129908880248e-07
, O 0 1.9780536320013198e-08
affecting O 0 2.317069771606839e-07
> O 0 7.704780387030041e-07
= O 0 5.567505354520108e-07
1 O 0 1.1788748111030145e-07
/ O 0 7.313087166949117e-07
300 O 0 1.1920041842472529e-08
individuals O 0 4.896238414708876e-10
of O 0 4.717853885338741e-10
northern O 0 1.1893039442156805e-08
European O 0 1.2210959354774786e-08
origin O 0 4.996573821358652e-09
, O 0 1.1214551509652892e-09
it O 0 2.6676667541636334e-09
has O 0 2.8970394971850055e-09
not O 0 6.747246650284922e-10
been O 0 8.81715533918026e-10
recognized O 0 7.219504438715774e-10
in O 0 1.9854535793228933e-09
other O 0 2.6019515431130458e-09
populations O 0 8.462419032184698e-08
. O 0 1.618986260609745e-07

The O 0 1.0582215281829122e-06
present O 0 1.839878081000279e-07
study O 0 3.9202422641437806e-08
used O 0 5.7142528930853587e-08
PCR O 0 7.60022612666944e-06
and O 0 3.452219132782375e-08
restriction O 0 3.659417586732161e-07
- O 0 3.8625361753474863e-07
enzyme O 0 2.508467673578707e-07
digestion O 0 2.7356071541362326e-07
to O 0 6.541942099147491e-09
analyze O 0 3.254802649621524e-08
the O 0 3.1834690439325186e-09
frequency O 0 1.1394033805345316e-07
of O 0 1.648943204202169e-09
the O 0 2.2651002851148405e-08
845 O 0 1.2997837757211528e-06
G O 0 2.1152063709450886e-05
- O 0 5.45243892702274e-06
- O 0 2.479068371030735e-06
> O 0 1.3666999620909337e-07
A O 0 3.974556150865283e-08
and O 0 1.213758160645284e-08
187 O 0 1.3803779097543156e-07
C O 0 9.222801963915117e-06
- O 0 1.2852404324803501e-05
- O 0 1.3259709703561384e-05
> O 0 2.667058197403094e-06
G O 0 1.2413935110089369e-05
mutations O 0 2.267795025545638e-06
in O 0 1.2743005584070488e-07
HLA O 0 1.882639480754733e-05
- O 0 7.460469078068854e-07
typed O 0 4.1160069486068096e-07
samples O 0 3.758142241849782e-08
from O 0 9.633021491595173e-09
non O 0 1.816577110957951e-08
- O 0 3.217076880446257e-07
Caucasian O 0 1.8171078863815637e-07
populations O 0 1.7642369343207065e-08
, O 0 9.343089635294177e-10
comprising O 0 1.6683201486955568e-09
Australian O 0 5.502041933169721e-09
Aboriginal O 0 7.786847611157555e-09
, O 0 7.4943207195588e-10
Chinese O 0 9.34558430643051e-10
, O 0 1.9102082138289234e-09
and O 0 1.3112170904605591e-08
Pacific O 0 5.104229217067768e-07
Islanders O 0 1.0434915566293057e-05
. O 0 6.316793701444112e-07

Results O 0 3.1781630241312087e-05
showed O 0 3.954505700676236e-06
that O 0 2.0302215020251424e-08
the O 0 3.8594276219328094e-08
845 O 0 2.3688805868005147e-06
G O 0 2.6318757591070607e-05
- O 0 8.352138138434384e-06
- O 0 2.691577719815541e-06
> O 0 5.863993806087819e-07
A O 0 1.987069140341191e-07
mutation O 0 8.216617288780981e-07
was O 0 7.514496047633656e-08
present O 0 3.170011808606432e-09
in O 0 1.934620685872801e-09
these O 0 1.0153594631745477e-09
populations O 0 7.423900605374456e-09
( O 0 6.0295017867417755e-09
allele O 0 1.705124645923206e-07
frequency O 0 3.0426184594034567e-07
0 O 0 2.001786469918443e-08
. O 0 1.997532805830815e-09
32 O 0 1.1281944267693689e-08
% O 0 1.5627104055226937e-09
) O 0 7.553214720346091e-10
, O 0 7.844220273334201e-10
and O 0 2.3305954943708684e-09
, O 0 1.2282523886852914e-09
furthermore O 0 5.77388226119524e-09
, O 0 1.4689549576729632e-09
it O 0 1.1083565176761567e-08
was O 0 1.022519654725329e-06
always O 0 4.814873388880869e-09
seen O 0 5.001493885714581e-09
in O 0 2.020007716652117e-09
conjunction O 0 4.000963826911175e-08
with O 0 3.178344343268691e-08
HLA O 0 6.307478543021716e-06
haplotypes O 0 9.056777798832627e-07
common O 0 4.332927616701454e-08
in O 0 4.205565318216031e-08
Caucasians O 0 2.090664708020995e-07
, O 0 2.986038527552637e-09
suggesting O 0 3.166810458310465e-08
that O 0 4.698307076722585e-09
845 O 0 8.035960377128504e-07
G O 0 1.3612561815534718e-05
- O 0 4.671289389079902e-06
- O 0 5.807876277685864e-06
> O 0 5.005476282349264e-07
A O 0 8.887976719051949e-07
may O 0 2.2371696104528382e-06
have O 0 1.7990152700875228e-09
been O 0 2.1162835928123513e-09
introduced O 0 1.2631876877833292e-08
into O 0 1.5858155899550752e-09
these O 0 1.2260241710748687e-09
populations O 0 6.709776290136915e-09
by O 0 1.1702514512990092e-08
Caucasian O 0 9.92363538898644e-07
admixture O 0 5.91509933656198e-06
. O 0 1.2164696272520814e-06

187 O 0 0.00016467996465507895
C O 0 0.00026884887483902276
- O 0 3.236237171222456e-05
- O 0 8.858613909978885e-06
> O 0 2.4728440166654764e-06
G O 0 1.4506963452731725e-05
was O 0 2.1861428933789284e-07
present O 0 4.443976742152245e-09
at O 0 9.91052573340312e-09
an O 0 1.8421414393898772e-09
allele O 0 2.0448695181585208e-07
frequency O 0 2.8528293682938966e-07
of O 0 1.3554740441179547e-08
2 O 0 2.908522276356962e-07
. O 0 4.310091696879681e-07

68 O 0 1.2972095646546222e-05
% O 0 1.636087603174019e-07
in O 0 1.190143539275823e-08
the O 0 4.819899590557952e-09
two O 0 3.288014527313976e-09
populations O 0 2.3677454663584285e-08
analyzed O 0 1.456724305626267e-07
( O 0 1.5631941963079043e-08
Australian O 0 2.8977153121445554e-08
Aboriginal O 0 2.4170574874915474e-08
and O 0 3.9683576424920375e-09
Chinese O 0 8.21970402853367e-09
) O 0 5.697416582961523e-08
. O 0 2.081183936297748e-07

In O 0 1.9027075950361905e-06
the O 0 9.863967420642439e-08
Australian O 0 1.5779843920427084e-07
Aboriginal O 0 6.751294989726375e-08
samples O 0 5.155096260978098e-08
, O 0 6.354433423894079e-09
187 O 0 1.5596597791045497e-07
C O 0 2.981933221235522e-06
- O 0 5.085443717689486e-06
- O 0 7.5478519647731446e-06
> O 0 9.889510010907543e-07
G O 0 1.0166730135097168e-05
was O 0 2.181615172958118e-07
found O 0 5.665111046937454e-09
to O 0 2.052851666434208e-09
be O 0 3.0616409407713263e-09
associated O 0 1.645943115136106e-08
with O 0 2.4413267851741693e-08
HLA O 0 9.99091389530804e-06
haplotypes O 0 7.546323104179464e-07
common O 0 4.101691786217998e-08
in O 0 2.9636389342613256e-08
Caucasians O 0 1.2300891683025839e-07
, O 0 2.2218136219720463e-09
suggesting O 0 2.3962314799064188e-08
that O 0 2.0545556367324025e-09
it O 0 4.164121047978142e-09
was O 0 4.3359950296917305e-08
introduced O 0 3.386531943760929e-08
by O 0 5.114683343521165e-09
recent O 0 1.2879108624019864e-07
admixture O 0 2.599699200800387e-06
. O 0 8.315645345646772e-07

In O 0 1.1470814342828817e-06
the O 0 4.5383060864878644e-08
Chinese O 0 1.2017106421069457e-08
samples O 0 3.1734558092466614e-08
analyzed O 0 7.462078599473898e-08
, O 0 5.086790988428902e-09
187 O 0 8.234426474018619e-08
C O 0 2.12544887290278e-06
- O 0 4.210736733512022e-06
- O 0 5.287131443765247e-06
> O 0 9.742558404468582e-07
G O 0 1.592217267898377e-05
was O 0 4.457153863768326e-07
present O 0 9.94718973856834e-09
in O 0 8.356043856849737e-09
association O 0 6.934118612633711e-09
with O 0 1.2844015850888013e-09
a O 0 6.579119027350089e-09
wide O 0 1.3216295613460716e-08
variety O 0 1.1045029779666038e-08
of O 0 7.298509352438032e-09
HLA O 0 2.5805729819694534e-06
haplotypes O 0 1.999242158490233e-07
, O 0 2.782237551457456e-09
showing O 0 5.583809326026312e-08
this O 0 3.722186558974272e-09
mutation O 0 7.105169430587921e-08
to O 0 4.051670110527539e-09
be O 0 2.050315917045964e-09
widespread O 0 9.726479177629699e-09
and O 0 7.356397269120407e-09
likely O 0 4.106561135586162e-08
to O 0 4.380289464478437e-09
predate O 0 2.72697491254803e-07
the O 0 4.746413928558013e-09
more O 0 2.7690711945638213e-09
genetically O 0 5.980460571208823e-08
restricted O 0 8.217685376621375e-08
845 O 0 2.4883061087166425e-06
G O 0 4.853059726883657e-05
- O 0 1.3729559213970788e-05
- O 0 7.967350938997697e-06
> O 0 1.519468810329272e-06
A O 0 5.828144935549062e-07
mutation O 0 1.210599748446839e-05
. O 0 7.156062338253832e-07

Genotype O 0 0.034920573234558105
- O 0 0.013816997408866882
phenotype O 0 0.00469448696821928
correlations O 0 0.0005414221668615937
in O 0 0.00013437811867333949
attenuated B-Disease 1 0.9999963045120239
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 1.0
. O 0 0.00027184729697182775

Germ O 0 0.018630046397447586
- O 0 0.0022595999762415886
line O 0 3.086803917540237e-05
mutations O 0 3.882414603140205e-06
of O 0 9.535750855604874e-09
the O 0 6.14732371673199e-08
tumor B-Disease 0 2.4238539481302723e-05
suppressor O 0 0.00012931243691127747
APC O 0 7.791085408825893e-06
are O 0 5.108534040232371e-08
implicated O 0 5.268050699669402e-06
in O 0 8.02694648882607e-06
attenuated B-Disease 1 0.9999985694885254
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.0598842054605484
AAPC B-Disease 1 1.0
) O 0 4.797413453161425e-07
, O 0 2.323224990163908e-08
a O 0 1.3215117178333458e-07
variant O 0 0.001430576085112989
of O 0 6.9196939875837415e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.0009991393890231848
FAP B-Disease 0 0.0013381444150581956
) O 0 4.78682886750903e-06
. O 0 2.139460775651969e-06

AAPC B-Disease 1 0.9999982118606567
is O 0 1.9924632397305686e-06
recognized O 0 1.0757880630762884e-07
by O 0 1.807211624793581e-08
the O 0 1.1239139396934661e-08
occurrence O 0 2.8398596896295203e-07
of O 0 2.216921224373891e-08
< O 0 6.72429393944185e-07
100 O 0 1.1716321068888647e-07
colonic B-Disease 0 1.4870367522235028e-05
adenomas I-Disease 0 9.96178096102085e-06
and O 0 4.190008340287932e-08
a O 0 1.71092509049231e-07
later O 0 1.1664311386994086e-05
onset O 1 0.9628845453262329
of O 0 0.2842065095901489
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.1548903532675467e-06
age O 0 4.289142623292719e-07
> O 0 3.262557015659695e-07
40 O 0 1.205420829819559e-07
years O 0 6.889167991630529e-08
) O 0 1.280804156067461e-07
. O 0 3.661589005332644e-07

The O 0 4.873082275480556e-07
aim O 0 3.0944491413720243e-07
of O 0 3.0007516471641793e-09
this O 0 4.201762937583453e-09
study O 0 8.535653961416756e-09
was O 0 7.733890328154303e-08
to O 0 2.1725167442809834e-08
assess O 0 1.3693291975869215e-06
genotype O 0 6.359801773214713e-05
- O 0 8.80961015354842e-05
phenotype O 0 7.488077972084284e-05
correlations O 0 4.894754056294914e-06
in O 0 2.8114941414969508e-06
AAPC B-Disease 1 0.9999994039535522
families O 0 1.0388498594693374e-06
. O 0 1.2064735983585706e-06

By O 0 2.3339612198469695e-06
protein O 0 5.450702701637056e-06
- O 0 5.290767603582935e-06
truncation O 0 1.8396640371065587e-05
test O 0 2.878992972910055e-06
( O 0 2.10270584943828e-07
PTT O 0 1.8640366761246696e-06
) O 0 1.5676191011948504e-08
assay O 0 3.6704588524116843e-07
, O 0 2.0651202969901306e-09
the O 0 4.612058734920765e-09
entire O 0 3.642092494260396e-08
coding O 0 2.6176138590017217e-07
region O 0 1.0962986962681498e-08
of O 0 1.2076887268008818e-09
the O 0 1.4343363829993905e-08
APC B-Disease 0 5.206241553423752e-07
gene O 0 2.4909127205319237e-07
was O 0 1.3083719352380285e-07
screened O 0 1.146755082004347e-07
in O 0 8.247830862728733e-09
affected O 0 2.22234444180458e-08
individuals O 0 3.7049319168147576e-09
from O 0 2.6257538365825894e-08
11 O 0 5.545979888665897e-07
AAPC B-Disease 1 0.9999972581863403
kindreds O 0 7.79091442382196e-06
, O 0 1.3041261404111992e-08
and O 0 2.127498621717905e-09
their O 0 4.89863216657227e-09
phenotypic O 0 3.418455492010253e-07
differences O 0 2.743094569268578e-07
were O 0 2.468352704454446e-07
examined O 0 1.0024996299762279e-05
. O 0 9.974967269954504e-07

Five O 0 4.7400521907547954e-06
novel O 0 7.89960722613614e-06
germ O 0 0.00013861246407032013
- O 0 0.00019486868404783309
line O 0 0.00022226772853173316
APC B-Disease 0 2.2030837499187328e-05
mutations O 0 3.927576472051442e-06
were O 0 2.461755777005692e-08
identified O 0 9.171337467250851e-08
in O 0 4.885236037921459e-08
seven O 0 2.1737896815920976e-07
kindreds O 0 3.6411667679203674e-05
. O 0 9.66043785410875e-07

Mutations O 0 0.0006880559958517551
were O 0 7.221176474558888e-07
located O 0 2.9727857508987654e-07
in O 0 1.552328576792661e-08
three O 0 2.2159816204236904e-09
different O 0 2.414931810079679e-09
regions O 0 1.661525139695641e-08
of O 0 1.8551912228659262e-09
the O 0 2.3553855754698816e-08
APC B-Disease 0 9.612007261239341e-07
gene O 0 4.414440866185032e-07
( O 0 1.2751461220261717e-08
1 O 0 9.085463048563724e-09
) O 0 1.5994883195702414e-09
at O 0 1.666876769945702e-08
the O 0 1.0363423896819768e-08
5 O 0 2.8819403752322614e-08
end O 0 7.836391091586847e-08
spanning O 0 5.4830621820656233e-08
exons O 0 2.1570912167589995e-07
4 O 0 2.5883359455747268e-08
and O 0 4.6726138513975e-09
5 O 0 2.123931608366547e-08
, O 0 3.1636333552853557e-09
( O 0 2.4196069592363756e-09
2 O 0 5.4972164598154905e-09
) O 0 1.7262823392982796e-09
within O 0 5.704797079175705e-09
exon O 0 2.298295243008397e-07
9 O 0 7.939478052776394e-08
, O 0 2.66532218518023e-09
and O 0 8.566545695032346e-09
( O 0 1.1992148607475883e-08
3 O 0 2.0121680321949498e-08
) O 0 2.530131881783859e-09
at O 0 2.6482311454856244e-08
the O 0 1.3973709300785231e-08
3 O 0 6.250516548789165e-08
distal O 0 1.4478797538686194e-06
end O 0 7.21167978667836e-08
of O 0 2.132763965434492e-09
the O 0 2.6101098171693593e-08
gene O 0 2.0322474938438972e-06
. O 0 2.655102662174613e-07

Variability O 0 0.00017129251500591636
in O 0 5.996440108901879e-07
the O 0 1.2554778550111223e-07
number O 0 3.9801545170803365e-08
of O 0 1.1364942338332185e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 3.600312629714608e-05
most O 0 5.4380033809309225e-09
apparent O 0 2.9676266777300953e-08
in O 0 9.243424692328972e-09
individuals O 0 4.985167278981351e-10
with O 0 3.7149729958940725e-09
mutations O 0 2.7670088798004144e-07
in O 0 2.1214416889847598e-08
region O 0 6.509880989824524e-08
1 O 0 4.231280215094557e-08
, O 0 5.569139371885967e-09
and O 0 4.6369169837134905e-08
upper O 1 0.958930253982544
- O 1 0.9956701993942261
gastrointestinal O 1 0.6041334271430969
manifestations O 0 2.453310116834473e-06
were O 0 6.72046027716533e-08
more O 0 6.193479062943652e-09
severe O 0 2.9768854801659472e-05
in O 0 1.0288488994092404e-07
them O 0 5.3147108047824076e-08
. O 0 2.3988067709979077e-07

In O 0 1.897798256322858e-06
individuals O 0 5.312490714004525e-08
with O 0 3.6775531953026075e-08
mutations O 0 1.4290026228991337e-06
in O 0 2.1388798288057842e-08
either O 0 3.521892821822803e-08
region O 0 6.816703290724035e-08
2 O 0 4.944226716929734e-08
or O 0 2.813559163428181e-08
region O 0 3.3813940092386474e-08
3 O 0 1.8241880894720452e-08
, O 0 9.095948994009007e-10
the O 0 2.242115604289552e-09
average O 0 1.152084205813253e-08
number O 0 1.5118774010502989e-09
of O 0 1.8155302816680319e-09
adenomas B-Disease 0 7.204804433058598e-07
tended O 0 5.336468689165486e-07
to O 0 1.158209261831189e-08
be O 0 3.380876689718093e-09
lower O 0 7.455561217284412e-07
than O 0 1.0812322148723297e-09
those O 0 3.7222555593352524e-10
in O 0 7.866994278238337e-10
individuals O 0 2.2175195013574012e-10
with O 0 1.309529373827445e-09
mutations O 0 1.1327671955996266e-07
in O 0 9.879799200973594e-09
region O 0 2.2504501373532548e-08
1 O 0 1.976711061502101e-08
, O 0 1.9841135401321708e-09
although O 0 9.356611485600297e-09
age O 0 2.5725174879198676e-08
at O 0 6.104839371801063e-07
diagnosis O 0 5.493718708748929e-05
was O 0 1.6273063465632731e-06
similar O 0 7.192152793322748e-07
. O 0 6.818802944508207e-07

In O 0 8.532271749572828e-06
all O 0 5.215932219471142e-07
AAPC B-Disease 1 0.9999607801437378
kindreds O 0 1.4775587260373868e-05
, O 0 2.5468080977475438e-08
a O 0 2.064849446981043e-08
predominance O 0 7.795661076670513e-07
of O 0 2.9687871716532754e-08
right O 0 0.035630002617836
- O 1 0.9999973773956299
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.0006893720128573477
rectal B-Disease 1 0.999112069606781
polyp I-Disease 0 0.03992490842938423
sparing O 0 1.0405580724182073e-05
was O 0 6.31724287813995e-06
observed O 0 3.144060201520915e-06
. O 0 1.1170343441335717e-06

No O 0 3.693225153256208e-05
desmoid B-Disease 1 0.5220803022384644
tumors I-Disease 1 1.0
were O 0 7.511715125474439e-07
found O 0 1.316508928539406e-07
in O 0 5.1644455822952295e-08
these O 0 8.76565167118315e-08
kindreds O 0 1.6454383512609638e-05
. O 0 6.287739893195976e-07

Our O 0 1.8177819356424152e-06
data O 0 6.717474434481119e-07
suggest O 0 1.292337685754319e-07
that O 0 5.280917481087499e-09
, O 0 2.6883228976259943e-09
in O 0 5.032692484974177e-08
AAPC B-Disease 1 0.9999996423721313
families O 0 2.774708462993658e-08
, O 0 1.2168173135762572e-09
the O 0 1.4925031210921702e-09
location O 0 2.6674035424889553e-08
of O 0 2.030809076458695e-09
the O 0 7.997018514060983e-08
APC B-Disease 0 1.3438480891636573e-05
mutation O 0 5.420006345957518e-06
may O 0 1.1137220781165524e-06
partially O 0 1.1544597100510146e-06
predict O 0 6.762571160834341e-07
specific O 0 1.9422016350745253e-07
phenotypic O 0 1.058158613886917e-05
expression O 0 6.054782261344371e-06
. O 0 1.4000461305840872e-06

This O 0 6.090916713219485e-07
should O 0 7.976954918831325e-08
help O 0 1.0733015365360643e-08
in O 0 5.743259645640819e-09
the O 0 8.149563690551531e-09
design O 0 1.185576437023883e-07
of O 0 2.5293696026551515e-09
tailored O 0 1.615936639609572e-06
clinical O 0 1.3205117284087464e-06
- O 0 0.0005069588660262525
management O 0 7.783492605994979e-07
protocols O 0 2.848403539701394e-07
in O 0 9.960308133827311e-09
this O 0 3.092275990823623e-09
subset O 0 3.196814546413407e-08
of O 0 1.3172757995505435e-08
FAP B-Disease 0 1.0820809620781802e-05
patients O 0 5.516082524081867e-07
. O 0 5.8241340639142436e-08
. O 0 4.2757184814945504e-07

Wilms B-Disease 0 0.2792537808418274
' I-Disease 0 0.00015501693997066468
tumor I-Disease 0 0.0002701317425817251
1 O 0 1.516561951575568e-06
and O 0 3.80259848498099e-07
Dax O 1 0.9994039535522461
- O 0 1.370252084598178e-05
1 O 0 1.4126275971193536e-07
modulate O 0 3.0785356557316845e-06
the O 0 8.187426914219031e-08
orphan O 0 1.809804302865814e-06
nuclear O 0 1.2005076541754534e-06
receptor O 0 2.6922248252958525e-06
SF O 0 0.00020315790607128292
- O 0 2.196274863308645e-06
1 O 0 4.401127995379284e-08
in O 0 2.1371141301074204e-08
sex O 0 1.0913087322705906e-07
- O 0 2.0536639055990236e-07
specific O 0 8.179077326531115e-08
gene O 0 1.1715712844306836e-06
expression O 0 7.534529800068412e-07
. O 0 4.0373123511017184e-07

Products O 0 8.375357538170647e-06
of O 0 2.066043833792719e-07
steroidogenic O 0 3.7963032809784636e-05
factor O 0 8.572103524784325e-07
1 O 0 2.204764655289182e-07
( O 0 4.146189098719333e-07
SF O 0 0.004756610374897718
- O 0 8.568477824155707e-06
1 O 0 1.2883850786238327e-07
) O 0 3.259343728245767e-08
and O 0 9.377769316643025e-08
Wilms B-Disease 0 8.48943818709813e-05
tumor I-Disease 0 3.2282441679853946e-05
1 O 0 1.4094302969169803e-07
( O 0 4.515149498729443e-08
WT1 O 0 5.169420546735637e-06
) O 0 1.2838756724420364e-08
genes O 0 2.9745118368396106e-08
are O 0 7.775474708537899e-10
essential O 0 1.5991589163988351e-09
for O 0 1.7706883737034218e-09
mammalian O 0 3.1881864970273455e-07
gonadogenesis O 0 1.675283897384361e-06
prior O 0 8.582003374613123e-08
to O 0 3.1738252914692566e-08
sexual O 0 3.1530754540654016e-07
differentiation O 0 2.2861809156893287e-06
. O 0 1.0453753702677204e-06

In O 0 4.296792667446425e-06
males O 0 3.5205541735194856e-06
, O 0 1.5685111520724604e-07
SF O 0 0.0005646042409352958
- O 0 3.96145878767129e-06
1 O 0 4.022634314537754e-08
participates O 0 3.531242498411302e-08
in O 0 6.16928597096944e-09
sexual O 0 1.9542182982945633e-08
development O 0 5.181996609593398e-09
by O 0 3.4180813734963067e-09
regulating O 0 1.3172663670957263e-07
expression O 0 3.489463296091344e-08
of O 0 2.8081319491946033e-09
the O 0 4.036014189523485e-08
polypeptide O 0 9.431612852495164e-06
hormone O 0 9.062878234544769e-06
Mullerian O 0 2.942502214864362e-05
inhibiting O 0 8.4805988080916e-06
substance O 0 8.238938789872918e-06
( O 0 8.839557494866312e-07
MIS O 0 9.90016560535878e-05
) O 0 8.212410307351092e-07
. O 0 8.555377917218721e-07

Here O 0 3.918503807653906e-06
, O 0 7.03048712580312e-08
we O 0 1.2482949784953234e-08
show O 0 1.1130854460361661e-07
that O 0 1.961907969416643e-08
WT1 O 0 3.848670166917145e-05
- O 0 5.471503754961304e-06
KTS O 0 2.197678441007156e-05
isoforms O 0 2.008799128816463e-06
associate O 0 1.0708441067208696e-07
and O 0 1.285431583397667e-08
synergize O 0 3.2579257549514296e-06
with O 0 1.1026784818568558e-07
SF O 0 0.19221223890781403
- O 0 1.3149987353244796e-05
1 O 0 8.443732468776943e-08
to O 0 2.9044050720017367e-08
promote O 0 1.8799920553647098e-07
MIS O 0 3.573478170437738e-05
expression O 0 1.6827937088237377e-06
. O 0 5.401664111559512e-07

In O 0 1.2562780284497421e-05
contrast O 0 1.2155255717516411e-05
, O 0 5.190962042433966e-07
WT1 O 0 0.0004312064265832305
missense O 0 0.0003010626242030412
mutations O 0 6.196014146553352e-05
, O 0 4.1576392106890125e-08
associated O 0 8.167525322733127e-08
with O 0 4.876578074686222e-08
male B-Disease 0 8.727695899324317e-07
pseudohermaphroditism I-Disease 1 0.9999991655349731
in O 0 2.246847543574404e-05
Denys B-Disease 1 0.9999382495880127
- I-Disease 1 0.999981164932251
Drash I-Disease 1 0.999997615814209
syndrome I-Disease 1 1.0
, O 0 5.7814009579715275e-08
fail O 0 9.802708973438712e-07
to O 0 3.780638380135315e-08
synergize O 0 7.836576514819171e-06
with O 0 5.017233206672245e-07
SF O 1 0.8034844398498535
- O 0 7.605423161294311e-05
1 O 0 1.1357033145031892e-06
. O 0 6.538576826642384e-07

Additionally O 0 7.94640709500527e-06
, O 0 1.0428447438926014e-07
the O 0 7.368505805516179e-08
X O 0 0.0001268339838134125
- O 0 1.888627593871206e-05
linked O 0 5.466908532980597e-06
, O 0 1.2118336556454778e-08
candidate O 0 1.0638450476108119e-07
dosage O 0 9.451692676520906e-06
- O 0 6.470838798122713e-06
sensitive O 0 8.700075341039337e-06
sex O 0 6.504704970211606e-07
- O 0 4.082881730482768e-07
reversal O 0 5.060525154476636e-07
gene O 0 4.0426792224934616e-07
, O 0 1.222149048629717e-08
Dax O 1 0.8802785277366638
- O 0 1.1954145975323627e-06
1 O 0 2.932588571979977e-08
, O 0 7.4210557698961566e-09
antagonizes O 0 1.123956735682441e-06
synergy O 0 4.1346356738358736e-07
between O 0 1.5234286365739536e-07
SF O 0 0.004073587246239185
- O 0 4.690713012678316e-06
1 O 0 5.485059872967213e-08
and O 0 8.986622113127396e-09
WT1 O 0 1.828370159273618e-06
, O 0 1.963771589785779e-09
most O 0 1.0670203609564055e-09
likely O 0 4.785146501262716e-09
through O 0 2.5001638537247572e-09
a O 0 4.615631432614009e-09
direct O 0 1.4449297758289958e-08
interaction O 0 3.1967474001248775e-08
with O 0 1.4738704123828938e-07
SF O 0 0.31754785776138306
- O 0 3.814964657067321e-05
1 O 0 1.1517148550410639e-06
. O 0 6.023883543093689e-07

We O 0 2.8390466013661353e-06
propose O 0 8.819280992611311e-06
that O 0 7.411581037786164e-08
WT1 O 0 1.7457350622862577e-05
and O 0 1.6352952059150994e-07
Dax O 1 0.9984013438224792
- O 0 1.2022504961350933e-05
1 O 0 6.607907465649987e-08
functionally O 0 1.8756672659492324e-07
oppose O 0 3.705046935920109e-08
each O 0 1.9329609024509864e-09
other O 0 1.0507903436263177e-09
in O 0 1.0825410790005208e-08
testis O 0 1.101809743886406e-06
development O 0 1.963229401269473e-08
by O 0 8.205515200643276e-08
modulating O 0 0.00016125754336826503
SF O 0 0.15053896605968475
- O 0 3.184740853612311e-05
1 O 0 4.522622418789979e-07
- O 0 2.8514714358607307e-06
mediated O 0 1.3878843674319796e-05
transactivation O 0 2.6493171390029602e-05
. O 0 2.764368787211424e-07
. O 0 6.078417982280371e-07

A O 0 2.0859755750279874e-05
mouse O 0 0.00022055271256249398
model O 0 4.369064117781818e-05
for O 0 7.2244388320541475e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9976275563240051
- O 0 0.46817803382873535
centre O 0 0.0003054747066926211
mutations O 0 0.00016063768998719752
. O 0 2.1471953459695214e-06

Imprinting O 0 0.0008179959841072559
in O 0 2.7090011371910805e-06
the O 0 1.4632196609909442e-07
15q11 O 0 4.659090336645022e-06
- O 0 1.8732284843281377e-06
q13 O 0 2.6345837795815896e-06
region O 0 1.8573507531982614e-07
involves O 0 4.1372143044782206e-08
an O 0 2.6750358372851224e-08
imprinting O 0 1.8606710000312887e-05
centre O 0 3.071392029596609e-06
( O 0 3.853190477798307e-08
IC O 0 1.1296240245428635e-06
) O 0 3.3770870544458376e-09
, O 0 8.338240098382244e-10
mapping O 0 1.9285353758391466e-08
in O 0 5.135358360774944e-09
part O 0 4.492280325507636e-09
to O 0 3.4724514375028548e-09
the O 0 8.922829586310854e-09
promoter O 0 2.804462155836518e-07
and O 0 4.449209445311908e-09
first O 0 1.4883506871399277e-08
exon O 0 6.621179977628344e-07
of O 0 3.803014791969872e-08
SNRPN O 0 0.0001891641441034153
. O 0 2.8407093850546516e-06

Deletion O 0 0.00011106013698736206
of O 0 5.608443416349473e-07
this O 0 2.3626934364529006e-07
IC O 0 3.8231515645748004e-05
abolishes O 0 3.036419911950361e-05
local O 0 3.987677814620838e-07
paternally O 0 7.4993772614107e-06
derived O 0 1.6352451837065018e-07
gene O 0 8.941843248067016e-07
expression O 0 1.2987524655727611e-07
and O 0 3.8284586167947054e-08
results O 0 2.0657889763242565e-06
in O 0 0.0014006684068590403
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00011459653615020216
PWS B-Disease 1 1.0
) O 0 3.078388772337348e-06
. O 0 1.4993510148997302e-06

We O 0 1.5398978803204955e-06
have O 0 7.056576123432023e-08
created O 0 6.834148535972417e-08
two O 0 1.961238282888189e-08
deletion O 0 1.9265630726295058e-06
mutations O 0 1.7680927157925908e-06
in O 0 1.9058387579207192e-07
mice O 0 0.00017556670354679227
to O 0 4.5014218130745576e-07
understand O 0 1.3028229659539647e-06
PWS B-Disease 1 1.0
and O 0 4.4039662583372774e-08
the O 0 5.041634221214508e-09
mechanism O 0 3.2870005384211254e-08
of O 0 2.4166184608986896e-09
this O 0 2.5641407219723078e-08
IC O 0 2.4702190785319544e-05
. O 0 4.772197144120582e-07

Mice O 0 0.011084171012043953
harbouring O 0 0.0001602017437107861
an O 0 3.2882553568924777e-07
intragenic O 0 2.4804594431770965e-05
deletion O 0 5.841661732119974e-06
in O 0 1.1982824332790187e-07
Snrpn O 0 1.3284758097142912e-05
are O 0 2.2910137786880114e-08
phenotypically O 0 2.4614914764242712e-06
normal O 0 4.3267178284622787e-07
, O 0 8.142820639989168e-09
suggesting O 0 6.358473569889611e-08
that O 0 2.7719406769932675e-09
mutations O 0 7.175690086569375e-08
of O 0 9.946804491178796e-10
SNRPN O 0 3.1566064535581972e-06
are O 0 2.0325219285410867e-09
not O 0 1.3575872648274867e-09
sufficient O 0 1.4374695211927246e-08
to O 0 5.72651650543321e-08
induce O 0 2.2700693079968914e-05
PWS B-Disease 1 0.9999997615814209
. O 0 4.393840754346456e-06

Mice O 0 0.0005929262842983007
with O 0 2.6201013270110707e-07
a O 0 1.7057230650152633e-07
larger O 0 2.2115791864507628e-07
deletion O 0 2.0300026335462462e-06
involving O 0 7.890700004509199e-08
both O 0 4.3192965648586323e-08
Snrpn O 0 3.7369031815615017e-06
and O 0 3.689799754624801e-08
the O 0 1.9034993670175027e-07
putative O 0 0.0001065250180545263
PWS O 1 1.0
- O 0 0.01661224290728569
IC O 0 0.00010449791443534195
lack O 0 1.7860759271570714e-07
expression O 0 4.5059270092906445e-08
of O 0 2.238253138386881e-09
the O 0 2.0365238384556505e-08
imprinted O 0 4.8602996685076505e-06
genes O 0 3.829050569947867e-07
Zfp127 O 0 3.0949795473134145e-06
( O 0 1.0893497659481e-07
mouse O 0 3.2297959933202947e-06
homologue O 0 4.215176431898726e-06
of O 0 2.103198859515487e-08
ZNF127 O 0 7.984648618730716e-06
) O 0 3.889971722514929e-08
, O 0 1.2906644641930143e-08
Ndn O 0 1.1510843251016922e-05
and O 0 5.61933433118611e-08
Ipw O 0 1.531629095552489e-05
, O 0 1.618957945481725e-08
and O 0 8.6526918963159e-09
manifest O 0 1.5154472521317075e-07
several O 0 2.8884890923563944e-08
phenotypes O 0 2.4759826828812947e-06
common O 0 9.184008717966208e-07
to O 0 4.117331627639942e-05
PWS B-Disease 1 1.0
infants O 1 0.9830583333969116
. O 0 3.658249170257477e-06

These O 0 3.7546462294812954e-07
data O 0 3.165434065977024e-07
demonstrate O 0 6.843475119922005e-08
that O 0 1.4404547554747182e-09
both O 0 9.485805474440667e-10
the O 0 1.0507201775311614e-09
position O 0 5.814773995638234e-09
of O 0 2.8326499479369716e-10
the O 0 2.428428569345442e-09
IC O 0 7.202303891062911e-07
and O 0 3.0107674131585327e-09
its O 0 7.996725059911114e-09
role O 0 5.560361504564071e-09
in O 0 2.426877365735436e-09
the O 0 2.49857157186284e-09
coordinate O 0 2.0065151318249264e-08
expression O 0 1.4378232826572912e-08
of O 0 1.1396674715058452e-09
genes O 0 1.876563082703342e-08
is O 0 1.62824431715336e-09
conserved O 0 1.6490636411958803e-08
between O 0 4.549840060263932e-09
mouse O 0 1.9322874322824646e-06
and O 0 7.406434132661843e-09
human O 0 1.4309854412530854e-09
, O 0 9.224345176583881e-10
and O 0 8.523480810040951e-10
indicate O 0 1.6800015600892948e-08
that O 0 6.37768282629736e-10
the O 0 4.781114171237277e-09
mouse O 0 6.027423182786151e-07
is O 0 1.2333442045431298e-09
a O 0 1.977336072656044e-09
suitable O 0 9.869816963714584e-09
model O 0 8.081907054702242e-08
system O 0 1.3551127153732523e-07
in O 0 5.2121404969796e-09
which O 0 4.140504383798316e-09
to O 0 1.3709936519390453e-09
investigate O 0 5.1105195630896105e-09
the O 0 1.4886678556536026e-09
molecular O 0 2.9224985098608158e-08
mechanisms O 0 2.4229150241694697e-08
of O 0 1.5199268510457387e-09
imprinting O 0 6.589984309357533e-07
in O 0 1.2460493969967956e-08
this O 0 2.1897426094596995e-09
region O 0 6.547209885354732e-09
of O 0 9.028917058451214e-10
the O 0 1.4803074321889653e-08
genome O 0 3.2958686801976e-07
. O 0 4.296355982091882e-08
. O 0 1.3954776534319535e-07

Mutations O 0 0.00011316853488096967
of O 0 1.4796277980622108e-07
the O 0 1.8886609609580773e-07
ATM O 0 2.330479401280172e-05
gene O 0 6.751797172910301e-06
detected O 0 2.150079126295168e-05
in O 0 1.1769285492846393e-06
Japanese O 1 0.5762277841567993
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.4958800673484802
: O 0 2.0589778770840894e-08
possible O 0 2.659442976948867e-08
preponderance O 0 1.0276936990294416e-07
of O 0 6.896852533522235e-10
the O 0 3.933572134684482e-09
two O 0 7.249353561888938e-09
founder O 0 2.9798110290357727e-07
mutations O 0 1.254421476915013e-06
4612del165 O 0 9.268794087802235e-07
and O 0 1.6019568249703298e-07
7883del5 O 0 1.584279198141303e-05
. O 0 1.668869003879081e-06

The O 0 2.5662795906100655e-06
ATM O 0 0.0002007823350140825
( O 0 1.961373072845163e-06
A O 1 0.9998987913131714
- O 1 0.9999598264694214
T O 1 1.0
, O 0 4.333481484763979e-08
mutated O 0 8.716250476936693e-07
) O 0 1.0826195051549803e-08
gene O 0 1.0776343373208874e-07
on O 0 4.252137486560059e-08
human O 0 1.2531333482002083e-07
chromosome O 0 1.1082222954428289e-05
11q22 O 0 2.4924791432567872e-05
. O 0 1.3285188060763176e-06

3 O 0 1.256673476746073e-05
has O 0 3.35298892650826e-07
recently O 0 3.680844997688837e-07
been O 0 1.6557484272539114e-08
identified O 0 6.749760306234975e-09
as O 0 1.4701938555461425e-09
the O 0 2.26223240140655e-09
gene O 0 4.8465995661217676e-08
responsible O 0 6.70863720131365e-09
for O 0 1.0794229954314005e-09
the O 0 1.9732302902752963e-08
human O 0 2.6800055366038578e-06
recessive B-Disease 1 0.9999997615814209
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0028576452750712633
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 9.161421417047677e-07
. O 0 5.807494289911119e-07

In O 0 1.462433033339039e-06
order O 0 1.0857549170850689e-07
to O 0 1.288209983130173e-08
define O 0 5.009783521359168e-08
the O 0 6.902647342599266e-09
types O 0 2.6675714082102786e-08
of O 0 8.667838891085466e-09
disease O 0 8.004638220882043e-05
- O 0 1.0904950613621622e-05
causing O 0 4.9908890105143655e-06
ATM O 0 0.0001244813611265272
mutations O 0 3.906034635292599e-06
in O 0 6.516812334211863e-08
Japanese O 0 1.5662910300306976e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.6578045460846624e-06
as O 0 8.250411021037962e-09
well O 0 1.6508124867087304e-09
as O 0 1.97000282753379e-09
to O 0 3.1074356421356697e-09
look O 0 3.1001142986042396e-08
for O 0 2.3341724109116058e-09
possible O 0 2.3117145531159622e-08
mutational O 0 6.875593953736825e-06
hotspots O 0 7.985706815816229e-07
, O 0 7.948217195519192e-09
reverse O 0 1.2850978237111121e-06
- O 0 3.659920366771985e-07
transcribed O 0 3.799955550221057e-07
RNA O 0 1.9724782873709046e-07
derived O 0 1.6605872232844376e-08
from O 0 8.218684399707854e-09
ten O 0 6.599718105348984e-09
patients O 0 9.695916958207818e-09
belonging O 0 1.7785215078447436e-08
to O 0 3.34781669053541e-09
eight O 0 5.2898494473652136e-09
unrelated O 0 5.1940816092610476e-08
Japanese O 0 1.8970038127008593e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
families O 0 5.9322793788396666e-08
was O 0 1.445219908191575e-07
analyzed O 0 5.3432717805890206e-08
for O 0 3.758391375896508e-09
mutations O 0 9.6340542654616e-08
by O 0 5.393585578161719e-09
the O 0 3.304892004507565e-08
restriction O 0 8.25761503620015e-07
endonuclease O 0 1.6788419088697992e-05
fingerprinting O 0 3.849639142572414e-06
method O 0 1.7719142988426029e-06
. O 0 4.4976283675168816e-07

As O 0 1.4344889223139035e-06
has O 0 7.371752985818603e-08
been O 0 8.736221523975018e-09
reported O 0 5.1305828918657426e-08
by O 0 3.6425005234264063e-09
others O 0 9.279814250362506e-09
, O 0 3.884676136323151e-09
mutations O 0 1.7530977913793322e-07
that O 0 1.8539532131711667e-09
lead O 0 2.4270590870401065e-08
to O 0 1.6893263676820425e-08
exon O 0 1.3537180620915024e-06
skipping O 0 5.42343173037807e-07
or O 0 1.539943355055584e-07
premature O 0 1.0945874464596272e-06
protein O 0 1.3258414810479735e-07
truncation O 0 7.927552019282302e-07
were O 0 5.0678128360459596e-08
also O 0 1.4219261323944465e-08
predominant O 0 2.3779426783221425e-07
in O 0 2.6567915867303782e-08
our O 0 7.60453886528012e-08
mutants O 0 3.0772089303354733e-06
. O 0 3.668677663881681e-07

Six O 0 1.2694962379100616e-06
different O 0 1.0961944951759506e-07
mutations O 0 1.1822190799648524e-06
were O 0 1.775315539020994e-08
identified O 0 2.0691979685238948e-08
on O 0 1.1716723946619823e-07
12 O 0 1.9326817479736746e-08
of O 0 1.9018755459399017e-09
the O 0 2.8983453859154906e-08
16 O 0 3.770010152948089e-07
alleles O 0 2.8099125302105676e-06
examined O 0 7.149403700168477e-06
. O 0 1.2697287274932023e-06

Four O 0 5.505014541995479e-07
were O 0 1.2354843192952103e-07
deletions O 0 1.4354715176523314e-06
involving O 0 1.4837043238458136e-07
a O 0 2.7578778372117085e-07
loss O 0 7.98914925326244e-07
of O 0 5.792612167709876e-09
a O 0 6.049963019449933e-08
single O 0 3.995169208792504e-07
exon O 0 3.3400422125851037e-06
exon O 0 2.845760946001974e-06
7 O 0 4.599397698257235e-07
, O 0 3.4059652875839674e-08
exon O 0 2.5588944936316693e-06
16 O 0 1.834717835436095e-07
, O 0 2.300625645546006e-08
exon O 0 1.908040758280549e-06
33 O 0 5.386530119722011e-07
or O 0 2.8800891982427856e-07
exon O 0 1.405629427608801e-05
35 O 0 2.0347335976111935e-06
. O 0 8.090650567282864e-07

The O 0 1.3528069757740013e-06
others O 0 1.8194940309967933e-07
were O 0 3.974161799646936e-08
minute O 0 2.3139341465139296e-07
deletions O 0 2.6060738491651136e-06
, O 0 1.954180994800936e-08
4649delA O 0 9.312262250205094e-07
in O 0 6.885463932349012e-08
exon O 0 2.4983212369988905e-06
33 O 0 1.6979521433313494e-07
and O 0 1.5697194655217572e-08
7883del5 O 0 1.107991806748032e-06
in O 0 1.6296532123760699e-07
exon O 0 1.9493658328428864e-05
55 O 0 2.840422212102567e-06
. O 0 1.2687579555858974e-06

The O 0 3.2072480280476157e-06
mutations O 0 3.246159394620918e-05
4612del165 O 0 3.5851430766342673e-06
and O 0 6.082360215486915e-08
7883del5 O 0 5.980574542263639e-07
were O 0 1.4283356719602125e-08
found O 0 2.6941335828922774e-09
in O 0 2.084495465126679e-09
more O 0 6.654878315082158e-10
than O 0 8.378414073639817e-10
two O 0 8.913113025421637e-10
unrelated O 0 2.638470242288804e-08
families O 0 2.178258018403767e-09
; O 0 3.3992921810721555e-09
44 O 0 8.417758046164181e-09
% O 0 2.5986532925514894e-09
( O 0 4.612287440863838e-09
7 O 0 1.4044437612881211e-08
of O 0 1.2119716341629783e-09
16 O 0 8.593286082714258e-09
) O 0 5.186701068637944e-10
of O 0 3.434148798664438e-10
the O 0 9.112363308361182e-09
mutant O 0 2.138044266075667e-07
alleles O 0 7.547735236812514e-08
had O 0 1.3472646998025084e-08
one O 0 3.293059158693268e-10
of O 0 2.0750531848356957e-10
the O 0 4.810440046298936e-09
two O 0 3.7749529724351305e-08
mutations O 0 5.5594641708012205e-06
. O 0 5.965547984487785e-07

The O 0 3.137716021228698e-06
4612del165 O 0 2.8505270165624097e-05
mutations O 0 5.203906312090112e-06
in O 0 2.6344874726191847e-08
three O 0 2.7437410121677885e-09
different O 0 1.2076980526742886e-09
families O 0 1.9511632309843208e-09
were O 0 3.165347539635377e-09
all O 0 5.388318680132897e-10
ascribed O 0 3.704764139911276e-08
to O 0 4.39828928833208e-09
the O 0 1.7768432059028783e-08
same O 0 3.6619104548663017e-07
T O 0 0.00015707369311712682
- O 0 2.4530247628717916e-06
- O 0 4.1276621232100297e-07
> O 0 7.350832476049618e-08
A O 0 9.977838999475352e-09
substitution O 0 2.0373745357460393e-08
at O 0 2.6930663921120868e-08
the O 0 1.0780245141006617e-08
splice O 0 1.7111957504312159e-06
donor O 0 7.440858240670423e-08
site O 0 1.3705700041555247e-07
in O 0 9.163329650618834e-08
intron O 0 3.6829093005508184e-05
33 O 0 2.4691914859431563e-06
. O 0 8.168348699655326e-07

Microsatellite O 0 0.0020115498919039965
genotyping O 0 0.00033126407652162015
around O 0 2.035108309428324e-06
the O 0 2.1206734857059928e-07
ATM O 0 1.1456939319032244e-05
locus O 0 2.2885760699864477e-06
also O 0 2.8336470947465386e-08
indicated O 0 7.676529634181861e-08
that O 0 1.126486570690588e-09
a O 0 1.1166574331866741e-08
common O 0 9.279941792783575e-08
haplotype O 0 1.8409171389066614e-05
was O 0 2.687479252472258e-07
shared O 0 9.679784973570804e-09
by O 0 3.44851880385022e-09
the O 0 8.568375342576928e-09
mutant O 0 4.93706977522379e-07
alleles O 0 2.90443921358019e-07
in O 0 2.530239484599406e-08
both O 0 1.135463563173289e-07
mutations O 0 1.9796028936980292e-05
. O 0 8.310000225719705e-07

This O 0 7.550080454166164e-07
suggests O 0 2.5801102765399264e-07
that O 0 3.836709616678036e-09
these O 0 4.887383830975978e-10
two O 0 1.7996434342748557e-09
founder O 0 1.1901984464657289e-07
mutations O 0 5.759585519626853e-07
may O 0 1.0750701306960764e-07
be O 0 5.782015310984434e-09
predominant O 0 1.8108697474872315e-07
among O 0 4.26441548739831e-09
Japanese O 0 1.9373271697986638e-07
ATM O 0 1.813687413232401e-05
mutant O 0 7.817393452569377e-06
alleles O 0 1.5722591342637315e-05
. O 0 8.25938741400023e-07

W474C O 0 0.00030255457386374474
amino O 0 2.3189379135146737e-05
acid O 0 4.735181846626801e-06
substitution O 0 5.102846785121073e-07
affects O 0 1.651746401876153e-07
early O 0 8.713858790088125e-08
processing O 0 4.460028080188749e-08
of O 0 1.5852863466392364e-09
the O 0 5.55245538436111e-09
alpha O 0 4.2923343102074796e-08
- O 0 5.017462711975895e-08
subunit O 0 3.973926965272767e-08
of O 0 3.0031794828744296e-09
beta O 0 9.099427700220986e-08
- O 0 2.9682135505026963e-07
hexosaminidase O 0 6.347289058794559e-07
A O 0 6.50528804158057e-08
and O 0 4.273698284151806e-09
is O 0 1.9769437198391415e-09
associated O 0 1.863305953975214e-08
with O 0 4.5439275453418304e-08
subacute O 0 0.0002766636316664517
G B-Disease 0 0.0002062334242509678
( I-Disease 0 2.833415635450365e-07
M2 I-Disease 0 0.0001124604677897878
) I-Disease 0 6.805660177633399e-07
gangliosidosis I-Disease 0 0.0001319996954407543
. O 0 1.8593742652228684e-06

Mutations O 0 0.00033611891558393836
in O 0 9.397515441378346e-07
the O 0 2.350669348061274e-07
HEXA O 0 0.00011901744437636808
gene O 0 1.664097908360418e-06
, O 0 1.040138641883459e-08
encoding O 0 8.126703932020973e-08
the O 0 1.1793489740341556e-08
alpha O 0 7.34647329636573e-08
- O 0 5.289912508033012e-08
subunit O 0 2.991381364836343e-08
of O 0 2.504741081210682e-09
beta O 0 1.2632652612865058e-07
- O 0 8.617636240160209e-07
hexosaminidase O 0 1.3894371022615815e-06
A O 0 1.9002200701834226e-07
( O 0 1.9864016209680813e-08
Hex O 0 2.1497555735550122e-07
A O 0 4.442538426019382e-08
) O 0 3.067796017219848e-09
, O 0 7.07120195730937e-10
that O 0 1.2482063160845769e-09
abolish O 0 6.301907546912844e-07
Hex O 0 5.199304951020167e-07
A O 0 4.215893412151672e-08
enzyme O 0 5.695177947018237e-07
activity O 0 3.66339850188524e-06
cause O 0 0.02820669673383236
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999784231185913
( O 0 1.4032141280040378e-06
TSD B-Disease 0 0.0002195498236687854
) O 0 6.818510911443809e-08
, O 0 1.10951985377028e-08
the O 0 1.2139021521306859e-07
fatal O 0 0.39267709851264954
infantile B-Disease 0 0.15379095077514648
form I-Disease 0 3.7524233675867436e-07
of I-Disease 0 4.2936200372878375e-08
G I-Disease 0 6.994069553911686e-05
( I-Disease 0 1.6515336653810664e-07
M2 I-Disease 0 1.4284999451774638e-05
) I-Disease 0 7.388574374544987e-08
gangliosidosis I-Disease 0 6.645600024057785e-06
, I-Disease 0 6.850422096249531e-08
Type I-Disease 0 5.355686880648136e-06
1 I-Disease 0 5.867383947588678e-07
. O 0 5.195973926674924e-07

Less O 0 6.205161480465904e-05
severe O 0 0.23117797076702118
, O 0 3.0757830700167688e-06
subacute O 0 0.4564129710197449
( O 0 6.369558832375333e-06
juvenile O 0 0.15601888298988342
- O 1 0.961578369140625
onset O 1 0.9997078776359558
) O 0 1.0752337402664125e-06
and O 0 3.030194875464076e-06
chronic O 0 0.20612066984176636
( O 0 4.3051826992268616e-07
adult O 0 4.291960067348555e-05
- O 0 0.08096494525671005
onset O 1 0.7019131183624268
) O 0 4.223426941507569e-08
variants O 0 6.876039719827531e-07
are O 0 2.4716251267875577e-09
characterized O 0 5.8866646668320755e-08
by O 0 5.4132605065149164e-09
a O 0 2.7429889470909075e-08
broad O 0 3.094168619099946e-07
spectrum O 0 1.8118679463441367e-06
of O 0 3.6292480132260607e-09
clinical O 0 1.0214812107278703e-07
manifestations O 0 1.8739847007509525e-07
and O 0 1.0773975489541954e-08
are O 0 9.144464074850589e-10
associated O 0 1.049729192459381e-08
with O 0 6.407106400985185e-09
residual O 0 4.473907040392078e-07
levels O 0 9.173523807248785e-08
of O 0 1.7011370090358469e-09
Hex O 0 3.1792600907465385e-07
A O 0 6.94566395509355e-08
enzyme O 0 6.879109264446015e-07
activity O 0 1.3911314908909844e-06
. O 0 5.276228876027744e-07

We O 0 1.4349158163895481e-06
identified O 0 4.89657054458803e-07
a O 0 4.147992456182692e-07
1422 O 0 0.0001772943651303649
G O 0 0.00015448530029971153
- O 0 5.6507200497435406e-05
- O 0 1.681085086602252e-05
> O 0 2.5003471364470897e-06
C O 0 2.4681414743099594e-06
( O 0 3.5655155272706907e-08
amino O 0 1.0885438683772009e-07
acid O 0 1.1810691802338624e-07
W474C O 0 1.2019862083434418e-07
) O 0 2.3321919950802794e-09
substitution O 0 4.835332134689452e-09
in O 0 1.6499593913366084e-09
the O 0 2.5759236965683385e-09
first O 0 1.146877171009919e-08
position O 0 2.0943678791240927e-08
of O 0 2.005381638525705e-09
exon O 0 4.0607162077321846e-07
13 O 0 1.6815659975577546e-08
of O 0 3.0297890862840404e-09
HEXA O 0 6.576037321792683e-06
of O 0 3.2747335954042e-09
a O 0 2.5679142368062458e-08
non O 0 5.364389465967179e-08
- O 0 5.134166372045001e-07
Jewish O 0 2.3293685558201105e-07
proband O 0 1.2388980394462124e-05
who O 0 7.143053437630442e-08
manifested O 0 6.728887456119992e-07
a O 0 3.5975611467620183e-07
subacute O 0 9.189559932565317e-05
variant O 0 9.35445204959251e-05
of O 0 2.3187874376162654e-07
G B-Disease 0 0.0007979403017088771
( I-Disease 0 7.936939709907165e-07
M2 I-Disease 0 0.0001366832002531737
) I-Disease 0 5.48461969174241e-07
gangliosidosis I-Disease 0 6.383200525306165e-05
. O 0 1.717172381177079e-06

On O 0 8.429525223618839e-06
the O 0 4.3737887267525366e-07
second O 0 7.851933787605958e-07
maternally O 0 2.9103055567247793e-05
inherited O 0 2.8935930458828807e-05
allele O 0 4.078541223861976e-06
, O 0 1.3052559033610578e-08
we O 0 4.154426580527115e-09
identified O 0 1.8847559957180238e-08
the O 0 1.9009263496627682e-08
common O 0 7.595589067932451e-06
infantile O 1 0.9999876022338867
disease O 1 0.996616542339325
- O 0 0.0021261039655655622
causing O 0 1.8614891814650036e-05
4 O 0 9.298675536228984e-07
- O 0 4.67031850348576e-06
bp O 0 1.3629062323161634e-06
insertion O 0 5.322739866642223e-07
, O 0 2.622645389749323e-08
+ O 0 5.137594598636497e-07
TATC O 0 8.53994151839288e-06
1278 O 0 1.6534213500563055e-05
, O 0 2.0388867483234208e-08
in O 0 4.1896246472106213e-08
exon O 0 9.740137102198787e-06
11 O 0 9.388128319187672e-07
. O 0 6.741714742020122e-07

Pulse O 0 0.007391834631562233
- O 0 9.488024079473689e-05
chase O 0 2.064494947262574e-05
analysis O 0 5.019271611672593e-07
using O 0 1.849733735070913e-07
proband O 0 7.412813829432707e-06
fibroblasts O 0 2.2626275040238397e-06
revealed O 0 5.253473887023574e-07
that O 0 2.9180744487433685e-09
the O 0 7.079194563885949e-09
W474C O 0 3.340311707233923e-07
- O 0 1.0966378738430649e-07
containing O 0 3.9000308760250846e-08
alpha O 0 6.343501013361674e-08
- O 0 6.613544201172772e-08
subunit O 0 9.185271920841842e-08
precursor O 0 1.4862860098219244e-07
was O 0 9.390244315454765e-08
normally O 0 2.927636799654465e-08
synthesized O 0 1.6151231818639644e-07
, O 0 3.1506144360093913e-09
but O 0 1.5997752011998045e-09
not O 0 1.1069721805867516e-09
phosphorylated O 0 4.28209645519928e-08
or O 0 5.362259081209686e-09
secreted O 0 2.2520302067619014e-08
, O 0 9.84871295628409e-10
and O 0 1.0623638635465227e-09
the O 0 1.2928819792534796e-08
mature O 0 2.100675544625119e-07
lysosomal O 0 3.7366962715168484e-06
alpha O 0 4.5133160142540873e-07
- O 0 3.8883146658008627e-07
subunit O 0 1.7886632974750682e-07
was O 0 4.947386855747027e-07
not O 0 4.2023899027299194e-08
detected O 0 6.917048267496284e-06
. O 0 4.7666483737884846e-07

When O 0 1.1591251904974342e-06
the O 0 1.2237987334628997e-07
W474C O 0 2.3931588657433167e-06
- O 0 3.0244561344261456e-07
containing O 0 1.1842203662126849e-07
alpha O 0 2.1863264976218488e-07
- O 0 2.0057733252087928e-07
subunit O 0 1.8244703881009627e-07
was O 0 2.9630237463607045e-07
transiently O 0 2.556811523390934e-06
co O 0 1.65112581385074e-07
- O 0 1.1948749545354076e-07
expressed O 0 7.032308513288399e-09
with O 0 2.1587731602323856e-09
the O 0 4.681151022367658e-09
beta O 0 3.809614312899612e-08
- O 0 2.453290370851846e-08
subunit O 0 1.710015773426221e-08
to O 0 5.486699983237031e-09
produce O 0 2.3389421954789213e-08
Hex O 0 3.2962176987894054e-07
A O 0 6.02360756829512e-08
( O 0 1.5232885175464617e-08
alphabeta O 0 7.380847932836332e-07
) O 0 6.054509338326852e-09
in O 0 2.0226535113465616e-08
COS O 0 1.0251060302834958e-05
- O 0 4.857918725065247e-07
7 O 0 3.749707744304942e-08
cells O 0 2.5384569113384714e-08
, O 0 1.2102391311330507e-09
the O 0 3.8375662647638364e-09
mature O 0 2.3710217789130184e-08
alpha O 0 2.5350216148467553e-08
- O 0 2.913432162188201e-08
subunit O 0 1.41196432323909e-08
was O 0 1.5175407597212143e-08
present O 0 1.0632253966136318e-09
, O 0 2.7513383238364497e-10
but O 0 3.5044134261141835e-10
its O 0 2.1856700893607695e-09
level O 0 1.4416650095938621e-08
was O 0 9.885872742643187e-08
much O 0 4.05388833613074e-09
lower O 0 6.379208912221657e-07
than O 0 8.443224452925335e-10
that O 0 3.993008423908151e-10
from O 0 1.6249184220384905e-09
normal O 0 2.8973559551559447e-08
alpha O 0 3.930079728320379e-08
- O 0 5.541845737866424e-08
subunit O 0 6.116178496995417e-08
transfections O 0 2.2545795275163982e-07
, O 0 1.8333783380342084e-09
although O 0 2.1480079936964103e-09
higher O 0 9.443999360314592e-09
than O 0 7.681223990196884e-10
in O 0 1.4835458417294944e-09
those O 0 8.869071588257782e-10
cells O 0 1.905467605922695e-08
transfected O 0 2.086461847738974e-07
with O 0 1.6652902390390523e-09
an O 0 5.621421550472405e-09
alpha O 0 1.2838260943226487e-07
- O 0 3.763185247862566e-07
subunit O 0 5.48703724234656e-07
associated O 0 5.628080543829128e-07
with O 0 5.856985012542282e-07
infantile O 1 0.8613358736038208
TSD B-Disease 0 0.010361015796661377
. O 0 5.080426490167156e-06

Furthermore O 0 6.043037046765676e-06
, O 0 4.3031217700217894e-08
the O 0 1.5729593627611393e-08
precursor O 0 9.543286694224662e-08
level O 0 1.736421140208222e-08
of O 0 1.1275399502963523e-09
the O 0 6.085444592685008e-09
W474C O 0 2.83978636161919e-07
alpha O 0 6.922796558228583e-08
- O 0 5.5995091230442995e-08
subunit O 0 5.4071026767132935e-08
was O 0 7.591988548938389e-08
found O 0 7.398879731113084e-09
to O 0 6.873074553936931e-09
accumulate O 0 1.321563303235962e-07
in O 0 3.6350327192735676e-09
comparison O 0 1.1078704176270548e-08
to O 0 5.171924666313998e-09
the O 0 1.261627513571284e-08
normal O 0 1.597124139607331e-07
alpha O 0 1.7060712309557857e-07
- O 0 2.3229949874803424e-07
subunit O 0 4.227391912081657e-07
precursor O 0 7.878570045249944e-07
levels O 0 1.463032958781696e-06
. O 0 6.30948477464699e-07

We O 0 2.4844741801643977e-06
conclude O 0 1.6200086747630849e-06
that O 0 2.722348924066864e-08
the O 0 1.2623236500530766e-07
1422 O 0 7.802981417626143e-05
G O 0 5.266728840069845e-05
- O 0 1.324959612247767e-05
- O 0 9.93001685856143e-06
> O 0 3.0052954116399633e-06
C O 0 1.0880309673666488e-05
mutation O 0 7.500561878259759e-07
is O 0 5.8150178006144415e-09
the O 0 4.0931009692712905e-09
cause O 0 3.966422568169037e-08
of O 0 5.5887929839570916e-09
Hex B-Disease 0 8.942271051637363e-06
A I-Disease 0 2.2939819245948456e-05
enzyme I-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999991655349731
in O 0 1.2361172707642254e-07
the O 0 3.709127440743032e-07
proband O 0 0.00015727063873782754
. O 0 1.503144972048176e-06

The O 0 5.106213848193875e-06
resulting O 0 4.269197233952582e-06
W474C O 0 1.1877987162733916e-05
substitution O 0 1.7031951529133948e-06
clearly O 0 4.923190317640547e-07
interferes O 0 1.2476699566832394e-06
with O 0 2.914243601992439e-08
alpha O 0 1.9995260913674429e-07
- O 0 7.158261183803916e-08
subunit O 0 6.576161126758961e-08
processing O 0 2.544603816545532e-08
, O 0 1.1024545720772494e-09
but O 0 6.444718092524226e-10
because O 0 5.153272253366481e-10
the O 0 3.5128946418439e-09
base O 0 3.398502812501647e-08
substitution O 0 5.416175596906214e-08
falls O 0 3.3164906199090183e-06
at O 0 2.0705995140701816e-08
the O 0 2.7690818527048577e-09
first O 0 3.4527110059912047e-09
position O 0 8.287948993768168e-09
of O 0 9.61352442097052e-10
exon O 0 3.0598681632909575e-07
13 O 0 2.9471900475641633e-08
, O 0 4.427698652165191e-09
aberrant O 0 6.055539643057273e-07
splicing O 0 3.88769058190519e-06
may O 0 2.084836069116136e-06
also O 0 1.0877195144587404e-08
contribute O 0 6.1729585887349e-09
to O 0 1.4075545173852788e-08
Hex B-Disease 0 4.326129783294164e-06
A I-Disease 0 8.144358616846148e-06
deficiency I-Disease 0 5.208520815358497e-05
in O 0 7.0970673782255744e-09
this O 0 8.872020451633489e-09
proband O 0 5.848261480423389e-06
. O 0 3.914108148705964e-08
. O 0 2.4943881271610735e-07

Two O 0 4.6514983296219725e-06
frequent O 0 3.211151124560274e-05
missense O 0 0.004638826008886099
mutations O 0 0.36648473143577576
in O 0 0.06410056352615356
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.9933667469304055e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00011799478670582175
an O 0 0.029446763917803764
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9938218593597412
by O 0 2.2416168576455675e-05
early O 1 0.9925192594528198
childhood O 1 0.9999995231628418
deafness B-Disease 1 1.0
and O 1 0.9946109056472778
goiter B-Disease 1 1.0
. O 0 4.4095275370636955e-05

A O 0 4.015255399281159e-06
century O 0 7.779663064866327e-07
after O 0 7.990279726755034e-08
its O 0 1.0860153665248617e-08
recognition O 0 1.0980460984910678e-08
as O 0 2.5669104175563007e-08
a O 0 4.361402716313023e-06
syndrome O 1 0.9897105097770691
by O 0 7.385192901665505e-08
Vaughan O 0 4.037091457576025e-06
Pendred O 0 4.042986802232917e-06
, O 0 1.6695940630029327e-08
the O 0 1.0820068041539344e-07
disease O 0 6.543274503201246e-05
gene O 0 4.052393705933355e-06
( O 0 1.4023522965089796e-07
PDS O 0 2.159632640541531e-05
) O 0 1.943523919578638e-08
was O 0 1.0203439870792863e-07
mapped O 0 6.221173975973215e-07
to O 0 7.154725523150773e-08
chromosome O 0 9.220919309882447e-06
7q22 O 0 9.180101187666878e-06
- O 0 2.287650750076864e-05
q31 O 0 3.7689747841795906e-05
. O 0 2.099603079841472e-06

1 O 0 1.7610046825211612e-06
and O 0 5.173880879283388e-08
, O 0 5.187425156094605e-09
recently O 0 4.391753094523665e-08
, O 0 1.4006683590750413e-09
found O 0 3.742232301817694e-09
to O 0 3.920090918541064e-09
encode O 0 1.4028420025624655e-07
a O 0 1.7625626469452982e-07
putative O 0 9.45387455431046e-06
sulfate O 0 2.9667027774848975e-05
transporter O 0 0.00016306103498209268
. O 0 1.98618749891466e-06

We O 0 2.3324480480368948e-06
performed O 0 2.538065928092692e-06
mutation O 0 1.6682387240507524e-06
analysis O 0 4.001391573638102e-08
of O 0 5.075190490089199e-09
the O 0 3.1140526601802776e-08
PDS B-Disease 0 1.1941204320464749e-05
gene O 0 6.909854732839449e-07
in O 0 6.009687325558843e-08
patients O 0 1.0110354509151875e-07
from O 0 1.3164117795838592e-08
14 O 0 2.3866890686008446e-08
Pendred B-Disease 0 4.5753404265269637e-07
families O 0 2.549674471552521e-09
originating O 0 1.1164914326400321e-08
from O 0 2.181488767405426e-09
seven O 0 1.505319757733048e-09
countries O 0 6.906133442896589e-10
and O 0 4.482454851739703e-09
identified O 0 4.097016059745329e-08
all O 0 1.5175464440631004e-08
mutations O 0 4.842034741159296e-06
. O 0 3.78418462787522e-07

The O 0 2.053880734820268e-06
mutations O 0 6.55813755656709e-06
include O 0 2.6135870356824853e-08
three O 0 8.475402601959559e-09
single O 0 3.8377436339942506e-08
base O 0 1.0642632020108067e-07
deletions O 0 8.766385235503549e-07
, O 0 1.1608920935657352e-08
one O 0 5.8718256923384615e-09
splice O 0 7.742251000308897e-06
site O 0 1.7810085637393058e-06
mutation O 0 1.643095629333402e-06
and O 0 5.18815035377429e-08
10 O 0 2.6675823505684093e-07
missense O 0 8.107108442345634e-05
mutations O 0 0.00010797065624501556
. O 0 2.7850107926497003e-06

One O 0 5.786381734651513e-06
missense O 0 0.0003108460223302245
mutation O 0 7.328327774303034e-05
( O 0 5.293011327012209e-07
L236P O 0 3.843959802907193e-06
) O 0 5.381627232736719e-08
was O 0 1.1350672934895556e-07
found O 0 6.092482518482711e-09
in O 0 2.1640540470713177e-09
a O 0 8.135152107513477e-09
homozygous O 0 1.8659275724530744e-07
state O 0 3.962314920613608e-09
in O 0 5.865020469286719e-09
two O 0 6.680341613218843e-09
consanguineous O 0 1.4200959412846714e-06
families O 0 6.136309238513604e-09
and O 0 1.2277979744013123e-09
in O 0 2.779977803513134e-09
a O 0 1.3067604776040298e-08
heterozygous O 0 1.4316637475531024e-07
state O 0 2.9657918343417577e-09
in O 0 3.302684792316768e-09
five O 0 2.583732783278947e-09
additional O 0 8.243584481704147e-09
non O 0 1.0791254823061536e-07
- O 0 9.99258099909639e-06
consanguineous O 0 4.9039459554478526e-05
families O 0 5.064324568593292e-07
. O 0 8.763292385083332e-07

Another O 0 3.79587581846863e-05
missense O 0 0.0011307159438729286
mutation O 0 0.00012106358917662874
( O 0 6.613619234485668e-07
T416P O 0 2.586165464890655e-06
) O 0 2.2743300576166803e-08
was O 0 3.522369595998498e-08
found O 0 3.0264739603325097e-09
in O 0 3.095232292693595e-09
a O 0 1.2545342542580329e-08
homozygous O 0 1.5157407062815764e-07
state O 0 2.176999469583052e-09
in O 0 3.457943931195473e-09
one O 0 1.779145053504294e-09
family O 0 6.203694002948623e-09
and O 0 9.554953495083396e-10
in O 0 3.3194140769410296e-09
a O 0 1.4201995135465495e-08
heterozygous O 0 1.311815367444069e-07
state O 0 2.251195896363356e-09
in O 0 5.136337577482664e-09
four O 0 9.923539323608566e-09
families O 0 3.296305095545904e-08
. O 0 2.076354661539881e-07

Pendred B-Disease 0 0.007604015525430441
patients O 0 3.9015143556753173e-05
in O 0 2.2562873880360712e-07
three O 0 3.499327405620534e-08
non O 0 1.2235022950335406e-07
- O 0 1.8400270391794038e-06
consanguineous O 0 4.6351406126632355e-06
families O 0 1.2067729926457105e-08
were O 0 5.078095277610828e-09
shown O 0 1.0823840490559178e-08
to O 0 5.055394325381712e-09
be O 0 2.7817865788648533e-09
compound O 0 6.212636094460322e-08
heterozygotes O 0 5.471778194987564e-07
for O 0 6.3296479169139275e-09
L236P O 0 6.800456731070881e-07
and O 0 5.194378971395963e-08
T416P O 0 1.041703944792971e-05
. O 0 6.946378334760084e-07

In O 0 5.386884254221513e-07
total O 0 1.4373050305493962e-08
, O 0 1.831539808705429e-09
one O 0 7.430384640905174e-10
or O 0 1.1053391535398305e-09
both O 0 2.587217939886699e-10
of O 0 2.0242570120121428e-10
these O 0 9.2750845892553e-10
mutations O 0 4.030883005157193e-08
were O 0 3.374331480898718e-09
found O 0 3.775670887051774e-09
in O 0 3.401536163849528e-09
nine O 0 2.152839684299579e-09
of O 0 3.785440017001207e-10
the O 0 6.680672903769391e-09
14 O 0 2.2626474915909967e-08
families O 0 1.4852679974808325e-08
analyzed O 0 1.0468278333064518e-06
. O 0 4.1485742485747323e-07

The O 0 5.446049726742785e-07
identification O 0 2.3537087656677613e-07
of O 0 8.026646014513972e-09
two O 0 1.3359644945865057e-08
frequent O 0 8.138458724715747e-07
PDS B-Disease 0 0.0003681097587104887
mutations O 0 4.026091573905433e-06
will O 0 9.436257997208486e-09
facilitate O 0 1.3229209727683156e-08
the O 0 5.598707630838362e-08
molecular O 0 1.6953865269897506e-05
diagnosis O 0 0.03649673983454704
of O 0 7.510765044571599e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 6.5037579588533845e-06

Insertional O 0 0.0016797402640804648
mutation O 0 0.00010724131425376981
by O 0 5.706486376766406e-07
transposable O 0 2.1990328605170362e-05
element O 0 5.561965394917934e-07
, O 0 4.814885556925219e-08
L1 O 0 1.3536220649257302e-05
, O 0 2.155988276797416e-08
in O 0 2.1421993068315714e-08
the O 0 2.0863943461790768e-07
DMD B-Disease 1 0.9999992847442627
gene O 0 7.565356554550817e-06
results O 0 7.348406256824092e-07
in O 0 6.133386705187149e-07
X B-Disease 1 0.9933706521987915
- I-Disease 1 0.9857439398765564
linked I-Disease 1 0.931441605091095
dilated I-Disease 1 0.926557719707489
cardiomyopathy I-Disease 1 1.0
. O 0 1.4165320862957742e-05

X B-Disease 1 0.9986336827278137
- I-Disease 1 0.9966148734092712
linked I-Disease 1 0.9869298934936523
dilated I-Disease 1 0.9997560381889343
cardiomyopathy I-Disease 1 1.0
( O 0 8.127623914333526e-06
XLDCM B-Disease 0 0.0007599149830639362
) O 0 5.864519891929376e-08
is O 0 4.8869575053345216e-09
a O 0 2.0923197396882642e-08
clinical O 0 3.5567404665926006e-07
phenotype O 0 3.932497747882735e-06
of O 0 7.197454188201391e-09
dystrophinopathy B-Disease 0 3.7443096516653895e-05
which O 0 9.670782930015775e-08
is O 0 9.21369469608635e-09
characterized O 0 8.016872499183592e-08
by O 0 1.9859470512528787e-08
preferential O 0 1.2147097550041508e-06
myocardial B-Disease 0 0.0001160033862106502
involvement I-Disease 0 3.629001241733931e-07
without O 0 3.160691619541467e-08
any O 0 2.523544928578758e-08
overt O 0 1.0814471806952497e-06
clinical O 0 1.8126819441022235e-06
signs O 0 9.689432772574946e-05
of O 0 5.631889507640153e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.00017556134844198823

To O 0 1.3480417919708998e-06
date O 0 3.8717189454473555e-07
, O 0 1.1276587663644477e-08
several O 0 1.4538757753257414e-08
mutations O 0 6.412702191482822e-07
in O 0 4.386144070167575e-08
the O 0 3.606634209063486e-06
Duchenne B-Disease 1 0.9999948740005493
muscular I-Disease 1 0.9999973773956299
dystrophy I-Disease 1 0.9999933242797852
gene O 0 0.0007435994339175522
, O 0 2.190800387324998e-06
DMD O 1 1.0
, O 0 1.4309458151728904e-07
have O 0 6.130039142959731e-09
been O 0 8.020646369288897e-09
identified O 0 2.774263840876756e-08
in O 0 3.366207579347247e-08
patients O 0 3.596661812821367e-08
with O 0 9.873074802158044e-09
XLDCM B-Disease 0 0.00034858431899920106
, O 0 6.082021553055483e-09
but O 0 2.6813891107480003e-09
a O 0 1.4320728602967847e-08
pathogenic O 0 4.568094311707682e-07
correlation O 0 5.754162302196164e-08
of O 0 2.9944453583397035e-09
these O 0 7.620332809210595e-09
cardiospecific O 0 4.8906240408541635e-06
mutations O 0 2.302545453858329e-06
in O 0 2.0762992392064916e-07
DMD O 1 0.999998927116394
with O 0 5.005743375363636e-08
the O 0 1.8450052152729768e-07
XLDCM B-Disease 0 0.002316822996363044
phenotype O 0 5.029937165090814e-05
has O 0 7.359684417451717e-08
remained O 0 6.018003659846727e-07
to O 0 1.1441722236327223e-08
be O 0 3.089311917392479e-08
elucidated O 0 5.475737907545408e-06
. O 0 6.195573405420873e-07

We O 0 1.1710952776411432e-06
report O 0 2.810478463288746e-07
here O 0 6.912739269893109e-09
the O 0 2.8427999954061534e-09
identification O 0 6.8212142600998504e-09
of O 0 6.807186481161409e-10
a O 0 7.305305249616367e-09
unique O 0 1.632387025551907e-08
de O 0 4.006546987511683e-07
novo O 0 1.368496327813773e-06
L1 O 0 3.910865416401066e-06
insertion O 0 2.988507787904382e-07
in O 0 3.348788979451456e-08
the O 0 5.784136192232836e-08
muscle O 0 2.6585090381558985e-05
exon O 0 5.924193828832358e-06
1 O 0 1.747132643004079e-07
in O 0 3.764053815302759e-07
DMD O 1 0.9999996423721313
in O 0 4.86921749143221e-07
three O 0 4.98775918345018e-08
XLDCM B-Disease 0 0.0001074426545528695
patients O 0 2.720994984883873e-07
from O 0 4.4653885034051655e-09
two O 0 4.3201344723797774e-09
unrelated O 0 1.693671407565489e-07
Japanese O 0 5.642693849949865e-07
families O 0 1.948323529177287e-07
. O 0 4.222637528528139e-07

The O 0 6.910256615810795e-07
insertion O 0 3.7573647659883136e-06
was O 0 6.865608384032384e-07
a O 0 4.536800446430789e-08
5 O 0 3.870669829098006e-08
- O 0 1.294041993560313e-07
truncated O 0 1.29567581552692e-07
form O 0 1.2096767143532361e-08
of O 0 1.754347223048569e-09
human O 0 8.765614900596574e-09
L1 O 0 5.1754982450802345e-06
inversely O 0 2.5415586151211755e-06
integrated O 0 1.9259664441051427e-07
in O 0 1.7262964391306923e-08
the O 0 1.2166972318539138e-08
5 O 0 3.4679917604307775e-08
- O 0 2.862198300590535e-07
untranslated O 0 4.2284810319870303e-07
region O 0 2.1683437267938643e-08
in O 0 1.2666813375972197e-08
the O 0 2.908568319526239e-08
muscle O 0 1.3979560208099429e-05
exon O 0 1.1960451047343668e-06
1 O 0 2.4830614009374585e-08
, O 0 1.3738415960418138e-09
which O 0 1.7283182662808372e-09
affected O 0 8.113921978747385e-09
the O 0 2.7611444242126026e-09
transcription O 0 8.486098579396639e-08
or O 0 5.300919259099146e-09
the O 0 2.662481790594029e-09
stability O 0 1.3140987853432762e-08
of O 0 3.4803268600391846e-10
the O 0 1.1663251697768828e-08
muscle O 0 2.949973804788897e-06
form O 0 1.425630191675964e-08
of O 0 2.7013062897651707e-09
dystrophin O 0 1.4650728417109349e-06
transcripts O 0 1.4088175248616608e-07
but O 0 4.5486512334491636e-09
not O 0 5.078334974761844e-10
that O 0 1.3284419397852076e-10
of O 0 2.1653245863006987e-10
the O 0 1.4035252071664672e-08
brain O 0 3.8573198253288865e-06
or O 0 3.172905138626447e-08
Purkinje O 0 9.734990271681454e-07
cell O 0 5.884037364012329e-07
form O 0 2.509375995884966e-08
, O 0 6.255237217089871e-09
probably O 0 3.428438688501956e-08
due O 0 3.61789425085135e-08
to O 0 4.1997596511578195e-09
its O 0 2.507945318086513e-08
unique O 0 6.103508809474079e-09
site O 0 3.0512889992451164e-08
of O 0 3.6084100152322662e-09
integration O 0 2.2398221233288496e-07
. O 0 3.9630350556763005e-07

We O 0 1.1318390988890314e-06
speculate O 0 1.2171670960015035e-06
that O 0 3.965694439500567e-09
this O 0 1.0827511109923194e-09
insertion O 0 2.7086546339205597e-08
of O 0 6.43083031270919e-10
an O 0 7.083057251833225e-09
L1 O 0 7.603923677379498e-06
sequence O 0 4.488728677642939e-07
in O 0 7.402171604553587e-07
DMD O 1 0.9999998807907104
is O 0 3.1983759640752396e-08
responsible O 0 8.616805047267917e-09
for O 0 3.2879879374725363e-10
some O 0 1.8646018062895564e-10
of O 0 1.0449876380880241e-10
the O 0 1.596008103454949e-09
population O 0 6.93185397970808e-10
of O 0 4.162149791486769e-10
Japanese O 0 2.3525261383383622e-07
patients O 0 8.745011115252055e-08
with O 0 3.291781425218687e-08
XLDCM B-Disease 0 8.353195153176785e-05
. O 0 1.0476274070470026e-07
. O 0 5.163450964573713e-07

Severe O 1 0.5382878184318542
early O 0 0.21320733428001404
- O 1 0.9999825954437256
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0063286335207521915
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.926676415881957e-06
red O 0 0.0058933221735060215
hair O 1 0.9999704360961914
pigmentation O 1 0.9744365811347961
caused O 0 3.9815891796024516e-05
by O 0 4.70626503101812e-07
POMC O 0 0.002267750445753336
mutations O 0 2.60798551607877e-05
in O 0 1.9981479226771626e-07
humans O 0 1.4507617152048624e-06
. O 0 4.4838765234089806e-07

Sequential O 0 0.00019149354193359613
cleavage O 0 8.345393143827096e-05
of O 0 8.152692743124135e-08
the O 0 4.621289306783183e-08
precursor O 0 4.682501639763359e-07
protein O 0 5.711353878723457e-07
pre O 0 2.6094134227605537e-05
- O 0 5.179831350687891e-05
pro O 0 1.7082727936212905e-05
- O 0 3.93355694541242e-05
opiomelanocortin O 0 3.6443350836634636e-05
( O 0 3.0844554999021057e-07
POMC O 0 1.6919058907660656e-05
) O 0 3.5133250975150077e-08
generates O 0 9.315266424891888e-08
the O 0 4.9761091247546574e-08
melanocortin O 0 3.6407225707080215e-05
peptides O 0 6.33046238363022e-06
adrenocorticotrophin O 0 1.9904762666556053e-05
( O 0 3.8611807440247503e-07
ACTH O 0 1.1470298886706587e-05
) O 0 4.6427402367044124e-08
, O 0 1.5611918868785324e-08
melanocyte O 0 1.1022470971511211e-05
- O 0 1.7627420675125904e-05
stimulating O 0 8.467813131574076e-06
hormones O 0 1.9178565707989037e-05
( O 0 1.452105493626732e-07
MSH O 0 1.0954459867207333e-05
) O 0 1.1529789567532589e-08
alpha O 0 3.057539998962966e-08
, O 0 1.519225523161083e-09
beta O 0 5.875623543261099e-09
and O 0 1.264676918744101e-09
gamma O 0 3.428936068416988e-08
as O 0 2.7335969043917885e-09
well O 0 1.9539041495875153e-09
as O 0 1.2840831731253388e-09
the O 0 6.008172181992677e-09
opioid O 0 4.738013785754447e-07
- O 0 7.190719202299078e-07
receptor O 0 1.471094378757698e-06
ligand O 0 8.932758532864682e-07
beta O 0 2.1411060515674762e-06
- O 0 3.7248642911436036e-05
endorphin O 0 0.00044591285404749215
. O 0 2.6935317691823e-06

While O 0 1.2324699127930216e-06
a O 0 1.2894840040189592e-07
few O 0 1.5093887029138386e-08
cases O 0 9.117665733526792e-09
of O 0 1.2069663490876792e-08
isolated O 0 0.003182811662554741
ACTH B-Disease 1 0.999754011631012
deficiency I-Disease 0 0.15589052438735962
have O 0 3.3008351607577424e-08
been O 0 6.396717822099163e-08
reported O 0 6.04333672526991e-06
( O 0 4.896785412711324e-07
OMIM O 0 5.102175418869592e-05
201400 O 0 3.4017502912320197e-06
) O 0 4.0133919299023546e-08
, O 0 5.597455832173637e-09
an O 0 4.538297559975035e-08
inherited O 0 0.19485585391521454
POMC O 1 0.9225675463676453
defect O 0 0.028753068298101425
has O 0 7.872691298871359e-08
not O 0 6.598610546859618e-09
been O 0 7.9273387854073e-09
described O 0 9.671133938127241e-08
so O 0 2.3269144833193423e-08
far O 0 1.277681036526701e-07
. O 0 3.6588244256563485e-07

Recent O 0 7.585352705063997e-06
studies O 0 7.523559020228276e-07
in O 0 9.840684356277052e-08
animal O 0 6.652231263615249e-07
models O 0 6.429143581954122e-07
elucidated O 0 5.819946977680956e-07
a O 0 2.4205039750313517e-08
central O 0 7.286925551852619e-08
role O 0 1.7541037067303478e-08
of O 0 3.2822251583297657e-09
alpha O 0 1.277693115753209e-07
- O 0 2.292868884978816e-06
MSH O 0 2.6317982701584697e-05
in O 0 1.8216637087675736e-08
the O 0 1.1887256512466138e-08
regulation O 0 1.3568973145083874e-07
of O 0 2.6376687500828666e-09
food O 0 1.9719060162515234e-08
intake O 0 8.591059952323121e-08
by O 0 1.840367969130341e-09
activation O 0 3.7526412199895276e-08
of O 0 1.8173559324097255e-09
the O 0 6.517359452118399e-08
brain O 0 3.885474143316969e-05
melanocortin O 0 8.311750571010634e-05
- O 0 9.11324968910776e-06
4 O 0 5.625075800708146e-07
- O 0 2.6140239697269863e-06
receptor O 0 3.050927261938341e-06
( O 0 2.5629091737755516e-07
MC4 O 0 0.0001540031807962805
- O 0 2.037820013356395e-05
R O 0 2.6651190637494437e-05
; O 0 5.339767383816252e-08
refs O 0 2.1886598915443756e-06
3 O 0 8.80366997080273e-08
- O 0 5.907979812036501e-07
5 O 0 2.075352156793997e-08
) O 0 1.1343953554288078e-09
and O 0 3.3770081175887867e-10
the O 0 2.0042956183630167e-09
linkage O 0 1.507616929075084e-07
of O 0 3.96657195977923e-09
human O 0 8.734559031609024e-08
obesity B-Disease 1 0.9999734163284302
to O 0 5.0202192625192765e-08
chromosome O 0 8.305420919896278e-07
2 O 0 1.2546443883820757e-08
in O 0 7.093535536739637e-09
close O 0 4.960889654626044e-08
proximity O 0 4.4461661019568055e-08
to O 0 1.0313220499824638e-08
the O 0 3.4392588332821106e-08
POMC O 0 1.0502904842724092e-05
locus O 0 2.1055834054095612e-07
, O 0 1.4001234616145553e-09
led O 0 2.3472310761718518e-09
to O 0 1.0944073425278589e-09
the O 0 3.1102285191764167e-09
proposal O 0 1.0246790971280006e-08
of O 0 5.207169695431446e-10
an O 0 3.664548886561647e-09
association O 0 2.510960861457079e-08
of O 0 4.2391135046671025e-09
POMC O 0 2.621490421006456e-05
with O 0 1.0626890656340038e-07
human O 0 5.956536369922105e-06
obesity B-Disease 1 0.9999996423721313
. O 0 2.639548256411217e-06

The O 0 1.1675580253722728e-06
dual O 0 1.3760197816736763e-06
role O 0 7.735246754236869e-08
of O 0 8.684734709163422e-09
alpha O 0 1.7395247198237485e-07
- O 0 1.574891825839586e-06
MSH O 0 2.9259343136800453e-05
in O 0 3.954788851956437e-08
regulating O 0 7.667865702387644e-07
food O 0 1.6505212840911554e-07
intake O 0 6.290637202255311e-07
and O 0 1.478792022169273e-08
influencing O 0 1.505664272372087e-06
hair O 0 0.4604590833187103
pigmentation O 0 0.038392312824726105
predicts O 0 4.174328296357999e-06
that O 0 4.680820619995529e-09
the O 0 2.1280351703012457e-08
phenotype O 0 2.4397406832576962e-06
associated O 0 4.15271763642977e-08
with O 0 6.307617095302476e-09
a O 0 7.014801326477027e-07
defect O 0 1.1881827958859503e-05
in O 0 1.1503303198878712e-07
POMC O 0 3.2520489185117185e-05
function O 0 1.7416860487173835e-07
would O 0 6.059132573454917e-08
include O 0 1.221939811557604e-07
obesity B-Disease 1 0.9999656677246094
, O 0 3.1159540725411716e-08
alteration O 0 1.6460206779811415e-06
in O 0 6.156453196126677e-07
pigmentation O 1 0.9581377506256104
and O 0 0.001936019049026072
ACTH B-Disease 1 0.9998421669006348
deficiency I-Disease 0 0.4545365273952484
. O 0 2.6799750685313484e-06

The O 0 1.6498019022037624e-06
observation O 0 2.0730713004013523e-06
of O 0 2.483975691802698e-08
these O 0 2.6908482553267277e-08
symptoms O 0 1.149602212535683e-05
in O 0 1.0521305604527242e-08
two O 0 6.06269079383992e-09
probands O 0 2.3588756903336616e-06
prompted O 0 1.671223088806073e-07
us O 0 1.1115087517055144e-08
to O 0 3.078023835811905e-09
search O 0 9.278061874340437e-09
for O 0 3.0582965049319455e-09
mutations O 0 2.430093957173085e-07
within O 0 1.486018952334689e-08
their O 0 7.931516421422202e-08
POMC O 0 0.00026357080787420273
genes O 0 5.838593096996192e-06
. O 0 7.295484465430491e-07

Patient O 0 0.0005757706239819527
1 O 0 1.600437371962471e-06
was O 0 4.635422499177366e-07
found O 0 9.695657610109265e-09
to O 0 3.764245359860752e-09
be O 0 1.6687242698765203e-09
a O 0 4.693739175110068e-09
compound O 0 8.075635093973688e-08
heterozygote O 0 1.6418709947174648e-07
for O 0 2.14889706029453e-09
two O 0 2.573905089064965e-09
mutations O 0 2.0222452690177306e-07
in O 0 3.2887626844058104e-08
exon O 0 2.432531573504093e-06
3 O 0 1.3943309795649839e-07
( O 0 3.5437519585457267e-08
G7013T O 0 7.17503269243025e-07
, O 0 7.131316426267631e-09
C7133delta O 0 5.577661568167969e-07
) O 0 4.024903965671456e-09
which O 0 3.28059779342027e-09
interfere O 0 2.240047969337411e-08
with O 0 1.4454473173941551e-09
appropriate O 0 1.1756656093098172e-08
synthesis O 0 5.4123542980732964e-08
of O 0 8.56309778640707e-09
ACTH O 0 6.920472515048459e-06
and O 0 7.433737891915371e-08
alpha O 0 2.568409854575293e-06
- O 0 6.672486051684245e-05
MSH O 0 0.0011527520837262273
. O 0 2.121471652571927e-06

Patient O 0 0.0004339544102549553
2 O 0 2.5238634862034814e-06
was O 0 3.8822861370135797e-07
homozygous O 0 4.381374196782417e-07
for O 0 3.803716897010645e-09
a O 0 2.655737674217562e-08
mutation O 0 3.611648367041198e-07
in O 0 5.956497872716682e-08
exon O 0 4.839071152673569e-06
2 O 0 3.3128000609394803e-07
( O 0 8.139144114238661e-08
C3804A O 0 1.650475496717263e-06
) O 0 6.134590790907168e-08
which O 0 1.9923176353131566e-07
abolishes O 0 9.960817988030612e-05
POMC O 0 0.0003234571195207536
translation O 0 8.308792530442588e-06
. O 0 1.4730878774571465e-06

These O 0 8.468148848805868e-07
findings O 0 4.712269685569481e-07
represent O 0 1.5232767935913216e-08
the O 0 5.961348303884506e-09
first O 0 4.66606797644431e-09
examples O 0 5.344125586503878e-09
of O 0 2.2384238906880682e-09
a O 0 2.184310005759471e-06
genetic B-Disease 1 0.9999994039535522
defect I-Disease 1 0.999976396560669
within O 0 1.95253477386359e-07
the O 0 4.671578324177972e-07
POMC O 0 0.00014565256424248219
gene O 0 9.802971590033849e-07
and O 0 1.3584168456759471e-08
define O 0 6.536942720458683e-08
a O 0 1.0791769256002226e-07
new O 0 3.792937786784023e-05
monogenic B-Disease 1 0.9932189583778381
endocrine I-Disease 1 0.9998868703842163
disorder I-Disease 0 0.4695792496204376
resulting O 0 1.8106503603121382e-06
in O 0 3.705004871790152e-07
early O 0 0.0843629315495491
- O 1 0.9999538660049438
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0008564399322494864
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.300861413255916e-06
red O 0 0.00017625406326260418
hair O 1 0.9991377592086792
pigmentation O 0 0.08122698962688446
. O 0 2.0624334240437747e-07
. O 0 6.366245770550449e-07

A O 0 6.738051069987705e-06
European O 0 3.943697265640367e-06
multicenter O 0 9.29016387090087e-05
study O 0 1.2746058928314596e-06
of O 0 2.631530605867738e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 3.325499733364268e-07
classification O 0 5.663260935762082e-07
of O 0 5.480988995998359e-09
105 O 0 4.7264470026675554e-07
mutations O 0 4.5814454097126145e-06
and O 0 1.2428734486036319e-08
a O 0 3.3580185743176116e-08
general O 0 2.3497408463413194e-08
system O 0 7.656042839698785e-07
for O 0 1.1835086688449792e-08
genotype O 0 4.65912535219104e-06
- O 0 3.3136893762275577e-06
based O 0 2.2162410573400848e-07
prediction O 0 3.2631808153382735e-06
of O 0 6.374161642952458e-08
metabolic O 0 0.0016856783768162131
phenotype O 0 0.0001976942439796403
. O 0 1.7301186971963034e-06

Phenylketonuria B-Disease 1 0.9998130202293396
( O 0 0.00024957756977528334
PKU B-Disease 0 0.36196184158325195
) O 0 1.7439975863453583e-06
and O 0 1.538996343697363e-06
mild B-Disease 1 0.9999819993972778
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.3282577395439148
MHP B-Disease 1 1.0
) O 0 1.5446265706486884e-06
are O 0 1.499300879004295e-07
allelic B-Disease 0 0.4088912010192871
disorders I-Disease 1 0.9999746084213257
caused O 0 1.0034657861979213e-05
by O 0 2.500013067674445e-07
mutations O 0 9.916115232044831e-06
in O 0 6.390875739725743e-08
the O 0 1.4379155288679613e-07
gene O 0 7.759533218631987e-06
encoding O 0 2.399438562861178e-05
phenylalanine O 0 0.003185608657076955
hydroxylase O 0 0.005956532899290323
( O 0 5.36782090421184e-06
PAH O 0 0.00041923526441678405
) O 0 2.0855043203482637e-06
. O 0 1.4478895309366635e-06

Previous O 0 8.134446943586227e-06
studies O 0 4.0821848301675345e-07
have O 0 1.5135833919543984e-08
suggested O 0 2.782021546465785e-08
that O 0 1.1758577445064589e-09
the O 0 5.4911386548894825e-09
highly O 0 2.151527667137998e-07
variable O 0 2.657870572875254e-05
metabolic O 0 0.025009483098983765
phenotypes O 0 8.725710358703509e-05
of O 0 8.331600724886812e-07
PAH B-Disease 1 0.9999668598175049
deficiency I-Disease 1 0.9821189641952515
correlate O 0 6.929646770004183e-05
with O 0 7.875641131249722e-06
PAH O 0 0.3026003837585449
genotypes O 0 0.0011562923900783062
. O 0 1.0480632226972375e-05

We O 0 1.2562627489387523e-06
identified O 0 3.0967134989623446e-07
both O 0 2.856416614349655e-08
causative O 0 1.1887367463714327e-06
mutations O 0 1.5054015420901123e-06
in O 0 7.690657355396979e-08
686 O 0 7.798273145454004e-06
patients O 0 9.680691164248856e-07
from O 0 3.259356162743643e-08
seven O 0 6.358072823786642e-08
European O 0 5.158716476216796e-07
centers O 0 8.588395417064021e-07
. O 0 6.341492735373322e-07

On O 0 1.3958278941572644e-06
the O 0 4.249591611937831e-08
basis O 0 1.2852477304647891e-08
of O 0 1.0238189185329816e-09
the O 0 1.0265002181597538e-08
phenotypic O 0 2.74175022241252e-07
characteristics O 0 6.949878184059344e-08
of O 0 7.009221647535924e-09
297 O 0 5.24301299265062e-07
functionally O 0 4.406555945024593e-06
hemizygous O 0 7.742822344880551e-05
patients O 0 3.5298694456287194e-07
, O 0 1.5695630350975875e-09
105 O 0 1.7036056121355614e-08
of O 0 1.1153775680838862e-09
the O 0 2.0524767663232524e-08
mutations O 0 3.4297346473977086e-07
were O 0 1.076068745220482e-08
assigned O 0 1.7836786270208904e-08
to O 0 2.8591733425287202e-09
one O 0 8.024436670694968e-10
of O 0 3.8113037725828747e-10
four O 0 4.597390912408628e-09
arbitrary O 0 2.1402658489932946e-07
phenotype O 0 1.1834377801278606e-05
categories O 0 5.032284775552398e-07
. O 0 5.515440761882928e-07

We O 0 1.303727799495391e-06
proposed O 0 5.42649445378629e-07
and O 0 4.444369139378068e-08
tested O 0 3.444162928190053e-07
a O 0 1.5894411120598306e-08
simple O 0 2.0748018414451508e-08
model O 0 3.355425448603455e-08
for O 0 1.000716620680464e-09
correlation O 0 5.7474821346659155e-08
between O 0 3.6284816928855435e-08
genotype O 0 3.3284552500845166e-06
and O 0 6.421189624461476e-08
phenotypic O 0 3.887468210450606e-06
outcome O 0 2.68217399934656e-06
. O 0 1.4222727031665272e-06

The O 0 5.02108059663442e-06
observed O 0 1.3229546311777085e-05
phenotype O 0 3.2811760320328176e-05
matched O 0 2.1605058009299682e-06
the O 0 1.2504544599778455e-07
predicted O 0 3.3237351999559905e-06
phenotype O 0 5.929704911977751e-06
in O 0 2.8353989378615552e-08
79 O 0 1.0657379334588768e-07
% O 0 1.0927594384924078e-09
of O 0 1.9885641744377125e-10
the O 0 3.543182414134094e-09
cases O 0 1.9665300499127625e-09
, O 0 7.792043676957405e-10
and O 0 1.3808031384954234e-09
in O 0 3.1090479080120303e-09
only O 0 1.6106257438863736e-09
5 O 0 5.034206829179766e-09
of O 0 1.4126073644149528e-09
184 O 0 1.5024440358502034e-07
patients O 0 7.403555457585753e-08
was O 0 9.419357382967064e-08
the O 0 1.0318670362607918e-08
observed O 0 3.31680240606147e-07
phenotype O 0 7.826254204701399e-07
more O 0 3.0105431481075584e-09
than O 0 1.6059017449165935e-09
one O 0 1.2456020659357137e-09
category O 0 5.9640661298487885e-09
away O 0 4.032980616130999e-09
from O 0 2.8237723270763126e-09
that O 0 3.7048470957756763e-09
expected O 0 2.0295600222652865e-07
. O 0 2.587176766155608e-07

Among O 0 4.3706447172553453e-07
the O 0 4.7263345237524845e-08
seven O 0 1.9400092199362007e-08
contributing O 0 2.1344417788782266e-08
centers O 0 9.80807612904755e-09
, O 0 6.681906139505145e-10
the O 0 2.8387145967201377e-09
proportion O 0 4.3430530283217195e-09
of O 0 1.8227471754173052e-09
patients O 0 2.399071341585568e-08
for O 0 2.1365180735699596e-09
whom O 0 7.952569269775722e-09
the O 0 1.8196704587580825e-08
observed O 0 1.641105200178572e-06
phenotype O 0 1.160935698862886e-05
did O 0 1.0303472208761377e-07
not O 0 4.220428895251871e-09
match O 0 1.4722543184575443e-08
the O 0 4.188290247952864e-08
predicted O 0 1.582977802172536e-06
phenotype O 0 1.2625609997485299e-06
was O 0 8.363652881371308e-08
4 O 0 1.703751983939128e-08
% O 0 2.801711973532406e-09
- O 0 1.1826222845456869e-07
23 O 0 7.485827779873944e-08
% O 0 6.400156848940242e-09
( O 0 2.8009814911911235e-08
P O 0 1.5944737242534757e-05
< O 0 6.036385684637935e-07
. O 0 1.555959805443763e-08
0001 O 0 7.482567525585182e-06
) O 0 5.7584852442005285e-09
, O 0 8.765911330144149e-10
suggesting O 0 2.1471159072916635e-08
that O 0 1.2181851083425954e-09
differences O 0 4.503656558796365e-09
in O 0 1.5764787253402801e-09
methods O 0 2.7837823157739194e-09
used O 0 4.639710393661289e-09
for O 0 9.217732688249214e-10
mutation O 0 9.935511968706123e-08
detection O 0 3.9237585269802366e-07
or O 0 7.740537171230244e-07
phenotype O 0 0.00015640562924090773
classification O 0 1.4431017007154878e-05
may O 0 1.6054990510383504e-06
account O 0 1.3848762137058657e-08
for O 0 1.5667603880942238e-09
a O 0 9.718616134080094e-09
considerable O 0 1.7058003010106404e-08
proportion O 0 1.3293430356497993e-08
of O 0 1.7992185519233317e-08
genotype O 0 0.0002608692739158869
- O 0 0.010606725700199604
phenotype O 0 0.0013389615342020988
inconsistencies O 0 3.873812238452956e-05
. O 0 3.22157302434789e-06

Our O 0 1.6769879493949702e-06
data O 0 8.734731409276719e-07
indicate O 0 2.2966629842358088e-07
that O 0 1.044942798955617e-08
the O 0 7.749364527853686e-08
PAH O 0 9.757043153513223e-05
- O 0 1.5024374988570344e-05
mutation O 0 3.233198412999627e-06
genotype O 0 1.9619812974269735e-06
is O 0 5.343758324727332e-09
the O 0 5.746361164682412e-09
main O 0 5.561827975952838e-08
determinant O 0 1.0521209503622231e-07
of O 0 8.026477260614229e-09
metabolic O 0 0.00023085092834662646
phenotype O 0 6.89102716933121e-06
in O 0 4.551899479565691e-08
most O 0 9.551882129699152e-08
patients O 0 4.611067652149359e-06
with O 0 4.125749910599552e-05
PAH B-Disease 1 0.9999946355819702
deficiency I-Disease 1 0.992620587348938
. O 0 1.8757991711026989e-06

In O 0 8.850623771650135e-07
the O 0 7.688267089633882e-08
present O 0 3.245782664862418e-08
study O 0 9.957553892547821e-09
, O 0 1.0575279540958604e-09
the O 0 4.185493285291386e-09
classification O 0 9.920003662955423e-08
of O 0 5.751437548440208e-09
105 O 0 5.090402737550903e-06
PAH O 0 0.002721932251006365
mutations O 0 2.718994437600486e-05
may O 0 1.2873582022621122e-07
allow O 0 6.43413411438587e-09
the O 0 8.192844624943518e-09
prediction O 0 1.783148775302834e-07
of O 0 1.3391068254264837e-09
the O 0 1.1963865453878952e-08
biochemical O 0 1.491246734985907e-06
phenotype O 0 4.780807103088591e-06
in O 0 5.173792416712786e-08
> O 0 2.7861986495736346e-07
10 O 0 3.057137476503158e-08
, O 0 3.0186910748852824e-09
000 O 0 1.3493116846063913e-08
genotypes O 0 2.765932549664285e-07
, O 0 5.0281037111687965e-09
which O 0 1.5336086178763253e-08
may O 0 6.42601705180823e-08
be O 0 6.270117203222014e-10
useful O 0 8.236507587078279e-10
for O 0 3.8149403081000344e-10
the O 0 6.6692278366531355e-09
management O 0 7.335887630688376e-08
of O 0 1.1435264291037583e-08
hyperphenylalaninemia B-Disease 1 0.9999997615814209
in O 0 8.08282129582949e-06
newborns O 0 0.0002953136572614312
. O 0 5.965104037386482e-07

Somatic O 0 0.00045439344830811024
instability O 0 8.26793911983259e-05
of O 0 1.0543708839350074e-07
the O 0 2.496248896477482e-07
CTG O 0 2.3762617274769582e-05
repeat O 0 2.5350082069053315e-06
in O 0 1.3335565540728567e-07
mice O 0 3.2409502637165133e-06
transgenic O 0 7.222209319479589e-07
for O 0 3.143412996564621e-08
the O 0 4.2408892113598995e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 6.258703251660336e-06
is O 0 1.697314360171731e-07
age O 0 2.732837067753735e-08
dependent O 0 9.606216266888623e-09
but O 0 3.537658610497374e-09
not O 0 1.6756036558263077e-09
correlated O 0 3.180151253445729e-08
to O 0 1.7179720979143553e-09
the O 0 4.868128122836879e-09
relative O 0 8.487490532615993e-08
intertissue O 0 2.1690425455744844e-06
transcription O 0 1.5746064718769048e-06
levels O 0 8.253891223830578e-07
and O 0 1.88263314271353e-07
proliferative O 0 0.00018732868193183094
capacities O 0 1.1337013347656466e-05
. O 0 1.0168755579798017e-06

A O 0 1.975856866920367e-05
( O 0 2.528469849494286e-06
CTG O 0 2.8280319384066388e-05
) O 0 6.553571552103676e-08
nexpansion O 0 9.275160550714645e-07
in O 0 1.915294767229625e-08
the O 0 2.6233808014808346e-08
3 O 0 2.2361426488259895e-07
- O 0 2.4033549834712176e-06
untranslated O 0 5.5290038289967924e-06
region O 0 3.918811160019686e-07
( O 0 5.464300656399246e-08
UTR O 0 9.426796054867737e-07
) O 0 7.213176278497713e-09
of O 0 2.3420880790325782e-09
the O 0 1.7888919501274358e-07
DM O 1 0.9999978542327881
protein O 0 2.917041001637699e-06
kinase O 0 1.9504072042764165e-05
gene O 0 3.1604977266397327e-06
( O 0 8.650435034951443e-08
DMPK O 0 6.896293143654475e-06
) O 0 2.031573309579926e-08
is O 0 5.090071475422064e-09
responsible O 0 7.790193023993197e-08
for O 0 1.845948531808972e-07
causing O 1 0.9817126393318176
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.3452017605304718
DM B-Disease 1 1.0
) O 0 7.5041780291940086e-06
. O 0 1.4720584431415773e-06

Major O 0 2.151225635316223e-05
instability O 0 2.103691440424882e-05
, O 0 1.9138633788884363e-08
with O 0 3.644474277919585e-09
very O 0 5.909735367737312e-09
large O 0 6.4395733190281135e-09
expansions O 0 1.0545720385835011e-07
between O 0 1.8661690859289592e-08
generations O 0 1.1558678458811755e-08
and O 0 4.7140695791370035e-09
high O 0 5.0081499836096555e-08
levels O 0 1.6329350316368618e-08
of O 0 1.4578402929288359e-09
somatic O 0 6.476769272012461e-07
mosaicism O 0 4.242612703819759e-06
, O 0 1.1070635075327573e-08
is O 0 3.531462899886151e-09
observed O 0 6.258628815203338e-08
in O 0 5.970145622313794e-08
patients O 0 6.74709781378624e-07
. O 0 4.148554353378131e-07

There O 0 1.0886348036365234e-06
is O 0 3.616411348161819e-08
a O 0 2.2621643225306798e-08
good O 0 1.3130464715516155e-08
correlation O 0 5.739725850162358e-08
between O 0 2.8317291622670382e-08
repeat O 0 1.5011380583018763e-06
size O 0 2.7166959171154303e-07
( O 0 1.278189998288326e-08
at O 0 2.222179240618516e-08
least O 0 4.510499529430945e-09
in O 0 1.1229582597138688e-08
leucocytes O 0 1.5450434602826135e-06
) O 0 6.3501439662161374e-09
, O 0 3.7193121915635174e-09
clinical O 0 9.772618625447649e-08
severity O 0 4.410423571243882e-06
and O 0 1.3230753381776594e-07
age O 0 6.213987546743738e-08
of O 0 1.2347925348876743e-08
onset O 0 0.000843623245600611
. O 0 1.4104106185186538e-06

The O 0 1.3648073945660144e-05
trinucleotide O 0 0.001377201871946454
repeat O 0 0.00012684680405072868
instability O 0 1.8473712771083228e-05
mechanisms O 0 2.0793040675926022e-06
involved O 0 2.667887599727692e-07
in O 0 8.9313954276804e-07
DM B-Disease 1 1.0
and O 0 7.386897493688593e-08
other O 0 1.2051582842786956e-08
human O 0 8.651967391415383e-07
genetic B-Disease 1 0.9999998807907104
diseases I-Disease 1 1.0
are O 0 3.544265680943681e-08
unknown O 0 4.328310865275853e-07
. O 0 5.06610206230107e-07

We O 0 3.1627230328012956e-06
studied O 0 3.6389860724739265e-06
somatic O 0 1.654232073633466e-05
instability O 0 6.154460152174579e-06
by O 0 9.777112097708596e-08
measuring O 0 1.8755522432911675e-06
the O 0 1.5755107085624331e-07
CTG O 0 1.235200761584565e-05
repeat O 0 2.4509809009032324e-06
length O 0 2.1388682114320545e-07
at O 0 6.331582369512034e-08
several O 0 3.5814764487440698e-09
ages O 0 1.7977640709432308e-08
in O 0 1.668905680318744e-09
various O 0 1.6963449533946573e-09
tissues O 0 8.915042570833975e-08
of O 0 2.25459051428345e-09
transgenic O 0 3.8318270867421234e-07
mice O 0 1.559424845254398e-06
carrying O 0 4.058509261994914e-08
a O 0 1.000627847247415e-07
( O 0 1.5178453338648978e-07
CTG O 0 7.589231699967058e-06
) O 0 3.8525584500348486e-08
55expansion O 0 6.302112183220743e-07
surrounded O 0 5.954782267281189e-08
by O 0 9.803082789971995e-09
45 O 0 3.2100366809117986e-08
kb O 0 9.566392691340297e-07
of O 0 1.434975804848193e-09
the O 0 2.073468685637181e-08
human O 0 1.1688287315791968e-07
DM B-Disease 1 0.9999998807907104
region O 0 1.7421693598862475e-07
, O 0 4.917383389368979e-09
using O 0 2.010514599248836e-08
small O 0 7.526559642201391e-08
- O 0 9.787531780602876e-06
pool O 0 4.119861387152923e-06
PCR O 0 9.126647637458518e-05
. O 0 1.098165398616402e-06

These O 0 1.404660110893019e-06
mice O 0 2.8900247343699448e-05
have O 0 2.478528315918993e-08
been O 0 8.796632755547762e-09
shown O 0 1.405145777511052e-08
to O 0 3.895122446806454e-09
reproduce O 0 5.147815613781859e-07
the O 0 8.721353417229238e-09
intergenerational O 0 9.252158861272619e-08
and O 0 9.317503213424061e-09
somatic O 0 4.8510850092498e-07
instability O 0 3.4680522276175907e-07
of O 0 3.874050857888278e-09
the O 0 3.3469117255435776e-08
55 O 0 1.4284424310062604e-07
CTG O 0 3.0528105980920373e-06
repeat O 0 8.768124075686501e-07
suggesting O 0 1.5159763222527545e-07
that O 0 3.4585705410705714e-09
surrounding O 0 1.975923069608143e-08
sequences O 0 2.7477016217858363e-08
and O 0 2.548371513810821e-09
the O 0 8.591925393375277e-09
chromatin O 0 6.842338393653336e-07
environment O 0 6.33131662652886e-08
are O 0 2.4900508321934467e-09
involved O 0 5.261894475694362e-09
in O 0 5.861467045065183e-08
instability O 0 5.43662326890626e-06
mechanisms O 0 8.48996114655165e-06
. O 0 1.4142480040391092e-06

As O 0 7.070810283948958e-07
observed O 0 3.3910311003637617e-07
in O 0 7.349217234775551e-09
some O 0 9.841089054773988e-10
of O 0 4.537643871760366e-10
the O 0 1.465111054699264e-08
tissues O 0 3.5766665860137437e-06
of O 0 1.6908808220250648e-07
DM B-Disease 1 1.0
patients O 0 1.4704670320497826e-05
, O 0 3.545000737403825e-09
there O 0 1.0917408088673142e-09
is O 0 5.998481711344539e-10
a O 0 7.435464244309742e-09
tendency O 0 9.739904527350518e-08
for O 0 3.124838166002064e-09
repeat O 0 7.315696279874828e-07
length O 0 1.3305357526860462e-07
and O 0 1.5447053414163747e-08
somatic O 0 5.011551706957107e-07
mosaicism O 0 1.5926113974273903e-06
to O 0 1.4945264581456286e-08
increase O 0 1.4447313567700348e-08
with O 0 1.6878890507499023e-09
the O 0 2.430037682188413e-08
age O 0 8.813763940906938e-09
of O 0 4.6552914301223325e-10
the O 0 1.613209121842374e-08
mouse O 0 1.847480598371476e-05
. O 0 4.53524307886255e-07

Furthermore O 0 1.4302583622338716e-05
, O 0 2.2327969873003894e-07
we O 0 1.497048529586209e-08
observed O 0 3.182978858262686e-08
no O 0 3.660029612717608e-09
correlation O 0 2.2336866578598347e-08
between O 0 3.191500397292657e-09
the O 0 1.436748586769454e-08
somatic O 0 1.6547955965506844e-06
mutation O 0 2.0955762920493726e-06
rate O 0 1.8381118707111455e-06
and O 0 5.050944196227647e-08
tissue O 0 8.969747796072625e-06
proliferation O 0 2.59673811342509e-06
capacity O 0 5.935572744419915e-07
. O 0 4.848291155212792e-07

The O 0 1.5632679151167395e-06
somatic O 0 2.621627936605364e-05
mutation O 0 2.154867979697883e-05
rates O 0 6.745490281900857e-06
in O 0 1.0109251213918924e-08
different O 0 4.8592410095693594e-09
tissues O 0 1.6454682736366522e-06
were O 0 1.9263849182493686e-08
also O 0 5.108570455547579e-09
not O 0 1.992844333997823e-09
correlated O 0 4.567048605963464e-08
to O 0 2.679947375128222e-09
the O 0 5.9792721884832645e-09
relative O 0 6.534312291250899e-08
inter O 0 4.3781540171039524e-07
- O 0 1.61428761202842e-05
tissue O 0 2.559512040534173e-06
difference O 0 9.599640193869163e-09
in O 0 4.0647978316599165e-09
transcriptional O 0 3.9656890749029117e-07
levels O 0 3.6469515407588915e-08
of O 0 6.944174124612346e-10
the O 0 2.6194446611782496e-09
three O 0 4.473435399887649e-09
genes O 0 5.7435368461256076e-08
( O 0 1.7394077289623056e-08
DMAHP O 0 2.9744180665147724e-06
, O 0 1.2557049622330396e-08
DMPK O 0 2.5469112188147847e-06
and O 0 1.997701382094874e-08
59 O 0 9.734723249721355e-08
) O 0 6.682788544765117e-09
surrounding O 0 1.9408679108323668e-08
the O 0 4.121509178389715e-08
repeat O 0 2.411721652606502e-06
. O 0 6.173407740561743e-08
. O 0 2.8277253250053036e-07

A O 0 2.9174525479902513e-05
novel O 0 1.6553225577808917e-05
missense O 0 0.00041027553379535675
mutation O 0 5.950338891125284e-05
in O 0 8.234605388679483e-07
patients O 0 9.930583928507986e-07
from O 0 6.4635344187991e-08
a O 0 3.757701847462158e-07
retinoblastoma B-Disease 0 0.00035989939351566136
pedigree O 0 8.017059735720977e-05
showing O 0 2.017930273723323e-05
only O 0 7.622720943345485e-08
mild O 0 2.972085894725751e-05
expression O 0 2.0452634430512262e-07
of O 0 6.108586525499504e-09
the O 0 2.3600316012561962e-07
tumor B-Disease 0 0.00022533551964443177
phenotype O 0 0.00010426968219690025
. O 0 1.7360986248604604e-06

We O 0 8.97886138773174e-07
have O 0 2.725518299939722e-08
used O 0 3.280030114183319e-08
single O 0 4.1449865761933324e-08
strand O 0 5.530198450287571e-07
conformation O 0 3.470888714218745e-06
polymorphism O 0 2.2648425783700077e-06
analysis O 0 4.620178373215822e-08
to O 0 1.1904862873279853e-08
study O 0 1.3378055108148601e-08
the O 0 1.8878896668184098e-08
27 O 0 7.351954423029383e-08
exons O 0 1.0823865892461981e-07
of O 0 2.916032304511873e-09
the O 0 4.1242770976168686e-08
RB1 O 0 1.0949844181595836e-05
gene O 0 1.8256227463098185e-07
in O 0 6.039077682373772e-09
individuals O 0 5.150019855015842e-10
from O 0 1.6524159818231965e-09
a O 0 3.419308924890174e-08
family O 0 2.65352554151832e-07
showing O 0 8.884536327968817e-06
mild O 0 0.0031695805955678225
expression O 0 2.1857802323665965e-07
of O 0 8.828519248993416e-09
the O 0 2.205151616863077e-07
retinoblastoma B-Disease 0 0.0006291610770858824
phenotype O 0 0.0004568880540318787
. O 0 1.3475623745762277e-06

In O 0 1.0308795026503503e-06
this O 0 7.035799143295662e-08
family O 0 1.1853864378963408e-07
affected O 0 5.376004708068649e-08
individuals O 0 6.867544755095878e-09
developed O 0 5.071937039247132e-07
unilateral B-Disease 0 0.018750017508864403
tumors I-Disease 1 1.0
and O 0 6.762886641809018e-07
, O 0 3.3092932838485467e-09
as O 0 2.5702602268751207e-09
a O 0 4.337465053794176e-09
result O 0 6.420845188870317e-09
of O 0 1.3655443442672777e-09
linkage O 0 4.963113724443247e-07
analysis O 0 4.085357829808345e-08
, O 0 1.1241583663945676e-08
unaffected O 0 1.3842578709954978e-06
mutation O 0 3.001869970375992e-07
carriers O 0 5.829635441045866e-08
were O 0 1.2790654757566244e-08
also O 0 5.88696469350225e-09
identified O 0 8.443373999966752e-09
within O 0 6.766220472798068e-09
the O 0 5.8304358674377e-08
pedigree O 0 1.1649993211904075e-05
. O 0 6.776916734452243e-07

A O 0 5.876102477486711e-06
single O 0 7.438637226186984e-07
band O 0 6.153289291432884e-07
shift O 0 3.461285302819306e-07
using O 0 6.228190585488846e-08
SSCP O 0 3.606517111620633e-06
was O 0 1.3588864078428742e-07
identified O 0 2.7146283443357788e-08
in O 0 1.561939555472236e-08
exon O 0 1.1108029411843745e-06
21 O 0 7.210318386796644e-08
which O 0 7.686591807498644e-09
resulted O 0 3.718831464993855e-08
in O 0 1.6658978196915086e-08
a O 0 1.420205535396235e-07
missense O 0 1.7926962755154818e-05
mutation O 0 3.081229124290985e-06
converting O 0 4.746869421978772e-07
a O 0 7.575966947115376e-07
cys O 0 0.018514558672904968
- O 0 8.047883602557704e-05
- O 0 2.4587287043686956e-05
> O 0 2.795298087221454e-06
arg O 0 1.8851137610909063e-06
at O 0 1.289132285364758e-07
nucleotide O 0 5.783562073702342e-07
position O 0 2.748562053511705e-07
28 O 0 8.420556696364656e-08
in O 0 1.1276092948264704e-08
the O 0 6.486183679044188e-08
exon O 0 1.1716108929249458e-05
. O 0 9.191035701405781e-07

The O 0 2.0387601580296177e-06
mutation O 0 8.547192919650115e-06
destroyed O 0 1.3613396276923595e-06
an O 0 7.022794079603045e-08
NdeI O 0 7.1397621468349826e-06
restriction O 0 1.991885710594943e-06
enzyme O 0 2.021101181526319e-06
site O 0 2.3453649191651493e-06
. O 0 8.272347145066306e-07

Analysis O 0 2.1661176106135827e-06
of O 0 1.0341663525537115e-08
all O 0 2.6015198884010715e-09
family O 0 8.536793494329231e-09
members O 0 1.306829644498464e-09
demonstrated O 0 5.083512277792579e-09
that O 0 9.150308843963728e-10
the O 0 1.9840992848685346e-08
missense O 0 1.2172680726507679e-05
mutation O 0 4.183407327218447e-06
co O 0 1.0778496744023869e-06
- O 0 2.0738148123200517e-06
segregated O 0 4.926867518406652e-07
with O 0 3.678079352198438e-08
patients O 0 3.084923037022236e-07
with O 0 3.2666496281308355e-06
tumors B-Disease 1 1.0
or O 0 1.4018582078278996e-05
who O 0 8.988716615476733e-08
, O 0 1.5226573335525018e-09
as O 0 1.4331433817460493e-09
a O 0 5.58346568979573e-09
result O 0 7.2521335603426e-09
of O 0 7.975882732047523e-10
linkage O 0 3.460790196641028e-07
analysis O 0 5.6805866677223094e-08
had O 0 1.570173822074139e-07
been O 0 1.0009443940361962e-08
predicted O 0 1.8787231681471894e-07
to O 0 8.811039897693718e-09
carry O 0 4.830347677398095e-08
the O 0 6.13185378028902e-08
predisposing O 0 6.800380106142256e-06
mutation O 0 7.269181423907867e-06
. O 0 7.347958330683468e-07

These O 0 3.4524700254223717e-07
observations O 0 4.4220971062713943e-07
point O 0 3.680184690324495e-08
to O 0 2.9860953709714977e-09
another O 0 2.8647519911828567e-09
region O 0 5.4809055072269075e-09
of O 0 1.1081910944454876e-09
the O 0 3.057528275007826e-08
RB1 O 0 9.697206223791e-06
gene O 0 2.2689665968300687e-07
where O 0 1.2208094091192834e-08
mutations O 0 1.620787628553444e-07
only O 0 2.4404827048130073e-09
modify O 0 1.9867660228101158e-07
the O 0 7.54858131557512e-09
function O 0 2.51417997532144e-09
of O 0 2.0786343479795022e-10
the O 0 1.6315271356148742e-09
gene O 0 3.438366391605996e-08
and O 0 1.7959400633316136e-09
raise O 0 9.12596487268047e-09
important O 0 1.6162944316278072e-09
questions O 0 4.666121267149492e-09
for O 0 7.906391652490186e-10
genetic O 0 4.094024319556411e-08
counseling O 0 1.496660217981116e-08
in O 0 4.5689372285551144e-09
families O 0 2.8984437072665514e-09
with O 0 2.1801824789946522e-09
these O 0 6.915205297275406e-09
distinctive O 0 3.537327529556933e-06
phenotypes O 0 4.685593467002036e-06
. O 0 5.99839609094488e-08
. O 0 2.780616341624409e-07

Maternal B-Disease 0 0.013980942778289318
disomy I-Disease 0 0.1559920608997345
and O 0 0.011732790619134903
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 3.406244650250301e-05
with O 0 1.526773871773912e-07
gamete O 0 4.854324288317002e-06
complementation O 0 2.6811641873791814e-05
in O 0 4.466770420208377e-08
a O 0 6.743148617260886e-08
case O 0 2.8103517735189598e-08
of O 0 7.115067202079217e-09
familial O 0 1.0504137208044995e-05
translocation O 0 2.4414151994278654e-05
( O 0 9.485651020213481e-08
3 O 0 6.183424972050489e-08
; O 0 1.8616965746787173e-08
15 O 0 4.2979380054930516e-08
) O 0 1.7482586045503012e-08
( O 0 2.108062346906081e-08
p25 O 0 1.2342247828200925e-06
; O 0 4.2324021620743224e-08
q11 O 0 3.902889318396774e-07
. O 0 9.421635915884963e-09
2 O 0 5.1612747853369e-08
) O 0 8.98283829542379e-08
. O 0 3.796601504291175e-07

Maternal B-Disease 0 0.09242870658636093
uniparental I-Disease 1 0.7341431379318237
disomy I-Disease 1 0.7400550246238708
( I-Disease 0 0.00017208713688887656
UPD I-Disease 1 0.9999991655349731
) I-Disease 0 2.3533024773314537e-07
for I-Disease 0 1.776070668313423e-08
chromosome I-Disease 0 1.0754511095001362e-06
15 I-Disease 0 2.069182158948024e-08
is O 0 1.2142230554346156e-09
responsible O 0 2.8145290542624934e-09
for O 0 6.298957466732702e-10
an O 0 1.048364062228302e-09
estimated O 0 2.7945445957300308e-09
30 O 0 4.9479123021001215e-09
% O 0 5.944121306278305e-10
of O 0 4.512614171225948e-10
cases O 0 3.5110740981281197e-08
of O 0 3.582124918466434e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0002092179493047297
PWS B-Disease 1 1.0
) O 0 2.9415009521471802e-06
. O 0 1.6507966620338266e-06

We O 0 7.450386760865513e-07
report O 0 2.962317466881359e-07
on O 0 2.3643336177769925e-08
an O 0 1.870091415057118e-09
unusual O 0 9.314056192977205e-09
case O 0 5.7290150401456685e-09
of O 0 4.317646684626197e-09
maternal B-Disease 0 1.856061203397985e-06
disomy I-Disease 0 8.381045518035535e-06
15 I-Disease 0 1.468503825208245e-07
in O 0 5.98588712819037e-07
PWS B-Disease 1 1.0
that O 0 2.973995805177765e-08
is O 0 3.566942075039492e-09
most O 0 8.569253084900197e-10
consistent O 0 1.4844523832380219e-08
with O 0 4.222602711934087e-09
adjacent O 0 3.220173994122888e-07
- O 0 7.797214607307978e-07
1 O 0 2.232954088299266e-08
segregation O 0 4.97530265874957e-08
of O 0 1.136953531322149e-09
a O 0 3.396843695213647e-08
paternal O 0 1.1850166629301384e-05
t O 0 1.8612336134538054e-05
( O 0 3.418539407107346e-08
3 O 0 3.475726373380894e-08
; O 0 1.3013133681738509e-08
15 O 0 2.4234880768858602e-08
) O 0 7.261642842593119e-09
( O 0 1.1814112355068573e-08
p25 O 0 6.160705083857465e-07
; O 0 1.8168716309219235e-08
q11 O 0 2.1193392285567825e-07
. O 0 3.6518084112202587e-09
2 O 0 1.0556603591282965e-08
) O 0 1.939519878035867e-09
with O 0 3.322771391367496e-09
simultaneous O 0 5.888123837394232e-07
maternal O 0 7.883035323175136e-06
meiotic O 0 2.0270781533326954e-05
nondisjunction O 0 3.349346297909506e-05
for O 0 1.2671893045990146e-07
chromosome O 0 2.2686930606141686e-05
15 O 0 1.183733161269629e-06
. O 0 7.588628250232432e-07

The O 0 5.417732609203085e-06
patient O 0 2.2197102225618437e-05
( O 0 7.040711693662161e-07
J O 0 9.587651584297419e-05
. O 0 1.6768323618521208e-08
B O 0 7.029615289866342e-08
. O 0 1.209302324944872e-09
) O 0 1.1098345575888402e-09
, O 0 8.046261990024561e-10
a O 0 1.0360242441720402e-08
17 O 0 8.399991457963552e-08
- O 0 8.203964512176753e-07
year O 0 4.75099035668336e-08
- O 0 9.591149137122557e-07
old O 0 6.572285542461032e-07
white O 0 1.9925913363749714e-07
male O 0 4.026841082804822e-08
with O 0 2.1689849916128878e-08
PWS B-Disease 1 1.0
, O 0 1.6636496624755637e-08
was O 0 8.533965001333854e-08
found O 0 2.8822577657905413e-09
to O 0 1.6693736393236236e-09
have O 0 1.8756425301802437e-09
47 O 0 1.7566215149145137e-08
chromosomes O 0 2.2774772290290457e-08
with O 0 1.629076762377224e-09
a O 0 3.5453069813229376e-08
supernumerary O 0 1.4653201105829794e-06
, O 0 2.8548154062946196e-08
paternal O 0 1.8053180610877462e-05
der O 0 0.004054572433233261
( O 0 5.2647482817747004e-08
15 O 0 6.958789100508511e-09
) O 0 1.0320614363124037e-09
consisting O 0 1.2563488027694802e-09
of O 0 3.2932287452602793e-10
the O 0 2.4065094805791887e-08
short O 0 1.587003225722583e-06
arm O 0 0.0013580755330622196
and O 0 8.676936502638455e-09
the O 0 1.6814890813066086e-08
proximal O 0 9.005909305415116e-06
long O 0 1.0888766155403573e-06
arm O 0 2.4305383703904226e-05
of O 0 8.593416644941954e-09
chromosome O 0 1.3133354741512449e-06
15 O 0 3.0290280506051204e-08
, O 0 6.475253666593517e-09
and O 0 3.5496643846499865e-08
distal O 0 0.011426527053117752
chromosome O 0 0.07553789019584656
arm O 1 0.8895113468170166
3p O 0 0.006546120624989271
. O 0 5.027242423238931e-06

The O 0 1.3738832421950065e-05
t O 0 0.00013128794671501964
( O 0 2.5965300665120594e-07
3 O 0 7.635219390067505e-08
; O 0 1.0556281182516614e-08
15 O 0 6.06941341629863e-09
) O 0 1.245563985285969e-09
was O 0 2.585074732053272e-08
present O 0 1.5828904853520953e-09
in O 0 2.052436443022998e-09
the O 0 5.040499573283341e-09
balanced O 0 2.8382881822608397e-08
state O 0 4.5225427847128685e-09
in O 0 7.55749773873049e-09
the O 0 5.8790796231278364e-08
patients O 0 1.0886144252708618e-07
father O 0 8.873479373505688e-08
and O 0 6.978181144035034e-09
a O 0 1.2458644960133824e-07
sister O 0 3.4003569453489035e-05
. O 0 5.671280973729154e-07

Fluorescent O 0 0.0002253785205539316
in O 0 1.0405732382423594e-06
situ O 0 3.83349333787919e-06
hybridization O 0 1.6488676237713662e-06
analysis O 0 1.7308435928953259e-07
demonstrated O 0 1.7500008198112482e-07
that O 0 1.1272888400526426e-08
the O 0 1.0282739992817369e-07
PWS B-Disease 1 0.9999986886978149
critical O 0 3.2914240932768735e-07
region O 0 1.3676309151833266e-07
resided O 0 3.963783399285603e-07
on O 0 3.547945226500815e-08
the O 0 8.679236884745478e-09
derivative O 0 1.3751196092925966e-07
chromosome O 0 5.748303806285548e-07
3 O 0 1.1963979140716674e-08
and O 0 2.007072730236814e-09
that O 0 1.2945913230311135e-09
there O 0 2.278731647820109e-09
was O 0 5.278161196997644e-08
no O 0 2.5577893136841112e-09
deletion O 0 6.358752102642029e-08
of O 0 1.8114936217727973e-09
the O 0 1.4385149427198485e-07
PWS B-Disease 1 0.9999998807907104
region O 0 1.3790055675144686e-07
on O 0 2.2326904058900254e-07
the O 0 1.0598284916341072e-08
normal O 0 6.978809352631288e-08
pair O 0 3.1366933939125374e-08
of O 0 2.25373075757318e-09
15s O 0 2.5012579385474965e-07
present O 0 3.267746961910234e-08
in O 0 1.7372600780163339e-07
J O 0 0.001691811135970056
. O 0 9.232359730049211e-07

B O 0 0.0016430830582976341
. O 0 2.9074843041598797e-05

Methylation O 0 0.00024173864221666008
analysis O 0 4.101429112779442e-06
at O 0 8.363236361219606e-07
exon O 0 2.8119500257162144e-06
alpha O 0 1.4938231629457732e-07
of O 0 2.6914062090099833e-09
the O 0 7.487852116128124e-09
small O 0 2.05918979645503e-08
nuclear O 0 6.390168891812209e-07
ribonucleoprotein O 0 8.45927388581913e-06
- O 0 2.3312161374633433e-06
associated O 0 5.461549790197751e-07
polypeptide O 0 3.8278490137599874e-06
N O 0 2.1847288280696375e-06
( O 0 4.5721389341224494e-08
SNRPN O 0 3.2813616144267144e-06
) O 0 1.6311917150346744e-08
gene O 0 2.0010922696656053e-07
showed O 0 2.214006116219025e-07
a O 0 2.7004627867199815e-08
pattern O 0 5.655369932355825e-07
characteristic O 0 2.7763443100070617e-08
of O 0 6.81641132427302e-10
only O 0 1.914358893628787e-09
the O 0 1.8770462517636588e-08
maternal O 0 2.9057573556201532e-06
chromosome O 0 4.325828285800526e-06
15 O 0 2.0319673410540418e-07
in O 0 3.8101816812741163e-07
J O 0 0.012925790622830391
. O 0 1.9211836388421943e-06

B O 0 0.0013484712690114975
. O 0 5.223672269494273e-05

Maternal B-Disease 0 0.0024860056582838297
disomy I-Disease 0 0.0011310288682579994
was O 0 5.536454409593716e-06
confirmed O 0 9.079504934561555e-07
by O 0 8.52408987839226e-08
polymerase O 0 7.837773409846704e-06
chain O 0 7.25809741197736e-06
reaction O 0 8.45046486119827e-07
analysis O 0 8.7311946117552e-08
of O 0 1.3075308835652777e-08
microsatellite O 0 8.451677786069922e-06
repeats O 0 1.4470844689640217e-05
at O 0 3.0852115173729544e-07
the O 0 4.395054631345374e-08
gamma O 0 1.2787870673491852e-06
- O 0 2.534761733841151e-06
aminobutyric O 0 9.737313121149782e-06
acid O 0 1.4394718164112419e-06
receptor O 0 2.8594638479262358e-06
beta3 O 0 1.0585299605736509e-05
subunit O 0 2.769173534034053e-06
( O 0 3.4755615274661977e-07
GABRB3 O 0 2.687733285711147e-05
) O 0 3.8476386521324457e-07
locus O 0 1.96885612240294e-05
. O 0 1.288526618736796e-06

A O 0 3.5513894545147195e-05
niece O 0 0.0003102547489106655
( O 0 5.511454901352408e-07
B O 0 5.615304985440162e-07
. O 0 6.492122395229671e-09
B O 0 4.54757760337543e-08
. O 0 7.54946993808403e-10
) O 0 5.394097390976071e-10
with O 0 7.348344710500498e-10
45 O 0 5.10442088597074e-09
chromosomes O 0 1.533977034284817e-08
and O 0 1.3956201749820707e-09
the O 0 6.625119119973988e-09
derivative O 0 6.386829909388325e-08
3 O 0 1.2938983218191424e-08
but O 0 1.86607218566337e-09
without O 0 2.4766368955653206e-09
the O 0 1.5593348834386234e-08
der O 0 2.0893321561743505e-05
( O 0 1.3243448115929368e-08
15 O 0 6.469056845759269e-09
) O 0 1.4494782041296617e-09
demonstrated O 0 1.0505864622700756e-08
a O 0 3.331867048927961e-08
phenotype O 0 4.282507234165678e-06
consistent O 0 8.88633451268106e-08
with O 0 4.096748718040999e-09
that O 0 6.109472039383945e-09
reported O 0 3.201501499461301e-07
for O 0 6.302590449536183e-09
haploinsufficiency O 0 1.4584052223653998e-06
of O 0 1.2115978442750475e-08
distal O 0 4.628315582522191e-05
3 O 0 5.136172148922924e-06
p O 0 0.00022124270617496222
. O 0 9.565964091962087e-07

Uniparental B-Disease 1 0.9999971389770508
disomy I-Disease 1 0.9999940395355225
associated O 0 3.9155365811893716e-05
with O 0 6.619632699766953e-07
unbalanced O 0 0.00015687850827816874
segregation O 0 3.435736061874195e-06
of O 0 1.0088332835778147e-08
non O 0 7.979739535812769e-08
- O 0 1.4844405313851894e-06
Robertsonian O 0 4.193273070995929e-06
translocations O 0 8.643012733955402e-06
has O 0 3.006980975328588e-08
been O 0 1.3948411314856912e-08
reported O 0 3.157390153774031e-07
previously O 0 2.6899449778738926e-08
but O 0 2.4151114441650634e-09
has O 0 1.3986101166096887e-09
not O 0 5.487879595200695e-10
, O 0 2.2214395600794745e-10
to O 0 7.198041052092208e-10
our O 0 9.805041223387434e-10
knowledge O 0 7.111250477365161e-10
, O 0 3.9078826286065294e-10
been O 0 7.381299460540447e-10
observed O 0 5.319839679884808e-09
in O 0 2.6927258200970527e-09
a O 0 1.2765721812968422e-08
case O 0 5.6345207610775105e-08
of O 0 1.4250163360429724e-07
PWS B-Disease 1 0.9999997615814209
. O 0 2.8329122869763523e-06

Furthermore O 0 1.0196440598519985e-05
, O 0 1.0278504447569503e-07
our O 0 3.43112098732945e-08
findings O 0 4.027109667958939e-08
are O 0 1.42451506146557e-09
best O 0 4.454159707734107e-09
interpreted O 0 2.7701608118491095e-08
as O 0 4.46472414594723e-09
true O 0 1.92564648671123e-08
gamete O 0 9.56650183070451e-07
complementation O 0 7.660537448828109e-06
resulting O 0 7.859545689825609e-07
in O 0 7.945065476633317e-07
maternal B-Disease 0 0.0365598164498806
UPD I-Disease 1 0.9999998807907104
15 I-Disease 0 4.514194733928889e-05
and O 0 1.9715280359378085e-05
PWS B-Disease 1 0.9999998807907104

Schwartz B-Disease 1 0.9474450945854187
- I-Disease 1 0.999494194984436
Jampel I-Disease 1 0.9998816251754761
syndrome I-Disease 1 0.9999995231628418
type I-Disease 0 0.00012712980969808996
2 I-Disease 0 8.179652013495797e-07
and O 0 3.613701835547545e-07
Stuve B-Disease 1 0.9611886739730835
- I-Disease 1 0.9999995231628418
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 2.9291225445149394e-08
a O 0 2.2890613848858266e-08
case O 0 2.1698085106436338e-08
for O 0 6.975013899790383e-09
" O 0 1.1220740780970573e-08
lumping O 0 6.764028626093932e-07
" O 0 1.392970006008909e-07
. O 0 3.1667084954278835e-07

Recent O 0 5.841611255164025e-06
studies O 0 5.107672222948167e-07
demonstrated O 0 1.6350924170183134e-07
the O 0 9.58445500742755e-09
existence O 0 7.4704482599941e-09
of O 0 4.882166337871752e-10
a O 0 1.2470241728124165e-08
genetically O 0 5.599380870080495e-08
distinct O 0 2.1970022245909604e-08
, O 0 7.977134508507788e-09
usually O 0 1.5599358249573925e-08
lethal O 0 5.366702637843446e-08
form O 0 6.250561845888569e-09
of O 0 3.7200853508778664e-09
the O 0 2.9936020951026876e-07
Schwartz B-Disease 0 0.19780860841274261
- I-Disease 1 0.9895016551017761
Jampel I-Disease 1 0.9998100399971008
syndrome I-Disease 1 0.9999996423721313
( O 0 1.8079206256516045e-06
SJS B-Disease 1 0.8060643076896667
) O 0 5.660944779606325e-08
of O 0 3.2140800243496415e-08
myotonia B-Disease 1 0.5820732712745667
and O 0 1.285343478230061e-05
skeletal B-Disease 1 0.999954104423523
dysplasia I-Disease 1 0.9999980926513672
, O 0 8.581152854958418e-08
which O 0 3.7175052369775585e-08
we O 0 1.088028600548796e-08
called O 0 1.928438223330886e-06
SJS B-Disease 1 0.9882104396820068
type I-Disease 0 1.9818467990262434e-05
2 I-Disease 0 5.198700137043488e-07
. O 0 3.229991420994338e-07

This O 0 3.688839206006378e-05
disorder O 1 0.9689754247665405
is O 0 2.0215162521708407e-07
reminiscent O 0 4.816538876184495e-06
of O 0 5.004623826465604e-09
another O 0 1.2896063772416255e-08
rare O 0 8.542254192889231e-08
condition O 0 1.767074536473956e-06
, O 0 1.2063265053541272e-08
the O 0 2.713205731197377e-07
Stuve B-Disease 1 0.9936286807060242
- I-Disease 1 0.9999992847442627
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.7688023439841345e-06
SWS B-Disease 1 0.9972208738327026
) O 0 5.757675225481762e-08
, O 0 4.105861872716332e-09
which O 0 7.2917747395706556e-09
comprises O 0 1.2581813813028475e-08
campomelia B-Disease 0 1.0929591098829405e-06
at O 0 5.853707421010768e-07
birth O 0 4.816336513613351e-06
with O 0 2.2702805324570363e-07
skeletal B-Disease 1 0.9997166991233826
dysplasia I-Disease 1 0.9999819993972778
, O 0 1.1345174755206244e-07
contractures B-Disease 0 0.000259971508057788
, O 0 2.4609576598777494e-08
and O 0 1.2348254863070451e-08
early B-Disease 0 4.879243533650879e-06
death I-Disease 0 1.0010942787630484e-05
. O 0 4.1524648963786603e-07

To O 0 1.5689120118622668e-06
test O 0 3.703902677898441e-07
for O 0 5.820366411057876e-09
possible O 0 6.449556622101227e-08
nosologic O 0 3.2919117529672803e-06
identity O 0 1.1174888214782186e-07
between O 0 5.7115613572022994e-08
these O 0 2.472746984949481e-07
disorders O 0 0.02334720455110073
, O 0 6.047630840555485e-09
we O 0 2.1602064581571767e-09
reviewed O 0 1.3118398811684528e-08
the O 0 2.7295485871547953e-09
literature O 0 1.4962256988937384e-09
and O 0 2.2289274870246345e-09
obtained O 0 6.44218944856334e-09
a O 0 9.239987441844733e-09
follow O 0 6.552759401756703e-08
- O 0 5.81198207783018e-07
up O 0 8.444130727980337e-09
of O 0 2.5159729855062096e-10
the O 0 9.95576399098752e-10
only O 0 4.3444675634773944e-10
two O 0 3.945751225753469e-10
surviving O 0 2.9223311770465443e-08
patients O 0 1.4379849311296766e-08
, O 0 1.1742620209531651e-09
one O 0 3.4212450650272785e-09
with O 0 5.040935135980362e-08
SJS B-Disease 1 0.7594247460365295
type I-Disease 0 6.022336947353324e-06
2 I-Disease 0 4.5605812459825756e-08
at O 0 5.892651415706496e-07
age O 0 1.1141215949805883e-08
10 O 0 1.7379147010387896e-09
years O 0 8.818803465260316e-10
and O 0 9.148197754882403e-10
another O 0 6.395251439528238e-09
with O 0 5.8815913916987483e-08
SWS B-Disease 1 0.9954924583435059
at O 0 1.6330448488588445e-05
age O 0 3.2040611586126033e-07
7 O 0 2.414850825971371e-07
years O 0 1.0803838534911847e-07
. O 0 1.778844875843788e-07

Patients O 0 0.00011657601862680167
reported O 0 1.1870388334500603e-05
as O 0 2.0219695784362557e-07
having O 0 5.528817155209254e-07
either O 0 5.71531563764438e-06
neonatal O 1 0.9999998807907104
SJS B-Disease 1 0.9999998807907104
or O 0 0.000598503858782351
SWS B-Disease 1 0.9994114637374878
presented O 0 2.795980833525391e-07
a O 0 2.2676809763311212e-08
combination O 0 4.54342483635628e-08
of O 0 1.873325716772456e-09
a O 0 1.109786893493947e-07
severe O 0 0.00033530371729284525
, O 0 6.239712888600479e-07
prenatal O 1 0.9793484210968018
- O 1 0.9999668598175049
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 2.50397920353862e-06
with O 0 6.263469003897626e-06
congenital B-Disease 1 0.9999998807907104
joint I-Disease 0 0.002694085706025362
contractures I-Disease 1 0.9999704360961914
, O 0 1.621384762984235e-05
respiratory O 1 0.9999691247940063
and O 0 1.0207074865320465e-06
feeding O 0 8.184277248801664e-06
difficulties O 0 1.4514299095935712e-07
, O 0 6.037972344330456e-09
tendency O 0 3.2741425570748106e-07
to O 0 1.4955023175389215e-07
hyperthermia B-Disease 0 0.0077010588720440865
, O 0 5.98728311373975e-09
and O 0 3.701569717406983e-09
frequent O 0 1.6919810263971158e-07
death O 0 2.310565605512238e-06
in O 0 6.550397984028677e-07
infancy O 0 6.125544314272702e-05
) O 0 5.736144004231392e-09
with O 0 2.714021229976993e-09
a O 0 3.586358943152845e-08
distinct O 0 5.77576258820045e-07
campomelic B-Disease 0 0.004974855110049248
- I-Disease 0 0.07050327956676483
metaphyseal I-Disease 1 0.5745729207992554
skeletal I-Disease 1 0.9998282194137573
dysplasia I-Disease 1 0.9999922513961792
. O 0 1.172150678030448e-05

The O 0 6.713920015499752e-07
similarity O 0 4.83643248117005e-07
of O 0 6.59496190991149e-09
the O 0 2.4982726998246108e-08
clinical O 0 1.4506301226901996e-07
and O 0 3.1518961662868605e-08
radiographic O 0 2.283809953951277e-05
findings O 0 8.8826550381782e-07
is O 0 6.052962131519735e-09
so O 0 3.095232292693595e-09
extensive O 0 8.961152708764075e-09
that O 0 1.1519458276154637e-08
these O 0 1.541412757433136e-07
disorders O 0 0.014400656335055828
appear O 0 2.746046732227114e-07
to O 0 1.3829468237247511e-08
be O 0 4.5828665307112715e-09
a O 0 1.3889342120876336e-08
single O 0 1.0128825778110695e-07
entity O 0 1.0954050821965211e-06
. O 0 3.8413912761825486e-07

The O 0 2.1386306343629258e-06
follow O 0 1.8461560102878138e-06
- O 0 2.47580078394094e-06
up O 0 8.211449653572345e-08
observation O 0 1.954058461706154e-07
of O 0 1.4627843381020966e-09
an O 0 2.0187675975336106e-09
identical O 0 1.075730651223239e-07
and O 0 2.4137254417411214e-09
unique O 0 4.085449312185574e-09
pattern O 0 1.2319152347117779e-06
of O 0 2.7833269911070602e-08
progressive O 0 0.3672545254230499
bone B-Disease 1 0.9999526739120483
dysplasia I-Disease 1 0.9999872446060181
in O 0 7.895154681136773e-07
the O 0 8.507149829029004e-08
two O 0 4.8924906792535694e-08
patients O 0 1.6907003441701818e-07
( O 0 6.5523568792968945e-09
one O 0 6.138369368358099e-09
with O 0 1.5551059107110632e-07
SJS B-Disease 1 0.9985242486000061
type I-Disease 0 1.496685672464082e-05
2 I-Disease 0 1.9989363053696252e-08
, O 0 1.9435637543807616e-09
one O 0 1.6943854097561939e-09
with O 0 2.3152711747798094e-08
SWS B-Disease 1 0.6460222601890564
) O 0 1.5141463194368043e-08
surviving O 0 5.9079685144070027e-08
beyond O 0 1.1422407197869688e-07
infancy O 0 3.5042280615016352e-06
adds O 0 4.5365577960865267e-08
to O 0 2.864451564832393e-09
the O 0 1.5281533816136061e-09
evidence O 0 1.377094660526268e-09
in O 0 2.262901199756584e-09
favor O 0 9.88206050323015e-09
of O 0 3.021040972939204e-09
identity O 0 5.52430606148846e-07
. O 0 3.534905772539787e-07

The O 0 2.139779326171265e-06
hypothesis O 0 3.461956112005282e-06
that O 0 2.099708069636108e-07
SWS B-Disease 0 0.2994688153266907
and O 0 1.353513994217792e-06
SJS B-Disease 1 0.9795525670051575
type I-Disease 0 2.5090874260058627e-05
2 I-Disease 0 5.8564271654404365e-08
are O 0 1.0291364427317262e-09
the O 0 1.1505623120910968e-08
same O 0 3.8266994124569464e-06
disorder O 0 0.009825808927416801
should O 0 1.1552660161839867e-08
be O 0 2.248020658512928e-09
testable O 0 4.086184191010034e-08
by O 0 4.110743745400214e-09
molecular O 0 1.1883327744044436e-07
methods O 0 1.410395782386331e-07
. O 0 3.73546669152347e-08
. O 0 1.5640746653389215e-07

A O 0 1.104113289329689e-05
mouse O 0 6.174544978421181e-05
model O 0 3.3257836093980586e-06
of O 0 2.939483181307878e-07
severe O 1 0.9999704360961914
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.22668801248073578
defects O 1 0.999998927116394
in O 0 8.92739262781106e-06
hemostasis O 1 0.9835415482521057
and O 0 6.994316208874807e-05
thrombosis B-Disease 1 0.8539710640907288
. O 0 8.657367288833484e-06

von B-Disease 1 0.9871857762336731
Willebrand I-Disease 1 0.979895830154419
factor I-Disease 0 0.0002102885046042502
( I-Disease 0 2.595599289634265e-05
vWf I-Disease 0 0.0012402080465108156
) I-Disease 0 0.00015456251276191324
deficiency I-Disease 1 0.9992510676383972
causes O 0 0.0033308162819594145
severe O 1 0.9999997615814209
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.00010061993089038879
humans O 0 1.7253245459869504e-05
. O 0 2.4137050331773935e-06

We O 0 7.519290647906018e-07
generated O 0 2.2769393126509385e-07
a O 0 6.890561365935355e-08
mouse O 0 2.73360387836874e-06
model O 0 1.8246132071908505e-07
for O 0 1.8657588807258207e-09
this O 0 6.764581783613721e-09
disease O 0 3.578487905997463e-07
by O 0 7.002233459729723e-09
using O 0 6.16021083033047e-08
gene O 0 1.1397678463254124e-06
targeting O 0 1.4857236010357155e-06
. O 0 3.0697913189214887e-07

vWf B-Disease 0 0.01828746311366558
- I-Disease 1 0.7532868385314941
deficient I-Disease 0 0.23722663521766663
mice O 0 0.000928934256080538
appeared O 0 3.7184811390034156e-06
normal O 0 8.228285537370539e-07
at O 0 7.413828484459373e-07
birth O 0 1.4947266890885658e-06
; O 0 5.175259776279972e-09
they O 0 2.6954802834211478e-09
were O 0 7.424311831982777e-09
viable O 0 5.579902406793735e-08
and O 0 4.162376043836957e-08
fertile O 0 7.776036454743007e-07
. O 0 4.831665592064383e-07

Neither O 0 0.000529820506926626
vWf O 0 0.004314614459872246
nor O 0 0.00013953809684608132
vWf O 0 0.0006667871493846178
propolypeptide O 0 0.0005060027469880879
( O 0 1.2321313079155516e-05
von B-Disease 0 0.010865279473364353
Willebrand I-Disease 0 0.01397895161062479
antigen O 0 0.0001539218646939844
II O 0 0.0001401095651090145
) O 0 4.254782126622558e-08
were O 0 1.92549229893757e-08
detectable O 0 2.831546339621127e-07
in O 0 1.640608715547387e-08
plasma O 0 7.222333238132705e-07
, O 0 1.1362733864928032e-08
platelets O 0 2.110730292770313e-07
, O 0 2.0090107355485998e-09
or O 0 9.427694180885737e-09
endothelial O 0 1.0240229642022314e-07
cells O 0 3.892168720653899e-08
of O 0 1.9314021493244127e-09
the O 0 3.362049483257579e-08
homozygous O 0 4.3292948248563334e-06
mutant O 0 7.882689715188462e-06
mice O 0 5.5631931900279596e-05
. O 0 9.99347662400396e-07

The O 0 7.0624596446577925e-06
mutant O 0 0.00012121144391130656
mice O 0 0.011840046383440495
exhibited O 0 0.21121084690093994
defects O 1 0.9924185276031494
in O 0 6.10748259077809e-07
hemostasis O 0 0.0001336484419880435
with O 0 7.799782508755015e-08
a O 0 1.0185001428908436e-06
highly O 0 1.9878354578395374e-05
prolonged O 1 0.8582431674003601
bleeding O 1 0.9395207762718201
time O 0 8.483604574394121e-07
and O 0 4.988872248645748e-08
spontaneous O 0 1.1326876574457856e-06
bleeding O 0 3.906290658051148e-05
events O 0 4.077052295770045e-08
in O 0 1.0646159509519748e-08
approximately O 0 1.9641507975620698e-08
10 O 0 2.0344350204481998e-08
% O 0 8.950528318507622e-09
of O 0 1.2153334338904642e-08
neonates O 0 2.5099199774558656e-05
. O 0 7.43533917102468e-07

As O 0 4.93919344535243e-07
in O 0 5.840831818204606e-08
the O 0 1.715039488203729e-08
human O 0 3.9992553269030395e-08
disease O 0 1.273041220883897e-06
, O 0 1.1240505193299555e-09
the O 0 5.805908198652787e-09
factor O 0 2.0099241382354194e-08
VIII O 0 8.034504617171478e-07
level O 0 3.038598705984441e-08
in O 0 6.9638876887268e-09
these O 0 4.328464697778145e-09
mice O 0 3.923881195078138e-06
was O 0 1.5058265034895157e-07
reduced O 0 3.2211438849572005e-08
strongly O 0 5.100122635326443e-08
as O 0 2.054512338034442e-09
a O 0 1.863162957249642e-09
result O 0 1.7925929629569737e-09
of O 0 2.998101489293248e-10
the O 0 3.0495941327757237e-09
lack O 0 6.712937761221838e-09
of O 0 1.0524832116942662e-09
protection O 0 2.8288734910120183e-08
provided O 0 3.1851044468567125e-08
by O 0 1.1225604623632535e-07
vWf O 0 1.7244592527276836e-05
. O 0 1.251226763088198e-06

Defective O 1 0.9894313812255859
thrombosis B-Disease 1 0.9540121555328369
in O 0 9.621485332900193e-06
mutant O 0 0.00010437582386657596
mice O 0 0.029710732400417328
was O 0 3.890665539074689e-06
also O 0 1.1262057064698183e-08
evident O 0 1.652334802315636e-08
in O 0 2.436882695633358e-09
an O 0 1.565246043888635e-09
in O 0 1.424640760916418e-08
vivo O 0 6.193529316078639e-07
model O 0 2.6735418146017764e-07
of O 0 3.9549171049202414e-08
vascular B-Disease 1 0.9054864048957825
injury I-Disease 0 0.006833177991211414
. O 0 1.988545136555331e-06

In O 0 7.567006150566158e-07
this O 0 4.281843146713982e-08
model O 0 1.684458936779265e-07
, O 0 5.131246094691733e-09
the O 0 1.3868852732912273e-08
exteriorized O 0 3.223638259441941e-06
mesentery O 0 2.1716527044191025e-05
was O 0 1.2236567954460043e-06
superfused O 0 1.6760477592470124e-06
with O 0 3.440892371031623e-08
ferric O 0 1.5777506632730365e-05
chloride O 0 7.093726708262693e-07
and O 0 1.1183839632167292e-08
the O 0 2.1323623755620247e-08
accumulation O 0 3.1045226478454424e-07
of O 0 1.6145850878501733e-08
fluorescently O 0 5.0529997679404914e-05
labeled O 0 1.0526330697757658e-05
platelets O 0 1.2398601029417478e-05
was O 0 3.096184855166939e-07
observed O 0 1.9471050904940057e-07
by O 0 7.522325518038997e-08
intravital O 0 1.5566221918561496e-05
microscopy O 0 2.540920104365796e-05
. O 0 1.2612229056685464e-06

We O 0 8.499849286636163e-07
conclude O 0 7.976785809660214e-07
that O 0 1.67415112883873e-08
these O 0 4.383783558381538e-09
mice O 0 5.014841235606582e-07
very O 0 2.4207624349514845e-08
closely O 0 1.2209977739985334e-06
mimic O 0 0.0008361420477740467
severe O 0 0.2724469304084778
human O 0 9.575206786394119e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.00016401005268562585
will O 0 8.891267810895442e-08
be O 0 2.8038611432634752e-09
very O 0 2.2670441079952752e-09
useful O 0 3.018765903917142e-09
for O 0 5.711882078429653e-10
investigating O 0 7.118026168484448e-09
the O 0 2.488939720990402e-09
role O 0 3.4514471280999715e-09
of O 0 9.750547036446733e-10
vWf O 0 2.2745389571809937e-07
in O 0 1.4671747372574373e-08
normal O 0 6.797487230869592e-07
physiology O 0 4.3234589952589886e-07
and O 0 2.3369667090378243e-08
in O 0 2.6259698415742605e-07
disease O 0 0.0006156743038445711
models O 0 2.3875466013123514e-06
. O 0 5.781566159157592e-08
. O 0 4.0059967432171106e-07

Oral O 0 0.00038191815838217735
contraceptives O 0 0.0017854329198598862
and O 0 1.3097827888941538e-07
the O 0 5.8940795355511e-08
risk O 0 9.214679721480934e-07
of O 0 5.287673729981179e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5503894246648997e-05

Hereditary B-Disease 1 0.9999998807907104
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.98162442445755
Clinical O 0 0.00010287015174981207
Study O 0 1.5757270830363268e-06
Group O 0 1.5749009207866038e-06
. O 0 9.383384167449549e-07

BACKGROUND O 0 4.139551310800016e-05
Women O 0 1.6919277356919338e-07
with O 0 2.9062061202012046e-08
mutations O 0 8.524413601662673e-07
in O 0 1.3587977854001565e-08
either O 0 1.6990172824193905e-08
the O 0 3.1158769786543417e-08
BRCA1 O 0 3.3820508633652935e-06
or O 0 2.8585422029436813e-08
the O 0 3.809200066484664e-08
BRCA2 O 0 5.500331099028699e-06
gene O 0 2.0343152584700874e-07
have O 0 5.330473840103878e-09
a O 0 1.4966003547556284e-08
high O 0 3.660715890418942e-07
lifetime O 0 4.107752147319843e-07
risk O 0 2.968022954519256e-06
of O 0 0.0001350125967292115
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.376227025204571e-06

Oral O 0 0.00040201545925810933
contraceptives O 0 0.046677425503730774
protect O 0 5.2210030844435096e-05
against O 1 0.9599213600158691
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.756668493475445e-07
general O 0 5.0495767567326766e-08
, O 0 4.855831292616131e-09
but O 0 2.1896799928811106e-09
it O 0 2.0365498176744268e-09
is O 0 6.683295583620463e-10
not O 0 4.33426239343504e-10
known O 0 1.5924869201100478e-09
whether O 0 1.389238279969618e-09
they O 0 1.2545144922881946e-09
also O 0 1.448787201319135e-09
protect O 0 3.929897740562183e-09
against O 0 1.217149758758751e-08
hereditary B-Disease 0 1.512050766905304e-05
forms I-Disease 0 8.778147275734227e-07
of I-Disease 0 0.00023413334565702826
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 4.661010279960465e-06

METHODS O 0 1.3892826245864853e-05
We O 0 1.3800804765651264e-07
enrolled O 0 2.4476472049173026e-07
207 O 0 2.1769317299913382e-06
women O 0 1.0505047498554632e-07
with O 0 6.997976015554741e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7304360255820939e-07
161 O 0 5.5810090771046816e-08
of O 0 1.9658363825669767e-09
their O 0 2.4292637235134862e-08
sisters O 0 5.389536639199832e-08
as O 0 4.289082866648641e-09
controls O 0 8.687619583724882e-07
in O 0 1.0133980765658634e-08
a O 0 3.5956052357732915e-08
case O 0 1.3198616954923637e-07
- O 0 5.0415442274243105e-06
control O 0 6.716745247103972e-06
study O 0 2.109740222522305e-07
. O 0 3.8946868130551593e-07

All O 0 2.5615702270442853e-07
the O 0 8.346665225644756e-08
patients O 0 1.2115197023376822e-07
carried O 0 7.491469489195879e-08
a O 0 2.8492124215517833e-08
pathogenic O 0 3.5578500501287635e-06
mutation O 0 6.456301093749062e-07
in O 0 2.6410782894004114e-08
either O 0 1.0687689666610822e-07
BRCA1 O 0 3.881348220602376e-06
( O 0 2.5422604466029952e-08
179 O 0 1.4060202602195204e-07
women O 0 1.9561277042612346e-08
) O 0 1.1677141031896099e-08
or O 0 2.6324639179620135e-07
BRCA2 O 0 1.3063490769127384e-05
( O 0 9.777857457038408e-08
28 O 0 2.71234682713839e-07
women O 0 4.256438046468247e-08
) O 0 5.915997292049724e-08
. O 0 2.589124221685779e-07

The O 0 1.048436388373375e-06
control O 0 3.5083812690572813e-06
women O 0 2.2859156345589327e-08
were O 0 2.673147259102393e-09
enrolled O 0 6.74945122014492e-09
regardless O 0 1.6612581310582186e-09
of O 0 4.152515553634828e-10
whether O 0 3.6179199636166004e-09
or O 0 2.1004245454037118e-08
not O 0 4.772513051420901e-09
they O 0 3.6562965988196083e-09
had O 0 4.073165982276805e-08
either O 0 6.221328163746875e-08
mutation O 0 1.5248980389515054e-06
. O 0 2.9277995849952276e-07

Lifetime O 0 2.4718145141378045e-05
histories O 0 9.425246389582753e-06
of O 0 1.5680983267429838e-07
oral O 0 2.830055336744408e-06
- O 0 9.166278687189333e-06
contraceptive O 0 6.561941063409904e-06
use O 0 3.485179789208814e-08
were O 0 4.712946033436083e-09
obtained O 0 5.699282823456997e-09
by O 0 3.958469552145516e-09
interview O 0 1.0187628873836729e-07
or O 0 4.489256966166977e-09
by O 0 1.6083356868534793e-09
written O 0 3.534474934951959e-09
questionnaire O 0 1.9878722667954207e-08
and O 0 1.5068221115299707e-09
were O 0 3.447295560121688e-09
compared O 0 2.0729506999828118e-08
between O 0 1.611517674859897e-08
patients O 0 5.1170768955444146e-08
and O 0 7.074996144496026e-09
control O 0 6.394999672920676e-06
women O 0 3.2919555970067904e-09
, O 0 1.059005549919334e-09
after O 0 9.523009047995856e-09
adjustment O 0 3.054811870129015e-08
for O 0 8.400624640358956e-10
year O 0 2.344617833216489e-09
of O 0 1.6497895272138408e-09
birth O 0 2.0988281903555617e-06
and O 0 5.7427044453106646e-08
parity O 0 4.235287178744329e-06
. O 0 4.2724289528450754e-07

RESULTS O 0 2.9313772756722756e-05
The O 0 9.067320547728741e-07
adjusted O 0 6.176058377604932e-05
odds O 0 2.0749639588757418e-05
ratio O 0 0.00010316132102161646
for O 0 0.006792627740651369
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 6.66685082251206e-07
with O 0 1.0023141427950577e-08
any O 0 3.3197813387175756e-09
past O 0 2.1439486630470128e-08
use O 0 1.2791605996653743e-08
of O 0 4.949649579089055e-09
oral O 0 2.3294915081351064e-06
contraceptives O 0 0.0030434837099164724
was O 0 2.916237008321332e-06
0 O 0 5.082352458884998e-07
. O 0 2.544599624343391e-07

5 O 0 1.520499699836364e-05
( O 0 8.099265755845408e-07
95 O 0 8.395088002544071e-07
percent O 0 3.186168555657787e-07
confidence O 0 5.156055067345733e-07
interval O 0 2.07292771392531e-07
, O 0 1.6534815738822317e-09
0 O 0 5.778112655008272e-09
. O 0 1.0173872855290256e-09
3 O 0 7.140422031426397e-09
to O 0 9.243530385560916e-09
0 O 0 3.023099992560674e-08
. O 0 6.636552196681578e-09
8 O 0 1.2475945254664111e-07
) O 0 6.779761463349132e-08
. O 0 1.921130916571201e-07

The O 0 4.132445610594004e-06
risk O 0 2.951926944660954e-06
decreased O 0 1.1272264828221523e-06
with O 0 1.2696322215788314e-08
increasing O 0 2.782966213032978e-08
duration O 0 8.516306593264744e-08
of O 0 1.9166168652162696e-09
use O 0 7.470166707435055e-08
( O 0 4.099971206983355e-08
P O 0 2.0549778128042817e-06
for O 0 2.945620636296553e-09
trend O 0 1.9666855166633468e-07
, O 0 6.830183973960402e-09
< O 0 1.111502783146534e-07
0 O 0 1.3938492138265701e-08
. O 0 2.8794993056635576e-09
001 O 0 7.573519411607776e-08
) O 0 1.7271485353020921e-09
; O 0 7.810419533349489e-10
use O 0 2.7048738804325012e-09
for O 0 4.975231338022468e-10
six O 0 1.1004146482918031e-09
or O 0 1.3463443693240151e-09
more O 0 3.983507690374921e-10
years O 0 2.734978910012842e-09
was O 0 3.0677274054369263e-08
associated O 0 2.2461006388141413e-09
with O 0 9.115175281237953e-10
a O 0 1.2849266539660675e-08
60 O 0 2.3047233455031346e-08
percent O 0 4.193342206804118e-08
reduction O 0 3.715598495546146e-08
in O 0 1.0648621184827789e-07
risk O 0 2.047442649200093e-06
. O 0 3.8985814398984076e-07

Oral O 0 0.0002653051633387804
- O 0 0.0001303742319578305
contraceptive O 0 5.785769099020399e-05
use O 0 8.303995855385438e-07
protected O 0 8.261473340098746e-06
against O 1 0.9494650363922119
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
both O 0 1.8959113390337734e-08
for O 0 4.42506431497236e-09
carriers O 0 1.506817071117439e-08
of O 0 1.0499628944060646e-09
the O 0 1.3448749314193265e-07
BRCA1 O 0 4.729747524834238e-05
mutation O 0 1.7224044768227031e-06
( O 0 5.886956344625105e-08
odds O 0 1.353737388853915e-06
ratio O 0 2.7164210791852383e-07
, O 0 3.6756302446150357e-09
0 O 0 1.234076663081396e-08
. O 0 1.815751882183747e-09
5 O 0 7.818039549079003e-09
; O 0 4.278787546496687e-09
95 O 0 7.686595182576639e-08
percent O 0 4.3171181118850654e-07
confidence O 0 3.613643286826118e-07
interval O 0 1.3680769939128368e-07
, O 0 3.4895948353153017e-09
0 O 0 6.340969971319055e-09
. O 0 9.468199557716162e-10
3 O 0 4.479164594783924e-09
to O 0 4.478575288402453e-09
0 O 0 1.5648618401087333e-08
. O 0 1.8593147022016865e-09
9 O 0 1.976560071170752e-08
) O 0 6.340616365285712e-10
and O 0 4.931610675384945e-10
for O 0 3.009984761437323e-10
carriers O 0 7.234008503331779e-09
of O 0 1.364583557261767e-09
the O 0 9.896399433273473e-08
BRCA2 O 0 2.761858377198223e-05
mutation O 0 1.729599034661078e-06
( O 0 7.380715061344745e-08
odds O 0 1.4473592955255299e-06
ratio O 0 3.916759965250094e-07
, O 0 3.889176536375771e-09
0 O 0 8.511982230174908e-09
. O 0 8.798709538737626e-10
4 O 0 8.517797134288685e-09
; O 0 2.831560319549453e-09
95 O 0 5.7622674631829796e-08
percent O 0 1.225999568532643e-07
confidence O 0 4.6576056433877966e-07
interval O 0 1.051653413242093e-07
, O 0 1.3600909287703189e-09
0 O 0 3.3146185796084637e-09
. O 0 5.266088676236791e-10
2 O 0 2.1551156415000605e-09
to O 0 2.903877360793672e-09
1 O 0 7.964698234275147e-09
. O 0 1.911655056474615e-09
1 O 0 2.4009528587498608e-08
) O 0 2.7016476167318615e-08
. O 0 2.0427721381111041e-07

CONCLUSIONS O 0 7.56299850763753e-05
Oral O 0 5.14361345267389e-05
- O 0 9.616007446311414e-05
contraceptive O 0 8.27820404083468e-05
use O 0 3.4654073033379973e-07
may O 0 2.5671803882687527e-07
reduce O 0 7.825905612435236e-08
the O 0 2.0165634495583618e-08
risk O 0 5.224076744525519e-07
of O 0 4.369204361864831e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.3221400624606758e-07
women O 0 1.3305302637434124e-08
with O 0 1.3659775532914864e-08
pathogenic O 0 6.2358381001104135e-06
mutations O 0 1.6488802430103533e-06
in O 0 4.850779689036244e-08
the O 0 2.5556701643836277e-07
BRCA1 O 0 6.320255488390103e-05
or O 0 2.5778081180760637e-06
BRCA2 O 0 0.00038665696047246456
gene O 0 0.0002645930799189955

A O 0 6.180334366945317e-06
Japanese O 0 4.301658918848261e-06
family O 0 1.329839733443805e-06
with O 0 2.3927498205011943e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 2.1128086302724114e-07
a O 0 6.583960612260853e-07
codon O 0 1.5640729543520138e-05
291 O 0 2.185651965191937e-06
deletion O 0 4.411710960994242e-06
: O 0 3.191356157117298e-08
a O 0 5.5602054516157295e-08
clinical O 0 3.595379780563235e-07
, O 0 2.1500747848790525e-08
biochemical O 0 8.682417842464929e-07
, O 0 8.53093418129447e-09
pathological O 0 1.8258489831168845e-07
, O 0 1.6362742272235664e-08
and O 0 4.608991943655383e-08
genetic O 0 1.915000893859542e-06
report O 0 3.071292439926765e-06
. O 0 1.426712287866394e-06

We O 0 9.428108569409233e-07
report O 0 4.529494503913156e-07
a O 0 4.5141163695916475e-08
Japanese O 0 3.5339752457730356e-07
family O 0 4.534749962203932e-07
with O 0 1.1762373333112919e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0006412318325601518
ALD B-Disease 1 1.0
) O 0 3.29692753098243e-08
with O 0 3.999665043608047e-09
a O 0 1.9736592804520114e-08
three O 0 4.002366438271565e-09
base O 0 8.172511911652691e-08
pair O 0 2.563535019817209e-07
deletion O 0 1.5740299659228185e-06
( O 0 3.168738160752582e-08
delGAG O 0 9.938694347511046e-07
291 O 0 2.2965927826135157e-07
) O 0 9.747465057330373e-09
in O 0 2.3467578103009146e-08
the O 0 2.259151642647339e-06
ALD B-Disease 1 1.0
gene O 0 0.00019791038357652724
. O 0 1.8811590507539222e-06

A O 0 3.63816707249498e-06
variety O 0 2.9049380145806936e-07
of O 0 4.169638856410529e-08
phenotypes O 0 2.4416306132479804e-06
were O 0 3.8507877775373345e-08
observed O 0 5.166485195218229e-08
within O 0 1.26052590587733e-08
this O 0 2.338206073204674e-08
family O 0 5.061958745500306e-07
. O 0 3.712991940574284e-07

While O 0 1.8711127722781384e-06
the O 0 4.47283213134142e-07
proband O 0 2.7201278498978354e-05
( O 0 2.2374823060999915e-07
patient O 0 6.903399594193615e-07
1 O 0 3.512761992396918e-08
) O 0 5.5600217763185356e-09
was O 0 9.225637853660373e-08
classified O 0 8.855181476974394e-09
as O 0 5.864740693084514e-09
having O 0 5.831900740105311e-09
a O 0 5.0236552695537284e-09
rare O 0 2.324089187766276e-08
intermediate O 0 7.091103526590814e-08
type O 0 2.4086088501462655e-07
of O 0 3.0449209820204715e-09
adult O 0 1.5326485254263389e-06
cerebral O 0 4.95105778099969e-05
and O 0 4.37156160160157e-07
cerebello O 0 0.21976906061172485
- O 0 0.37876230478286743
brain O 0 0.008226834237575531
stem O 0 1.3631064348373911e-06
forms O 0 8.20715868599109e-08
, O 0 8.79527384256562e-09
his O 0 1.4578139939658286e-07
younger O 0 1.1131359087812598e-06
brother O 0 2.1412672595033655e-06
( O 0 8.569359977173008e-08
patient O 0 5.578688160312595e-07
2 O 0 6.539773522717951e-08
) O 0 1.8567355652976403e-08
and O 0 6.787279005493474e-08
nephew O 0 3.096154978265986e-05
( O 0 8.475518598061171e-08
patient O 0 6.460976464950363e-07
3 O 0 6.584117784314003e-08
) O 0 1.163401197601388e-08
had O 0 1.347771387827379e-07
a O 0 8.513064244652924e-07
childhood O 0 0.31786954402923584
ALD B-Disease 1 1.0
type O 1 0.6655732989311218
. O 0 2.994852366100531e-06

Another O 0 2.4807644877000712e-05
nephew O 0 0.0008904790156520903
( O 0 2.334593546038377e-06
patient O 0 3.531034735715366e-06
4 O 0 1.5341255732437276e-07
) O 0 7.573746962918904e-09
of O 0 2.2358934703703426e-09
patient O 0 9.715762416817597e-07
1 O 0 4.887295901312427e-08
was O 0 3.4963261441589566e-07
classified O 0 1.9950968876969455e-08
as O 0 4.753408333613152e-09
having O 0 1.0674443551295099e-08
an O 0 1.4855343621889006e-08
adolescent O 0 4.738745701615699e-06
form O 0 7.637461862941564e-07
. O 0 8.928619763537426e-07

The O 0 1.911409981403267e-06
tau O 0 2.243863946205238e-06
level O 0 1.9716884480658337e-07
in O 0 7.404233315355668e-08
the O 0 3.2179451636693557e-07
cerebrospinal O 0 0.0010299594141542912
fluid O 0 8.609049837104976e-05
( O 0 1.305228238379641e-06
CSF O 0 0.05879179760813713
) O 0 2.923981767821715e-08
in O 0 5.727903840124782e-08
patient O 0 1.0703249699872686e-06
1 O 0 5.8040615869003886e-08
was O 0 7.046750738481933e-07
as O 0 7.147261893436507e-09
high O 0 6.2741065676164e-08
as O 0 1.19817167298919e-09
that O 0 3.991554309301648e-10
of O 0 1.5031936806408908e-09
patients O 0 1.8069157192712737e-07
with O 0 7.38825337975868e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9980453252792358
( O 0 4.903837407255196e-07
AD B-Disease 0 2.2890126274432987e-05
) O 0 2.494739987923822e-07
. O 0 4.7348339649033733e-07

His O 0 7.2609154813108034e-06
brain O 0 0.00030487478943541646
magnetic O 0 1.4616418411605991e-05
resonance O 0 7.141281821532175e-05
image O 0 0.0002972264774143696
( O 0 6.384747166521265e-07
MRI O 0 0.044584084302186966
) O 0 1.7101599780744436e-07
showed O 0 0.000761435367166996
abnormalities B-Disease 0 0.2612752318382263
in I-Disease 0 1.4251464008907533e-08
the I-Disease 0 1.815247152592292e-08
bilateral I-Disease 0 1.792139698864048e-07
cerebellar I-Disease 0 7.807491056155413e-05
hemispheres I-Disease 0 8.098546459223144e-06
and O 0 5.216271006247553e-07
brain O 0 0.00028271196060813963
stem O 0 1.591293653291359e-06
, O 0 7.2421260099986284e-09
but O 0 4.20295709346874e-09
not O 0 2.169443069632848e-09
in O 0 8.039055643394022e-09
the O 0 9.42316731311621e-08
cerebral O 0 3.907151040039025e-05
white O 0 8.842440593070933e-07
matter O 0 1.1521962939298191e-08
, O 0 1.1613764394624582e-09
where O 0 2.3712467545067284e-09
marked O 0 1.590805887019542e-08
reductions O 0 2.945532351361635e-08
of O 0 8.694874265025021e-10
the O 0 3.6536633274408814e-08
cerebral O 0 7.805356290191412e-06
blood O 0 2.224836634923122e-07
flow O 0 7.255651013338138e-08
and O 0 4.787833063346625e-08
oxygen O 0 1.125918970501516e-06
metabolism O 0 1.1522133718244731e-05
were O 0 3.3347983929843394e-08
clearly O 0 3.982843210792453e-08
demonstrated O 0 5.386607426771661e-08
by O 0 2.4749191140926996e-08
positron O 0 2.1561178073170595e-05
emission O 0 9.544047497911379e-05
tomography O 0 0.03525671362876892
( O 0 1.1355245987942908e-06
PET O 0 4.417145100887865e-05
) O 0 3.656107310234802e-07
. O 0 4.905750756734051e-07

In O 0 4.8455081014253665e-06
patients O 0 1.7518555068818387e-06
2 O 0 9.388722332914767e-08
and O 0 9.804859146811395e-09
3 O 0 2.290052769637896e-08
, O 0 1.0937478700512315e-09
the O 0 6.281947850794722e-09
autopsy O 0 0.0011181015288457274
findings O 0 4.2992252247131546e-07
showed O 0 1.4642984751844779e-05
massive O 0 4.523383267951431e-06
demyelination B-Disease 1 0.9999997615814209
of I-Disease 0 2.356189909846762e-08
the I-Disease 0 7.122862939468178e-07
cerebral I-Disease 0 0.002298003761097789
white I-Disease 0 9.979211199606652e-07
matter I-Disease 0 5.270995195871819e-09
with O 0 1.6223790089142653e-09
sparing O 0 7.398696322269416e-09
of O 0 4.6189049807132676e-10
the O 0 1.1988581682942367e-08
U O 0 8.269381623904337e-07
- O 0 2.9091734177200124e-06
fibers O 0 2.278208285133587e-06
, O 0 1.210405331519837e-09
compatible O 0 5.024750393545219e-08
with O 0 1.9958343866477435e-09
the O 0 1.1242526909427397e-08
findings O 0 1.3703464674108545e-07
of O 0 2.743763261037202e-08
childhood O 0 0.0030788364820182323
ALD B-Disease 1 0.9999998807907104
. O 0 7.443409231200349e-06

Oleic O 0 0.014554674737155437
and O 0 7.769285730319098e-06
erucic O 0 0.0008373125456273556
acids O 0 1.7606787878321484e-05
( O 0 2.0128749156356207e-07
Lorenzos O 0 1.9471697214612504e-06
Oil O 0 1.1858929838126642e-07
) O 0 3.3735976234794407e-09
were O 0 2.393256703925317e-09
administered O 0 1.0817071682822643e-08
to O 0 9.026218883434467e-09
patients O 0 3.21042854523057e-08
1 O 0 5.9841323007958636e-09
and O 0 3.4770644141701723e-09
4 O 0 1.1066411786941899e-08
, O 0 8.185702671248407e-10
but O 0 1.2115140002322278e-09
sufficient O 0 5.693361782022066e-09
effectiveness O 0 6.189797119304785e-08
was O 0 1.5180985712959227e-07
not O 0 6.022514043024785e-09
obtained O 0 6.531795548880837e-08
. O 0 1.6765132215823542e-07

The O 0 5.080723894934636e-07
findings O 0 2.52094054076224e-07
in O 0 2.6688539378483256e-08
this O 0 7.971567406173108e-09
family O 0 3.288844396820423e-08
suggest O 0 2.5072708353945927e-08
that O 0 2.742590154980462e-09
delGAG291 O 0 2.0967625857792882e-07
is O 0 3.0212312651656248e-09
part O 0 2.781118224604029e-09
of O 0 5.373497757865664e-10
the O 0 6.472006042201883e-09
cause O 0 6.932772578238655e-08
of O 0 9.992599636632349e-09
Japanese O 0 3.008610656252131e-05
ALD B-Disease 1 0.9999998807907104
with O 0 5.240393647909514e-07
phenotypic O 0 2.1432475477922708e-05
variations O 0 1.6770818547229283e-05
. O 0 1.0897316542468616e-06

Moreover O 0 6.513024800369749e-06
, O 0 3.702313122744272e-08
although O 0 5.988173956694709e-09
the O 0 3.5417702104467708e-09
scale O 0 2.2504757168917422e-08
of O 0 1.068264587900103e-09
the O 0 9.504264930626505e-09
study O 0 6.636970084628047e-09
is O 0 2.5144533122301027e-09
limited O 0 6.594483625832481e-09
, O 0 1.05528541460842e-09
there O 0 5.166992389504799e-10
is O 0 4.471701897656999e-10
a O 0 2.170995383465879e-09
possibility O 0 9.801661704500475e-09
that O 0 8.767989001512433e-09
PET O 0 3.7439945117512252e-06
can O 0 2.0186220694995427e-08
detect O 0 2.271361836392316e-06
an O 0 3.2769595037507315e-08
insidious B-Disease 0 2.7051779397879727e-05
lesion I-Disease 0 0.10354047268629074
which O 0 1.274798933081911e-07
is O 0 8.269853246645198e-09
undetectable O 0 1.9869668221872416e-07
by O 0 8.70908589689634e-09
computed O 0 6.79005552228773e-07
tomogram O 0 6.081205356167629e-06
( O 0 1.6002589120489574e-07
CT O 0 0.058138407766819
) O 0 3.3434854884717424e-08
or O 0 8.13942406807655e-08
MRI O 0 1.4181730875861831e-05
analysis O 0 3.345865096093803e-08
, O 0 1.7020101994447145e-09
and O 0 7.907522414640766e-10
that O 0 6.702366994737474e-10
the O 0 3.0802320694078844e-09
higher O 0 4.75882657724469e-08
level O 0 1.0761714186457993e-08
of O 0 1.320467291066052e-09
tau O 0 3.306102414057932e-08
reflects O 0 1.0443709896890141e-08
the O 0 1.1346852346605374e-09
process O 0 1.6377658118571503e-09
of O 0 1.912931812952934e-09
neuronal B-Disease 0 4.784355496667558e-06
degeneration I-Disease 0 0.000574179517570883
in O 0 2.3046408387017436e-05
ALD B-Disease 1 1.0
. O 0 4.9994923756457865e-06

Lorenzos O 0 0.00037388806231319904
Oil O 0 6.872854100947734e-06
should O 0 5.581179607361264e-08
be O 0 3.1681985923626144e-09
given O 0 1.187519416134819e-09
in O 0 2.2035564484212955e-09
the O 0 4.497235472911143e-09
early O 0 2.1519134918435157e-07
stage O 0 2.2849290814974665e-07
. O 0 4.5426450157037834e-08
. O 0 2.8729675705108093e-07

Nonsense O 0 0.0003095436259172857
mutation O 0 6.794004730181769e-05
in O 0 5.564957632486767e-07
exon O 0 4.163018274994101e-06
4 O 0 8.33934450383822e-08
of O 0 3.873947385102383e-09
human O 0 1.3180097013787417e-08
complement O 0 8.784196126043753e-08
C9 O 0 8.734658877074253e-06
gene O 0 9.832726846070727e-07
is O 0 5.231931776705778e-09
the O 0 4.076435633493247e-09
major O 0 6.79473721731938e-09
cause O 0 4.9776279098523446e-08
of O 0 1.3642069696118142e-08
Japanese O 0 1.118202544603264e-05
complement B-Disease 0 0.00010942747030640021
C9 I-Disease 1 0.9647451043128967
deficiency I-Disease 1 0.8063185811042786
. O 0 1.968870947166579e-06

Deficiency B-Disease 1 0.9864771366119385
of I-Disease 0 1.6490265863922104e-07
the I-Disease 0 7.075445296322869e-08
ninth I-Disease 0 2.942122137028491e-07
component I-Disease 0 3.329961018039285e-08
of I-Disease 0 2.662893239246955e-09
human I-Disease 0 8.362835757225184e-09
complement I-Disease 0 1.1783487252614577e-07
( O 0 5.460998053763433e-08
C9 O 0 2.1993391783325933e-06
) O 0 6.90165924410735e-09
is O 0 8.380731664203722e-10
the O 0 1.9831452036100927e-09
most O 0 3.1492926044762726e-09
common O 0 2.2991005153016886e-06
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 2.6054894419758057e-07
Japan O 0 2.281452225361136e-06
but O 0 1.5359034932771465e-08
is O 0 1.2883026867527292e-09
rare O 0 2.86674173288759e-09
in O 0 3.098155731962038e-09
other O 0 1.9154910990692997e-09
countries O 0 9.79616654461779e-09
. O 0 1.4881895538110257e-07

We O 0 3.7625966342602624e-07
studied O 0 7.447887639955297e-08
the O 0 1.129378635056355e-08
molecular O 0 9.152150681757121e-08
basis O 0 3.5909994977600945e-08
of O 0 2.6531910890525978e-08
C9 B-Disease 0 0.4467848241329193
deficiency I-Disease 0 0.020869750529527664
in O 0 6.892585702189535e-08
four O 0 4.7388812873805364e-08
Japanese O 0 2.7492014851304702e-06
C9 B-Disease 0 0.4053610563278198
- I-Disease 1 0.9856641292572021
deficient I-Disease 1 0.9615870118141174
patients O 0 1.614444590813946e-05
who O 0 4.506168238549435e-07
had O 0 1.743066604831256e-05
suffered O 1 0.9875044226646423
from O 0 0.0008130100904963911
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 3.237835699110292e-05

Direct O 0 6.685163953079609e-06
sequencing O 0 5.468113158713095e-06
of O 0 1.4134360526441014e-07
amplified O 0 8.72385408001719e-06
C9 O 0 2.097207288898062e-05
cDNA O 0 3.3667586194496835e-06
and O 0 7.58164162562025e-08
DNA O 0 4.127685713228857e-07
revealed O 0 5.949287356088462e-07
a O 0 6.263250185156721e-08
nonsense O 0 7.443043728017074e-07
substitution O 0 4.6447817680927983e-07
( O 0 1.1302797986445512e-07
CGA O 0 4.6371602365979925e-05
- O 0 3.901053059962578e-05
- O 0 1.1798677405749913e-05
> O 0 4.2617448343662545e-06
TGA O 0 1.232206432177918e-05
) O 0 3.9811112628740375e-08
at O 0 9.824443480965783e-08
codon O 0 7.953199769872299e-07
95 O 0 6.673187158412475e-08
in O 0 1.491533652142607e-08
exon O 0 2.917025199167256e-07
4 O 0 2.8776010907449745e-08
in O 0 5.316776352515262e-09
the O 0 1.487425560497968e-08
four O 0 4.789486141021371e-08
C9 B-Disease 0 8.731894195079803e-05
- I-Disease 0 0.0024961812887340784
deficient I-Disease 0 0.00025302148424088955
individuals O 0 8.978829413308631e-08
. O 0 4.6782525942035136e-07

An O 0 2.8083534289180534e-06
allele O 0 5.9188270824961364e-05
- O 0 2.6231814445054624e-06
specific O 0 1.6631364019303874e-07
polymerase O 0 4.618981165549485e-06
chain O 0 1.1493731108203065e-05
reaction O 0 1.0117586271007895e-06
system O 0 8.438706800006912e-07
designed O 0 1.209711058436369e-06
to O 0 1.0205829070741856e-08
detect O 0 1.2174468793091364e-06
exclusively O 0 7.272690005777349e-09
only O 0 6.006312669448732e-10
one O 0 1.7468167190504147e-10
of O 0 1.321406456478158e-10
the O 0 1.9861470246240742e-09
normal O 0 3.325638786577656e-08
and O 0 5.380854428693738e-09
mutant O 0 8.581381649719333e-08
alleles O 0 9.355329666504986e-08
indicated O 0 5.3221157259031315e-08
that O 0 9.90808213252592e-10
all O 0 2.1452635501351125e-10
the O 0 1.544701699884854e-09
four O 0 3.304909235168907e-09
patients O 0 9.16343001478026e-09
were O 0 2.2340220784400344e-09
homozygous O 0 4.430108191399995e-08
for O 0 1.1777140374036321e-09
the O 0 8.384780869619135e-09
mutation O 0 1.6090153565073706e-07
in O 0 1.7555061404550543e-08
exon O 0 9.119145261138328e-07
4 O 0 4.5930288905537964e-08
and O 0 4.453879487442691e-09
that O 0 1.149905837216636e-09
the O 0 7.328500473136046e-09
parents O 0 9.235970210852429e-09
of O 0 1.297988494464164e-09
patient O 0 1.560802473932199e-07
2 O 0 6.851363565374413e-08
were O 0 1.3084120098483254e-07
heterozygous O 0 8.361661457456648e-06
. O 0 6.558817062796152e-07

The O 0 3.319445795568754e-06
common O 0 1.6728763512219302e-06
mutation O 0 4.166191502008587e-06
at O 0 4.79108564377384e-07
codon O 0 3.196094212398748e-06
95 O 0 3.1276010759029305e-07
in O 0 6.109544159471625e-08
exon O 0 2.998547415700159e-06
4 O 0 1.3582929625499673e-07
might O 0 6.844297217867279e-08
be O 0 3.8449439188070755e-09
responsible O 0 1.0202987787977236e-08
for O 0 2.245805097444986e-09
most O 0 9.13683262382392e-09
Japanese O 0 1.553774745843839e-05
C9 B-Disease 1 0.9880433082580566
deficiency I-Disease 0 0.1518554538488388
. O 0 1.7110899364070065e-07
. O 0 4.923072651763505e-07

BRCA1 O 0 0.0010022922651842237
required O 0 1.4730064776813379e-06
for O 0 9.201966122418526e-08
transcription O 0 1.1642729077721015e-05
- O 0 0.0002280626358697191
coupled O 0 0.00020958234381396323
repair O 0 0.0001777049619704485
of O 0 4.835408518033546e-08
oxidative O 0 1.731733573251404e-05
DNA O 0 1.8438458937453106e-05
damage O 0 0.0003423551097512245
. O 0 5.381568371376488e-06

The O 0 5.597644849331118e-05
breast B-Disease 1 0.9999911785125732
and I-Disease 1 0.9988501071929932
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0013296062825247645
gene O 0 9.866341133601964e-05
BRCA1 O 0 8.463975973427296e-05
encodes O 0 3.124350541838794e-06
a O 0 2.7884341307071736e-06
zinc O 0 0.004382511600852013
finger O 0 1.8836846720660105e-05
protein O 0 2.0805468636808655e-07
of O 0 3.023819639125236e-09
unknown O 0 6.138137820244083e-08
function O 0 3.7221957427391317e-07
. O 0 3.14950483470966e-07

Association O 0 4.720028755400563e-06
of O 0 3.642113455271101e-08
the O 0 5.9305147459554064e-08
BRCA1 O 0 1.694210709501931e-06
protein O 0 8.086424685416205e-08
with O 0 6.940205299343916e-09
the O 0 1.902413515608714e-08
DNA O 0 1.5562246744593722e-06
repair O 0 0.00040551775600761175
protein O 0 1.0890418025155668e-06
Rad51 O 0 6.184195626701694e-06
and O 0 1.7743811753234695e-08
changes O 0 1.790000681012316e-08
in O 0 2.745484284361055e-09
the O 0 2.6014703724541732e-09
phosphorylation O 0 3.661909531160745e-08
and O 0 2.469956905670756e-09
cellular O 0 8.961379194261099e-08
localization O 0 8.61899493997953e-08
of O 0 8.98629226586678e-10
the O 0 5.059542562690922e-09
protein O 0 2.5003320303085275e-08
after O 0 1.6336016983586887e-08
exposure O 0 1.852014435144156e-07
to O 0 8.021442177152949e-09
DNA O 0 1.7597376711364632e-07
- O 0 8.011458589862741e-07
damaging O 0 6.803531391597062e-07
agents O 0 4.924462260191831e-08
are O 0 8.611543145242706e-10
consistent O 0 6.908640326486193e-09
with O 0 8.861884559507871e-10
a O 0 5.925650192750709e-09
role O 0 1.193594467707726e-08
for O 0 9.107428589061328e-09
BRCA1 O 0 1.985530388992629e-06
in O 0 7.780036526128242e-08
DNA O 0 1.6160094673978165e-05
repair O 0 0.04324131831526756
. O 0 1.5729285678389715e-06

Here O 0 1.047199361892126e-06
, O 0 2.675694155129804e-08
it O 0 3.164526640730969e-09
is O 0 1.7712220579113591e-09
shown O 0 5.5340794169467245e-09
that O 0 1.5176963019669643e-09
mouse O 0 8.10334483958286e-07
embryonic O 0 4.0726851580075163e-07
stem O 0 8.827425972413039e-07
cells O 0 1.225005348715058e-06
deficient B-Disease 0 6.5552985688555054e-06
in I-Disease 0 3.4631401746310075e-08
BRCA1 I-Disease 0 4.471348802326247e-06
are O 0 3.236310330834158e-09
defective O 0 8.25784354674397e-07
in O 0 4.646502738125946e-09
the O 0 4.341885073699814e-09
ability O 0 6.110754124932782e-09
to O 0 3.035671936046924e-09
carry O 0 1.1551757772565452e-08
out O 0 4.3064121157954105e-09
transcription O 0 2.224325470479016e-07
- O 0 2.275043016197742e-06
coupled O 0 5.585115104622673e-06
repair O 0 9.0627918325481e-06
of O 0 3.94042087847879e-09
oxidative O 0 1.0843140216820757e-06
DNA O 0 8.440300689471769e-07
damage O 0 7.607201951032039e-06
, O 0 2.5710065187922737e-08
and O 0 1.642857050399016e-08
are O 0 3.517621305348939e-09
hypersensitive O 0 1.7985610611503944e-05
to O 0 5.7804857789278685e-08
ionizing O 0 1.0410702088847756e-05
radiation O 0 4.0756247472018003e-05
and O 0 6.455648815517634e-08
hydrogen O 0 3.523073246469721e-06
peroxide O 0 0.00015694867761339992
. O 0 1.4259654790294007e-06

These O 0 7.891752034083765e-07
results O 0 7.027550168459129e-07
suggest O 0 1.9576660292841552e-07
that O 0 1.3514416252746742e-08
BRCA1 O 0 1.102581222767185e-06
participates O 0 6.653881001739137e-08
, O 0 1.925759329779453e-09
directly O 0 6.177387046335525e-09
or O 0 2.1363398161611258e-08
indirectly O 0 3.7883403081195866e-08
, O 0 1.996214971100585e-09
in O 0 3.8977536753748154e-09
transcription O 0 3.6610896358979517e-07
- O 0 9.088106708077248e-06
coupled O 0 1.6943229638854973e-05
repair O 0 2.226626020274125e-05
of O 0 3.903370515700999e-09
oxidative O 0 1.4183608527673641e-06
DNA O 0 1.6573555967624998e-06
damage O 0 1.0610141544020735e-05
. O 0 1.6125453328186268e-07
. O 0 7.853266765778244e-07

Truncation O 0 0.0013409026432782412
mutations O 0 0.0010509892599657178
in O 0 1.4476325986834127e-06
the O 0 3.34658352585393e-07
transactivation O 0 2.3750426407787018e-05
region O 0 3.016983498582704e-07
of O 0 3.3151195566460956e-08
PAX6 O 0 1.7678330550552346e-05
result O 0 9.651029841961645e-08
in O 0 6.664995311211896e-08
dominant O 0 2.452438639011234e-05
- O 0 8.917773084249347e-05
negative O 0 9.345711987407412e-06
mutants O 0 9.373989996674936e-06
. O 0 8.131802360367146e-07

PAX6 O 0 0.002281737979501486
is O 0 8.329002412210684e-07
a O 0 1.3320871516953048e-07
transcription O 0 8.864113851814182e-07
factor O 0 6.378758854452826e-08
with O 0 3.3626124107399846e-09
two O 0 3.7368756977684825e-09
DNA O 0 4.116803893339238e-07
- O 0 1.008617914521892e-06
binding O 0 4.650477194445557e-07
domains O 0 2.824226896791515e-07
( O 0 3.7311796319272617e-08
paired O 0 5.166106120668701e-07
box O 0 2.6919833544525318e-06
and O 0 6.311783096180079e-08
homeobox O 0 1.4199199540598784e-06
) O 0 1.672057514667813e-08
and O 0 6.350035164359724e-09
a O 0 5.386320012235046e-08
proline O 0 4.489424100029282e-05
- O 0 7.851283953641541e-06
serine O 0 2.5127556000370532e-05
- O 0 3.378365363460034e-05
threonine O 0 9.911652159644291e-05
( O 0 3.21983009143878e-07
PST O 0 4.113249815418385e-05
) O 0 1.7580619271484466e-07
- O 0 1.2167655540906708e-06
rich O 0 2.783104946502135e-07
transactivation O 0 1.545833220006898e-05
domain O 0 4.143566457059933e-06
. O 0 1.3494631048160954e-06

PAX6 O 0 0.012246177531778812
regulates O 0 0.0007016034796833992
eye O 0 0.00021500024013221264
development O 0 1.7435871768611833e-07
in O 0 4.277582377198996e-08
animals O 0 3.982918883593811e-08
ranging O 0 3.153832750513175e-08
from O 0 1.3520527808452698e-08
jellyfish O 0 1.881333560049825e-07
to O 0 1.7308328992271527e-08
Drosophila O 0 2.691639338081586e-07
to O 0 4.168445855157188e-08
humans O 0 3.8805538338237966e-07
. O 0 3.905734047293663e-07

Heterozygous O 0 0.0008543276926502585
mutations O 0 0.00021379660756792873
in O 0 3.720527388395567e-07
the O 0 1.020715743038636e-07
human O 0 1.5545661824489798e-07
PAX6 O 0 2.872932600439526e-05
gene O 0 1.4512515917886049e-06
result O 0 7.744902319473113e-08
in O 0 1.4794803604445406e-08
various O 0 6.72134259360746e-09
phenotypes O 0 7.761188953736564e-07
, O 0 1.0398708560899195e-08
including O 0 3.2478567391081015e-08
aniridia B-Disease 1 1.0
, O 0 0.00012671758304350078
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.025091134782997e-06
autosomal B-Disease 0 0.30154338479042053
dominant I-Disease 0 0.002442031167447567
keratitis I-Disease 0 0.2901821732521057
, O 0 4.973604177394009e-07
and O 0 8.044502237680717e-07
familial B-Disease 1 0.6609250903129578
foveal I-Disease 1 0.9999420642852783
dysplasia I-Disease 1 0.9999996423721313
. O 0 2.87352449959144e-05

It O 0 6.999952120168018e-07
is O 0 2.2337847127573696e-08
believed O 0 1.1393637144863078e-08
that O 0 1.0636878045033882e-09
the O 0 8.535067763659754e-09
mutated O 0 7.359024039033102e-07
allele O 0 4.871196210842754e-07
of O 0 7.2306014509138095e-09
PAX6 O 0 2.224653144367039e-06
produces O 0 3.899807765606056e-08
an O 0 8.387596395209584e-09
inactive O 0 1.623733254518811e-07
protein O 0 1.137414429308592e-07
and O 0 3.662496439460483e-08
aniridia B-Disease 1 0.9999996423721313
is O 0 6.328286161760843e-08
caused O 0 3.0507538895108155e-07
due O 0 8.980508425793232e-08
to O 0 5.1372023079920837e-08
genetic O 0 3.5852831388183404e-06
haploinsufficiency O 0 8.374593016924337e-05
. O 0 1.0272131021338282e-06

However O 0 1.801614189389511e-06
, O 0 4.536705233704197e-08
several O 0 3.831037176382779e-08
truncation O 0 4.704174898506608e-06
mutations O 0 5.706612228095764e-06
have O 0 1.2673071481117404e-08
been O 0 1.2850492225879862e-08
found O 0 1.1381343867356009e-08
to O 0 6.935613416914066e-09
occur O 0 1.1271297672976743e-08
in O 0 4.5918260305199965e-09
the O 0 6.242343175699716e-08
C O 0 2.6993178835255094e-05
- O 0 1.229530198543216e-06
terminal O 0 4.2402402300467656e-07
half O 0 1.4273906501216516e-08
of O 0 2.972315504834455e-09
PAX6 O 0 2.6240672923449893e-06
in O 0 4.809506748415515e-08
patients O 0 6.06648740131277e-08
with O 0 1.501165947104255e-08
Aniridia B-Disease 1 0.9999204874038696
resulting O 0 1.4870289533064351e-07
in O 0 1.13942242307985e-08
mutant O 0 6.650848405342913e-08
proteins O 0 9.887566321253871e-09
that O 0 1.0263176974945054e-09
retain O 0 2.052504122218579e-08
the O 0 6.232930171989892e-09
DNA O 0 2.0066534034413053e-07
- O 0 1.7122097517585644e-07
binding O 0 7.46622106362338e-08
domains O 0 3.691749839163094e-08
but O 0 4.509880024983204e-09
have O 0 2.271129728725896e-09
lost O 0 1.9752524949012695e-08
most O 0 1.0301458575057154e-09
of O 0 1.6358271404115499e-09
the O 0 4.561303157402108e-08
transactivation O 0 9.586023224983364e-06
domain O 0 1.537966454634443e-06
. O 0 6.442517701543693e-07

It O 0 1.5823982266738312e-06
is O 0 6.408991026773947e-08
not O 0 3.463138442683089e-09
clear O 0 6.947688646619099e-09
whether O 0 6.4305512026408e-09
such O 0 4.909286310805783e-09
mutants O 0 5.520987542695366e-07
really O 0 5.289246374218237e-08
behave O 0 7.095865584005878e-08
as O 0 1.1302427438408813e-08
loss O 0 1.6492718657445948e-07
- O 0 3.2675606576049177e-07
of O 0 9.138592993451766e-09
- O 0 1.0284902600687928e-06
function O 0 6.350789050202366e-08
mutants O 0 1.4456774977134046e-07
as O 0 6.434183408288163e-09
predicted O 0 1.350666565258507e-07
by O 0 4.161447364481319e-08
haploinsufficiency O 0 1.7011489035212435e-05
. O 0 5.129506917000981e-07

Contrary O 0 5.0958765314135235e-06
to O 0 1.1221965223739971e-07
this O 0 9.374635290271272e-09
theory O 0 1.2963217166372942e-08
, O 0 8.438716947445357e-10
our O 0 1.8189685313529935e-09
data O 0 4.402706110795407e-08
showed O 0 1.1661298060516856e-07
that O 0 8.459279943195952e-10
these O 0 1.3559930955864274e-09
mutants O 0 3.5169119172451246e-08
are O 0 6.266889229777917e-10
dominant O 0 1.7596704537936603e-07
- O 0 7.876953986851731e-07
negative O 0 2.5972977368837746e-07
in O 0 2.7794225587740584e-08
transient O 0 2.614679601720127e-07
transfection O 0 3.839329110633116e-06
assays O 0 1.9290744148747763e-06
when O 0 3.620089472633481e-08
they O 0 5.041951744999551e-09
are O 0 1.0077501055860694e-09
coexpressed O 0 1.402372333814128e-07
with O 0 6.539647046110986e-09
wild O 0 4.4055877879145555e-07
- O 0 0.00022038370661903173
type O 0 0.00039757415652275085
PAX6 O 0 0.0005591987282969058
. O 0 3.09810388898768e-06

We O 0 8.992950029096392e-07
found O 0 1.4238020185075584e-07
that O 0 1.1594536886150308e-08
the O 0 2.5759593569318895e-08
dominant O 0 3.2706334422982763e-06
- O 0 3.878069946949836e-06
negative O 0 8.100842023850419e-07
effects O 0 3.96951833181447e-07
result O 0 1.6211268771826326e-08
from O 0 6.406031261008138e-09
the O 0 5.223216970051681e-09
enhanced O 0 8.867895928688085e-08
DNA O 0 5.005275482972138e-08
binding O 0 3.532724690558098e-08
ability O 0 1.6910059130736954e-08
of O 0 1.7806625063343517e-09
these O 0 9.737764372630409e-09
mutants O 0 1.2814496130886255e-06
. O 0 2.212212137919778e-07

Kinetic O 0 3.254409966757521e-05
studies O 0 1.014612621474953e-06
of O 0 2.1904332569988583e-08
binding O 0 3.0488226343550195e-07
and O 0 5.025296800909018e-08
dissociation O 0 1.3924189943281817e-06
revealed O 0 3.0188454047674895e-07
that O 0 2.539172205828777e-09
various O 0 2.400205367791841e-09
truncation O 0 4.3530323523555126e-07
mutants O 0 3.8231979715419584e-07
have O 0 7.621801856316779e-09
3 O 0 1.9330135714312746e-08
- O 0 3.81540331773067e-07
5 O 0 7.387588141227752e-08
- O 0 4.941587121720659e-07
fold O 0 1.3986580427172157e-07
higher O 0 9.772950448905249e-09
affinity O 0 7.5841839475288e-09
to O 0 1.5231887973143898e-09
various O 0 1.1627528939683884e-09
DNA O 0 4.4387945763446623e-08
- O 0 1.0141565098820138e-07
binding O 0 3.522437097558395e-08
sites O 0 2.1432864372172844e-08
when O 0 4.410924514530734e-09
compared O 0 9.223892760701347e-09
with O 0 1.924697956567911e-09
the O 0 1.889366529894687e-08
wild O 0 5.70095949115057e-07
- O 0 6.506097997771576e-05
type O 0 0.00011872432514792308
PAX6 O 0 0.00034749502083286643
. O 0 2.672774598977412e-06

These O 0 1.0536015224715811e-06
results O 0 8.158757509590941e-07
provide O 0 4.1014651230852905e-08
a O 0 4.002322739893316e-08
new O 0 6.86359271639958e-08
insight O 0 3.3663297926977975e-08
into O 0 3.5207894377720095e-09
the O 0 5.738737485216916e-09
role O 0 8.3052134058903e-09
of O 0 2.126103071375951e-09
mutant O 0 2.940913077509322e-07
PAX6 O 0 3.535897349138395e-06
in O 0 7.729716600124448e-08
causing O 0 1.3847959053236991e-05
aniridia B-Disease 1 0.9999992847442627
. O 0 6.854525622657093e-07
. O 0 6.619575856348092e-07

Reversal O 0 0.000548609416000545
of O 0 6.828598088759463e-06
severe O 1 0.9999707937240601
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
and O 0 4.969277506461367e-05
excellent O 0 7.035301223368151e-06
neuropsychologic O 0 0.0005701113259419799
outcome O 0 1.1413438869567472e-06
in O 0 2.3525666392743005e-07
very B-Disease 0 9.148020012617053e-07
- I-Disease 0 2.1045421817689203e-05
long I-Disease 0 2.6829206944967154e-06
- I-Disease 0 9.63606817094842e-06
chain I-Disease 0 3.181468491675332e-05
acyl I-Disease 0 8.06678053777432e-06
- I-Disease 0 4.78566971651162e-06
coenzyme I-Disease 0 5.456069629872218e-06
A I-Disease 0 5.680728008883307e-06
dehydrogenase I-Disease 0 0.10714974254369736
deficiency I-Disease 0 0.13890188932418823
. O 0 1.4862989701214246e-06

Very B-Disease 0 4.3454827391542494e-05
- I-Disease 0 0.00022343467571772635
long I-Disease 0 3.5397706596995704e-06
- I-Disease 0 9.936448805092368e-06
chain I-Disease 0 3.177172038704157e-05
acyl I-Disease 0 1.5638790500815958e-05
- I-Disease 0 3.3944006645469926e-06
coenzyme I-Disease 0 2.3937113837746438e-06
A I-Disease 0 4.113676084216422e-07
dehydrogenase I-Disease 0 2.3797629182809032e-05
( I-Disease 0 3.2852648246262106e-07
VLCAD I-Disease 0 0.0020614885725080967
) I-Disease 0 2.2696685846312903e-06
deficiency I-Disease 0 0.00034097922616638243
is O 0 1.9264657424855613e-08
a O 0 5.639347477881529e-07
disorder O 0 0.006124037783592939
of O 0 2.435155366242725e-08
fatty O 0 4.708963388111442e-06
acid O 0 4.862534979110933e-07
beta O 0 1.5092669514160661e-07
oxidation O 0 2.3723592335045396e-07
that O 0 6.24276985661254e-09
reportedly O 0 1.1167048086235809e-07
has O 0 2.6191161239808025e-08
high O 0 6.389852273969154e-07
rates O 0 7.532614290539641e-06
of O 0 3.668698056458197e-08
morbidity O 0 0.02406715601682663
and O 0 7.024909791653045e-07
mortality O 0 4.665121377911419e-05
. O 0 1.1494522595967283e-06

We O 0 9.52429957123968e-07
describe O 0 2.4513079210919386e-07
the O 0 1.0913603354367751e-08
outcome O 0 2.1273576678026984e-08
of O 0 8.087250313870697e-10
a O 0 1.6143388847922324e-08
5 O 0 5.7162910849228865e-08
- O 0 8.159543654073786e-07
year O 0 1.2716951403035637e-07
- O 0 7.615171853103675e-06
old O 0 1.4738756362930872e-05
girl O 0 9.046625564224087e-06
with O 0 1.325965854448441e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 8.870686940554151e-08
was O 0 2.2155015244607057e-07
first O 0 1.2224148804307333e-08
seen O 0 7.540468516253895e-08
at O 0 4.580186541147668e-08
5 O 0 1.3014970434710449e-08
months O 0 1.1127624155449212e-08
of O 0 1.9620642888185102e-09
age O 0 4.019918975473047e-08
with O 0 8.028057862929927e-08
severe O 1 0.9987515211105347
hypertrophic B-Disease 1 0.9999997615814209
cardiomyopathy I-Disease 1 1.0
, O 0 0.2737545967102051
hepatomegaly B-Disease 1 1.0
, O 0 0.021356865763664246
encephalopathy B-Disease 1 0.9999799728393555
, O 0 4.951058940605435e-07
and O 0 1.2631655863515334e-06
hypotonia B-Disease 1 0.9979578256607056
. O 0 6.339694209600566e-06

Biochemical O 0 0.0009158322936855257
studies O 0 0.00016006156511139125
indicated O 1 0.999373733997345
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 5.437553409137763e-05
by O 0 1.109786893493947e-07
a O 0 4.0922955690803064e-07
stable O 0 2.92267413897207e-05
yet O 0 5.092579726806434e-07
inactive O 0 6.899424533912679e-06
enzyme O 0 4.183630608167732e-06
. O 0 7.01391797974793e-07

Molecular O 0 0.00010364990885136649
genetic O 0 1.193741354654776e-05
analysis O 0 4.88624266381521e-07
of O 0 1.702608543041606e-08
her O 0 4.171699856669875e-07
VLCAD O 0 0.0001571563770994544
gene O 0 6.150059562060051e-06
revealed O 0 1.8179587186750723e-06
a O 0 4.352243649918819e-07
T1372C O 0 3.458606670392328e-06
( O 0 1.867070409389271e-07
F458L O 0 1.744724613672588e-06
) O 0 9.473916406932403e-08
missense O 0 1.84200398507528e-05
mutation O 0 4.225705652061151e-06
and O 0 8.615198510142363e-08
a O 0 1.5156133486016188e-06
1668 O 0 0.062294285744428635
ACAG O 0 0.0016306745819747448
1669 O 0 0.0004027902032248676
splice O 0 0.000505611882545054
site O 0 4.462984361452982e-05
mutation O 0 0.00016267232422251254
. O 0 4.306547452870291e-06

After O 0 6.387326266121818e-06
initial O 0 1.9501692349876976e-06
treatment O 0 7.675313327126787e-07
with O 0 5.474639408475923e-08
intravenous O 0 5.53396830582642e-06
glucose O 0 7.806478242855519e-05
and O 0 1.1020792101135157e-07
carnitine O 0 2.774934046101407e-06
, O 0 8.416940033839637e-09
the O 0 1.5993183666296318e-08
patient O 0 6.146344730950659e-07
has O 0 1.898382784304431e-08
thrived O 0 8.390159678128839e-08
on O 0 2.4420579336492665e-08
a O 0 6.084808745754344e-08
low O 0 0.00011747991084121168
- O 0 3.547757296473719e-05
fat O 0 1.4099497093411628e-05
diet O 0 5.519776777873631e-07
supplemented O 0 8.480903801455497e-08
with O 0 1.4525397773468285e-08
medium O 0 1.0093569926539203e-06
- O 0 2.4731955363677116e-06
chain O 0 6.331404620141257e-06
triglyceride O 0 4.117795015190495e-06
oil O 0 3.116973914529808e-07
and O 0 1.7324776280247534e-08
carnitine O 0 1.7281698774240795e-06
and O 0 2.311436908541964e-08
avoidance O 0 7.200704317256168e-07
of O 0 2.7683174863568638e-08
fasting O 0 2.1702777303289622e-05
. O 0 1.005818944577186e-06

Her O 0 0.00014196758274920285
ventricular O 1 0.7709023356437683
hypertrophy O 0 0.03212057426571846
resolved O 0 5.211828010942554e-06
significantly O 0 1.601325948286103e-06
over O 0 3.326926645286221e-08
1 O 0 3.323755137785156e-08
year O 0 9.416839752418582e-09
, O 0 1.971679264300974e-09
and O 0 1.1319837511791775e-08
cognitively O 0 5.786856036138488e-06
, O 0 4.7468216024526555e-09
she O 0 5.388690826890752e-09
is O 0 6.435088018008628e-10
in O 0 1.2305690910707767e-09
the O 0 4.9573398719360284e-09
superior O 0 8.980748589237919e-08
range O 0 1.6243667744220147e-07
for O 0 3.2601395361098184e-08
age O 0 3.98865921624747e-07
. O 0 2.451151317472977e-07

Clinical O 0 6.0928909078938887e-05
recognition O 0 2.3608763513038866e-06
of O 0 3.692747213790426e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 6.557597487244493e-08
important O 0 5.255064383646868e-09
because O 0 8.54547632656022e-09
it O 0 2.5835651396022286e-09
is O 0 3.5978314771867304e-10
one O 0 2.0533047484505573e-10
of O 0 1.3951217958663165e-10
the O 0 3.3225240336776096e-09
few O 0 2.01711340963584e-08
directly O 0 2.0782286469511746e-07
treatable O 0 1.5124517631193157e-05
causes O 0 1.4969691619626246e-07
of O 0 5.0513396132600974e-08
cardiomyopathy B-Disease 1 1.0
in O 0 4.211804935039254e-06
children O 0 1.5926949004096969e-07
. O 0 4.0878052942616705e-08
. O 0 3.684111220536579e-07

Cloning O 0 1.2745992535201367e-05
of O 0 3.4684155991726584e-08
a O 0 5.7306355216724114e-08
novel O 0 7.294531911838931e-08
member O 0 1.7249469408398e-08
of O 0 1.68592639848697e-09
the O 0 2.926570452643773e-08
low O 0 3.073307016165927e-05
- O 0 1.1368301784386858e-05
density O 0 1.123422975979338e-06
lipoprotein O 0 8.500982221448794e-05
receptor O 0 7.284379535121843e-06
family O 0 2.9767393243673723e-06
. O 0 8.491990115544468e-07

A O 0 7.344444838963682e-06
gene O 0 1.0923361514869612e-05
encoding O 0 2.2465960682893638e-06
a O 0 1.7852177336408204e-07
novel O 0 1.84257501700813e-07
transmembrane O 0 7.841427418497915e-07
protein O 0 3.650880842087645e-07
was O 0 1.9052900768201653e-07
identified O 0 1.4272735882059351e-08
by O 0 3.1531754984825966e-09
DNA O 0 4.474257053743713e-08
sequence O 0 4.060715852460817e-08
analysis O 0 1.8827222447725944e-08
within O 0 8.307003085405995e-09
the O 0 8.090250958048273e-08
insulin B-Disease 1 0.6479766964912415
- I-Disease 1 0.9979231953620911
dependent I-Disease 1 0.9886248111724854
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.1297483928938163e-06
IDDM B-Disease 0 0.00024714801111258566
) O 0 3.8863831264279725e-07
locus O 0 7.234194072225364e-06
IDDM4 O 0 4.0273760532727465e-05
on O 0 2.8250451578060165e-06
chromosome O 0 6.082198160584085e-05
11q13 O 0 4.559310764307156e-05
. O 0 3.5269761156087043e-06

Based O 0 3.0995106499176472e-06
on O 0 7.41962878691993e-07
its O 0 3.419883967126225e-07
chromosomal O 0 0.00015401258133351803
position O 0 6.353023991323425e-07
, O 0 4.432092026718237e-09
this O 0 2.028904155793043e-09
gene O 0 7.442717731009907e-08
is O 0 1.8696275638774296e-09
a O 0 4.488717841866219e-09
candidate O 0 1.891180012592031e-08
for O 0 3.1589002524867738e-09
conferring O 0 2.905204041780962e-07
susceptibility O 0 9.678571586846374e-06
to O 0 2.378791805313085e-06
diabetes B-Disease 1 0.6904796361923218
. O 0 3.2494917832082137e-06

The O 0 2.8146437216491904e-06
gene O 0 1.2264243196113966e-05
, O 0 9.277853507683176e-08
termed O 0 1.1620415989455068e-06
low O 0 1.3101618606015109e-05
- O 0 8.662404979986604e-06
density O 0 1.0139298183275969e-06
lipoprotein O 0 2.138172567356378e-05
receptor O 0 1.2502379149736953e-06
related O 0 2.1381950432441954e-07
protein O 0 5.135312335369235e-07
5 O 0 1.1783914999341505e-07
( O 0 3.28151301687285e-08
LRP5 O 0 4.010486918559764e-06
) O 0 5.828220128734074e-09
, O 0 1.0356305812919686e-09
encodes O 0 1.7464222068497293e-08
a O 0 1.0456985499729399e-08
protein O 0 6.193516810526489e-08
of O 0 6.947914243937703e-09
1615 O 0 2.8001435566693544e-05
amino O 0 2.1030709262959135e-07
acids O 0 4.421809762789053e-08
that O 0 9.582475923863853e-10
contains O 0 3.0456530630829093e-09
conserved O 0 2.7901092991555743e-08
modules O 0 3.9558674558293205e-08
which O 0 4.025134447971368e-09
are O 0 4.696244504387437e-10
characteristic O 0 9.592281635661948e-09
of O 0 9.618568164171393e-10
the O 0 2.289729650328809e-08
low O 0 6.205972022144124e-05
- O 0 3.987718082498759e-05
density O 0 1.6678982319717761e-06
lipoprotein O 0 0.0002013210323639214
( O 0 5.99917996169097e-07
LDL O 0 4.41661431977991e-05
) O 0 1.0865442590102248e-07
receptor O 0 4.131531113671372e-06
family O 0 1.113284497478162e-06
. O 0 6.335689022307633e-07

These O 0 7.937272812341689e-07
modules O 0 1.0223509434581501e-06
include O 0 3.5967577360906944e-08
a O 0 4.397469055561487e-08
putative O 0 1.011467247735709e-06
signal O 0 1.178312231786549e-06
peptide O 0 3.6196720998304954e-07
for O 0 4.947280363154505e-09
protein O 0 4.63656348870245e-08
export O 0 2.2097697893741497e-08
, O 0 1.8020958059139502e-09
four O 0 3.539399884289196e-09
epidermal O 0 4.3271140270917385e-07
growth O 0 1.6154235993326438e-07
factor O 0 7.107989574706153e-08
( O 0 3.601480713655292e-08
EGF O 0 2.4738915271882433e-06
) O 0 2.6198456737347442e-08
repeats O 0 1.0597171922199777e-06
with O 0 1.1282913270349582e-08
associated O 0 1.6336834107733011e-07
spacer O 0 2.144351128663402e-06
domains O 0 1.7789567152703967e-07
, O 0 8.572822451924367e-09
three O 0 4.5708919316211905e-08
LDL O 0 0.00015621335478499532
- O 0 1.767789217410609e-05
receptor O 0 5.485339443112025e-06
( O 0 2.245434274072977e-07
LDLR O 0 8.063727364060469e-06
) O 0 3.4316709474069285e-08
repeats O 0 9.238983125214872e-07
, O 0 3.515032487300118e-09
a O 0 7.0361183546197026e-09
single O 0 3.6680400938848834e-08
transmembrane O 0 6.612472702727246e-08
spanning O 0 5.414739590037243e-08
domain O 0 7.821652303618976e-08
, O 0 4.685045240648833e-09
and O 0 6.963077670008033e-09
a O 0 7.808490209981755e-08
cytoplasmic O 0 6.879345619381638e-06
domain O 0 3.271893774581258e-06
. O 0 7.328461038014211e-07

The O 0 9.062842991625075e-07
encoded O 0 9.63798470365873e-07
protein O 0 3.43786894063669e-07
has O 0 8.636039439124943e-09
a O 0 3.1894555885259024e-09
unique O 0 2.016343092492434e-09
organization O 0 5.976170669441672e-09
of O 0 3.4503544465991354e-09
EGF O 0 1.8760281363938702e-06
and O 0 2.7967587357125012e-08
LDLR O 0 1.6759944628574885e-05
repeats O 0 6.320545253402088e-06
; O 0 2.0318019267051568e-08
therefore O 0 1.2396560222782682e-08
, O 0 5.8161493399211395e-09
LRP5 O 0 3.2730486054788344e-06
likely O 0 4.504500594748606e-08
represents O 0 3.041652929525185e-09
a O 0 5.159273896993e-09
new O 0 2.2004622124427442e-08
category O 0 1.4335185483105306e-08
of O 0 1.4930384706346445e-09
the O 0 3.041590801444727e-08
LDLR O 0 6.229084101505578e-05
family O 0 1.5493698128921096e-06
. O 0 4.912740223517176e-07

Both O 0 1.2814166439056862e-06
human O 0 2.8173565169709036e-07
and O 0 1.4407116566417244e-07
mouse O 0 3.0098792194621637e-05
LRP5 O 0 5.56584564037621e-05
cDNAs O 0 4.808452558791032e-06
have O 0 9.621563989981041e-09
been O 0 8.7878113674833e-09
isolated O 0 4.685583832042539e-08
and O 0 4.274578913054938e-09
the O 0 4.929261887554048e-09
encoded O 0 6.97674593652664e-08
mature O 0 4.881556847635693e-08
proteins O 0 1.2680639649431669e-08
are O 0 7.223691644853147e-10
95 O 0 1.2762849443959112e-08
% O 0 4.643720519226235e-09
identical O 0 9.302820558332314e-08
, O 0 4.105400019938088e-09
indicating O 0 1.5548924636732409e-07
a O 0 4.463227654127877e-08
high O 0 2.1409191219845525e-07
degree O 0 1.3488999250910183e-08
of O 0 2.5910611434198927e-09
evolutionary O 0 8.779774418599118e-08
conservation O 0 6.846582323305483e-08
. O 0 2.553252720360888e-08
. O 0 2.4908842988224933e-07

The O 0 2.925766921180184e-06
APC B-Disease 0 1.2650327334995382e-05
variants O 0 2.6942434487864375e-06
I1307K O 0 2.8644478788919514e-06
and O 0 2.7150996118052717e-08
E1317Q O 0 5.035410026721365e-07
are O 0 7.333366802697583e-09
associated O 0 1.6567614693485666e-06
with O 1 0.9921312928199768
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.214968354674056e-05
but O 0 1.560561315727682e-07
not O 0 1.1102014418895578e-08
always O 0 3.3501674767677514e-09
with O 0 1.5304694178652767e-09
a O 0 3.129874315277448e-08
family O 0 1.6509683575804956e-07
history O 0 9.979023474215865e-08
. O 0 3.1683396173320943e-07

Classical O 0 0.1766686886548996
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 0.010335621424019337
FAP B-Disease 0 0.000590276438742876
) O 0 2.8780465299860225e-07
is O 0 1.2993615072787179e-08
a O 0 8.036591481186406e-08
high O 0 0.0003726223949342966
- O 1 0.9843373894691467
penetrance O 1 0.9995278120040894
autosomal B-Disease 1 0.999998927116394
dominant I-Disease 1 0.9996178150177002
disease I-Disease 1 0.9720252156257629
that O 0 3.3853179814968826e-08
predisposes O 0 8.815546834739507e-07
to O 0 7.120973144481013e-09
hundreds O 0 7.904781718082177e-09
or O 0 1.1369497343594048e-08
thousands O 0 1.3364895856682324e-08
of O 0 2.1971170554024866e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9737560153007507
carcinoma I-Disease 1 1.0
and O 0 4.1531859551469097e-07
that O 0 1.0719267251602105e-08
results O 0 1.3139076315837883e-07
from O 0 2.291604062065744e-08
truncating O 0 3.1724168820801424e-06
mutations O 0 2.1330372419470223e-06
in O 0 3.6801004910103075e-08
the O 0 2.2036421398752282e-07
APC B-Disease 0 1.0905366252700333e-05
gene O 0 8.461516699753702e-06
. O 0 8.878776043275138e-07

A O 0 1.2922399037051946e-05
variant O 0 0.0001214018338941969
of O 0 3.9684698549535824e-07
FAP B-Disease 0 0.00015807058662176132
is O 0 3.7286299630068243e-06
attenuated B-Disease 1 0.9985734224319458
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999996423721313
coli I-Disease 1 1.0
, O 0 7.063982252475398e-07
which O 0 3.829057604320951e-08
results O 0 5.7263200403667724e-08
from O 0 4.8127642315876074e-08
germ O 0 6.0407524870242923e-05
- O 0 5.621990203508176e-05
line O 0 0.0001758505095494911
mutations O 0 4.971973339706892e-07
in O 0 5.4140243399558585e-09
the O 0 5.002505076845409e-09
5 O 0 5.744596354162468e-09
and O 0 1.2462959553261044e-09
3 O 0 4.382127993807217e-09
regions O 0 5.113122814037752e-09
of O 0 2.4372917017956297e-09
the O 0 8.347476665448994e-08
APC B-Disease 0 4.7473854465351906e-06
gene O 0 4.478561095311306e-06
. O 0 5.985573352518259e-07

Attenuated B-Disease 1 0.9999932050704956
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9990178346633911
have O 0 1.534494344923587e-06
" O 0 2.771820959424076e-07
multiple O 0 1.167129994428251e-05
" O 0 0.018857674673199654
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.9588253508118214e-06
typically O 0 4.977562184649287e-07
fewer O 0 4.0777443643946754e-08
than O 0 6.871383462225822e-09
100 O 0 9.427766123337733e-09
) O 0 3.0664621952780635e-09
without O 0 5.627386112649901e-09
the O 0 3.364628753388388e-08
florid O 0 0.00010580704838503152
phenotype O 0 1.8935546904685907e-05
of O 0 4.2962085444742115e-08
classical O 0 4.5510932977776974e-06
FAP B-Disease 0 0.00011362116492819041
. O 0 2.0776251403731294e-06

Another O 0 1.0247835007248796e-06
group O 0 1.6985936213131936e-07
of O 0 1.3266681975210304e-08
patients O 0 8.566565412593263e-08
with O 0 1.5242010320548616e-08
multiple O 0 2.1169284991628956e-06
adenomas B-Disease 0 5.493094795383513e-05
has O 0 1.0461597099720166e-07
no O 0 2.2511798647428805e-08
mutations O 0 2.225418285206615e-07
in O 0 1.1902093532967228e-08
the O 0 1.776399294328712e-08
APC B-Disease 0 4.29439381832708e-07
gene O 0 1.3224344286300038e-07
, O 0 2.87456036751621e-09
and O 0 2.636557416835217e-09
their O 0 1.5515146500888477e-08
phenotype O 0 1.1029873348888941e-05
probably O 0 1.370006685874614e-07
results O 0 1.8058472051052377e-08
from O 0 3.5232483597269493e-09
variation O 0 5.413448889157735e-08
at O 0 1.9083196889368992e-07
a O 0 5.7987723067753905e-08
locus O 0 6.617859185098496e-07
, O 0 4.783804907759759e-09
or O 0 7.744751506777448e-09
loci O 0 2.594851089554595e-08
, O 0 1.0874575684383103e-09
elsewhere O 0 1.8686588276750626e-08
in O 0 5.291968641074618e-09
the O 0 3.436360174191577e-08
genome O 0 1.498471874583629e-06
. O 0 3.883685906203027e-07

Recently O 0 3.559787728590891e-05
, O 0 1.1499881225063291e-07
however O 0 3.78446181059644e-08
, O 0 6.304646138488579e-09
a O 0 2.104739849073667e-08
missense O 0 2.4960875180113362e-06
variant O 0 5.017691364628263e-06
of O 0 2.2004872590741797e-08
APC B-Disease 0 4.876261755271116e-06
( O 0 4.930402397462785e-08
I1307K O 0 5.996108143335732e-07
) O 0 1.7810947383622988e-08
was O 0 6.212612646550042e-08
described O 0 2.4377669660680112e-08
that O 0 8.380044436151479e-10
confers O 0 1.6799374336073924e-08
an O 0 4.102072903577891e-09
increased O 0 2.511021364171029e-07
risk O 0 2.491920440661488e-06
of O 0 0.0032830701675266027
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.837935989598918e-07
including O 0 1.4760360933507854e-08
multiple O 0 1.340181597697665e-06
adenomas B-Disease 0 4.7205867304001004e-05
, O 0 6.354302684030699e-08
in O 0 5.502889166564273e-07
Ashkenazim O 0 0.0005208703223615885
. O 0 1.4976075135564315e-06

We O 0 8.473674597553327e-07
have O 0 3.033167317312291e-08
studied O 0 3.309603968659758e-08
a O 0 7.688337078093355e-09
set O 0 5.886369613961051e-09
of O 0 1.2690553052863152e-09
164 O 0 1.4522537128414115e-07
patients O 0 1.1516166864566912e-07
with O 0 1.4772251688555116e-07
multiple O 1 0.9997032284736633
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.003982603084295988
/ I-Disease 1 0.998464822769165
or I-Disease 0 0.34296998381614685
carcinoma I-Disease 1 1.0
and O 0 1.3073059790258412e-06
analyzed O 0 6.375320026563713e-06
codons O 0 1.9213090126868337e-05
1263 O 0 0.00014581320283468813
- O 0 5.2998700994066894e-05
1377 O 0 0.00011480018292786554
( O 0 5.805877094644529e-07
exon O 0 9.470550139667466e-06
15G O 0 4.798346708412282e-06
) O 0 1.7831682797009307e-08
of O 0 1.8284473934926382e-09
the O 0 1.4128963776727232e-08
APC B-Disease 0 6.402466965482745e-07
gene O 0 3.1431139291271393e-07
for O 0 1.51077692578383e-08
germ O 0 3.480543091427535e-05
- O 0 5.0752383685903624e-05
line O 0 0.0001018070470308885
variants O 0 2.4880568162188865e-05
. O 0 8.82256188106112e-07

Three O 0 1.2870946193288546e-06
patients O 0 3.5914251839130884e-07
with O 0 9.70316804682625e-09
the O 0 1.6366643151854987e-08
I1307K O 0 1.2226734042997123e-06
allele O 0 1.0969281447614776e-06
were O 0 1.3186508773799233e-08
detected O 0 3.0410694762394996e-07
, O 0 2.710110580395053e-09
each O 0 1.981950159546386e-09
of O 0 7.445696947883107e-09
Ashkenazi O 0 1.3639226381201297e-05
descent O 0 7.370870207523694e-06
. O 0 1.1143317806272535e-06

Four O 0 4.305627953726798e-06
patients O 0 3.540179250194342e-06
had O 0 3.909609631591593e-07
a O 0 2.782945784929325e-07
germ O 0 0.00016033790598157793
- O 0 0.00013159375521354377
line O 0 2.4909011699492112e-05
E1317Q O 0 6.167080755403731e-06
missense O 0 6.4717032728367485e-06
variant O 0 3.917390131391585e-06
of O 0 1.6805591585011825e-08
APC O 0 9.349680567538599e-07
that O 0 6.248380479689786e-09
was O 0 5.871761743492243e-08
not O 0 6.451864043022226e-10
present O 0 1.4322879549055756e-09
in O 0 7.623778941479031e-09
controls O 0 1.259352302440675e-05
; O 0 3.6025094019009885e-09
one O 0 4.080260851413442e-10
of O 0 1.8585052941055835e-10
these O 0 7.188725170692578e-10
individuals O 0 2.771452789485096e-10
had O 0 4.813395459990488e-09
an O 0 2.122205522425702e-09
unusually O 0 4.922105745208682e-07
large O 0 8.316896504823035e-09
number O 0 3.4070553045495444e-09
of O 0 4.903773831443914e-09
metaplastic B-Disease 0 3.412705336813815e-05
polyps I-Disease 0 3.009517286045593e-06
of I-Disease 0 4.780165596685038e-09
the I-Disease 0 8.133201134796764e-08
colorectum I-Disease 0 3.0615417927037925e-05
. O 0 1.0661175338100293e-06

There O 0 5.585907274507917e-07
is O 0 1.4439381246234007e-08
increasing O 0 4.771130157621428e-09
evidence O 0 1.4380774349120884e-09
that O 0 8.104313331536162e-10
there O 0 9.037962600544347e-10
exist O 0 7.789179079509267e-09
germ O 0 1.8221001027995953e-06
- O 0 8.270603757409845e-07
line O 0 9.481234997110732e-07
variants O 0 6.236250271740573e-08
of O 0 1.36183531118661e-09
the O 0 1.3263469433866248e-08
APC B-Disease 0 4.367352914869116e-07
gene O 0 8.028425924067051e-08
that O 0 1.459685039506553e-09
predispose O 0 2.2586375436617345e-08
to O 0 1.0597450694760369e-09
the O 0 2.442746005471008e-09
development O 0 4.950971188577569e-09
of O 0 8.997290024126414e-09
multiple O 1 0.9675123691558838
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9947376847267151
carcinoma I-Disease 1 1.0
, O 0 1.7648366679168248e-07
but O 0 1.752097489315929e-08
without O 0 1.2627060286263259e-08
the O 0 4.325644553659913e-08
florid O 0 0.00010287544864695519
phenotype O 0 7.841406841180287e-06
of O 0 6.285471254585673e-09
classical O 0 2.1580294173872971e-07
FAP B-Disease 0 9.582042821421055e-07
, O 0 1.9905233017425417e-09
and O 0 8.005877627503821e-10
possibly O 0 4.794419528053595e-09
with O 0 2.312132485471352e-09
importance O 0 2.215552257212039e-07
for O 1 0.8616730570793152
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 2.7871367365150945e-06
in O 0 2.1161234542432794e-08
the O 0 6.9087984222448995e-09
general O 0 9.4614520662617e-09
population O 0 6.209885938801563e-09
. O 0 8.935670869902879e-09
. O 0 1.3488902084191068e-07

Genomic O 0 0.00015224672097247094
structure O 0 3.248952680223738e-06
of O 0 6.119854134567504e-08
the O 0 4.290468211820553e-07
human O 0 0.0001873533328762278
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.0002417527139186859
CLD B-Disease 1 0.9742816686630249
) O 0 2.1252665192150744e-06
gene O 0 2.4770812160568312e-05
. O 0 2.5313747755717486e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.007975520566105843
CLD B-Disease 1 0.9988831877708435
) O 0 5.251991410659684e-07
is O 0 2.3901421286609548e-08
caused O 0 1.3137947973973496e-07
by O 0 2.0419534507709614e-08
mutations O 0 9.425428970644134e-07
in O 0 1.9136697559929416e-08
a O 0 8.190379219286115e-08
gene O 0 5.782823109257151e-07
which O 0 2.723439429530572e-08
encodes O 0 6.72801434120629e-07
an O 0 1.6400993274601205e-07
intestinal O 0 0.0028267225716263056
anion O 0 5.895264621358365e-05
transporter O 0 0.0005140758003108203
. O 0 5.4264191930997185e-06

We O 0 1.1343632877469645e-06
report O 0 4.0064782069748617e-07
here O 0 1.167571550553248e-08
the O 0 3.0798268380038962e-09
complete O 0 9.089588637323232e-09
genomic O 0 1.3086889794067247e-07
organization O 0 7.132322732417151e-09
of O 0 1.4488755750718951e-09
the O 0 1.8965659265290924e-08
human O 0 1.3101413287586183e-07
CLD B-Disease 0 0.00012819861876778305
gene O 0 1.6831307902975823e-06
which O 0 4.146678378447177e-08
spans O 0 1.307399202232773e-07
approximately O 0 2.2657397735770246e-08
39kb O 0 1.6237098634519498e-06
, O 0 9.414253376860415e-09
and O 0 8.897948156061375e-09
comprises O 0 4.9645812794096855e-08
21 O 0 4.315492105888552e-07
exons O 0 1.09694728962495e-05
. O 0 1.5082122217791039e-06

All O 0 7.119751444406575e-06
exon O 0 0.00020729564130306244
/ O 0 0.00011078112584073097
intron O 0 0.00016588780272286385
boundaries O 0 2.5818528683885233e-06
conform O 0 1.1475725841592066e-05
to O 0 1.7749539438227657e-07
the O 0 3.0079681323513796e-07
GT O 0 0.0002423603436909616
/ O 0 0.0033124445471912622
AG O 1 0.7410964369773865
rule O 0 8.792367225396447e-06
. O 0 1.4685321048091282e-06

An O 0 4.1852879917314567e-07
analysis O 0 1.716345963131971e-07
of O 0 5.4571218655041775e-09
the O 0 3.13764481063572e-08
putative O 0 8.799361808087269e-07
promoter O 0 9.613107749828487e-07
region O 0 5.724059093381584e-08
sequence O 0 4.981047041496822e-08
shows O 0 7.084411635105425e-08
a O 0 5.234189970337866e-08
putative O 0 1.812901473385864e-06
TATA O 0 5.3675494200433604e-06
box O 0 4.1496800804452505e-06
and O 0 3.788347413546944e-08
predicts O 0 6.628065989389142e-07
multiple O 0 1.3438197754567227e-07
transcription O 0 1.8830761518984218e-06
factor O 0 1.1883338402185473e-07
binding O 0 3.6014228044223273e-07
sites O 0 4.3926073090005957e-07
. O 0 6.355344908115512e-07

The O 0 2.063902456939104e-06
genomic O 0 1.0151092283194885e-05
structure O 0 8.824522410577629e-07
was O 0 2.419673421627522e-07
determined O 0 2.488637207420652e-08
using O 0 1.779817893066138e-08
DNA O 0 2.994903880448874e-08
from O 0 3.2737843547181456e-09
several O 0 1.0544725093097895e-09
sources O 0 3.860411990075363e-09
including O 0 1.0677186912388947e-09
multiple O 0 1.3684522848222969e-08
large O 0 5.838971262051018e-08
- O 0 0.00019666696607600898
insert O 0 8.990256174001843e-05
libaries O 0 4.944429292663699e-06
and O 0 1.8462685602571582e-08
genomic O 0 5.672060297001735e-07
DNA O 0 5.797876383439871e-07
from O 0 2.296242485044786e-07
Finnish O 0 0.000320360588375479
CLD B-Disease 1 0.8755177855491638
patients O 0 1.3954997484688647e-05
and O 0 2.891096926305181e-07
controls O 0 0.001203093328513205
. O 0 3.032588892892818e-06

Exon O 0 0.0010297303088009357
- O 0 3.0011542548891157e-05
specific O 0 9.156041187452502e-07
primers O 0 9.874932402453851e-06
developed O 0 7.949203677526384e-07
in O 0 1.9456678046481102e-08
this O 0 4.097451711260192e-09
study O 0 5.586789697531458e-09
will O 0 2.8412334707184073e-09
facilitate O 0 2.015671185517931e-08
mutation O 0 3.804270534146781e-07
screening O 0 1.4554620975104626e-07
studies O 0 1.129734084059919e-08
of O 0 1.5668829567161424e-09
patients O 0 4.522596697142944e-08
with O 0 1.6133876457047336e-08
the O 0 1.1627550520643126e-05
disease O 0 0.11082910746335983
. O 0 1.0624028163874755e-06

Genomic O 0 0.00018997192091774195
sequencing O 0 1.588763734616805e-05
of O 0 2.379215402470436e-07
a O 0 1.690192220848985e-06
BAC O 0 0.008578726090490818
clone O 0 0.000575459620449692
H O 1 0.999997615814209
_ O 0 2.933579708042089e-07
RG364P16 O 0 1.4863160231470829e-06
revealed O 0 1.459280127846796e-07
the O 0 6.737733482253816e-09
presence O 0 7.490052134073721e-09
of O 0 1.0167335862121263e-09
another O 0 5.4696891460537245e-09
, O 0 3.0678664053596094e-09
highly O 0 1.418234329975121e-08
homologous O 0 1.1887646422792386e-07
gene O 0 1.9676254225942102e-07
3 O 0 1.508208669065425e-08
of O 0 1.1119004605930627e-09
the O 0 3.717930852076279e-08
CLD B-Disease 0 0.00017520312394481152
gene O 0 6.190488193169585e-07
, O 0 1.8717720706717955e-09
with O 0 9.490094265984794e-10
a O 0 1.2744409971787718e-08
similar O 0 7.142890012801217e-08
genomic O 0 3.093127247666416e-07
structure O 0 2.884831076244154e-07
, O 0 3.1256668364676443e-09
recently O 0 3.802006887099196e-08
identified O 0 1.6547886616535834e-08
as O 0 2.1048080611762998e-08
the O 0 5.8172781791654415e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.00016337214037775993
( O 0 3.9046614119797596e-07
PDS B-Disease 0 1.9806187992799096e-05
) O 0 6.853402112483309e-08
. O 0 5.024980609391605e-08
. O 0 2.521924216125626e-07

The O 0 7.452635600202484e-06
APCI1307K O 0 0.0004616488004103303
allele O 0 0.00018685165559872985
and O 0 3.832027687167283e-06
cancer B-Disease 0 0.00019548468117136508
risk O 0 3.4705536222645605e-07
in O 0 2.082199479502833e-08
a O 0 5.830257876482392e-08
community O 0 3.2093264934474064e-08
- O 0 7.813360412001202e-07
based O 0 2.7104736233241056e-08
study O 0 6.771010419015511e-09
of O 0 3.801149173199292e-09
Ashkenazi O 0 2.7942026008531684e-06
Jews O 0 3.342596528455033e-07
. O 0 4.072001331678621e-07

Mutations O 0 0.0036000898107886314
in O 0 6.002658665238414e-06
APC O 0 4.745162368635647e-05
are O 0 9.334867456800566e-08
classically O 0 3.279307929915376e-05
associated O 0 7.811549949110486e-06
with O 0 5.0046124670188874e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0004111693997401744
FAP B-Disease 0 0.00010965445108013228
) O 0 1.7539038310587785e-07
, O 0 2.6441226097517756e-08
a O 0 2.126153475501269e-07
highly O 0 0.00030553818214684725
penetrant O 1 0.9999994039535522
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.01980690099298954
by O 0 9.197752319778374e-07
multiple O 0 0.0003139431355521083
intestinal O 1 0.9999536275863647
polyps B-Disease 0 0.11369466781616211
and O 0 3.757748459065624e-07
, O 0 1.708731112159967e-08
without O 0 1.0653553594863752e-08
surgical O 0 1.2367296449156129e-06
intervention O 0 1.885943134993795e-07
, O 0 2.7165900640113705e-09
the O 0 6.247224515476546e-09
development O 0 8.476715862570927e-08
of O 0 0.0008324139635078609
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.2073423679103144e-05
CRC B-Disease 0 0.0012868806952610612
) O 0 3.5675569165505294e-07
. O 0 7.108537829481065e-07

APC B-Disease 0 0.00031559966737404466
is O 0 4.3494222268236626e-07
a O 0 1.4376745411937009e-06
tumour O 1 0.9999998807907104
- O 0 7.145144627429545e-05
suppressor O 0 0.00011650722444755957
gene O 0 2.185614448535489e-06
, O 0 1.103637536914448e-08
and O 0 1.2791899095532244e-08
somatic O 0 1.982882849915768e-06
loss O 0 4.215462013235083e-06
occurs O 0 8.559457569390361e-07
in O 0 7.4535669227770995e-06
tumours B-Disease 1 1.0
. O 0 4.222898041916778e-06

The O 0 1.0399468919786159e-05
germline O 0 0.0009738685330376029
T O 0 0.019149141386151314
- O 0 7.977812856552191e-06
to O 0 1.2927395687256649e-07
- O 0 5.383012080528715e-07
A O 0 7.938705692822623e-08
transversion O 0 9.78403022600105e-07
responsible O 0 2.267079857176668e-08
for O 0 1.177002273422545e-09
the O 0 1.2873061727702861e-08
APC O 0 9.116135970543837e-07
I1307K O 0 1.0222310038443538e-06
allele O 0 1.2067497436873964e-06
converts O 0 1.5370559935945494e-07
the O 0 2.3743528032582617e-08
wild O 0 1.0116836079987479e-07
- O 0 8.282119665636856e-07
type O 0 5.068847599432047e-07
sequence O 0 4.7003894110275724e-08
to O 0 1.457679843497317e-08
a O 0 1.616457723230269e-07
homopolymer O 0 0.011758565902709961
tract O 0 0.024161510169506073
( O 0 2.3374754221094918e-07
A8 O 0 0.00010362550528952852
) O 0 1.802887261703745e-08
that O 0 5.2002544492779634e-09
is O 0 1.682669648062074e-08
genetically O 0 1.1595220712479204e-06
unstable O 0 0.00036190057289786637
and O 0 3.56357503505933e-07
prone O 0 8.750784218136687e-06
to O 0 3.7216665305095376e-07
somatic O 0 6.367581954691559e-05
mutation O 0 9.935564594343305e-05
. O 0 2.7683126972988248e-06

The O 0 2.651997419889085e-06
I1307K O 0 2.6925919883069582e-05
allele O 0 1.3522300832846668e-05
was O 0 4.894077392236795e-07
found O 0 5.380867662552191e-08
in O 0 9.53639087697411e-08
6 O 0 9.806449270399753e-07
. O 0 6.977823545639694e-07

1 O 0 3.931620085495524e-06
% O 0 1.2157188677974773e-07
of O 0 1.9420157926219872e-08
unselected O 0 1.3043475519225467e-05
Ashkenazi O 0 1.119730768550653e-05
Jews O 0 1.2649809377762722e-07
and O 0 3.106963220034231e-08
higher O 0 1.4953084814806061e-07
proportions O 0 1.9446443388915213e-07
of O 0 5.5774198592928315e-09
Ashkenazim O 0 2.094371438943199e-06
with O 0 2.416868660759519e-08
family O 0 2.1766193469829886e-07
or O 0 2.9511840082818708e-08
personal O 0 5.096096700185626e-08
histories O 0 3.869441513870697e-07
of O 0 2.3953585781555375e-08
CRC B-Disease 0 0.00016304751625284553
( O 0 2.6693689392232045e-07
ref O 0 7.0941177909844555e-06
. O 0 1.6514526635091897e-08
2 O 0 8.535381113006224e-08
) O 0 9.553121316230317e-08
. O 0 2.1073914524549764e-07

To O 0 9.984979669752647e-07
evaluate O 0 4.502121555560734e-07
the O 0 1.1801836841129898e-08
role O 0 1.4708789741746386e-08
of O 0 1.6576973127513384e-09
I1307K O 0 5.271832606013049e-07
in O 0 2.5827148419921286e-07
cancer B-Disease 0 6.4965124693117104e-06
, O 0 7.88922260852587e-09
we O 0 9.915100740442995e-09
genotyped O 0 1.4084253052715212e-06
5 O 0 5.741674868886548e-08
, O 0 2.1153850227051407e-08
081 O 0 5.847764896316221e-06
Ashkenazi O 0 2.162062173738377e-06
volunteers O 0 5.7614652604343064e-08
in O 0 1.0621253210274517e-08
a O 0 6.773260707859663e-08
community O 0 9.593456695711211e-08
survey O 0 2.0687837150035193e-06
. O 0 5.194091841076443e-07

Risk O 0 3.658985224319622e-05
of O 0 4.6437321543635335e-07
developing O 0 4.443546640686691e-05
colorectal B-Disease 1 1.0
, I-Disease 0 1.0066912182082888e-05
breast I-Disease 0 0.035474974662065506
and I-Disease 0 7.245252220400289e-08
other I-Disease 0 2.1483778311903734e-08
cancers I-Disease 0 2.164535726478789e-05
were O 0 2.5402101755389594e-08
compared O 0 5.764598043356273e-08
between O 0 3.376019463985358e-08
genotyped O 0 2.6763991627376527e-06
I1307K O 0 8.697036264493363e-07
carriers O 0 1.2786391323516e-07
and O 0 3.6841580897117865e-09
non O 0 9.534205425154596e-09
- O 0 5.140388452673506e-07
carriers O 0 6.045060985115924e-08
and O 0 2.451128411351533e-09
their O 0 2.533319110042953e-09
first O 0 2.0526568889067676e-08
- O 0 2.054980541288387e-07
degree O 0 4.8952909281752e-08
relatives O 0 3.4533655934865237e-07
. O 0 4.4721539893544104e-07

Sperm O 0 4.5208038500277326e-05
DNA O 0 1.5331426766351797e-05
analysis O 0 1.259910163753375e-06
in O 0 2.4097482764773304e-07
a O 0 3.2915445444814395e-06
Friedreich B-Disease 1 0.9997346997261047
ataxia I-Disease 1 0.9999980926513672
premutation O 0 0.25544053316116333
carrier O 0 0.0002632453397382051
suggests O 0 1.606551222721464e-06
both O 0 5.764466237678789e-08
meiotic O 0 4.637501660909038e-06
and O 0 3.889170585580359e-08
mitotic O 0 5.022220193495741e-06
expansion O 0 4.377961886348203e-07
in O 0 1.1455723836206744e-07
the O 0 2.4248248564617825e-07
FRDA B-Disease 0 7.5404008384794e-05
gene O 0 2.3551627236884087e-05
. O 0 1.9785722997767152e-06

Friedreich B-Disease 1 0.9999951124191284
ataxia I-Disease 1 1.0
is O 0 4.6886660129530355e-05
usually O 0 2.8118829504819587e-06
caused O 0 3.574743061562913e-07
by O 0 6.5960437112266845e-09
an O 0 2.9297915205006575e-09
expansion O 0 5.158115712333711e-08
of O 0 9.257450805932876e-09
a O 0 5.920563239669718e-07
GAA O 0 0.00013909241533838212
trinucleotide O 0 6.555678555741906e-05
repeat O 0 8.05776198831154e-06
in O 0 1.8051503047900042e-07
intron O 0 8.531695129931904e-06
1 O 0 4.929405506004514e-08
of O 0 4.632282557537337e-09
the O 0 8.719828059611245e-08
FRDA B-Disease 0 4.442534191184677e-05
gene O 0 1.8696891856961884e-05
. O 0 1.2162538496340858e-06

Occasionally O 0 2.9731490940321237e-05
, O 0 1.3026051703945996e-07
a O 0 4.656468632902033e-08
fully O 0 8.309384469384895e-08
expanded O 0 7.225530396226532e-08
allele O 0 4.1980479181802366e-07
has O 0 6.058668233777098e-09
been O 0 3.010675264647489e-09
found O 0 2.8870112966927763e-09
to O 0 3.4091225398213965e-09
arise O 0 7.224108422576592e-09
from O 0 3.7786969109276924e-09
a O 0 1.4660670011323873e-08
premutation O 0 5.257503516986617e-07
of O 0 1.4818039018038576e-09
100 O 0 1.0045476450670776e-08
or O 0 2.224477668733016e-08
less O 0 1.537475355917195e-07
triplet O 0 0.0002531300706323236
repeats O 0 9.947660873876885e-05
. O 0 1.2354624914223677e-06

We O 0 2.82751244640167e-07
have O 0 9.525789046449518e-09
examined O 0 4.024598965202131e-08
the O 0 7.0214518643751944e-09
sperm O 0 8.565650233549604e-08
DNA O 0 6.215552161847882e-08
of O 0 4.641798945215214e-09
a O 0 1.5610376635777357e-07
premutation O 0 3.983761780546047e-05
carrier O 0 1.8950939193018712e-05
. O 0 7.316714913940814e-07

This O 0 2.6882455586019205e-06
mans O 0 2.122832665918395e-05
leucocyte O 0 2.008308183576446e-05
DNA O 0 2.221557679149555e-06
showed O 0 5.363725108509243e-07
one O 0 1.199201093982083e-08
normal O 0 1.6364808175239887e-07
allele O 0 7.823173291399144e-07
and O 0 5.391508128838041e-09
one O 0 2.1933712623933843e-09
allele O 0 5.6362836176049314e-08
of O 0 1.2591025999597605e-09
approximately O 0 1.7204289548544693e-08
100 O 0 1.3545454180530214e-07
repeats O 0 1.2032680388074368e-05
. O 0 1.2358194680928136e-06

His O 0 1.6449175745947286e-06
sperm O 0 1.5193559192994144e-06
showed O 0 3.174642699832475e-07
an O 0 9.687930457857874e-09
expanded O 0 1.410107870469801e-07
allele O 0 6.451610943258856e-07
in O 0 2.006101773588398e-08
a O 0 9.577532011917356e-08
tight O 0 9.731408681545872e-06
range O 0 1.1861757798214967e-07
centering O 0 3.4496000012040895e-07
on O 0 5.112374523719154e-08
a O 0 2.153390887826845e-08
size O 0 2.785759534162935e-08
of O 0 1.8538612867047277e-09
approximately O 0 3.966853512338275e-08
320 O 0 1.7380733652316849e-06
trinucleotide O 0 0.0002100140118272975
repeats O 0 0.0001262552832486108
. O 0 2.813385208355612e-06

His O 0 1.8855394955608062e-05
affected O 0 1.022707874653861e-05
son O 0 4.5387518184725195e-05
has O 0 1.4311696361346549e-07
repeat O 0 1.2770271951012546e-06
sizes O 0 5.31147804849752e-07
of O 0 1.7320118672614626e-08
1040 O 0 7.817542609700467e-06
and O 0 1.7149812947536702e-07
540 O 0 6.306118848442566e-06
. O 0 1.3660110198543407e-06

These O 0 2.843895003934449e-07
data O 0 6.495332627309836e-07
suggest O 0 1.1803935251464281e-07
that O 0 4.290678479179633e-09
expansion O 0 3.4950716099046986e-08
occurs O 0 1.4562210104429596e-08
in O 0 5.102338107576543e-09
two O 0 2.6852480239369925e-09
stages O 0 2.6373482953090388e-08
, O 0 9.574765424957832e-10
the O 0 1.4042341733855324e-09
first O 0 4.9138955127148165e-09
during O 0 2.351803374267547e-08
meiosis O 0 9.214488017050826e-08
followed O 0 1.4425507011139871e-08
by O 0 3.6552088023000806e-09
a O 0 1.7816317310348495e-08
second O 0 7.81261704219105e-08
mitotic O 0 1.1333358997944742e-05
expansion O 0 3.873487912642304e-06
. O 0 8.435504810222483e-07

We O 0 6.552971854034695e-07
also O 0 2.0574232095782463e-08
show O 0 3.973275042312707e-08
that O 0 1.949009620361153e-09
in O 0 2.4364363859774585e-09
all O 0 5.915855583182861e-10
informative O 0 4.3799577298386794e-08
carrier O 0 3.139926150197425e-07
father O 0 4.5945007798309234e-08
to O 0 5.9893392467813555e-09
affected O 0 3.9108620342176437e-08
child O 0 1.3590651803951914e-07
transmissions O 0 2.2637781512457877e-05
, O 0 8.757789493607504e-10
with O 0 2.8808161411930655e-10
the O 0 2.026251388898004e-09
notable O 0 2.9940683266005408e-09
exception O 0 2.8264612872419548e-09
of O 0 6.636891036748693e-10
the O 0 1.689642026292404e-08
premutation O 0 1.5086337725733756e-06
carrier O 0 2.8184905431771767e-07
, O 0 1.5857731794355345e-09
the O 0 3.070020460071987e-09
expansion O 0 8.296445486166704e-08
size O 0 2.1197838862008211e-07
decreases O 0 3.0394454597626464e-07
. O 0 3.5916780660727454e-08
. O 0 2.8042990152243874e-07

The O 0 5.649269496643683e-06
R496H O 0 3.495054988889024e-05
mutation O 0 7.3419309956079815e-06
of O 0 3.072546661542219e-08
arylsulfatase O 0 8.278350833279546e-06
A O 0 8.34325646792422e-07
does O 0 4.3182586750845076e-07
not O 0 4.061614902184374e-07
cause O 0 5.5517451983178034e-05
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999997615814209
. O 0 2.1501549781532958e-05

Deficiency B-Disease 1 0.9922926425933838
of I-Disease 0 6.334191198220651e-07
arylsulfatase I-Disease 0 6.483349716290832e-05
A I-Disease 0 4.89182775709196e-06
( O 0 1.656680865380622e-06
ARSA O 0 0.0007124350522644818
) O 0 4.1955584606512275e-07
enzyme O 0 8.741108104004525e-06
activity O 0 4.018579056719318e-05
causes O 0 0.0003393347724340856
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
( O 0 0.00033623017952777445
MLD B-Disease 1 0.9999994039535522
) O 0 2.190363829868147e-06
. O 0 1.0832039833985618e-06

A O 0 3.696030944411177e-06
number O 0 1.12690450748687e-07
of O 0 7.732975859653379e-08
ARSA O 0 0.000642016064375639
gene O 0 1.7364533050567843e-05
mutations O 0 1.3849002243659925e-05
responsible O 0 7.794873226885102e-07
for O 0 3.2870670452211925e-07
MLD B-Disease 1 0.9999998807907104
have O 0 1.7701734122965718e-07
been O 0 9.857366478627227e-08
identified O 0 5.302651402416814e-07
. O 0 3.3731174653439666e-07

Recently O 0 3.154255318804644e-05
, O 0 2.1193633870097983e-07
the O 0 1.0432903252421966e-07
R496H O 0 2.2162334971653763e-06
mutation O 0 9.768943982635392e-07
of O 0 1.4647310919713163e-08
ARSA O 0 0.00028371100779622793
was O 0 1.0425796972413082e-06
proposed O 0 1.822136397322538e-08
to O 0 3.864323971924932e-09
be O 0 2.727191361628911e-09
a O 0 1.624252909948609e-08
cause O 0 1.6910357203414605e-07
of O 0 3.299815176660559e-08
MLD B-Disease 1 0.999996542930603
( O 0 1.4482208143817843e-07
Draghia O 0 6.2392937252298e-06
et O 0 1.4760719295736635e-06
al O 0 4.0661183220436214e-07
. O 0 1.1706823066504057e-08
, O 0 1.0048216481095551e-08
1997 O 0 1.2431786444722093e-07
) O 0 5.735567398801322e-08
. O 0 2.325047461226859e-07

We O 0 6.513849371003744e-07
have O 0 3.6301013750517086e-08
investigated O 0 9.751094864896004e-08
the O 0 1.063649879284867e-08
R496H O 0 5.313160045261611e-07
mutation O 0 3.283739431481081e-07
and O 0 3.735586062703078e-09
found O 0 4.685554610972531e-09
this O 0 2.773553609003443e-09
mutation O 0 1.4715418217292608e-07
at O 0 6.273065622508511e-08
a O 0 1.244040337411434e-08
relatively O 0 1.511920686425583e-07
high O 0 4.96432107865985e-07
frequency O 0 2.9464647468557814e-06
in O 0 8.078359314822592e-09
an O 0 9.996902194941981e-10
African O 0 2.503079299387423e-09
American O 0 3.4665219583729368e-09
population O 0 3.5346234827926537e-09
( O 0 1.4631561739975041e-08
f O 0 7.145335416680609e-07
= O 0 3.09205972826021e-07
0 O 0 6.159517340620368e-08
. O 0 8.63098392756001e-09
09 O 0 2.6438308964316093e-07
, O 0 1.5394640229260403e-08
n O 0 7.044419021440262e-07
= O 0 8.571825560466095e-07
61 O 0 3.725483850303135e-07
subjects O 0 2.1439491604269278e-07
) O 0 1.342086903832751e-07
. O 0 4.4779881136491895e-07

The O 0 4.956225893693045e-06
ARSA O 0 0.000731397420167923
enzyme O 0 7.089194696163759e-06
activity O 0 6.498002562693728e-07
in O 0 7.74078188214844e-08
subjects O 0 3.7837619260017163e-08
with O 0 3.360099309901443e-09
and O 0 3.696821515575266e-09
without O 0 1.5656939078567689e-09
the O 0 6.923704276573517e-09
R496H O 0 3.6912291534463293e-07
mutation O 0 3.3265305887653085e-07
was O 0 1.87332716450328e-07
determined O 0 3.07063103832661e-08
and O 0 3.7129681551562044e-09
found O 0 5.9335443225450035e-09
to O 0 1.021461315531269e-08
be O 0 1.3310048174730582e-08
normal O 0 4.322857307670347e-07
. O 0 2.6810997155735095e-07

It O 0 8.032972118598991e-07
is O 0 3.2202287059135415e-08
therefore O 0 1.0789460880289425e-08
concluded O 0 9.680394263966718e-09
that O 0 6.720672907079006e-10
the O 0 5.457184482082766e-09
R496H O 0 4.594167819504946e-07
mutation O 0 3.5389129493523797e-07
of O 0 8.492052394615257e-09
ARSA O 0 0.00010506896069273353
does O 0 5.8403529124007036e-08
not O 0 6.868592361541914e-09
negatively O 0 5.225860633117918e-08
influence O 0 1.3935407494614083e-08
the O 0 5.079761500326185e-09
activity O 0 9.98829676746027e-08
of O 0 8.459897671286853e-09
ARSA O 0 6.0801969084423035e-05
and O 0 1.383814840494324e-08
is O 0 1.6434923422181669e-09
not O 0 1.0683460782701104e-09
a O 0 2.0386496046853608e-08
cause O 0 7.657035894226283e-07
of O 0 8.594729479227681e-07
MLD B-Disease 1 0.9999995231628418

Down O 0 0.0002521282876841724
- O 0 1.2831780622946098e-05
regulation O 0 2.5126623768301215e-06
of O 0 3.7787856399518205e-08
transmembrane O 0 1.5243805364661966e-06
carbonic O 0 1.8465540051693097e-05
anhydrases O 0 6.158948963275179e-05
in O 0 1.273396446777042e-05
renal B-Disease 1 0.9999861717224121
cell I-Disease 1 0.9999974966049194
carcinoma I-Disease 1 1.0
cell O 0 0.19353307783603668
lines O 0 1.7602373191039078e-05
by O 0 1.0782942183595878e-07
wild O 0 1.1102247299277224e-06
- O 0 0.00030864542350172997
type O 0 0.009775365702807903
von B-Disease 1 0.9986447691917419
Hippel I-Disease 1 0.9951753616333008
- I-Disease 1 0.6294230818748474
Lindau I-Disease 1 0.5592859387397766
transgenes O 0 0.0013224893482401967
. O 0 9.80012282525422e-06

To O 0 3.634290351328673e-06
discover O 0 3.55355700776272e-06
genes O 0 1.5855736137382337e-06
involved O 0 2.2968163193581859e-07
in O 0 9.04474575236236e-07
von B-Disease 1 0.996371865272522
Hippel I-Disease 1 0.9999306201934814
- I-Disease 1 0.9970663189888
Lindau I-Disease 1 0.9956974983215332
( O 0 1.5091920886334265e-06
VHL B-Disease 0 0.0004003636713605374
) O 0 1.4882716925512796e-07
- O 0 1.0520482192077907e-06
mediated O 0 2.4599592052254593e-06
carcinogenesis O 0 1.1146858014399186e-05
, O 0 1.4763119615679443e-08
we O 0 8.39137204167173e-09
used O 0 2.3575889827043284e-06
renal B-Disease 1 0.8270792365074158
cell I-Disease 1 0.9986991882324219
carcinoma I-Disease 1 1.0
cell O 0 0.12221371382474899
lines O 0 0.0001411320990882814
stably O 0 4.487806654651649e-05
transfected O 0 1.474750206398312e-05
with O 0 8.730412304203128e-08
wild O 0 1.908404783534934e-06
- O 0 0.0031734879594296217
type O 0 0.01716507226228714
VHL O 0 0.04186322167515755
- O 0 0.00011239495506742969
expressing O 0 5.2023779062437825e-06
transgenes O 0 0.00015570031246170402
. O 0 2.828037168001174e-06

Large O 0 5.001256795367226e-06
- O 0 5.264304490992799e-06
scale O 0 1.0196644097959506e-06
RNA O 0 2.1191301584622124e-06
differential O 0 8.627034731034655e-07
display O 0 1.2632101515919203e-06
technology O 0 1.398871489755038e-07
applied O 0 3.4562248174552224e-08
to O 0 6.647853378893842e-09
these O 0 2.265833742853829e-09
cell O 0 1.6222737997395598e-07
lines O 0 2.4098906692415767e-07
identified O 0 1.9688167540721224e-08
several O 0 6.091483317760549e-09
differentially O 0 2.4614558924440644e-07
expressed O 0 1.2024191420323405e-08
genes O 0 3.648948521117745e-08
, O 0 9.010663881703351e-10
including O 0 1.3130407872097294e-09
an O 0 1.1408446631833158e-08
alpha O 0 9.233592663804302e-07
carbonic O 0 1.2534489542304073e-05
anhydrase O 0 2.7349829906597733e-05
gene O 0 7.324755188165e-06
, O 0 1.1792234033691784e-07
termed O 0 6.569699507963378e-06
CA12 O 0 0.0003853480739053339
. O 0 3.064855491174967e-06

The O 0 2.7209193831367884e-06
deduced O 0 8.691798939253204e-06
protein O 0 1.2379853160382481e-06
sequence O 0 2.905142935105687e-07
was O 0 9.175851545251135e-08
classified O 0 4.8797694773838884e-08
as O 0 7.63699326000733e-09
a O 0 1.1572664604386773e-08
one O 0 1.9596528844090244e-08
- O 0 2.3983773189684143e-06
pass O 0 5.143104999660864e-07
transmembrane O 0 7.575583822472254e-07
CA O 0 5.790781187897664e-07
possessing O 0 2.792148201535838e-08
an O 0 6.7973298101264845e-09
apparently O 0 1.2552838768442598e-07
intact O 0 2.613886920244113e-07
catalytic O 0 7.007059252828185e-07
domain O 0 6.229129922985521e-08
in O 0 1.601207699764018e-08
the O 0 2.4006963528222514e-08
extracellular O 0 1.3026590295339702e-06
CA O 0 6.6666621023614425e-06
module O 0 7.006323357927613e-06
. O 0 6.604996656278672e-07

Reintroduced O 0 0.0009640377247706056
wild O 0 8.752694702707231e-05
- O 0 0.000937888165935874
type O 0 0.00031857972498983145
VHL B-Disease 0 0.0019315923564136028
strongly O 0 9.165020856016781e-06
inhibited O 0 4.399782483233139e-06
the O 0 3.80413958112058e-08
overexpression O 0 6.419464284590504e-07
of O 0 5.417525983375526e-09
the O 0 2.7789456069626794e-08
CA12 O 0 3.1813331133889733e-06
gene O 0 4.3888306322514836e-07
in O 0 2.3412496830133023e-08
the O 0 1.2342607647042314e-07
parental O 0 0.0726400762796402
renal B-Disease 1 0.9991047978401184
cell I-Disease 1 0.9999668598175049
carcinoma I-Disease 1 1.0
cell O 1 0.9474851489067078
lines O 0 0.005655677989125252
. O 0 4.826710210181773e-06

Similar O 0 9.557087651046459e-06
results O 0 1.1744864423235413e-06
were O 0 6.655874074112944e-08
obtained O 0 3.94403940617849e-08
with O 0 1.6136091574026068e-08
CA9 O 0 6.003276212140918e-05
, O 0 1.6420017345808446e-08
encoding O 0 2.7633697641249455e-07
another O 0 1.8265143353346502e-07
transmembrane O 0 9.375601166539127e-07
CA O 0 8.905199706532585e-07
with O 0 3.484872390657756e-09
an O 0 1.5388858187748156e-08
intact O 0 1.1850715964101255e-06
catalytic O 0 6.270557150855893e-06
domain O 0 2.2810345399193466e-06
. O 0 7.304527684937057e-07

Although O 0 2.0271315861464245e-06
both O 0 9.833836145389796e-08
domains O 0 2.0812593959362857e-07
of O 0 7.2906760628654865e-09
the O 0 5.6299445105878476e-08
VHL B-Disease 0 2.845030030584894e-05
protein O 0 4.417317427396483e-07
contribute O 0 3.082619670635722e-08
to O 0 1.5141809583951726e-08
regulation O 0 2.839696833234484e-07
of O 0 5.987375040206189e-09
CA12 O 0 8.381093721254729e-06
expression O 0 1.2699985063591157e-07
, O 0 3.5789564645227756e-09
the O 0 7.007390667723712e-09
elongin O 0 5.781367349300126e-07
binding O 0 1.4437843276482454e-07
domain O 0 1.3388705610850593e-07
alone O 0 7.122781653379207e-08
could O 0 3.892814604000705e-08
effectively O 0 6.962608267713222e-07
regulate O 0 8.100732884486206e-06
CA9 O 0 0.00029146784800104797
expression O 0 7.37281743568019e-06
. O 0 1.1048095984733663e-06

We O 0 6.50869060336845e-06
mapped O 0 6.135219155112281e-05
CA12 O 0 0.00014802960504312068
and O 0 1.258591510122642e-06
CA9 O 0 0.00047144212294369936
loci O 0 8.631605851405766e-06
to O 0 3.2465385402247193e-07
chromosome O 0 8.892639925761614e-06
bands O 0 2.806168822644395e-06
15q22 O 0 7.540664228145033e-06
and O 0 2.5981771045735513e-07
17q21 O 0 2.3394932213705033e-05
. O 0 1.1733781093425932e-06

2 O 0 1.2152834642620292e-05
respectively O 0 2.354910520807607e-06
, O 0 3.293056138886641e-08
regions O 0 5.210791442777918e-08
prone O 0 1.4454033134825295e-06
to O 0 5.1023214098222525e-08
amplification O 0 6.0795869103458244e-06
in O 0 2.7034829486183298e-08
some O 0 1.5276995668500604e-08
human O 0 5.542289045479265e-07
cancers B-Disease 0 0.00035470115835778415
. O 0 1.486412315898633e-06

Additional O 0 1.667104811531317e-06
experiments O 0 1.96720429812558e-06
are O 0 9.829294711494185e-09
needed O 0 2.0983424775522508e-08
to O 0 3.721149832713877e-09
define O 0 1.2712751740195927e-08
the O 0 2.859364078844351e-09
role O 0 8.485803171254247e-09
of O 0 5.005063030694146e-09
CA O 0 4.490408173296601e-06
IX O 0 5.411721758719068e-06
and O 0 1.7376245864397788e-07
CA O 0 2.4938510705396766e-06
XII O 0 2.269631977469544e-06
enzymes O 0 1.3268761733797874e-07
in O 0 7.265716028825864e-09
the O 0 9.554229407626735e-09
regulation O 0 2.750974772425252e-07
of O 0 7.418649250467979e-09
pH O 0 1.2601660728250863e-06
in O 0 8.766584791430887e-09
the O 0 9.185951554968597e-09
extracellular O 0 1.7711950306420476e-07
microenvironment O 0 6.093182491895277e-07
and O 0 4.654956420324652e-09
its O 0 1.0705741182448492e-08
potential O 0 9.064865302832459e-09
impact O 0 4.040358092538554e-08
on O 0 1.4715518545926898e-06
cancer B-Disease 0 2.155213223886676e-05
cell O 0 4.852403435506858e-06
growth O 0 1.7409382735422696e-06
. O 0 4.606609991242294e-07

A O 0 3.6692551930173067e-06
gene O 0 6.355784535116982e-06
encoding O 0 1.322020011684799e-06
a O 0 2.1142882644653582e-07
transmembrane O 0 8.967523399405763e-07
protein O 0 5.054500888945768e-07
is O 0 9.086122076951142e-09
mutated O 0 3.8361704923772777e-07
in O 0 1.2649121572394506e-07
patients O 0 2.760811867119628e-06
with O 0 0.07236205786466599
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.8527261018753052
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999998807907104
( O 1 0.8418737053871155
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 5.578035597864073e-06
. O 0 2.321166903129779e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0011404564138501883
WFS B-Disease 0 0.21418672800064087
; O 0 9.86472878139466e-06
OMIM O 0 0.0014646378112956882
222300 O 0 5.106444950797595e-05
) O 0 2.9344693075472605e-07
is O 0 3.9829263442925367e-08
an O 0 4.789847025676863e-07
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
defined O 0 3.3321009595965734e-06
by O 0 1.2018269046620844e-07
young O 0 3.1694577273810864e-07
- O 0 1.8361113689024933e-05
onset O 0 0.012179167941212654
non O 0 2.5753804493433563e-06
- O 0 0.0010934901656582952
immune O 0 0.04336363077163696
insulin B-Disease 1 0.9939401149749756
- I-Disease 1 0.9989845156669617
dependent I-Disease 1 0.9792417883872986
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0025688414461910725
progressive O 1 0.9952877759933472
optic B-Disease 1 0.9999995231628418
atrophy I-Disease 1 0.999417781829834
. O 0 9.692250387161039e-06

Linkage O 0 8.93905817065388e-05
to O 0 1.1129840231660637e-06
markers O 0 5.715849511034321e-06
on O 0 1.3361297988012666e-06
chromosome O 0 0.00010075847967527807
4p O 0 0.0002884243440348655
was O 0 8.253931014223781e-07
confirmed O 0 8.543671725647073e-08
in O 0 1.3434566348280441e-08
five O 0 1.5584667778512085e-08
families O 0 2.9695801373463837e-08
. O 0 1.4904705381013628e-07

On O 0 1.6827134459163062e-06
the O 0 7.101363053152454e-08
basis O 0 2.3479756805500074e-08
of O 0 6.946932806783934e-09
meiotic O 0 1.3975588444736786e-05
recombinants O 0 0.0006748567684553564
and O 0 3.7457409689523047e-06
disease O 0 0.001362165086902678
- O 0 3.249953078920953e-05
associated O 0 1.6091794350359123e-06
haplotypes O 0 4.479351446207147e-06
, O 0 1.4662963288003539e-08
the O 0 9.190949867843301e-08
WFS B-Disease 0 4.984522456652485e-05
gene O 0 1.7307426105617196e-06
was O 0 1.5376453177395888e-07
localized O 0 6.301618782345031e-07
to O 0 4.640845574499508e-08
a O 0 7.292027817129565e-07
BAC O 0 0.005515783093869686
/ O 0 4.9050682719098404e-05
P1 O 0 1.3655336260853801e-05
contig O 0 2.3182421955425525e-06
of O 0 8.318228772452585e-09
less O 0 2.444751601160533e-08
than O 0 1.6259546598007546e-08
250 O 0 2.9456455763465783e-07
kb O 0 0.0001477915357099846
. O 0 1.4970762549637584e-06

Mutations O 0 0.0010179999517276883
in O 0 1.101494490285404e-06
a O 0 5.782823109257151e-07
novel O 0 2.1613200260617305e-06
gene O 0 5.87475778957014e-06
( O 0 1.2720373376851057e-07
WFS1 O 0 6.126714652054943e-06
) O 0 1.9009842588957326e-08
encoding O 0 1.3356567762912164e-07
a O 0 2.9613110186232916e-08
putative O 0 3.438629789798142e-07
transmembrane O 0 2.1836800101482368e-07
protein O 0 9.656332622398622e-08
were O 0 8.195391920651218e-09
found O 0 7.0352865755296534e-09
in O 0 4.151092358739561e-09
all O 0 1.1539375011082598e-09
affected O 0 9.321378335869213e-09
individuals O 0 1.0908416392396703e-09
in O 0 4.5057788611302385e-09
six O 0 2.4007970722550454e-08
WFS B-Disease 0 9.058142495632637e-06
families O 0 8.241555882193552e-09
, O 0 2.1646773262773422e-09
and O 0 2.578283142540272e-09
these O 0 1.865452903260234e-09
mutations O 0 1.072056008410982e-07
were O 0 1.0207736877987372e-08
associated O 0 1.301745378157193e-08
with O 0 1.1230268270878696e-08
the O 0 5.53653853785363e-06
disease O 0 0.20673170685768127
phenotype O 0 0.00033579065348021686
. O 0 1.4730092061654432e-06

WFS1 O 0 0.0003870571090374142
appears O 0 3.905729045072803e-06
to O 0 7.057963102852227e-08
function O 0 7.246163846730269e-08
in O 0 2.2669457422352934e-08
survival O 0 1.1863250648502799e-07
of O 0 5.084540344313382e-09
islet O 0 9.56400299401139e-07
beta O 0 3.598700288875989e-07
- O 0 9.703261412141728e-07
cells O 0 2.872984055102279e-07
and O 0 2.175029223394631e-08
neurons O 0 9.70981545833638e-07
. O 0 5.81518726505692e-08
. O 0 2.443591426981584e-07

Stable O 0 5.8582383644534275e-05
interaction O 0 4.7537463387925527e-07
between O 0 5.314315032478589e-08
the O 0 8.887720781558528e-09
products O 0 1.9528098249566028e-08
of O 0 1.691227713429555e-09
the O 0 3.137943949127475e-08
BRCA1 O 0 8.809144674160052e-06
and O 0 1.9580916443828755e-07
BRCA2 O 0 3.909141742042266e-05
tumor B-Disease 0 1.095118022931274e-05
suppressor O 0 9.383435099152848e-06
genes O 0 5.886001872568158e-07
in O 0 6.620194881179486e-08
mitotic O 0 1.591761792951729e-05
and O 0 2.3109657831810182e-07
meiotic O 0 7.763665780657902e-05
cells O 0 2.767342266452033e-05
. O 0 2.805146550599602e-06

BRCA1 O 0 0.016650019213557243
and O 0 2.9179368539189454e-06
BRCA2 O 0 4.720307333627716e-05
account O 0 1.901245951785313e-07
for O 0 5.2754609569660715e-09
most O 0 2.0812893630761664e-09
cases O 0 1.8193571094116123e-09
of O 0 2.0462684879873905e-09
familial O 0 2.673638846317772e-06
, O 0 3.021532180014219e-08
early O 0 2.6097990485141054e-05
onset O 1 0.9996167421340942
breast B-Disease 1 0.9951595664024353
and I-Disease 0 0.00012703407264780253
/ I-Disease 1 0.9999991655349731
or I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.341916503060929e-08
encode O 0 1.7016157016769284e-07
products O 0 4.1893693492056627e-07
that O 0 1.6290456761325345e-09
each O 0 1.3828828082651512e-09
interact O 0 1.7831750298569204e-08
with O 0 2.8359288251067483e-08
hRAD51 O 0 1.2277081623324193e-05
. O 0 9.093143944483018e-07

Results O 0 6.380732884281315e-06
presented O 0 6.155372602734133e-07
here O 0 5.267731495450789e-08
show O 0 2.2660472609459248e-07
that O 0 2.5273696024896708e-08
BRCA1 O 0 4.7428557081730105e-06
and O 0 6.573815625188217e-08
BRCA2 O 0 4.912899385089986e-06
coexist O 0 1.7723576206662983e-07
in O 0 2.2937772570230663e-08
a O 0 5.702972316612431e-08
biochemical O 0 8.85066640421428e-07
complex O 0 1.1124657106620361e-07
and O 0 1.8370721832638992e-08
colocalize O 0 1.9620053990365705e-06
in O 0 5.5965831080584394e-08
subnuclear O 0 3.7413676636788296e-06
foci O 0 1.342680093330273e-06
in O 0 2.3486474987066686e-08
somatic O 0 4.6249220986283035e-07
cells O 0 3.3387382813998556e-07
and O 0 5.890952170517494e-09
on O 0 2.425532130700958e-08
the O 0 3.535075343563676e-09
axial O 0 3.8948869018895493e-08
elements O 0 1.7378855687866235e-08
of O 0 2.4776289908601257e-09
developing O 0 8.253767447286009e-08
synaptonemal O 0 1.2030282050545793e-05
complexes O 0 7.758364517940208e-06
. O 0 6.889114843033894e-07

Like O 0 1.675387284194585e-05
BRCA1 O 0 0.0003031727683264762
and O 0 9.472377655583841e-07
RAD51 O 0 0.0002681883634068072
, O 0 4.757964404689119e-07
BRCA2 O 0 4.0252220060210675e-05
relocates O 0 7.5967050179315265e-06
to O 0 2.524782871660136e-07
PCNA O 0 3.876739356201142e-05
+ O 0 9.747838021212374e-07
replication O 0 7.289454515557736e-07
sites O 0 1.2033785878884373e-07
following O 0 1.1560214829842153e-07
exposure O 0 5.909343485654972e-07
of O 0 8.160825792913329e-09
S O 0 2.8142785595264286e-06
phase O 0 3.1761658192408504e-07
cells O 0 4.4738047222381283e-07
to O 0 1.281361221572297e-07
hydroxyurea O 0 2.5040268155862577e-05
or O 0 9.682130439614411e-07
UV O 0 0.00022471207194030285
irradiation O 0 4.059224738739431e-05
. O 0 1.305488353864348e-06

Thus O 0 7.370075763901696e-06
, O 0 3.765806297906238e-07
BRCA1 O 0 7.049311079754261e-06
and O 0 5.889607024300858e-08
BRCA2 O 0 2.6076772883243393e-06
participate O 0 1.841527641488483e-08
, O 0 2.938208121250341e-09
together O 0 4.644668649689265e-09
, O 0 9.977358939039505e-10
in O 0 2.975384161274519e-09
a O 0 3.158606531883379e-08
pathway O 0 1.9191203648460942e-07
( O 0 3.117880353897817e-08
s O 0 1.2849054655816872e-06
) O 0 3.5422769162352097e-09
associated O 0 6.705899835424134e-09
with O 0 8.602694112624931e-10
the O 0 3.787456570591985e-09
activation O 0 5.99091833919374e-08
of O 0 1.1298887381272493e-09
double O 0 1.2462722054351616e-07
- O 0 1.8180141978518805e-06
strand O 0 3.171252274114522e-06
break O 0 6.267770459089661e-06
repair O 0 0.006730323191732168
and O 0 2.3385568681533186e-07
/ O 0 9.009637324197683e-06
or O 0 1.2931981530073244e-07
homologous O 0 2.7022665562981274e-06
recombination O 0 5.34727587364614e-06
. O 0 9.987321618609712e-07

Dysfunction O 0 0.0003645320248324424
of O 0 1.0425980434547455e-07
this O 0 4.1031473330122026e-08
pathway O 0 1.8949683067148726e-07
may O 0 1.913287093202598e-07
be O 0 1.8459576089924212e-09
a O 0 3.32068683661646e-09
general O 0 3.720376229310318e-09
phenomenon O 0 1.0551933549152182e-08
in O 0 2.7869964114302093e-09
the O 0 4.620599458604602e-09
majority O 0 2.4442934343227307e-09
of O 0 1.9035693854529967e-10
cases O 0 1.1754451856305081e-09
of O 0 4.260334307559788e-09
hereditary B-Disease 1 0.7717265486717224
breast I-Disease 0 0.438802033662796
and I-Disease 0 3.858769196085632e-05
/ I-Disease 1 0.9999997615814209
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.564948431427183e-07
. O 0 5.262519948701083e-07

A O 0 1.0264736374665517e-05
novel O 0 4.668768724513939e-06
Arg362Ser O 0 3.830673449556343e-05
mutation O 0 6.767120794393122e-06
in O 0 8.398789930197381e-08
the O 0 3.66033177101599e-08
sterol O 0 2.342949665035121e-05
27 O 0 4.841378995479317e-06
- O 0 1.5083263861015439e-05
hydroxylase O 0 8.455925126327202e-05
gene O 0 9.430173122382257e-06
( O 0 1.0951433182526671e-07
CYP27 O 0 6.121026672190055e-06
) O 0 1.6059209073659986e-08
: O 0 3.298013862007565e-09
its O 0 1.204188659897909e-08
effects O 0 2.622651038564072e-07
on O 0 1.1015328738039898e-07
pre O 0 2.086419044644572e-06
- O 0 3.40525161846017e-07
mRNA O 0 4.577417769269232e-07
splicing O 0 1.0915767916230834e-06
and O 0 4.785039564580984e-08
enzyme O 0 8.217776894525741e-07
activity O 0 1.0939997991954442e-06
. O 0 5.648362844112853e-07

A O 0 1.365646949125221e-05
novel O 0 3.346080802657525e-06
C O 0 6.3984221014834475e-06
to O 0 4.0177575044708647e-08
A O 0 1.0227483926428249e-07
mutation O 0 5.8750322295964e-07
in O 0 1.659371484663552e-08
the O 0 3.914234980584297e-08
sterol O 0 8.895320206647739e-06
27 O 0 1.693377157607756e-06
- O 0 3.508853069433826e-06
hydroxylase O 0 1.818103191908449e-05
gene O 0 2.2267226995609235e-06
( O 0 4.108707685190893e-08
CYP27 O 0 2.6768484531203285e-06
) O 0 1.1483765938180568e-08
was O 0 2.640030771772217e-08
identified O 0 1.5946154618973196e-08
by O 0 8.92621709880359e-09
sequencing O 0 3.854984811368922e-07
amplified O 0 4.950189122610027e-06
CYP27 O 0 8.095813427644316e-06
gene O 0 1.4262959666666575e-06
products O 0 2.4225272454714286e-07
from O 0 1.0735943689610394e-08
a O 0 6.846320843578724e-08
patient O 0 1.7353901284877793e-06
with O 0 1.0357673545513535e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 2.648807594596292e-06
CTX B-Disease 0 0.0006795976660214365
) O 0 6.787996653656592e-07
. O 0 6.831404562035459e-07

The O 0 8.816270565148443e-06
mutation O 0 3.9604092307854444e-05
changed O 0 3.718573680089321e-06
the O 0 1.8016160652223334e-07
adrenodoxin O 0 1.4755309166503139e-05
cofactor O 0 2.5980609734688187e-06
binding O 0 7.024588626336481e-07
residue O 0 1.9338931451784447e-06
362Arg O 0 2.282070454384666e-06
to O 0 9.601016870419699e-08
362Ser O 0 5.738795607612701e-06
( O 0 1.9130791883981146e-07
CGT O 0 1.2380169209791347e-05
362Arg O 0 7.143916718632681e-06
to O 0 1.2319557640694256e-07
AGT O 0 1.535852970846463e-05
362Ser O 0 1.3702044725505402e-06
) O 0 7.230656517975831e-09
, O 0 1.1368321839455575e-09
and O 0 1.91168414431786e-09
was O 0 5.839918770789154e-08
responsible O 0 2.2940572108609558e-08
for O 0 5.285122028908518e-08
deficiency O 0 1.0333035788789857e-05
in O 0 8.58646931334306e-09
the O 0 2.224808604012196e-08
sterol O 0 6.793158718210179e-06
27 O 0 8.114743650367018e-07
- O 0 1.1126816161777242e-06
hydroxylase O 0 4.089329650014406e-06
activity O 0 2.664858982370788e-07
, O 0 3.530405523477498e-09
as O 0 1.5333240233061929e-09
confirmed O 0 9.779737908388597e-09
by O 0 3.1080400475502756e-09
expression O 0 1.7397660201368126e-08
of O 0 1.907564772807291e-09
mutant O 0 2.484722756435076e-07
cDNA O 0 6.188605539136915e-07
into O 0 2.097406479606434e-07
COS O 0 4.8370817239629105e-05
- O 0 2.354039452256984e-06
1 O 0 2.82521313010875e-07
cells O 0 1.4212611176844803e-06
. O 0 3.6791749380427063e-07

Quantitative O 0 4.826824806514196e-05
analysis O 0 1.7426907561457483e-06
showed O 0 9.729893690746394e-07
that O 0 5.3664543919751395e-09
the O 0 3.1405946732121492e-09
expression O 0 1.4088491262498337e-08
of O 0 2.1450314857673902e-09
CYP27 O 0 5.552007564801897e-07
gene O 0 1.803197449135041e-07
mRNA O 0 1.0016895402031878e-07
in O 0 1.8057921380432163e-08
the O 0 4.1057777622199865e-08
patient O 0 7.892692792665912e-07
represented O 0 1.9648634008717636e-07
52 O 0 1.4362274214363424e-06
. O 0 5.016764248466643e-07

5 O 0 2.1194534838286927e-06
% O 0 4.5394664027753606e-08
of O 0 4.29107149813035e-09
the O 0 2.4271981757806316e-08
normal O 0 1.3058867125437246e-06
level O 0 1.9727576727746055e-06
. O 0 6.227181188478426e-07

As O 0 1.6465670569232316e-06
the O 0 2.2165878021951357e-07
mutation O 0 1.6553590285184328e-06
occurred O 0 5.279893571241701e-07
at O 0 9.137917089674374e-08
the O 0 2.2293578538779002e-08
penultimate O 0 5.578964987762447e-07
nucleotide O 0 1.8066573659325513e-07
of O 0 5.230614608109363e-09
exon O 0 1.2994379403608036e-06
6 O 0 2.656371691500681e-07
( O 0 4.006263765177209e-08
- O 0 6.535547072417103e-07
2 O 0 2.8813026631269167e-08
position O 0 5.283217419105313e-08
of O 0 3.90416721174347e-09
exon O 0 1.1670726962620392e-06
6 O 0 3.7052842571938527e-07
- O 0 2.1715904949815013e-06
intron O 0 1.1838645150419325e-05
6 O 0 2.8614314828701026e-07
splice O 0 4.839763732888969e-06
site O 0 1.8668140455702087e-07
) O 0 1.6470540487034668e-09
of O 0 3.233550649461847e-10
the O 0 5.551120896285511e-09
gene O 0 9.883402896093685e-08
, O 0 1.7519061756843257e-09
we O 0 1.7759106407666536e-09
hypothesized O 0 2.3772438240143856e-08
that O 0 1.4636355460950767e-09
the O 0 2.921233566155479e-08
mutation O 0 2.480792545611621e-06
may O 0 5.199503334551991e-07
partially O 0 4.853639552493405e-07
affect O 0 3.4717647423576636e-08
the O 0 6.69518973595018e-09
normal O 0 1.4252623259380925e-07
splicing O 0 6.630620532632747e-07
efficiency O 0 2.3790428826941934e-07
in O 0 3.6988897278433797e-08
exon O 0 6.93739536927751e-07
6 O 0 5.270605996088307e-08
and O 0 4.714771240088567e-09
cause O 0 2.1001802963382943e-08
alternative O 0 1.2951353767221008e-08
splicing O 0 1.5178858348008362e-07
elsewhere O 0 6.624262738341713e-08
, O 0 1.631938029156288e-09
which O 0 1.2780698721570616e-09
resulted O 0 7.936522550267e-09
in O 0 5.662875057765859e-09
decreased O 0 2.137603871688043e-07
transcript O 0 1.1379540865164017e-06
in O 0 3.4800052617356414e-08
the O 0 6.470713032058484e-08
patient O 0 3.961292804888217e-06
. O 0 8.158998525686911e-07

Transfection O 0 0.00040216383058577776
of O 0 3.1083385465535684e-07
constructed O 0 1.5471401866307133e-06
minigenes O 0 6.346880581986625e-06
, O 0 7.381274702566998e-09
with O 0 1.7180670219829608e-09
or O 0 1.2046297293011321e-08
without O 0 2.316732139462374e-09
the O 0 6.994264278858964e-09
mutation O 0 6.601798219207922e-08
, O 0 1.2810937866092331e-09
into O 0 1.6173745009950835e-08
COS O 0 1.081115442502778e-05
- O 0 4.504513810843491e-07
1 O 0 1.2045308750430195e-08
cells O 0 1.4487326005507839e-08
confirmed O 0 1.2786873782033581e-08
that O 0 8.362560643959682e-10
the O 0 4.121656349553859e-09
mutant O 0 1.931797868337526e-07
minigene O 0 6.85226439145481e-07
was O 0 3.717065766295491e-08
responsible O 0 8.445773858056782e-09
for O 0 1.4000299808358818e-09
a O 0 6.384014650251402e-09
mRNA O 0 1.1257165510869527e-07
species O 0 8.366409787186058e-09
alternatively O 0 1.4221083688426006e-07
spliced O 0 1.929762674990343e-06
at O 0 2.280790312170211e-07
an O 0 2.4819012622856462e-08
activated O 0 1.8568845916888677e-05
cryptic O 0 1.8638091887623887e-06
5 O 0 9.215103347059994e-08
splice O 0 3.540209490893176e-06
site O 0 3.3728088055795524e-07
88 O 0 1.5929289531868562e-07
bp O 0 2.2287080980731844e-07
upstream O 0 6.393497642420698e-08
from O 0 6.066531277326703e-09
the O 0 5.502566846615764e-09
3 O 0 1.201004895534652e-08
end O 0 3.51388109720574e-08
of O 0 9.748710283474793e-09
exon O 0 5.944211352471029e-06
6 O 0 8.804322533251252e-07
. O 0 5.153838174010161e-07

Our O 0 1.7676222796580987e-06
data O 0 9.594917855793028e-07
suggest O 0 7.585619243855035e-08
that O 0 2.0104828912792527e-09
the O 0 3.2423528306679827e-09
C O 0 1.3310891233686561e-07
to O 0 1.7303402044532845e-09
A O 0 3.157112615781443e-08
mutation O 0 1.407917551432547e-07
at O 0 2.009655730716986e-08
the O 0 6.307183664233662e-09
penultimate O 0 3.837242843474087e-07
nucleotide O 0 9.71750822031936e-08
of O 0 2.592262404732537e-09
exon O 0 7.748661232653831e-07
6 O 0 2.533484710909306e-08
of O 0 1.0873393296861877e-09
the O 0 1.1105572461644897e-08
CYP27 O 0 3.0460141715593636e-06
gene O 0 1.9161174691362248e-07
not O 0 4.222675542564502e-09
only O 0 2.1398540717143533e-09
causes O 0 3.834297501725814e-08
the O 0 1.5323519164667232e-07
deficiency B-Disease 0 1.1667916623991914e-05
in I-Disease 0 7.052981310096129e-09
the I-Disease 0 4.6766999162173306e-08
sterol I-Disease 0 1.1323430044285487e-05
27 I-Disease 0 6.900569360368536e-07
- I-Disease 0 8.146239451889414e-07
hydroxylase I-Disease 0 3.822625330940355e-06
activity I-Disease 0 5.613580924546113e-07
, O 0 5.181679973986775e-09
but O 0 4.730949410003404e-09
also O 0 1.244937575251015e-08
partially O 0 1.8513662780605955e-07
leads O 0 1.8554823455474434e-08
to O 0 6.407436803357314e-09
alternative O 0 3.736578335633567e-08
pre O 0 5.841444590259925e-07
- O 0 1.7759360559921333e-07
mRNA O 0 2.1539213435062265e-07
splicing O 0 2.661199403064529e-07
of O 0 2.0536583544839004e-09
the O 0 3.056630148989825e-08
gene O 0 2.1411467514553806e-06
. O 0 2.9578120575024514e-07

To O 0 1.0541552910581231e-06
our O 0 3.8713196204298583e-08
knowledge O 0 9.735053652093484e-09
, O 0 5.831319871418827e-10
this O 0 5.010543091543695e-10
is O 0 4.677382370310568e-10
the O 0 1.4957975968954429e-09
first O 0 4.109552254050186e-09
report O 0 2.123328179948203e-08
regarding O 0 8.765380421493774e-09
effects O 0 7.369320798034096e-08
on O 0 6.934214269449512e-08
pre O 0 9.364717357129848e-07
- O 0 1.1563599144892578e-07
mRNA O 0 6.992813439410384e-08
splicing O 0 7.267839663427367e-08
of O 0 8.851917532304299e-10
a O 0 7.76535635793607e-09
mutation O 0 8.523228700596519e-08
at O 0 4.877108139567099e-08
the O 0 3.5429138733888976e-08
- O 0 1.1057054507546127e-06
2 O 0 2.4188700820104714e-08
position O 0 2.9236526088993742e-08
of O 0 1.729314136333926e-09
a O 0 4.389341157207127e-08
5 O 0 1.9067297785113624e-07
splice O 0 2.2852455003885552e-05
site O 0 3.524148269207217e-06
. O 0 1.0492345836610184e-06

ATM O 0 0.004439354874193668
germline O 0 0.008506113663315773
mutations O 0 0.004983111750334501
in O 0 1.6472833522129804e-05
classical O 0 0.4286920428276062
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.5010905265808105
in O 0 7.200347340585722e-07
the O 0 1.3250148356291902e-07
Dutch O 0 5.6427866184094455e-06
population O 0 1.393153326034735e-07
. O 0 2.2703216018271632e-07

Germline O 0 0.007453429978340864
mutations O 0 0.0010976055637001991
in O 0 6.270984158618376e-07
the O 0 1.49581325104009e-07
ATM O 0 1.1993646694463678e-05
gene O 0 1.1707847988873255e-06
are O 0 3.2946187999982612e-09
responsible O 0 2.252747677289335e-08
for O 0 3.62247938312521e-08
the O 0 0.04435501992702484
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.08067654818296432
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 1.8565710888651665e-06
. O 0 7.559360710729379e-07

In O 0 1.956297637661919e-06
our O 0 8.767892722971737e-08
study O 0 1.6924223800174332e-08
, O 0 2.207775962048686e-09
we O 0 9.484684149185796e-10
have O 0 6.148290765395359e-10
determined O 0 6.1902434289606845e-09
the O 0 1.669371130219588e-08
ATM O 0 9.15242617338663e-06
mutation O 0 1.3324522569746478e-06
spectrum O 0 2.3549010563783668e-07
in O 0 2.6159110433354726e-08
19 O 0 7.62884369009953e-08
classical O 0 3.114861044650752e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.081342351331841e-06
, O 0 9.308404047558838e-10
including O 0 1.609970629035118e-10
some O 0 4.763598404622371e-10
immigrant O 0 1.80739778699035e-08
populations O 0 6.922014517130037e-09
, O 0 7.146644942501723e-10
as O 0 1.3476879612284165e-09
well O 0 1.178093733678054e-09
as O 0 2.221474559860326e-09
12 O 0 3.284554850324639e-09
of O 0 1.087382850428753e-09
Dutch O 0 1.871106007911294e-07
ethnic O 0 2.157099032729093e-08
origin O 0 9.807388323679334e-08
. O 0 2.3844125962568796e-07

Both O 0 5.703004148926993e-07
the O 0 1.6224934995534568e-07
protein O 0 6.935972578503424e-07
truncation O 0 5.510752998816315e-06
test O 0 2.0238323941157432e-06
( O 0 1.0979542963696076e-07
PTT O 0 1.3452151961246273e-06
) O 0 6.6707412926803045e-09
and O 0 2.376286056815502e-09
the O 0 1.5615343684771688e-08
restriction O 0 3.8350589193214546e-07
endonuclease O 0 1.6046758901211433e-05
fingerprinting O 0 2.7258097361482214e-06
( O 0 1.5983127354957105e-07
REF O 0 3.1899007808533497e-06
) O 0 4.835774891631672e-09
method O 0 4.473435399887649e-09
were O 0 7.762271936329057e-10
used O 0 2.274623822628996e-09
and O 0 9.478842155630218e-10
compared O 0 6.197083290970795e-09
for O 0 4.1916187187851506e-10
their O 0 2.0803765377053196e-09
detection O 0 1.0629202051859465e-07
efficiency O 0 7.435708226921633e-08
, O 0 1.6003459668567643e-09
identifying O 0 9.8216670352258e-09
76 O 0 1.7826922160679715e-08
% O 0 1.8277395152921372e-09
and O 0 2.356696393590596e-09
60 O 0 6.622137949108264e-09
% O 0 1.218931067192841e-09
of O 0 2.8714464139767415e-10
the O 0 3.5061688663518e-08
mutations O 0 1.7503758726888918e-06
, O 0 1.8795791589809596e-08
respectively O 0 3.645477875124925e-07
. O 0 7.711528837717196e-07

Most O 0 2.064120963041205e-06
patients O 0 2.0195905108266743e-06
were O 0 4.226690464292915e-08
found O 0 1.9467181644472475e-08
to O 0 7.501975929358196e-09
be O 0 7.987868144709864e-09
compound O 0 4.202967147648451e-07
heterozygote O 0 1.135760703618871e-05
. O 0 5.86261307944369e-07

Seventeen O 0 2.4721868612687103e-05
mutations O 0 4.153930058237165e-05
were O 0 9.467684236597051e-08
distinct O 0 3.04859533173385e-08
, O 0 1.880069655513239e-09
of O 0 2.7800400870248154e-10
which O 0 3.966261541421545e-09
10 O 0 3.308838758542265e-09
were O 0 3.719801799917377e-09
not O 0 4.816435250631912e-09
reported O 0 6.418857765311259e-07
previously O 0 7.412994591504685e-07
. O 0 3.8198740526240726e-07

Mutations O 0 0.0006191212451085448
are O 0 2.3240941970925633e-07
small O 0 1.9510046911364043e-07
deletions O 0 1.3649946595251095e-05
or O 0 5.095241704111686e-07
point O 0 4.950671836922993e-07
mutations O 0 7.821718099876307e-06
frequently O 0 7.208227543742396e-07
affecting O 0 1.835428179219889e-06
splice O 0 0.00010496361210243776
sites O 0 9.842777217272669e-06
. O 0 2.303371275047539e-06

Moreover O 0 1.2752193470078055e-05
, O 0 3.2728908649914956e-07
a O 0 3.3758786344151304e-07
16 O 0 2.168486162190675e-06
. O 0 1.215606857840612e-06

7 O 0 7.463397923856974e-05
- O 0 4.978113793185912e-05
kb O 0 5.2697534556500614e-05
genomic O 0 7.030337656033225e-06
deletion O 0 1.7912357179739047e-06
of O 0 1.044205610867266e-08
the O 0 1.3008196297903396e-08
3 O 0 1.9827751884804456e-08
end O 0 1.1923952492054468e-08
of O 0 4.462593350407218e-10
the O 0 4.4874335358713324e-09
gene O 0 5.3928065568698e-08
, O 0 5.582206363818898e-10
most O 0 6.068553437543756e-10
likely O 0 1.0602065891873735e-08
a O 0 7.254430389735944e-09
result O 0 4.150054966345351e-09
of O 0 7.743698460238591e-10
recombination O 0 2.700215517847937e-08
between O 0 4.668516240258214e-09
two O 0 6.732260970920834e-09
LINE O 0 3.985597686551046e-06
elements O 0 2.5324411012661585e-08
, O 0 8.93270613033792e-09
was O 0 6.171430300128122e-08
identified O 0 9.470591777471782e-08
. O 0 1.5123173113806843e-07

The O 0 5.908914886276762e-07
most O 0 5.3296837165817124e-08
frequently O 0 1.0584572152083638e-07
found O 0 5.581232542795078e-08
mutation O 0 2.475281064562296e-07
, O 0 2.6471593805865723e-09
identified O 0 8.603420198483036e-09
in O 0 4.2132062283428695e-09
three O 0 2.685068833940818e-09
unrelated O 0 6.872578950378738e-08
Turkish O 0 2.1157606511224003e-07
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999536275863647
T I-Disease 1 1.0
individuals O 0 1.0953225881848994e-08
, O 0 4.476055970314974e-09
was O 0 8.391552341890929e-08
previously O 0 6.762891580081032e-09
described O 0 7.4329120636207335e-09
to O 0 1.5274103093432245e-09
be O 0 9.848412085844416e-10
a O 0 6.2961023061802734e-09
Turkish O 0 1.4350784738326183e-07
A B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999942779541016
T I-Disease 1 1.0
founder O 0 2.5394958356628194e-05
mutation O 0 1.9886812879121862e-05
. O 0 8.225084684454487e-07

The O 0 6.201981364029052e-07
presence O 0 2.416799986804108e-07
of O 0 9.56958512432493e-09
a O 0 4.314125945370506e-08
founder O 0 4.706938341314526e-07
mutation O 0 4.1757115809559764e-07
among O 0 4.008646303788055e-09
relatively O 0 1.9978957155331045e-08
small O 0 5.421164406271828e-09
ethnic O 0 2.452802405628063e-09
population O 0 1.3644795293643597e-09
groups O 0 3.791256475427218e-10
in O 0 2.2911701424987996e-09
Western O 0 2.8859998835173428e-08
Europe O 0 6.147745921225578e-07
could O 0 4.5427750450244275e-08
indicate O 0 2.751624528229968e-08
a O 0 1.477621847101318e-08
high O 0 1.5243935536091158e-07
carrier O 0 1.734726993163349e-07
frequency O 0 5.641510369969183e-07
in O 0 1.2999515242029247e-08
such O 0 5.8672466884956975e-09
communities O 0 5.072464048794245e-08
. O 0 1.9145429064337804e-07

In O 0 6.264042440307094e-06
patients O 0 1.0394702485427842e-06
of O 0 8.745640656115938e-09
Dutch O 0 2.2184340764397348e-07
ethnic O 0 3.3901494944643673e-09
origin O 0 2.229233464490221e-09
, O 0 1.5079089088487763e-09
however O 0 3.2772706770600735e-09
, O 0 7.110613209349026e-10
no O 0 9.237797193861752e-10
significant O 0 2.4090343053728702e-09
founder O 0 5.276671544152123e-08
effect O 0 4.5966832118438106e-08
could O 0 3.002373460958552e-08
be O 0 1.8401967949444042e-08
identified O 0 1.7192981260905071e-07
. O 0 1.982061235139554e-07

The O 0 2.2946276203583693e-06
observed O 0 3.401977210160112e-06
genetic O 0 1.2989894457859918e-06
heterogeneity O 0 9.051199754139816e-07
including O 0 1.0579198850280136e-08
the O 0 1.6947319991800214e-08
relative O 0 1.2698144757905538e-07
high O 0 5.614255655927991e-07
percentage O 0 5.8464603824859296e-08
of O 0 3.697096406796163e-09
splice O 0 0.0001462159852962941
- O 0 0.00023411394795402884
site O 0 9.3714061222272e-06
mutations O 0 7.657184141862672e-06
had O 0 9.77215250941299e-08
no O 0 8.344320789888116e-09
reflection O 0 5.252852375292605e-08
on O 0 9.696808689341196e-08
the O 0 8.262918527179863e-08
phenotype O 0 3.104833740508184e-05
. O 0 7.44473993563588e-07

All O 0 3.1986985504772747e-06
patients O 0 5.020391199650476e-06
manifested O 0 3.0969520139478846e-06
classical O 0 1.208488811244024e-06
A B-Disease 1 0.9999713897705078
- I-Disease 1 0.9995487332344055
T I-Disease 1 0.9999997615814209
and O 0 7.606686125427586e-08
increased O 0 1.956669422042978e-07
cellular O 0 1.858945211097307e-06
radioresistant O 0 6.134923751233146e-06
DNA O 0 2.900845402109553e-06
synthesis O 0 1.457962571294047e-05
. O 0 2.9812053981004283e-06

Determination O 0 6.216089786903467e-06
of O 0 4.623545990511957e-08
the O 0 4.7470322783738084e-08
genomic O 0 4.5658555336558493e-07
structure O 0 1.3090685513361677e-07
of O 0 2.1483397283361683e-09
the O 0 1.9336846790452e-08
COL4A4 O 0 7.582373200420989e-06
gene O 0 3.4876541121775517e-07
and O 0 4.34651692415855e-09
of O 0 4.290523047956185e-09
novel O 0 2.9843743050150806e-06
mutations O 0 0.0023567371536046267
causing O 0 0.07543802261352539
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00010474185546627268

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 8.8801161837182e-06
a O 0 8.15971361589618e-06
progressive O 0 0.43734562397003174
hematuric B-Disease 1 0.9986395239830017
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.0036023620050400496
by O 0 2.065215767288464e-06
glomerular B-Disease 1 0.7104789614677429
basement I-Disease 1 0.9999253749847412
membrane I-Disease 1 0.8724797368049622
abnormalities I-Disease 1 0.9999895095825195
and O 0 9.796656286198413e-08
associated O 0 9.363577646581689e-08
with O 0 1.8786616706734094e-08
mutations O 0 1.1121683201054111e-06
in O 0 2.1305288200323957e-08
either O 0 1.354143197573876e-08
the O 0 2.989174063827704e-08
COL4A3 O 0 5.774188139184844e-06
or O 0 1.8837138071603476e-08
the O 0 1.2551637951219163e-08
COL4A4 O 0 1.768726860973402e-06
gene O 0 1.4710282414398534e-07
, O 0 2.913953078831355e-09
which O 0 1.88880355800336e-09
encode O 0 4.4559463674431754e-08
the O 0 1.3381271202206335e-08
alpha3 O 0 1.167287564385333e-06
and O 0 2.0582318072115413e-08
alpha4 O 0 4.938750407745829e-06
type O 0 4.190566323813982e-05
IV O 0 0.001706738374195993
collagen O 0 2.6658310162019916e-05
chains O 0 2.1810772523167543e-05
, O 0 3.5202944559387106e-08
respectively O 0 2.657656352766935e-07
. O 0 2.9203988560766447e-07

To O 0 1.1206964245502604e-06
date O 0 5.083088581159245e-07
, O 0 1.6237510891414786e-08
mutation O 0 3.642207673237863e-07
screening O 0 1.3423864686501474e-07
in O 0 1.2511696567685249e-08
the O 0 6.669901964073688e-09
two O 0 3.795382674809389e-09
genes O 0 4.642705064838992e-08
has O 0 1.739142341250499e-08
been O 0 1.5431300681711946e-08
hampered O 0 4.722423341263493e-07
by O 0 6.2093055142042886e-09
the O 0 8.388283845306432e-09
lack O 0 1.9450444810331646e-08
of O 0 3.238829870966242e-09
genomic O 0 7.366692216237425e-07
structure O 0 5.039584607402503e-07
information O 0 2.6891248694482783e-07
. O 0 7.463059432666341e-07

We O 0 7.323864110730938e-07
report O 0 1.232103841175558e-07
here O 0 7.680788449704323e-09
the O 0 3.0431792641394395e-09
complete O 0 1.1588390691485984e-08
characterization O 0 2.532827458878728e-08
of O 0 4.864608160737305e-10
the O 0 4.479378201693862e-09
48 O 0 1.660656856472542e-08
exons O 0 7.849540395454824e-08
of O 0 8.145954466520777e-10
the O 0 8.432735398855584e-09
COL4A4 O 0 2.8180572826386197e-06
gene O 0 2.2621952666668221e-07
, O 0 1.6268100200278468e-09
a O 0 4.288567723165215e-09
comprehensive O 0 5.269811964581095e-08
gene O 0 7.951190355015569e-07
screen O 0 4.275064384273719e-06
, O 0 4.683258669757606e-09
and O 0 1.0959949614530728e-09
the O 0 2.834791956729532e-09
subsequent O 0 2.0434612224562443e-08
detection O 0 7.927266665319621e-08
of O 0 2.8732887180638045e-09
10 O 0 1.5837942513030612e-08
novel O 0 3.7645271788733226e-08
mutations O 0 2.801174616706703e-07
in O 0 2.994218561980233e-08
eight O 0 7.783515343362524e-07
patients O 0 0.0004171777400188148
diagnosed O 1 0.9215157628059387
with O 0 0.00011768555123126134
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.6798021028516814e-05

Furthermore O 0 1.4863802789477631e-05
, O 0 1.0661506166798063e-07
we O 0 1.7257070439313793e-08
identified O 0 3.1800603039755515e-08
a O 0 2.7973831251415504e-08
glycine O 0 2.870031494239811e-06
to O 0 2.6500197591872166e-08
alanine O 0 1.1781481816797168e-06
substitution O 0 5.506863942628115e-08
in O 0 8.93178597749511e-09
the O 0 2.6014816967290244e-08
collagenous O 0 2.2884210011397954e-06
domain O 0 5.470776898164331e-08
that O 0 3.1601958827565113e-09
is O 0 2.543350641204256e-09
apparently O 0 3.7525552443185006e-08
silent O 0 9.984429993892263e-08
in O 0 5.989361895331058e-09
the O 0 8.278248309068204e-09
heterozygous O 0 3.13915649030605e-07
carriers O 0 3.0476012824465215e-08
, O 0 3.3499243379253585e-09
in O 0 1.99735854522487e-08
11 O 0 2.7229182819610287e-07
. O 0 2.5215393861799384e-07

5 O 0 4.612162683770293e-06
% O 0 4.679474585600474e-08
of O 0 1.073108601978845e-09
all O 0 4.163452083094654e-10
control O 0 5.735698849207438e-08
individuals O 0 4.422530675007863e-10
, O 0 8.194200318278888e-10
and O 0 3.105859347485307e-09
in O 0 7.517732214523676e-09
one O 0 3.406535498129415e-09
control O 0 1.9419127283981652e-07
individual O 0 3.6889113985694166e-09
homozygous O 0 9.362648256683315e-08
for O 0 1.5403620601261991e-09
this O 0 8.87838513818906e-09
glycine O 0 5.541514838114381e-06
substitution O 0 1.7314195019935141e-06
. O 0 8.00102895937016e-07

There O 0 5.290669378155144e-07
has O 0 4.968787692405385e-08
been O 0 4.691447674787241e-09
no O 0 1.1176178871252773e-09
previous O 0 3.775728618649055e-09
finding O 0 6.445123879039727e-10
of O 0 1.9091653258307417e-10
a O 0 3.870129106076092e-09
glycine O 0 5.980996888865775e-07
substitution O 0 2.650995689634783e-08
that O 0 3.1457025873038447e-09
is O 0 1.0419272111761302e-09
not O 0 7.592111384013833e-10
associated O 0 4.533925679339745e-09
with O 0 2.47314368984064e-09
any O 0 5.914877476698166e-09
obvious O 0 1.1796710452927073e-07
phenotype O 0 2.6081745545525337e-06
in O 0 8.320263589212118e-08
homozygous O 0 4.315115347708343e-06
individuals O 0 9.941881273789477e-08
. O 0 4.532873560947337e-07

Founder O 0 0.0002763991942629218
BRCA1 O 0 0.0005858101649209857
and O 0 1.3624566008729744e-06
BRCA2 O 0 8.438959048362449e-05
mutations O 0 6.1532928157248534e-06
in O 0 1.0779240966485304e-07
French O 0 3.593594328776817e-06
Canadian O 0 0.012523485347628593
breast B-Disease 1 0.9999982118606567
and I-Disease 1 0.99989914894104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.75127818492183e-07
. O 0 1.668590471126663e-06

We O 0 6.76310662584001e-07
have O 0 3.364076661682702e-08
identified O 0 2.5216683852136157e-08
four O 0 5.293402161044014e-09
mutations O 0 1.1236250685442428e-07
in O 0 3.3017022449399747e-09
each O 0 1.5823379273527394e-09
of O 0 1.4687251415068658e-09
the O 0 1.9783647076110356e-06
breast B-Disease 1 0.9963505268096924
cancer I-Disease 0 7.918552728369832e-05
- O 0 1.2466703083191533e-05
susceptibility O 0 4.224089934723452e-06
genes O 0 2.8616960889848997e-07
, O 0 1.719736708594155e-08
BRCA1 O 0 1.6133249118865933e-06
and O 0 1.9912230087015814e-08
BRCA2 O 0 1.1788225720010814e-06
, O 0 2.7665583157698848e-09
in O 0 1.3833767908977279e-08
French O 0 1.8028999875241425e-06
Canadian O 0 0.0014101180713623762
breast B-Disease 1 0.9998939037322998
cancer I-Disease 0 0.44748827815055847
and O 0 0.29234737157821655
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.37057037111299e-07
from O 0 3.240914452362631e-07
Quebec O 0 0.00011568015906959772
. O 0 1.4780653145862743e-06

To O 0 1.7253144051210256e-06
identify O 0 1.5558997574771638e-06
founder O 0 1.1337424439261667e-06
effects O 0 2.056834546237951e-06
, O 0 1.824389883609001e-08
we O 0 5.869261521240787e-09
examined O 0 2.0667098965532205e-07
independently O 0 1.313567992156095e-07
ascertained O 0 2.9789640620947466e-07
French O 0 1.883155533732861e-07
Canadian O 0 1.312051040258666e-06
cancer B-Disease 0 2.2485187400889117e-06
families O 0 2.4622286431963403e-09
for O 0 8.844070475966248e-10
the O 0 3.1631566255185817e-09
distribution O 0 5.677821768301783e-09
of O 0 8.958192521113517e-10
these O 0 2.6883126835741677e-09
eight O 0 3.926842495616256e-08
mutations O 0 6.712806680297945e-06
. O 0 4.5632870637746237e-07

Mutations O 0 0.0005660979659296572
were O 0 3.81580349539945e-07
found O 0 5.0664596074057044e-08
in O 0 2.417034572488319e-08
41 O 0 5.858247931200822e-08
of O 0 5.959028825941459e-09
97 O 0 5.969388894300209e-07
families O 0 1.2001547133877466e-07
. O 0 2.804039809234382e-07

Six O 0 8.105323558993405e-07
of O 0 2.286133593543127e-08
eight O 0 3.9819617825287423e-08
mutations O 0 6.29067869795108e-07
were O 0 1.8113562205712697e-08
observed O 0 7.418638148237733e-08
at O 0 1.8415842362173862e-07
least O 0 3.733436315656036e-08
twice O 0 9.226955626218114e-07
. O 0 3.93672735299333e-07

The O 0 5.84884173804312e-06
BRCA1 O 0 0.00014182442100718617
C4446T O 0 1.9516352040227503e-05
mutation O 0 7.789977644279134e-06
was O 0 2.1792260440633981e-07
the O 0 5.150965431965915e-09
most O 0 2.3424189254939165e-09
common O 0 4.75309356318121e-08
mutation O 0 5.114364967084839e-07
found O 0 2.2294004864420458e-08
, O 0 2.5811959236676785e-09
followed O 0 1.9290322228471268e-08
by O 0 1.5289529642359412e-08
the O 0 3.4192609632555104e-07
BRCA2 O 0 8.464750135317445e-05
8765delAG O 0 4.432614878169261e-05
mutation O 0 5.248433808446862e-05
. O 0 3.5284060686535668e-06

Together O 0 1.2448828101696563e-06
, O 0 4.1418882545940505e-08
these O 0 9.49210843259607e-09
mutations O 0 2.056270460570886e-07
were O 0 5.136641334502201e-09
found O 0 5.568098426778079e-09
in O 0 6.100878469084137e-09
28 O 0 2.0667918931849272e-08
of O 0 8.022508768412706e-10
41 O 0 1.3191213454888384e-08
families O 0 1.3958011413350846e-09
identified O 0 6.493384940853275e-09
to O 0 7.704087146009897e-09
have O 0 5.850629758441528e-09
a O 0 7.688516490134134e-08
mutation O 0 5.584295195149025e-06
. O 0 3.878840857396426e-07

The O 0 1.8530439547248534e-06
odds O 0 2.5585627554391976e-06
of O 0 7.686651315452764e-09
detection O 0 4.531317543410296e-08
of O 0 7.700969306689842e-10
any O 0 1.2790379866345347e-09
of O 0 7.0094324788883e-10
the O 0 8.045238253373554e-09
four O 0 4.029868350130528e-08
BRCA1 O 0 2.0382651200634427e-05
mutations O 0 4.740662461699685e-06
was O 0 1.5201849237200804e-06
18 O 0 4.2403615907460335e-07
. O 0 3.9508088889306237e-07

7x O 0 0.0008914956706576049
greater O 0 1.0158480563404737e-06
if O 0 4.314125945370506e-08
one O 0 4.1895829028248954e-09
or O 0 2.1935342431333993e-09
more O 0 1.0092640057024482e-09
cases O 0 7.875075702656886e-09
of O 0 3.92701122109429e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.0732441896598175e-07
also O 0 7.3297306002473306e-09
present O 0 5.256267421316352e-09
in O 0 1.1641914987592372e-08
the O 0 8.344292723450053e-08
family O 0 5.474607291944267e-07
. O 0 3.0842610954096017e-07

The O 0 2.1096445834700717e-06
odds O 0 1.4516447208734462e-06
of O 0 6.572922650605051e-09
detection O 0 8.153610053796001e-08
of O 0 7.224242315473361e-10
any O 0 7.353027076106855e-10
of O 0 2.785427444251809e-10
the O 0 4.687655597024332e-09
four O 0 2.3778605751090254e-08
BRCA2 O 0 1.1230181371502113e-05
mutations O 0 2.0523455077636754e-06
was O 0 9.619656111681252e-07
5 O 0 5.120806463310146e-07
. O 0 5.992141609567625e-07

3x O 0 0.00014971173368394375
greater O 0 1.239537596120499e-06
if O 0 5.261114566224023e-08
there O 0 7.160757320434641e-09
were O 0 5.0225539283133e-09
at O 0 1.016127271213918e-08
least O 0 7.400287604930611e-10
five O 0 1.1631211549456566e-09
cases O 0 3.3614644401325222e-09
of O 0 2.573538182559787e-08
breast B-Disease 1 0.9467281699180603
cancer I-Disease 0 1.2433235497155692e-05
in O 0 2.5057076413759205e-08
the O 0 2.0270414324841113e-07
family O 0 1.7032131154337549e-06
. O 0 6.152039304652135e-07

Interestingly O 0 2.7922080334974453e-05
, O 0 6.416366460371137e-08
the O 0 1.1781123632204071e-08
presence O 0 2.7538401781157518e-08
of O 0 4.934218811314395e-09
a O 0 1.1396394938856247e-06
breast B-Disease 1 0.9736966490745544
cancer I-Disease 0 1.8061547962133773e-05
case O 0 8.766688353034624e-08
< O 0 3.645849915301369e-07
36 O 0 3.4906680212998253e-08
years O 0 3.0686799767920547e-09
of O 0 1.1242199393635133e-09
age O 0 1.723960174615513e-08
was O 0 3.0253900717980287e-08
strongly O 0 2.3112427527394175e-08
predictive O 0 4.869987790812047e-08
of O 0 7.480611130539216e-10
the O 0 2.1227966051640124e-09
presence O 0 1.9761143832397465e-09
of O 0 2.401554788367122e-10
any O 0 4.492141103540348e-10
of O 0 2.1330029409405427e-10
the O 0 5.779920542181571e-09
eight O 0 5.493372867704238e-08
mutations O 0 2.1605881102004787e-06
screened O 0 4.489384991757106e-06
. O 0 6.243903385438898e-07

Carriers O 0 4.4958715079701506e-06
of O 0 2.7927395507276742e-08
the O 0 9.45250633321848e-09
same O 0 8.951211327712372e-09
mutation O 0 4.60803377677621e-08
, O 0 6.256343776378515e-10
from O 0 7.83042242158416e-10
different O 0 3.6225999977546053e-10
families O 0 1.0431739916327842e-09
, O 0 6.285803544336943e-10
shared O 0 2.5949979942652135e-09
similar O 0 2.710706326070067e-08
haplotypes O 0 3.779413191296044e-07
, O 0 3.332679021639251e-09
indicating O 0 1.7828725162871706e-08
that O 0 1.1989306214488238e-09
the O 0 4.519558949311886e-09
mutant O 0 1.0635407221570858e-07
alleles O 0 5.4028134854888776e-08
were O 0 2.9206748131116456e-09
likely O 0 5.470096375859157e-09
to O 0 1.9719614829938337e-09
be O 0 1.4139983628425057e-09
identical O 0 3.194449504917429e-08
by O 0 2.53069187827748e-09
descent O 0 1.5952785759054677e-08
for O 0 1.1740739491727936e-09
a O 0 2.6209852066472195e-08
mutation O 0 1.995344973693136e-07
in O 0 8.471717549696223e-09
the O 0 3.0656977401122276e-08
founder O 0 5.323608434082416e-07
population O 0 5.57046995197652e-08
. O 0 1.3889705030578625e-07

The O 0 7.717635526205413e-07
identification O 0 3.912093404778716e-07
of O 0 2.9403233625657776e-08
common O 0 3.265380144057417e-07
BRCA1 O 0 2.603040775284171e-05
and O 0 4.361426135801594e-07
BRCA2 O 0 7.108316640369594e-05
mutations O 0 3.0798864827374928e-06
will O 0 1.847801023302509e-08
facilitate O 0 3.067669140932594e-08
carrier O 0 4.0159270042749995e-07
detection O 0 1.9343418955486413e-07
in O 0 3.0857492561153776e-08
French O 0 1.7423916460757027e-06
Canadian O 0 0.0007256737444549799
breast B-Disease 1 0.999936580657959
cancer I-Disease 1 0.6117197871208191
and O 0 0.39843910932540894
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3061022627880448e-06
. O 0 9.520794606032723e-07

Are O 0 1.0289376177752274e-06
Dp71 O 0 5.525631786440499e-05
and O 0 5.778313720838923e-07
Dp140 O 0 3.981110785389319e-05
brain O 0 0.00026165563031099737
dystrophin O 0 0.000153612025314942
isoforms O 0 9.662293450674042e-06
related O 0 7.435353381879395e-07
to O 0 3.669192096822371e-07
cognitive B-Disease 0 1.5016382349131163e-05
impairment I-Disease 0 0.00017362291691824794
in O 0 0.0002694791473913938
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.0006511490209959447

Molecular O 0 9.125062933890149e-05
study O 0 3.4445547498762608e-06
and O 0 2.5590941277187085e-07
neuropsychological O 0 9.43128816288663e-06
analysis O 0 9.694533531501293e-08
were O 0 3.9806252516427776e-08
performed O 0 8.738525281160037e-08
concurrently O 0 4.056767721749566e-08
on O 0 1.8535091328431008e-07
49 O 0 4.168351495081879e-07
patients O 0 1.966453027080206e-07
with O 0 3.1137940368353156e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.4128714358084835e-05
DMD B-Disease 1 1.0
) O 0 6.273496211406382e-08
in O 0 1.271934824131904e-08
order O 0 4.85746154410549e-09
to O 0 2.11982675857314e-09
find O 0 2.303768509293036e-09
a O 0 4.37136726816334e-09
molecular O 0 6.01081069362408e-08
explanation O 0 1.711464570064436e-08
for O 0 2.657266628958155e-09
the O 0 5.665275892852151e-08
cognitive B-Disease 0 1.765551701282675e-06
impairment I-Disease 0 8.093520591501147e-07
observed O 0 1.7544658703627647e-07
in O 0 2.063533059981637e-07
most O 0 2.0386862615850987e-06
DMD B-Disease 1 1.0
patients O 0 0.0010020970366895199
. O 0 2.233019358754973e-06

Complete O 0 3.877049493894447e-06
analysis O 0 4.699931821505743e-07
of O 0 9.392246980155505e-09
the O 0 3.3791248910119975e-08
dystrophin O 0 1.6472817151225172e-05
gene O 0 1.6690391930751503e-06
was O 0 6.853427407804702e-07
performed O 0 8.760002856433857e-08
to O 0 6.222904413988317e-09
define O 0 1.2290966466821374e-08
the O 0 5.727376795050532e-09
localization O 0 1.5367628236617747e-07
of O 0 2.7691184900646704e-09
deletions O 0 4.0879308471630793e-07
and O 0 1.0408312434151412e-08
duplications O 0 4.379724032332888e-07
in O 0 2.4845157042818755e-08
relation O 0 4.428494548847084e-08
to O 0 1.0039308051545959e-08
the O 0 6.199000779361086e-08
different O 0 4.562695608001377e-07
DMD B-Disease 1 0.9999991655349731
promoters O 0 5.175190744921565e-05
. O 0 1.953372475327342e-06

Qualitative O 0 4.27737322752364e-05
analysis O 0 1.4481076959782513e-06
of O 0 2.5967622718781058e-08
the O 0 3.546165672219104e-08
Dp71 O 0 4.024033842142671e-06
transcript O 0 1.507284014223842e-05
and O 0 4.0012846369563704e-08
testing O 0 2.4816456445364565e-08
for O 0 4.710543621833096e-10
the O 0 1.2744598709701904e-09
specific O 0 2.775194074544629e-09
first O 0 5.415387693830098e-09
exon O 0 9.541722079120518e-08
of O 0 2.3834081375184724e-09
Dp140 O 0 1.5993327906471677e-07
were O 0 1.0279482154373909e-08
also O 0 6.11852168930227e-09
carried O 0 9.780376331036678e-08
out O 0 1.0479910628191647e-07
. O 0 2.910178693582566e-07

Neuropsychological O 0 0.0025507472455501556
analysis O 0 2.3820017304387875e-05
assessed O 0 9.674243301560637e-06
verbal O 0 9.948994375008624e-06
and O 0 4.0264228573505534e-07
visuospatial O 0 2.9572713174275123e-05
intelligence O 0 2.49842355515284e-06
, O 0 6.190339973954906e-08
verbal O 0 8.400822366638749e-07
memory O 0 0.0005304382648319006
, O 0 8.027797804288639e-08
and O 0 7.863971518418111e-08
reading O 0 3.7794595755258342e-06
skills O 0 1.400040900989552e-06
. O 0 6.11170150932594e-07

Comparison O 0 5.37478217665921e-06
of O 0 9.660717381620998e-08
molecular O 0 9.420360811418504e-07
and O 0 5.24666425860687e-08
psychometric O 0 6.438055606849957e-06
findings O 0 4.853861241826962e-07
demonstrated O 0 1.5127989172469825e-07
that O 0 4.016613708301975e-09
deletions O 0 3.159269681418664e-07
and O 0 5.224273458281914e-09
duplications O 0 1.270163210165265e-07
that O 0 2.130877474471049e-09
were O 0 3.5553542332422694e-09
localized O 0 1.6099698996185907e-07
in O 0 2.530200760020307e-08
the O 0 3.498873724083751e-08
distal O 0 2.1431326331367018e-06
part O 0 9.44826972215651e-09
of O 0 7.916289845866231e-10
the O 0 6.777948868830208e-09
gene O 0 1.3654870656409912e-07
seemed O 0 3.5155437672074186e-08
to O 0 4.957292798479784e-09
be O 0 2.76593548065307e-09
preferentially O 0 4.742317472050672e-08
associated O 0 2.9119989974901728e-08
with O 0 4.762004479630377e-08
cognitive B-Disease 0 1.8108876247424632e-05
impairment I-Disease 0 3.6534103855956346e-05
. O 0 2.4825794753269292e-06

Two O 0 1.3325106920092367e-06
altered O 0 1.3790050616080407e-05
Dp71 O 0 1.4407118214876391e-05
transcripts O 0 1.3665660389960976e-06
and O 0 1.5771290051702636e-08
two O 0 7.49938688926477e-09
deleted O 0 5.672033580594871e-07
Dp140 O 0 5.673883265444601e-07
DNA O 0 2.293440957146231e-07
sequences O 0 6.818432751742876e-08
were O 0 7.133248214330479e-09
found O 0 3.680309168530016e-09
in O 0 2.7886182252245817e-09
four O 0 1.8775798693582146e-08
patients O 0 1.5021490185063158e-07
with O 0 8.466824397146411e-07
severe O 1 0.9999967813491821
cerebral B-Disease 1 0.9999995231628418
dysfunction I-Disease 1 0.9998610019683838
. O 0 1.7454121916671284e-05

These O 0 1.0011601716541918e-06
findings O 0 9.656163229010417e-07
suggest O 0 1.1229737140183715e-07
that O 0 3.750070920460757e-09
some O 0 1.9843786613904513e-09
sequences O 0 2.7196293217457423e-08
located O 0 3.900231959619305e-08
in O 0 4.763609950941827e-09
the O 0 5.45983924737925e-09
distal O 0 3.8632541077276983e-07
part O 0 5.959358340135168e-09
of O 0 4.152460320039353e-10
the O 0 4.4626804474035e-09
gene O 0 4.3293095330909637e-08
and O 0 2.251359099147976e-09
, O 0 7.430087656246087e-10
in O 0 2.1417689843872267e-09
particular O 0 4.469205450163827e-09
, O 0 2.525040843082138e-09
some O 0 8.662252248825553e-09
DMD B-Disease 1 0.9987025260925293
isoforms O 0 6.005012664900278e-07
expressed O 0 2.3164551166132696e-08
in O 0 1.2018092299115324e-08
the O 0 5.277657777469358e-08
brain O 0 0.004217610228806734
may O 0 7.079399324538826e-07
be O 0 2.202526827588258e-09
related O 0 3.8841498906094785e-09
to O 0 2.6340289949189355e-09
the O 0 3.8172153438154055e-08
cognitive B-Disease 0 9.440953363082372e-06
impairment I-Disease 0 3.8107373256934807e-06
associated O 0 7.246633231261512e-07
with O 0 1.3389692412602017e-06
DMD B-Disease 1 1.0
. O 0 8.391565984311455e-07
. O 0 8.331886647283682e-07

I1307K O 0 0.0007440725457854569
APC O 0 0.00021146738436073065
and O 0 1.338955257779162e-06
hMLH1 O 0 1.4978651051933412e-05
mutations O 0 1.1821068255812861e-05
in O 0 4.8737419433564355e-08
a O 0 7.494456610857014e-08
non O 0 6.670603625025251e-08
- O 0 4.193718439182703e-07
Jewish O 0 9.228612185552265e-08
family O 0 5.571734362774805e-08
with O 0 5.2355680679738725e-08
hereditary B-Disease 1 0.6347798705101013
non I-Disease 0 0.001683362410403788
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.12170923280064e-05

We O 0 1.4984060499045881e-06
describe O 0 8.028561069295392e-07
a O 0 1.7519779760277743e-07
French O 0 1.6495029058205546e-06
Canadian O 0 5.440783297672169e-06
hereditary B-Disease 0 0.24142129719257355
non I-Disease 0 0.0012804660946130753
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0018691880395635962
HNPCC B-Disease 1 0.9798799157142639
) O 0 4.825890300708124e-07
kindred O 0 3.74765977539937e-06
which O 0 5.2316348586600725e-08
carries O 0 7.681553881866421e-08
a O 0 6.674727615063603e-08
novel O 0 4.637819301933632e-07
truncating O 0 2.2555552277481183e-05
mutation O 0 9.439008863409981e-06
in O 0 4.7383031187564484e-07
hMLH1 O 0 5.875845090486109e-05
. O 0 3.2220862067333655e-06

Interestingly O 0 8.525604789610952e-05
, O 0 1.3386546982019354e-07
the O 0 9.550807078539947e-08
I1307K O 0 2.081975026158034e-06
APC O 0 2.404019596724538e-06
polymorphism O 0 1.5954115042404737e-06
, O 0 5.5873861093402866e-09
associated O 0 6.724766521415404e-09
with O 0 8.065068057838687e-10
an O 0 2.852223124349962e-09
increased O 0 8.299569458358746e-07
risk O 0 5.046046680945437e-06
of O 0 0.0032014804892241955
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.6958871640326834e-07
is O 0 5.081282949959132e-09
also O 0 2.914403385290143e-09
present O 0 3.035631301884223e-09
in O 0 9.257733246670341e-09
this O 0 1.1851667203188754e-08
family O 0 2.7888597742276033e-07
. O 0 2.171332482703292e-07

The O 0 2.8846818622696446e-06
I1307K O 0 1.835566945374012e-05
polymorphism O 0 1.3051986570644658e-05
has O 0 8.031779685779838e-08
previously O 0 2.396103582213982e-08
only O 0 1.4998686737044409e-09
been O 0 1.5681684839563559e-09
identified O 0 2.248080610556258e-09
in O 0 2.254010089686176e-09
individuals O 0 1.0854349641320482e-09
of O 0 1.4658230185204957e-09
self O 0 7.084329354256624e-07
- O 0 1.8254819224239327e-05
reported O 0 7.991031452547759e-06
Ashkenazi O 0 6.338708317343844e-06
Jewish O 0 4.077912194588862e-07
origins O 0 2.040826075244695e-06
. O 0 1.002344788503251e-06

In O 0 1.0481675190021633e-06
addition O 0 6.474861180549851e-08
, O 0 5.133066416362908e-09
in O 0 4.765781991267204e-09
this O 0 1.380950687135396e-09
family O 0 1.0119764581872914e-08
, O 0 5.458742902142433e-10
there O 0 1.161981288966274e-09
appears O 0 2.0543097889458295e-08
to O 0 1.8290019498934385e-09
be O 0 1.602902810482476e-09
no O 0 1.2169611984802486e-09
relationship O 0 4.641206086120064e-09
between O 0 2.9501245890628525e-09
the O 0 7.801059354051176e-09
I1307K O 0 1.7458400236591842e-07
polymorphism O 0 1.6310494288518385e-07
and O 0 2.011568467352731e-09
the O 0 1.6749263087589839e-09
presence O 0 1.3158343747932122e-08
or O 0 9.661745181688275e-09
absence O 0 1.354182010970817e-08
of O 0 5.867918151380991e-09
cancer B-Disease 0 4.603905381372897e-06
. O 0 5.0429932230144914e-08
. O 0 5.186954012970091e-07

Identification O 0 3.87656882594456e-06
of O 0 4.899251493384327e-08
a O 0 1.0114404602745708e-07
novel O 0 1.4183457608396566e-07
mutation O 0 1.6929396906562033e-07
of O 0 2.25947682785943e-09
the O 0 3.1824448853967624e-08
CPO O 0 4.369791895442177e-06
gene O 0 2.7434947469373583e-07
in O 0 1.191467635663912e-08
a O 0 6.87932057985563e-08
Japanese O 0 5.366710411180975e-06
hereditary B-Disease 0 0.21827511489391327
coproporphyria I-Disease 0 0.00025829588412307203
family O 0 4.600341526384e-06
. O 0 1.1818437997135334e-06

Hereditary B-Disease 1 0.9992865920066833
coproporphyria I-Disease 1 0.7843865752220154
( O 0 3.2445808756165206e-05
HCP B-Disease 0 0.010189673863351345
) O 0 1.221820866703638e-07
is O 0 1.3564646295094462e-08
an O 0 6.948354069891138e-08
autosomal B-Disease 1 0.9992414712905884
dominant I-Disease 1 0.9994953870773315
disease I-Disease 1 0.9978793859481812
characterized O 0 1.794856507331133e-05
by O 0 1.3196502379742014e-07
a O 0 1.843603422457818e-05
deficiency B-Disease 0 0.001321749878115952
of I-Disease 0 2.30257484190588e-08
coproporphyrinogen I-Disease 0 0.00016241008415818214
oxidase I-Disease 0 3.665718759293668e-05
( O 0 2.5706100359457196e-07
CPO O 0 2.1365744032664225e-05
) O 0 1.098226221074583e-08
caused O 0 7.475753704966337e-08
by O 0 4.852192869719829e-09
a O 0 3.9430542386753586e-08
mutation O 0 3.177762835093745e-07
in O 0 2.8491472292557773e-08
the O 0 1.1854407233613529e-07
CPO O 0 3.800139165832661e-05
gene O 0 7.618528343300568e-06
. O 0 5.508365461537323e-07

Only O 0 1.3118294646119466e-06
11 O 0 5.41087786132266e-07
mutations O 0 7.248665383485786e-07
of O 0 4.108642759348413e-09
the O 0 1.4857128860512603e-08
gene O 0 3.621402129283524e-07
have O 0 7.02048774670061e-09
been O 0 1.754900225137135e-08
reported O 0 9.521975243842462e-07
in O 0 1.0353071502322564e-06
HCP B-Disease 1 0.9365386962890625
patients O 0 2.235314968856983e-05
. O 0 1.4857434962323168e-06

We O 0 1.1912447916984092e-06
report O 0 3.6652642165790894e-07
another O 0 3.603775766691797e-08
mutation O 0 2.34905584761691e-07
in O 0 1.0190540855603558e-08
a O 0 5.866780128371829e-08
Japanese O 0 2.3210518520500045e-06
family O 0 1.0444634881423553e-06
. O 0 3.345501795593009e-07

Polymerase O 0 0.0011793412268161774
chain O 0 0.0005849626031704247
reaction O 0 3.3029544283635914e-05
- O 0 1.4106438356975559e-05
single O 0 9.40784559588792e-07
strand O 0 5.757181952503743e-06
conformational O 0 1.7742883073879057e-06
polymorphism O 0 2.6790703486767597e-06
and O 0 2.602851445487886e-08
direct O 0 3.5039693813132544e-08
sequence O 0 1.5852999979415472e-07
analyses O 0 1.2453965325676108e-07
demonstrated O 0 6.701644394979667e-08
a O 0 9.294803504644733e-08
C O 0 3.976455445808824e-06
to O 0 3.9324191902778693e-08
T O 0 1.3363106745600817e-06
substitution O 0 5.018314297444704e-08
in O 0 2.2279678546510695e-08
exon O 0 5.005552452530537e-07
1 O 0 9.42267863734969e-09
of O 0 1.229482959885786e-09
the O 0 1.3124330955349706e-08
CPO O 0 1.006763113764464e-06
gene O 0 1.5387132634714362e-07
at O 0 4.708411083242936e-08
nucleotide O 0 1.3153005795629724e-07
position O 0 6.212565750729482e-08
85 O 0 2.3336793830708302e-08
, O 0 1.0757194024435535e-09
which O 0 1.5216382598381983e-09
lies O 0 4.846698598015564e-09
in O 0 2.9385558431016534e-09
the O 0 3.1457505489385085e-09
putative O 0 2.352894199475486e-07
presequence O 0 2.9716434823967575e-07
for O 0 3.3076523742181507e-09
targeting O 0 5.1298393088927696e-08
to O 0 4.1392581806576345e-08
mitochondria O 0 6.648262569797225e-06
. O 0 5.028700797993224e-07

This O 0 4.587072453432484e-06
mutation O 0 1.4327376447909046e-05
changes O 0 4.457026534510078e-07
the O 0 8.219316072199945e-08
codon O 0 1.8128150713891955e-06
for O 0 7.378853528194895e-09
glutamine O 0 4.1660786109787296e-07
to O 0 1.9436166454056547e-08
a O 0 5.401700775564677e-08
termination O 0 7.881928922870429e-07
codon O 0 2.931081553469994e-06
at O 0 2.611195952795242e-07
amino O 0 2.0268173273052525e-07
acid O 0 4.3229644575148996e-07
position O 0 5.697676783711358e-07
29 O 0 1.3236524409876438e-06
. O 0 4.3550750206122757e-07

MaeI O 0 0.0003395751991774887
restriction O 0 5.210799372434849e-06
analysis O 0 3.3253920150855265e-07
showed O 0 1.24788599009662e-07
two O 0 2.837377666153884e-09
other O 0 1.6470667052459476e-09
carriers O 0 1.4062397468705967e-08
in O 0 6.65224186846558e-09
the O 0 2.5837191941491255e-08
family O 0 5.537239076147671e-07
. O 0 2.504666554159485e-07

The O 0 9.267209861718584e-06
C O 0 0.006784358061850071
- O 0 0.003166693728417158
T O 0 0.0006387803005054593
mutation O 0 2.272185156471096e-06
is O 0 6.889086634487285e-09
located O 0 3.405802928568846e-08
within O 0 6.64711796716233e-09
a O 0 2.433674062274349e-08
recently O 0 1.586440276923895e-07
proposed O 0 6.841295174808693e-08
putative O 0 3.232660219509853e-07
alternative O 0 7.628407416859773e-08
translation O 0 2.3632793499928084e-07
initiation O 0 2.472692983701563e-07
codon O 0 2.5412678041902836e-06
( O 0 9.691630964425713e-08
TIC O 0 8.70935673447093e-06
- O 0 1.4494949027721304e-06
1 O 0 2.4539550835811497e-08
) O 0 3.0286220198405545e-09
, O 0 7.815053604254274e-10
supporting O 0 3.539305293287498e-09
that O 0 4.6497565797665175e-09
TIC O 0 7.747886229481082e-06
- O 0 1.0680317927835858e-06
1 O 0 1.5672364739316436e-08
is O 0 1.4300631789865292e-09
the O 0 5.0939661377924494e-09
real O 0 3.402692883014424e-08
TIC O 0 1.7964053995456197e-06
rather O 0 3.3153597200907825e-08
than O 0 2.4825261846217472e-08
TIC O 0 9.156529813481029e-06
- O 0 1.5309262835216941e-06
2 O 0 5.12620097481431e-08
. O 0 2.143302602064523e-08
. O 0 2.4831805944813823e-07

Human B-Disease 0 1.7597287296666764e-05
complement I-Disease 0 4.8024994612205774e-05
factor I-Disease 0 0.00016465091903228313
H I-Disease 1 1.0
deficiency I-Disease 1 0.9995478987693787
associated O 0 5.4052721679909155e-05
with O 0 0.015629161149263382
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00013435736764222383

This O 0 1.1085614914918551e-06
study O 0 2.063476074454229e-07
reports O 0 2.0937474687343638e-07
on O 0 8.924978089908109e-08
six O 0 1.2099213186900215e-08
cases O 0 6.777948868830208e-09
of O 0 1.03847144217184e-08
deficiency B-Disease 0 1.5444864402525127e-05
in I-Disease 0 3.585604702038836e-09
the I-Disease 0 3.861966302309838e-09
human I-Disease 0 7.842801963420243e-09
complement I-Disease 0 4.8191850510193035e-08
regulatory I-Disease 0 4.638173152216041e-07
protein I-Disease 0 5.899207735637901e-07
Factor I-Disease 0 6.067280082788784e-07
H I-Disease 1 0.9999932050704956
( O 0 5.22809898484411e-07
FH O 0 2.3140864868764766e-05
) O 0 4.802226172273549e-09
in O 0 1.9183210575590692e-09
the O 0 2.1140447170608923e-09
context O 0 9.13090936194294e-09
of O 0 2.486093109155263e-09
an O 0 1.3144293689038022e-06
acute B-Disease 1 0.9999984502792358
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 6.233648309716955e-05

Five O 0 3.0039259968361876e-07
of O 0 4.954079368957309e-09
the O 0 6.261503315840855e-09
cases O 0 3.5475371529258837e-09
were O 0 5.7630229477467765e-09
observed O 0 2.7430779425685614e-08
in O 0 1.5620496895962788e-08
children O 0 1.809598515478683e-08
presenting O 0 4.5706914875154325e-07
with O 0 7.874591392464936e-05
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0005984679446555674
HUS B-Disease 1 0.9999927282333374
) O 0 2.683647380763432e-06
. O 0 1.6286073787341593e-06

Two O 0 1.446952069272811e-07
of O 0 1.72321072966497e-08
the O 0 2.4273138166108765e-08
children O 0 1.6626376719841574e-08
exhibited O 0 1.0152263030249742e-06
a O 0 1.916442442961852e-06
homozygous O 1 0.7903385162353516
deficiency O 0 0.09779734909534454
characterized O 0 3.2871830057956686e-07
by O 0 1.1081302986326591e-08
the O 0 2.7483201492373155e-08
absence O 0 2.6744695347247216e-08
of O 0 1.3073132576479907e-09
the O 0 7.143732272396619e-09
150 O 0 1.9243026727622237e-08
- O 0 2.6231663241560454e-07
kD O 0 4.386495788821776e-07
form O 0 1.2670824389715563e-08
of O 0 2.472035465217459e-09
Factor O 0 4.323953817220172e-08
H O 1 0.7047971487045288
and O 0 1.9246171323317185e-09
the O 0 1.09378972545926e-09
presence O 0 3.1470588357507268e-09
, O 0 3.9757347414237643e-10
upon O 0 2.3784354485911763e-09
immunoblotting O 0 1.6282551484891883e-07
, O 0 5.048040319088898e-10
of O 0 1.5811997544634693e-10
the O 0 1.1186869208756889e-08
42 O 0 1.1624234730334138e-07
- O 0 8.743557486923237e-07
kD O 0 2.9082107175781857e-06
Factor O 0 3.0557214358850615e-07
H O 1 0.9817522764205933
- O 0 1.3128283171681687e-06
like O 0 4.2366018249140325e-08
protein O 0 1.1366238794607852e-07
1 O 0 4.247630513987133e-08
( O 0 5.841500083647588e-08
FHL O 0 1.916843575600069e-05
- O 0 1.689889245426457e-06
1 O 0 4.640031292524327e-08
) O 0 3.598142006566718e-09
and O 0 2.792109654592423e-09
other O 0 4.925756247331492e-09
FH O 0 7.235804514493793e-05
- O 0 1.0529736300668446e-06
related O 0 2.8185175438011356e-07
protein O 0 1.2111667047065566e-06
( O 0 1.0740043876467098e-07
FHR O 0 8.985184649645817e-06
) O 0 6.170606781097376e-08
bands O 0 1.3784720067633316e-06
. O 0 4.972238230038784e-07

Southern O 0 4.366510984255001e-05
blot O 0 0.0010433814022690058
and O 0 6.153904905659147e-07
PCR O 0 1.0886038580792956e-05
analysis O 0 4.509796269758226e-08
of O 0 1.4226468891820332e-09
DNA O 0 2.8716575783960252e-08
of O 0 1.592049603260648e-09
one O 0 7.474453944666948e-09
patient O 0 3.1987607940209273e-07
with O 0 2.425676086659223e-07
homozygous O 0 0.17469632625579834
deficiency O 0 0.02413213439285755
ruled O 0 1.1564063129299029e-07
out O 0 3.3930540599413916e-09
the O 0 2.0643797782327056e-09
presence O 0 4.129998121271683e-09
of O 0 4.1467143607754053e-10
a O 0 2.6837734257156853e-09
large O 0 2.5875841469513716e-09
deletion O 0 8.513042359936662e-08
of O 0 2.0382129317653153e-09
the O 0 4.9524945922030383e-08
FH O 0 1.7146332538686693e-05
gene O 0 2.524944306969701e-07
as O 0 9.789069110865967e-09
the O 0 2.5136394299352105e-08
underlying O 0 1.4330669273476815e-06
defect O 0 3.713597607202246e-06
for O 0 2.4313033364364856e-08
the O 0 4.586822797136847e-06
deficiency O 0 0.01097828708589077
. O 0 1.0889089026022702e-06

The O 0 4.3345025346752664e-07
other O 0 6.094063031980568e-09
four O 0 5.59045609804798e-09
children O 0 3.288967986847524e-09
presented O 0 1.6414601233805115e-08
with O 0 9.015244728516336e-08
heterozygous O 0 0.06678356230258942
deficiency O 0 0.0013976735062897205
and O 0 2.09821440222413e-08
exhibited O 0 2.2283561520453077e-06
a O 0 1.964098998996633e-07
normal O 0 4.6197519623092376e-06
immunoblotting O 0 1.0951692274829838e-05
pattern O 0 8.424080419899838e-07
of O 0 2.2122694787185537e-09
proteins O 0 1.7799706597543263e-08
of O 0 3.506695600563603e-09
the O 0 1.5643880146853917e-07
FH O 0 0.0008368211565539241
family O 0 8.091128052001295e-07
. O 0 5.612263862531108e-07

Factor B-Disease 0 0.0043963901698589325
H I-Disease 1 1.0
deficiency I-Disease 1 0.9952318072319031
is O 0 5.567495975355996e-08
the O 0 6.92352273290453e-08
only O 0 2.655513071658788e-07
complement B-Disease 1 0.9999946355819702
deficiency I-Disease 1 1.0
associated O 0 2.5318092866655206e-06
with O 0 1.4089802107264404e-06
HUS B-Disease 1 0.9999850988388062
. O 0 6.589798431377858e-06

These O 0 6.891111752338475e-07
observations O 0 1.3600744068753556e-06
suggest O 0 2.0026654112825781e-07
a O 0 6.791319151489006e-08
role O 0 1.20552655857864e-07
for O 0 3.675533832847577e-08
FH O 0 0.0003005294711329043
and O 0 3.38741756422678e-07
/ O 0 9.78330645011738e-05
or O 0 2.415404424027656e-06
FH O 0 0.00016883874195627868
receptors O 0 1.940781203302322e-06
in O 0 4.738601333542647e-08
the O 0 7.227983900293111e-08
pathogenesis O 0 7.2061502578435466e-06
of O 0 9.482051410714121e-08
idiopathic O 1 0.7880704402923584
HUS B-Disease 1 0.9999603033065796
. O 0 1.7162327594633098e-06
. O 0 2.573742904132814e-06

Further O 0 1.0410237791802501e-06
evidence O 0 7.120921452496987e-08
for O 0 4.686609322845925e-09
a O 0 8.636088288938026e-09
major O 0 1.311344632881628e-08
ancient O 0 1.4644578527622798e-07
mutation O 0 0.0007133713806979358
underlying O 0 0.13330847024917603
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.4278052731242497e-05
linkage O 0 0.00016860917094163597
disequilibrium O 0 0.0001426593807991594
studies O 0 2.4544610255361476e-07
in O 0 2.1685918838443285e-08
the O 0 1.4050063334991592e-08
Japanese O 0 3.671799788662611e-07
population O 0 1.4128377756605914e-07
. O 0 3.447712231263722e-07

The O 0 0.001794100971892476
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9487274289131165
DM B-Disease 1 1.0
) O 0 4.15652812080225e-06
mutation O 0 1.2257708476681728e-05
is O 0 3.783357627185069e-08
an O 0 4.178986401370821e-08
unstable O 0 0.00013452040730044246
( O 0 2.406129340215557e-07
CTG O 0 6.2833614720148034e-06
) O 0 4.174031431602998e-08
n O 0 4.526998509390978e-07
repeat O 0 8.862973004397645e-07
, O 0 4.547983323277549e-09
present O 0 7.666606016698552e-09
at O 0 3.092607769872302e-08
a O 0 5.301566297077898e-09
copy O 0 6.002721875120187e-08
number O 0 5.723289620007677e-10
of O 0 4.4955353328823833e-10
5 O 0 3.6966188332598904e-08
- O 0 7.937704253890843e-07
37 O 0 8.571240073251829e-08
repeats O 0 4.703994704868819e-07
on O 0 1.0874419587025841e-07
normal O 0 2.090620796479925e-07
chromosomes O 0 1.264764932784601e-07
but O 0 5.0204178592139215e-09
amplified O 0 3.3493230944259267e-07
to O 0 1.0707579711777271e-08
50 O 0 2.004510690767347e-08
- O 0 9.985743787410684e-08
3000 O 0 1.4418304772334523e-07
copies O 0 1.1908399244475731e-07
on O 0 5.60282705919235e-06
DM B-Disease 1 0.9999997615814209
chromosomes O 0 2.3648406568099745e-05
. O 0 1.1124927823402686e-06

Previous O 0 1.7087633750634268e-05
findings O 0 5.474113550008042e-06
in O 0 2.135507202183362e-07
Caucasian O 0 2.0063714600837557e-06
populations O 0 1.960206645890139e-07
of O 0 1.0334762379216045e-08
a O 0 5.7754109548113775e-06
DM B-Disease 1 1.0
founder O 0 2.6943387638311833e-05
chromosome O 0 1.478620197303826e-05
raise O 0 2.9886101060583314e-07
a O 0 3.260923264747362e-08
question O 0 5.7942255438092616e-09
about O 0 9.438592130095458e-10
the O 0 1.871140131726179e-09
molecular O 0 2.3409370442095678e-08
events O 0 5.894818855267658e-09
involved O 0 4.220880089889079e-09
in O 0 6.087081061423305e-09
the O 0 2.8123304574023678e-08
expansion O 0 1.4471771692114999e-06
mutation O 0 7.129283858375857e-06
. O 0 4.6566017886107147e-07

To O 0 2.505981001377222e-06
investigate O 0 1.769472532942018e-06
whether O 0 1.4075121157475223e-07
a O 0 7.82326381454368e-08
founder O 0 6.514998176498921e-07
chromosome O 0 1.0701207884267205e-06
for O 0 1.7216960301880135e-08
the O 0 6.77998059472884e-07
DM B-Disease 1 1.0
mutation O 0 4.976297987013822e-06
exists O 0 2.030101420302799e-08
in O 0 2.9389257694134585e-09
the O 0 2.8290716436174534e-09
Japanese O 0 2.217733374720865e-08
population O 0 2.6068447400717787e-09
, O 0 1.4598103836860332e-09
we O 0 1.5443542000781463e-09
genotyped O 0 2.869533943794522e-07
families O 0 1.1183541204218272e-08
using O 0 7.121369804963251e-08
polymorphic O 0 4.14125133829657e-06
markers O 0 1.057256213243818e-06
near O 0 1.1312864671708667e-06
the O 0 1.4863087471894687e-07
( O 0 9.625622965359071e-08
CTG O 0 4.687345608545002e-06
) O 0 4.5597374764838605e-08
n O 0 3.553258522970282e-07
repeat O 0 5.094357220514212e-07
region O 0 1.3727270697927452e-07
and O 0 6.725846191102391e-08
constructed O 0 3.134868393317447e-06
haplotypes O 0 3.059183291043155e-05
. O 0 1.2090445125068072e-06

Six O 0 1.6590635141255916e-06
different O 0 2.0041557036165614e-07
haplotypes O 0 4.1284356484538876e-06
were O 0 1.1508240049806773e-07
found O 0 8.401642048738722e-08
and O 0 8.131011668410792e-07
DM B-Disease 1 1.0
alleles O 0 1.2000625247310381e-05
were O 0 3.1818868251320964e-07
always O 0 2.0396419131429866e-07
haplotype O 0 2.2638170776190236e-05
A O 0 1.369266556139337e-06
. O 0 8.105254210022395e-07

To O 0 4.064555980676232e-07
find O 0 3.6126124314250774e-08
an O 0 1.4743190002164397e-09
origin O 0 2.3037640684009375e-09
of O 0 1.2967907858651984e-09
the O 0 2.0139687251230498e-08
( O 0 4.4390993991783034e-08
CTG O 0 2.392887154201162e-06
) O 0 1.0644210846066926e-08
n O 0 1.5305525380426843e-07
repeat O 0 3.7698808341701806e-07
mutation O 0 2.488566508418444e-07
and O 0 5.381244339019986e-09
to O 0 4.935649666748532e-09
investigate O 0 2.8157494114111614e-08
the O 0 3.1863061078496457e-09
mechanism O 0 1.130652460545889e-08
of O 0 4.4655565356599425e-10
the O 0 1.5477719106371524e-09
expansion O 0 1.6683941339579178e-08
mutation O 0 4.294848210406599e-08
in O 0 2.1553088203063453e-09
the O 0 2.647083441331688e-09
Japanese O 0 4.227916150512101e-08
population O 0 5.544105619037509e-09
we O 0 9.563759784114723e-10
have O 0 1.317305264869617e-09
studied O 0 2.130130738464686e-08
90 O 0 3.128089787196586e-08
Japanese O 0 3.626092393460567e-06
DM B-Disease 1 0.9999997615814209
families O 0 6.236250271740573e-08
comprising O 0 1.7162500753897802e-08
190 O 0 1.3855941460860777e-07
affected O 0 1.0293356211832361e-07
and O 0 1.706210461804858e-08
130 O 0 3.652758095995523e-07
unaffected O 0 1.663278635533061e-05
members O 0 1.3720830338570522e-07
. O 0 4.4672052013083885e-07

The O 0 9.427263307770772e-07
results O 0 4.981123424840916e-07
suggest O 0 6.362633797607486e-08
that O 0 2.0320722882161135e-09
a O 0 5.704111405435697e-09
few O 0 5.642518896564752e-09
common O 0 1.3423398392831132e-08
ancestral O 0 1.7055052126124792e-07
mutations O 0 2.9802060907968553e-07
in O 0 9.094877739812546e-09
both O 0 7.65028929095024e-09
Caucasian O 0 1.6600527885657357e-07
and O 0 8.283223884575364e-09
Japanese O 0 7.235998822352485e-08
populations O 0 1.1565823854198243e-08
have O 0 1.247594472175706e-09
originated O 0 1.0188324850446406e-08
by O 0 8.523968197948761e-10
expansion O 0 3.3359925932785472e-09
of O 0 3.071881915506225e-10
an O 0 2.4989956770582467e-09
ancestral O 0 1.9162234821124002e-07
n O 0 3.158823744797701e-07
= O 0 1.6902875188407052e-07
5 O 0 3.211157206806092e-08
repeat O 0 4.337343284532835e-07
to O 0 2.9617854835350954e-08
n O 0 8.196159342332976e-07
= O 0 4.4075798655285325e-07
19 O 0 1.8261937384522753e-07
- O 0 1.046264969772892e-06
37 O 0 2.105458918322256e-07
copies O 0 4.0136947632163356e-07
. O 0 3.8920097722439095e-07

These O 0 8.54945653827599e-07
data O 0 5.981955268907768e-07
support O 0 7.555873082765174e-08
multistep O 0 1.9361630165803945e-06
models O 0 3.3508533192616596e-07
of O 0 9.706297099398853e-09
triplet O 0 6.509832928713877e-06
repeat O 0 4.802255944014178e-07
expansion O 0 3.727004482811935e-08
that O 0 6.5040701713314775e-09
have O 0 1.6528257651415856e-09
been O 0 2.3218635902821916e-09
proposed O 0 8.402119000550101e-09
for O 0 2.7403415092663863e-09
both O 0 1.4220567834399844e-07
DM B-Disease 1 1.0
and O 0 1.4644427892562817e-06
Friedreichs B-Disease 0 0.0026348624378442764
ataxia I-Disease 1 0.9990948438644409
. O 0 5.972196390757745e-07
. O 0 6.511594961011724e-07

The O 0 8.685183843226696e-07
molecular O 0 3.667589680844685e-06
basis O 0 5.848233399774472e-07
of O 0 2.0995369141019182e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.659613826011991e-08
the O 0 1.8954667169168715e-08
western O 0 1.036038526081029e-07
Cape O 0 2.278417014167644e-06
, O 0 1.5030799715987087e-08
South O 0 7.365090937128116e-08
Africa O 0 2.3692685147125303e-07
. O 0 3.414855029859609e-07

Deficiency B-Disease 1 0.9909672141075134
of I-Disease 0 1.2640920488138363e-07
the I-Disease 0 1.0311060805179295e-07
sixth I-Disease 0 1.932306474827783e-07
component I-Disease 0 9.002666701007911e-08
of I-Disease 0 2.6411022258088224e-09
human I-Disease 0 1.7241641003806762e-08
complement I-Disease 0 1.8454556993674487e-07
( O 0 9.422646485290898e-08
C6 O 0 3.473192919045687e-05
) O 0 8.313818966598774e-09
has O 0 4.17472989511225e-09
been O 0 4.420020349726883e-09
reported O 0 6.781481687312407e-08
in O 0 3.1629938668231716e-09
a O 0 3.169903006750019e-09
number O 0 5.628950638936203e-10
of O 0 2.2280421951847984e-10
families O 0 8.678139873374846e-10
from O 0 1.4547987259305728e-09
the O 0 2.850928604303249e-09
western O 0 5.822467841198886e-08
Cape O 0 1.057352960742719e-06
, O 0 6.742271629889274e-09
South O 0 6.289431553341274e-08
Africa O 0 1.9255790562056063e-07
. O 0 3.675674520309258e-07

Meningococcal B-Disease 1 0.9999455213546753
disease I-Disease 1 0.9999006986618042
is O 0 2.9728792583227914e-07
endemic O 0 6.856801064714091e-07
in O 0 3.960344585607345e-08
the O 0 6.496471627315259e-08
Cape O 0 3.388485083632986e-06
and O 0 8.2633881959282e-09
almost O 0 5.229806365747436e-09
all O 0 5.806989888945679e-10
pedigrees O 0 1.1948840494824253e-07
of O 0 1.2287966200119627e-08
total O 0 1.6878823316801572e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.5310006296640495e-07
C6Q0 O 0 6.787011079723015e-05
) O 0 2.8235259463826878e-08
have O 0 4.5951993321580176e-09
been O 0 8.421548791659461e-09
ascertained O 0 9.279835211373211e-08
because O 0 9.662722177949945e-09
of O 0 2.6790083040850732e-08
recurrent O 0 0.02507384866476059
disease O 1 0.6445072889328003
. O 0 3.5630180263979128e-06

We O 0 9.676905392552726e-07
have O 0 4.135044662234577e-08
sequenced O 0 3.84921321483489e-07
the O 0 1.8399266110691315e-08
expressed O 0 3.1889218377045836e-08
exons O 0 3.031461801583646e-07
of O 0 5.085131871140902e-09
the O 0 4.514271623179411e-08
C6 O 0 1.0269407539453823e-05
gene O 0 1.7584828526651108e-07
from O 0 6.786292860994081e-09
selected O 0 4.656670604674673e-09
cases O 0 1.3297557499569734e-09
and O 0 2.066416371349078e-09
have O 0 7.431448234562765e-10
found O 0 1.9487977898080544e-09
three O 0 3.5115814700503734e-09
molecular O 0 5.535377113119466e-06
defects O 0 0.029618535190820694
leading O 0 4.933939479201399e-08
to O 0 3.0320336463773856e-08
total O 0 8.240726856456604e-08
deficiency O 0 0.00011158124107168987
879delG O 0 1.0764299531729193e-06
, O 0 6.236830607520005e-09
which O 0 4.2560137636371564e-09
is O 0 8.484698499344745e-10
the O 0 6.149490694440374e-09
common O 0 1.471597954605386e-07
defect O 0 1.017974796013732e-06
in O 0 1.1679702538458514e-08
the O 0 2.199488768894753e-08
Cape O 0 6.01654051024525e-07
and O 0 6.7038277151709735e-09
hitherto O 0 5.789411972045855e-08
unreported O 0 1.535019045206809e-08
, O 0 2.0066366346327413e-09
and O 0 1.9180832477871945e-09
1195delC O 0 8.346760438371348e-08
and O 0 3.782915758421268e-09
1936delG O 0 1.5464749480997853e-07
, O 0 2.850134794840642e-09
which O 0 2.6445048373346935e-09
have O 0 5.819597581613323e-10
been O 0 1.2491041534445912e-09
previously O 0 8.762087055913526e-09
reported O 0 2.7550907333306895e-08
in O 0 7.645679644951997e-09
African O 0 2.5446231788350815e-08
- O 0 1.4416863223232212e-06
Americans O 0 1.6923941359436867e-07
. O 0 2.50443974891823e-07

We O 0 6.142635697869991e-07
also O 0 4.201147874027811e-08
show O 0 4.199089076450946e-08
that O 0 1.6203564046080032e-09
the O 0 6.809644848004837e-09
879delG O 0 7.687393122068897e-07
and O 0 7.389913037059159e-08
1195delC O 0 7.609558815602213e-05
defects O 0 0.09356037527322769
are O 0 2.560854861499706e-09
associated O 0 5.6865602005018445e-08
with O 0 4.456830637877829e-08
characteristic O 0 0.0006624918314628303
C6 O 1 0.9712467789649963
/ O 0 0.010189169086515903
C7 O 0 8.958933176472783e-05
region O 0 3.484376236428943e-07
DNA O 0 2.768621698123752e-06
marker O 0 2.6994487143383594e-06
haplotypes O 0 1.5543187146249693e-06
, O 0 6.803270391486649e-09
although O 0 8.439219989497815e-09
small O 0 1.5850817547402585e-08
variations O 0 3.274180073731259e-07
were O 0 6.581330325161616e-08
observed O 0 8.971294960247178e-07
. O 0 4.410022711454076e-07

The O 0 5.186762791709043e-06
1936delG O 0 0.00011765929230023175
defect O 0 0.0003101677866652608
was O 0 3.484376236428943e-07
observed O 0 9.423958147181111e-08
only O 0 2.825873757217323e-09
once O 0 5.113717893578951e-09
in O 0 3.487618416286864e-09
the O 0 9.409567347518077e-09
Cape O 0 2.0393035526922176e-07
, O 0 8.567422882244102e-10
but O 0 5.30176569313312e-10
its O 0 4.48489245741257e-09
associated O 0 2.5546409432308792e-08
haplotype O 0 3.1654960821470013e-06
could O 0 5.570214867134382e-08
be O 0 1.8464092477188387e-08
deduced O 0 7.35944524876686e-07
. O 0 2.5212412424480135e-07

The O 0 1.011125846162031e-06
data O 0 1.0095822062794468e-06
from O 0 1.861394949287387e-08
the O 0 1.1344802430812706e-08
haplotypes O 0 5.627109089800797e-07
indicate O 0 1.4626796485117666e-07
that O 0 1.48848333658691e-09
these O 0 1.0781514570012973e-09
three O 0 2.9994240424713325e-09
molecular O 0 1.959647534022224e-06
defects O 0 0.021151520311832428
account O 0 1.738814070506578e-08
for O 0 3.840121554077314e-09
the O 0 2.1805221877002623e-06
defects O 1 0.7994986176490784
in O 0 1.0992069476856159e-08
all O 0 1.2758096801235297e-09
the O 0 6.82927181472337e-09
38 O 0 3.531943093548762e-08
unrelated O 0 4.3044927622304385e-08
C6Q0 O 0 1.8211898122899584e-06
individuals O 0 2.7105240274494236e-09
we O 0 1.0901614055924824e-09
have O 0 1.0425076357734042e-09
studied O 0 6.458909851403405e-09
from O 0 6.769357518976449e-09
the O 0 5.092715227306144e-08
Cape O 0 9.359447176393587e-06
. O 0 7.765609666421369e-07

We O 0 7.849807843740564e-07
have O 0 2.0600934291792328e-08
also O 0 8.854877719954857e-09
observed O 0 4.058695068920315e-08
the O 0 1.4114823088107187e-08
879delG O 0 2.973207301693037e-06
defect O 0 2.2441206510848133e-06
in O 0 2.5788255086922618e-08
two O 0 1.1405622757365563e-07
Dutch O 1 0.9253730773925781
C6 B-Disease 1 1.0
- I-Disease 1 0.9999635219573975
deficient I-Disease 1 0.9999998807907104
kindreds O 0 2.296577804372646e-05
, O 0 1.7375542782360753e-08
but O 0 6.854732337302494e-09
the O 0 8.983863430955807e-09
879delG O 0 8.848531365401868e-07
defect O 0 3.128651258066384e-07
in O 0 4.0636813913863534e-09
the O 0 1.501360813449537e-08
Cape O 0 2.008300953093567e-06
probably O 0 1.3815947852435784e-07
did O 0 1.5450353885171353e-08
not O 0 1.4732788322646684e-09
come O 0 2.277280586326924e-09
from O 0 3.0964841801761622e-09
The O 0 1.2959829653880206e-08
Netherlands O 0 3.555041416802851e-07
. O 0 2.567267820552388e-08
. O 0 1.597898062755121e-07

Complement B-Disease 1 0.9955464601516724
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.295536655263277e-07
seven O 0 7.181139238809919e-08
further O 0 1.437258987380119e-07
molecular O 0 0.0001204813233925961
defects O 1 0.9788652658462524
and O 0 4.7246938805756145e-08
their O 0 6.14046768987464e-08
associated O 0 2.5247879875678336e-06
marker O 0 2.732787652348634e-05
haplotypes O 0 7.500584615627304e-05
. O 0 2.409898343103123e-06

Seven O 0 1.3474594879880897e-06
further O 0 3.295026260730083e-07
molecular O 0 1.0357169912822428e-06
bases O 0 8.684538101988437e-07
of O 0 2.3701638838247163e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.0365287295144299e-07
described O 0 2.8520398700493388e-06
. O 0 9.684172255219892e-07

All O 0 3.2358249768549285e-07
these O 0 3.7774736227902395e-08
new O 0 1.896161450076761e-07
molecular O 0 2.3488646547775716e-05
defects O 0 0.013295075856149197
involve O 0 4.985428603276887e-08
single O 0 3.5522691632650094e-07
- O 0 1.2159035804870655e-06
nucleotide O 0 2.5858548724499997e-07
events O 0 1.6076096898132164e-08
, O 0 2.57477905662995e-09
deletions O 0 1.2918027891828388e-07
and O 0 4.66067762161515e-09
substitutions O 0 3.029773054663565e-08
, O 0 1.4219362354239706e-09
some O 0 2.589375380779302e-10
of O 0 5.652641688058679e-10
which O 0 9.592281635661948e-09
alter O 0 8.305230494443094e-07
splice O 0 1.9969527329521952e-06
sites O 0 4.7421185200846594e-08
, O 0 2.4144206633991416e-09
and O 0 5.209834341712849e-09
others O 0 3.6051986285201565e-08
codons O 0 2.5243930394935887e-06
. O 0 4.979033860763593e-07

They O 0 6.042906193215458e-07
are O 0 7.695804882246193e-09
distributed O 0 9.982559667776059e-09
along O 0 7.59846052744706e-09
the O 0 2.061209691817112e-08
C7 O 0 1.099014207284199e-05
gene O 0 4.04921593144536e-07
, O 0 3.368158418837197e-09
but O 0 1.2119276693312031e-09
predominantly O 0 5.103545142048915e-09
towards O 0 5.851020556946196e-09
the O 0 1.77972285797523e-08
3 O 0 1.7802737772854016e-07
end O 0 1.327118297922425e-06
. O 0 3.8486001585624763e-07

All O 0 3.2050269282990484e-07
were O 0 3.807928905530389e-08
found O 0 5.995945517867085e-09
in O 0 7.434301618758354e-09
compound O 0 3.8426736637120484e-07
heterozygous O 0 3.440772616158938e-06
individuals O 0 5.575869721496929e-08
. O 0 1.8521944866733975e-07

The O 0 7.243363506859168e-05
C6 O 1 0.8858130574226379
/ O 0 0.04413366690278053
C7 O 0 0.0024475688114762306
marker O 0 3.670074147521518e-05
haplotypes O 0 3.775640652747825e-05
associated O 0 1.4648185242549516e-06
with O 0 1.3941023269126163e-07
most O 0 2.989045697177062e-06
C7 B-Disease 1 0.9999953508377075
defects I-Disease 1 0.9999942779541016
are O 0 6.11593335975158e-08
tabulated O 0 1.1748442375392187e-05
. O 0 1.2222101020142873e-07
. O 0 6.783816388633568e-07

A O 0 6.491117801488144e-06
genome O 0 6.481573109340388e-06
- O 0 1.7797997315938119e-06
wide O 0 2.7193499363420415e-07
search O 0 1.458998895031982e-07
for O 0 2.174606095195486e-08
chromosomal O 0 9.411160135641694e-05
loci O 0 3.197734713467071e-06
linked O 0 3.0038914701435715e-05
to O 0 1.6393329360653297e-06
mental O 0 6.550903344759718e-05
health O 0 1.1701150697263074e-06
wellness O 0 1.1751878901122836e-06
in O 0 3.5169925638456334e-08
relatives O 0 7.225117570897055e-08
at O 0 1.023262939270353e-06
high O 0 1.1188905773451552e-05
risk O 0 2.6899790555034997e-06
for O 0 1.5463407407878549e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 0.9991973042488098
disorder I-Disease 1 0.9934600591659546
among O 0 3.612749921444447e-08
the O 0 7.12695396032359e-08
Old O 0 5.802340183436172e-06
Order O 0 1.7083537784401415e-07
Amish O 0 1.6840631360537373e-05
. O 0 7.51261723053176e-07

Bipolar B-Disease 1 0.9999998807907104
affective I-Disease 1 0.9999979734420776
disorder I-Disease 1 0.9999998807907104
( O 0 0.0008439713274128735
BPAD B-Disease 1 1.0
; O 0 0.3973828852176666
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9999521970748901
) O 0 2.783009449558449e-07
is O 0 2.2231457563748336e-08
characterized O 0 1.9843724885504344e-07
by O 0 1.0062831456991717e-08
episodes O 0 1.0433739561221955e-07
of O 0 8.303486787042402e-09
mania B-Disease 0 0.00013694935478270054
and O 0 4.584831856391247e-07
/ O 0 0.0010183131089434028
or O 0 1.7543800368002849e-06
hypomania B-Disease 0 0.00031950254924595356
interspersed O 0 2.2096617158240406e-06
with O 0 2.871066229204189e-08
periods O 0 1.0851581464521587e-06
of O 0 8.344945712224217e-08
depression B-Disease 0 0.0003382837167009711
. O 0 1.6645375353618874e-06

Compelling O 0 6.919753104739357e-06
evidence O 0 6.158520022836456e-07
supports O 0 2.6388460128146107e-07
a O 0 2.796780229630258e-08
significant O 0 1.484982004029689e-08
genetic O 0 1.2780148495039612e-07
component O 0 6.110710160101007e-08
in O 0 9.304254255937394e-09
the O 0 2.986962854834019e-08
susceptibility O 0 2.3036875518300803e-06
to O 0 1.4341166831854935e-07
develop O 0 4.974485364073189e-06
BPAD B-Disease 1 0.9999998807907104
. O 0 3.7604154385917354e-06

To O 0 1.0963874501612736e-06
date O 0 3.686346303766186e-07
, O 0 8.916687832538628e-09
however O 0 6.0609801622035775e-09
, O 0 2.049362013423206e-09
linkage O 0 7.747295427407153e-08
studies O 0 4.797758190733248e-09
have O 0 9.208453999320909e-10
attempted O 0 3.177774487994611e-08
only O 0 2.067512383518988e-09
to O 0 5.858423968163606e-09
identify O 0 1.3258517128633684e-07
chromosomal O 0 1.4363739865075331e-05
loci O 0 2.1442845365982066e-07
that O 0 6.149724729453965e-09
cause O 0 9.86541692782339e-08
or O 0 2.7047155626291897e-08
increase O 0 3.911189949690197e-08
the O 0 5.086968002387948e-08
risk O 0 2.501434437363059e-07
of O 0 2.8231706750148078e-08
developing O 0 3.0123023861960974e-06
BPAD B-Disease 1 0.9999996423721313
. O 0 6.251844297366915e-06

To O 0 4.918318836644175e-07
determine O 0 6.136897212627446e-08
whether O 0 1.2980709840348936e-08
there O 0 2.667208898188278e-09
could O 0 9.900700703724397e-09
be O 0 5.3669251265375806e-09
protective O 0 3.0950306495469704e-07
alleles O 0 9.637748377144817e-08
that O 0 1.2336571764137716e-09
prevent O 0 1.582133535293906e-08
or O 0 1.0023829766225845e-08
reduce O 0 5.027300531423862e-08
the O 0 8.92189344625649e-09
risk O 0 1.767810786645896e-08
of O 0 1.7882901826027364e-09
developing O 0 8.413861962708324e-08
BPAD B-Disease 1 0.9999998807907104
, O 0 1.5158020616468093e-08
similar O 0 1.8771034504538875e-08
to O 0 6.725240808691524e-09
what O 0 1.53064450003626e-09
is O 0 1.1063389093735054e-09
observed O 0 8.07922173606812e-09
in O 0 1.079279421389856e-08
other O 0 1.418289059529343e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 7.151314207476389e-08
we O 0 1.8430384329803928e-08
used O 0 6.9721436375402845e-06
mental O 0 3.732825643965043e-05
health O 0 2.1993182599544525e-06
wellness O 0 4.7440453272429295e-06
( O 0 2.1183888421205666e-08
absence O 0 2.6895191851394884e-08
of O 0 3.82345799465611e-09
any O 0 7.031894710962661e-07
psychiatric B-Disease 1 0.9994871616363525
disorder I-Disease 1 0.6128227114677429
) O 0 1.6530851354445986e-08
as O 0 5.0793258488113224e-09
the O 0 2.5105777012868202e-08
phenotype O 0 1.9125095604977105e-06
in O 0 1.9851214005939255e-08
our O 0 3.681953941736538e-08
genome O 0 3.313413117211894e-07
- O 0 1.3258558055895264e-06
wide O 0 1.7050139433649747e-07
linkage O 0 1.1320485100441147e-06
scan O 0 8.470495231449604e-06
of O 0 1.0789537041588915e-09
several O 0 2.3377100255572714e-09
large O 0 6.595112900242839e-09
multigeneration O 0 2.479891236362164e-06
Old O 0 3.7422415744003956e-07
Order O 0 3.0066715339671646e-08
Amish O 0 8.409656402363908e-07
pedigrees O 0 1.5906836097201449e-06
exhibiting O 0 6.094124387345801e-07
an O 0 2.5092948163774054e-08
extremely O 0 2.99690373140038e-06
high O 0 8.095782686723396e-05
incidence O 0 8.020937093533576e-05
of O 0 2.9288443670338893e-07
BPAD B-Disease 1 1.0
. O 0 8.49134630698245e-06

We O 0 4.2769133301590045e-07
have O 0 1.18353575828678e-08
found O 0 9.766316644288509e-09
strong O 0 1.0672835060177022e-08
evidence O 0 4.093951844197363e-09
for O 0 1.04654795940462e-09
a O 0 1.612889022339914e-08
locus O 0 7.394346539513208e-07
on O 0 4.128453383600572e-07
chromosome O 0 3.768220267375e-05
4p O 0 8.854744373820722e-05
at O 0 7.112266757758334e-07
D4S2949 O 0 2.8522520096885273e-06
( O 0 1.0776343373208874e-07
maximum O 0 2.94398887490388e-07
GENEHUNTER O 0 8.538524707546458e-05
- O 0 5.197339760343311e-06
PLUS O 0 9.932809916790575e-07
nonparametric O 0 5.848462478752481e-06
linkage O 0 2.991164365084842e-06
score O 0 4.4441361524150125e-07
= O 0 7.256384151332895e-07
4 O 0 1.1235585617441757e-07
. O 0 1.03382724603307e-08
05 O 0 1.8754235497908667e-06
, O 0 2.511387009462851e-08
P O 0 6.105809916334692e-06
= O 0 4.0036289306044637e-07
5 O 0 6.021976162173814e-08
. O 0 6.172864441822412e-09
22 O 0 3.699976502957725e-08
x O 0 7.52625680888741e-07
10 O 0 3.944957427393092e-08
( O 0 3.902635370423013e-08
- O 0 1.21856191981351e-06
4 O 0 6.76849509773092e-08
) O 0 1.0730559552030172e-08
; O 0 1.0694209962025525e-08
SIBPAL O 0 1.8498445797376917e-06
Pempirical O 0 1.2605927395270555e-06
value O 0 3.458915287524178e-08
< O 0 1.6312641548665852e-07
3 O 0 3.2262473581567974e-08
x O 0 7.005374982327339e-07
10 O 0 2.655580644272959e-08
( O 0 2.5924961732926022e-08
- O 0 7.77866944190464e-07
5 O 0 3.759117106483245e-08
) O 0 3.248443958270286e-09
) O 0 2.9323801165048735e-09
and O 0 5.057468221991712e-09
suggestive O 0 2.746926952568174e-07
evidence O 0 5.8446065764883315e-09
for O 0 2.3066308862951246e-09
a O 0 2.025676515415853e-08
locus O 0 7.545229436800582e-07
on O 0 1.3113867680658586e-06
chromosome O 0 0.00012228531704749912
4q O 0 0.0021252199076116085
at O 0 8.595827125645883e-07
D4S397 O 0 3.1956615202943794e-06
( O 0 5.378158718372106e-08
maximum O 0 2.477368639119959e-07
GENEHUNTER O 0 5.783364031231031e-05
- O 0 7.025311333563877e-06
PLUS O 0 7.706257747486234e-07
nonparametric O 0 8.001296009751968e-06
linkage O 0 3.058810989386984e-06
score O 0 1.991322449157451e-07
= O 0 5.505865487975825e-07
3 O 0 3.5221280114683395e-08
. O 0 4.916726581427611e-09
29 O 0 6.316480494206189e-08
, O 0 7.026837778312256e-09
P O 0 5.861796580575174e-06
= O 0 1.8831286752174492e-07
2 O 0 2.5738033926359094e-08
. O 0 4.8846651168332755e-09
57 O 0 9.08234838448152e-08
x O 0 1.9993156001874013e-06
10 O 0 5.252411483525066e-08
( O 0 4.035575784655521e-08
- O 0 1.3562339518102817e-06
3 O 0 8.695114672718773e-08
) O 0 9.095762365518567e-09
; O 0 1.2880724931108034e-08
SIBPAL O 0 1.917797135320143e-06
Pempirical O 0 1.365367666039674e-06
value O 0 3.391030389821026e-08
< O 0 1.2851673147906695e-07
1 O 0 1.7725207968055656e-08
x O 0 5.165943548490759e-07
10 O 0 3.708369789023891e-08
( O 0 2.320620851037347e-08
- O 0 1.9443750716163777e-06
3 O 0 3.537430970368405e-08
) O 0 3.46846662502287e-09
) O 0 2.0822223945060614e-09
that O 0 7.534379786733325e-10
are O 0 1.0359585411734429e-09
linked O 0 2.584099547675578e-07
to O 0 1.1382726938791166e-07
mental O 0 2.82614983007079e-05
health O 0 6.929189567017602e-06
wellness O 0 3.687953358166851e-05
. O 0 2.073898031085264e-06

These O 0 1.0101697398567921e-06
findings O 0 6.666456897619355e-07
are O 0 5.68579761051069e-09
consistent O 0 1.7766330628887772e-08
with O 0 1.4023203709356835e-09
the O 0 8.692191855175224e-09
hypothesis O 0 1.6742916386647266e-08
that O 0 5.278477654968583e-10
certain O 0 3.953520177901737e-09
alleles O 0 1.3503498053069052e-07
could O 0 1.6256446855322793e-08
prevent O 0 7.42425783073486e-08
or O 0 2.9041116178518678e-08
modify O 0 3.9772712057128956e-07
the O 0 2.2502526064727135e-08
clinical O 0 1.3929486897268362e-07
manifestations O 0 6.536818375479925e-08
of O 0 8.462608391823778e-09
BPAD B-Disease 1 1.0
and O 0 3.910414392294115e-08
perhaps O 0 2.162000356520366e-08
other O 0 1.2674957972080847e-08
related O 0 6.9823095145693514e-06
affective B-Disease 1 0.8398594856262207
disorders I-Disease 1 0.9997908473014832
. O 0 3.5297150589030934e-06

Segregation O 0 0.005703172646462917
distortion O 0 0.3015279769897461
in O 0 0.001283644000068307
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00016569685249123722

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9987751841545105
DM B-Disease 1 1.0
) O 0 1.5927663525872049e-06
is O 0 3.519905078519514e-08
an O 0 4.741177761502513e-08
autosomal B-Disease 1 0.9291191697120667
dominant I-Disease 1 0.969545304775238
disease I-Disease 1 0.8760865926742554
which O 0 5.701765104504375e-08
, O 0 2.018555766980512e-09
in O 0 3.5034131151689962e-09
the O 0 1.464616428137333e-08
typical O 0 7.033316364868369e-07
pedigree O 0 1.084173391063814e-06
, O 0 2.2188066939321516e-09
shows O 0 2.0389178345681103e-08
a O 0 1.0345965861802142e-08
three O 0 2.2498879204135847e-08
generation O 0 3.6137464576313505e-07
anticipation O 0 1.033224975799385e-06
cascade O 0 1.9669963876367547e-05
. O 0 8.973639751275186e-07

This O 0 6.979467457313149e-07
results O 0 1.7124217492892058e-06
in O 0 4.169641670159763e-06
infertility B-Disease 1 0.9670268893241882
and O 0 0.1988585889339447
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.125141175696626e-05
CDM B-Disease 0 5.7055494835367426e-05
) O 0 1.6187726714633754e-08
with O 0 5.135534220102045e-09
the O 0 1.9595482569911837e-08
disappearance O 0 3.87413479074894e-07
of O 0 3.0025340436168335e-08
DM B-Disease 1 1.0
in O 0 2.1269036665216845e-07
that O 0 5.6144813243008684e-08
pedigree O 0 9.522687832941301e-06
. O 0 4.7039679884619545e-07

The O 0 7.307259579647507e-07
concept O 0 3.7080238257658493e-07
of O 0 1.4426882799511986e-08
segregation O 0 8.31397983347415e-07
distortion O 0 1.4940412711439421e-06
, O 0 2.9430542447528296e-09
where O 0 2.9162048331698998e-09
there O 0 9.716498716727529e-10
is O 0 1.4142438331532503e-09
preferential O 0 3.7483346204680856e-08
transmission O 0 4.46958028987865e-06
of O 0 1.1028604696150524e-09
the O 0 5.9432059273945015e-09
larger O 0 2.7851328354699945e-08
allele O 0 5.600062991106824e-07
at O 0 1.9655192318168702e-07
the O 0 2.4083882976810855e-07
DM B-Disease 1 1.0
locus O 0 1.4081942936172709e-06
, O 0 7.286269365636144e-09
has O 0 3.7436671540547195e-09
been O 0 3.218053601372617e-09
put O 0 1.1413974654317371e-08
forward O 0 1.3070894588906867e-08
to O 0 5.748904463587223e-09
explain O 0 3.420757366257021e-08
partially O 0 9.068136819223582e-08
the O 0 7.275562374786659e-09
maintenance O 0 2.125470075498015e-07
of O 0 1.3204252802268002e-08
DM B-Disease 1 1.0
in O 0 4.731204583663384e-08
the O 0 5.368125854943173e-08
population O 0 7.293169090871743e-08
. O 0 2.137538501756353e-07

In O 0 1.8788713305184501e-06
a O 0 7.840694706828799e-07
survey O 0 1.303561248278129e-06
of O 0 4.695317556979717e-08
DM B-Disease 1 1.0
in O 0 6.487977657343436e-07
Northern O 0 1.3184039744373877e-06
Ireland O 0 1.4105100945016602e-06
, O 0 1.568887419978182e-08
59 O 0 8.150096419967667e-08
pedigrees O 0 2.112551783284289e-06
were O 0 1.740908714964462e-07
ascertained O 0 4.759343937621452e-06
. O 0 9.972009138436988e-07

Sibships O 0 0.00011956482194364071
where O 0 1.4404396608824754e-07
the O 0 8.157432951350074e-09
status O 0 2.104445728789983e-09
of O 0 2.4921401053923375e-10
all O 0 1.588293940812946e-10
the O 0 4.2663172994394927e-10
members O 0 2.84688994600657e-10
had O 0 8.219296354639027e-09
been O 0 1.4436509765403116e-09
identified O 0 4.617551230268191e-09
were O 0 4.0664414058255716e-09
examined O 0 5.736704977721274e-08
to O 0 3.472974796636663e-09
determine O 0 9.482517882020147e-09
the O 0 1.7184611067477817e-08
transmission O 0 2.018819395743776e-05
of O 0 1.859297049655595e-09
the O 0 4.3631313673131444e-08
DM B-Disease 1 0.9999946355819702
expansion O 0 1.543915288948483e-07
from O 0 3.34123519962759e-08
affected O 0 7.11231535888146e-08
parents O 0 2.1969519536924054e-08
to O 0 5.824164261980513e-09
their O 0 6.626827797617807e-08
offspring O 0 1.8479437358109863e-06
. O 0 2.9190732675488107e-07

Where O 0 1.4222442814570968e-06
the O 0 2.76773761243021e-07
transmitting O 0 3.113239290541969e-05
parent O 0 3.175695155732683e-06
was O 0 2.5686227900223457e-07
male O 0 4.472815007261488e-08
, O 0 2.2669761179372472e-08
58 O 0 7.176045073720161e-07
. O 0 5.643979648084496e-07

3 O 0 1.936336730068433e-06
% O 0 3.222262634494655e-08
of O 0 2.0045478610342116e-09
the O 0 1.1384623022081541e-08
offspring O 0 7.225572318247941e-08
were O 0 8.756022573663813e-09
affected O 0 1.1579773584458053e-08
, O 0 2.1432033925350424e-09
and O 0 1.82901238598987e-09
in O 0 3.114051017050201e-09
the O 0 2.3909252355736044e-09
case O 0 2.8459954393156295e-09
of O 0 4.1227238289920365e-10
a O 0 1.1964321089408259e-08
female O 0 4.6753442006775003e-08
transmitting O 0 6.019593001838075e-06
parent O 0 1.0003039960793103e-06
, O 0 1.3284381594758088e-08
68 O 0 6.835985573161452e-07
. O 0 6.108659249548509e-07

7 O 0 3.3280273783020675e-05
% O 0 5.967129368400492e-07
were O 0 1.500253574704402e-07
affected O 0 6.763706323908991e-07
. O 0 5.88583361604833e-07

Studies O 0 1.4544518307957333e-05
on O 0 1.508607851974375e-06
meiotic O 0 4.9104408390121534e-05
drive O 0 4.35773326898925e-05
in O 0 5.051733296568273e-06
DM B-Disease 1 1.0
have O 0 6.392131979282567e-08
shown O 0 6.397364415988704e-08
increased O 0 9.510814891200425e-08
transmission O 0 2.6742866339191096e-06
of O 0 8.297213471841758e-10
the O 0 4.556605315286788e-09
larger O 0 2.4529722253419095e-08
allele O 0 4.339428585353744e-07
at O 0 1.2268088767086738e-07
the O 0 1.254588681831592e-07
DM B-Disease 1 0.9999995231628418
locus O 0 4.578859716275474e-06
in O 0 2.15240177681153e-07
non O 0 1.51918050050881e-06
- O 0 0.16623975336551666
DM O 1 0.9999998807907104
heterozygotes O 0 8.081266423687339e-05
for O 0 3.9473667357015074e-07
CTGn O 0 8.626603084849194e-05
. O 0 3.3721696581778815e-06

This O 0 3.121331815236772e-07
study O 0 6.593668189225355e-08
provides O 0 6.913095429439409e-09
further O 0 4.972709799488939e-09
evidence O 0 2.2525745713153356e-09
that O 0 3.723152008916486e-09
the O 0 8.858192757088545e-08
DM B-Disease 1 0.9999996423721313
expansion O 0 6.951852924430568e-07
tends O 0 1.308253899878764e-06
to O 0 2.530176779202975e-08
be O 0 3.035169626741663e-08
transmitted O 0 1.8372234990238212e-05
preferentially O 0 5.54413600184489e-06
. O 0 3.826875172308064e-07

Diagnosis O 1 0.963083803653717
of O 0 2.0475854398682714e-05
hemochromatosis B-Disease 1 1.0
. O 0 3.705226117745042e-05

If O 0 1.705468093859963e-05
untreated O 0 0.0009038846474140882
, O 0 3.210544264220516e-06
hemochromatosis B-Disease 1 1.0
can O 0 0.00020461944222915918
cause O 0 0.00029486208222806454
serious O 0 0.00020262805628590286
illness O 0 0.31266435980796814
and O 0 3.9454360489799e-07
early B-Disease 0 0.0004607224836945534
death I-Disease 0 3.805543883572682e-06
, O 0 4.172278078584668e-09
but O 0 4.345646509307244e-09
the O 0 1.6586348294822528e-07
disease O 0 1.2214743037475273e-05
is O 0 5.704579475462879e-09
still O 0 2.3338305510378632e-08
substantially O 0 1.6957042134890798e-06
under O 0 1.0494354683032725e-05
- O 1 0.9959119558334351
diagnosed O 0 0.38163992762565613
. O 0 9.915461305354256e-07

The O 0 1.2877724202553509e-06
cornerstone O 0 1.9121284822176676e-06
of O 0 3.366470835430846e-08
screening O 0 3.9003069218779274e-07
and O 0 1.961238282888189e-08
case O 0 1.8823129721567966e-08
detection O 0 3.567512578683818e-07
is O 0 4.976011602764174e-09
the O 0 3.6622431753841056e-09
measurement O 0 1.3959196110135963e-07
of O 0 5.035992955981783e-09
serum O 0 1.4719391856488073e-06
transferrin O 0 1.5340552863563062e-06
saturation O 0 1.1674912911985302e-06
and O 0 2.2035154145783054e-08
the O 0 1.568538010587872e-07
serum O 0 1.3831026080879383e-05
ferritin O 0 4.069612987223081e-05
level O 0 2.7077924187324243e-06
. O 0 1.0050824812424253e-06

Once O 0 5.723988579120487e-06
the O 0 4.4405734911379113e-07
diagnosis O 0 2.2335018002195284e-05
is O 0 2.4186302738371523e-08
suspected O 0 2.8557309406096465e-07
, O 0 1.4806744275119854e-08
physicians O 0 9.177671955740152e-08
must O 0 1.8929158684954928e-08
use O 0 2.5678122028693906e-07
serum O 0 6.503832082671579e-06
ferritin O 0 1.7527814634377137e-05
levels O 0 6.738455340382643e-07
and O 0 6.684614106688969e-08
hepatic O 0 5.028886880609207e-05
iron O 0 6.223954551387578e-05
stores O 0 1.7542030036565848e-05
on O 0 2.035801844613161e-05
liver O 0 0.017503192648291588
biopsy O 0 0.001079984474927187
specimens O 0 2.0851651072462118e-07
to O 0 7.354296371886448e-08
assess O 0 6.314264169304806e-07
patients O 0 9.967229175344983e-08
for O 0 1.6399945845790853e-09
the O 0 3.254844616051855e-09
presence O 0 1.692784046269935e-08
of O 0 9.255155752896371e-09
iron B-Disease 0 0.014869396574795246
overload I-Disease 0 0.00010128898429684341
. O 0 6.171760560391704e-07

Liver O 1 0.9995802044868469
biopsy O 1 0.9959944486618042
is O 0 3.810610564869421e-07
also O 0 2.092415485321908e-08
used O 0 2.124713560647251e-08
to O 0 3.682921523306959e-09
establish O 0 1.318645814762931e-08
the O 0 2.7251163547958868e-09
presence O 0 8.09954237013244e-09
or O 0 5.757847976184394e-09
absence O 0 8.57162874012829e-09
of O 0 4.638205819418317e-09
cirrhosis B-Disease 0 9.234877325070556e-06
, O 0 5.622322607479191e-09
which O 0 1.7810609875823502e-08
can O 0 3.529794767587191e-08
affect O 0 2.3367243784377933e-07
prognosis O 0 9.674557077232748e-06
and O 0 1.544762113780962e-07
management O 0 3.1990216484700795e-06
. O 0 6.68372138079576e-07

A O 0 5.369054633774795e-06
DNA O 0 8.205081030610017e-06
- O 0 6.104272870288696e-06
based O 0 1.2860672882197832e-07
test O 0 7.230894283338785e-08
for O 0 2.423847345056629e-09
the O 0 1.1775327379837108e-08
HFE O 0 7.227608875837177e-06
gene O 0 2.7680542302732647e-07
is O 0 5.190730956172729e-09
commercially O 0 3.406842452591263e-08
available O 0 8.50750225822594e-09
, O 0 5.970938188326613e-10
but O 0 6.59168830630108e-10
its O 0 7.570540638823786e-09
place O 0 9.79024594727207e-09
in O 0 4.740117631740759e-09
the O 0 3.4028939666086444e-08
diagnosis O 0 4.073293530382216e-05
of O 0 5.4630188373039346e-08
hemochromatosis B-Disease 1 1.0
is O 0 3.940318151762767e-07
still O 0 7.009679592329121e-08
being O 0 8.841751508725793e-08
evaluated O 0 1.0550685374255409e-06
. O 0 5.687264774678624e-07

Currently O 0 5.776946636615321e-07
, O 0 7.586267614101416e-09
the O 0 2.5627409083739394e-09
most O 0 9.513418941509144e-10
useful O 0 1.7270397334456788e-09
role O 0 2.033444745919155e-09
for O 0 7.795313838876439e-10
this O 0 9.88475301610947e-10
test O 0 2.2906556651491883e-08
is O 0 6.050419609771041e-10
in O 0 1.0191119059754783e-09
the O 0 3.251990010610939e-09
detection O 0 1.480315177104785e-07
of O 0 2.238916074759345e-08
hemochromatosis B-Disease 1 1.0
in O 0 1.416999140246844e-07
the O 0 2.6787732920752205e-08
family O 0 1.1919586206943222e-08
members O 0 6.946797026508023e-10
of O 0 5.489250720636107e-10
patients O 0 6.4416494360841625e-09
with O 0 1.4983104756893795e-09
a O 0 7.950707470172347e-08
proven O 0 5.813556569478351e-08
case O 0 7.27733828753685e-09
of O 0 2.569966017773595e-09
the O 0 5.138658139003383e-07
disease O 0 0.0002498882822692394
. O 0 8.250515293184435e-07

It O 0 1.4281770290835993e-06
is O 0 1.2554778550111223e-07
crucial O 0 3.5684075783137814e-07
to O 0 1.6248375231953105e-06
diagnose O 1 0.9999921321868896
hemochromatosis B-Disease 1 1.0
before O 0 0.042490407824516296
hepatic B-Disease 1 0.9999833106994629
cirrhosis I-Disease 1 0.999790608882904
develops O 0 0.0014960620319470763
because O 0 3.0568280635634437e-06
phlebotomy O 0 0.015326431952416897
therapy O 0 0.004358502570539713
can O 0 2.7110274913866306e-06
avert O 1 0.5632672905921936
serious O 1 0.9992272853851318
chronic O 1 1.0
disease O 1 0.9999957084655762
and O 0 2.179571993110585e-06
can O 0 7.633515508587152e-08
even O 0 2.2653335207678538e-08
lead O 0 4.236609996155494e-08
to O 0 1.4907856282775356e-08
normal O 0 1.211329504258174e-06
life O 0 2.0474570305850648e-07
expectancy O 0 2.8076362923457054e-07
. O 0 2.0670007927492406e-08
. O 0 2.088285526724576e-07

Prevalence O 0 0.0001903082156786695
of O 0 2.3819171701688902e-07
the O 0 2.510037404590548e-07
I1307K O 0 7.572486993012717e-06
APC B-Disease 0 5.614819656329928e-06
gene O 0 1.8937628283310914e-06
variant O 0 4.0885029193304945e-06
in O 0 3.030981332585725e-08
Israeli O 0 4.9217767639220256e-08
Jews O 0 1.3722003089355894e-08
of O 0 1.1706170477410183e-09
differing O 0 1.8126385725736327e-08
ethnic O 0 3.02105251925866e-09
origin O 0 8.642927262769717e-09
and O 0 5.037897921056356e-08
risk O 0 4.479338713281322e-06
for O 0 0.026619087904691696
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0059463420475367e-05

BACKGROUND O 0 0.00014143818407319486
& O 0 1.763158979883883e-05
AIMS O 0 5.163500418348121e-07
Israeli O 0 2.0923242516346363e-07
Jews O 0 2.692973843920754e-08
of O 0 2.2608908079035928e-09
European O 0 1.8385975408818922e-07
birth O 0 4.165158770774724e-06
, O 0 6.9449592743353605e-09
i O 0 1.5044911094719282e-08
. O 0 1.8096942833167873e-09
e O 0 1.5541891329462487e-08
. O 0 1.3012679822566042e-09
, O 0 2.215947869643742e-09
Ashkenazim O 0 3.517737923175446e-07
, O 0 1.597601051450681e-09
have O 0 1.919225001145719e-09
the O 0 2.1724032706060825e-07
highest O 1 0.9979265928268433
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.007723220624029636
of O 0 5.207619224734117e-09
any O 0 5.349541254418e-09
Israeli O 0 1.0647342207903421e-07
ethnic O 0 4.227472416573619e-08
group O 0 2.646822849783348e-07
. O 0 5.481649623106932e-07

The O 0 6.505885266960831e-06
I1307K O 0 4.48855098511558e-05
APC B-Disease 0 2.949194094981067e-05
gene O 0 1.0907134310400579e-05
variant O 0 0.00011750635894713923
was O 0 4.15984732171637e-06
found O 0 1.61551909627633e-07
in O 0 2.1398432181740645e-07
6 O 0 1.368290099890146e-06
. O 0 6.257656082198082e-07

1 O 0 1.8121253333447385e-06
% O 0 2.7518082035271618e-08
of O 0 1.2548735384143583e-09
American O 0 2.9491566966299843e-09
Jews O 0 6.0151665870478155e-09
, O 0 1.1792381515718375e-09
28 O 0 4.418569954367513e-09
% O 0 5.072449127396794e-10
of O 0 1.0900096381050162e-09
their O 0 6.643825327046216e-05
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 4.990051365894033e-06
, O 0 1.9899170311532544e-08
but O 0 8.528070694069356e-09
not O 0 3.105770307598732e-09
in O 0 1.0489506152566719e-08
non O 0 2.993282066654501e-08
- O 0 5.640638391923858e-07
Jews O 0 1.3212117266903078e-07
. O 0 2.4056933511928946e-07

We O 0 1.4453909216172178e-06
assessed O 0 5.856124971614918e-07
the O 0 8.181557831221653e-08
I1307K O 0 4.577213530865265e-06
prevalence O 0 1.5451481658601551e-06
in O 0 2.009172916928037e-08
Israeli O 0 5.347635578800691e-08
Jews O 0 9.92115456455167e-09
of O 0 7.004380409014743e-10
differing O 0 1.1358053164656212e-08
ethnic O 0 1.6658303625405324e-09
origin O 0 7.381176558851621e-09
and O 0 2.2507506969304814e-08
risk O 0 2.1616021967929555e-06
for O 0 0.0015972111141309142
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1003733561665285e-05

METHODS O 0 1.021438765747007e-05
DNA O 0 2.2540000372828217e-06
samples O 0 1.6159691540451604e-07
from O 0 2.3226665035736005e-08
500 O 0 2.473866800301039e-08
unrelated O 0 4.908239858991692e-08
Jews O 0 1.5170574130252135e-08
of O 0 2.1154038520876384e-09
European O 0 4.3409350780621025e-08
or O 0 2.8317021616430793e-08
non O 0 1.4742438381176726e-08
- O 0 7.222898545933276e-08
European O 0 1.3360510919824264e-08
origin O 0 1.8243054844546691e-09
, O 0 4.342172732485494e-10
with O 0 6.631361570974548e-10
or O 0 3.6362601818495932e-09
without O 0 8.48704495570729e-10
a O 0 4.670431152931087e-09
personal O 0 3.9646675276117094e-08
and O 0 6.854670431266641e-08
/ O 0 1.3604189916804899e-05
or O 0 6.079287118154753e-08
family O 0 2.8605056101582704e-08
history O 0 6.073257452499092e-09
of O 0 5.837398564523255e-09
neoplasia B-Disease 0 2.47858879447449e-05
, O 0 9.423595237478821e-09
were O 0 1.1208953765162732e-08
examined O 0 1.1033495184165076e-07
for O 0 1.2008347649583584e-09
the O 0 1.0214866286162305e-08
I1307K O 0 4.378537710181263e-07
variant O 0 1.023672894007177e-06
by O 0 1.6163321348017234e-08
the O 0 3.611730292618631e-08
allele O 0 2.088796236421331e-06
- O 0 5.084553436063288e-07
specific O 0 1.3819901312217553e-07
oligonucleotide O 0 2.447982842568308e-05
( O 0 8.584612487538834e-07
ASO O 0 0.0030689409468322992
) O 0 1.3131648302078247e-07
method O 0 4.992803610548435e-07
. O 0 4.706830623035785e-07

RESULTS O 0 7.640027433808427e-06
In O 0 1.21888575677076e-07
persons O 0 4.999588654186482e-08
at O 0 1.630996564472298e-07
average O 0 1.2298633009777404e-06
risk O 0 4.9584100452193525e-06
for O 0 0.0332074835896492
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.212150545550685e-07
I1307K O 0 3.8106793454062426e-06
was O 0 2.382592356298119e-06
found O 0 4.739821690691315e-08
in O 0 6.883388437017857e-08
5 O 0 5.5521820740978e-07
. O 0 7.754508146717853e-07

0 O 0 4.599876319844043e-06
% O 0 4.653902507811836e-08
of O 0 4.931697272780866e-09
120 O 0 5.171286687755128e-08
European O 0 1.2625126544207887e-07
and O 0 4.028638755926295e-08
1 O 0 3.5142005572197377e-07
. O 0 3.335046869779035e-07

6 O 0 9.330715329269879e-06
% O 0 5.656066548453964e-08
of O 0 4.827462429801699e-09
188 O 0 1.6407940961471468e-07
non O 0 4.026426481118506e-08
- O 0 4.194702398763184e-07
European O 0 1.4918499857685674e-07
Jews O 0 9.882780460657159e-08
( O 0 4.9112177435972626e-08
P O 0 6.161072633403819e-06
= O 0 3.8150028558447957e-07
0 O 0 7.339119889593348e-08
. O 0 1.2741445232222759e-08
08 O 0 5.47686852314655e-07
) O 0 3.804850479127708e-08
. O 0 1.2507716462550889e-07

It O 0 2.4584815037087537e-06
occurred O 0 7.093157364579383e-06
in O 0 2.2903591911926924e-07
15 O 0 6.254869617805525e-07
. O 0 6.606376814488613e-07

4 O 0 5.412919108493952e-06
% O 0 9.433561842797644e-08
of O 0 9.099198727824387e-09
52 O 0 1.571724510540662e-07
Ashkenazi O 0 2.7402234081819188e-06
Israelis O 0 2.7691896775650093e-07
with O 0 3.3782166042328754e-07
familial O 1 0.8538749814033508
cancer B-Disease 0 0.20135502517223358
( O 0 7.36594699901616e-07
P O 0 0.0001519349025329575
= O 0 1.1576878478081198e-06
0 O 0 1.3146986077572365e-07
. O 0 1.3663683517961545e-08
02 O 0 4.2603326733114955e-07
) O 0 4.240294337876094e-09
and O 0 5.038587325145727e-09
was O 0 5.7319471835626246e-08
not O 0 2.1909751790616383e-09
detected O 0 2.309674727030142e-07
in O 0 1.5132773256709697e-08
51 O 0 3.084960553678684e-08
non O 0 1.0098979430495092e-08
- O 0 7.738375984445156e-08
European O 0 2.160862777600414e-08
Jews O 0 1.6239649625049424e-08
at O 0 2.428485856853513e-07
increased O 0 7.1204167397809215e-06
cancer B-Disease 0 0.00021498936985153705
risk O 0 2.988341520904214e-06
. O 0 1.2081546856279601e-06

Colorectal B-Disease 1 0.9999724626541138
neoplasia I-Disease 1 0.9267141222953796
occurred O 0 0.00041650421917438507
personally O 0 6.634828878304688e-06
or O 0 1.0144042050796998e-07
in O 0 5.990470341998844e-09
the O 0 3.6903964328871552e-09
families O 0 9.137141598891674e-10
of O 0 3.7218436665931165e-10
13 O 0 3.883431354267941e-09
of O 0 9.325641370239168e-10
20 O 0 1.1169258407051075e-08
Ashkenazi O 0 5.630856207972101e-07
I1307K O 0 3.609430905271438e-07
carriers O 0 6.933102980610784e-08
, O 0 3.4407725557628055e-09
8 O 0 8.14204437205035e-09
of O 0 4.972053324614478e-10
whom O 0 5.6172413387400866e-09
also O 0 5.57609025619854e-09
had O 0 1.346211409014586e-08
a O 0 1.0275913453483554e-08
personal O 0 9.748658413855082e-08
or O 0 7.656029765712447e-08
family O 0 5.899635979744744e-08
history O 0 2.9445830662666594e-08
of O 0 3.2188779641728615e-08
noncolonic O 0 0.000517072796355933
neoplasia B-Disease 0 0.0032187430188059807
. O 0 4.142317720834399e-06

CONCLUSIONS O 0 2.852669967978727e-05
The O 0 1.1978544307567063e-06
I1307K O 0 3.266751446062699e-05
APC O 0 2.483683238097001e-05
variant O 0 0.00011518407700350508
may O 0 6.20240712123632e-07
represent O 0 2.3889572986490748e-08
a O 0 2.7583137551800974e-08
susceptibility O 0 2.115923280143761e-06
gene O 0 1.8881219148170203e-06
for O 0 3.7160774013500486e-07
colorectal B-Disease 1 1.0
, I-Disease 0 2.7603400454268012e-08
or I-Disease 0 2.2901225804616843e-08
other I-Disease 0 3.3509726105052096e-09
, I-Disease 0 2.9355323505342312e-08
cancers I-Disease 0 3.640290969997295e-06
in O 0 4.054029645317314e-08
Ashkenazi O 0 2.613139031382161e-06
Jews O 0 2.708923396710361e-08
, O 0 4.3267154303805455e-09
and O 0 8.643405102759516e-09
partially O 0 1.9626963876362424e-07
explains O 0 2.977600033204908e-08
the O 0 6.704338861851511e-09
higher O 0 1.375627448396699e-06
incidence O 0 0.0017201360315084457
of O 0 0.0003909659862983972
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.5726311037033156e-07
European O 0 6.738764000147057e-07
Israelis O 0 1.3935508604845381e-06
. O 0 6.662148166469706e-07

Systematic O 0 4.699028067989275e-05
analysis O 0 6.917410701134941e-06
of O 0 6.051095056136546e-07
coproporphyrinogen O 0 0.0011188474018126726
oxidase O 0 0.0028583656530827284
gene O 0 0.20617549121379852
defects O 1 0.9984285235404968
in O 0 1.048025524141849e-06
hereditary B-Disease 0 0.4927055239677429
coproporphyria I-Disease 0 0.007998510263860226
and O 0 1.537469415779924e-06
mutation O 0 5.489340401254594e-05
update O 0 0.00024253442825283855
. O 0 3.920873950846726e-06

Hereditary B-Disease 1 0.9986050724983215
coproporphyria I-Disease 1 0.514974057674408
( O 0 3.282550096628256e-05
HC B-Disease 0 0.0011848852736875415
) O 0 5.415730583990808e-07
is O 0 6.548823705543327e-08
an O 0 2.5289759264524037e-07
acute O 1 0.7543853521347046
hepatic B-Disease 1 0.9999946355819702
porphyria I-Disease 1 0.9999998807907104
with O 0 0.0008899718523025513
autosomal O 1 0.9999988079071045
dominant O 1 0.9858074188232422
inheritance O 0 0.00017143091827165335
caused O 0 1.1421134331612848e-05
by O 0 1.1544538125463077e-07
deficient B-Disease 0 1.8865970560000278e-05
activity I-Disease 0 3.178963083882991e-07
of I-Disease 0 2.161600498595817e-08
coproporphyrinogen I-Disease 0 4.255788371665403e-05
III I-Disease 0 5.78291728743352e-05
oxidase I-Disease 0 1.536884519737214e-05
( O 0 4.0389184619016305e-07
CPO O 0 1.2320067071414087e-05
) O 0 2.1101446634474996e-07
. O 0 3.373474726231507e-07

Clinical O 0 0.00012234364112373441
manifestations O 0 1.5459247151738964e-05
of O 0 7.953255476422783e-08
the O 0 1.7747114497979055e-06
disease O 0 0.0036110826767981052
are O 0 1.7210689762237052e-08
characterized O 0 1.1699276001309045e-06
by O 0 1.3201889714764548e-07
acute O 0 6.545221549458802e-05
attacks O 0 0.00015978250303305686
of O 0 4.324025667301612e-06
neurological B-Disease 1 0.9999998807907104
dysfunction I-Disease 1 0.9687247276306152
often O 0 2.152255319742835e-06
precipitated O 0 2.99800149150542e-06
by O 0 2.8379417926771566e-08
drugs O 0 7.644429445008427e-08
, O 0 5.787200940687853e-09
fasting O 0 1.3450227243083646e-06
, O 0 3.3341557070798444e-08
cyclical O 0 2.911457522714045e-05
hormonal O 0 2.321995998499915e-05
changes O 0 3.3817559597082436e-07
, O 0 4.184226298775684e-08
or O 0 5.973648057988612e-06
infectious B-Disease 0 0.4007202386856079
diseases I-Disease 0 0.11375844478607178
. O 0 3.339379645694862e-06

Skin O 1 0.9999997615814209
photosensitivity O 1 0.9999686479568481
may O 0 0.2314891517162323
also O 0 2.866943589197035e-07
be O 0 1.9273624474180906e-08
present O 0 1.2255061676569312e-07
. O 0 3.554814327344502e-07

The O 0 1.6051330931077246e-06
seven O 0 3.773157573050412e-07
exons O 0 2.259427674289327e-06
, O 0 2.4105384355266324e-08
the O 0 9.303832371188037e-08
exon O 0 1.2593546671268996e-05
/ O 0 1.3545067304221448e-05
intron O 0 1.240101300936658e-05
boundaries O 0 3.03739994933494e-07
and O 0 1.0408014894380813e-08
part O 0 1.0125016380868601e-08
of O 0 2.6440407641104002e-09
3 O 0 4.8157577481333647e-08
noncoding O 0 3.4986808827852656e-07
sequence O 0 4.0748677321289506e-08
of O 0 2.421703060306868e-09
the O 0 1.2210539246382268e-08
CPO O 0 2.2742922283214284e-06
gene O 0 2.5878898668452166e-07
were O 0 6.10477801643583e-09
systematically O 0 3.5024793731963655e-08
analyzed O 0 2.080790117986453e-08
by O 0 5.473352437945778e-09
an O 0 9.743413187379701e-09
exon O 0 1.9125716335111065e-06
- O 0 7.067055207699013e-07
by O 0 1.483758040876637e-07
- O 0 1.807540320442058e-05
exon O 0 4.379146412247792e-05
denaturing O 0 0.0002614952973090112
gradient O 0 4.069349233759567e-05
gel O 0 9.583007340552285e-05
electrophoresis O 0 1.8462598745827563e-05
( O 0 2.2302813817987044e-07
DGGE O 0 3.486274863462313e-06
) O 0 2.6716294954098885e-08
strategy O 0 6.343065450664653e-08
followed O 0 1.4366801082132952e-08
by O 0 2.462670289915536e-09
direct O 0 1.4588286134653572e-08
sequencing O 0 5.191169805129903e-08
in O 0 8.650579808033854e-09
seven O 0 1.1048275183611622e-08
unrelated O 0 2.983672118261893e-07
heterozygous O 0 7.812504009052645e-06
HC B-Disease 0 0.00027259293710812926
patients O 0 1.7410512782589649e-06
from O 0 5.630900190567445e-08
France O 0 1.1574295513128163e-06
, O 0 9.497505892852587e-09
Holland O 0 1.6655155832268065e-06
, O 0 9.530896072362793e-09
and O 0 1.731655174808111e-08
Czech O 0 7.394703061436303e-06
Republic O 0 1.9403219084779266e-06
. O 0 7.993904773684335e-07

Seven O 0 3.2277050650009187e-06
novel O 0 1.660513476053893e-06
mutations O 0 5.084396434540395e-06
and O 0 5.166426220171161e-08
two O 0 2.711073499028771e-08
new O 0 6.837628916400718e-07
polymorphisms O 0 3.8371188566088676e-05
were O 0 3.721783912169485e-07
detected O 0 4.229784099152312e-05
. O 0 1.576015733917302e-06

Among O 0 9.445531645724259e-07
these O 0 9.823656910157297e-08
mutations O 0 1.1883536217283108e-06
two O 0 1.5852448242981154e-08
are O 0 7.085029896103379e-09
missense O 0 2.8551637569762534e-06
( O 0 9.128422817639148e-08
G197W O 0 1.071313477041258e-06
, O 0 1.1228769025706242e-08
W427R O 0 2.776112353330973e-07
) O 0 2.9883291396970435e-09
, O 0 6.292257270779089e-10
two O 0 1.1712065761670942e-09
are O 0 1.5078225334974604e-09
nonsense O 0 1.0843661613080258e-07
( O 0 1.5941409969855158e-08
Q306X O 0 1.9959425401339104e-07
, O 0 4.271318410076219e-09
Q385X O 0 1.1422995527254898e-07
) O 0 1.6453083340195462e-09
, O 0 3.8912889577247256e-10
two O 0 2.9232036236059855e-10
are O 0 2.603464388517551e-10
small O 0 3.5510236973124165e-09
deletions O 0 6.796722118451726e-07
( O 0 6.735140800628869e-08
662de14bp O 0 1.5058624285302358e-06
; O 0 4.790728880266215e-08
1168del3bp O 0 1.1721904229489155e-06
removing O 0 1.7174822630749986e-07
a O 0 4.7708773820431816e-08
glycine O 0 4.739762516692281e-06
at O 0 4.41764143488399e-07
position O 0 1.2778150448866654e-07
390 O 0 1.240742335539835e-07
) O 0 5.695936167171567e-09
, O 0 1.1603822347439063e-09
and O 0 9.021566826916683e-10
one O 0 1.3620976568873289e-09
is O 0 1.3980232527188718e-09
a O 0 1.9603257683797892e-08
splicing O 0 4.092130893695867e-06
mutation O 0 3.698114596772939e-06
( O 0 1.0630154179125384e-07
IVS1 O 0 2.0682155081885867e-05
- O 0 9.796104677661788e-06
15c O 0 4.041056672576815e-05
- O 0 2.3729146050754935e-05
- O 0 1.4064284187043086e-05
> O 0 2.651532213349128e-06
g O 0 1.9508499917719746e-06
) O 0 5.1401793932370765e-09
which O 0 3.068732601363422e-09
creates O 0 1.4594993658079147e-08
a O 0 1.36381679283204e-08
new O 0 6.910751437771978e-08
acceptor O 0 1.072063696483383e-06
splice O 0 2.8598880817298777e-05
site O 0 5.612495897366898e-06
. O 0 1.1993575981250615e-06

The O 0 9.367870461574057e-07
pathological O 0 2.999282514792867e-06
significance O 0 1.094320651873204e-07
of O 0 3.412681026659925e-09
the O 0 1.0901536562357705e-08
point O 0 5.940432146189778e-08
mutations O 0 3.628063325322728e-07
G197W O 0 3.972457420786668e-07
, O 0 5.076787878977029e-09
W427R O 0 8.85478002032869e-08
, O 0 1.3744181348585016e-09
and O 0 1.0593873556175026e-09
the O 0 4.404795639345593e-09
in O 0 6.797798590696402e-08
- O 0 3.0625355975644197e-06
frame O 0 4.9749771278584376e-05
deletion O 0 9.679527011030586e-07
390delGly O 0 4.684448811076436e-07
were O 0 7.59985230303073e-09
assessed O 0 8.397361028755768e-09
by O 0 1.2210322752892466e-09
their O 0 6.0399538703848066e-09
respective O 0 1.5052890489641868e-08
expression O 0 2.4866539050094616e-08
in O 0 8.593564082559624e-09
a O 0 1.8149250990973087e-08
prokaryotic O 0 1.2295497242575948e-07
system O 0 2.1072307276881475e-07
using O 0 1.3758764794147282e-07
site O 0 1.5907504575807252e-06
- O 0 1.6183562365768012e-06
directed O 0 6.384967150552256e-07
mutagenesis O 0 2.1610912881442346e-05
. O 0 1.4996242043707753e-06

These O 0 1.2015293577860575e-06
mutations O 0 1.0414009921078105e-05
resulted O 0 2.345471870057736e-07
in O 0 3.479155452623672e-08
the O 0 1.876409072565366e-08
absence O 0 6.885108660981132e-08
or O 0 2.6194060254169926e-08
a O 0 3.4729367826003e-08
dramatic O 0 5.360436716728145e-07
decrease O 0 6.249711645978095e-07
of O 0 4.319922553008837e-08
CPO O 0 3.343072967254557e-05
activity O 0 3.959170044254279e-06
. O 0 8.737289931559644e-07

The O 0 6.734343855896441e-07
two O 0 9.980831805478374e-08
polymorphisms O 0 8.10969140729867e-06
were O 0 7.372497634605679e-08
localized O 0 1.885602728179947e-06
in O 0 1.7552659414832306e-07
noncoding O 0 1.2836917449021712e-06
part O 0 1.49433265761445e-08
of O 0 2.8520490413797006e-09
the O 0 1.6711203087993454e-08
gene O 0 1.6408753822361177e-07
1 O 0 1.712388630892292e-08
) O 0 4.468131642454409e-09
a O 0 4.396639141646119e-08
C O 0 1.3285341083246749e-05
/ O 0 6.0528477661137e-06
G O 0 4.612369593814947e-06
polymorphism O 0 1.3099892157697468e-06
in O 0 3.196070608169066e-08
the O 0 3.5773069839706295e-08
promotor O 0 3.696101202876889e-06
region O 0 7.053346706697994e-08
, O 0 5.721775053757483e-09
142 O 0 6.29535961138572e-08
bp O 0 3.130358550151868e-07
upstream O 0 1.1400011601381266e-07
from O 0 7.282197955760239e-09
the O 0 7.174291383194031e-09
transcriptional O 0 5.221666015131632e-07
initiation O 0 9.716450932728549e-08
site O 0 2.7601566898738383e-07
( O 0 4.3641467328825456e-08
- O 0 5.385898020904278e-07
142C O 0 3.12936049340351e-06
/ O 0 1.7753951397025958e-05
G O 0 3.2685318274161546e-06
) O 0 4.788351049000994e-09
, O 0 7.824316194948722e-10
and O 0 1.7009715858051777e-09
2 O 0 7.691813408428061e-09
) O 0 2.6318343060438565e-09
a O 0 1.7799198559487195e-08
6 O 0 1.2180653641280514e-07
bp O 0 8.71982535954885e-07
deletion O 0 7.205230758700054e-07
polymorphism O 0 8.707103233973612e-07
in O 0 3.128221237602702e-08
the O 0 1.826729700837859e-08
3 O 0 3.315720320529181e-08
noncoding O 0 3.182014438607439e-07
part O 0 9.990274385529574e-09
of O 0 2.8247744143783393e-09
the O 0 3.568576900647713e-08
CPO O 0 2.9528196137107443e-06
gene O 0 2.678625889984687e-07
, O 0 4.086275318115895e-09
574 O 0 1.4744271936706355e-07
bp O 0 1.461143313008506e-07
downstream O 0 2.3411246274918085e-08
of O 0 5.960969495788504e-10
the O 0 4.289246735567076e-09
last O 0 1.4334911924152038e-08
base O 0 6.096702254154707e-09
of O 0 5.731722874102729e-10
the O 0 1.2583758035589199e-08
normal O 0 7.201102221188194e-07
termination O 0 1.6697046021363349e-06
codon O 0 5.313004294293933e-06
( O 0 1.1345283468244816e-07
+ O 0 5.510866571967199e-07
574 O 0 2.1047915197414113e-06
delATTCTT O 0 6.107614808570361e-06
) O 0 3.215110950804956e-07
. O 0 4.3436102714622393e-07

Five O 0 3.61234833690105e-06
intragenic O 0 3.731352262548171e-05
dimorphisms O 0 2.3520924514741637e-05
are O 0 3.419759053713278e-08
now O 0 9.948213808286255e-09
well O 0 3.616209331980258e-09
characterized O 0 6.667563923201669e-08
and O 0 4.479830728598699e-09
the O 0 8.003775420206694e-09
high O 0 1.254216499546601e-07
degree O 0 1.0589191745680182e-08
of O 0 6.935177321309993e-09
allelic O 0 3.7032955333415885e-06
heterogeneity O 0 3.6902370084135327e-06
in O 0 1.141538746196602e-06
HC B-Disease 0 0.000948229106143117
is O 0 4.6437943268529125e-08
demonstrated O 0 2.0888544227659622e-08
with O 0 4.26488755422838e-09
seven O 0 4.183258628387421e-09
new O 0 1.1429682089669768e-08
different O 0 2.418559796879549e-09
mutations O 0 5.885452125653501e-08
making O 0 1.4637890899393824e-09
a O 0 3.326728448271865e-09
total O 0 1.2060452636575292e-09
of O 0 3.2741340749709025e-09
nineteen O 0 2.3073279464824736e-07
CPO O 0 0.00034564363886602223
gene B-Disease 0 0.0017777972389012575
defects I-Disease 1 0.7647114992141724
reported O 0 1.551158788970497e-06
so O 0 3.312565866053774e-08
far O 0 6.131784147100916e-08
. O 0 4.185950430724006e-08
. O 0 2.096830655773374e-07

Coincidence O 0 2.2811349481344223e-05
of O 0 1.3842721102719224e-07
two O 0 7.809264701563734e-08
novel O 0 4.45178415020564e-07
arylsulfatase O 0 2.6271272872691043e-06
A O 0 3.368970169503882e-07
alleles O 0 1.6246222003246658e-06
and O 0 1.2487799949667533e-07
mutation O 0 4.454822374100331e-06
459 O 0 3.993434802396223e-06
+ O 0 3.1242313980328618e-06
1G O 0 8.92157549969852e-05
> O 0 8.12324515209184e-07
A O 0 8.643639404226633e-08
within O 0 2.0410618972732664e-08
a O 0 7.251058065094185e-08
family O 0 3.483213220079051e-07
with O 0 3.6755170640390133e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999996423721313
: O 0 2.8368758009378325e-08
molecular O 0 1.9942149265261833e-07
basis O 0 1.5786097762315876e-08
of O 0 1.8750174746173798e-08
phenotypic O 0 9.29823909245897e-06
heterogeneity O 0 5.420716479420662e-05
. O 0 2.606613179523265e-06

In O 0 1.2915826346215908e-06
a O 0 2.921727570992516e-07
family O 0 9.574847581461654e-08
with O 0 8.620125946379176e-09
three O 0 8.344289703643426e-09
siblings O 0 1.9662580541535135e-07
, O 0 2.83069634399169e-09
one O 0 4.225753524877973e-09
developed O 0 1.655696877378432e-07
classical O 0 9.81288621915155e-07
late O 1 0.9285967946052551
infantile O 1 0.9999995231628418
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 4.461635398911312e-05
MLD B-Disease 1 0.9999988079071045
) O 0 1.338098201131288e-07
, O 0 2.0502231024011053e-08
fatal O 0 1.4220002412912436e-05
at O 0 7.626094884471968e-06
age O 0 8.462193079594726e-08
5 O 0 1.3113696795130636e-08
years O 0 5.682198711554065e-09
, O 0 3.1801616895421603e-09
with O 0 3.553973115799636e-08
deficient O 0 0.00016035212320275605
arylsulfatase O 0 1.412178244208917e-05
A O 0 2.4322646368091227e-06
( O 0 2.51485346325353e-07
ARSA O 0 2.9835446184733883e-05
) O 0 1.5136842890228763e-08
activity O 0 6.732507529250142e-08
and O 0 8.65373106506695e-09
increased O 0 1.586202813541604e-07
galactosylsulfatide O 0 3.438676867517643e-05
( O 0 7.057262791931862e-07
GS O 1 0.9999964237213135
) O 0 4.463330185444647e-07
excretion O 0 8.196479029720649e-06
. O 0 5.53844813566684e-07

The O 0 2.3863529463596933e-07
two O 0 2.496319773115374e-08
other O 0 6.716984746191201e-09
siblings O 0 2.781953298836015e-07
, O 0 8.067103429709732e-09
apparently O 0 1.999001710828452e-07
healthy O 0 2.3205947741189448e-07
at O 0 3.413099989302282e-07
12 O 0 4.6587956603616476e-08
( O 0 1.8341626883966455e-08
1 O 0 4.8232312366280894e-08
/ O 0 1.5998483604562352e-06
2 O 0 1.9253674210517602e-08
) O 0 2.333727211478731e-09
and O 0 1.7941083063632846e-09
15 O 0 3.4587619435200168e-09
years O 0 1.534289473248407e-09
, O 0 8.511328863924916e-10
respectively O 0 7.240468669067468e-09
, O 0 4.272163733887169e-10
and O 0 8.599741474490941e-10
their O 0 5.261161728498109e-09
father O 0 1.6007564340725366e-07
, O 0 2.801931131557467e-09
apparently O 0 5.7280018950223166e-08
healthy O 0 3.081767374624178e-08
as O 0 4.569983058644311e-09
well O 0 3.891543531864272e-09
, O 0 2.823018485642592e-09
presented O 0 5.233571087615019e-08
ARSA O 0 0.0001436561724403873
and O 0 4.6410269760599476e-07
GS O 1 0.999906063079834
values O 0 9.643228082722999e-08
within O 0 9.846614190678338e-09
the O 0 1.2442634478304626e-08
range O 0 2.2249916753480647e-07
of O 0 2.0969906699974672e-07
MLD B-Disease 1 1.0
patients O 0 2.914079959737137e-05
. O 0 1.1862158544317936e-06

Mutation O 0 0.00024585332721471786
screening O 0 1.0081514119519852e-05
and O 0 1.264123454802757e-07
sequence O 0 1.1163938751224123e-07
analysis O 0 5.4119929870921624e-08
disclosed O 0 7.005869662179975e-08
the O 0 5.326520557957792e-09
involvement O 0 1.2508356128648757e-08
of O 0 8.23930423887731e-10
three O 0 7.006829783051671e-09
different O 0 4.3708027419597784e-08
ARSA O 0 0.0022384291514754295
mutations O 0 2.0074317035323475e-06
being O 0 1.040378716510304e-08
the O 0 7.2270025519571846e-09
molecular O 0 7.400591073292162e-08
basis O 0 1.8482204211522912e-08
of O 0 2.1028659702437835e-08
intrafamilial O 0 2.6341809643781744e-05
phenotypic O 0 5.2235176553949714e-05
heterogeneity O 0 9.392583888256922e-05
. O 0 4.0039062696450856e-06

The O 0 4.1474331737845205e-06
late O 0 0.0004502561059780419
infantile O 1 0.9998149275779724
patient O 0 0.09270358085632324
inherited O 0 0.005093964282423258
from O 0 1.9276460250239325e-07
his O 0 4.1717399312801717e-07
mother O 0 6.769604397049989e-07
the O 0 1.1921929221614391e-08
frequent O 0 1.637492488271164e-07
0 O 0 3.533520498422149e-07
- O 0 7.765751433908008e-06
type O 0 3.677900895127095e-05
mutation O 0 3.803824029091629e-06
459 O 0 1.0817628890436026e-06
+ O 0 7.171748848122661e-07
1G O 0 1.1016102689609397e-05
> O 0 2.599096546873625e-07
A O 0 7.4937986482837e-08
, O 0 4.308762235893937e-09
and O 0 2.5341888587604444e-09
from O 0 5.852091700120354e-09
his O 0 8.886232905069846e-08
father O 0 2.1397943328338442e-07
a O 0 3.090196187827132e-08
novel O 0 2.2528592324988495e-08
, O 0 2.985440339386969e-09
single O 0 3.3808394306333867e-08
basepair O 0 1.013243718261947e-06
microdeletion O 0 7.615162189722469e-07
of O 0 1.1685116874105006e-08
guanine O 0 4.5858379849050834e-07
at O 0 8.932624950830359e-08
nucleotide O 0 3.55621807557327e-07
7 O 0 7.45738262253326e-08
in O 0 4.99196559644588e-08
exon O 0 3.528789420670364e-06
1 O 0 2.643989773787325e-07
( O 0 1.8072293528348382e-07
7delG O 0 5.158547082828591e-06
) O 0 2.2404866228953324e-07
. O 0 4.3605527366707975e-07

The O 0 1.2138852980569936e-06
two O 0 2.7402288083067106e-07
clinically O 0 1.773055009834934e-05
unaffected O 0 4.587182411341928e-05
siblings O 0 1.524057779533905e-06
carried O 0 2.0104000952869683e-07
the O 0 7.408640811945588e-08
maternal O 0 5.8328992054157425e-06
mutation O 0 4.212134172121296e-06
459 O 0 2.978781367346528e-06
+ O 0 1.5441332834598143e-06
1G O 0 3.6545035982271656e-05
> O 0 1.2845905530411983e-06
A O 0 2.5985463025790523e-07
and O 0 1.4135352444100135e-08
, O 0 2.536248766560334e-09
on O 0 3.7863824076111996e-08
their O 0 1.8167087389997505e-08
paternal O 0 3.172958486175048e-06
allele O 0 1.0849439604498912e-06
, O 0 3.54710416594628e-09
a O 0 1.3410883958897557e-08
novel O 0 5.839840255816853e-08
cytosine O 0 6.579604132639361e-07
to O 0 2.731622750218321e-08
thymidine O 0 2.1656051103491336e-06
transition O 0 2.9386197297753824e-07
at O 0 1.1358556406548814e-07
nucleotide O 0 5.967209517621086e-07
2435 O 0 1.3281844985613134e-05
in O 0 9.416879009904733e-08
exon O 0 1.7910716678670724e-06
8 O 0 9.250359056522939e-08
, O 0 1.9053685296199774e-09
resulting O 0 1.536873561747143e-08
in O 0 9.274169876505312e-09
substitution O 0 6.106317584908538e-08
of O 0 9.76968905774811e-09
alanine O 0 7.461304448952433e-06
464 O 0 1.959617748070741e-06
by O 0 1.8062368667415285e-07
valine O 0 0.0002101526188198477
( O 0 3.5166578982170904e-07
A464V O 0 6.922314241819549e-06
) O 0 4.25315562324613e-07
. O 0 5.00322357765981e-07

The O 0 5.660195256496081e-06
fathers O 0 9.657926057116129e-06
genotype O 0 2.5082403226406313e-05
thus O 0 4.977618459633959e-07
was O 0 1.1200702374480898e-06
7delG O 0 3.612129148677923e-05
/ O 0 5.322946890373714e-05
A464V O 0 3.606996688176878e-05
. O 0 2.297763330716407e-06

Mutation O 0 0.0003539593890309334
A464V O 0 3.826496686087921e-05
was O 0 2.4185185338865267e-06
not O 0 7.96901389321647e-09
found O 0 1.2527409332108164e-08
in O 0 2.5934458136589456e-08
18 O 0 1.5926281093925354e-07
unrelated O 0 9.294276424043346e-06
MLD B-Disease 1 1.0
patients O 0 1.2251513908267953e-05
and O 0 7.198170948186089e-08
50 O 0 2.2231547802675777e-07
controls O 0 0.00013135731569491327
. O 0 6.92086814524373e-07

A464V O 0 0.00029711509705521166
, O 0 1.0802494898598525e-06
although O 0 2.903253744079848e-07
clearly O 0 5.79348238716193e-07
modifying O 0 7.144325081753777e-06
ARSA O 0 0.0015856042737141252
and O 0 2.3028396753943525e-06
GS O 1 0.9999990463256836
levels O 0 4.1928451537387446e-06
, O 0 1.5892895888214298e-08
apparently O 0 8.937072237813481e-08
bears O 0 1.6468672470182355e-07
little O 0 3.385446945003423e-08
significance O 0 1.9553814567530026e-08
for O 0 4.476892634386331e-09
clinical O 0 1.9115253735435545e-07
manifestation O 0 4.584276496188977e-07
of O 0 8.863888467658398e-08
MLD B-Disease 1 0.9999985694885254
, O 0 6.807166386124663e-08
mimicking O 0 2.438935780446627e-06
the O 0 3.337585781082453e-07
frequent O 0 1.1868475667142775e-05
ARSA O 0 0.020185554400086403
pseudodeficiency O 0 0.0007267998298630118
allele O 0 0.0002574945392552763
. O 0 4.881054337602109e-06

Our O 0 2.069726861009258e-06
results O 0 6.132632393018866e-07
demonstrate O 0 7.627883746863517e-08
that O 0 3.5322242908364387e-09
in O 0 5.377468692557841e-09
certain O 0 1.3855527392081513e-08
genetic O 0 8.265880069302511e-07
conditions O 0 3.437467239564285e-05
MLD B-Disease 1 0.9999998807907104
- O 0 0.0001252636720892042
like O 0 6.711686069138523e-07
ARSA O 0 0.004249576013535261
and O 0 3.081426029893919e-06
GS O 1 0.9999996423721313
values O 0 6.410726882677409e-08
need O 0 3.8216936282253755e-09
not O 0 7.193717843634317e-10
be O 0 1.3753439498387365e-09
paralleled O 0 1.0205522471551376e-07
by O 0 3.079968990959969e-08
clinical O 0 3.639985607151175e-06
disease O 0 4.413263741298579e-05
, O 0 2.6489572757526503e-09
a O 0 1.7652263650802524e-08
finding O 0 9.192945071845315e-09
with O 0 2.3677635851981904e-08
serious O 0 7.0444320954266e-07
diagnostic O 0 9.717385546537116e-05
and O 0 8.373411333195691e-07
prognostic O 0 5.513452197192237e-05
implications O 0 4.143297701375559e-06
. O 0 1.6347383962056483e-06

Moreover O 0 3.563897917047143e-05
, O 0 6.928020184204797e-07
further O 0 9.09318771391554e-07
ARSA O 0 0.000737639784347266
alleles O 0 9.267634595744312e-06
functionally O 0 1.920736622196273e-06
similar O 0 1.1839019009585172e-07
to O 0 2.969398771313081e-08
A464V O 0 8.107224971354299e-07
might O 0 3.920354174624663e-08
exist O 0 8.363378434239621e-09
which O 0 3.6931142588514376e-09
, O 0 7.307029981085122e-10
together O 0 1.6914147860092044e-09
with O 0 4.686725674218906e-09
0 O 0 1.1897740392896594e-07
- O 0 8.491904736729339e-06
type O 0 0.0017963506979867816
mutations O 0 1.0253357686451636e-05
, O 0 3.007176019309554e-08
may O 0 1.142953806265723e-06
cause O 0 6.032564670022111e-07
pathological O 0 4.341169187682681e-06
ARSA O 0 0.011293631047010422
and O 0 8.463114681944717e-06
GS O 1 0.9999997615814209
levels O 0 3.7544139104284113e-06
, O 0 6.079249548207599e-09
but O 0 4.776884665602665e-09
not O 0 1.4450015406453076e-08
clinical O 0 2.1214623302512337e-07
outbreak O 0 1.5888431335042696e-06
of O 0 8.25625168232591e-09
the O 0 1.6351250451407395e-06
disease O 0 0.0003790781775023788
. O 0 7.698480430917698e-08
. O 0 3.449823964274401e-07

Human O 0 0.000814658182207495
MLH1 O 1 0.999943733215332
deficiency O 1 0.9995386600494385
predisposes O 0 0.00032223243033513427
to O 0 7.937772352306638e-06
hematological B-Disease 1 0.9933838248252869
malignancy I-Disease 1 0.995461642742157
and O 0 4.04173115384765e-05
neurofibromatosis B-Disease 1 0.9999939203262329
type I-Disease 0 0.31724992394447327
1 I-Disease 0 5.614750079985242e-06
. O 0 2.1226899207249517e-06

Heterozygous O 0 0.0016013188287615776
germ O 0 0.005487694405019283
- O 0 0.001521134632639587
line O 0 2.8471145924413577e-05
mutations O 0 4.262683887645835e-06
in O 0 2.3908945934181247e-08
the O 0 2.2834491630874254e-08
DNA O 0 2.7446878902992466e-06
mismatch O 0 3.9254813600564376e-05
repair O 0 0.00019661389524117112
genes O 0 5.399521683102648e-07
lead O 0 2.9220981900834886e-07
to O 0 1.6387842833864852e-06
hereditary B-Disease 1 0.9999996423721313
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.467471313138958e-05

The O 0 1.6157351637957618e-05
disease O 0 0.03523401543498039
susceptibility O 0 1.5820234693819657e-05
of O 0 2.572036805759126e-08
individuals O 0 1.900201240800925e-08
who O 0 7.494899989524129e-08
constitutionally O 0 2.1287512481649173e-06
lack O 0 1.1275387379328095e-07
both O 0 2.432922308059915e-08
wild O 0 1.0071952374346438e-06
- O 0 0.0011692078551277518
type O 0 0.0004137728246860206
alleles O 0 2.589798441476887e-06
is O 0 4.685029963980014e-08
unknown O 0 2.588442953310732e-07
. O 0 3.7402580232992477e-07

We O 0 7.690480288147228e-07
have O 0 2.908867990925046e-08
identified O 0 2.157679013237157e-08
three O 0 4.956858035143341e-09
offspring O 0 3.649804725114336e-08
in O 0 2.1161193686225488e-08
a O 0 1.7081239320759778e-06
hereditary B-Disease 1 0.9999997615814209
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0012395733501762152
who O 0 8.227846137742745e-07
developed O 0 2.364114516240079e-05
hematological B-Disease 0 0.1522318720817566
malignancy I-Disease 0 0.0023308286909013987
at O 0 2.3907955437607598e-06
a O 0 1.3493919936991006e-07
very O 0 7.19126802550818e-08
early O 0 9.900957593345083e-06
age O 0 1.642956419800612e-07
, O 0 1.8486353559055146e-09
and O 0 3.1294609126319983e-09
at O 0 2.0009695234080027e-08
least O 0 1.6128114399549531e-09
two O 0 3.416195937244737e-10
of O 0 1.6126351642942183e-10
them O 0 1.053352849389455e-09
displayed O 0 4.4838765234089806e-07
signs O 0 8.807244853414886e-07
of O 0 2.0995475580321e-08
neurofibromatosis B-Disease 0 0.4647931456565857
type I-Disease 0 8.829424041323364e-05
1 I-Disease 0 6.522135436171084e-07
( O 0 4.849997594646993e-07
NF1 B-Disease 0 4.351927782408893e-05
) O 0 3.551947429514257e-07
. O 0 6.4622520312696e-07

DNA O 0 3.804232619586401e-05
sequence O 0 7.039556294330396e-06
analysis O 0 1.0637897958076792e-06
and O 0 5.851022777392245e-08
allele O 0 3.4514500839577522e-06
- O 0 3.7987962286933907e-07
specific O 0 5.070171482657315e-08
amplification O 0 2.6454047201696085e-06
in O 0 2.6791258989078415e-08
two O 0 1.2549171479747656e-08
siblings O 0 4.535948221473518e-07
revealed O 0 3.0731743549949897e-07
a O 0 1.7189962875363562e-07
homozygous O 0 1.8241296857013367e-05
MLH1 O 0 0.0005135328974574804
mutation O 0 9.17262786970241e-06
( O 0 2.1163640440136078e-07
C676T O 0 1.0744837709353305e-05
- O 0 8.536978566553444e-05
- O 0 5.8974965213565156e-05
> O 0 6.38274150333018e-06
Arg226Stop O 0 2.3996331947273575e-05
) O 0 5.335257355909562e-07
. O 0 5.92137098465173e-07

Thus O 0 2.8748472686856985e-06
, O 0 1.1764870322394927e-07
a O 0 1.9224616210067325e-07
homozygous O 0 1.1145360076625366e-05
germ O 0 0.00013236016093287617
- O 0 0.00026107527082785964
line O 0 0.00048235684516839683
MLH1 O 0 0.0032060109078884125
mutation O 0 2.392245914961677e-05
and O 0 3.596463500343816e-07
consequent O 0 0.0002903354761656374
mismatch O 1 0.9980155229568481
repair O 1 1.0
deficiency O 1 0.9998810291290283
results O 0 1.8257912870467408e-06
in O 0 9.417489366114751e-08
a O 0 1.3913358998252079e-06
mutator O 0 0.1048400029540062
phenotype O 0 0.0004319906292948872
characterized O 0 7.6094220275990665e-06
by O 0 7.402270512102405e-07
leukemia B-Disease 1 0.9957193732261658
and O 0 2.9732767870882526e-05
/ O 1 0.9998961687088013
or O 1 0.9904497265815735
lymphoma B-Disease 1 1.0
associated O 0 8.765341044636443e-05
with O 0 1.1199699656572193e-05
neurofibromatosis B-Disease 1 0.9999959468841553
type I-Disease 0 0.04714946821331978
1 I-Disease 0 6.167300625747885e-07
. O 0 8.278851737486548e-08
. O 0 4.5834852357984346e-07

Missense O 0 0.021295826882123947
mutations O 0 0.0019059532787650824
in O 0 9.548928119329503e-07
the O 0 5.851011763979841e-08
most O 0 8.289973152386665e-09
ancient O 0 1.1873999561373694e-08
residues O 0 9.648858423361162e-08
of O 0 1.8802344126100934e-09
the O 0 2.0593862615214675e-08
PAX6 O 0 1.3723250049224589e-05
paired O 0 5.972378858132288e-07
domain O 0 3.434048210237961e-07
underlie O 0 1.5252500134010916e-06
a O 0 1.2747722166750464e-07
spectrum O 0 2.829650611602119e-06
of O 0 8.03476751798371e-08
human O 0 0.00010890064004343003
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999881982803345
malformations I-Disease 1 0.9999967813491821
. O 0 1.1393307431717403e-05

Mutations O 0 0.00021506010671146214
of O 0 2.3195748610760347e-07
the O 0 3.675583286621986e-07
human O 0 8.000021693987946e-07
PAX6 O 0 0.0010906365932896733
gene O 0 0.002812005812302232
underlie O 1 0.9651890993118286
aniridia B-Disease 1 1.0
( O 1 0.573215663433075
congenital B-Disease 1 0.9999998807907104
absence I-Disease 0 1.1546479754542815e-06
of I-Disease 0 8.641839244205585e-09
the I-Disease 0 6.990132561668361e-08
iris I-Disease 0 2.5343182642245665e-05
) O 0 1.039220531851015e-08
, O 0 1.7970810395340209e-09
a O 0 1.495085300007304e-08
rare O 0 1.2907477184853633e-06
dominant O 1 0.6405509114265442
malformation B-Disease 1 0.6290841698646545
of I-Disease 0 1.727515019922521e-08
the I-Disease 0 3.7702798749705835e-07
eye I-Disease 0 0.0009092474356293678
. O 0 1.031876877277682e-06

The O 0 1.6657030528222094e-06
spectrum O 0 5.546960437641246e-06
of O 0 1.6360516497115896e-07
PAX6 O 0 0.0003871150256600231
mutations O 0 0.00013845975627191365
in O 0 1.0074103556689806e-05
aniridia B-Disease 1 1.0
patients O 0 6.49130524834618e-05
is O 0 1.4310243656723287e-08
highly O 0 3.315473406928504e-08
biased O 0 3.5403206766204676e-07
, O 0 3.5747746984782225e-09
with O 0 3.1037452608018157e-09
92 O 0 7.434800863848068e-08
% O 0 8.725160038913771e-10
of O 0 1.820814193864706e-10
all O 0 1.0626840518668246e-09
reported O 0 9.522755703983421e-07
mutations O 0 4.5128854253562167e-07
leading O 0 7.350524100502298e-08
to O 0 8.608414248101326e-08
premature O 0 4.465954589250032e-06
truncation O 0 7.350333817157662e-07
of O 0 3.9519520989017565e-09
the O 0 2.641441021467017e-08
protein O 0 3.688551544200891e-07
( O 0 2.3102600721358613e-08
nonsense O 0 1.0933797511825105e-07
, O 0 3.8429863735700565e-09
splicing O 0 1.5145860743359663e-07
, O 0 3.6723928342752288e-09
insertions O 0 1.9975459508714266e-07
and O 0 1.3076381755183775e-08
deletions O 0 2.9752987984466017e-07
) O 0 4.462050728903932e-09
and O 0 1.991127041023333e-09
just O 0 4.957387389481482e-09
2 O 0 9.006646983777955e-09
% O 0 9.159528691071728e-10
leading O 0 2.801749499070638e-09
to O 0 1.4307234286192738e-09
substitution O 0 8.300351517220861e-09
of O 0 7.899909615360912e-10
one O 0 2.713715918645221e-09
amino O 0 1.910085245526716e-08
acid O 0 2.69596505120262e-08
by O 0 8.367909920536931e-09
another O 0 5.8466053332040246e-08
( O 0 1.894494801035762e-07
missense O 0 1.2770156899932772e-05
) O 0 3.0582461363337643e-07
. O 0 5.478368052536098e-07

The O 0 5.061649517301703e-07
extraordinary O 0 3.304829476746818e-07
conservation O 0 7.030526916196322e-08
of O 0 3.0426454689091997e-09
the O 0 3.0228637371010336e-08
PAX6 O 0 6.8344488681759685e-06
protein O 0 4.3257108472971595e-07
at O 0 7.615890496026623e-08
the O 0 3.044022633957866e-08
amino O 0 1.2122086445742752e-07
acid O 0 2.875133020552312e-07
level O 0 6.365171145716886e-08
amongst O 0 4.7442714645740125e-08
vertebrates O 0 3.884467503212363e-07
predicts O 0 1.1905168548764777e-06
that O 0 2.318426517433636e-08
pathological O 0 2.027959226325038e-06
missense O 0 5.554361268877983e-05
mutations O 0 3.426346302148886e-05
should O 0 6.577452893452573e-08
in O 0 2.889657224613984e-08
fact O 0 1.0508810710518901e-08
be O 0 2.395677212163605e-09
common O 0 7.47723394312061e-09
even O 0 5.88705439952264e-09
though O 0 7.418875735965003e-09
they O 0 1.1747167683040516e-09
are O 0 5.036153716275749e-10
hardly O 0 1.7659640860756554e-08
ever O 0 1.2513702074556932e-08
seen O 0 6.671227481547248e-08
in O 0 3.520650864174968e-07
aniridia B-Disease 1 0.9999998807907104
patients O 0 2.68891471932875e-05
. O 0 4.943217390973587e-07

This O 0 2.83161654124342e-07
indicates O 0 1.476884250450894e-07
that O 0 2.9990978589466977e-09
there O 0 1.7615393588243933e-09
is O 0 9.060711625430429e-10
a O 0 9.283142254901122e-09
heavy O 0 2.7851894628838636e-05
ascertainment O 0 4.0381211874773726e-05
bias O 0 1.921828697959427e-06
in O 0 1.1656957177308414e-08
the O 0 1.0518195203701453e-08
selection O 0 1.1909633279572063e-08
of O 0 2.6776481032442234e-09
patients O 0 4.4000952215128564e-08
for O 0 1.5285912979834393e-08
PAX6 O 0 2.8583228413481265e-05
mutation O 0 1.769015170793864e-06
analysis O 0 5.9549645214929114e-08
and O 0 7.210769314980325e-09
that O 0 2.092438444734057e-09
the O 0 1.4962806105245363e-08
missing O 0 4.786901968145685e-07
PAX6 O 0 0.00013668855535797775
missense O 0 0.0001324472832493484
mutations O 0 0.0002057490637525916
frequently O 0 3.066129283979535e-05
may O 0 3.692337486427277e-05
underlie O 0 6.0230708186281845e-05
phenotypes O 0 1.8571856344351545e-05
distinct O 0 1.1487400115584023e-06
from O 0 1.0624737569742138e-06
textbook O 0 0.0008588825585320592
aniridia B-Disease 1 0.9999997615814209
. O 0 1.2892276572529227e-05

Here O 0 2.96032249025302e-06
we O 0 1.112295962002463e-07
present O 0 6.337091917885118e-08
four O 0 5.5462134440631417e-08
novel O 0 6.175339990477369e-07
PAX6 O 0 0.00011859058577101678
missense O 0 9.656300244387239e-05
mutations O 0 1.2087691175111104e-05
, O 0 1.0480547096847204e-08
two O 0 8.526362726968273e-09
in O 0 3.749085664139784e-08
association O 0 1.52421620214227e-07
with O 0 1.1046087422528217e-07
atypical O 0 0.00026298596640117466
phenotypes O 0 0.0002039350220002234
ectopia B-Disease 0 0.0005424708360806108
pupillae I-Disease 0 0.00036028079921379685
( O 0 4.890354716735601e-07
displaced B-Disease 0 2.0198436345708615e-07
pupils I-Disease 0 3.3586439940336277e-07
) O 0 9.990754534783264e-08
and O 0 6.528260200866498e-06
congenital B-Disease 1 0.9999983310699463
nystagmus I-Disease 0 0.00044105169945396483
( O 0 1.3366927475999546e-07
searching B-Disease 0 3.504942753806972e-07
gaze I-Disease 0 5.7257248045061715e-06
) O 0 9.98299753973697e-09
, O 0 9.393389399647845e-10
and O 0 6.278494946165836e-10
two O 0 1.0754157564463185e-09
in O 0 9.793215127729127e-09
association O 0 1.3306038049165636e-08
with O 0 3.922342006745794e-09
more O 0 3.0361889002961107e-08
recognizable O 0 0.00011980722774751484
aniridia B-Disease 1 0.9999996423721313
phenotypes O 0 0.000467165868030861
. O 0 3.2711700441723224e-06

Strikingly O 0 0.00047767875366844237
, O 0 2.919062183082133e-07
all O 0 5.608527420264409e-09
four O 0 1.3086362216085945e-08
mutations O 0 3.7534218222390336e-07
are O 0 2.870500503959761e-09
located O 0 4.6571081213642174e-08
within O 0 1.4900918721139078e-08
the O 0 3.839720719156503e-08
PAX6 O 0 1.3105443031236064e-05
paired O 0 7.588266726088477e-07
domain O 0 1.9596272693434003e-07
and O 0 1.9758440217287898e-08
affect O 0 7.057155215761668e-08
amino O 0 6.88819596916801e-08
acids O 0 3.09577714574516e-08
which O 0 5.029849425852717e-09
are O 0 7.127056722566749e-10
highly O 0 6.023214815797928e-09
conserved O 0 4.6117616392393757e-08
in O 0 6.474932590094795e-09
all O 0 1.4597937303406638e-09
known O 0 1.5104427930623388e-08
paired O 0 1.6456144180665433e-07
domain O 0 1.6688211701421096e-07
proteins O 0 4.736522782877728e-07
. O 0 3.5993318192595325e-07

Our O 0 1.4598105053664767e-06
results O 0 4.1888981172633066e-07
support O 0 1.3325696990307279e-08
the O 0 5.3325179827368174e-09
hypothesis O 0 1.1864015547757845e-08
that O 0 4.1094558311804974e-10
the O 0 1.5668261132972816e-09
under O 0 7.244294941699536e-09
- O 0 4.3693692219903824e-08
representation O 0 8.09663802670002e-09
of O 0 2.4116546537555905e-09
missense O 0 5.620552201435203e-06
mutations O 0 3.007480017913622e-06
is O 0 1.553617146043962e-08
caused O 0 1.9750683577512973e-07
by O 0 7.336362983778599e-08
ascertainment O 0 5.853893162566237e-05
bias O 0 2.139335083484184e-05
and O 0 5.659973112415173e-08
suggest O 0 6.9406716818321e-08
that O 0 3.879715215759916e-09
a O 0 1.2791069536888244e-08
substantial O 0 3.004567616926579e-08
burden O 0 1.7721328049447038e-07
of O 0 1.0276031581213374e-08
PAX6 B-Disease 0 0.00039220217149704695
- I-Disease 0 0.07030919939279556
related I-Disease 0 2.5137356715276837e-05
disease I-Disease 0 0.027883747592568398
remains O 0 1.7707338884065393e-07
to O 0 1.0133247130283962e-08
be O 0 8.010356822296671e-09
uncovered O 0 4.888311764261744e-07
. O 0 4.3596955379143765e-08
. O 0 4.010641418972227e-07

The O 0 2.865464011847507e-06
chromosomal O 0 8.947577589424327e-05
order O 0 1.455302509612011e-07
of O 0 1.0463669042337642e-08
genes O 0 1.8792464118178032e-07
controlling O 0 7.025794843684707e-07
the O 0 8.887622726660993e-08
major O 0 1.0617429069270656e-07
histocompatibility O 0 4.383252417028416e-06
complex O 0 2.3132149351567932e-07
, O 0 1.5166898847951416e-08
properdin O 0 3.3092176181526156e-06
factor O 0 1.6560379378915968e-07
B O 0 4.431215643307951e-07
, O 0 9.661727418119881e-09
and O 0 1.8630221632065513e-07
deficiency B-Disease 0 1.341285042144591e-06
of I-Disease 0 2.8880564606481585e-10
the I-Disease 0 4.036528000739281e-09
second I-Disease 0 1.6324678497880996e-08
component I-Disease 0 2.0803655687018363e-08
of I-Disease 0 3.064305031941217e-09
complement I-Disease 0 2.6016931542471866e-07
. O 0 3.3876955285450094e-07

The O 0 6.245892336664838e-07
relationship O 0 1.5289215582470206e-07
of O 0 2.9852924576800888e-09
the O 0 8.50244141759049e-09
genes O 0 9.53979295559293e-08
coding O 0 5.591156764239713e-07
for O 0 1.2597710430384268e-08
HLA O 0 8.985200565803098e-07
to O 0 6.266414498412587e-09
those O 0 2.598345982818273e-09
coding O 0 3.0924283578315226e-07
for O 0 5.852091700120354e-09
properdin O 0 4.360562797955936e-06
Factor O 0 1.6333189023498562e-07
B O 0 2.889399013383809e-07
allotypes O 0 9.42159203987103e-07
and O 0 2.4526260133939104e-08
for O 0 2.7686763104384227e-08
deficiency B-Disease 0 2.9230002382973908e-06
of I-Disease 0 5.764031474342346e-10
the I-Disease 0 3.7974392519402045e-09
second I-Disease 0 2.093597117891477e-08
component I-Disease 0 2.1784751780273837e-08
of I-Disease 0 2.076859795252517e-09
complement I-Disease 0 8.799892015076693e-08
( O 0 6.557660725547976e-08
C2 O 0 4.430270564625971e-06
) O 0 9.344733875593647e-09
was O 0 2.6386766549535423e-08
studied O 0 9.286205582270668e-09
in O 0 3.810149973304533e-09
families O 0 1.6307836192552827e-09
of O 0 1.462198473412002e-09
patients O 0 1.4821303295775579e-07
with O 0 5.552563493438356e-07
connective O 1 0.9999862909317017
tissue O 1 0.9999997615814209
disorders O 1 0.9999949932098389
. O 0 4.345700745034264e-06

Patients O 0 5.556830365094356e-05
were O 0 2.743968252616469e-07
selected O 0 3.918522750723241e-08
because O 0 5.21368148653778e-09
they O 0 1.590689802100087e-09
were O 0 8.807007567668279e-09
heterozygous O 0 4.913874249723449e-07
or O 0 9.888494645338142e-08
homozygous O 0 1.4462236322287936e-05
for O 0 1.660144334891811e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.926715180568863e-06

12 O 0 3.673225364764221e-06
families O 0 1.1997529725249478e-07
with O 0 2.231055340473631e-08
15 O 0 9.326804928377896e-08
matings O 0 6.045538611942902e-06
informative O 0 1.2421490282576997e-05
for O 0 0.004300425294786692
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 5.199335078032163e-07
found O 0 9.566539347360958e-07
. O 0 9.059118042387126e-07

Of O 0 1.148197839029308e-06
57 O 0 4.094488758710213e-06
informative O 0 2.6414572857902385e-06
meioses O 0 1.3296164979692549e-05
, O 0 1.4478900745018564e-08
two O 0 3.2216647127825127e-09
crossovers O 0 1.3468540771555126e-07
were O 0 1.0062350952466659e-08
noted O 0 2.195791637404909e-08
between O 0 3.13122967554591e-08
the O 0 0.002618749625980854
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
gene O 0 2.2114872990641743e-06
and O 0 4.091986838261619e-08
the O 0 8.355042524499368e-08
HLA O 0 6.463657337008044e-05
- O 0 8.14898157841526e-06
B O 0 7.91825812029856e-07
gene O 0 1.849564483791255e-07
, O 0 9.504749209909846e-10
with O 0 6.779833361392207e-10
a O 0 7.87319809347764e-09
recombinant O 0 6.154127873969628e-08
fraction O 0 4.049222823709897e-08
of O 0 2.0872652939374348e-08
0 O 0 5.025469249630987e-07
. O 0 3.394432042114204e-07

035 O 0 0.09614922851324081
. O 0 0.00025546125834807754

A O 0 3.155813828925602e-05
lod O 0 0.0016411984106525779
score O 0 1.2237268265380408e-06
of O 0 1.2821699257870023e-08
13 O 0 6.331461577246955e-08
was O 0 7.008075186831775e-08
calculated O 0 4.935379749326785e-08
for O 0 1.4670740178246433e-08
linkage O 0 3.0378969313460402e-05
between O 0 0.008202793076634407
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 6.21304536707612e-07
HLA O 0 7.570337038487196e-05
- O 0 8.764497579250019e-06
B O 0 3.6677715797850396e-07
at O 0 2.365483986466188e-08
a O 0 7.013180258752527e-09
maximum O 0 9.408921641806955e-09
likelihood O 0 1.713025632454901e-08
value O 0 1.1590240989178824e-09
of O 0 3.4112868085856007e-10
the O 0 3.4977911678168994e-09
recombinant O 0 5.5095640050240036e-08
fraction O 0 2.2195443705186335e-08
of O 0 6.666760032913999e-09
0 O 0 2.810100738770416e-07
. O 0 2.633347833125299e-07

04 O 0 0.005334360525012016
. O 0 6.550466059707105e-05

18 O 0 7.955574801599141e-06
families O 0 2.3697340623130003e-07
with O 0 6.477269920424078e-08
21 O 0 1.8164338655424217e-07
informative O 0 2.7236012556386413e-07
matings O 0 1.6191328313652775e-06
for O 0 1.2880920330360368e-08
both O 0 2.1528734350795276e-08
properdin O 0 5.605413662124192e-06
Factor O 0 1.5036238210086594e-07
B O 0 3.125883552002051e-07
allotype O 0 1.8618726471686387e-06
and O 0 7.244975108733342e-08
HLA O 0 3.0874602089170367e-05
- O 0 5.2191844588378444e-06
B O 0 9.444666488889197e-07
were O 0 1.7823181153175938e-08
found O 0 6.59725358787e-08
. O 0 1.7712693534122081e-07

Of O 0 1.0856839480766212e-06
72 O 0 2.078243596770335e-06
informative O 0 9.331313322036294e-07
meioses O 0 6.255649168451782e-06
, O 0 8.744323487519523e-09
three O 0 3.0011124696471825e-09
recombinants O 0 7.046488690320984e-07
were O 0 6.385743933634558e-09
found O 0 4.694348021416772e-09
, O 0 5.934299718290958e-10
giving O 0 2.395718290415516e-09
a O 0 4.915113649417435e-09
recombinant O 0 1.7849657751867198e-07
fraction O 0 7.002262947253257e-08
of O 0 1.2629709722489224e-08
0 O 0 4.7565038130414905e-07
. O 0 2.520798716432182e-07

042 O 0 0.012092947959899902
. O 0 0.0001789189118426293

A O 0 4.83928743051365e-05
lod O 0 0.0005484322318807244
score O 0 7.193614237621659e-07
of O 0 1.4041383167295862e-08
16 O 0 5.4321596110185055e-08
between O 0 6.414408915134118e-08
HLA O 0 2.7182451958651654e-05
- O 0 5.141509518580278e-06
B O 0 7.474213248315209e-07
and O 0 2.0730851701955544e-08
Factor O 0 7.784252176179507e-08
B O 0 1.5801603581167e-07
allotypes O 0 7.277986355802568e-07
was O 0 7.977153160254602e-08
calculated O 0 4.1385323612530556e-08
at O 0 1.2181880393313804e-08
a O 0 3.101390033677376e-09
maximum O 0 6.733507085243673e-09
likelihood O 0 7.489594722187576e-09
value O 0 8.595280598377997e-10
of O 0 2.94573726522529e-10
the O 0 1.7317435263564107e-09
recombinant O 0 5.8593542462404e-08
fraction O 0 1.439417474102811e-08
of O 0 7.76046960027088e-09
0 O 0 3.6174810702505056e-07
. O 0 3.7001709074502287e-07

04 O 0 0.006835864391177893
. O 0 6.744506390532479e-05

A O 0 1.6030923006837838e-06
crossover O 0 7.969227908688481e-07
was O 0 6.124070068835863e-07
shown O 0 6.172654565261837e-08
to O 0 9.234208064867744e-09
have O 0 2.172971358405107e-09
occurred O 0 1.5116127016767678e-08
between O 0 3.864891517935121e-09
genes O 0 3.384439750675483e-08
for O 0 2.88079560206711e-09
Factor O 0 1.610940003615724e-08
B O 0 5.481890497094355e-08
and O 0 2.5539588222045495e-08
HLA O 0 1.419333966623526e-05
- O 0 9.25190579437185e-06
D O 0 2.4301674784510396e-05
, O 0 5.273468772770684e-09
in O 0 1.1688906731421866e-08
which O 0 1.569399898926349e-07
HLA O 0 2.8480759283411317e-05
- O 0 8.210913620132487e-06
D O 0 9.401438546774443e-06
segregared O 0 1.1222922466913587e-06
with O 0 8.279010188516622e-08
HLA O 0 1.786103894119151e-05
- O 0 8.334826588907163e-07
A O 0 3.294344708137942e-07
and O 0 7.239256660795945e-08
B O 0 1.9468875507300254e-06
. O 0 2.947280961507204e-07

These O 0 3.0327626632242755e-07
studies O 0 6.08860517559151e-08
suggest O 0 2.740144289248292e-08
that O 0 1.2204758315093045e-09
the O 0 1.961937057259888e-09
genes O 0 3.1381652831896645e-08
for O 0 6.117658379878321e-09
Factor O 0 7.325736817165307e-08
B O 0 5.431979843706358e-06
and O 0 0.001009596511721611
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 3.975008766587962e-09
located O 0 3.089500566488823e-08
outside O 0 1.2769326040995566e-08
those O 0 2.403013343865723e-09
for O 0 2.1929611460080878e-09
HLA O 0 6.00782527726551e-07
, O 0 4.1991968235954857e-10
that O 0 1.7679607777765227e-10
the O 0 5.71276470573423e-10
order O 0 8.516135574510031e-10
of O 0 6.432953059132274e-10
genese O 0 6.763203259652073e-07
is O 0 1.764617074684338e-08
HLA O 0 1.298308234254364e-06
- O 0 1.8785260635922896e-07
A O 0 1.2650833980387688e-07
, O 0 1.3381015406821462e-08
- O 0 3.0214405910555797e-07
B O 0 1.69758635593098e-07
, O 0 6.223331627808193e-09
- O 0 6.76975901114929e-07
D O 0 1.94451217794267e-06
, O 0 4.770283723587454e-09
Factor O 0 2.7145816261509026e-08
B O 0 2.3491004697007156e-07
allotype O 0 2.7622008929029107e-05
, O 0 0.0001478004123782739
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 3.3739000482313486e-09
that O 0 7.918524724814802e-10
the O 0 8.589320366070297e-09
genes O 0 3.641572163814999e-07
coding O 0 1.113449161493918e-05
for O 0 4.736333357868716e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.0121468818624635e-07
Factor O 0 1.5450331147803809e-07
B O 0 3.3500961649224337e-07
allotypes O 0 1.312435301770165e-06
are O 0 3.8034992932978184e-09
approximately O 0 1.5188321711434583e-08
3 O 0 5.365330935092061e-08
- O 0 6.665084129053866e-07
- O 0 4.3586484821389604e-07
5 O 0 2.1728565613443607e-08
centimorgans O 0 3.3499043183837784e-07
from O 0 4.753707205651381e-09
the O 0 1.683013195474814e-08
HLA O 0 3.0829426123091253e-06
- O 0 1.7304245147897745e-07
A O 0 1.019750612840653e-07
and O 0 9.856370297711692e-08
HLA O 0 1.3965462130727246e-05
- O 0 1.595813273524982e-06
B O 0 1.617165423795086e-07
loci O 0 7.846307426007115e-08
, O 0 1.7666603735477793e-09
and O 0 1.0494664026694522e-09
that O 0 6.354466397517911e-10
the O 0 4.128178687778927e-09
apparent O 0 4.7929312074757036e-08
lack O 0 1.2345688027437518e-08
of O 0 1.1801560839685976e-09
recombinants O 0 2.5343649667775026e-07
between O 0 4.610757109446695e-09
the O 0 1.1651066778028962e-08
Factor O 0 5.647895306992723e-08
B O 0 4.642111548491812e-07
gene O 0 5.441940629680175e-06
and O 0 0.0018922652816399932
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 4.325131158111617e-06
suggests O 0 1.6405655856033263e-07
that O 0 2.7639104338561538e-09
these O 0 8.25708168505912e-10
two O 0 1.0093486046969247e-09
genes O 0 2.6462267044280452e-08
lie O 0 7.558507597593689e-09
in O 0 3.539791348927679e-09
close O 0 4.689580279659822e-08
proximity O 0 5.780232115171202e-08
to O 0 1.152723783093279e-08
one O 0 6.303624289216714e-09
another O 0 7.425673942407229e-08
. O 0 2.328082757685479e-07

Distribution O 0 2.8880870104330825e-06
of O 0 1.1631875196371766e-07
emerin O 0 1.3420690265775193e-05
and O 0 1.2764120072006335e-07
lamins O 0 1.0160312740481459e-05
in O 0 5.8727025020743895e-08
the O 0 1.1800198507216919e-07
heart O 0 6.233400199562311e-06
and O 0 2.5907562317684096e-08
implications O 0 2.391355735653633e-07
for O 0 6.15454993635467e-08
Emery B-Disease 1 0.9679157137870789
- I-Disease 1 0.9993056058883667
Dreifuss I-Disease 1 0.999970555305481
muscular I-Disease 1 0.9999970197677612
dystrophy I-Disease 1 0.9999947547912598
. O 0 1.1604486644500867e-05

Emerin O 0 0.00034273264463990927
is O 0 2.0564861813454627e-07
a O 0 5.156640270342905e-08
nuclear O 0 1.9265067408014147e-07
membrane O 0 1.9692680552907404e-07
protein O 0 8.620671820835923e-08
which O 0 1.631646107114193e-08
is O 0 2.3320765318857184e-09
missing O 0 1.2887752198764701e-08
or O 0 3.097560963283286e-08
defective O 0 8.572483238822315e-06
in O 0 9.608048685549875e-07
Emery B-Disease 1 0.9904683232307434
- I-Disease 1 0.9992411136627197
Dreifuss I-Disease 1 0.9999904632568359
muscular I-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999998807907104
( O 0 1.8327295038034208e-05
EDMD B-Disease 1 0.9999997615814209
) O 0 1.0374855037298403e-06
. O 0 6.337151603474922e-07

It O 0 8.22078732198861e-07
is O 0 2.118093966885226e-08
one O 0 2.407343879795576e-09
member O 0 2.009060473540103e-09
of O 0 3.420525529485019e-10
a O 0 1.105388136579677e-08
family O 0 2.031724477546959e-08
of O 0 3.5607563564354905e-09
lamina O 0 1.2495437658799347e-05
- O 0 3.143067942801281e-06
associated O 0 9.152499558240379e-08
proteins O 0 3.05018907909016e-08
which O 0 5.6724531738439055e-09
includes O 0 6.012620179518535e-09
LAP1 O 0 1.7087007790905773e-06
, O 0 1.728332321704329e-08
LAP2 O 0 4.5678948481509e-06
and O 0 1.7987900946536683e-07
lamin O 0 7.357590220635757e-05
B O 0 9.273920113628265e-06
receptor O 0 1.0958284292428289e-05
( O 0 5.982605557619536e-07
LBR O 0 2.461637632222846e-05
) O 0 1.8414473856864788e-07
. O 0 4.668865756229934e-07

A O 0 9.71075496636331e-06
panel O 0 4.189435912849149e-06
of O 0 4.37125322605425e-08
16 O 0 2.327745249885993e-07
monoclonal O 0 2.5719907625898486e-06
antibodies O 0 5.330565272743115e-06
( O 0 9.18080615974759e-08
mAbs O 0 2.7680011953634676e-06
) O 0 1.8002413781914584e-08
has O 0 1.100062707592997e-08
been O 0 5.7383982010605905e-09
mapped O 0 3.703096851381815e-08
to O 0 2.3442376928528574e-09
six O 0 1.1631543506140929e-09
specific O 0 1.5518807350289876e-09
sites O 0 8.222949432479254e-09
throughout O 0 9.332514316895413e-09
the O 0 1.8084357122916117e-08
emerin O 0 1.0517774171603378e-06
molecule O 0 1.923976498119373e-07
using O 0 8.70140297593025e-08
phage O 0 7.460170081685646e-07
- O 0 2.7411383030084835e-07
displayed O 0 9.41445463809032e-08
peptide O 0 8.831048603497038e-08
libraries O 0 1.1262208055029532e-08
and O 0 1.358628654024585e-09
has O 0 1.6689183368612248e-09
been O 0 9.931260258611019e-10
used O 0 3.1936315814107274e-09
to O 0 5.352021048565803e-09
localize O 0 1.464889805902203e-06
emerin O 0 1.3590176877187332e-06
in O 0 1.743277167065571e-08
human O 0 2.457481862450095e-08
and O 0 8.152350972068234e-08
rabbit O 0 0.00025712678325362504
heart O 0 0.00013846371439285576
. O 0 2.4095652406685986e-06

Several O 0 7.1039548856788315e-06
mAbs O 0 7.447614189004526e-05
against O 0 7.245361643981596e-07
different O 0 1.861590703811089e-07
emerin O 0 1.7387550542480312e-05
epitopes O 0 2.0990501070627943e-05
did O 0 4.136027769163775e-07
not O 0 2.040594715424504e-08
recognize O 0 8.092226266853686e-08
intercalated O 0 4.0647384480507753e-07
discs O 0 1.624571041247691e-06
in O 0 1.8266671730771122e-08
the O 0 3.768924017322206e-08
heart O 0 1.403873966410174e-06
, O 0 2.165234880280309e-09
though O 0 4.818621945901214e-09
they O 0 1.8350611030726327e-09
recognized O 0 6.702217003606847e-09
cardiomyocyte O 0 3.678486848457396e-07
nuclei O 0 2.400161349669361e-07
strongly O 0 8.662867401199037e-08
, O 0 2.733930637432991e-09
both O 0 1.7461249113281951e-09
at O 0 2.4531312092790358e-08
the O 0 8.184269262301314e-09
rim O 0 1.4370026235610567e-07
and O 0 6.401218666240993e-09
in O 0 3.0278840768005466e-08
intranuclear O 0 6.356851372402161e-06
spots O 0 1.1024887953681173e-06
or O 0 9.216597618433298e-08
channels O 0 1.8718391174843418e-06
. O 0 6.743585458934831e-07

A O 0 9.474551916355267e-05
polyclonal O 0 0.0015119919553399086
rabbit O 0 0.0003881915472447872
antiserum O 0 0.00017423488316126168
against O 0 2.259451321151573e-06
emerin O 0 4.5349665015237406e-05
did O 0 3.256951686125831e-07
recognize O 0 7.91622127849223e-08
both O 0 8.915174376511459e-09
nuclear O 0 1.3856801217571046e-07
membrane O 0 1.8492170283934684e-07
and O 0 2.0279342649587306e-08
intercalated O 0 3.015384208993055e-07
discs O 0 1.1884715149790281e-06
but O 0 2.5233750644559905e-09
, O 0 5.121973400967761e-10
after O 0 4.657878527325465e-09
affinity O 0 1.302977459261001e-08
purification O 0 1.3333501414081184e-08
against O 0 3.596577924369626e-09
a O 0 1.5185889878921444e-08
pure O 0 6.02021898998828e-08
- O 0 1.937526349138352e-06
emerin O 0 2.5023462058015866e-06
band O 0 1.493740597879878e-07
on O 0 1.0049558518687718e-08
a O 0 7.279629343770466e-09
western O 0 4.8823668663544595e-08
blot O 0 2.613986362121068e-05
, O 0 7.119302480873557e-09
it O 0 3.797822945017515e-09
stained O 0 3.7707902720285347e-06
only O 0 2.5476085685482985e-09
the O 0 9.738210238197098e-09
nuclear O 0 6.871503615002439e-07
membrane O 0 2.234565954495338e-06
. O 0 9.544503427605378e-07

These O 0 5.562654905588715e-07
results O 0 4.084497788880981e-07
would O 0 2.70833950821725e-08
not O 0 3.795368019865464e-09
be O 0 2.883005389975324e-09
expected O 0 1.8394457512727058e-08
if O 0 4.083470450666482e-09
immunostaining O 0 4.3839693830705073e-07
at O 0 5.708925598923997e-08
intercalated O 0 2.7929638690693537e-07
discs O 0 1.4081741710469942e-06
were O 0 7.025886095135547e-09
due O 0 1.2802492399544008e-08
to O 0 1.7738793767207994e-09
a O 0 2.922491582069142e-09
product O 0 2.9629250164475707e-09
of O 0 3.2959998619297437e-10
the O 0 3.935110459707403e-09
emerin O 0 4.5278184757080453e-07
gene O 0 6.784819817085008e-08
and O 0 4.805579489897127e-09
, O 0 1.0569896069512197e-09
therefore O 0 1.65387914474735e-09
, O 0 3.8250752565360813e-10
cast O 0 5.222499765977773e-09
some O 0 4.682836340919039e-10
doubt O 0 2.787873709664268e-09
upon O 0 6.48476716769153e-10
the O 0 3.873518839014878e-09
hypothesis O 0 5.889989296292697e-08
that O 0 3.0033014297714544e-08
cardiac B-Disease 0 0.1662359982728958
defects I-Disease 1 0.9013159275054932
in O 0 3.141931756545091e-06
EDMD B-Disease 1 1.0
are O 0 2.580163638299382e-08
caused O 0 1.248221650484993e-07
by O 0 6.461583712535912e-09
absence O 0 2.943471066885195e-08
of O 0 7.988066208497457e-09
emerin O 0 1.4195099538483191e-05
from O 0 2.1571035802026017e-07
intercalated O 0 8.620754670118913e-06
discs O 0 6.677833152934909e-05
. O 0 1.0827144478753326e-06

Although O 0 5.67901133763371e-06
emerin O 0 4.4319087464828044e-05
was O 0 3.0783135684941954e-07
abundant O 0 3.9876393742588334e-08
in O 0 9.348299023770323e-09
the O 0 6.984239853125018e-09
membranes O 0 2.2967022061948228e-07
of O 0 3.109920099220176e-09
cardiomyocyte O 0 1.665056743149762e-06
nuclei O 0 8.096500891952019e-07
, O 0 6.9473702346556365e-09
it O 0 5.889648768686584e-09
was O 0 1.6746787423471687e-07
absent O 0 3.941588033740118e-08
from O 0 2.453396819035447e-09
many O 0 2.0864723282443265e-09
non O 0 2.777430019307303e-08
- O 0 7.178221608228341e-07
myocyte O 0 6.175909220473841e-06
cells O 0 1.572651058268093e-07
in O 0 2.360152429048412e-08
the O 0 6.78659262121073e-08
heart O 0 1.123643869505031e-05
. O 0 4.412496537042898e-07

This O 0 4.2174460190835816e-07
distribution O 0 1.2527988246802124e-07
of O 0 9.377622234296723e-09
emerin O 0 4.831978912989143e-06
was O 0 2.2537540189659921e-07
similar O 0 1.5599358249573925e-08
to O 0 3.0629785374713947e-09
that O 0 7.528562218084289e-10
of O 0 1.91673366067846e-09
lamin O 0 7.727607567176165e-07
A O 0 6.17012361203706e-08
, O 0 1.1782556041950443e-09
a O 0 4.441062184667999e-09
candidate O 0 1.9386332539284012e-08
gene O 0 8.759718639339553e-08
for O 0 2.3930102344138504e-09
an O 0 2.2792807641280888e-08
autosomal O 0 0.0004949599970132113
form O 0 5.575810746449861e-07
of O 0 6.518292252621904e-07
EDMD B-Disease 1 1.0
. O 0 6.094825948821381e-06

In O 0 3.69933854926785e-06
contrast O 0 5.576504008786287e-06
, O 0 3.4994417319467175e-07
lamin O 0 0.00018009598716162145
B1 O 0 0.0028860121965408325
was O 0 1.3314437410372193e-06
absent O 0 3.082549824284797e-07
from O 0 3.5593050284887795e-08
cardiomyocyte O 0 1.0634215641402989e-06
nuclei O 0 1.0435784361106926e-06
, O 0 1.1120537379838424e-08
showing O 0 3.049305234981148e-07
that O 0 2.5398614766913852e-08
lamin O 0 2.2155481929075904e-05
B1 O 0 3.380285488674417e-05
is O 0 2.917634578381012e-09
not O 0 5.350395682057751e-10
essential O 0 4.321409896590467e-10
for O 0 3.098231393661166e-10
localization O 0 2.6718639745126893e-08
of O 0 1.024995199827572e-09
emerin O 0 7.251002216435154e-07
to O 0 1.1896736928918017e-08
the O 0 5.7268550790468e-08
nuclear O 0 5.731450073653832e-06
lamina O 0 5.227224755799398e-05
. O 0 1.0998570587616996e-06

Lamin O 0 0.15103232860565186
B1 O 1 0.69835364818573
is O 0 5.491538672686147e-07
also O 0 6.721730017034133e-08
almost O 0 5.662618463020408e-08
completely O 0 3.384088813618291e-07
absent O 0 5.179598474569502e-07
from O 0 1.3510427265828184e-07
skeletal O 0 0.008473332040011883
muscle O 0 0.01625463180243969
nuclei O 0 0.000177176741999574
. O 0 1.8006284108196269e-06

In O 0 1.9939019693993032e-05
EDMD B-Disease 1 0.9999964237213135
, O 0 7.738420038094773e-08
the O 0 1.48864023330475e-08
additional O 0 1.1167363034303435e-08
absence O 0 6.539736574495691e-08
of O 0 2.3179092423220027e-08
lamin O 0 7.65189397498034e-05
B1 O 0 0.0005642131436616182
from O 0 2.054858896372025e-07
heart O 0 5.2202063670847565e-05
and O 0 4.4396415432856884e-07
skeletal O 0 0.32758328318595886
muscle O 0 0.0032845870591700077
nuclei O 0 9.603517355571967e-06
which O 0 5.861813789920234e-08
already O 0 3.345009957911316e-08
lack O 0 4.251602092608664e-08
emerin O 0 1.7496582586318254e-05
may O 0 2.880556166928727e-07
offer O 0 3.1235569686316467e-09
an O 0 1.7857542111698876e-09
alternative O 0 1.3615503391406492e-08
explanation O 0 5.774488442966685e-09
of O 0 7.782863797878292e-10
why O 0 9.498519304429465e-09
these O 0 3.2751021894483756e-09
tissues O 0 5.554639415095153e-07
are O 0 4.433884814858402e-09
particularly O 0 4.130945541191977e-08
affected O 0 1.0045728515706287e-07
. O 0 3.9878674584770124e-08
. O 0 4.3793312443085597e-07

Genetic O 0 7.388195081148297e-05
mapping O 0 6.4219093474093825e-06
of O 0 1.2552527550724335e-07
the O 0 5.738887693951256e-07
copper B-Disease 0 0.0001027409452944994
toxicosis I-Disease 0 0.0003650486178230494
locus O 0 1.1103115866717417e-05
in O 0 3.065072746721853e-07
Bedlington O 0 0.00011350269778631628
terriers O 0 0.000247308547841385
to O 0 5.873721420357469e-07
dog O 0 0.0003413236699998379
chromosome O 0 5.138009328220505e-06
10 O 0 3.322741193301226e-08
, O 0 1.7217050007900525e-09
in O 0 2.4982855784116964e-09
a O 0 1.796715132229565e-08
region O 0 5.647743961390006e-08
syntenic O 0 3.2293892218149267e-06
to O 0 3.8695773696417746e-08
human O 0 7.516602806845185e-08
chromosome O 0 3.6785120300919516e-06
region O 0 6.242337349249283e-07
2p13 O 0 2.536296051403042e-05
- O 0 2.4884271624614485e-05
p16 O 0 9.489290096098557e-05
. O 0 3.387506239960203e-06

Abnormal O 1 0.9979471564292908
hepatic B-Disease 1 0.999763548374176
copper I-Disease 0 0.4064418375492096
accumulation I-Disease 0 1.6852296539582312e-05
is O 0 3.4896697087560824e-08
recognized O 0 1.5154784094306706e-08
as O 0 1.4103977541424229e-08
an O 0 1.4712373967995518e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.099436869684723e-06
man O 0 4.326253474573605e-06
, O 0 2.0714567838808762e-08
mouse O 0 2.7490297725307755e-05
, O 0 1.0340406220166187e-07
rat O 0 5.305018203216605e-05
and O 0 1.9852468824410607e-07
dog O 0 0.000502364244312048
. O 0 1.294900243919983e-06

The O 0 9.54936581365473e-07
major O 0 4.546268428384792e-07
cause O 0 8.557661885788548e-07
of O 0 2.945380828123234e-08
hepatic B-Disease 0 0.006952708121389151
copper I-Disease 0 0.01309510413557291
accumulation I-Disease 0 2.134089299943298e-06
in O 0 9.715747495420146e-08
man O 0 5.552404900299734e-07
is O 0 9.593782657191241e-09
a O 0 5.4842228536244875e-08
dysfunctional O 0 1.9240997062297538e-05
ATP7B O 0 3.402017682674341e-05
gene O 0 4.896541668131249e-06
, O 0 7.146637415189616e-08
causing O 0 5.35408325958997e-05
Wilson B-Disease 0 0.004571355413645506
disease I-Disease 1 0.7032387256622314
( O 0 3.2116006423166255e-06
WD B-Disease 0 0.011223146691918373
) O 0 1.3573053365689702e-06
. O 0 1.2333658787611057e-06

Mutations O 0 0.00033964449539780617
in O 0 3.559091794613778e-07
the O 0 6.601332103173263e-08
ATP7B O 0 9.102253898163326e-06
genes O 0 2.737318993695226e-07
have O 0 1.114729553108873e-08
also O 0 7.343696317718695e-09
been O 0 5.8939981784078554e-09
demonstrated O 0 1.8723049777236156e-08
in O 0 2.6983931533663963e-08
mouse O 0 2.9813005312462337e-05
and O 0 5.06192009197548e-07
rat O 0 0.0001597382070031017
. O 0 1.0103835847985465e-06

The O 0 2.821273483277764e-06
ATP7B O 0 7.893740985309705e-05
gene O 0 7.569974513899069e-06
has O 0 4.4026894130411165e-08
been O 0 4.767873207356388e-09
excluded O 0 1.308930741572567e-08
in O 0 2.811980426287164e-09
the O 0 4.464741021337204e-09
much O 0 1.29463400000418e-08
rarer O 0 4.4999410420132335e-07
human O 0 1.4643768508904031e-07
copper B-Disease 1 0.7771807909011841
overload I-Disease 0 0.07179898768663406
disease O 0 3.28389614878688e-05
non B-Disease 0 1.2780198233031115e-07
- I-Disease 0 3.607318376452895e-06
Indian I-Disease 0 2.4376933538405865e-07
childhood I-Disease 0 0.00015644468658138067
cirrhosis I-Disease 0 0.0001139921005233191
, O 0 6.030884236452039e-08
indicating O 0 3.336941290399409e-06
genetic O 0 9.856829819909763e-06
heterogeneity O 0 3.4548487747088075e-05
. O 0 2.502007419025176e-06

By O 0 1.2397018736010068e-06
investigating O 0 1.7765810298442375e-06
the O 0 4.018739332423138e-07
common O 0 1.576132490299642e-05
autosomal O 1 0.999742329120636
recessive O 1 0.9999967813491821
copper B-Disease 1 0.9961775541305542
toxicosis I-Disease 1 0.9809973239898682
( O 0 2.0802563085453585e-06
CT B-Disease 1 0.5753796100616455
) O 0 7.253547806840288e-08
in O 0 9.807780543269473e-08
Bedlington O 0 0.0001543651451356709
terriers O 0 0.0025020702742040157
, O 0 2.389531417179569e-08
we O 0 2.4501607409632697e-09
have O 0 1.20540599723995e-09
identified O 0 3.997422837187514e-09
a O 0 8.604553514146573e-09
new O 0 6.0267446144735e-08
locus O 0 3.366722012287937e-07
involved O 0 2.7345837594339173e-08
in O 0 6.065982688596705e-06
progressive O 1 0.999998927116394
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.7205235053552315e-05

We O 0 2.118774546033819e-06
examined O 0 3.406704308872577e-06
whether O 0 1.0234176528456373e-07
the O 0 9.79405925249921e-08
WD B-Disease 0 0.00012376777885947376
gene O 0 5.1924448598583695e-06
ATP7B O 0 6.63751779939048e-05
was O 0 9.70835344560328e-07
also O 0 9.046228655051891e-09
causative O 0 1.1245533926285134e-07
for O 0 3.912098645031392e-09
CT B-Disease 0 0.0006045750342309475
by O 0 2.136380494732748e-08
investigating O 0 5.7513091178407194e-08
the O 0 9.099375830601275e-08
chromosomal O 0 0.0005991345387883484
co O 0 1.6778196822997415e-06
- O 0 8.568409270992561e-07
localization O 0 1.021155298985832e-06
of O 0 9.755908969566462e-09
ATP7B O 0 5.875430360902101e-06
and O 0 1.4679586435306646e-08
C04107 O 0 2.8033633725499385e-07
, O 0 2.1665815808091793e-09
using O 0 1.3192722470023455e-08
fluorescence O 0 3.248842688208242e-07
in O 0 5.004110548156859e-08
situ O 0 8.027978992686258e-07
hybridization O 0 5.760739441029727e-07
( O 0 6.59843664152504e-08
FISH O 0 3.1127351007853576e-07
) O 0 1.1674651290149995e-07
. O 0 3.842563671696553e-07

C04107 O 0 0.00020527996821328998
is O 0 2.6478480208425026e-07
an O 0 5.07851467546061e-08
anonymous O 0 1.3738131201534998e-06
microsatellite O 0 5.501813211594708e-05
marker O 0 1.1396871741453651e-05
closely O 0 3.1099505122256232e-06
linked O 0 1.989846168726217e-05
to O 0 1.199274038299336e-06
CT B-Disease 1 0.9974592328071594
. O 0 3.731119932126603e-06

However O 0 4.775885372509947e-06
, O 0 3.5223368399783794e-07
BAC O 0 4.353995245764963e-05
clones O 0 2.5807453312154394e-06
containing O 0 1.7139905139629263e-07
ATP7B O 0 6.0704105635522865e-06
and O 0 3.496498734989473e-08
C04107 O 0 6.423407512556878e-07
mapped O 0 1.0255901088385144e-06
to O 0 2.7387022427660668e-08
the O 0 5.1489937646920225e-08
canine O 0 1.6100044376798905e-05
chromosome O 0 5.222689651418477e-06
regions O 0 2.74558090040955e-07
CFA22q11 O 0 7.316035407711752e-06
and O 0 5.43439782063615e-08
CFA10q26 O 0 1.928167876030784e-06
, O 0 6.397520291301362e-09
respectively O 0 3.4660608605463494e-08
, O 0 3.3306075675199054e-09
demonstrating O 0 2.9055019723500664e-08
that O 0 2.996938164301355e-08
WD B-Disease 0 2.8395170375006273e-05
cannot O 0 1.1610175931764388e-07
be O 0 1.0762596147628756e-08
homologous O 0 3.971828448356973e-07
to O 0 1.9756166125262098e-07
CT B-Disease 1 0.9649838805198669
. O 0 2.6416989840072347e-06

The O 0 3.208092493878212e-06
copper O 0 1.8576283764559776e-05
transport O 0 8.615343745077553e-07
genes O 0 1.0325718449166743e-06
CTR1 O 0 8.369751412828919e-06
and O 0 6.113297956744645e-08
CTR2 O 0 7.003463906585239e-06
were O 0 3.329510178673445e-08
also O 0 8.599286616117752e-09
excluded O 0 1.639654634288945e-08
as O 0 4.419800969657217e-09
candidate O 0 1.393482307321392e-08
genes O 0 2.1006570705139893e-08
for O 0 1.1001046296144068e-08
CT B-Disease 1 0.9131522178649902
since O 0 7.882928798608191e-07
they O 0 3.343936461064345e-09
both O 0 6.297699695068104e-09
mapped O 0 3.453095587246935e-07
to O 0 4.4565414469843745e-08
canine O 0 3.7548183172475547e-05
chromosome O 0 2.463107739458792e-05
region O 0 1.6645423102090717e-06
CFA11q22 O 0 0.00021446934260893613
. O 0 1.945397116287495e-06

2 O 0 5.5135838920250535e-05
- O 0 0.0001678275439189747
22 O 0 6.5921872192120645e-06
. O 0 1.60215540745412e-06

5 O 0 0.00011302402708679438
. O 0 1.32895229398855e-05

A O 0 4.181309122941457e-06
transcribed O 0 9.290084562962875e-06
sequence O 0 5.728252858716587e-07
identified O 0 9.997083338930679e-08
from O 0 8.798293649192601e-09
the O 0 7.809068058861612e-09
C04107 O 0 6.597907713512541e-07
- O 0 4.2560728275020665e-07
containing O 0 1.5174025236319721e-07
BAC O 0 2.5547551558702253e-05
was O 0 1.5597223068652966e-07
found O 0 2.9891042974128368e-09
to O 0 1.4964196548561404e-09
be O 0 1.0275751360921959e-09
homologous O 0 2.0462538330434654e-08
to O 0 2.407352983624378e-09
a O 0 6.662552731739879e-09
gene O 0 1.1188154047658827e-07
expressed O 0 1.2316311526205936e-08
from O 0 5.468979935585594e-09
human O 0 1.5245353424120367e-08
chromosome O 0 1.7964568996831076e-06
2p13 O 0 1.3381471717366367e-06
- O 0 8.355519298675063e-07
p16 O 0 8.088343292911304e-07
, O 0 5.2477622247693034e-09
a O 0 1.3180348368280193e-08
region O 0 5.021723126219513e-08
devoid O 0 7.275676239260065e-08
of O 0 1.55120005729259e-09
any O 0 1.2380326985805823e-08
positional O 0 2.7843364023283357e-06
candidate O 0 5.467657047120156e-07
genes O 0 1.4369123846336151e-06
. O 0 6.515731456602225e-07

Molecular O 0 2.7069067073171027e-05
analysis O 0 1.1171110827490338e-06
of O 0 1.1346620532037832e-08
the O 0 1.7309252697828015e-08
APC B-Disease 0 8.914275326787902e-07
gene O 0 2.5002108827720804e-07
in O 0 2.7006379355043464e-08
205 O 0 2.2448347181125428e-07
families O 0 3.458044517401504e-08
: O 0 1.624122880627965e-08
extended O 0 4.870963721259614e-07
genotype O 0 3.276757706771605e-05
- O 0 6.415280950022861e-05
phenotype O 0 3.3288302802247927e-05
correlations O 0 1.2498028354457347e-06
in O 0 1.4376372803326376e-07
FAP B-Disease 0 5.125966140440141e-07
and O 0 2.6936917141284766e-09
evidence O 0 1.6852704787240214e-09
for O 0 5.244618073163565e-10
the O 0 2.2340818084387593e-09
role O 0 4.9141295477284075e-09
of O 0 1.775947944260281e-09
APC B-Disease 0 3.6903915656694153e-07
amino O 0 1.5790530483172915e-07
acid O 0 5.793626201011648e-07
changes O 0 2.668895376700675e-06
in O 1 0.8244834542274475
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.4002797305583954
. O 0 3.118795348200365e-06

BACKGROUND O 0 0.0001862390636233613
/ O 0 2.8391243176884018e-05
AIMS O 0 6.003592716297135e-07
The O 0 1.4399337722181826e-08
development O 0 3.0794112149123976e-08
of O 0 5.056437203165842e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.2738703958348196e-07
a O 0 2.2583797942843375e-07
variable O 0 1.4723561889695702e-06
range O 0 1.2849417885263392e-07
of O 0 2.054827064057463e-08
extracolonic O 0 6.253295578062534e-05
manifestations O 0 1.756020719767548e-05
in O 0 7.187582377810031e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 0.00033254121080972254
FAP B-Disease 0 8.551856444682926e-05
) O 0 4.72324330758056e-08
is O 0 3.436751994101428e-09
the O 0 2.410436072963762e-09
result O 0 3.4283649252841997e-09
of O 0 9.377350007611085e-10
the O 0 2.854357994408474e-08
dominant O 0 1.0092460797750391e-05
inheritance O 0 2.2952053768676706e-06
of O 0 1.274421151720162e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999979734420776
coli I-Disease 1 1.0
( O 0 1.722454180708155e-05
APC B-Disease 0 5.764823799836449e-05
) O 0 7.252613158925669e-07
gene O 0 1.933108433149755e-05
mutations O 0 8.74099278007634e-05
. O 0 3.212917818018468e-06

In O 0 1.0383149628978572e-06
this O 0 3.568651862906336e-08
study O 0 1.304185826001003e-08
, O 0 2.4975661538917393e-09
direct O 0 2.0367838970969387e-08
mutation O 0 2.9651636168637197e-07
analysis O 0 1.3274402910212757e-08
of O 0 9.689958835323864e-10
the O 0 1.795420345729326e-08
APC B-Disease 0 7.94787013091991e-07
gene O 0 2.1585233866971976e-07
was O 0 9.245631815701927e-08
performed O 0 2.7540504987655368e-08
to O 0 7.783283351159298e-09
determine O 0 1.1717460779436806e-07
genotype O 0 1.4229146472644061e-05
- O 0 1.150783555203816e-05
phenotype O 0 7.2462157731933985e-06
correlations O 0 4.2779416276061966e-07
for O 0 9.55913215250348e-09
nine O 0 4.015367238707768e-08
extracolonic O 0 4.837382221012376e-06
manifestations O 0 3.795573206843983e-07
and O 0 8.15954948052422e-09
to O 0 6.7094818589907845e-09
investigate O 0 7.378800148671871e-08
the O 0 5.588114149190915e-08
incidence O 0 1.2860982678830624e-06
of O 0 1.1462647719895358e-08
APC B-Disease 0 3.6382571124704555e-06
mutations O 0 3.7082536437083036e-06
in O 0 4.297356213101011e-07
non O 0 5.995072206133045e-05
- O 1 0.9999994039535522
FAP O 1 0.9999995231628418
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.2621898096986115e-05

METHODS O 0 1.479824732086854e-05
The O 0 9.784478152141673e-07
APC B-Disease 0 9.29341695155017e-06
gene O 0 2.4599310108897043e-06
was O 0 2.577493489752669e-07
analysed O 0 2.7778628464147914e-07
in O 0 3.5236531914506486e-08
190 O 0 3.997444366632408e-07
unrelated O 0 1.4420769502976327e-06
FAP B-Disease 0 9.424140444025397e-06
and O 0 8.566026110656821e-08
15 O 0 4.885795306108776e-07
non O 0 9.990875696530566e-06
- O 1 0.9999998807907104
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0001801782491384074
using O 0 2.9595009891636437e-06
denaturing O 0 0.0006344059365801513
gradient O 0 4.2069190385518596e-05
gel O 0 2.967079126392491e-05
electrophoresis O 0 2.3724796847091056e-06
, O 0 7.530088552698544e-09
the O 0 1.721167386392608e-08
protein O 0 1.6871375407845335e-07
truncation O 0 1.747560418152716e-06
test O 0 7.598506499562063e-07
, O 0 4.4088381834228585e-09
and O 0 6.514349948361087e-09
direct O 0 9.007251833281771e-08
sequencing O 0 1.9364142644917592e-06
. O 0 3.9822208464102005e-07

RESULTS O 0 5.449264062917791e-05
Chain O 0 3.753006967599504e-05
terminating O 0 4.7902908590913285e-06
signals O 0 5.00656324220472e-06
were O 0 1.9621138491743295e-08
only O 0 1.337447708138484e-09
identified O 0 8.863969114258907e-09
in O 0 1.0495389446418812e-08
patients O 0 1.9754596181087436e-08
belonging O 0 1.737922161737515e-08
to O 0 1.0802886585281612e-08
the O 0 5.759850196795924e-08
FAP B-Disease 0 3.146393737551989e-06
group O 0 5.8944955583228875e-08
( O 0 4.062094660639559e-08
105 O 0 7.101755272742594e-07
patients O 0 8.809210498839093e-07
) O 0 1.9048975730129314e-07
. O 0 4.4587650904759357e-07

Amino O 0 4.740575604955666e-05
acid O 0 1.3156723980500828e-05
changes O 0 4.072265369359229e-07
were O 0 2.2871892824127826e-08
identified O 0 8.999022860223249e-09
in O 0 9.245839649452137e-09
four O 0 1.0276148820764774e-08
patients O 0 1.9200351530912485e-08
, O 0 7.9855794199446e-10
three O 0 5.336178166004402e-10
of O 0 6.444287325990672e-10
whom O 0 4.097459260776759e-09
belonged O 0 1.6403207681037202e-08
to O 0 2.5602786557499257e-09
the O 0 7.0184662526173724e-09
non O 0 3.844359142135545e-08
- O 0 3.8008940919098677e-06
FAP O 0 3.227926754334476e-06
group O 0 3.5130244668835076e-07
of O 0 3.5389242839301005e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.000890923838596791
. O 0 3.510416036078823e-06

Genotype O 0 0.09511633962392807
- O 0 0.00655240286141634
phenotype O 0 0.0007550579612143338
correlations O 0 1.244401755684521e-05
identified O 0 2.266332472800059e-07
significant O 0 2.2657699716432944e-08
differences O 0 4.2190144711184985e-08
in O 0 1.5070584780119134e-08
the O 0 8.173536514277657e-09
nature O 0 4.6867434377873e-09
of O 0 8.975432064239897e-10
certain O 0 9.509214748959494e-09
extracolonic O 0 2.180517867600429e-06
manifestations O 0 3.4440907370481e-07
in O 0 1.0215006085445566e-07
FAP B-Disease 0 4.165818154433509e-06
patients O 0 8.158681907843857e-08
belonging O 0 3.2728369347978514e-08
to O 0 2.696098633236943e-08
three O 0 5.829357263564816e-08
mutation O 0 3.800466402026359e-06
subgroups O 0 1.1404331416997593e-06
. O 0 5.10199072323303e-07

CONCLUSIONS O 0 6.67419153614901e-05
Extended O 0 1.2576648259710055e-05
genotype O 0 0.00021865798044018447
- O 0 3.3519921998959035e-05
phenotype O 0 2.1758067305199802e-05
correlations O 0 7.80996344929008e-07
made O 0 1.7067247171098643e-08
in O 0 1.517885195312374e-08
this O 0 6.650211936687356e-09
study O 0 1.655056891536333e-08
may O 0 8.523862504716817e-08
have O 0 6.417658071633525e-10
the O 0 1.4100043355114167e-09
potential O 0 1.467356014472898e-09
to O 0 1.0459433319454092e-09
determine O 0 1.8320674977090334e-09
the O 0 1.8366227427790704e-09
most O 0 1.1470515648426272e-09
appropriate O 0 6.302578015038307e-09
surveillance O 0 4.0966574488265906e-07
and O 0 2.0047821180924075e-08
prophylactic O 0 9.614391274226364e-07
treatment O 0 3.8992357076494955e-07
regimens O 0 1.2294212865526788e-06
for O 0 6.479256686731105e-09
those O 0 7.45868877771727e-09
patients O 0 2.6066819813763686e-08
with O 0 9.694769431689565e-09
mutations O 0 1.8987287830896094e-06
associated O 0 6.975828625854774e-08
with O 0 6.471280755704356e-08
life O 0 7.803553216945147e-07
threatening O 0 0.00010645515430951491
conditions O 0 0.00014424776600208133
. O 0 2.2018323306838283e-06

This O 0 3.595564805891627e-07
study O 0 1.0514147419371511e-07
also O 0 1.0606151512604356e-08
provided O 0 3.209398524717244e-09
evidence O 0 4.815599474738974e-09
for O 0 1.2521478298666011e-09
the O 0 3.976039941733234e-09
pathological O 0 1.0725734966854361e-07
nature O 0 1.1321370507744177e-08
of O 0 1.6052402740385219e-09
amino O 0 6.413063147192588e-08
acid O 0 2.1156637330932426e-07
changes O 0 4.8584649192662255e-08
in O 0 5.380190160053644e-08
APC O 0 6.94168363679637e-07
associated O 0 2.8273307250969992e-08
with O 0 6.280545861159226e-09
both O 0 1.6354411158658877e-08
FAP B-Disease 0 1.0750574119811063e-06
and O 0 4.691181842986225e-08
non O 0 3.213074251107173e-06
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00018191488925367594
. O 0 2.249510941965127e-07
. O 0 6.785006689824513e-07

Inherited B-Disease 1 0.9999990463256836
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999988079071045
and O 1 0.8249843120574951
cancer B-Disease 1 0.9911017417907715
risk O 0 1.5888234656813438e-06
of O 0 2.3967068329966423e-08
the O 0 3.818759353180212e-07
APC O 0 3.268356522312388e-05
I1307K O 0 5.82913780817762e-05
polymorphism O 0 0.0001361367612844333
. O 0 3.603543291319511e-06

Germ O 0 0.01148554589599371
- O 0 0.00155883957631886
line O 0 3.768450187635608e-05
and O 0 1.1262115862109567e-07
somatic O 0 2.9644359074154636e-06
truncating O 0 1.5877005353104323e-05
mutations O 0 4.697754775406793e-06
of O 0 1.1877306249630237e-08
the O 0 6.714797962104058e-08
APC B-Disease 0 1.6341989521606592e-06
gene O 0 4.1933344618882984e-07
are O 0 2.7312829775638647e-09
thought O 0 2.3393882386812948e-08
to O 0 5.383515855328369e-08
initiate O 0 0.00020409998251125216
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.037924788892269135
formation O 0 1.1024930245184805e-05
in O 0 0.00010700677376007661
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0003379732952453196
sporadic O 1 0.9999918937683105
colorectal O 1 1.0
carcinogenesis O 1 0.9990323781967163
, O 0 2.087784650939284e-06
respectively O 0 4.016496404801728e-06
. O 0 1.2327990361882257e-06

Recently O 0 3.384172305231914e-05
, O 0 3.3366470120199665e-07
an O 0 1.6522899670690094e-07
isoleucine O 0 0.00036039756378158927
- O 0 4.4888332922710106e-05
- O 0 3.351889972691424e-05
> O 0 9.86235863820184e-06
lysine O 0 6.514782580779865e-05
polymorphism O 0 3.61613419954665e-05
at O 0 2.143099891327438e-06
codon O 0 1.7485508578829467e-05
1307 O 0 3.6580186133505777e-05
( O 0 1.5097738526037574e-07
I1307K O 0 6.016913403072977e-07
) O 0 7.541256508147853e-09
of O 0 9.691123459276696e-10
the O 0 1.3686375588406463e-08
APC B-Disease 0 4.92681124342198e-07
gene O 0 1.0990542875788378e-07
has O 0 4.284046895008942e-09
been O 0 2.1164452412847368e-09
identified O 0 9.488144492308948e-09
in O 0 4.4578061242361855e-09
6 O 0 2.7610035147063172e-08
% O 0 4.83273199236578e-09
- O 0 1.123560693372383e-07
7 O 0 2.6749031434292192e-08
% O 0 8.914047278096859e-10
of O 0 2.4501362050344255e-10
the O 0 6.452076650731442e-09
Ashkenazi O 0 8.500108492626168e-07
Jewish O 0 1.43636825100657e-07
population O 0 8.674111029449705e-08
. O 0 2.557625293775345e-07

To O 0 1.8103082766174339e-06
assess O 0 2.3787893042026553e-06
the O 0 1.0243062575909789e-07
risk O 0 7.33065661506771e-08
of O 0 1.4694676586657351e-09
this O 0 8.23362178437037e-09
common O 0 1.838092487105314e-07
APC B-Disease 0 6.166775165183935e-06
allelic O 0 1.4836642549198586e-05
variant O 0 0.14923524856567383
in O 0 0.01389206014573574
colorectal O 1 1.0
carcinogenesis O 0 0.24267379939556122
, O 0 1.5764982208565925e-07
we O 0 6.701756927185443e-09
have O 0 2.536713283873837e-09
analyzed O 0 3.5686994692696317e-08
a O 0 8.53794990263168e-09
large O 0 1.9253819871778433e-08
cohort O 0 1.8819007152615086e-07
of O 0 1.291041229478651e-08
unselected O 0 6.6943507590622175e-06
Ashkenazi O 0 8.309926670335699e-06
Jewish O 0 3.8754834008614125e-07
subjects O 0 4.778472657562816e-07
with O 0 1.5489634108689643e-07
adenomatous B-Disease 0 0.0012697024503722787
polyps I-Disease 0 0.00043808415648527443
and O 0 2.1038512443283253e-07
. O 0 9.875852811092045e-07
or O 1 0.999982476234436
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 4.1358966029747535e-08
for O 0 6.453996448385624e-09
the O 0 7.566271165160288e-08
APC O 0 1.0915082384599373e-05
I1307K O 0 1.2874535968876444e-05
polymorphism O 0 4.195708970655687e-05
. O 0 1.4228912732505705e-06

The O 0 5.069415692560142e-06
APC O 0 2.4033683075685985e-05
I1307K O 0 6.517647761938861e-06
allele O 0 5.826016604260076e-06
was O 0 2.786451318570471e-07
identified O 0 4.300651923472287e-08
in O 0 1.498920099152201e-08
48 O 0 6.79834357697473e-08
( O 0 1.0413614859317022e-08
10 O 0 3.504362133810446e-09
. O 0 9.154096924923749e-10
1 O 0 5.241880263184839e-09
% O 0 9.548504209533348e-10
) O 0 9.098257147677202e-10
of O 0 4.258863928185974e-09
476 O 0 3.535277073751786e-06
patients O 0 3.320658606753568e-06
. O 0 1.2620000688912114e-06

Compared O 0 3.3489025099697756e-06
with O 0 5.853188156379474e-08
the O 0 3.0526102534622623e-08
frequency O 0 1.826846869334986e-06
in O 0 6.155111531569446e-09
two O 0 7.877399843536637e-10
separate O 0 4.326682123689807e-09
population O 0 2.821860967117118e-09
control O 0 3.110514867898928e-08
groups O 0 1.7111175809603196e-09
, O 0 1.1060372617777148e-09
the O 0 9.622517893603799e-09
APC O 0 4.5497554879148083e-07
I1307K O 0 6.208301215337997e-07
allele O 0 6.442481321755622e-07
is O 0 2.860165881912735e-09
associated O 0 3.5315503854604913e-09
with O 0 5.098279021176211e-10
an O 0 1.7148552577950227e-09
estimated O 0 9.655169108668815e-09
relative O 0 1.4834368755600735e-07
risk O 0 5.802224123385713e-08
of O 0 6.074369895969767e-09
1 O 0 2.453263050483656e-07
. O 0 3.9868146473054367e-07

5 O 0 4.03391859435942e-05
- O 0 5.760571002610959e-05
1 O 0 3.235132226109272e-06
. O 0 1.3647193100041477e-06

7 O 0 9.765812137629837e-05
for O 0 1.0604051567497663e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9946446418762207
( O 0 2.848744998118491e-06
both O 0 3.8765443832744495e-07
P O 0 0.0020825734827667475
= O 0 4.54122982773697e-06
. O 0 1.4887005761465844e-07
01 O 0 1.0215332622465212e-05
) O 0 1.5651579587938613e-07
. O 0 3.539925614859385e-07

Furthermore O 0 6.592891168111237e-06
, O 0 1.86490638043324e-07
compared O 0 1.216098013401279e-07
with O 0 2.3933356629868285e-08
noncarriers O 0 6.43269095235155e-06
, O 0 3.546131921439155e-08
APC O 0 7.765868872411374e-07
I1307K O 0 7.473158234461152e-07
carriers O 0 1.8288150727130414e-07
had O 0 3.840635898200162e-08
increased O 0 3.316472785286351e-08
numbers O 0 1.335477950448194e-08
of O 0 1.2580782637883203e-08
adenomas B-Disease 0 0.00011727754463208839
and O 0 0.014085712842643261
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9985313415527344
per O 0 4.216056822770042e-06
patient O 0 0.00013811717508360744
( O 0 4.99630971262377e-07
P O 0 0.0004005793889518827
= O 0 6.888142820571375e-07
. O 0 1.1153228562932327e-08
03 O 0 1.7523389317375404e-07
) O 0 2.560532452733355e-09
, O 0 8.468288292817761e-10
as O 0 1.1989237380660711e-09
well O 0 1.5806608244517406e-09
as O 0 1.400863425260468e-09
a O 0 1.7094189175281826e-08
younger O 0 2.3144527006024873e-07
age O 0 5.8455572826687785e-08
at O 0 1.6687113202351611e-06
diagnosis O 0 0.00044824701035395265
. O 0 1.2200456467326148e-06

We O 0 9.717152806842932e-07
conclude O 0 8.121371024571999e-07
that O 0 2.3632470202983313e-08
the O 0 3.433805062513784e-08
APC O 0 1.316223119829374e-06
I1307K O 0 9.777555760592804e-07
variant O 0 2.994692295033019e-06
leads O 0 1.3603749948742916e-07
to O 0 5.199156660751214e-08
increased O 0 1.5542149185421295e-06
adenoma B-Disease 1 0.9999927282333374
formation O 0 7.844539027246356e-07
and O 0 5.269065184165811e-09
directly O 0 1.0660017757402329e-08
contributes O 0 2.1257189786183517e-08
to O 0 2.755157435530009e-09
3 O 0 1.1127645471731284e-08
% O 0 3.2632050395164924e-09
- O 0 4.6075765425257487e-08
4 O 0 1.523509318701599e-08
% O 0 6.93649637728555e-10
of O 0 3.9253633676850086e-10
all O 0 8.937647955065131e-09
Ashkenazi O 0 0.011759242974221706
Jewish O 1 0.9989266991615295
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3421880794339813e-05

The O 0 5.874113639947609e-07
estimated O 0 2.2619600770212855e-07
relative O 0 1.982401585109983e-07
risk O 0 8.185428868046074e-08
for O 0 1.0604129130342699e-08
carriers O 0 2.365286064787142e-07
may O 0 2.1077974565741897e-07
justify O 0 1.4430271733090194e-07
specific O 0 3.2924969417535976e-08
clinical O 0 1.821626085529715e-07
screening O 0 2.5561138272678363e-07
for O 0 4.64850602455158e-09
the O 0 1.2677545235817433e-08
360 O 0 7.722628225792505e-08
, O 0 2.3351831579532245e-09
000 O 0 5.33259925106222e-09
Americans O 0 1.1532664823121763e-09
expected O 0 4.800962294382316e-09
to O 0 3.2137477123939107e-09
harbor O 0 6.263572771558756e-08
this O 0 1.4273517923157897e-09
allele O 0 6.959827203445457e-08
, O 0 8.628560088652648e-10
and O 0 1.77021219904816e-09
genetic O 0 2.3475458021948725e-08
testing O 0 5.5913549346087166e-08
in O 0 8.077604363165847e-09
the O 0 6.9537207103564924e-09
setting O 0 1.9177658572289147e-08
of O 0 1.6054362284023682e-09
long O 0 9.240977050239962e-08
- O 0 2.1475436824403005e-06
term O 0 2.5919729296219884e-07
- O 0 2.5269508796554874e-07
outcome O 0 4.151529608975579e-08
studies O 0 3.3906168539488135e-08
may O 0 7.707354399144606e-08
impact O 0 1.402375175985071e-07
significantly O 0 0.00021007606119383126
on O 1 0.9999991655349731
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.00011257323058089241
in O 0 9.220659791253638e-08
this O 0 3.069547815925944e-08
population O 0 6.504233596160702e-08
. O 0 1.6957902460035257e-07

Localization O 0 7.098067726474255e-05
of O 0 3.8552860814888845e-07
human O 0 3.362989957622631e-07
BRCA1 O 0 9.799357030715328e-06
and O 0 2.8086049042030936e-08
its O 0 9.31901666945123e-08
loss O 0 1.4809577351115877e-06
in O 0 8.188317934809675e-08
high O 0 9.339458301838022e-06
- O 0 9.890341061691288e-06
grade O 0 4.679997402945446e-07
, O 0 2.42111344306295e-08
non B-Disease 0 1.1700280992954504e-06
- I-Disease 1 0.9958433508872986
inherited I-Disease 1 0.9999903440475464
breast I-Disease 1 0.9999977350234985
carcinomas I-Disease 1 0.9999998807907104
. O 0 1.8728871509665623e-05

Although O 0 1.8667512904357864e-06
the O 0 7.56384750388861e-08
link O 0 3.6328657415651833e-07
between O 0 2.7684228243174402e-08
the O 0 2.6642874217941426e-07
BRCA1 O 0 0.0013872944982722402
tumour B-Disease 1 0.9999997615814209
- O 0 5.2190116548445076e-05
suppressor O 0 0.00014923738490324467
gene O 0 1.2818644790968392e-05
and O 0 2.526763182686409e-06
hereditary B-Disease 1 0.9999923706054688
breast I-Disease 1 1.0
and I-Disease 1 0.9999985694885254
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.103423201698206e-07
established O 0 2.0090617169898906e-08
, O 0 6.152479081755757e-10
the O 0 1.3405608845218353e-09
role O 0 3.413442639654818e-09
, O 0 4.768161421253581e-10
if O 0 2.1528959170957762e-10
any O 0 2.2565771473637142e-10
, O 0 3.515661095576661e-10
of O 0 7.890151310085969e-10
BRCA1 O 0 5.309847210810403e-07
in O 0 2.5051294372246957e-08
non B-Disease 0 3.952651468352997e-07
- I-Disease 0 0.1322791576385498
familial I-Disease 0 0.2520483434200287
cancers I-Disease 0 0.43689972162246704
is O 0 5.467689234706086e-08
unclear O 0 6.617442522838246e-07
. O 0 5.204832405070192e-07

BRCA1 O 0 0.32890576124191284
mutations O 0 0.00039723218651488423
are O 0 5.651084578062182e-08
rare O 0 1.1696404556005291e-07
in O 0 1.3087763761632232e-07
sporadic B-Disease 0 0.3492268919944763
cancers I-Disease 1 0.9944323897361755
, O 0 5.226289445658949e-08
but O 0 2.084679273650636e-08
loss O 0 1.365300761335675e-07
of O 0 4.768618833139726e-09
BRCA1 O 0 2.548792053858051e-06
resulting O 0 1.0808145844976025e-07
from O 0 4.115138807492258e-08
reduced O 0 3.2159695706468483e-07
expression O 0 2.447817735173885e-07
or O 0 9.487732199886523e-08
incorrect O 0 8.362430889974348e-07
subcellular O 0 2.3279192191694165e-06
localization O 0 1.5678336922064773e-06
is O 0 8.796398276444961e-09
postulated O 0 8.461095291067977e-08
to O 0 4.496274907950237e-09
be O 0 1.0825116358859077e-09
important O 0 6.888715153863245e-10
in O 0 6.445421973921839e-09
non B-Disease 0 1.0483809376182762e-07
- I-Disease 0 0.00608648918569088
familial I-Disease 1 0.9890643954277039
breast I-Disease 1 0.9999996423721313
and I-Disease 1 0.999957799911499
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.0844591997738462e-05

Epigenetic O 0 0.0027434832882136106
loss O 0 0.00033988195355050266
, O 0 1.193599388216171e-07
however O 0 2.1368288471990127e-08
, O 0 3.1761913099614958e-09
has O 0 2.384576758274193e-09
not O 0 5.658520874085582e-10
received O 0 1.67336799972162e-09
general O 0 4.9502255627942304e-09
acceptance O 0 4.07639113575442e-08
due O 0 1.0324659882599008e-07
to O 0 1.3002217968960395e-08
controversy O 0 3.5150609534184696e-08
regarding O 0 8.04608113469385e-09
the O 0 1.0275639006351867e-08
subcellular O 0 8.312600243698398e-07
localization O 0 2.8552244657475967e-07
of O 0 7.567812154718467e-09
BRCA1 O 0 2.3456088911189e-06
proteins O 0 5.2215465728977506e-08
, O 0 1.6361173527101869e-09
reports O 0 5.7034803546685e-09
of O 0 2.790101205629725e-10
which O 0 2.15861239993842e-09
have O 0 1.1671924537992595e-09
ranged O 0 2.458865111520936e-08
from O 0 2.753234973340568e-09
exclusively O 0 1.0983372433770455e-08
nuclear O 0 5.116169532470849e-08
, O 0 8.870610912481425e-10
to O 0 2.9664763978587416e-09
conditionally O 0 1.9738746459552203e-07
nuclear O 0 5.595067520403063e-08
, O 0 1.608872590708188e-09
to O 0 4.003435360999674e-09
the O 0 8.724868649778728e-08
ER O 0 1.0331892553949729e-05
/ O 0 2.299258312632446e-06
golgi O 0 3.955003649025457e-06
, O 0 4.914232576425093e-09
to O 0 6.580712419435031e-09
cytoplasmic O 0 2.2152268286390608e-07
invaginations O 0 6.166289381326351e-07
into O 0 1.6216342046959653e-08
the O 0 2.562673984130015e-08
nucleus O 0 9.962589047063375e-07
. O 0 4.045294303978153e-07

In O 0 4.909907147521153e-07
an O 0 1.9201303658178404e-08
attempt O 0 8.207863544384963e-08
to O 0 9.220216590222208e-09
resolve O 0 7.750487895918923e-08
this O 0 4.138103637529866e-09
issue O 0 1.5639278316825767e-08
, O 0 3.0931195382777332e-09
we O 0 1.5354634230746456e-09
have O 0 3.915614499305775e-09
comprehensively O 0 5.107102651891182e-07
characterized O 0 5.513084602171148e-07
19 O 0 1.3007866073166952e-07
anti O 0 2.0724128262372687e-05
- O 0 0.007000692188739777
BRCA1 O 0 0.0003818220866378397
antibodies O 0 2.829860932251904e-05
. O 0 1.8147991340811132e-06

These O 0 3.194985083609936e-06
reagents O 0 2.7959698854829185e-05
detect O 0 3.254565308452584e-05
a O 0 8.515361287209089e-07
220 O 0 2.0522613795037614e-06
- O 0 6.785545338061638e-06
kD O 0 1.3970017789688427e-05
protein O 0 1.1639448302958044e-06
localized O 0 3.6282647215557517e-06
in O 0 1.1365750651748385e-07
discrete O 0 2.97132601190242e-07
nuclear O 0 6.76258366638649e-07
foci O 0 2.6311288365832297e-06
in O 0 2.432472001601127e-08
all O 0 1.242474678697647e-09
epithelial O 0 1.3570009116392612e-07
cell O 0 6.744640472788888e-07
lines O 0 5.216897989157587e-07
, O 0 1.6560728344217068e-09
including O 0 4.4661355169672845e-10
those O 0 1.2457397335907672e-09
derived O 0 2.753892758278198e-08
from O 0 3.301194340110669e-07
breast B-Disease 0 0.022087370976805687
malignancies I-Disease 0 0.00014659152657259256
. O 0 1.7886990235638223e-06

Immunohistochemical O 0 0.0019762988667935133
staining O 0 0.00020183248852845281
of O 0 2.8986448796786135e-07
human O 0 8.044364676607074e-07
breast O 0 0.00012208352563902736
specimens O 0 3.5634391792882525e-07
also O 0 1.8540750090778602e-07
revealed O 0 3.1523948109679623e-06
BRCA1 O 0 1.601374060555827e-05
nuclear O 0 2.8755848688888364e-06
foci O 0 3.473663309705444e-05
in O 0 4.942246505379444e-06
benign O 1 0.9997765421867371
breast O 1 0.939145565032959
, O 0 4.010889824712649e-07
invasive B-Disease 0 0.024307595565915108
lobular I-Disease 1 0.999854326248169
cancers I-Disease 1 0.9976966977119446
and O 0 4.8895703912421595e-06
low B-Disease 1 0.9798367619514465
- I-Disease 1 0.9916228652000427
grade I-Disease 0 0.04057642072439194
ductal I-Disease 1 0.9960869550704956
carcinomas I-Disease 1 0.9999998807907104
. O 0 2.692422640393488e-05

Conversely O 0 0.00012023181625409052
, O 0 1.1160855137859471e-06
BRCA1 O 0 1.3587398825620767e-05
expression O 0 5.660642159455165e-07
was O 0 4.7608648401364917e-07
reduced O 0 1.2629834600375034e-07
or O 0 3.968927231312591e-08
undetectable O 0 3.712546003953321e-07
in O 0 9.791870425601701e-09
the O 0 6.472833824489044e-09
majority O 0 5.64211033449169e-09
of O 0 1.9439012621802476e-09
high O 0 2.920712404375081e-06
- O 0 1.9108043488813564e-05
grade O 0 1.354684059151623e-06
, O 0 1.5855236767947645e-07
ductal B-Disease 0 0.008105005137622356
carcinomas I-Disease 1 0.9999998807907104
, O 0 4.944830322983762e-08
suggesting O 0 2.2834498736301612e-07
that O 0 2.772617246904474e-09
absence O 0 1.4760162869720261e-08
of O 0 5.393421265154075e-09
BRCA1 O 0 8.105238521238789e-06
may O 0 8.343115354136899e-08
contribute O 0 1.900722468306526e-09
to O 0 1.7535141116908903e-09
the O 0 4.782774176703697e-09
pathogenesis O 0 1.053078548807207e-07
of O 0 3.526870462344789e-10
a O 0 8.875642443229026e-09
significant O 0 1.0676479256233051e-08
percentage O 0 4.513892548629883e-08
of O 0 1.4845996432200081e-08
sporadic B-Disease 1 0.9575047492980957
breast I-Disease 1 0.999995231628418
cancers I-Disease 0 0.30060431361198425
. O 0 2.559167455729039e-07
. O 0 5.768589517174405e-07

